PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	JOHNSON, PJ; MCFARLANE, IG; WILLIAMS, R				JOHNSON, PJ; MCFARLANE, IG; WILLIAMS, R			AZATHIOPRINE FOR LONG-TERM MAINTENANCE OF REMISSION IN AUTOIMMUNE HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; KILLER CELL-ACTIVITY; RHEUMATOID-ARTHRITIS; CORTICOSTEROID-THERAPY; CONTROLLED TRIAL; WITHDRAWAL; LIVER; 6-MERCAPTOPURINE; PHARMACOGENETICS; SUPPRESSION	Background. In most patients with autoimmune hepatitis, remission can be maintained with prednisolone, usually in combination with azathioprine, but the majority of patients have a relapse when treatment is stopped and therefore require long-term therapy. Because prolonged corticosteroid therapy may have serious toxic effects, in 1984 we undertook a controlled trial of maintenance therapy with azathioprine alone. None of the 25 patients in that trial had relapses during the followup period of one year. We have now followed these 25 patients for 10 years and have treated an additional 47 patients in a similar manner. Methods. The 72 patients (median age, 47 years; range, 14 to 71) had been in complete remission for at least one year with 5 to 15 mg of prednisolone per day and 1 mg of azathioprine per kilogram of body weight per day. The dose of azathioprine was increased to 2 mg per kilogram per day, and the prednisolone was gradually withdrawn. Remission was defined as the absence of symptoms suggestive of a relapse and serum globulin and aspartate aminotransferase concentrations within the normal range, with or without a liver biopsy showing only minimal inflammation. Results. Sixty patients (83 percent) remained in remission while receiving azathioprine alone for a median of 67 months (range, 12 to 128). Of 48 follow-up liver biopsies in 42 patients, 45 showed inactive or minimal disease, and 3 showed moderate disease (2 after one year of therapy and 1 after eight years). After the prednisolone had been withdrawn, 26 patients lost their cushingoid facies, and 32 patients lost weight (median loss, 6.4 kg; range, 1.5 to 22.3). The most common adverse effect was arthralgia (in 38 patients). With the higher dose of azathioprine, four patients had myelosuppression, defined as a decrease in the leukocyte and platelet counts to less than 4000 and 150,000 per cubic millimeter, respectively. Two of these patients (both with pancytopenia) relapsed when the azathioprine was withdrawn; in the other two, remission was maintained with the resumption of prednisolone. Lymphopenia developed in 32 of 56 patients treated with 2 mg of azathioprine per kilogram per day for more than two years. During follow-up, nine patients died: one of liver failure and eight of causes not directly related to their liver disease. Conclusions. Many patients with autoimmune hepatitis who have been in complete remission for at least one year with prednisolone and azathioprine can remain in remission with a higher dose of azathioprine alone.	UNIV LONDON KINGS COLL HOSP, INST LIVER STUDIES, LONDON SE5 9RS, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON WC2R 2LS, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London				opoku, anita/0000-0001-7243-8157				COOK GC, 1971, Q J MED, V40, P159, DOI 10.1093/oxfordjournals.qjmed.a067264; Czaja Albert J., 1994, P283; Czaja AJ, 1987, GASTROENTEROLOGY, V92, P215, DOI 10.1016/0016-5085(87)90862-6; Diem K., 1982, GEIGY SCI TABLES; DOHERTY DG, 1992, HUM IMMUNOL, V34, P53, DOI 10.1016/0198-8859(92)90085-2; DONALDSON PT, 1991, HEPATOLOGY, V13, P701, DOI 10.1016/0270-9139(91)92567-R; GANE E, 1994, HEPATOLOGY, V20, P88, DOI 10.1016/0270-9139(94)90138-4; GOLBUS MS, 1980, OBSTET GYNECOL, V55, P269, DOI 10.1097/00006250-198003000-00001; HEGARTY JE, 1983, HEPATOLOGY, V3, P685; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1989, CLIN PHARMACOL THER, V46, P149, DOI 10.1038/clpt.1989.119; MCFARLANE BM, 1986, J HEPATOL, V3, P196, DOI 10.1016/S0168-8278(86)80026-5; MCFARLANE IG, 1990, IMMUNOLOGY IMMUNOPAT, P281; MURRAYLYON IM, 1973, LANCET, V1, P735; NABER AHJ, 1991, J HEPATOL, V12, P94, DOI 10.1016/0168-8278(91)90916-Y; NOURIARIA KT, 1982, NEW ENGL J MED, V307, P1301, DOI 10.1056/NEJM198211183072102; NOURIARIA KT, 1985, CLIN EXP IMMUNOL, V61, P290; PEDERSEN BK, 1984, ACTA PATH MICRO IM C, V92, P221; PEDERSEN BK, 1986, ALLERGY, V41, P286, DOI 10.1111/j.1398-9995.1986.tb02030.x; PRINCE HE, 1984, J CLIN IMMUNOL, V4, P312, DOI 10.1007/BF00915299; SCHMIEGELOW K, 1993, ANN RHEUM DIS, V52, P152, DOI 10.1136/ard.52.2.152; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P988, DOI 10.1136/ard.47.12.988; SOLOWAY RD, 1972, GASTROENTEROLOGY, V63, P820; STELLON AJ, 1988, HEPATOLOGY, V8, P781, DOI 10.1002/hep.1840080414; STELLON AJ, 1985, LANCET, V1, P668; VANSCOIK KG, 1985, DRUG METAB REV, V16, P157, DOI 10.3109/03602538508991433; VITERI A, 1976, GASTROENTEROLOGY, V71, P1075; WANG KK, 1989, HEPATOLOGY, V10, P39, DOI 10.1002/hep.1840100110; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WITTER FR, 1984, DRUG USE PREGNANCY, P190; 1969, LANCET, V1, P119	33	281	293	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					958	963		10.1056/NEJM199510123331502	http://dx.doi.org/10.1056/NEJM199510123331502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666914				2022-12-28	WOS:A1995RY58600002
J	CAREY, TS; GARRETT, J; JACKMAN, A; MCLAUGHLIN, C; FRYER, J; SMUCKER, DR; CURTIS, P; DARTER, J; DEFRIESE, G; EVANS, A; HADLER, N; HUNTER, G; JOINES, J; KALSBEEK, W; KONRAD, T; MCNUTT, R; RICKETTS, T; TAYLOR, D				CAREY, TS; GARRETT, J; JACKMAN, A; MCLAUGHLIN, C; FRYER, J; SMUCKER, DR; CURTIS, P; DARTER, J; DEFRIESE, G; EVANS, A; HADLER, N; HUNTER, G; JOINES, J; KALSBEEK, W; KONRAD, T; MCNUTT, R; RICKETTS, T; TAYLOR, D			THE OUTCOMES AND COSTS OF CARE FOR ACUTE LOW-BACK-PAIN AMONG PATIENTS SEEN BY PRIMARY-CARE PRACTITIONERS, CHIROPRACTORS, AND ORTHOPEDIC SURGEONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MANIPULATION	Background. Patients with back pain receive quite different care from different types of health care practitioners. We performed a prospective observational study to determine whether the outcomes of and charges for care differ among primary care practitioners, chiropractors, and orthopedic surgeons. Methods. Two hundred eight practitioners in North Carolina were randomly selected from six strata: urban primary care physicians (n = 39), rural primary care physicians (n = 48), urban chiropractors (n = 32), rural chiropractors (n = 32), orthopedic surgeons (n = 29), and primary care providers at a group-model health maintenance organization (HMO) (n = 28). The practitioners enrolled consecutive patients with acute low back pain. The patients were contacted by telephone periodically for up to 24 weeks to assess functional status, work status, use of health care services, and satisfaction with the care received. Results. The status at six months was ascertained for 1555 of the 1633 patients enrolled in the study (95 percent). The times to functional recovery, return to work, and complete recovery from low back pain were similar among patients seen by all six groups of practitioners, but there were marked differences in the use of health care services. The mean total estimated outpatient charges were highest for the patients seen by orthopedic surgeons and chiropractors and were lowest for the patients seen by HMO and primary care providers. Satisfaction was greatest among the patients who went to the chiropractors. Conclusions. Among patients with acute low back pain, the outcomes are similar whether they receive care from primary care practitioners, chiropractors, or orthopedic surgeons. Primary care practitioners provide the least expensive care for acute low back pain.	UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT FAMILY MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOSTAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BUSINESS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	CAREY, TS (corresponding author), UNIV N CAROLINA, SHEPS CTR HLTH SERV RES, 725 AIRPORT RD, 2ND FLOOR, CB 7590, CHAPEL HILL, NC 27599 USA.				AHRQ HHS [HS06664] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588; CAREY TS, IN PRESS SPINE; CHERKIN DC, 1989, WESTERN J MED, V150, P351; CONOVER W. J, 1980, PRACTICAL NONPARAMET; COYER AB, 1955, BRIT MED J, V1, P705, DOI 10.1136/bmj.1.4915.705; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHEKELLE PG, 1995, SPINE, V20, P221, DOI 10.1097/00007632-199501150-00018; SURLES KB, 1993, CHES STUDIES, V72; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008; 1994, 1994 RED BOOK; 1987, PC SAS VERSION 6 04; 1995, 1995 STATA STATISTIC	24	422	424	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					913	917		10.1056/NEJM199510053331406	http://dx.doi.org/10.1056/NEJM199510053331406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666878	Bronze			2022-12-28	WOS:A1995RX19900006
J	SEIDEN, MV; PINS, MR; KAUFFMAN, MG; LYNCH, TJ; BLOCH, KJ; COLVIN, RB				SEIDEN, MV; PINS, MR; KAUFFMAN, MG; LYNCH, TJ; BLOCH, KJ; COLVIN, RB			A 69-YEAR-OLD WOMAN WITH LUPUS-ERYTHEMATOSUS AND PAINFUL SKIN-LESIONS OF THE FEET - MULTIPLE-MYELOMA, WITH IGG-KAPPA SERUM-M COMPONENT - CRYOGLOBULINEMIA, TYPE-I - (OVERLAP SYNDROME OF CALCINOSIS, RAYNAUDS-PHENOMENON, ESOPHAGEAL DYSMOTILITY, SCLERODACTYL, AND TELANGIECTASIA [CREST] AND SYSTEMIC LUPUS-ERYTHEMATOSUS)	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							LYMPHOMATOID GRANULOMATOSIS; LIVEDO RETICULARIS; VASCULITIS; CLASSIFICATION; ANTIBODIES; MALIGNANCY; FEATURES; CRITERIA		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	SEIDEN, MV (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.							AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; CAIRNS SA, 1978, BRIT MED J, V2, P474, DOI 10.1136/bmj.2.6135.474-a; COHEN RD, 1980, MAYO CLIN PROC, V55, P146; COHEN SJ, 1991, J AM ACAD DERMATOL, V25, P21, DOI 10.1016/0190-9622(91)70168-2; DONNER LR, 1990, CANCER-AM CANCER SOC, V65, P249, DOI 10.1002/1097-0142(19900115)65:2<249::AID-CNCR2820650212>3.0.CO;2-Y; DUPLA ML, 1993, LUPUS, V2, P377, DOI 10.1177/096120339300200608; FLEISCHER AB, 1990, DERMATOL CLIN, V8, P347; FREUNDLICH B, 1988, ANN INTERN MED, V109, P295, DOI 10.7326/0003-4819-109-4-295; GORE I, 1960, AM J CLIN PATHOL, V33, P416; GRATTAN CEH, 1989, BRIT J DERMATOL, V120, P441, DOI 10.1111/j.1365-2133.1989.tb04172.x; GREER JM, 1988, MEDICINE, V67, P220, DOI 10.1097/00005792-198807000-00003; HAWLEY PR, 1967, BRIT MED J, V3, P208, DOI 10.1136/bmj.3.5559.208; JONSSON H, 1989, MEDICINE, V68, P141, DOI 10.1097/00005792-198905000-00002; LIEBOW AA, 1972, HUM PATHOL, V3, P457, DOI 10.1016/S0046-8177(72)80005-4; MCDUFFIE FC, 1973, MAYO CLIN PROC, V48, P340; MENON S, 1993, LUPUS, V2, P177, DOI 10.1177/096120339300200309; MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; POZZATO G, 1994, BLOOD, V84, P3047; SANCHEZGUERRERO J, 1990, J RHEUMATOL, V17, P1458; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WADE JP, 1988, J RHEUMATOL, V15, P1759; WILSON DM, 1991, AM J MED, V91, P186, DOI 10.1016/0002-9343(91)90013-N; ZAX RH, 1990, ARCH DERMATOL, V126, P69, DOI 10.1001/archderm.126.1.69; ZEEK PM, 1948, AM J PATHOL, V24, P889	26	10	10	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					862	868		10.1056/NEJM199509283331308	http://dx.doi.org/10.1056/NEJM199509283331308			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651478				2022-12-28	WOS:A1995RW88300008
J	VARMUS, H				VARMUS, H			SHATTUCK-LECTURE - BIOMEDICAL-RESEARCH ENTERS THE STEADY-STATE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											VARMUS, H (corresponding author), NIH,BLDG 1,RM 126,1 CTR DR,MSC 0148,BETHESDA,MD 20892, USA.							[Anonymous], 1995, RESHAPING GRADUATE E; BISHOP JM, 1993, SCIENCE, V259, P444, DOI 10.1126/science.8424162; GARFIELD B, 1995, WASHINGTON POST 0205, P1; GOODSTEIN D, 1993, SCI RES SOC, P23; Price Derek J. de Solla, 1961, SCI BABYLON; VARMUS H, 1994, MOL BIOL CELL, V5, P267, DOI 10.1091/mbc.5.3.267; 1994, FUNDING YOUNG INVEST	7	27	29	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					811	815		10.1056/NEJM199509213331224	http://dx.doi.org/10.1056/NEJM199509213331224			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643903				2022-12-28	WOS:A1995RU80900030
J	BOWRING, SA; HOUSH, T				BOWRING, SA; HOUSH, T			THE EARTH EARLY EVOLUTION	SCIENCE			English	Article							SOUTHERN WEST GREENLAND; LOWER CONTINENTAL-CRUST; ND-ISOTOPIC EVIDENCE; MEAN-LIFE; CLASTIC METASEDIMENTS; MANTLE FRACTIONATION; DETRITAL ZIRCONS; GNEISS COMPLEX; HF ISOTOPES; GROWTH	The Archean crust contains direct geochemical information of the Earth's early planetary differentiation. A major outstanding question in the Earth sciences is whether the volume of continental crust today represents nearly all that formed over Earth's history or whether its rates of creation and destruction have been approximately balanced since the Archean. Analysis of neodymium isotopic data from the oldest remnants of Archean crust suggests that crustal recycling is important and that preserved continental crust comprises fragments of crust that escaped recycling. Furthermore, the data suggest that the isotopic evolution of Earth's mantle reflects progressive eradication of primordial heterogeneities related to early differentiation.	UNIV TEXAS, DEPT GEOL SCI, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	BOWRING, SA (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA.							ABBOTT D, 1991, GEOPHYS RES LETT, V18, P585, DOI 10.1029/91GL00813; ALLEGRE CJ, 1989, EARTH PLANET SC LETT, V96, P61, DOI 10.1016/0012-821X(89)90124-6; ANDERSON DL, 1994, GEOLOGY, V22, P39, DOI 10.1130/0091-7613(1994)022<0039:SOS>2.3.CO;2; ANDERSON DL, 1981, SCIENCE, V213, P82, DOI 10.1126/science.213.4503.82; ANDERSON DL, 1994, EARTH PLANET SC LETT, V128, P303, DOI 10.1016/0012-821X(94)90152-X; ARMSTRONG RL, 1981, PHILOS T R SOC A, V301, P443, DOI 10.1098/rsta.1981.0122; ARMSTRONG RL, 1968, REV GEOPHYS, V6, P175, DOI 10.1029/RG006i002p00175; ARMSTRONG RL, 1991, AUST J EARTH SCI, V38, P613, DOI 10.1080/08120099108727995; ARMSTRONG RL, 1981, GEOCHIM COSMOCHIM AC, V45, P1251, DOI 10.1016/0016-7037(81)90149-6; ARNDT NT, 1989, TECTONOPHYSICS, V161, P201, DOI 10.1016/0040-1951(89)90154-6; ARTH JG, 1975, GEOCHIM COSMOCHIM AC, V39, P325, DOI 10.1016/0016-7037(75)90200-8; BARKER F, 1976, GEOLOGY, V4, P596, DOI 10.1130/0091-7613(1976)4<596:GOTLAA>2.0.CO;2; BENNETT VC, 1993, EARTH PLANET SC LETT, V119, P299, DOI 10.1016/0012-821X(93)90140-5; BLACK LP, 1986, CONTRIB MINERAL PETR, V94, P427, DOI 10.1007/BF00376336; BLICHERTTOFT J, 1994, SCIENCE, V263, P1593, DOI 10.1126/science.263.5153.1593; BOAK JM, 1993, GEOL SOC AM ABSTR, V25, P74; BOWRING SA, 1989, GEOLOGY, V17, P971, DOI 10.1130/0091-7613(1989)017<0971:GGFTSP>2.3.CO;2; BOWRING SA, 1989, NATURE, V340, P222, DOI 10.1038/340222a0; BOWRING SA, UNPUB; BOWRING SA, 1990, ORIGIN EARTH, P319; BOWRING SA, 1994, EOS, V75, P59; CAMPBELL IH, 1983, GEOPHYS RES LETT, V10, P1061, DOI 10.1029/GL010i011p01061; CAMPBELL IH, 1988, EARTH PLANET SC LETT, V90, P11, DOI 10.1016/0012-821X(88)90107-0; CARLSON RW, 1979, EARTH PLANET SC LETT, V45, P123, DOI 10.1016/0012-821X(79)90114-6; CARLSON RW, 1994, REV GEOPHYS, V32, P337, DOI 10.1029/94RG01874; CHASE CG, 1988, EARTH PLANET SC LETT, V91, P66, DOI 10.1016/0012-821X(88)90151-3; CHRISTENSEN NI, 1995, J GEOPHYS RES-SOL EA, V100, P9761, DOI 10.1029/95JB00259; Collerson K.D., 1979, TRONDHJEMITES DACITE, V6, P205; COLLERSON KD, 1991, NATURE, V349, P209, DOI 10.1038/349209a0; CONDIE KC, 1984, GEOPHYS RES LETT, V11, P283, DOI 10.1029/GL011i004p00283; DePaolo, 1988, MINERALS ROCKS; DEPAOLO DJ, 1980, GEOCHIM COSMOCHIM AC, V44, P1185, DOI 10.1016/0016-7037(80)90072-1; DEPAOLO DJ, 1983, GEOPHYS RES LETT, V10, P705, DOI 10.1029/GL010i008p00705; DEPAOLO DJ, 1984, GEOPHYS RES LETT, V11, P154, DOI 10.1029/GL011i002p00154; DEPAOLO DJ, 1981, GEOCHIM COSMOCHIM AC, V45, P1253, DOI 10.1016/0016-7037(81)90150-2; DEWIT MJ, 1992, NATURE, V357, P553, DOI 10.1038/357553a0; DRUMMOND MS, 1990, J GEOPHYS RES-SOLID, V95, P21503, DOI 10.1029/JB095iB13p21503; ENGLAND P, 1993, TECTONOPHYSICS, V223, P67, DOI 10.1016/0040-1951(93)90158-G; FROST CD, 1993, GEOLOGY, V21, P351, DOI 10.1130/0091-7613(1993)021<0351:NIEFTA>2.3.CO;2; FROUDE DO, 1983, NATURE, V304, P616, DOI 10.1038/304616a0; FYFE WS, 1978, CHEM GEOL, V23, P89, DOI 10.1016/0009-2541(78)90068-2; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; Goldstein S. L., 1992, EOS T AM GEOPHYS UN, V73, P323; GOODWIN AM, 1991, PRECAMBRIAN GEOLOGY; GURNIS M, 1986, GEOLOGY, V14, P396, DOI 10.1130/0091-7613(1986)14<396:AECGAF>2.0.CO;2; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, 1992, P LUNAR PLANET SCI C, V23, P487; HOFFMAN PF, 1989, GEOLOGY, V17, P135, DOI 10.1130/0091-7613(1989)017<0135:SOLSFG>2.3.CO;2; HOUSH TB, UNPUB; HOUSH TB, 1993, GEOL SOC AM ABSTR, V25, P73; HURLEY PM, 1969, SCIENCE, V164, P1229, DOI 10.1126/science.164.3885.1229; JACOBSEN SB, 1981, TECTONOPHYSICS, V75, P163, DOI 10.1016/0040-1951(81)90214-6; JACOBSEN SB, 1988, J GEOPHYS RES-SOLID, V93, P338, DOI 10.1029/JB093iB01p00338; JACOBSEN SB, 1988, EARTH PLANET SC LETT, V90, P315, DOI 10.1016/0012-821X(88)90133-1; JACOBSEN SB, IN PRESS AM GEOPHYS; JACOBSEN SB, 1993, P LUNAR PLANET SCI C, V24, P709; JAHN B, 1984, CONTRIB MINERAL PETR, V86, P398, DOI 10.1007/BF01187143; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; JORDAN TH, 1988, J PETROL, P11, DOI DOI 10.1093/PETROLOGY/SPECIAL_VOLUME.1.11; KAY RW, 1991, GEOL RUNDSCH, V80, P259, DOI 10.1007/BF01829365; LAUBSCHER H, 1990, TECTONOPHYSICS, V182, P9, DOI 10.1016/0040-1951(90)90338-9; LIU DY, 1992, GEOLOGY, V20, P339, DOI 10.1130/0091-7613(1992)020<0339:ROMCIT>2.3.CO;2; LUAIS B, 1994, J PETROL, V35, P43, DOI 10.1093/petrology/35.1.43; Lugmair G. W., 1978, LUNAR PLANETARY SCI, V9, P689; MAAS R, 1991, GEOCHIM COSMOCHIM AC, V55, P1915, DOI 10.1016/0016-7037(91)90033-2; MAAS R, 1992, GEOCHIM COSMOCHIM AC, V56, P1281, DOI 10.1016/0016-7037(92)90062-N; MARTIN H, 1986, GEOLOGY, V14, P753, DOI 10.1130/0091-7613(1986)14<753:EOSAGG>2.0.CO;2; MCCULLOCH MT, 1993, LITHOS, V30, P237, DOI 10.1016/0024-4937(93)90038-E; MCCULLOCH MT, 1993, EARTH PLANET SC LETT, V115, P89, DOI 10.1016/0012-821X(93)90215-U; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P4717, DOI 10.1016/0016-7037(94)90203-8; MORGAN P, 1989, 28TH INT GEOL C 1989, V2, P462; MORGAN P, 1985, P LUNAR PLANET SCI C, V15, pC561; MUELLER PA, 1992, GEOLOGY, V20, P327, DOI 10.1130/0091-7613(1992)020<0327:GZFAAQ>2.3.CO;2; NUTMAN AP, 1986, CONTRIB MINERAL PETR, V94, P137, DOI 10.1007/BF00592931; NUTMAN AP, 1993, GEOLOGY, V21, P415, DOI 10.1130/0091-7613(1993)021<0415:AOAEAG>2.3.CO;2; NUTMAN AP, 1991, GEOLOGY, V19, P791, DOI 10.1130/0091-7613(1991)019<0791:VEACAC>2.3.CO;2; NYQUIST LE, 1992, GEOCHIM COSMOCHIM AC, V56, P2213, DOI 10.1016/0016-7037(92)90185-L; PATCHETT J, 1984, GEOPHYS RES LETT, V11, P151, DOI 10.1029/GL011i002p00151; RAPP RP, 1991, PRECAMBRIAN RES, V51, P1, DOI 10.1016/0301-9268(91)90092-O; REYMER A, 1984, TECTONICS, V3, P63, DOI 10.1029/TC003i001p00063; SCHREYER W, 1995, J GEOPHYS RES-SOL EA, V100, P8353, DOI 10.1029/94JB02912; SHEARER CK, 1993, GEOCHIM COSMOCHIM AC, V57, P4785, DOI 10.1016/0016-7037(93)90200-G; SHIREY SB, 1986, GEOCHIM COSMOCHIM AC, V50, P2631, DOI 10.1016/0016-7037(86)90215-2; SILVER PG, 1988, ANNU REV EARTH PL SC, V16, P477, DOI 10.1146/annurev.ea.16.050188.002401; SNYDER GA, 1994, GEOCHIM COSMOCHIM AC, V58, P4795, DOI 10.1016/0016-7037(94)90209-7; STEVENSON RK, 1990, GEOCHIM COSMOCHIM AC, V54, P1683, DOI 10.1016/0016-7037(90)90400-F; Taylor S.R., 1974, P 5 LUNAR SCI C, V1287-1305; Taylor S.R., 1985, CONTINENTAL CRUST IT; TAYLOR SR, 1975, LUNAR SCI POST APOLL; VONHUENE R, 1991, REV GEOPHYS, V29, P279, DOI 10.1029/91RG00969; WARREN PH, 1989, TECTONOPHYSICS, V161, P165, DOI 10.1016/0040-1951(89)90153-4; WILLIAMS IS, 1992, EOS, V73, P324; ZARTMAN RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1327, DOI 10.1016/0016-7037(88)90204-9	93	235	245	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1535	1540		10.1126/science.7667634	http://dx.doi.org/10.1126/science.7667634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667634				2022-12-28	WOS:A1995RU81300030
J	KELEPOURIS, N; HARPER, KD; GANNON, F; KAPLAN, FS; HADDAD, JG				KELEPOURIS, N; HARPER, KD; GANNON, F; KAPLAN, FS; HADDAD, JG			SEVERE OSTEOPOROSIS IN MEN	ANNALS OF INTERNAL MEDICINE			English	Review							QUANTITATIVE COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY; SPINAL OSTEOPOROSIS; TRABECULAR BONE; SEX-DIFFERENCES; LUMBAR SPINE; HEALTHY-MEN; AGE; PATHOPHYSIOLOGY; REDUCTION	Objective: To evaluate men with severe osteoporosis for pathogenetic factors and to review the reported features of primary osteoporosis in men. Design: Case series and clinical review. Patients: 47 men consecutively referred to a metabolic bone center because of atraumatic (or minimally traumatic) fractures (91%) or radiographic osteopenia (9%) Measurements: Clinical assessment, radiographs, chemical analyses of serum and urine, hormone assays, skeletal densitometry, and histomorphometry of iliac crest biopsy specimens. Results: 27 of the 47 men (57%) had vertebral fractures, and 16 (34%) had appendicular fractures. Causal factors identified in 30 men (64%) included glucocorticosteroid treatment (8 men); hypogonadism (7 men); excessive alcohol consumption (7 men); and anticonvulsant use, osteomalacia, severe hyperthyroidism, or bone marrow neoplasia (8 men). Seventeen men (36%) had no medical conditions or known risk factors associated with bone disease. Spinal mineral density was well below the mean value for healthy young men in 94% of the patients with primary osteoporosis tested. Examination of biopsy specimens from 13 of 17 men with primary osteoporosis showed reduced trabecular bone volumes, normal bone formation rates, and slightly increased resorption surfaces. Fasting hypercalciuria was seen in some men (41%). In the primary osteoporosis group, eight men were followed serially (range of follow-up, 6 months to 9 years) while they were receiving a nonpharmacologic regimen (diet and activity); the mean axial bone mineral density of these men increased slightly. Conclusions: A thorough evaluation for identifiable causes of severe osteoporosis in men is warranted because definable pathogenetic factors are seen in many cases. A few men with severe osteoporosis have primary or idiopathic osteoporosis. Primary osteoporosis in men is probably caused by many factors because heterogeneous clinical, laboratory, and histologic features were seen in our series and in those of others. Further studies of primary osteoporosis are needed to define the course of the disease, to identify pathogenetic mechanisms, and to develop therapeutic interventions.	UNIV PENN, SCH MED, DIV ENDOCRINOL DIABET & METAB, PHILADELPHIA, PA 19104 USA	University of Pennsylvania					NCRR NIH HHS [MO1-RR00040] Funding Source: Medline; NIADDK NIH HHS [R01 AM28292, AM32760] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM028292] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AARON JE, 1989, CLIN ORTHOP RELAT R, P294; BAILLIE SP, 1992, AGE AGEING, V21, P139, DOI 10.1093/ageing/21.2.139; BIGGEMANN M, 1988, SKELETAL RADIOL, V17, P264, DOI 10.1007/BF00401809; BIKLE DD, 1985, ANN INTERN MED, V103, P42, DOI 10.7326/0003-4819-103-1-42; Bordier P J, 1973, Clin Endocrinol Metab, V2, P277, DOI 10.1016/S0300-595X(73)80044-1; BRESSOT C, 1979, METAB BONE DIS RELAT, V1, P303, DOI 10.1016/0221-8747(79)90024-9; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; DEMPSTER DW, 1989, J BONE MINER RES, V4, P137; DEVERNEJOUL MC, 1983, CLIN ORTHOP RELAT R, V179, P107; DIAMOND T, 1989, AM J MED, V86, P282, DOI 10.1016/0002-9343(89)90297-0; FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FORESTA C, 1984, HORM RES, V19, P18, DOI 10.1159/000179855; FRANCIS RM, 1989, BONE MINER, V5, P347, DOI 10.1016/0169-6009(89)90012-3; Genant HK, 1988, OSTEOPOROSIS ETIOLOG, P221; GREENSPAN SL, 1986, ANN INTERN MED, V104, P777, DOI 10.7326/0003-4819-104-6-777; HILLS E, 1989, J CLIN PATHOL, V42, P391, DOI 10.1136/jcp.42.4.391; HIOCO D, 1964, BONE TOOTH, P365; JACKSON JA, 1987, J CLIN ENDOCR METAB, V65, P53, DOI 10.1210/jcem-65-1-53; JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792-199005000-00002; JACKSON WPU, 1958, J BONE JOINT SURG BR, V40, P420, DOI 10.1302/0301-620X.40B3.420; KALENDER WA, 1989, EUR J RADIOL, V9, P75; KAPLAN FS, 1989, ORTHOPEDICS, V12, P949; KAPLAN FS, 1988, CLIN ORTHOP RELAT R, P26; KAPLAN FS, 1993, CLIN ORTHOP RELAT R, V297, P161; KELLY PJ, 1990, J BONE MINER RES, V5, P1169; KHOSLA S, 1994, BONE, V15, P551, DOI 10.1016/8756-3282(94)90280-1; LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227; MACADAMS MR, 1986, ANN INTERN MED, V104, P648, DOI 10.7326/0003-4819-104-5-648; MARIE PJ, 1991, J CLIN INVEST, V88, P1167, DOI 10.1172/JCI115418; MAZESS R, 1990, R290 LUN CORP; MAZESS RB, 1982, CLIN ORTHOP RELAT R, P239; MEIER DE, 1987, J AM GERIATR SOC, V35, P189, DOI 10.1111/j.1532-5415.1987.tb02308.x; MEIER DE, 1984, ANN INTERN MED, V101, P605, DOI 10.7326/0003-4819-101-5-605; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; MOSEKILDE L, 1990, BONE, V11, P67, DOI 10.1016/8756-3282(90)90052-Z; NORDIN BEC, 1984, SCOT MED J, V29, P171, DOI 10.1177/003693308402900307; ORWOLL ES, 1990, ANN INTERN MED, V112, P29, DOI 10.7326/0003-4819-112-1-29; ORWOLL ES, 1995, ENDOCR REV, V16, P87, DOI 10.1210/er.16.1.87; ORWOLL ES, 1994, RHEUM DIS CLIN N AM, V20, P671; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PERRY HM, 1982, ARCH INTERN MED, V142, P1295, DOI 10.1001/archinte.142.7.1295; RESCH H, 1992, EUR J CLIN INVEST, V22, P542, DOI 10.1111/j.1365-2362.1992.tb01503.x; RIGGS BL, 1981, J CLIN INVEST, V67, P328, DOI 10.1172/JCI110039; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Saville P D, 1973, Clin Endocrinol Metab, V2, P177, DOI 10.1016/S0300-595X(73)80038-6; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SEEMAN E, 1995, AM J MED, V98, pS76, DOI 10.1016/S0002-9343(05)80082-8; SEEMAN E, 1993, AM J MED, V95, pS22, DOI 10.1016/0002-9343(93)90377-2; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SPENCER H, 1986, AM J MED, V80, P393, DOI 10.1016/0002-9343(86)90712-6; STEPAN JJ, 1989, J CLIN ENDOCR METAB, V69, P523; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060; WAHNER HW, 1985, RADIOLOGY, V156, P203, DOI 10.1148/radiology.156.1.4001406; ZERWEKH JE, 1992, OSTEOPOROSIS INT, V2, P128, DOI 10.1007/BF01623819	55	146	150	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					452	460		10.7326/0003-4819-123-6-199509150-00010	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639446				2022-12-28	WOS:A1995RU43700009
J	HIGGINS, CF				HIGGINS, CF			THE ABC OF CHANNEL REGULATION	CELL			English	Review							RESISTANCE P-GLYCOPROTEIN; STREPTOCOCCUS-PNEUMONIAE; CHLORIDE CHANNELS; TRANSPORT; PROTEINS; LOCUS; CFTR		UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford	HIGGINS, CF (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND.							AGULLARBRYAN L, 1995, SCIENCE, V268, P423; ALLOING G, 1990, MOL MICROBIOL, V4, P633, DOI 10.1111/j.1365-2958.1990.tb00632.x; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; EGAN M, 1993, NATURE, V358, P581; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JIRSCH J, 1993, CANCER RES, V53, P4156; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; Mills J W, 1994, Curr Opin Nephrol Hypertens, V3, P529, DOI 10.1097/00041552-199409000-00009; PARRALOPEZ C, 1994, EMBO J, V13, P3964, DOI 10.1002/j.1460-2075.1994.tb06712.x; PARRALOPEZ C, 1993, EMBO J, V12, P4053, DOI 10.1002/j.1460-2075.1993.tb06089.x; REUTZ S, 1994, CELL, V77, P1071; ROEPE PD, 1994, BIOCHEMISTRY-US, V33, P11008, DOI 10.1021/bi00202a021; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; STEED PM, 1993, J BACTERIOL, V175, P6797, DOI 10.1128/jb.175.21.6797-6809.1993; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TROMBE MC, 1993, MOL MICROBIOL, V8, P199, DOI 10.1111/j.1365-2958.1993.tb01216.x; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANES HHG, 1994, MOL BIOCHEM PARASIT, V68, P209, DOI 10.1016/0166-6851(94)90166-X	29	335	344	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					693	696		10.1016/0092-8674(95)90465-4	http://dx.doi.org/10.1016/0092-8674(95)90465-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671298	Bronze			2022-12-28	WOS:A1995RU75500003
J	PAULOVICH, AG; HARTWELL, LH				PAULOVICH, AG; HARTWELL, LH			A CHECKPOINT REGULATES THE RATE OF PROGRESSION THROUGH S-PHASE IN SACCHAROMYCES-CEREVISIAE IN RESPONSE TO DNA-DAMAGE	CELL			English	Article							DOUBLE-STRAND BREAKS; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; REPAIR; ARREST; GENE; RECOMBINATION; TRANSCRIPTION; REPLICATION	We demonstrate that in S. cerevisiae the rate of ongoing S phase is slowed when the DNA is subjected to alkylation. Slowing of replication is dependent on the MEC1 and RAD53 genes, indicating that lesions alone do not slow replication in vivo and that the slowing is an active process. While it has been shown that a MEC1- and RAD53-dependent checkpoint responds to blocked replication or DNA damage by inhibiting the onset of mitosis, we demonstrate that this checkpoint must also have an additional target within S phase that controls replication rate. MEC1 is a homolog of the human ATM gene, which is mutated in ataxia telangiectasia (AT) patients. Like mec1 yeast, AT cells are characterized by damage-resistant DNA synthesis, highlighting the congruence of the yeast and mammalian systems.			PAULOVICH, AG (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.							Allen JB, 1994, GENE DEV, V8, P2416; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BRUNBORG G, 1980, RADIAT RES, V82, P547, DOI 10.2307/3575321; BRUNBORG G, 1978, MOL GEN GENET, V182, P277; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KADYK LC, 1993, GENETICS, V133, P469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LEADON SA, 1992, J BIOL CHEM, V267, P23175; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1993, CURR OPIN GENET DEV, V5, P5; NAEGELI H, 1994, BIOESSAYS, V16, P557, DOI 10.1002/bies.950160809; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PAULES RS, 1995, CANCER RES, V55, P1763; PETES TD, 1973, BIOCHEM BIOPH RES CO, V55, P603, DOI 10.1016/0006-291X(73)91186-8; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SINGER B, 1983, MOL BIOL MUTAGENS CA, P68; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040; ZAMPETTIBOSSELE.F, 1981, INT J RADIAT BIOL, V39, P547	40	531	537	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					841	847		10.1016/0092-8674(95)90481-6	http://dx.doi.org/10.1016/0092-8674(95)90481-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671311	Bronze			2022-12-28	WOS:A1995RU75500019
J	CHRISTAKIS, NA				CHRISTAKIS, NA			THE SIMILARITY AND FREQUENCY OF PROPOSALS TO REFORM US MEDICAL-EDUCATION - CONSTANT CONCERNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review								Objectives.-To identify the values and agendas underlying reports advocating the reform of medical education and to account for their similarity and repeated promulgation. Data Sources.-Major reports regarding undergraduate medical education reform published between 1910 and 1993 were identified through a manual bibliographic search. Study Selection.-Nineteen of a total of 24 reports met the two inclusion criteria: they directly addressed undergraduate medical education and contained a coherent body of recommendations. Data Extraction.-Content analysis of 19 reports. Data Synthesis.-All the reports articulate a specifically social vision of the medical profession, in which medical schools are seen as serving society. The reports are remarkably consistent regarding the objectives of reform and the specific reforms proposed. Core objectives of reform include the following. (1) to better serve the public interest, (2) to address physician workforce needs, (3) to cope with burgeoning medical knowledge, and (4) to increase the emphasis on generalism. Proposed reforms have tended to suggest changes in manner of teaching, content of teaching, faculty development, and organizational factors. Reforms such as increasing generalist training, increasing ambulatory care exposure, providing social science courses, teaching lifelong and self-learning skills, rewarding teaching, clarifying the school mission, and centralizing curriculum control have appeared almost continuously since 1910. Conclusion.-The similarity of the reports' objectives and reforms results not only from a similar body of problems, but also from the reaffirmation of similar values. The reports have two implicit agendas that transcend the reform of medical education: the affirmation of the social nature of the medical profession and self-regulation of the profession. These agendas help account for the reports' similarity and their repeated promulgation.	UNIV CHICAGO,MED CTR,DEPT SOCIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago Medical Center	CHRISTAKIS, NA (corresponding author), UNIV CHICAGO,MED CTR,DEPT MED,5841 S MARYLAND AVE,MC 6098,CHICAGO,IL 60637, USA.		Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009					[Anonymous], 1992, ED MED STUDENTS ASSE; ASHFORD M, 1949, TRENDS MED ED; BANE F, 1959, PHYSICIANS GROWING A; BLOOM SW, 1988, J HEALTH SOC BEHAV, V29, P294, DOI 10.2307/2136864; CANTOR JC, 1991, JAMA-J AM MED ASSOC, V265, P1002, DOI 10.1001/jama.265.8.1002; CHRISTAKIS NA, 1995, IMPLICIT PURPOSES PR; Coggeshall LT., 1965, PLANNING MED PROGR E; COPE O, 1966, MED ED RECONSIDERED; DEIRICK JE, 1953, MED SCH US MID CENTU; ENARSON C, 1992, JAMA-J AM MED ASSOC, V268, P1141, DOI 10.1001/jama.268.9.1141; Flexner A., 1910, FLEXNER REPORT; FOX R, 1990, ED COMPETENT HUMAN P, P119; Freidson E., 1988, PROFESSION MED; FRIEDMAN CP, 1983, NMEW BIOL MED ED MER; GASTE B, 1989, CLIN ED DOCTOR TOMOR; GRAHAM R, 1972, HDB CHANGE; HARRIS DL, 1991, REFORM MED ED MED ED; LEVIT EJ, 1973, EVALUATION CONTINUUM; LUDMERER KM, 1985, LEARNING HEAL; MARSTON RQ, 1992, MED ED TRANSITION; MILLIS JS, 1966, GRADUATE ED PHYSICIA; O'Neil EH, 1993, HLTH PROFESSIONS ED; RAPPLEYE WC, 1932, MED ED FINAL REPORT; Shugars DA, 1991, HLTH AM PRACTITIONER; Weiskotten HG, 1940, MED ED US 1934 1939; WHITE KC, 1992, MED SCH MISSION POPU; 1983, MED ED SOC NEEDS PLA; 1992, IMPROVING ACCESS HLT; 1984, PHYSICIANS 21ST CENT; 1970, HIGHER ED NATIONS HL; 1982, FUTURE DIRECTIONS ME	31	115	119	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					706	711		10.1001/jama.274.9.706	http://dx.doi.org/10.1001/jama.274.9.706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650823				2022-12-28	WOS:A1995RR83500016
J	PEACOCK, JL; BLAND, JM; ANDERSON, HR				PEACOCK, JL; BLAND, JM; ANDERSON, HR			PRETERM DELIVERY - EFFECTS OF SOCIOECONOMIC-FACTORS, PSYCHOLOGICAL STRESS, SMOKING, ALCOHOL, AND CAFFEINE	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; PSYCHOSOCIAL STRESS; PREGNANCY; CONSUMPTION; CIGARETTE; LABOR	Objective-To examine the relation between preterm birth and socioeconomic and psychological factors, smoking, and alcohol and caffeine consumption. Design-Prospective study of outcome of pregnancy. Setting-District general hospital in inner London. Participants-1860 consecutive white women booking for delivery; 1513 women studied after exclusion because of multiple pregnancy and diabetes, refusals, and loss to follow up. Measurements-Gestational age was determined from ultrasound and maternal dates; preterm birth was defined as less than 37 completed weeks. Independent variables included smoking, alcohol and caffeine consumption, and a range of indicators of socioeconomic status and psychological stress. Main results-Unifactorial analyses showed that lower social class, less education, single marital status, low income, trouble with ''nerves'' and depression, help from professional agencies, and little contact with neighbours were all significantly associated with an increased risk of preterm birth. There were no apparent effects of smoking, alcohol, or caffeine on the length of gestation overall, although there was an association between smoking and delivery before 32 weeks. Cluster analysis indicated three subgroups of women delivering preterm: two predominantly of low social status and a third of older women with higher social status who did not smoke. Mean gestational age was highest in the third group. Conclusions-Adverse social circumstances are associated with preterm birth but smoking is not, apart from an association with very early births. This runs counter to findings for fetal growth (birth weight for gestational age) in this study, where a strong effect of smoking on fetal growth was observed but there was no evidence for any association with psychosocial factors.			PEACOCK, JL (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Peacock, Janet/0000-0002-0310-2518				ABERNATHY JR, 1966, AM J PUBLIC HEALTH N, V56, P626, DOI 10.2105/AJPH.56.4.626; [Anonymous], 1980, CLASSIFICATION OCCUP; ARBUCKLE RE, 1989, PAEDIATRIC PERINATAL, V3, P115; BAKKETEIG LS, 1981, PRETERM LABOR, P17; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BERENDES H, 1992, P INT COLLABORATIVE, V3; BERKOWITZ GS, 1981, AM J EPIDEMIOL, V113, P81, DOI 10.1093/oxfordjournals.aje.a113068; BERKOWITZ GS, 1983, J PSYCHOM RES, V27, P282; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; Everitt B., 1980, CLUSTER ANAL; FEDRICK J, 1976, BRIT J OBSTET GYNAEC, V83, P342, DOI 10.1111/j.1471-0528.1976.tb00840.x; FORTIER I, 1993, AM J EPIDEMIOL, V137, P931, DOI 10.1093/oxfordjournals.aje.a116763; GARN SM, 1977, EPIDEMIOLOGY PREMATU, P127; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRIFFIN J, 1993, BORN TOO SOON; HARTIKAINENSORR.AL, 1989, OBSTET GYNECOL, V74, P13; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HEDEGAARD M, 1993, BMJ-BRIT MED J, V307, P234, DOI 10.1136/bmj.307.6898.234; MACNAUGHTONSMIT.P, 1965, SOME STATISTICAL OTH; MAIN DM, 1988, CLIN OBSTET GYNECOL, V31, P521, DOI 10.1097/00003081-198809000-00004; MCDONALD AD, 1992, AM J PUBLIC HEALTH, V82, P87, DOI 10.2105/AJPH.82.1.87; McIntosh I D, 1984, Public Health Rev, V12, P29; MEYER LC, 1994, PAEDIATR PERINAT EP, V8, P145, DOI 10.1111/j.1365-3016.1994.tb00445.x; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; MEYER MB, 1977, EPIDEMIOLOGY PREMATU, P81; NEWTON RW, 1979, BRIT MED J, V2, P411, DOI 10.1136/bmj.2.6187.411; PAYKEL ES, 1969, ARCH GEN PSYCHIAT, V21, P753; PEACOCK JL, 1991, J EPIDEMIOL COMMUN H, V45, P159, DOI 10.1136/jech.45.2.159; PEACOCK JL, 1991, INT J EPIDEMIOL, V20, P405, DOI 10.1093/ije/20.2.405; PICKERING RM, 1991, INT J EPIDEMIOL, V20, P456, DOI 10.1093/ije/20.2.456; ROBERTS WE, 1990, OBSTET GYNECOL, V76, pS85; Rose G., 1992, STRATEGY PREVENTIVE; RUTTER DR, 1990, SOC SCI MED, V30, P553, DOI 10.1016/0277-9536(90)90154-K; STEIN A, 1987, BRIT MED J, V295, P291, DOI 10.1136/bmj.295.6593.291; 1985, SAS USERS GUIDE	35	234	241	0	30	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					531	535		10.1136/bmj.311.7004.531	http://dx.doi.org/10.1136/bmj.311.7004.531			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663207	Green Published			2022-12-28	WOS:A1995RR73700015
J	ZHOU, W; REINES, D; DOETSCH, PW				ZHOU, W; REINES, D; DOETSCH, PW			T7 RNA-POLYMERASE BYPASS OF LARGE GAPS ON THE TEMPLATE STRAND REVEALS A CRITICAL ROLE OF THE NONTEMPLATE STRAND IN ELONGATION	CELL			English	Article							TRANSCRIPTION TERMINATION; DNA; SEQUENCE; ELEMENTS; INVITRO	We show that T7 RNA polymerase can efficiently transcribe DNA containing gaps from one to five bases in the template strand. Surprisingly, broken template strands missing up to 24 bases can still be transcribed, although at reduced efficiency. The resulting transcripts contain the full template sequence with the RNA deleted for the gapped region missing on the template strand. These findings indicate that the end of a downstream template strand can be brought into the polymerase and transcribed as ii it were a part of an intact polynucleotide chain by utilizing the unpaired nontemplate strand. This, as well as transcription of an intact template strand, relies heavily upon the nontemplate strand, suggesting that a duplex DNA-binding site on the leading edge of RNA polymerase is required for RNA chain elongation on DNA templates. This work contributes substantially to the emerging picture that the nontemplate strand is an important element of the transcription elongation complex.	EMORY UNIV,SCH MED,DIV BIOL & BIOMED SCI,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,ATLANTA,GA 30322	Emory University; Emory University	ZHOU, W (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322, USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL CANCER INSTITUTE [R01CA055896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NCI NIH HHS [CA55896] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331, GM46311] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLIN M, 1964, J MOL BIOL, V8, P297, DOI 10.1016/S0022-2836(64)80139-X; Chamberlin M., 1982, ENZYMES, V15, P87; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JENG ST, 1990, J BIOL CHEM, V265, P3823; JENG ST, 1992, J BIOL CHEM, V267, P19306; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORRIS CE, 1986, RNA POLYM REGULATION, P47; OAKLEY JL, 1977, P NATL ACAD SCI USA, V74, P4266, DOI 10.1073/pnas.74.10.4266; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; ROSA MD, 1979, CELL, V16, P815, DOI 10.1016/0092-8674(79)90097-7; RYAN T, 1987, J BIOL CHEM, V258, P4690; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SAUCIER JM, 1972, NATURE-NEW BIOL, V239, P167, DOI 10.1038/newbio239167a0; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHI YB, 1988, J BIOL CHEM, V263, P527; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZHOU W, 1994, BIOCHEMISTRY-US, V33, P14926, DOI 10.1021/bi00253a032	28	48	49	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					577	585		10.1016/0092-8674(95)90030-6	http://dx.doi.org/10.1016/0092-8674(95)90030-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664337	Green Accepted, Bronze			2022-12-28	WOS:A1995RR73400009
J	VEEKEN, H				VEEKEN, H			FRENCH-POLYNESIA - A NUCLEAR PARADISE IN THE PACIFIC	BRITISH MEDICAL JOURNAL			English	Article											VEEKEN, H (corresponding author), MED SANS FRONTIERES NETHERLANDS,POB 10014,1001 EA AMSTERDAM,NETHERLANDS.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					497	499		10.1136/bmj.311.7003.497	http://dx.doi.org/10.1136/bmj.311.7003.497			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647649	Green Published			2022-12-28	WOS:A1995RQ67000020
J	GARG, R; YUSUF, S				GARG, R; YUSUF, S			OVERVIEW OF RANDOMIZED TRIALS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS ON MORTALITY AND MORBIDITY IN PATIENTS WITH HEART-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; LONG-TERM; EXERCISE PERFORMANCE; ENALAPRIL; LISINOPRIL; TOLERANCE; THERAPY	Objective.-To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitors on mortality and morbidity in patients with symptomatic congestive heart failure. Data Sources and Study Selection.-Data were obtained for all completed, published or unpublished, randomized, placebo-controlled trials of ACE inhibitors that were at least 8 weeks in duration and had determined total mortality by intention to treat, regardless of sample size. Trials were identified based on literature review and correspondence with investigators and pharmaceutical firms. Data Extraction.-Using standard tables, data were extracted by one author and confirmed where necessary by the other author or the principal investigator of the trial, Unpublished data were obtained by direct correspondence with the principal investigator of each study or pharmaceutical firm. Data Synthesis.-The data for each outcome were combined using the Yusuf-Peto adaptation of the Mantel-Haenszel method. Overall, there was a statistically significant reduction in total mortality (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.67 to 0.88; P<.001) and in the combined endpoint of mortality or hospitalization for congestive heart failure (OR, 0.65; 95% CI, 0.57 to 0.74; P<.001). Similar benefits were observed with several different ACE inhibitors, although the data were largely based on enalapril maleate, captopril, ramipril, quinapril hydrochloride, and lisinopril. Reductions for total mortality and the combined endpoint were similar for various subgroups examined (age, sex, etiology, and New York Heart Association class). However, patients with the lowest ejection fraction appeared to have the greatest benefit. The greatest effect was seen during the first 3 months, but additional benefit was observed during further treatment. The reduction in mortality was primarily due to fewer deaths from progressive heart failure (OR, 0.69; 95% CI, 0.58 to 0.83); point estimates for effects on sudden or presumed arrhythmic deaths (OR, 0.91; 95% CI, 0.73 to 1.12) and fatal myocardial infarction (OR, 0.82; 95% CI, 0.60 to 1.11) were less than 1 but were not significant. Conclusions.-Total mortality and hospitalization for congestive heart failure are significantly reduced by ACE inhibitors with consistent effects in a broad range of patients.	MCMASTER UNIV, HAMILTON GEN HOSP, DIV CARDIOL, HAMILTON, ON, CANADA	McMaster University	GARG, R (corresponding author), NHLBI, CLIN TRIALS BRANCH, FED BLDG, ROOM 5C10, BETHESDA, MD 20892 USA.		Jennings, Garry/B-3914-2009	Yusuf, Salim/0000-0003-4776-5601				[Anonymous], 1988, NEW ENGL J MED, V319, P1681; BARABINO A, 1991, CARDIOLOGY, V78, P243, DOI 10.1159/000174791; BUSSMANN WD, 1987, J CARDIOVASC PHARM, V9, pS50, DOI 10.1097/00005344-198700002-00012; CHALMERS JP, 1987, J CARDIOVASC PHARM, V9, pS89, DOI 10.1097/00005344-198700003-00021; CHRYSANT SG, 1985, CLIN CARDIOL, V8, P585, DOI 10.1002/clc.4960081107; CLELAND JGF, 1985, BRIT HEART J, V54, P305; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; COLFER HT, 1992, AM J CARDIOL, V70, P354, DOI 10.1016/0002-9149(92)90618-9; CREAGER MA, 1985, J AM COLL CARDIOL, V6, P163, DOI 10.1016/S0735-1097(85)80269-2; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKSTEIN K, 1991, J AM COLL CARDIOL, V18, P596, DOI 10.1016/0735-1097(91)90619-K; DREXLER H, 1989, CIRCULATION, V79, P491, DOI 10.1161/01.CIR.79.3.491; FRANCIOSA JA, 1985, J AM COLL CARDIOL, V5, P101, DOI 10.1016/S0735-1097(85)80090-5; GILBERT EM, 1993, CIRCULATION, V88, P472, DOI 10.1161/01.CIR.88.2.472; GILES TD, 1990, CIRCULATION, V82, P323; GILES TD, 1989, J HUM HYPERTENS, V3, P83; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; GORDON M, 1991, UNPUB EVALUATION EFF; HELD PH, 1991, TXB INTERVENTIONAL C, P49; JENNINGS G, 1984, MED J AUSTRALIA, V141, P723; JOY M, 1987, INT J CARDIOL, V16, P137, DOI 10.1016/0167-5273(87)90244-0; KLEBER FX, 1992, BRIT HEART J, V67, P289; KRAMER BL, 1983, CIRCULATION, V67, P807, DOI 10.1161/01.CIR.67.4.807; LECHAT P, 1993, AM HEART J, V126, P798, DOI 10.1016/0002-8703(93)90933-Z; LEMARIE JC, 1992, UNPUB MULTICENTER DO; LEWIS GR, 1989, AM J CARDIOL, V63, pD12, DOI 10.1016/0002-9149(89)90411-6; LEWIS GRJ, 1988, AM J MED, V85, P48, DOI 10.1016/0002-9343(88)90351-8; MAASS L, 1991, UNPUB EVALUATION EFF; MAASS L, 1991, UNPUB EFFICACY SAFET; MAASS L, 1991, UNPUB DOUBLE BLIND C; MAGNANI B, 1986, POSTGRAD MED J, V62, P153; MAGNANI B, 1990, SCIC SOPRAVIVENZA CO; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCGARRY R, 1991, UNPUB RANDOMIZED DOU; MCGRATH BP, 1985, BRIT HEART J, V54, P405; MCGRATH BP, 1986, EUR J CLIN PHARMACOL, V30, P485, DOI 10.1007/BF00607965; Newman T J, 1988, Am J Med, V84, P140, DOI 10.1016/0002-9343(88)90221-5; NIITANI H, 1992, RINSHIOYAKU, V8, P1273; NORTHRIDGE D B, 1991, European Heart Journal, V12, P184; REMES J, 1986, ANN CLIN RES, V18, P124; RIEGGER GAJ, 1990, J CARDIOVASC PHARM, V15, pS41, DOI 10.1097/00005344-199000152-00008; RUCINSKA EJ, 1991, UNPUB ENALAPRIL VS P; RUCINSKA EJ, 1991, UNPUB DOUBLE BLIND P; RUCINSKA EJ, UNPUB LISINOPRIL 1ST; SHARPE DN, 1984, CIRCULATION, V70, P271, DOI 10.1161/01.CIR.70.2.271; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWEDBERG K, 1991, CIRCULATION, V57, P226; UPRICHARD A, 1994, 90663 PARK PHARM RES; UPRICHARD A, 1994, 906226 PARK PHARM RE; UPRICHARD A, 1994, 906276 PARK PHARM RE; WEBSTER MWI, 1985, DRUGS, V30, P74, DOI 10.2165/00003495-198500301-00011; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZWEHL W, 1990, FOCUS CLIN EFFECTS L, P31; 1987, HEART FAILURE, V3, P102	55	1450	1496	6	64	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1450	1456		10.1001/jama.273.18.1450	http://dx.doi.org/10.1001/jama.273.18.1450			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7654275				2022-12-28	WOS:A1995QW27900034
J	ROZMAN, C; MONTSERRAT, E				ROZMAN, C; MONTSERRAT, E			CURRENT CONCEPTS - CHRONIC LYMPHOCYTIC-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MULTIVARIATE SURVIVAL ANALYSIS; FLUDARABINE; PREDNISONE; PROGNOSIS; GENE; CLASSIFICATION; EXPRESSION; CANCER; TRIAL				ROZMAN, C (corresponding author), UNIV BARCELONA, HOSP CLIN, POSTGRAD SCH HEMATOL FARRERAS VALENTI, DEPT MED, VILLARROEL 170, E-08036 BARCELONA, SPAIN.							ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; ANAISSIE E, 1992, ANN INTERN MED, V117, P466, DOI 10.7326/0003-4819-117-6-466; BARTLETTPANDITE L, 1994, BLOOD, V84, pA536; BINET JL, 1990, BLOOD, V75, P1414; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; BUNCH C, 1988, NEW ENGL J MED, V319, P902; CALIGARISCAPPIO F, 1993, BLOOD CELLS, V19, P601; CATOVSKY D, 1989, BRIT J HAEMATOL, V72, P141, DOI 10.1111/j.1365-2141.1989.tb07674.x; CATOVSKY D, 1991, LEUKEMIA LYMPHOMA, V5, P105, DOI 10.3109/10428199109103389; CHAPEL H, 1994, BRIT J HAEMATOL, V88, P209, DOI 10.1111/j.1365-2141.1994.tb05002.x; CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; CHIKKAPPA G, 1992, AM J HEMATOL, V41, P5, DOI 10.1002/ajh.2830410103; DELANNOY A, 1995, LEUKEMIA, V9, P1130; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; ELROUBY S, 1993, BLOOD, V82, P3452; FINCH SC, 1992, BAILLIERE CLIN HAEM, V5, P27, DOI 10.1016/S0950-3536(11)80034-X; GAIDANO G, 1994, AM J PATHOL, V144, P1312; GALE RP, 1994, LEUKEMIA, V8, P1610; HANADA M, 1993, BLOOD, V82, P1820; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; HIDDEMANN W, 1993, BLOOD, V82, pA199; HO AD, 1990, J NATL CANCER I, V82, P1416, DOI 10.1093/jnci/82.17.1416; HOFFBRAND AV, 1993, SEMIN HEMATOL, V30, P306; HOLLANDER AAMJ, 1991, ANN HEMATOL, V62, P32, DOI 10.1007/BF01714981; JULIUSSON G, 1993, BAILLIERE CLIN HAEM, V6, P821, DOI 10.1016/S0950-3536(05)80178-7; JURLANDER J, 1994, EUR J HAEMATOL, V53, P114; KEATING MJ, 1993, BLOOD, V81, P2878; KHOURI IF, 1994, J CLIN ONCOL, V12, P748, DOI 10.1200/JCO.1994.12.4.748; LENORMAND B, 1994, LEUKEMIA, V8, P1019; MATOLCSY A, 1994, BLOOD, V83, P1363, DOI 10.1182/blood.V83.5.1363.bloodjournal8351363; MATUTES E, 1994, LEUKEMIA, V8, P1640; MICHALLET M, 1995, BONE MARROW TRANS S2, V15, pS11; MOLICA S, 1994, LEUKEMIA LYMPHOMA, V13, P203, DOI 10.3109/10428199409056283; MONTSERRAT E, 1989, ANN INTERN MED, V110, P236; MONTSERRAT E, 1988, NOUV REV FR HEMATOL, V30, P359; MONTSERRAT E, 1986, BRIT J HAEMATOL, V62, P567, DOI 10.1111/j.1365-2141.1986.tb02969.x; MONTSERRAT E, 1995, ANN ONCOL, V6, P219, DOI 10.1093/oxfordjournals.annonc.a059151; MONTSERRAT E, 1991, EUR J CANCER, V27, pS74, DOI 10.1016/0277-5379(91)90580-7; PANGALIS GA, 1995, BRIT J HAEMATOL, V89, P627, DOI 10.1111/j.1365-2141.1995.tb08374.x; PENG BH, 1995, LEUKEMIA RES, V19, P159, DOI 10.1016/0145-2126(94)00129-X; PETERSON LC, 1993, P AN M AM SOC CLIN, V12, P313; QUE TH, 1993, BLOOD, V82, P571; RABINOWE SN, 1993, BLOOD, V82, P1366; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; ROBERTSON LE, 1993, J CLIN ONCOL, V11, P1985, DOI 10.1200/JCO.1993.11.10.1985; ROBERTSON LE, 1992, BLOOD, V80, P29; ROZMAN C, 1984, BLOOD, V64, P642; ROZMAN C, 1982, BLOOD, V59, P1001; SAVEN A, 1995, J CLIN ONCOL, V13, P570, DOI 10.1200/JCO.1995.13.3.570; SCHROEDER HW, 1994, IMMUNOL TODAY, V15, P288, DOI 10.1016/0167-5699(94)90009-4; STHOEGER ZM, 1993, AM J HEMATOL, V43, P259, DOI 10.1002/ajh.2830430406; VANKRIEKEN JHJM, 1990, LEUKEMIA, V4, P811; WALLNER J, 1994, LEUKEMIA LYMPHOMA, V13, P333, DOI 10.3109/10428199409056298; ZOMAS A, 1994, BONE MARROW TRANSPL, V14, P799; 1994, BLOOD S1, V84, pA461; 1991, LEUK LYMPHOMA S, V5, P89	59	645	685	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1052	1057		10.1056/NEJM199510193331606	http://dx.doi.org/10.1056/NEJM199510193331606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675049				2022-12-28	WOS:A1995RZ34000006
J	FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M				FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M			DO-NOT-RESUSCITATE ORDERS AT A TEACHING HOSPITAL IN JAPAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CARDIOPULMONARY RESUSCITATION; POLICY; CHOICE; STILL				FUKAURA, A (corresponding author), SHOWA UNIV,SCH MED,TOKYO 142,JAPAN.							[Anonymous], 1990, CRIT CARE MED, V18, P1435; Arai T, 1994, Masui, V43, P600; ARAI T, 1994, ICU CCU, V18, P657; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BERLOWITZ DR, 1991, J AM GERIATR SOC, V39, P472, DOI 10.1111/j.1532-5415.1991.tb02492.x; BROWN BW, 1977, STATISTICS BIOMEDICA; Fukaura Asato, 1994, Journal of Japan Society for Cancer Therapy, V29, P1696; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; MILES SH, 1982, ANN INTERN MED, V96, P660, DOI 10.7326/0003-4819-96-5-660; Murakami K, 1986, Gan To Kagaku Ryoho, V13, P2693; Murakami K, 1989, Gan To Kagaku Ryoho, V16, P740; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Sato Ikuyo, 1994, Journal of Japan Society for Cancer Therapy, V29, P1677; SCHWARTZ DA, 1986, J AM GERIATR SOC, V34, P807, DOI 10.1111/j.1532-5415.1986.tb03986.x; SHAPIRO GR, 1991, PROG P AM SOC CLIN O, V10, P325; STANLEY DP, 1989, MED J AUSTRALIA, V151, P257, DOI 10.5694/j.1326-5377.1989.tb101190.x; STANLEY DP, 1989, MED J AUSTRALIA, V151, P260; STERN SG, 1992, CRIT CARE MED, V20, P1263, DOI 10.1097/00003246-199209000-00013; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; TAZAWA H, 1990, Journal of Japan Society for Cancer Therapy, V25, P1448; TAZAWA H, 1986, Journal of Japan Society for Cancer Therapy, V21, P2454; Teshima H, 1987, Nihon Kyobu Shikkan Gakkai Zasshi, V25, P305; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; VANDELDEN JJM, 1993, J MED ETHICS, V19, P200, DOI 10.1136/jme.19.4.200; WITTE KL, 1984, HEART LUNG, V13, P159; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1989, J MED ETHICS, V15, P129; 1995, ASSAHI SHIMBUN  0328, P3; 1991, PUBLIC OPINION POLL, V23, P46; 1992, NIHON ISIKAI ZASSI, V107, P1209; 1974, JAMA-J AM MED ASSOC, V227, P864	34	27	28	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					805	808		10.1056/NEJM199509213331218	http://dx.doi.org/10.1056/NEJM199509213331218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU809	7643902				2022-12-28	WOS:A1995RU80900028
J	HYMAN, SE; DELBANCO, TL				HYMAN, SE; DELBANCO, TL			A MAN WITH ALCOHOLISM AND HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							DOPAMINE-D2 RECEPTOR GENE; ASSOCIATION; ETHANOL; NEURONS; ADDICTION; ABUSE; RAT		HARVARD UNIV, SCH MED, BOSTON, MA USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital					NIDA NIH HHS [DA07134, DA00257] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; DELBANCO TL, 1992, JAMA-J AM MED ASSOC, V267, P702, DOI 10.1001/jama.267.5.702; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GESSA GL, 1985, BRAIN RES, V348, P201, DOI 10.1016/0006-8993(85)90381-6; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; GOODWIN DW, 1974, ARCH GEN PSYCHIAT, V31, P164; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HYMAN SE, 1993, CURR OPIN NEUROL NEU, V6, P609; HYMAN SE, 1993, MOL F PSYCHIATRY; HYMAN SE, 1993, SCI AM MED, V13, P1; JOHNSON SW, 1992, J NEUROSCI, V12, P483; KOOB GF, 1993, BIOL BASIS SUBSTANCE, P339; LITT MD, 1992, ARCH GEN PSYCHIAT, V49, P609; MEREU G, 1984, BRAIN RES, V292, P63, DOI 10.1016/0006-8993(84)90890-4; MORSE RM, 1992, JAMA-J AM MED ASSOC, V268, P1012, DOI 10.1001/jama.268.8.1012; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; Phillips AG, 1986, HDB PHYSL NERVOUS SY, P647; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; SUZDAK PD, 1986, SCIENCE, V234, P1243, DOI 10.1126/science.3022383; Vaillant G.E., 1995, WISDOM EGO; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WALSH DC, 1992, JAMA-J AM MED ASSOC, V267, P663, DOI 10.1001/jama.267.5.663; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250; 1990, BROADENING BASE TREA	34	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					837	843		10.1001/jama.274.10.837	http://dx.doi.org/10.1001/jama.274.10.837			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650809				2022-12-28	WOS:A1995RU32400033
J	OLDACH, D				OLDACH, D			ANTIBIOTIC-PROPHYLAXIS FOR NECROTIZING PANCREATITIS	LANCET			English	Editorial Material							NECROTIZING PANCREATITIS; MANAGEMENT				OLDACH, D (corresponding author), UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201, USA.			Oldach, David/0000-0002-8811-2562				BEGER HG, 1989, SURG CLIN N AM, V69, P529; BRADLEY EL, 1989, AM J SURG, V158, P472, DOI 10.1016/0002-9610(89)90290-0; FINCH WT, 1976, ANN SURG, V183, P667, DOI 10.1097/00000658-197606000-00008; HOWES R, 1975, J SURG RES, V18, P197, DOI 10.1016/0022-4804(75)90016-5; KIVILAAKSO E, 1984, ANN SURG, V199, P426, DOI 10.1097/00000658-198404000-00009; KIVISAARI L, 1984, GASTROINTEST RADIOL, V9, P27, DOI 10.1007/BF01887796; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; RANSON JHC, 1974, SURG GYNECOL OBSTET, V139, P69; SCHOLMERICH J, 1993, HEPATO-GASTROENTEROL, V40, P531; 1994, NEW ENGL J MED, V330, P1247	10	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					652	652		10.1016/S0140-6736(95)92273-3	http://dx.doi.org/10.1016/S0140-6736(95)92273-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658813				2022-12-28	WOS:A1995RU04800002
J	POLLOCK, AM				POLLOCK, AM			THE NHS GOES PRIVATE	LANCET			English	Editorial Material											POLLOCK, AM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			pollock, allyson/0000-0002-7388-3110				CORRY D, 1995, RENEWAL, V3, P41; POLLOCK AM, 1995, BRIT MED J, V310, P1580, DOI 10.1136/bmj.310.6994.1580; WILLETS D, 1993, OPPORTUNITIES PRIVAT; 1995, PRIVATE FINANCE NHS; 1995, PRIVATE FINANCE CAPI; 1995, PUBLIC POLICY REV, V2, P45; 1995, TAKARE PLC INTERIM R	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					683	684		10.1016/S0140-6736(95)92286-5	http://dx.doi.org/10.1016/S0140-6736(95)92286-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658824				2022-12-28	WOS:A1995RU04800015
J	MCGUIRE, PK; SILBERSWEIG, DA; WRIGHT, I; MURRAY, RM; DAVID, AS; FRACKOWIAK, RSJ; FRITH, CD				MCGUIRE, PK; SILBERSWEIG, DA; WRIGHT, I; MURRAY, RM; DAVID, AS; FRACKOWIAK, RSJ; FRITH, CD			ABNORMAL MONITORING OF INNER SPEECH - A PHYSIOLOGICAL-BASIS FOR AUDITORY HALLUCINATIONS	LANCET			English	Article							CEREBRAL BLOOD-FLOW; PET IMAGES; SCHIZOPHRENIA; AREA	Auditory verbal hallucinations (''voices'') are thought to arise from a disorder of inner speech (thinking in words). We examined the neural correlates of tasks which involve inner speech in subjects with schizophrenia who hear voices (hallucinators), subjects with schizophrenia who do not (nonhallucinators), and normal controls. There were no differences between hallucinators and controls in regional cerebral blood flow during thinking in sentences. However, when imagining sentences being spoken in another person's voice-which entails both the generation and monitoring of inner speech-hallucinators had a normal left frontal response, but reduced activation in the left middle temporal gyrus and the rostral supplementary motor area, regions which were activated by both normal subjects and nonhallucinators (p<0.001). These findings suggest that a predisposition to verbal hallucinations is associated with a failure to activate areas concerned with the monitoring of inner speech.	HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, WELLCOME DEPT COGNIT NEUROL, LONDON W12 0HS, ENGLAND; CORNELL MED CTR, DEPT PSYCHIAT, NEW YORK, NY USA; CORNELL MED CTR, DEPT NEUROL, NEW YORK, NY USA	Imperial College London; University of London; University College London; Cornell University; Cornell University	MCGUIRE, PK (corresponding author), INST PSYCHIAT, DEPT PSYCHOL MED, LONDON SE5 8AF, ENGLAND.		David, Anthony S/C-1315-2011; Frackowiak, Richard/H-4383-2011; Frith, Chris D/A-2171-2009; Murray, Robin M/F-8658-2012; ellison-wright, ian/T-1246-2019; Frackowiak, Richard S/I-1809-2013; David, Anthony/O-1750-2019	David, Anthony S/0000-0003-0967-774X; Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; Murray, Robin M/0000-0003-0829-0519; David, Anthony/0000-0003-0967-774X; McGuire, Philip/0000-0003-4381-0532	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREASEN NC, 1986, COMPREHENSIVE ASSESS; BAILEY DL, 1991, J CEREB BLOOD FLO S2, V11, pS150; BENTALL RP, 1985, BRIT J CLIN PSYCHOL, V24, P159, DOI 10.1111/j.2044-8260.1985.tb01331.x; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P475; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; FIRSTON KJ, IN PRESS BIOL SCHIZO; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRITH CD, 1988, BRIT J PSYCHIAT, V153, P437, DOI 10.1192/bjp.153.4.437; GASQUOINE PG, 1993, J CLIN EXP NEUROPSYC, V15, P653, DOI 10.1080/01688639308402587; GOLDBERG G, 1985, BEHAV BRAIN SCI, V8, P567, DOI 10.1017/S0140525X00045167; GRASBY P, 1994, SCHIZOPHR RES, V11, P170; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; LIST SJ, 1993, BRIT J PSYCHIAT, V22, P25; LUPPINO G, 1993, J COMP NEUROL, V338, P114, DOI 10.1002/cne.903380109; McGuire PK, 1991, CEREB CORTEX, V1, P390, DOI 10.1093/cercor/1.5.390; MCGUIRE PK, 1993, LANCET, V342, P703, DOI 10.1016/0140-6736(93)91707-S; MCGUIRE PK, IN PRESS PSYCHOL MED; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; MULLERPREUSS P, 1980, BRAIN RES, V202, P307, DOI 10.1016/0006-8993(80)90143-2; NAYANI A, IN PRESS PSYCHOL MED; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; PANDYA D, 1985, CEREBRAL CORTEX, V4; PASSINGHAM RE, 1989, SUPPLEMENTARY MOTOR; PRICE CJ, 1994, BRAIN, V117, P1255, DOI 10.1093/brain/117.6.1255; SILBERSWEIG DA, 1993, J CEREBR BLOOD F MET, V13, P617, DOI 10.1038/jcbfm.1993.80; SMITH JD, 1992, AUDITORY IMAGERY; Talairach J., 1988, COPLANAR STEREOTAXIC; WOLF SS, 1993, CURR OPIN NEUROL NEU, V6, P86; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	31	261	267	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					596	600		10.1016/S0140-6736(95)91435-8	http://dx.doi.org/10.1016/S0140-6736(95)91435-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RT188	7651003				2022-12-28	WOS:A1995RT18800008
J	EVERITT, BS				EVERITT, BS			CLASSIFICATION AND CLUSTER-ANALYSIS - COMMENTARY	BRITISH MEDICAL JOURNAL			English	Note											EVERITT, BS (corresponding author), INST PSYCHIAT,LONDON SE5 8AL,ENGLAND.							Everitt B. S., 1993, CLUSTER ANAL; PAYKEL ES, 1978, BRIT J PSYCHIAT, V133, P45, DOI 10.1192/bjp.133.1.45	2	21	22	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					535	536		10.1136/bmj.311.7004.535	http://dx.doi.org/10.1136/bmj.311.7004.535			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663208	Green Published			2022-12-28	WOS:A1995RR73700016
J	SUMMERFIELD, D				SUMMERFIELD, D			RAISING THE DEAD - WAR, REPARATION, AND THE POLITICS OF MEMORY	BRITISH MEDICAL JOURNAL			English	Article								All societies attach a different range of meanings to war than to natural disasters, and questions of societal recognition, reparation, and justice are generally central. Most modern conflict has been grounded in the use of terror to control and silence whole populations. Those abusing power typically refuse to acknowledge their dead victims, as if they had never existed and were mere wraiths in the memories of those left behind. This denial, and the impunity of those who maintain it, must be challenged if survivors are to make sense of their losses and the social fabric is to mend. For the names and fate of the dead to be properly lodged in the public record of their times also illuminates the costs that may flow from the philosophies and practices of the Western led world order, ones which health workers should be in a position to influence.			SUMMERFIELD, D (corresponding author), MED FDN CARE VICTIMS TORTURE,LONDON NW5 3EJ,ENGLAND.							HARRISON MR, 1990, J AM SOC ECHOCARDIOG, V3, P228; LYKES MB, 1994, SOC SCI MED, V38, P543, DOI 10.1016/0277-9536(94)90250-X; Summerfield D, 1991, Med War, V7, P84, DOI 10.1080/07488009108408972	3	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					495	497		10.1136/bmj.311.7003.495	http://dx.doi.org/10.1136/bmj.311.7003.495			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RQ670	7647648	Green Published			2022-12-28	WOS:A1995RQ67000019
J	HAY, J				HAY, J			COMPLICATIONS AT SITE OF INJECTION OF DEPOT NEUROLEPTICS	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT PSYCHIAT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BELANGERANNABLE MC, 1985, CANADIAN NURSE, V81, P1; FOSTER P, 1989, PHARM J, V243, P431; HAMANN GL, 1990, J CLIN PSYCHIAT, V51, P502; SVENDSEN O, 1989, STUDIES TISSUE INJUR; WRIGHT NF, 1990, PSYCHIATRIC B, V14, P594	5	38	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					421	421		10.1136/bmj.311.7002.421	http://dx.doi.org/10.1136/bmj.311.7002.421			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640587	Green Published			2022-12-28	WOS:A1995RP55400014
J	SIDDIQUE, AK; SALAM, A; ISLAM, MS; AKRAM, K; MAJUMDAR, RN; ZAMAN, K; FRONCZAK, N; LASTON, S				SIDDIQUE, AK; SALAM, A; ISLAM, MS; AKRAM, K; MAJUMDAR, RN; ZAMAN, K; FRONCZAK, N; LASTON, S			WHY TREATMENT CENTERS FAILED TO PREVENT CHOLERA DEATHS AMONG RWANDAN REFUGEES IN GOMA, ZAIRE	LANCET			English	Article							BANGLADESH; EPIDEMIC	In July, 1994, in one of the worst cholera outbreaks in recent times, an estimated 12 000 Rwandan refugees died in Goma in eastern Zaire, The Vibrio cholerae strains were resistant to tetracycline and doxycycline, the commonly used drugs for cholera treatment. Despite the efforts of international organisations, which provided medical relief by establishing treatment centres in Goma, mortality from the disease was much higher than expected. In the area of Muganga camp, which had the largest concentration of refugees and where most of the medical aid organisations were active, the highest reported case-fatality ratio for a single day was 48%. The slow rate of rehydration, inadequate use of oral rehydration therapy, use of inappropriate intravenous fluids, and inadequate experience of health workers in management of severe cholera are thought to be some of the factors associated with the failure to prevent so many deaths during the epidemic. In one of the temporary treatment centres with the worst case-fatality record, our team showed that improvement of these factors could increase the odds of survival of cholera patients even in a disaster setting.	INT CTR DIARRHOEAL DIS RES, DIV CLIN SCI, DHAKA 1000, BANGLADESH; INT CTR DIARRHOEAL DIS RES, DIV SCI LAB, DHAKA 1000, BANGLADESH; INT CTR DIARRHOEAL DIS RES, DIV FAMILY PLANNING & POPULAT, DHAKA 1000, BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)	SIDDIQUE, AK (corresponding author), INT CTR DIARRHOEAL DIS RES, DIV COMMUNITY HLTH, GPO BOX 128, DHAKA 1000, BANGLADESH.		Salam, Abdul/GWC-1029-2022					BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; PIERCE NF, 1969, ANN INTERN MED, V70, P1173, DOI 10.7326/0003-4819-70-6-1173; SACK R B, 1970, Bulletin of the World Health Organization, V43, P351; SIDDIQUE AK, 1990, TROP DOCT, V20, P83, DOI 10.1177/004947559002000215; SIDDIQUE AK, 1989, TROP GEOGR MED, V41, P377; SIDDIQUE AK, 1992, J DIARRHOEAL DIS RES, V10, P79; SIDDIQUE AK, 1991, J DIARRHOEAL DIS RES, V9, P310; 1987, MANUAL LABORATORY IN; 1992, WEEKLY EPIDEMIOL REC, V67, P253	9	122	124	3	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	1995	345	8946					359	361		10.1016/S0140-6736(95)90344-5	http://dx.doi.org/10.1016/S0140-6736(95)90344-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7646639				2022-12-28	WOS:A1995QF72200012
J	KUBESCH, P; DORK, T; WULBRAND, U; KALIN, N; NEUMANN, T; WULF, B; GEERLINGS, H; WEISSBRODT, H; VONDERHARDT, H; TUMMLER, B				KUBESCH, P; DORK, T; WULBRAND, U; KALIN, N; NEUMANN, T; WULF, B; GEERLINGS, H; WEISSBRODT, H; VONDERHARDT, H; TUMMLER, B			GENETIC-DETERMINANTS OF AIRWAYS COLONIZATION WITH PSEUDOMONAS-AERUGINOSA IN CYSTIC-FIBROSIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; DELTA-F508 MUTATION; DNA; IDENTIFICATION; PATHOGENESIS; DISEASE	Exocrine pancreatic insufficiency and lung infection with Pseudomonas aeruginosa are major features of cystic fibrosis (CF). This monogenic disease is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. 267 children and adolescents with CF who were regularly seen at the same centre were assessed for an association of the CFTR mutation genotype with exocrine pancreatic function and the age of onset of chronic colonisation with P aeruginosa. The major mutation DELTAF508 accounted for 74% of CF alleles; 33 further CFTR mutations had been detected on the CF chromosomes of the study population by June, 1992. With the exception of DELTAF508/R347P compound heterozygotes, patients of the same mutation genotype were either pancreas insufficient (PI) or pancreas sufficient (PS). The age-specific colonisation rates with P aeruginosa were significantly lower in PS than in PI patients. The missense and splice site mutations that are ''mild'' CF alleles with respect to exocrine pancreatic function were also ''low risk'' alleles for the acquisition of P aeruginosa. On the other hand, the proportion of P aeruginosa-positive patients increased most rapidly in the PI DELTAF508 compound heterozygotes who were carrying a termination mutation in the nucleotide binding fold-encoding exons. Pancreatic status and the risk of chronic airways' colonisation with P aeruginosa are predisposed by the CFTR mutation genotype and can be differentiated by the type and location of the mutations in the CFTR gene.	HANNOVER MED SCH, DEPT BIOPHYS CHEM,BIOPHYS CHEM ABT, ZENTRUM BIOCHEM 2,KONSTANTY GUTSCHOW STR 8, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT PAEDIAT RESP DIS, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT BIOMETRY, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT MED MICROBIOL, W-3000 HANNOVER 61, GERMANY	Hannover Medical School; Hannover Medical School; Hannover Medical School; Hannover Medical School			Dörk, Thilo/J-8620-2012	Dörk, Thilo/0000-0002-9458-0282				BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650, DOI 10.1164/ajrccm/140.6.1650; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; CLAUSTRES M, 1992, GENOMICS, V13, P907, DOI 10.1016/0888-7543(92)90187-W; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DORK T, 1992, HUM GENET, V88, P417, DOI 10.1007/BF00215676; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; GEOKAS MC, 1979, AM J PHYSIOL, V236, pE77, DOI 10.1152/ajpendo.1979.236.1.E77; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HOIBY N, 1989, ACTA PAEDIATR SCAND, V78, P395, DOI 10.1111/j.1651-2227.1989.tb11099.x; HOIBY N, 1986, ANNU REV MICROBIOL, V40, P29, DOI 10.1146/annurev.mi.40.100186.000333; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; Suter S, 1989, Antibiot Chemother (1971), V42, P158; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; Tsui L C, 1991, Adv Hum Genet, V20, P153; TUMMLER B, 1991, J CLIN MICROBIOL, V29, P1265; VANDEKAMER JH, 1949, J BIOL CHEM, V177, P347; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	31	83	83	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					189	193		10.1016/0140-6736(93)90062-L	http://dx.doi.org/10.1016/0140-6736(93)90062-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	7678316				2022-12-28	WOS:A1993KJ21900001
J	TOWNSEND, SE; ALLISON, JP				TOWNSEND, SE; ALLISON, JP			TUMOR REJECTION AFTER DIRECT COSTIMULATION OF CD8+ T-CELLS BY B7-TRANSFECTED MELANOMA-CELLS	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-I; ACTIVATION ANTIGEN-B7; INTERLEUKIN-2; GENERATION; PROLIFERATION; RECOGNITION; EXPRESSION; RESPONSES; PEPTIDES	A variety of tumors are potentially immunogenic but do not stimulate an effective anti-tumor immune response in vivo. Tumors may be capable of delivering antigen-specific signals to T cells, but may not deliver the costimulatory signals necessary for full activation of T cells. Expression of the costimulatory ligand B7 on melanoma cells was found to induce the rejection of a murine melanoma in vivo. This rejection was mediated by CD8+ T cells; CD4+ T cells were not required. These results suggest that B7 expression renders tumor cells capable of effective antigen presentation, leading to their eradication in vivo.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Allison, James/0000-0001-8980-5697	NCI NIH HHS [CA57986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTH RJ, 1990, J IMMUNOL, V144, P1531; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CANTOR H, 1975, J EXP MED, V141, P1390, DOI 10.1084/jem.141.6.1390; DONAWHO C, 1990, CANCER COMMUN, V2, P101, DOI 10.3727/095535490820874597; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GREENBERG PD, 1981, J IMMUNOL, V126, P2100; GROSS JA, 1992, J IMMUNOL, V149, P380; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARDING FR, UNPUB; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1991, J IMMUNOL, V147, P2461; KAHN M, 1991, J IMMUNOL, V146, P3235; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; LARSEN CP, 1992, J EXP MED, V176, P1215, DOI 10.1084/jem.176.4.1215; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MIZUOCHI T, 1986, J EXP MED, V163, P603, DOI 10.1084/jem.163.3.603; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; RESTIFO NP, 1992, J EXP MED, V175, P1423, DOI 10.1084/jem.175.6.1423; SCHREIBER H, 1988, ANNU REV IMMUNOL, V6, P465; SPRENT J, 1985, J EXP MED, V162, P2068, DOI 10.1084/jem.162.6.2068; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VONBOEHMER H, 1984, J IMMUNOL, V133, P59; VONBOEHMER H, 1983, EUR J IMMUNOL, V13, P176, DOI 10.1002/eji.1830130216; WAGNER H, 1978, J EXP MED, V148, P1523, DOI 10.1084/jem.148.6.1523	36	1179	1288	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					368	370		10.1126/science.7678351	http://dx.doi.org/10.1126/science.7678351			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	7678351				2022-12-28	WOS:A1993KG62400034
J	WALSH, JH; PETERSON, WL				WALSH, JH; PETERSON, WL			THE TREATMENT OF HELICOBACTER-PYLORI INFECTION IN THE MANAGEMENT OF PEPTIC-ULCER DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND TRIAL; RAPID UREASE TEST; DUODENAL-ULCER; CAMPYLOBACTER-PYLORI; TRIPLE THERAPY; METRONIDAZOLE RESISTANCE; BREATH TEST; ANTIMICROBIAL AGENTS; BISMUTH SUBCITRATE		UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV TEXAS,SW MED SCH,DEPT INTERNAL MED,DALLAS,TX 75230; VET AFFAIRS MED CTR,MED SERV,DALLAS,TX	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	WALSH, JH (corresponding author), UNIV CALIF LOS ANGELES,W LOS ANGELES VET AFFAIRS MED CTR,CTR GASTROENTER BIOL,LOS ANGELES,CA 90073, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R37DK017294, R01DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41301, DK 17294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMEK RJ, 1993, AM J GASTROENTEROL, V88, P792; ALASSI MT, 1994, AM J GASTROENTEROL, V89, P1203; ALASSI MT, 1994, ALIMENT PHARM THERAP, V8, P453; BAMFORD KB, 1993, GUT, V34, P1348, DOI 10.1136/gut.34.10.1348; BARRADELL LB, 1992, DRUGS, V44, P225, DOI 10.2165/00003495-199244020-00007; BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; BELL GD, 1992, ALIMENT PHARM THERAP, V6, P427; BELL GD, 1995, ALIMENT PHARM THERAP, V9, P41; BELL GD, 1991, LANCET, V337, P310, DOI 10.1016/0140-6736(91)90933-G; BORODY TJ, 1989, MED J AUSTRALIA, V151, P431, DOI 10.5694/j.1326-5377.1989.tb101251.x; BORSCH G, 1987, HEPATO-GASTROENTEROL, V34, P236; BROWN KE, 1993, GASTROENTEROL CLIN N, V22, P105; BUCK GE, 1987, J CLIN MICROBIOL, V25, P597, DOI 10.1128/JCM.25.4.597-599.1987; BURETTE A, 1992, EUR J GASTROEN HEPAT, V4, P817; CARRICK J, 1989, GUT, V30, P790, DOI 10.1136/gut.30.6.790; CEDERBRANT G, 1992, J ANTIMICROB CHEMOTH, V29, P115, DOI 10.1093/jac/29.2.115; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; COGHLAN JG, 1987, LANCET, V2, P1109; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; COVER TL, 1992, HUM PATHOL, V23, P1004, DOI 10.1016/0046-8177(92)90261-Z; CULLEN DJE, 1993, GASTROENTEROLOGY, V104, pA60; CUTLER A, 1993, DIGEST DIS SCI, V38, P2262, DOI 10.1007/BF01299906; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P505; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P1359; DEBOER W, 1995, LANCET, V345, P817, DOI 10.1016/S0140-6736(95)92962-2; DELCHIER IC, 1995, GASTROENTEROLOGY S, V108, pA81; GOODWIN CS, 1988, J CLIN PATHOL, V41, P207, DOI 10.1136/jcp.41.2.207; GOODWIN CS, 1985, J CLIN PATHOL, V38, P1127, DOI 10.1136/jcp.38.10.1127; GORBACH SL, 1990, GASTROENTEROLOGY, V99, P863, DOI 10.1016/0016-5085(90)90983-8; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1571, DOI 10.1016/0016-5085(91)90654-4; GRAHAM DY, 1993, NEW ENGL J MED, V328, P349, DOI 10.1056/NEJM199302043280512; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GRAHAM DY, 1991, AM J GASTROENTEROL, V86, P1158; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GRAHAM DY, 1987, LANCET, V1, P1174; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P493, DOI 10.1016/0016-5085(92)90095-G; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P939, DOI 10.3109/00365529309098288; GRAHAM DY, 1994, GASTROENTEROLOGY, V106, pA83; GRAHAM KS, 1995, GASTROENTEROLOGY, V108, pA104; GRAYSON ML, 1989, EUR J CLIN MICROBIOL, V8, P888, DOI 10.1007/BF01963775; HACHEM CY, 1994, GASTROENTEROLOGY, V106, pA86; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOLTMANN G, 1994, DIGEST DIS SCI, V39, P1090, DOI 10.1007/BF02087563; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; ISAACSON PG, 1994, NEW ENGL J MED, V330, P1310, DOI 10.1056/NEJM199405053301812; ISENBERG JI, 1987, NEW ENGL J MED, V316, P374, DOI 10.1056/NEJM198702123160704; IWAHI T, 1991, ANTIMICROB AGENTS CH, V35, P490, DOI 10.1128/AAC.35.3.490; JENSEN DM, 1994, NEW ENGL J MED, V330, P382, DOI 10.1056/NEJM199402103300602; KOSUNEN TU, 1992, LANCET, V339, P893, DOI 10.1016/0140-6736(92)90929-W; LABENZ J, 1993, GUT, V34, P1167, DOI 10.1136/gut.34.9.1167; LAINE L, 1995, GASTROENTEROLOGY, V108, pA142, DOI 10.1016/0016-5085(95)23232-X; LOGAN RPH, 1991, EUR J GASTROEN HEPAT, V3, P915; LOGAN RPH, 1995, ALIMENT PHARM THER, V9, P417; LOGAN RPH, 1991, LANCET, V338, P1249, DOI 10.1016/0140-6736(91)92111-E; MARSHALL BJ, 1987, AM J GASTROENTEROL, V82, P200; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1991, AM J GASTROENTEROL, V86, P438; MASSOOMI F, 1993, PHARMACOTHERAPY, V13, P46; MCCOLL KEL, 1991, SCAND J GASTROENTERO, V26, P339, DOI 10.3109/00365529109025052; MONTBRIAND JR, 1989, AM J GASTROENTEROL, V84, P1513; NOACH LA, 1994, SCAND J INFECT DIS, V26, P321, DOI 10.3109/00365549409011802; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PENSTON JG, 1994, ALIMENT PHARM THER, V8, P369; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P2038; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; PETERSON WL, 1995, GASTROENTEROLOGY, V108, pA190; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SCHEMBRI MA, 1993, J CLIN MICROBIOL, V31, P2621, DOI 10.1128/JCM.31.10.2621-2624.1993; SIPPONEN P, 1989, GUT, V30, P922, DOI 10.1136/gut.30.7.922; TAHA AS, 1993, GUT, V34, P461, DOI 10.1136/gut.34.4.461; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; TYTGAT GNJ, 1994, ALIMENT PHARM THERAP, V8, P359; VALLE J, 1991, SCAND J GASTROENTERO, V26, P1057, DOI 10.3109/00365529109003956; VANCAEKENBERGHE DL, 1987, ANTIMICROB AGENTS CH, V31, P1429, DOI 10.1128/AAC.31.9.1429; VANDEVENTER GM, 1989, NEW ENGL J MED, V320, P1113, DOI 10.1056/NEJM198904273201704; VANZANTEN SJOV, 1992, J CLIN PATHOL, V45, P225, DOI 10.1136/jcp.45.3.225; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P177; VONWULFFEN H, 1992, EUR J CLIN MICROBIOL, V11, P577; WESTBLOM TU, 1988, J CLIN MICROBIOL, V26, P1393, DOI 10.1128/JCM.26.7.1393-1394.1988; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P1431, DOI 10.1016/0016-5085(93)90148-6; YOUSFI MM, 1995, ALIMENT PHARM THERAP, V9, P209; 1992, EUR J CLIN MICROBIOL, V11, P777; 1994, JAMA-J AM MED ASSOC, V272, P65	94	386	405	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					984	991		10.1056/NEJM199510123331508	http://dx.doi.org/10.1056/NEJM199510123331508			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666920				2022-12-28	WOS:A1995RY58600008
J	CHI, TH; LIEBERMAN, P; ELLWOOD, K; CAREY, M				CHI, TH; LIEBERMAN, P; ELLWOOD, K; CAREY, M			A GENERAL MECHANISM FOR TRANSCRIPTIONAL SYNERGY BY EUKARYOTIC ACTIVATORS	NATURE			English	Article							EPSTEIN-BARR-VIRUS; RNA POLYMERASE-II; PREINITIATION COMPLEX; GAL4 DERIVATIVES; DNA-BINDING; PROMOTER; DOMAINS; ZEBRA; INITIATION; INTERACTS	One of the important regulatory concepts to emerge from studies of eukaryotic gene expression is that RNA polymerase II promoters and their upstream activators are composed of functional modules whose synergistic action regulates the transcriptional activity of a nearby gene(1-3). Biochemical analysis of synergy by ZEBRA, a non-acidic activator of the Epstein-Barr virus (EBV) lytic cycle(4), showed that the synergistic transcriptional effect of promoter sites and activation modules correlates with assembly of the TFIID:TFIIA (DA) complex in DNase I footprinting and gel shift assays, The activator-dependent DA complex differs from a basal DA complex by its ability to bind TFIIB stably in an interaction regulated by TATA-binding protein-associated factors (TAFs), TFIIB enhances the degree of synergism by increasing complex stability. Similar findings were made with the acidic activator GAL4-VP16. Our data suggest a unifying mechanism for gene activation and synergy by acidic and non-acidic activators, and indicate that synergy is manifested at the earliest stage of preinitiation complex assembly.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; ROCHE INST MOLEC BIOL,DEPT GENE EXPRESS,NUTLEY,NJ 07110	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Carey, Michael/0000-0003-3899-6280				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MILLER G, 1993, J VIROL, V67, P7472, DOI 10.1128/JVI.67.12.7472-7481.1993; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDYKE MW, 1990, MOL CELL BIOL, V10, P3415, DOI 10.1128/MCB.10.7.3415; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	29	175	180	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					254	257		10.1038/377254a0	http://dx.doi.org/10.1038/377254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675113				2022-12-28	WOS:A1995RV87200047
J	HUNTER, CP; KENYON, C				HUNTER, CP; KENYON, C			SPECIFICATION OF ANTEROPOSTERIOR CELL FATES IN CAENORHABDITIS-ELEGANS BY DROSOPHILA HOX PROTEINS	NATURE			English	Article							C-ELEGANS; FUNCTIONAL SPECIFICITY; BODY REGION; GENE; HOMEODOMAIN; NEMATODE; EMBRYOS; LARVAE	ANTENNAPEDIA class homeobox (Hox) genes specify cell fates in successive anteroposterior body domains in vertebrates, insects and nematodes(1-3). The DNA-binding homeodomain sequences are very similar between vertebrate and Drosophila Hox proteins, and this similarity allows vertebrate Hox proteins to function in Drosophila(4-7). In contrast, the Caenorhabditis elegans homeodomains are substantially divertent(8). Further, C. elegans differs from both insects and vertebrates in having a non-segmented body as well as a distinctive mode of development that involves asymmetric early cleavages and invariant cell lineages. Here we report that, despite these differences, Drosophila Hox proteins expressed in C. elegans can substitute for C. elegans Hox proteins in the control of three different cell-fate decisions: the regulation of cell migration, the specification of serotonergic neurons, and the specification of a sensory structure. We also show that the specificity of one C. elegans Hox protein is partly determined by two amino acids that have been implicated in sequence-specific DNA binding. Together these findings suggest that factors important for target recognition by specific Hox proteins have been conserved throughout much of the animal kingdom.			HUNTER, CP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MALICKI J, 1993, MECH DEVELOP, V42, P139, DOI 10.1016/0925-4773(93)90003-G; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLO CC, 1991, EMBO J, V12, P3959; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; ZENG WL, 1993, DEVELOPMENT, V118, P339; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	23	40	43	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					229	232		10.1038/377229a0	http://dx.doi.org/10.1038/377229a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675107				2022-12-28	WOS:A1995RV87200039
J	DECOCK, KM; WILKINSON, D				DECOCK, KM; WILKINSON, D			TUBERCULOSIS-CONTROL IN RESOURCE-POOR COUNTRIES - ALTERNATIVE APPROACHES IN THE ERA OF HIV	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY; CHEMOTHERAPY; INFECTION; THERAPY; AFRICA		CTR EPIDEMIOL RES S AFRICA,HLABISA 3937,SOUTH AFRICA; HLABISA HOSP,HLABISA 3937,SOUTH AFRICA		DECOCK, KM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846				ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; CROFTON J, 1992, CLIN TUBERCULOSIS; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; KUMARESAN JA, 1992, BRIT MED J, V305, P340, DOI 10.1136/bmj.305.6849.340; NUNN P, 1991, LANCET, V377, P627; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK AL, 1992, AIDS, V6, P809, DOI 10.1097/00002030-199208000-00007; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; 1995, MMWR-MORBID MORTAL W, V44, P387; 1993, TREATMENT TUBERCULOS; 1995, WHOTB95183 REP; 1993, INVESTING HLTH; 1994, AM J RESP CRIT CARE, V149, P1359; 1992, MMWR-MORBID MORTAL W, V41, P1	28	62	62	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					675	677		10.1016/S0140-6736(95)92284-9	http://dx.doi.org/10.1016/S0140-6736(95)92284-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658822				2022-12-28	WOS:A1995RU04800013
J	ZHANG, YH; EMMONS, SW				ZHANG, YH; EMMONS, SW			SPECIFICATION OF SENSE-ORGAN IDENTITY BY A CAENORHABDITIS-ELEGANS PAX-6 HOMOLOG	NATURE			English	Article							C-ELEGANS; NEMATODE; GENE; EXPRESSION; SEQUENCE; PATTERN; MUTANTS; VECTORS; CELL	The Pax-6 transcription-factor gene, containing a paired domain and a paired-type homeodomain, is conserved in structure and ubiquitously present among Metazoa(1-5). It is required for development of the central nervous system, and is mutated in human aniridia, mouse and rat small eye and Drosophila eyeless(6). We identified the Pax-6 gene of the nematode Caenorhabditis elegans in genetic studies of male tail morphology(7,8). C. elegans Pax-6 encodes at least two independent genetic functions. One, like other Pax-6 genes, contains paired and homeodomains; this constitutes the genetic locus vab-3 (ref. 9). The other, described here, is expressed from an internal promoter and contains only the homeodomain portion; this constitutes the genetic locus mab-18 (ref. 7), The mab-18 form of the gene is expressed in a peripheral sense organ and is necessary for specification of sense-organ identity. Its function in this context could be to regulate the expression of cell recognition and adhesion proteins required for sense-organ assembly.			ZHANG, YH (corresponding author), ALBERT EINSTEIN COLL MED, DEPT MOLEC GENET, 1300 MORRIS PK AVE, NEW YORK, NY 10461 USA.			Zhang, Yinhua/0000-0003-0592-9153				BAIRD SE, 1991, DEVELOPMENT, V113, P515; BURR AH, 1985, PHOTOCHEM PHOTOBIOL, V41, P577, DOI 10.1111/j.1751-1097.1985.tb03529.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAMBERLIN HM, 1995, DEV BIOL, V170, P679, DOI 10.1006/dbio.1995.1246; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CHOW KL, 1994, DEVELOPMENT, V120, P2579; CHOW KL, IN PRESS DEVELOPMENT; CLARK SG, 1994, GENETICS, V137, P987; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HEDGECOCK EM, 1985, TRENDS NEUROSCI, V8, P288, DOI 10.1016/0166-2236(85)90104-3; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WALTHER C, 1991, DEVELOPMENT, V113, P1435	24	125	127	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					55	59		10.1038/377055a0	http://dx.doi.org/10.1038/377055a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659160				2022-12-28	WOS:A1995RT72500054
J	GANEM, JL; BERAN, RL; KRAKOWER, JK				GANEM, JL; BERAN, RL; KRAKOWER, JK			REVIEW OF US MEDICAL-SCHOOL FINANCES, 1993-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									ASSOC AMER MED COLL,DIV MED STUDENT & RESIDENT EDUC,WASHINGTON,DC 20037	Association of American Medical Colleges	GANEM, JL (corresponding author), ASSOC AMER MED COLL,OPERAT STUDIES SECT,2450 N ST NW,WASHINGTON,DC 20037, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					723	730						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650826				2022-12-28	WOS:A1995RR83500019
J	COOK, JD				COOK, JD			IRON SUPPLEMENTATION - IS LESS BETTER	LANCET			English	Editorial Material							GASTRIC DELIVERY SYSTEM; RATS; FE				COOK, JD (corresponding author), UNIV KANSAS,MED CTR,DEPT INTERNAL MED,KANSAS CITY,KS 66103, USA.							COOK JD, 1995, AM J CLIN NUTR, V62, P117, DOI 10.1093/ajcn/62.1.117; COOK JD, 1990, LANCET, V335, P1136, DOI 10.1016/0140-6736(90)91135-W; DeMaeyer E, 1985, World Health Stat Q, V38, P302; FAIRWEATHERTAIT SJ, 1985, BRIT J NUTR, V54, P79, DOI 10.1079/BJN19850094; FOGELHOLM M, 1994, EUR J CLIN NUTR, V48, P753; GILLESPIE S, 1991, ACC SCN WORKSHOP LAV, P1; HEYMANN DL, 1990, T ROY SOC TROP MED H, V84, P496, DOI 10.1016/0035-9203(90)90011-3; SCHULTINK W, 1995, AM J CLIN NUTR, V61, P111, DOI 10.1093/ajcn/61.1.111; SIMMONS WK, 1993, AM J CLIN NUTR, V58, P622, DOI 10.1093/ajcn/58.5.622; Viteri F E, 1994, SCN News, P14; WRIGHT AJA, 1990, BRIT J NUTR, V63, P579, DOI 10.1079/BJN19900144	11	9	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					587	587		10.1016/S0140-6736(95)91430-7	http://dx.doi.org/10.1016/S0140-6736(95)91430-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7650998				2022-12-28	WOS:A1995RT18800003
J	TOGHILL, P				TOGHILL, P			1895 - DR GRACE,WG GOLDEN SUMMER	BRITISH MEDICAL JOURNAL			English	Article								One hundred years ago there was another wonderful summer. Dr W G Grace, England's greatest cricketer, in his 47th year, completed his ''century of centuries'' and scored 2346 runs. This remarkable achievement was celebrated with enthusiasm and affection by the Victorian public. In more practical terms generous testimonials raised pound 9073 8s 6d, which made it a golden summer in more ways than one.			TOGHILL, P (corresponding author), ROYAL COLL PHYSICIANS,LONDON NW1 4LE,ENGLAND.							DARWIN B, 1978, WG GRACE; Grace William G., 1980, WG CRICKETING REMINI; HAWKE, 1919, MEMORIAL BIOGRAPHY W; TOGHILL PJ, 1983, J MED BIOGRAPHY, V1, P157	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					618	619		10.1136/bmj.311.7005.618	http://dx.doi.org/10.1136/bmj.311.7005.618			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663257	Green Published			2022-12-28	WOS:A1995RT72300024
J	SHYUE, SK; HEWETTEMMETT, D; SPERLING, HG; HUNT, DM; BOWMAKER, JK; MOLLON, JD; LI, WH				SHYUE, SK; HEWETTEMMETT, D; SPERLING, HG; HUNT, DM; BOWMAKER, JK; MOLLON, JD; LI, WH			ADAPTIVE EVOLUTION OF COLOR-VISION GENES IN HIGHER PRIMATES	SCIENCE			English	Article							POLYMORPHISM; PIGMENTS; MONKEY; GREEN; PHOTOPIGMENTS; SCIUREUS; SAIMIRI	The intron 4 sequences of the three polymorphic alleles at the X-linked color photopigment locus in the squirrel monkey and the marmoset reveal that the alleles in each species are exceptionally divergent. The data further suggest either that each triallelic system has arisen independently in these two New World monkey lineages, or that in each species at least seven deletions and insertions (14 in the two species) in intron 4 have been transferred acid homogenized among the alleles by gene conversion or recombination. In either case, the alleles in each species apparently have persisted more than 5 million years and probably have been maintained by overdominant selection.	UNIV TEXAS,CTR HUMAN GENET,SCH PUBL HLTH,HOUSTON,TX 77225; UNIV TEXAS,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,HOUSTON,TX 77030; UNIV LONDON,INST OPHTHALMOL,DEPT MOLEC GENET,LONDON EC1V 9EL,ENGLAND; UNIV LONDON,INST OPHTHALMOL,DEPT VISUAL SCI,LONDON EC1V 9EL,ENGLAND; UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of London; University College London; University of London; University College London; University of Cambridge			Mollon, John/C-3520-2009; Shyue, Song-Kun/Q-2583-2018; Hunt, David M/K-6024-2012; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Shyue, Song-Kun/0000-0002-1057-8696; Hunt, David M/0000-0002-9264-3948; Mollon, John/0000-0001-8533-033X; Li, Wen-Hsiung/0000-0003-1086-1456	NEI NIH HHS [EY10317] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010317] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOWMAKER JK, 1987, PROC R SOC SER B-BIO, V231, P383, DOI 10.1098/rspb.1987.0051; DEEB SS, 1994, P NATL ACAD SCI USA, V91, P7262, DOI 10.1073/pnas.91.15.7262; DULAI KS, 1994, VISION RES, V34, P2483, DOI 10.1016/0042-6989(94)90233-X; HUNT DM, 1993, VISION RES, V33, P147, DOI 10.1016/0042-6989(93)90153-N; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; JACOBS GH, 1993, VISION RES, V33, P269, DOI 10.1016/0042-6989(93)90083-9; JACOBS GH, 1984, VISION RES, V24, P1267, DOI 10.1016/0042-6989(84)90181-0; JACOBS GH, 1987, P NATL ACAD SCI USA, V84, P2545, DOI 10.1073/pnas.84.8.2545; KAWAMURA S, 1993, FEBS LETT, V323, P247, DOI 10.1016/0014-5793(93)81350-9; KIMURA M, 1969, GENETICS, V63, P701; LI WH, 1991, GENETICS, V129, P513; MOLLON JD, 1989, J EXP BIOL, V146, P21; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; MORGAN MJ, 1992, P ROY SOC B-BIOL SCI, V248, P291, DOI 10.1098/rspb.1992.0074; MORRIS A, 1993, P ROY SOC B-BIOL SCI, V254, P233, DOI 10.1098/rspb.1993.0151; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; NEITZ M, 1995, SCIENCE, V267, P1013, DOI 10.1126/science.7863325; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHNEIDER H, 1993, MOL PHYLOGENET EVOL, V2, P225, DOI 10.1006/mpev.1993.1022; SHYUE SK, 1994, MOL BIOL EVOL, V11, P548; TAJIMA F, 1984, MOL BIOL EVOL, V1, P269; TAKAHATA N, 1990, GENETICS, V124, P967; TOVEE MJ, 1992, VISION RES, V32, P867, DOI 10.1016/0042-6989(92)90029-I; TRAVIS DS, 1988, VISION RES, V28, P481, DOI 10.1016/0042-6989(88)90170-8; YOKOYAMA R, 1990, P NATL ACAD SCI USA, V87, P9315, DOI 10.1073/pnas.87.23.9315	26	76	79	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1265	1267		10.1126/science.7652574	http://dx.doi.org/10.1126/science.7652574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652574				2022-12-28	WOS:A1995RR84200034
J	WOLFEL, T; HAUER, M; SCHNEIDER, J; SERRANO, M; WOLFEL, C; KLEHMANNHIEB, E; DEPLAEN, E; HANKELN, T; ZUMBUSCHENFELDE, KHM; BEACH, D				WOLFEL, T; HAUER, M; SCHNEIDER, J; SERRANO, M; WOLFEL, C; KLEHMANNHIEB, E; DEPLAEN, E; HANKELN, T; ZUMBUSCHENFELDE, KHM; BEACH, D			A P16(INK4A)-INSENSITIVE CDK4 MUTANT TARGETED BY CYTOLYTIC T-LYMPHOCYTES IN A HUMAN-MELANOMA	SCIENCE			English	Article							MALIGNANT-MELANOMA; PEPTIDE; CELLS; ANTIGENS; GENE; IDENTIFICATION; INHIBITION; MOLECULES; SUBUNIT; BINDING	A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HL4-A2.1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16(INK4a), but not of p21 or of p27(KIP1). The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16(INK4a).	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; CATHOLIC UNIV LEUVEN,LUDWIG INST CANC RES,B-1200 BRUSSELS,BELGIUM; UNIV MAINZ,INST MOLEK GENET,D-55099 MAINZ,GERMANY	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; KU Leuven; Ludwig Institute for Cancer Research; Johannes Gutenberg University of Mainz	WOLFEL, T (corresponding author), UNIV MAINZ,MED KLIN & POLIKLIN 1,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.		Serrano, Manuel/H-2634-2015; Wölfel, Thomas/G-6519-2012	Serrano, Manuel/0000-0001-7177-9312; 				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; DEBERGEYCK V, 1994, EUR J IMMUNOL, V24, P2203, DOI 10.1002/eji.1830240941; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNUTH A, 1984, P NATL ACAD SCI-BIOL, V81, P3511, DOI 10.1073/pnas.81.11.3511; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIVINGSTON PO, 1979, INT J CANCER, V24, P34, DOI 10.1002/ijc.2910240107; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI T, 1994, CANCER RES, V54, P3396; NIJMAN HW, 1993, EUR J IMMUNOL, V23, P1215, DOI 10.1002/eji.1830230603; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PREHN RT, 1957, J NATL CANCER I, V18, P769; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SRIVASTAVA PK, 1987, P NATL ACAD SCI USA, V84, P3807, DOI 10.1073/pnas.84.11.3807; SZIKORA JP, 1993, IMMUNOGENETICS, V37, P135, DOI 10.1007/BF00216837; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VOLKENANDT M, 1991, J CUTAN PATHOL, V18, P210, DOI 10.1111/j.1600-0560.1991.tb00155.x; WARD PL, 1989, J EXP MED, V170, P217, DOI 10.1084/jem.170.1.217; WOLFEL T, 1993, INT J CANCER, V55, P237, DOI 10.1002/ijc.2910550212; WOLFEL T, 1994, EUR J IMMUNOL, V24, P759, DOI 10.1002/eji.1830240340; XIONG Y, 1993, CELL, V75, P817	50	866	918	1	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1281	1284		10.1126/science.7652577	http://dx.doi.org/10.1126/science.7652577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652577				2022-12-28	WOS:A1995RR84200039
J	BECHARA, A; TRANEL, D; DAMASIO, H; ADOLPHS, R; ROCKLAND, C; DAMASIO, AR				BECHARA, A; TRANEL, D; DAMASIO, H; ADOLPHS, R; ROCKLAND, C; DAMASIO, AR			DOUBLE DISSOCIATION OF CONDITIONING AND DECLARATIVE KNOWLEDGE RELATIVE TO THE AMYGDALA AND HIPPOCAMPUS IN HUMANS	SCIENCE			English	Article							MEMORY; FEAR; AMNESIA; SYSTEMS; DAMAGE	A patient with selective bilateral damage to the amygdala did not acquire conditioned autonomic responses to visual or auditory stimuli but did acquire the declarative facts about which visual or auditory stimuli were paired with the unconditioned stimulus. By contrast, a patient with selective bilateral damage to the hippocampus failed to acquire the facts but did acquire the conditioning. Finally, a patient with bilateral damage to both amygdala and hippocampal formation acquired neither the conditioning nor the facts. These findings demonstrate a double dissociation of conditioning and declarative knowledge relative to the human amygdala and hippocampus.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROSCI, IOWA CITY, IA 52242 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA; MIT, INFORMAT & DECIS SYST LAB, CAMBRIDGE, MA 02139 USA	University of Iowa; Salk Institute; Massachusetts Institute of Technology (MIT)			Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS019632] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS19632] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; ADOLPHS R, IN PRESS J NEUROSCI; Amaral D. G., 1987, HDB PHYSL NERVOUS SY, P211; [Anonymous], 1987, HDB PHYSL 1 NERVOUS; BERGER TW, 1983, BEHAV BRAIN RES, V8, P49, DOI 10.1016/0166-4328(83)90171-7; Damasio A.R., 2005, DESCARTES ERROR EMOT; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEBAR KS, IN PRESS J NEUROSCI; LEBAR KS, 1994, SOC NEUR ABSTR, V20, P360; LEDOUX JE, 1994, SCI AM, V270, P50, DOI 10.1038/scientificamerican0694-50; LEE GP, 1988, NEUROPSY NEUROPSY BE, V1, P119; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MISHKIN M, 1994, CURR OPIN NEUROBIOL, V4, P200, DOI 10.1016/0959-4388(94)90073-6; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TRANEL D, 1994, PSYCHOPHYSIOLOGY, V31, P427, DOI 10.1111/j.1469-8986.1994.tb01046.x; TRANEL D, 1989, NEUROPSYCHOLOGIA, V27, P381, DOI 10.1016/0028-3932(89)90046-8; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; VANHOESEN GW, 1985, ANN NY ACAD SCI, V444, P97; Wechsler D., 1945, WECHSLER MEMORY SCAL; Wechsler D., 1991, WECHSLER ADULT INTEL; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	27	905	921	0	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1115	1118		10.1126/science.7652558	http://dx.doi.org/10.1126/science.7652558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RQ748	7652558				2022-12-28	WOS:A1995RQ74800048
J	HENNING, KA; LI, L; IYER, N; MCDANIEL, LD; REAGAN, MS; LEGERSKI, R; SCHULTZ, RA; STEFANINI, M; LEHMANN, AR; MAYNE, LV; FRIEDBERG, EC				HENNING, KA; LI, L; IYER, N; MCDANIEL, LD; REAGAN, MS; LEGERSKI, R; SCHULTZ, RA; STEFANINI, M; LEHMANN, AR; MAYNE, LV; FRIEDBERG, EC			THE COCKAYNE-SYNDROME GROUP-A GENE ENCODES A WD REPEAT PROTEIN THAT INTERACTS WITH CSB PROTEIN AND A SUBUNIT OF RNA-POLYMERASE-II TFIIH	CELL			English	Article							DNA-REPAIR; XERODERMA-PIGMENTOSUM; INCREASED SENSITIVITY; CELLULAR-SENSITIVITY; ULTRAVIOLET-LIGHT; UV IRRADIATION; CELLS; FIBROBLASTS; TRANSFORMATION; TRANSCRIPTION	The hereditary disease Cockayne syndrome (CS) is characterized by a complex clinical phenotype, CS cells are abnormally sensitive to ultraviolet radiation and are defective in the repair of transcriptionally active genes, The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf, We report the cloning of the CSA cDNA, which can encode a WD repeat protein, Mutations in the cDNA have been identified in CS-A cell lines, CSA protein. interacts with CSB protein and with p44 protein, a subunit of the human RNA polymerase II transcription factor IIH. These observations suggest that the products of the CSA and CSB genes are involved in transcription.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; INST GENET BIOCHEM & EVOLUTIONIST,I-27100 PAVIA,ITALY; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND; UNIV SUSSEX,TRAFFORD CTR MED RES,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Sussex; University of Brighton; University of Sussex					NATIONAL CANCER INSTITUTE [R01CA052461, P30CA016672, R01CA044247] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44247, CA-52461, CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BRUMBACK RA, 1978, ARCH NEUROL-CHICAGO, V35, P337, DOI 10.1001/archneur.1978.00500300011002; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FRIEDBERG EC, 1994, MUTAT RES, V307, P5, DOI 10.1016/0027-5107(94)90272-0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P655; HOAR DI, 1978, AM J HUM GENET, V30, P590; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KENNEDY RM, 1980, NEUROLOGY, V30, P1268, DOI 10.1212/WNL.30.12.1268; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEHMANN AR, 1979, CANCER RES, V39, P4237; LEHMANN AR, 1993, J MED GENET, V30, P679, DOI 10.1136/jmg.30.8.679; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LEHMANN AR, 1994, MUTAT RES, V315, P41, DOI 10.1016/0921-8777(94)90026-4; MARSHALL RR, 1980, MUTAT RES, V69, P107, DOI 10.1016/0027-5107(80)90180-3; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MULLENDERS LHF, 1992, DNA REPAIR MECHANISM, P247; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OTSUKA F, 1984, J INVEST DERMATOL, V82, P480, DOI 10.1111/1523-1747.ep12260999; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHMICKEL RD, 1977, PEDIATRICS, V60, P135; SCHWEIGER M, 1987, EUR J BIOCHEM, V165, P235, DOI 10.1111/j.1432-1033.1987.tb11433.x; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; SUGITA K, 1987, PEDIATR RES, V21, P34, DOI 10.1203/00006450-198701000-00009; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Swirski Richard A., 1992, Methods (Orlando), V4, P133, DOI 10.1016/1046-2023(92)90045-A; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4704; VERMEULEN W, 1995, COLD SPRING HARB SYM, V59, P317; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5	50	383	392	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					555	564		10.1016/0092-8674(95)90028-4	http://dx.doi.org/10.1016/0092-8674(95)90028-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664335	Bronze			2022-12-28	WOS:A1995RR73400007
J	GEDDES, JR; JUSZCZAK, E				GEDDES, JR; JUSZCZAK, E			PERIOD TRENDS IN RATE OF SUICIDE IN FIRST 28 DAYS AFTER-DISCHARGE FROM PSYCHIATRIC-HOSPITAL IN SCOTLAND, 1968-92	BRITISH MEDICAL JOURNAL			English	Article							AFTER-DISCHARGE; INPATIENT CARE; PREVENTION; RISK	Objective-To examine period trends in the rate of suicide in the first 28 days after discharge from psychiatric hospital. Design-Cohort study of patients discharged from psychiatric hospital. Setting-Scotland. Subjects-Ah patients aged 15-84 who were discharged from Scottish psychiatric hospitals during 1968 to 1992. Outcome measure-The rate of suicide (classified as codes E950-9 and E980-9 according to the International Classification of Diseases, Ninth Revision) within 28 days of discharge per 100 000 person years at risk for five year periods during 1968 to 1992. Crude, within cohort rates and externally standardised rates were calculated. Results-Overall, 196 male patients committed suicide in 20 520 person years at risk, and 171 female patients committed suicide in 24 114 person years at risk. A significant Linear trend was seen in period effect on externally standardised mortality ratios in both sexes: a decrease in male patients (P=0.008) and an increase in female patients (P=0.0001). The adjusted standardised mortality ratio in 1988-92 compared with 1968-72 was 0.62 (95% confidence interval 0.39 to 0.98) in male patients and 2.73 (1.64 to 4.56) in female patients. Conclusion-The increase in the rate of suicide in the 28 days after discharge in female psychiatric patients makes this an increasingly important period to target. The rise has occurred against the background of a reduction of 60% in the number of psychiatric beds for adults.	ROYAL EDINBURGH & ASSOCIATED HOSP,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; NATL HLTH SERV SCOTLAND,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; NHS National Services Scotland				Geddes, John/0000-0002-5281-5960				ALLEBECK P, 1987, ACTA PSYCHIAT SCAND, V76, P414, DOI 10.1111/j.1600-0447.1987.tb05626.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; BAKER RJ, 1978, GLIM SYSTEM; Breslow N. E., 1987, STATISTICAL METHODS, VII; Charlton J., 1992, Population Trends, P10; Clayton DHM, 1993, STATISTICAL METHODS; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P1347; DIEKSTRA RFW, 1993, ACTA PSYCHIATR SCA S, V371, P9; ENGBERG M, 1994, ACTA PSYCHIAT SCAND, V89, P35, DOI 10.1111/j.1600-0447.1994.tb01482.x; FLOOD RA, 1968, BRIT J PSYCHIAT, V114, P443, DOI 10.1192/bjp.114.509.443; FULLEN I, 1993, BRIT MED J, V306, P710; GEDDES JR, 1994, BRIT J PSYCHIAT, V164, P564, DOI 10.1192/S0007125000051989; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; ISOMETSA E, 1993, LANCET, V342, P1055, DOI 10.1016/0140-6736(93)92913-E; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KING E, 1994, BRIT J PSYCHIAT, V165, P658, DOI 10.1192/bjp.165.5.658; KING EA, 1993, LANCET, V342, P744; KREITMAN N, 1994, HLTH B EDINB, V52, P300; MCGONIGAL G, 1992, Health Bulletin (Edinburgh), V50, P309; MORGAN HG, 1992, BRIT J PSYCHIAT, V160, P149, DOI 10.1192/bjp.160.2.149; VASSILAS CA, 1993, BRIT MED J, V307, P300, DOI 10.1136/bmj.307.6899.300; 1978, MENTAL DISORDERS GLO; 1986, MAKING REALITY COMMU; 1992, HLTH NATION STRATEGY; 1991, EGRET EPIDEMIOLOGICA	26	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					357	360		10.1136/bmj.311.7001.357	http://dx.doi.org/10.1136/bmj.311.7001.357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640540	Green Published			2022-12-28	WOS:A1995RN46900014
J	SWEDO, SE				SWEDO, SE			SYDENHAMS CHOREA - A MODEL FOR CHILDHOOD AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSESSIVE-COMPULSIVE DISORDER; RHEUMATIC-FEVER; VITUS-DANCE; SYMPTOMS; CHILDREN				SWEDO, SE (corresponding author), NIMH,CHILD PSYCHIAT BRANCH,BEHAV PEDIAT SECT,BLDG 10,ROOM 6N240,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ARON AM, 1965, AM J MED, V38, P83, DOI 10.1016/0002-9343(65)90162-2; AYOUB EM, 1966, PEDIATRICS, V38, P946; CHAPMAN AH, 1958, PEDIATRICS, V21, P582; CHASE TN, 1992, TOURETTE SYNDROME GE, V58; Cheadle WB, 1889, LANCET, V1, P921; CHEADLE WB, 1889, LANCET, V1, P871; CHEADLE WB, 1889, LANCET, V1, P821; COBURN AF, 1931, FACTOR INFECTION RHE; Collis WRF, 1939, LANCET, V2, P817; DAJANI AS, 1988, CIRCULATION, V78, P1082, DOI 10.1161/01.CIR.78.4.1082; DENNY FW, 1950, JAMA-J AM MED ASSOC, V143, P151, DOI 10.1001/jama.1950.02910370001001; Diefendorf AR, 1912, J NERV MENT DIS, V39, P161, DOI 10.1097/00005053-191203000-00003; FREEMAN JM, 1965, PEDIATRICS, V35, P42; GOLDMAN S, 1993, MOVEMENT DISORD, V8, P355, DOI 10.1002/mds.870080318; GRIMSHAW L, 1964, J NEUROL NEUROSUR PS, V27, P229, DOI 10.1136/jnnp.27.3.229; Imbach P, 1989, Int Rev Immunol, V5, P181, DOI 10.3109/08830188909061985; INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739; KIENZLE GD, 1991, AM J NEURORADIOL, V12, P73; KIESSLING LS, 1993, PEDIATRICS, V92, P39; KUSHNER HI, IN PRESS B HIST MED; LEONARD HL, 1992, AM J PSYCHIAT, V149, P1244; LESSOF M, 1958, Guys Hosp Rep, V107, P185; Leung D Y, 1989, Int Rev Immunol, V5, P197, DOI 10.3109/08830188909061987; Osler W, 1894, CHOREA CHOREIFORM AF, P33; PARK RHR, 1990, J ROY SOC MED, V83, P512, DOI 10.1177/014107689008300814; RAPOPORT JL, 1988, PSYCHOPHARMACOL BULL, V24, P380; SHULMAN ST, 1984, MANAGEMENT PHARYNGIT; SWEDO S E, 1988, Pediatric Research, V23, p558A; SWEDO SE, 1989, AM J PSYCHIAT, V146, P246; SWEDO SE, 1994, PEDIATRICS, V93, P323; SWEDO SE, 1989, ARCH GEN PSYCHIAT, V46, P335; SWEDO SE, 1993, PEDIATRICS, V91, P706; SWEDO SE, 1976, J EXP MED, V144, P1094; Taranta A, 1989, RHEUMATIC FEVER; THIEBAUT F, 1968, HDB CLIN NEUROLOGY, P409; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WANNAMAKER LW, 1951, AM J MED, V10, P673, DOI 10.1016/0002-9343(51)90336-1; WILCOX JA, 1986, NEUROPSYCHOBIOLOGY, V15, P13, DOI 10.1159/000118234; 1987, DIAGNOSTIC STATISTIC; 1993, JAMA-J AM MED ASSOC, V269, P476; 1992, JAMA-J AM MED ASSOC, V268, P2069	41	231	241	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1788	1791		10.1001/jama.272.22.1788	http://dx.doi.org/10.1001/jama.272.22.1788			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV815	7661914				2022-12-28	WOS:A1994PV81500030
J	GARDNER, AW; POEHLMAN, ET				GARDNER, AW; POEHLMAN, ET			EXERCISE REHABILITATION PROGRAMS FOR THE TREATMENT OF CLAUDICATION PAIN - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PERIPHERAL ARTERIAL INSUFFICIENCY; INTERMITTENT CLAUDICATION; WALKING TOLERANCE; OCCLUSIVE DISEASE; VASCULAR-DISEASE; BLOOD-FLOW; DISTANCE; MUSCLE; ENZYME; RANGE	Objective.-To identify the components of exercise rehabilitation programs that were most effective in improving claudication pain symptoms in patients with peripheral arterial disease. Data Sources.-English-language articles were identified by a computer Search using Index Medicus and MEDLINE, followed by an extensive bibliography review. Study Selection.-Studies were included if they provided the mean or individual walking distances or times to the onset of claudication pain and to maximal pain during a treadmill test before and after rehabilitation. Data Extraction.-Walking distances and times and characteristics of the exercise programs were independently abstracted by two observers. Data Synthesis.-Thirty-three English-language studies were identified, of which 21 met the inclusion criteria, Overall, following a program of exercise rehabilitation, the distance (mean+/-SD) to onset of claudication pain increased 179% from 125.9+/-57.3 m to 351.2+/-188.7 m (P<.001), and the distance to maximal claudication pain increased 122% from 325.8+/-148.1 m to 723.3+/-591.5 m (P<.001). The greatest improvement in pain distances occurred with the following exercise program: duration greater than 30 minutes per session, frequency of at least three sessions per week, walking used as the mode of exercise, use of near-maximal pain during training as claudication pain end point, and program length of greater than 6 months, However, the claudication pain end point, program length, and mode of exercise were the only independent predictors (P<.001) for improvement in distances. Conclusions.-The optimal exercise program for improving claudication pain distances in patients with peripheral arterial disease uses intermittent walking to near-maximal pain during a program of at least 6 months. Such a program should be part of the standard medical care for patients with intermittent claudication.	UNIV MARYLAND,CLAUDE PEPPER OLDER AMER INDEPENDENCE CTR,DEPT MED,DIV GERONTOL,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore	GARDNER, AW (corresponding author), VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN 18,GERIATR SERV,10 N GREENE ST,BALTIMORE,MD 21201, USA.				NATIONAL INSTITUTE ON AGING [K01AG000657, K07AG000608, R01AG007857] Funding Source: NIH RePORTER; NIA NIH HHS [K07-AG-00608, K01-AG-00657, R01-AG-07857] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALPERT JS, 1969, CIRCULATION, V39, P353, DOI 10.1161/01.CIR.39.3.353; ANDRIESSEN MPHM, 1989, VASA-J VASCULAR DIS, V18, P63; ANDRIESSEN MPHM, 1989, VASA-J VASCULAR DIS, V18, P56; BLUMCHEN G, 1970, CARDIOLOGY, V55, P114, DOI 10.1159/000169274; CARTER SA, 1989, J VASC SURG, V10, P642; CLIFFORD PC, 1980, BRIT MED J, V281, P1508; DAHLLOF AG, 1974, EUR J CLIN INVEST, V4, P9, DOI 10.1111/j.1365-2362.1974.tb00365.x; DAHLLOF AG, 1976, SCAND J REHABIL MED, V8, P19; EKROTH R, 1978, SURGERY, V84, P640; ERICSSON B, 1970, ANGIOLOGY, V21, P188, DOI 10.1177/000331977002100306; ERNST E, 1987, VASA-J VASCULAR DIS, V16, P227; ERNST EEW, 1987, CIRCULATION, V76, P1110, DOI 10.1161/01.CIR.76.5.1110; FEINBERG RL, 1992, J VASC SURG, V16, P244, DOI 10.1016/0741-5214(92)90114-N; FITZGERALD DE, 1971, ANGIOLOGY, V22, P99, DOI 10.1177/000331977102200208; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; GARDNER AW, 1993, ANGIOLOGY, V44, P353, DOI 10.1177/000331979304400503; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HALL JA, 1982, J CARDIAC REHABIL, V2, P569; Hedges L, 1985, STATISTICAL METHODS; HIATT WR, 1990, CIRCULATION, V81, P602, DOI 10.1161/01.CIR.81.2.602; Hiatt WR, 1988, J CARDIOPULM REHABIL, V12, P525, DOI DOI 10.1097/00008483-198812200-00005; HOLM J, 1973, SCAND J CLIN LAB INV, V31, P201; JONASON T, 1987, CLIN PHYSIOL, V7, P63, DOI 10.1111/j.1475-097X.1987.tb00635.x; JONASON T, 1979, ACTA MED SCAND, V206, P253; JONASON T, 1987, SCAND J REHABIL MED, V19, P47; JONASON T, 1981, SCAND J REHABIL MED, V13, P137; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; LARSEN OA, 1966, LANCET, V2, P1093, DOI 10.1016/S0140-6736(66)92191-X; LEPANTALO M, 1984, SCAND J REHABIL MED, V16, P159; LINDGARDE F, 1989, CIRCULATION, V80, P1549, DOI 10.1161/01.CIR.80.6.1549; LUNDGREN F, 1989, ANN SURG, V209, P346, DOI 10.1097/00000658-198903000-00016; LUNDGREN F, 1989, CLIN SCI, V77, P485, DOI 10.1042/cs0770485; MANNARINO E, 1991, ANGIOLOGY, V42, P513, DOI 10.1177/000331979104200701; MANNARINO E, 1989, ANGIOLOGY, V40, P5, DOI 10.1177/000331978904000102; Pedhazur EJ, 1982, MULTIPLE REGRESSION, V2, P101; ROSETZSKY A, 1985, ANN CHIR GYNAECOL FE, V74, P261; ROSFORS S, 1989, SCAND J REHABIL MED, V21, P7; RUELL PA, 1984, EUR J APPL PHYSIOL O, V52, P420, DOI 10.1007/BF00943373; SCHERSTEN T, 1982, PRACT CARDIOL, V8, P45; SKINNER JS, 1967, CIRCULATION, V36, P23, DOI 10.1161/01.CIR.36.1.23; SORLIE D, 1978, SCAND J CLIN LAB INV, V38, P217, DOI 10.3109/00365517809108414; TRAN ZV, 1989, J CARDIOPULM REHABIL, V9, P250; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; WILLIAMS LR, 1991, J VASC SURG, V14, P320, DOI 10.1016/0741-5214(91)90083-7; ZETTERQUIST S, 1970, SCAND J CLIN LAB INV, V25, P101, DOI 10.3109/00365517009046196; 1991, GUIDELINES EXERCISE, V16, P99; 1992, J NIH RES, V4, P95; 1986, SPSS X USERS GUIDE, P620	50	560	581	1	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					975	980		10.1001/jama.274.12.975	http://dx.doi.org/10.1001/jama.274.12.975			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674529				2022-12-28	WOS:A1995RV73400033
J	NAKANE, H; TAKEUCHI, S; YUBA, S; SAIJO, M; NAKATSU, Y; MURAI, H; NAKATSURU, Y; ISHIKAWA, T; HIROTA, S; KITAMURA, Y; KATO, Y; TSUNODA, Y; MIYAUCHI, H; HORIO, T; TOKUNAGA, T; MATSUNAGA, T; NIKAIDO, O; NISHIMUNE, Y; OKADA, Y; TANAKA, K				NAKANE, H; TAKEUCHI, S; YUBA, S; SAIJO, M; NAKATSU, Y; MURAI, H; NAKATSURU, Y; ISHIKAWA, T; HIROTA, S; KITAMURA, Y; KATO, Y; TSUNODA, Y; MIYAUCHI, H; HORIO, T; TOKUNAGA, T; MATSUNAGA, T; NIKAIDO, O; NISHIMUNE, Y; OKADA, Y; TANAKA, K			HIGH-INCIDENCE OF ULTRAVIOLET-B-INDUCED OR CHEMICAL-CARCINOGEN-INDUCED SKIN TUMORS IN MICE LACKING THE XERODERMA-PIGMENTOSUM GROUP-A GENE	NATURE			English	Article							REPAIR GENE; DAMAGED DNA; PROTEIN; BINDING; CELLS	XERODERMA pigmentosum (XP) is an autosomal recessive disorder characterized by a high frequency of skin cancer on sun-exposed areas, and neurological complications, XP has a defect in the early step(s) of nucleotide-excision repair (NER) and consists of eight different genetic complementation groups (groups A-G and a variant)(1). We established XPA (group-A XP) gene-deficient mice by gene targeting of mouse embryonic stem (ES) cells. The XPA-deficient mice showed neither obvious physical abnormalities nor pathological alterations, but were defective in NER and highly susceptible to ultraviolet-B- or 9,10-dimethyl-1,2-benz[a]anthracene-induced skin carcinogenesis. These findings provide is vivo evidence that the XPA protein protects mice from carcinogenesis initiated by ultraviolet or chemical carcinogen, The XPA-deficient mice may provide a good in vivo model to study the high incidence of skin carcinogenesis in group A XP patients.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,DEPT PATHOL,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,OSAKA 565,JAPAN; KINKI UNIV,COLL AGR,ANIM REPROD LAB,NARA 631,JAPAN; KANSAI MED UNIV,DEPT DERMATOL,OSAKA 570,JAPAN; NATL INST ANIM IND,REPROD BIOCHEM LAB,TSUKUBA,IBARAKI 305,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV RADIAT BIOL,KANAZAWA,ISHIKAWA 920,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,OSAKA 565,JAPAN	Osaka University; University of Tokyo; Osaka University; Kindai University (Kinki University); Kansai Medical University; National Agriculture & Food Research Organization - Japan; Kanazawa University; Osaka University			中根, 裕信/V-9816-2019	Nakatsu, Yoshimichi/0000-0001-7408-7071				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; BRADLEY A, 1992, BIO-TECHNOL, V10, P534, DOI 10.1038/nbt0592-534; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; IKAI K, 1986, ARCH DERMATOL RES, V278, P445, DOI 10.1007/BF00455161; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1990, MUTAT RES, V235, P187, DOI 10.1016/0921-8777(90)90073-E; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; TANAKA K, 1980, SOMAT CELL GENET, V6, P739, DOI 10.1007/BF01538973; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561	17	247	251	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					165	168		10.1038/377165a0	http://dx.doi.org/10.1038/377165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675085				2022-12-28	WOS:A1995RU75400053
J	MODAN, B; SHPILBERG, O; BARUCH, Y; SIKULER, E; ANIS, E; ASHUR, Y; CHETRIT, A; LUXENBURG, O; ROSENBERG, E; ROSENTHOL, N; SADETZKI, S; BENAIM, H; ECKSTEIN, H; SHOUVAL, D				MODAN, B; SHPILBERG, O; BARUCH, Y; SIKULER, E; ANIS, E; ASHUR, Y; CHETRIT, A; LUXENBURG, O; ROSENBERG, E; ROSENTHOL, N; SADETZKI, S; BENAIM, H; ECKSTEIN, H; SHOUVAL, D			THE NEED FOR LIVER-TRANSPLANTATION - A NATIONWIDE ESTIMATE BASED ON CONSENSUS REVIEW	LANCET			English	Article							ALCOHOLIC CIRRHOSIS; SELECTION CRITERIA; DISEASE	Orthotopic liver transplantation (OLT) is widely practised in developed countries. The procedure is costly, the supply of donor organs limited, and it is not known how many patients need transplantation. A community-wide estimate of the needs for OLT was performed over two years in all general hospitals in Israel. Records of 1851 patients with liver disease were screened to identify those who might eventually need OLT. The annual estimate of transplantation needs in the country was 10-15.5 per million population, with equal numbers of males and females. The addition of patients with non-reformed alcoholism and end-stage liver disease, originally set as an exclusion criteria, would have added 20% to this estimate. 37% of potential candidates were under 40 years of age at diagnosis, and about 50% were 55-64 years old. Almost 80% of patients had cirrhosis of the liver and 13.6% had fulminant hepatitis. These findings provide a basis for a national plan of OLT in Israel, and similar studies might be useful in other countries.	TECHNION ISRAEL INST TECHNOL,SCH MED,RAMBAM MED CTR,DEPT MED,LIVER UNIT,HAIFA,ISRAEL; HADASSAH UNIV HOSP,LIVER UNIT,IL-91120 JERUSALEM,ISRAEL; BEER SHEBA UNIV,SOROKA MED CTR,DEPT MED,BEER SHEVA,ISRAEL	Rambam Health Care Campus; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Ben Gurion University; Soroka Medical Center	MODAN, B (corresponding author), TEL AVIV UNIV,SCH MED,CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,NELT STUDY,IL-52621 TEL HASHOMER,ISRAEL.		Shouval, Daniel/U-2779-2017; Eckstein, Hans-Henning/AAF-9200-2022; Eckstein, Hans-Henning/AFK-1881-2022	Shouval, Daniel/0000-0002-0512-6513; 				ALMDAL TP, 1991, HEPATOLOGY, V13, P650, DOI 10.1002/hep.1840130407; ASCHER NL, 1989, TRANSPLANT P, V21, P3482; BELLE SH, 1993, CLIN TRANSPLANTS, pCH2; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; BIRD GLA, 1990, BRIT MED J, V301, P15, DOI 10.1136/bmj.301.6742.15; CALNE R, 1994, HEPATOLOGY, V20, pS3, DOI 10.1002/hep.1840200703; GISH RG, 1993, AM J GASTROENTEROL, V88, P1337; GORDON RD, 1991, TRANSPLANTATION, V51, P128, DOI 10.1097/00007890-199101000-00020; LEEVY CM, 1994, DISEASE LIVER BILIAR, P1; LUCEY MR, 1992, GASTROENTEROLOGY, V102, P1736, DOI 10.1016/0016-5085(92)91737-O; MCCURRY KR, 1992, ARCH SURG-CHICAGO, V127, P772; MUNOZ SJ, 1989, MED CLIN N AM, V73, P1011, DOI 10.1016/S0025-7125(16)30651-4; OLTHOFF KM, 1990, ARCH SURG-CHICAGO, V125, P1261; SHAW BW, 1989, SEMIN LIVER DIS, V9, P159, DOI 10.1055/s-2008-1040508; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; 1984, HEPATOLOGY, V4, pS1; 1993, JAMA-J AM MED ASSOC, V365, P569; 1989, STAT ABSTR ISR; 1994, HEPATOLOGY, V20, pS1	20	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					660	662		10.1016/S0140-6736(95)92279-2	http://dx.doi.org/10.1016/S0140-6736(95)92279-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658818				2022-12-28	WOS:A1995RU04800008
J	CAMACHO, P; LECHLEITER, JD				CAMACHO, P; LECHLEITER, JD			CALRETICULIN INHIBITS REPETITIVE INTRACELLULAR CA2+ WAVES	CELL			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; XENOPUS-LAEVIS OOCYTES; CALCIUM-BINDING PROTEIN; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; RELEASE; STORES; IDENTIFICATION; CALSEQUESTRIN; CHANNELS	Inositol 1,4,5-trisphosphate (IP3)-mediated calcium (Ca2+) signaling is subject to cytosolic and luminal regulatory mechanisms. In Xenopus oocytes, Ca2+-sensitive gating of the IP3 receptor (IP(3)R) produces repetitive waves of Ca2+ release. We examined the role of the luminal Ca2+-binding protein calreticulin (CRT) in IP3-mediated Ca2+ signaling by using Ca2+ wave activity as a sensitive Ca2+ release assay. Overexpression of CRT inhibited repetitive IP3-induced Ca2+ waves. Deletion mutagenesis demonstrated that CRT inhibition was mediated by the high affinity-low capacity Ca2+-binding domain, which contributes little to Ca2+ storage. This novel function of CRT in intracellular Ca2+ signaling may be regulated by Ca2+ occupancy of the high affinity binding site.			CAMACHO, P (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048451] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CALLAMARAS N, 1994, CELL CALCIUM, V15, P66, DOI 10.1016/0143-4160(94)90105-8; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HAUSEN P, 1981, STAIN TECHNOL, V56, P287, DOI 10.3109/10520298109067329; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LIU NG, 1994, J BIOL CHEM, V269, P28635; LONGIN A, 1993, J HISTOCHEM CYTOCHEM, V41, P1833, DOI 10.1177/41.12.8245431; LYTTON J, 1991, HEART CARDIOVASCULAR, P1203; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OSBORN M, 1982, METHOD CELL BIOL, V24, P97; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	41	198	202	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					765	771		10.1016/0092-8674(95)90473-5	http://dx.doi.org/10.1016/0092-8674(95)90473-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671304	Bronze			2022-12-28	WOS:A1995RU75500011
J	VOGEL, KS; BRANNAN, CI; JENKINS, NA; COPELAND, NG; PARADA, LF				VOGEL, KS; BRANNAN, CI; JENKINS, NA; COPELAND, NG; PARADA, LF			LOSS OF NEUROFIBROMIN RESULTS IN NEUROTROPHIN-INDEPENDENT SURVIVAL OF EMBRYONIC SENSORY AND SYMPATHETIC NEURONS	CELL			English	Article							NERVE GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; TRK PROTOONCOGENE PRODUCT; DORSAL-ROOT-GANGLIA; TYPE-1 GENE; CAENORHABDITIS-ELEGANS; PROTEIN PRODUCT; TYROSINE KINASE; RAS P21; MOUSE	Mutations at the neurofibromatosis 1 (NF1) locus in humans and mice result in abnormal growth of neural crest-derived cells, including melanocytes and Schwann cells. We have exploited a targeted disruption of the NF1 gene in mice to examine the role of neurofibromin in the acquisition of neurotrophin dependence in embryonic neurons. We show that both neural crest- and placode-derived sensory neurons isolated from NF1 (-/-) embryos develop, extend neurites, and survive in the absence of neurotrophins, whereas their wild-type counterparts die rapidly unless nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF) is added to the culture medium. Moreover, NF1 (-/-) sympathetic neurons survive for extended periods and acquire mature morphology in the presence of NGF-blocking antibodies. Our results are consistent with a model wherein neurofibromin acts as a negative regulator of neurotrophin-mediated signaling for survival of embryonic peripheral neurons.	NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	VOGEL, KS (corresponding author), UNIV TEXAS,SW MED CTR,CTR DEV BIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Parada, luis F/B-9400-2014		NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COUGHLIN MD, 1985, DEV BIOL, V110, P392, DOI 10.1016/0012-1606(85)90098-3; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; DAVIES A, 1984, J COMP NEUROL, V223, P124, DOI 10.1002/cne.902230110; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DEDOUARIN NM, 1992, SENSORY NEURONS DIVE, P143; DICICCOBLOOM E, 1990, J CELL BIOL, V110, P2073, DOI 10.1083/jcb.110.6.2073; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ERNSBERGER U, 1988, DEV BIOL, V126, P420, DOI 10.1016/0012-1606(88)90151-0; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HAN M, 1990, GENETICS, V126, P899; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAWSON SN, 1979, J NEUROCYTOL, V8, P265, DOI 10.1007/BF01236122; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NG NFL, 1993, J BIOL CHEM, V268, P25329; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; ROHRER H, 1988, DEVELOPMENT, V103, P545; RUBIN E, 1985, J NEUROSCI, V5, P673; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THEILER K, 1989, HOUSE MOUSE; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; Vogel Kristine S., 1992, P171; VOGEL KS, 1991, NEURON, V7, P819, DOI 10.1016/0896-6273(91)90284-7; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weston J A, 1970, Adv Morphog, V8, P41; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	58	132	133	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					733	742		10.1016/0092-8674(95)90470-0	http://dx.doi.org/10.1016/0092-8674(95)90470-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671302	Bronze			2022-12-28	WOS:A1995RU75500008
J	DARBY, SC; EWART, DW; GIANGRANDE, PLF; DOLIN, PJ; SPOONER, RJD; RIZZA, CR				DARBY, SC; EWART, DW; GIANGRANDE, PLF; DOLIN, PJ; SPOONER, RJD; RIZZA, CR			MORTALITY BEFORE AND AFTER HIV-INFECTION IN THE COMPLETE UK POPULATION OF HEMOPHILIACS	NATURE			English	Article							HEMOPHILIA CENTERS; UNITED-KINGDOM; AIDS; COHORT; DIRECTORS; BRITAIN; BEHALF; STATES; DEATH	DURING 1977-91, 6,278 males diagnosed with haemophilia were living in the UK. During 1979-86, 1,227 were infected with the human immunodeficiency virus (HIV-1) as a result of transfusion therapy (median estimated seroconversion date, October 1982). Among 2,448 with severe haemophilia, the annual death rate was stable at 8 per 1,000 during 1977-84; during 1985-92 death rates remained at 8 per 1,000 among HIV-seronegative patients but rose steeply in seropositive patients, reaching 81 per 1,000 in 1991-92. Among 3,830 with mild or moderate haemophilia, the pattern was similar, with an initial death rate of 4 per 1,000 in 1977-84, rising to 85 per 1,000 in 1991-92 in seropositive patients. During 1985-92, there were 403 deaths in HIV seropositive patients, whereas 60 would have been predicted from rates in seronegatives, suggesting that 85% of the deaths in seropositive patients were due to HIV infection. Most of the excess deaths were certified as due to AIDS or to conditions recognized as being associated with AIDS.	CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND	University of Oxford	DARBY, SC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.		Semple, Malcolm Gracie/A-8790-2008	Semple, Malcolm Gracie/0000-0001-9700-0418; Laffan, Michael/0000-0002-8268-3268				ARONSON DL, 1988, AM J HEMATOL, V27, P7, DOI 10.1002/ajh.2830270103; ARONSTAM A, 1993, ARCH DIS CHILD, V68, P521, DOI 10.1136/adc.68.4.521; CHEINSONGPOPOV R, 1986, BRIT MED J, V293, P168, DOI 10.1136/bmj.293.6540.168; CHORBA TL, 1994, AM J HEMATOL, V45, P112, DOI 10.1002/ajh.2830450204; COLOMBO M, 1991, AM J HEMATOL, V37, P243, DOI 10.1002/ajh.2830370406; CUTHBERT RJG, 1990, BMJ-BRIT MED J, V301, P956, DOI 10.1136/bmj.301.6758.956; DARBY SC, 1990, STAT MED, V9, P681, DOI 10.1002/sim.4780090615; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JONES P, 1985, BRIT MED J, V291, P695, DOI 10.1136/bmj.291.6497.695; KOUMBARELIS E, 1994, THROMB HAEMOSTASIS, V72, P808; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; MCCORMICK A, 1994, POPULATION TRENDS, V76, P1; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SMITH GM, 1991, CLIN LAB HAEMATOL, V13, P115; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; WILLIAMS MD, 1988, THROMB HAEMOSTASIS, V60, P97; 1994, LANCET, V343, P871; 1989, MORBIDITY MORTALITY, V38, P1; 1971, MANUAL INT STATISTIC; 1989, PHIL T R SOC LOND B, V325, P179	24	103	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					79	82		10.1038/377079a0	http://dx.doi.org/10.1038/377079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659168				2022-12-28	WOS:A1995RT72500061
J	PEKKANEN, J; TUOMILEHTO, J; UUTELA, A; VARTIAINEN, E; NISSINEN, A				PEKKANEN, J; TUOMILEHTO, J; UUTELA, A; VARTIAINEN, E; NISSINEN, A			SOCIAL-CLASS, HEALTH BEHAVIOR, AND MORTALITY AMONG MEN AND WOMEN IN EASTERN FINLAND	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; INEQUALITIES; ASSOCIATION; MAGNITUDE; EDUCATION; SMOKING; DEATH; OSLO	Objective-To evaluate the associations between social class as defined by occupation, health behaviour, and mortality from all causes and coronary heart disease among middle aged men and women in eastern Finland. Design-Prospective observational study of two independent, random population samples examined in 1972 and 1977. Setting-North Karelia and Kuopio, Finland. Subjects-8967 men and 9694 women aged 30-64 years at the beginning of the follow up study. The subjects were followed up for mortality up till 1987 by using the National Death Registry. Measurements and main results-Altogether 1429 men and 620 women died during the follow up, 603 men and 164 women of coronary heart disease. Among both sexes, compared with white collar workers unskilled blue collar workers had more adverse risk factors and also higher mortality due to coronary heart disease, other cardiovascular diseases, cancer, violent causes, and all other causes. Among men the age adjusted relative risk for all cause mortality in unskilled blue collar workers v white collar workers was reduced from 1.85 (95% confidence interval 1.55 to 2.22) to 1.47 (1.23 to 1.77) when adjusted for smoking, serum cholesterol concentration, hypertension, body mass index, and physical activity in leisure time. Among women the corresponding reduction in hazard ratio was from 1.49 (1.15 to 1.92) to 1.39 (1.07 to 1.81). The respective hazard ratios for coronary heart disease were 1.54 (1.16 to 2.02) and 1.22 (0.92 to 1.61) among men and 1.74 (1.05 to 2.90) and 1.66 (0.99 to 2.79) among women. Conclusions-Unfavourable cardiovascular risk factors and high mortality are concentrated among lower social classes in Finland. Among men about half of the excess coronary and all cause,mortality among unskilled blue collar workers was associated with their unfavourable risk factor profile. The association was smaller in women.	NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,SF-00300 HELSINKI,FINLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,SF-70211 KUOPIO,FINLAND	Finland National Institute for Health & Welfare; University of Eastern Finland	PEKKANEN, J (corresponding author), NATL PUBL HLTH INST,DEPT ENVIRONM EPIDEMIOL,POB 95,SF-70701 KUOPIO,FINLAND.							ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ARBER S, 1990, NEW DIRECTIONS SOCIO; COX DR, 1972, J R STAT SOC B, V34, P187; CROUSE JR, 1989, LANCET, V1, P318, DOI 10.1016/S0140-6736(89)91320-2; DENNIS BH, 1993, INT J EPIDEMIOL, V22, P420, DOI 10.1093/ije/22.3.420; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HOLME I, 1976, LANCET, V2, P1396; HOLME I, 1980, J EPIDEMIOL COMMUN H, V34, P48, DOI 10.1136/jech.34.1.48; KUNST AE, 1994, INT J EPIDEMIOL, V23, P742, DOI 10.1093/ije/23.4.742; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; LUOTO R, 1994, J EPIDEMIOL COMMUN H, V48, P348, DOI 10.1136/jech.48.4.348; MACKENBACH JP, 1995, BRIT MED J, V310, P1152, DOI 10.1136/bmj.310.6988.1152; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; MARTIKAINEN P, IN PRESS SOCIOLOGY H; PEKKANEN J, 1995, J EPIDEMIOL COMMUN H, V49, P144, DOI 10.1136/jech.49.2.144; POCOCK SJ, 1987, LANCET, V2, P197; PUSKA P, 1981, N KARELIA PROJECT EV; ROSENGREN A, 1988, BRIT MED J, V297, P1497, DOI 10.1136/bmj.297.6662.1497; SALONEN JT, 1982, J EPIDEMIOL COMMUN H, V36, P294, DOI 10.1136/jech.36.4.294; SALONEN JT, 1980, 11980 SER OR REP; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1062, DOI 10.1093/oxfordjournals.aje.a115210; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1991, SOC SCI MED, V32, P1297, DOI 10.1016/0277-9536(91)90046-F; Townsend P., 1988, BLACK REPORT HLTH DI; Valkonen T, 1992, Int J Health Sci, V3, P157; VALKONEN T, 1990, SOCIOECONOMIC MORTAL; WING S, 1987, LANCET, V2, P1067; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8; 1987, HLTH ALL YEAR 2000 F; 1973, OFFICIAL STATISTIC C, V6, P104	35	150	151	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					589	593		10.1136/bmj.311.7005.589	http://dx.doi.org/10.1136/bmj.311.7005.589			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663252	Green Published			2022-12-28	WOS:A1995RT72300015
J	HAYLLAR, J; BJARNASON, I				HAYLLAR, J; BJARNASON, I			NSAIDS, COX-2 INHIBITORS, AND THE GUT	LANCET			English	Editorial Material							RISK		UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	HAYLLAR, J (corresponding author), MT ISA BASE HOSP,MT ISA,QLD,AUSTRALIA.							AKARASEREENONT P, 1994, BRIT J PHARMACOL, V110, pP183; ASLANIAN R, 1994, EXPERT OPIN INV DRUG, V3, P1323; Bjarnason I., 1994, Gastroenterology, V106, pA53; EVERSMEYER W, 1993, AM J MED S2A, V95, P10; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEWIS AJ, 1994, NONSTEROIDAL ANTIINF, P1; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SAVAGE RL, 1993, ARTHRITIS RHEUM, V36, P84, DOI 10.1002/art.1780360114; SOMASUNDARAM S, 1995, SCAND J GASTROENTERO, V30, P289, DOI 10.3109/00365529509093280; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0	13	85	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					521	522		10.1016/S0140-6736(95)91378-5	http://dx.doi.org/10.1016/S0140-6736(95)91378-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658776				2022-12-28	WOS:A1995RQ98600006
J	KEEN, J; PACKWOOD, T				KEEN, J; PACKWOOD, T			QUALITATIVE RESEARCH - CASE-STUDY EVALUATION	BRITISH MEDICAL JOURNAL			English	Article								Case study evaluations, using one or more qualitative methods, have been used to investigate important practical and policy questions in health care. This paper describes the features of a well designed case study and gives examples showing how qualitative methods are used in evaluations of health services and health policy.			KEEN, J (corresponding author), BRUNEL UNIV,UXBRIDGE UB8 3PH,MIDDX,ENGLAND.		altun, feyza/AAS-1401-2021					[Anonymous], 1990, SHORT CUT BETTER SER; BERWICK DM, 1991, CURING HLTH CARE; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; Griffiths Roy, 1983, NHS MANAGEMENT INQUI; JICK TD, 1979, ADMIN SCI QUART, V24, P602, DOI 10.2307/2392366; KNAPP M, 1993, PSSRU919 U KENT CANT; MAYS N, 1995, BRIT MED J, V311, P182, DOI 10.1136/bmj.311.6998.182; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; PACKWOOD T, 1991, HOSPITALS TRANSITION; Patton M. Q., 1990, QUALITATIVE EVALUATI; POLLITT C, 1990, J SOC POLICY, V19, P169, DOI 10.1017/S0047279400001987; Pollitt C., 1988, FINANCIAL ACCOUNTABI, V4, P213, DOI [https://doi.org/10.1111/j.1468-0408.1988.tb00299.x, DOI 10.1111/J.1468-0408.1988.TB00299.X]; ROBINSON R, 1994, INFORMATION MANAGEME, P3; Robinson R, 1994, EVALUATING NHS REFOR; St Leger A., 1992, EVALUATING HLTH SERV; Yin R.K., 1994, CASE STUDY RES; 1990, 329 NAT AUD OFF REP; 1990, OTA H405 OFF TECHN A; 1989, CMND555; 1993, PAC63RD COMM PUBL AC	20	64	66	2	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					444	446		10.1136/bmj.311.7002.444	http://dx.doi.org/10.1136/bmj.311.7002.444			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640596	Green Published			2022-12-28	WOS:A1995RP55400025
J	SU, Y; DOSTMANN, WRG; HERBERG, FW; DURICK, K; XUONG, NH; TENEYCK, L; TAYLOR, SS; VARUGHESE, KI				SU, Y; DOSTMANN, WRG; HERBERG, FW; DURICK, K; XUONG, NH; TENEYCK, L; TAYLOR, SS; VARUGHESE, KI			REGULATORY SUBUNIT OF PROTEIN-KINASE-A - STRUCTURE OF DELETION MUTANT WITH CAMP BINDING DOMAINS	SCIENCE			English	Article							CYCLIC-NUCLEOTIDE ANALOGS; CATALYTIC SUBUNIT; 8-AZIDOADENOSINE 3',5'-MONOPHOSPHATE; ADENOSINE 3'-5'-MONOPHOSPHATE; COVALENT MODIFICATION; R-SUBUNIT; SITE-A; ACTIVATION; AMP; PHOSPHOROTHIOATES	In the molecular scheme of living organisms, adenosine 3',5'-monophosphate (cyclic AMP or cAMP) has been a universal second messenger. In eukaryotic cells, the primary receptors for cAMP are the regulatory subunits of cAMP-dependent protein kinase. The crystal structure of a 1-91 deletion mutant of the type I alpha regulatory subunit was refined to 2.8 Angstrom resolution. Each of the two tandem cAMP binding domains provides an extensive network of hydrogen bonds that buries the cyclic phosphate and the ribose between two beta strands that are linked by a short alpha helix. Each adenine base stacks against an aromatic ring that lies outside the beta barrel. This structure provides a molecular basis for understanding how cAMP binds cooperatively to its receptor protein, thus mediating activation of the kinase.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; SAN DIEGO SUPERCOMP CTR, LA JOLLA, CA 92186 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01644] Funding Source: Medline; NIGMS NIH HHS [GM34921, GM07313] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDRIDGE K, UNPUB; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1985, BIOCHEMISTRY-US, V24, P2163, DOI 10.1021/bi00330a009; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CORBIN JD, 1982, EUR J BIOCHEM, V125, P259, DOI 10.1111/j.1432-1033.1982.tb06677.x; CREIGHTON TE, 1984, PROTEINS, P139; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; JASTORFF B, 1979, EUR J BIOCHEM, V101, P555, DOI 10.1111/j.1432-1033.1979.tb19750.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERLAVAGE AR, 1980, J BIOL CHEM, V255, P8483; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KREBS EG, 1993, BIOSCIENCE REP, V13, P127, DOI 10.1007/BF01149958; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCCP4 ESF EACM; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; NELSON NC, 1983, J BIOL CHEM, V258, P981; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHABB JB, 1991, J BIOL CHEM, V266, P24320; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1993, J MOL BIOL, V230, P1091, DOI 10.1006/jmbi.1993.1224; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WOODFORD TA, 1987, J BIOL CHEM, V262, P13321; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035	60	327	334	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					807	813		10.1126/science.7638597	http://dx.doi.org/10.1126/science.7638597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638597				2022-12-28	WOS:A1995RN65000036
J	ARUFFO, A; FARRINGTON, M; HOLLENBAUGH, D; LI, X; MILATOVICH, A; NONOYAMA, S; BAJORATH, J; GROSMAIRE, LS; STENKAMP, R; NEUBAUER, M; ROBERTS, RL; NOELLE, RJ; LEDBETTER, JA; FRANCKE, U; OCHS, HD				ARUFFO, A; FARRINGTON, M; HOLLENBAUGH, D; LI, X; MILATOVICH, A; NONOYAMA, S; BAJORATH, J; GROSMAIRE, LS; STENKAMP, R; NEUBAUER, M; ROBERTS, RL; NOELLE, RJ; LEDBETTER, JA; FRANCKE, U; OCHS, HD			THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME	CELL			English	Article							HUMAN B-CELLS; TUMOR NECROSIS FACTOR; HYPERIMMUNOGLOBULINEMIA-M; LYMPHOCYTES-B; RECEPTOR; IMMUNODEFICIENCY; SEQUENCES; INTERLEUKIN-4; CARCINOMAS; ANTIBODY	The prominent role of the CD40 receptor in B cell responses led us to investigate the role of the gp39-CD40 interaction in a group of primary immunodeficient patients with defective antibody production. Here we report that patients with hyper-IgM syndrome (HIM) have a defective gp39-CD40 interaction. B cells from HIM patients express functional CD40, but their T cells do not bind CD40-Ig. These patients expressed normal levels of gp39 mRNA, but these mRNAs encode defective gp39 proteins owing to mutations in the extracellular domain of gp39. Soluble recombinant forms of gp39 containing these mutations were unable to bind CD40 and drive normal B cell proliferation. The gene encoding gp39 was mapped to Xq26, the X chromosome region where the gene responsible for HIM had previously been mapped. These data suggest that a defect in gp39 is the basis of X-linked HIM.	UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV CALIF LOS ANGELES, MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; DARTMOUTH COLL, SCH MED, DEPT MICROBIOL, LEBANON, NH 03756 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; Howard Hughes Medical Institute; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Dartmouth College	ARUFFO, A (corresponding author), BRISTOL MEYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA.		Bajorath, Jürgen/F-7493-2014		NHGRI NIH HHS [R01 HG00298] Funding Source: Medline; NIAID NIH HHS [AI26296] Funding Source: Medline; NICHD NIH HHS [HD17427] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026296, R37AI026296] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; BURTIN P, 1961, REV FR ETUD CLIN BIO, V6, P286; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; GALY AHM, 1992, J IMMUNOL, V149, P775; GASCAN H, 1991, J IMMUNOL, V147, P8; GIACALONE J, 1992, NAT GENET, V1, P137, DOI 10.1038/ng0592-137; GORDON J, 1987, EUR J IMMUNOL, V17, P1535, DOI 10.1002/eji.1830171026; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; MOLLER P, 1989, LEUCOCYTE TYPING, V4, P175; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; OCHS HD, 1989, IMMUNOLOGIC DISORDER, P226; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PELTZ GA, 1988, J IMMUNOL, V141, P1891; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEDGWOOD RJ, 1980, INSERM S, V16, P69; WIEACKER P, 1984, AM J HUM GENET, V36, P265; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679; ZHANG K, 1991, J IMMUNOL, V146, P1836; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	47	768	801	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					291	300		10.1016/0092-8674(93)90668-G	http://dx.doi.org/10.1016/0092-8674(93)90668-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678782				2022-12-28	WOS:A1993KK03800013
J	BARNARD, MR; MICHELSON, AD				BARNARD, MR; MICHELSON, AD			A MORPHOLOGIC QUESTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BARNARD, MR (corresponding author), UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA 01655, USA.		Michelson, Alan/ABE-8487-2021	Michelson, Alan/0000-0002-1746-4819					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1051	1051		10.1056/NEJM199510193331605	http://dx.doi.org/10.1056/NEJM199510193331605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675048				2022-12-28	WOS:A1995RZ34000005
J	FRETTS, RC; SCHMITTDIEL, J; MCLEAN, FH; USHER, RH; GOLDMAN, MB				FRETTS, RC; SCHMITTDIEL, J; MCLEAN, FH; USHER, RH; GOLDMAN, MB			INCREASED MATERNAL AGE AND THE RISK OF FETAL DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DELAYED CHILDBEARING; PREGNANCY; BIRTH	Background. Although the fetal death rate has declined over the past 30 years among women of all ages, ii is unknown whether particular characteristics of the mother, such as age, still affect the risk of fetal death. We undertook a study to determine whether older age, having a first child (nulliparity), or other characteristics of the mother are risk factors for fetal death. Methods. We used data from the McGill Obstetrical Neonatal Database to evaluate risk factors for fetal death among all deliveries at the Royal Victoria Hospital in Montreal (n=94,346) from 1961 through 1993, Data were available for two time periods (1961 through 1974 and 1978 through 1993); data for 1975 through 1977 have not been entered into the data base and were therefore not included. Using logistic regression, we estimated the effect of specific maternal characteristics and complications of pregnancy on the risk of fetal death. Results. The fetal death rate decreased significantly from 11.5 per 1000 total births (including live births and stillbirths) in the 1960s to 3.2 per 1000 in 1990 through 1993 (P<0,001), Between these periods, the average maternal age at delivery increased from 27 to 30 years (P<0.001), and the frequency of the diagnosis of diabetes and hypertension during pregnancy increased fivefold (P<0.001), Nevertheless, after we controlled for these and other maternal characteristics, women 35 years of age or older continued to have a significantly higher rate of fetal death than their younger counterparts (odds ratio for women 35 to 39 years of age as compared with women <30 years of age, 1.9; 95 percent confidence interval, 1.3 to 2.7; for those 40 or older, 2.4; 95 percent confidence interval, 1.3 to 4.5). Conclusions. Changes in maternal health and obstetrical practice have resulted in a 70 percent decline in the rate of fetal death among pregnant women of all ages since the 1960s. Advancing maternal age, however, continues to be a risk factor for fetal death.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; ROYAL VICTORIA HOSP, DEPT OBSTET & GYNECOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, MONTREAL, PQ, CANADA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; McGill University; Royal Victoria Hospital; McGill University	FRETTS, RC (corresponding author), BETH ISRAEL HOSP, DEPT OBSTET & GYNECOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ALES KL, 1990, SURG GYNECOL OBSTET, V171, P209; BARKAN SE, 1987, AM J EPIDEMIOL, V125, P101, DOI 10.1093/oxfordjournals.aje.a114491; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CNATTINGIUS S, 1992, Journal of the American Medical Association, V268, P886, DOI 10.1001/jama.268.7.886; CNATTINGIUS S, 1993, OBSTET GYNECOL, V81, P512; CUNNINGHAM FG, 1990, NEW ENGL J MED, V323, P414; EDGE V, 1993, AM J OBSTET GYNECOL, V168, P1881, DOI 10.1016/0002-9378(93)90706-O; FORMAN MR, 1984, JAMA-J AM MED ASSOC, V252, P3135, DOI 10.1001/jama.252.22.3135; FRETTS RC, 1992, OBSTET GYNECOL, V79, P35; KIELY JL, 1986, AM J EPIDEMIOL, V123, P444, DOI 10.1093/oxfordjournals.aje.a114259; KIRZ DS, 1985, AM J OBSTET GYNECOL, V152, P7, DOI 10.1016/S0002-9378(85)80166-6; LEYLAND AH, 1990, NEW ENGL J MED, V323, P413; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; PITKIN RM, 1991, AM J OBSTET GYNECOL, V164, P1045, DOI 10.1016/0002-9378(91)90584-E; PRYSAK M, 1995, OBSTET GYNECOL, V85, P65, DOI 10.1016/0029-7844(94)00330-G; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P285; SLUTSKER L, 1992, OBSTET GYNECOL, V79, P778; 1990, SAS USERS GUIDE STAT; 1989, VITAL HLTH STATIS 21, V47; 1979, LANCET, V1, P142	21	293	306	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					953	957		10.1056/NEJM199510123331501	http://dx.doi.org/10.1056/NEJM199510123331501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666913				2022-12-28	WOS:A1995RY58600001
J	KENT, KC; KUNTZ, KM; PATEL, MR; KIM, D; KLUFAS, RA; WHITTEMORE, AD; POLAK, JF; SKILLMAN, JJ; EDELMAN, RR				KENT, KC; KUNTZ, KM; PATEL, MR; KIM, D; KLUFAS, RA; WHITTEMORE, AD; POLAK, JF; SKILLMAN, JJ; EDELMAN, RR			PERIOPERATIVE IMAGING STRATEGIES FOR CAROTID ENDARTERECTOMY - AN ANALYSIS OF MORBIDITY AND COST-EFFECTIVENESS IN SYMPTOMATIC PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAGNETIC-RESONANCE ANGIOGRAPHY; MR-ANGIOGRAPHY; ARTERY STENOSIS; CONVENTIONAL ANGIOGRAPHY; DOPPLER SONOGRAPHY; ECONOMIC COSTS; DISEASE; ARTERIOGRAPHY; STROKE; CANDIDATES	Objective.-To assess the cost-effectiveness of four diagnostic strategies for the preoperative evaluation of symptomatic patients who are potential candidates for carotid endarterectomy tie, 70% to 99% stenosis): (1) duplex sonography (DS), (2) magnetic resonance angiography (MRA), (3) contrast angiography (CA), and (4) the combination of DS and MRA supplemented by CA for disparate results. Methods.-Cost-effectiveness analysis based largely on published clinical trial data, Sensitivities and specificities of noninvasive tests were estimated from 81 patients undergoing prospective evaluation with DS, MRA, and CA. Outcome Measure.-Incremental cost per quality-adjusted year of life gained. Results.-For a hypothetical cohort of symptomatic patients undergoing evaluation for carotid endarterectomy, the combination of tests resulted in the greatest quality-adjusted life expectancy of the four options considered. After incorporating the costs of testing, surgery, and stroke, we found that neither the MRA nor the CA strategy was cost-effective. The combination of tests was more effective but more costly than DS, resulting in an additional cost of $22 400 per quality-adjusted year of life gained, For centers that do not have adequate MRA, CA resulted in an additional cost of $99 200 per quality-adjusted year of life saved compared with DS. Conclusions.-Our results suggest that for the preoperative detection of a 70% to 99% carotid stenosis, the combination of DS and MRA, supplemented by CA for disparate results, is associated with the lowest long-term morbidity and mortality and has a favorable cost-effectiveness ratio. The combination of tests, or DS alone when MRA is not available, could potentially replace the current practice of using CA alone in the preoperative evaluation of patients with symptomatic carotid stenosis.	BETH ISRAEL HOSP,DEPT RADIOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT SURG,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RADIOL,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	KENT, KC (corresponding author), BETH ISRAEL HOSP,DEPT SURG,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ANDERSON CM, 1992, AM J NEURORADIOL, V13, P989; BAUM HM, 1991, STROKE S1, V12, pI59; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; CALLOW AD, 1987, SURGERY CEREBROVASCU; Chervu A, 1994, Ann Vasc Surg, V8, P296, DOI 10.1007/BF02018179; DAWSON DL, 1993, J VASC SURG, V18, P673, DOI 10.1016/0741-5214(93)90077-Y; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P408; FAUGHT WE, 1993, J VASC SURG, V18, P512, DOI 10.1016/0741-5214(93)90270-V; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; GOODSON SF, 1987, J VASC SURG, V5, P551, DOI 10.1067/mva.1987.avs0050551; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HARTUNIAN NS, 1980, AM J PUBLIC HEALTH, V70, P1249, DOI 10.2105/AJPH.70.12.1249; Horn M, 1994, Ann Vasc Surg, V8, P221, DOI 10.1007/BF02018167; HUNINK MGM, 1993, AM J ROENTGENOL, V160, P619, DOI 10.2214/ajr.160.3.8430567; HUSTON J, 1993, RADIOLOGY, V186, P339, DOI 10.1148/radiology.186.2.8421731; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LI W, 1992, AM J NEURORADIOL, V13, P1423; MACKEY WC, 1989, J VASC SURG, V10, P432; MASARYK AM, 1991, RADIOLOGY, V179, P797, DOI 10.1148/radiology.179.3.2027995; MATCHAR DB, 1987, JAMA-J AM MED ASSOC, V258, P793, DOI 10.1001/jama.258.6.793; MATTLE HP, 1991, J VASC SURG, V13, P838; MILLS E, 1978, NEW ENGL J MED, V299, P415, DOI 10.1056/NEJM197808242990810; MONETA GL, 1993, J VASC SURG, V17, P152, DOI 10.1016/0741-5214(93)90019-I; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; POLAK JF, 1992, RADIOLOGY, V182, P35, DOI 10.1148/radiology.182.1.1727306; POLAK JF, 1993, RADIOLOGY, V186, P333, DOI 10.1148/radiology.186.2.8421730; ROBINSON ML, 1988, AM J ROENTGENOL, V151, P1045, DOI 10.2214/ajr.151.5.1045; SCHULER JJ, 1982, SURGERY, V92, P1058; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SWETS JA, 1979, INVEST RADIOL, V14, P109, DOI 10.1097/00004424-197903000-00002; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; TURNIPSEED WD, 1993, SURGERY, V114, P643; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; 1991, LANCET, V337, P1235; 1990, VITAL STATISTICS US, V2; 1991, NEW ENGL J MED, V325, P445	38	131	132	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					888	893		10.1001/jama.274.11.888	http://dx.doi.org/10.1001/jama.274.11.888			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674503				2022-12-28	WOS:A1995RU60300028
J	HANKS, GW				HANKS, GW			MORPHINE SANS MORPHEUS	LANCET			English	Editorial Material							PAIN				HANKS, GW (corresponding author), BRISTOL ONCOL CTR, DEPT PALLIAT MED, BRISTOL, AVON, ENGLAND.							FOLEY KM, 1993, SYMP PAIN R, P331; HANKS GW, 1984, LANCET, V1, P1477; HANKS GW, IN PRESS EUR J CLIN; LASAGNA L, 1965, NARCOTICS, P53; ONEILL WM, IN PRESS EUR J CLIN; SJOGREN P, 1989, PAIN, V39, P5, DOI 10.1016/0304-3959(89)90168-1	6	23	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 9	1995	346	8976					652	653		10.1016/S0140-6736(95)92274-1	http://dx.doi.org/10.1016/S0140-6736(95)92274-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658814				2022-12-28	WOS:A1995RU04800003
J	VAINIO, A; OLLILA, J; MATIKAINEN, E; ROSENBERG, P; KALSO, E				VAINIO, A; OLLILA, J; MATIKAINEN, E; ROSENBERG, P; KALSO, E			DRIVING ABILITY IN CANCER-PATIENTS RECEIVING LONG-TERM MORPHINE ANALGESIA	LANCET			English	Article							PAIN; BUPRENORPHINE; PSYCHOMOTOR; OPIOIDS	When given in single doses to healthy volunteers, opioid analgesics impair reaction time, muscle coordination, attention, and short-term memory sufficiently to affect driving and other skilled activities. Despite the increasing use of oral morphine daily, little is known about the effect of long-term opioid therapy on psychomotor performance. To examine the effects of continuous morphine medication, psychological and neurological tests originally designed for professional motor vehicle drivers were conducted in two groups of cancer patients who were similar apart from experience of pain, 24 were on continuous morphine (mean 209 mg oral morphine daily) for cancer pain; and 25 were pain-free without regular analgesics. Though the results were a little worse in the patients taking morphine, there were no significant differences between the groups in intelligence, vigilance. concentration, fluency of motor reactions, or division of attention. Of the neural function tests, reaction times (auditory, visual, associative), thermal discrimination, and body sway with eyes open were similar in the two groups; only balancing ability with closed eyes was worse in the morphine group. These results indicate that, in cancer patients receiving long-term morphine treatment with stable doses, morphine has only a slight and selective effect on functions related to driving.	UNIV HELSINKI,CENT HOSP,DEPT ANAESTHESIA,SF-00290 HELSINKI,FINLAND; FINNISH INST OCCUPAT HLTH,HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; Finnish Institute of Occupational Health								BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BUKASA B, 1985, VERKEHRSPSYCHOLOGISC, V23; Bukasa B, 1990, DIAGNOSTICA, V36, P148; Gardziella M., 1985, WARTEGG PIIRUSTUSTES; GORDON N, 1976, PSYCHOPHARMACOLOGIA, V16, P337; HAKKINEN S, 1979, ACCIDENT ANAL PREV, V11, P7, DOI 10.1016/0001-4575(79)90033-2; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; JOO S, 1994, J TRAFFIC MED, V22, P101; KERR B, 1991, NEUROPSYCHOPHARMACOL, V5, P157; LEQUESNE PM, 1990, J NEUROL NEUROSUR PS, V53, P558, DOI 10.1136/jnnp.53.7.558; LINNOILA M, 1986, DRUGS DRIVING, P29; LOMBARDO WK, 1976, INT J ADDICT, V11, P389, DOI 10.3109/10826087609056158; MACDONALD FC, 1989, BRIT J CLIN PHARMACO, V27, P453, DOI 10.1111/j.1365-2125.1989.tb05393.x; OHANLON JF, 1986, DRUGS DRIVING; OJALA M, 1989, ACTA NEUROL SCAND, V80, P118, DOI 10.1111/j.1600-0404.1989.tb03852.x; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; ROTHENBERG S, 1977, PSYCHOPHARMACOLOGY, V52, P299, DOI 10.1007/BF00426715; SAARIALHOKERE U, 1987, EUR J CLIN PHARMACOL, V33, P139, DOI 10.1007/BF00544557; SJOGREN P, 1989, PAIN, V39, P5, DOI 10.1016/0304-3959(89)90168-1; SVENSSON JO, 1982, J CHROMATOGR, V230, P427, DOI 10.1016/S0378-4347(00)80494-6; TREAT JR, 1977, DOTHS03453577TAC IND; VAINIO A, 1988, ACTA ANAESTH SCAND, V32, P179, DOI 10.1111/j.1399-6576.1988.tb02711.x; WARTEGG E, 1955, TESTS KLINISCHEN PSY, V2, P520; YATES IW, 1980, CANCER, V45, P228	24	152	156	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					667	670		10.1016/S0140-6736(95)92281-4	http://dx.doi.org/10.1016/S0140-6736(95)92281-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658820				2022-12-28	WOS:A1995RU04800010
J	LEVIN, M; JOHNSON, RL; STERN, CD; KUEHN, M; TABIN, C				LEVIN, M; JOHNSON, RL; STERN, CD; KUEHN, M; TABIN, C			A MOLECULAR PATHWAY DETERMINING LEFT-RIGHT ASYMMETRY IN CHICK EMBRYOGENESIS	CELL			English	Article							AXIAL STRUCTURES; BODY ASYMMETRY; EMBRYO; PATTERN; ACTIVIN; BLASTODERM; EXPRESSION; INDUCTION; MUTATION; HEART	While significant progress has been made in understanding the molecular events underlying the early specification of the antero-posterior and dorso-ventral axes, little information is available regarding the cellular or molecular basis for left-right (LR) differences in animal morphogenesis. We describe the expression patterns of three genes involved in LR determination in chick embryos: activin receptor IIa, Sonic hedgehog (Shh), and cNR-1 (related to the mouse gene nodal). These genes are expressed asymmetrically during and after gastrulation and regulate the expression of one another in a sequential pathway. Moreover, manipulation of the sidedness of either activin protein or Shh expression alters heart situs. Together, these observations identify a cascade of molecular asymmetry that determines morphological LR asymmetry in the chick embryo.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NIH,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	Columbia University; National Institutes of Health (NIH) - USA	LEVIN, M (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.		Stern, Claudio D/C-6265-2008; Levin, Michael/A-5918-2011; Stern, Claudio/AAZ-7381-2021; Kuehn, Michael R/A-4573-2014	Stern, Claudio D/0000-0002-9907-889X; Levin, Michael/0000-0001-7292-8084; Stern, Claudio/0000-0002-9907-889X; Kuehn, Michael R/0000-0002-7703-9160				BROWN NA, 1991, CIBA F SYMP, V162, P182; CONLON FL, 1994, DEVELOPMENT, V120, P1919; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; DANOS MC, 1995, DEVELOPMENT, V121, P1467; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELDER FF, 1993, SCIENCE, V260, P679; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; FUJINAGA M, 1991, DEV BIOL, V143, P203, DOI 10.1016/0012-1606(91)90067-D; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1978, ORG MILESTONE HALF C, P221; HOYLE C, 1992, DEVELOPMENT, V115, P1071; Hummel K. P., 1959, Journal of Heredity, V50, P9; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KAUFMAN MH, 1981, J ANAT, V133, P235; KINOSHITA K, 1993, DEV BIOL, V160, P276, DOI 10.1006/dbio.1993.1305; KLAR AJS, 1994, TRENDS GENET, V10, P292; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAYTON WM, 1993, TERATOLOGY, V47, P595, DOI 10.1002/tera.1420470611; MCCAIN ER, 1994, DEVELOPMENT, V120, P395; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSLINK H, 1994, CELL, V76, P761; SALAZAR DEL RIO J, 1974, Journal of Embryology and Experimental Morphology, V31, P199; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHREINER CM, 1993, DEV BIOL, V158, P560, DOI 10.1006/dbio.1993.1214; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; STALSBER.H, 1969, DEV BIOL, V19, P109, DOI 10.1016/0012-1606(69)90051-7; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; Stern CD, 1993, ESSENTIAL DEV BIOL P; STERN CD, 1995, IN PRESS DEV BIOL; STOREY KG, 1992, DEVELOPMENT, V114, P729; STREIT A, 1994, TRENDS GENET, V10, P181, DOI 10.1016/0168-9525(94)90240-2; TOYAMA R, 1995, DEVELOPMENT, V121, P383; VIRAGH S, 1989, J MOL CELL CARDIOL, V21, P123, DOI 10.1016/0022-2828(89)90856-0; Waddington CH, 1933, J EXP BIOL, V10, P38; WADDINGTON CH, 1932, PHILOS T ROY SOC B, V13, P221; Wilhelmi H, 1921, ARCH ENTWICKLUNG ORG, V48, P517, DOI 10.1007/BF02554577; YOKOTA C, 1995, BIOCHEM BIOPH RES CO, V207, P1, DOI 10.1006/bbrc.1995.1144; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YOST HJ, 1991, CIBA F SYMP, V162, P165; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0; ZIV T, 1992, DEVELOPMENT, V115, P689	53	638	656	0	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					803	814		10.1016/0092-8674(95)90477-8	http://dx.doi.org/10.1016/0092-8674(95)90477-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671308	Bronze			2022-12-28	WOS:A1995RU75500015
J	DAVIS, DA; THOMSON, MA; OXMAN, AD; HAYNES, RB				DAVIS, DA; THOMSON, MA; OXMAN, AD; HAYNES, RB			CHANGING PHYSICIAN PERFORMANCE - A SYSTEMATIC REVIEW OF THE EFFECT OF CONTINUING MEDICAL-EDUCATION STRATEGIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIAL; PRIMARY-CARE PHYSICIANS; TEST-ORDERING BEHAVIOR; HEALTH MAINTENANCE ORGANIZATION; QUALITY ASSURANCE; SMOKING CESSATION; CLINICAL-TRIAL; COMPUTERIZED REMINDERS; MYOCARDIAL-INFARCTION; PREDICTIVE INSTRUMENT	Objective.-To review the literature relating to the effectiveness of education strategies designed to change physician performance and health care outcomes. Data Sources.-We searched MEDLINE, ERIC, NTIS, the Research and Development Resource Base in Continuing Medical Education, and other relevant data sources from 1975 to 1994, using continuing medical education (CME) and related terms as keywords. We manually searched journals and the bibliographies of other review articles and called on the opinions of recognized experts. Study Selection.-We reviewed studies that met the following criteria: randomized controlled trials of education strategies or interventions that objectively assessed physician performance and/or health care outcomes. These intervention strategies included (alone and in combination) educational materials, formal CME activities, outreach visits such as academic detailing, opinion leaders, patient-mediated strategies, audit with feedback, and reminders. Studies were selected only if more than 50% of the subjects were either practicing physicians or medical residents. Data Extraction.-We extracted the specialty of the physicians targeted by the interventions and the clinical domain and setting of the trial. We also determined the details of the educational intervention, the extent to which needs or barriers to change had been ascertained prior to the intervention, and the main outcome measure(s). Data Synthesis.-We found 99 trials, containing 160 interventions, that met our criteria. Almost two thirds of the interventions (101 of 160) displayed an improvement in at least one major outcome measure: 70% demonstrated a change in physician performance, and 48% of interventions aimed at health care outcomes produced a positive change. Effective change strategies included reminders, patient-mediated interventions, outreach visits, opinion leaders, and multifaceted activities. Audit with feedback and educational materials were less effective, and formal CME conferences or activities, without enabling or practice-reinforcing strategies, had relatively little impact. Conclusion.-Widely used CME delivery methods such as conferences have little direct impact on improving professional practice. More effective methods such as systematic practice-based interventions and outreach visits are seldom used by CME providers.	MCMASTER UNIV, FAC HLTH SCI, HAMILTON, ON, CANADA; NATL INST PUBL HLTH, OSLO, NORWAY	McMaster University	DAVIS, DA (corresponding author), UNIV TORONTO, FAC MED, OFF CONTINUING EDUC, 150 COLL ST, TORONTO, ON M5S 1A8, CANADA.		Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061; Haynes, Robert Brian/0000-0002-1453-3196				AMARA R, 1988, LOOKING AHEAD AM HLT; ANDERSON FA, 1994, ARCH INTERN MED, V154, P669, DOI 10.1001/archinte.154.6.669; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; BANDURA A, 1986, SOCIAL F THOUGHT ACT; BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BASS MJ, 1986, CAN MED ASSOC J, V134, P1247; Beaudry JS, 1989, J CONTIN EDUC HEALTH, V9, P285, DOI DOI 10.1002/CHP.4750090414; BERTRAM DA, 1977, HEALTH EDUC QUART, V5, P330, DOI 10.1177/109019817700500404; BERWICK DM, 1986, JAMA-J AM MED ASSOC, V255, P1450, DOI 10.1001/jama.255.11.1450; BILLI JE, 1987, J GEN INTERN MED, V2, P306, DOI 10.1007/BF02596163; BRIMBERRY R, 1988, J FAM PRACTICE, V26, P397; BRITTON ML, 1991, AM J HOSP PHARM, V48, P265, DOI 10.1093/ajhp/48.2.265; BROWNER WS, 1994, WESTERN J MED, V161, P572; BUNTINX F, 1993, BRIT J GEN PRACT, V43, P194; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; CHAMBERS CV, 1989, J FAM PRACTICE, V29, P273; CHASE CR, 1983, MED CARE, V21, P410, DOI 10.1097/00005650-198304000-00004; CHASSIN MR, 1986, JAMA-J AM MED ASSOC, V256, P1012, DOI 10.1001/jama.256.8.1012; CHENEY C, 1987, AM J MED, V83, P129, DOI 10.1016/0002-9343(87)90507-9; COCKBURN J, 1992, BRIT MED J, V304, P691, DOI 10.1136/bmj.304.6828.691; COHEN DI, 1982, MED CARE, V20, P286, DOI 10.1097/00005650-198203000-00005; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; COHEN SJ, 1985, SOC SCI MED, V21, P909, DOI 10.1016/0277-9536(85)90147-9; COWAN JA, 1992, AM J PREV MED, V8, P104, DOI 10.1016/S0749-3797(18)30843-2; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; CUMMINGS SR, 1989, J GEN INTERN MED, V4, P482, DOI 10.1007/BF02599545; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DAVIS DA, 1994, PHYSICIAN LEARNER LI, pR13; DICKINSON JC, 1981, MED CARE, V19, P843, DOI 10.1097/00005650-198108000-00004; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; EVANS CE, 1986, JAMA-J AM MED ASSOC, V255, P501; EVERETT GD, 1983, ARCH INTERN MED, V143, P942, DOI 10.1001/archinte.143.5.942; Fox RD., 1989, CHANGING LEARNING LI; Freemantle N, 1995, Qual Health Care, V4, P45, DOI 10.1136/qshc.4.1.45; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; Green LW., 1980, HLTH ED PLANNING DIA, V1; GULLION DS, 1988, J CONTIN EDUC HEALTH, V8, P239; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; HEALE J, 1988, P ANN C RES MED ED, V27, P72; HERSHEY CO, 1986, MED CARE, V24, P472, DOI 10.1097/00005650-198606000-00002; HERSHEY CO, 1988, MED CARE, V26, P88, DOI 10.1097/00005650-198801000-00010; JAY SJ, 1993, J CONTINUING ED HLTH, V13, P195; JENNETT PA, 1988, MED EDUC, V22, P139, DOI 10.1111/j.1365-2923.1988.tb00424.x; KOTTKE TE, 1989, JAMA-J AM MED ASSOC, V261, P2101, DOI 10.1001/jama.261.14.2101; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LINN BS, 1980, JAMA-J AM MED ASSOC, V244, P565, DOI 10.1001/jama.244.6.565; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MAGRUDERHABIB K, 1990, MED CARE, V28, P239, DOI 10.1097/00005650-199003000-00004; MAIMAN LA, 1988, AM J DIS CHILD, V142, P773, DOI 10.1001/archpedi.1988.02150070087033; MANHEIM LM, 1990, MED CARE, V28, P29, DOI 10.1097/00005650-199001000-00005; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; MARTON KI, 1985, ARCH INTERN MED, V145, P816, DOI 10.1001/archinte.145.5.816; MAYEFSKY JH, 1993, MED EDUC, V27, P170, DOI 10.1111/j.1365-2923.1993.tb00248.x; MAZZUCA SA, 1990, AM EDUC RES J, V27, P473, DOI 10.3102/00028312027003473; MCALISTER NH, 1986, BRIT MED J, V293, P670, DOI 10.1136/bmj.293.6548.670; MCCONNELL TS, 1982, WESTERN J MED, V137, P448; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCLAUGHLIN PJ, 1991, J CONTIN EDUC HEALTH, V11, P65; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MEYER TJ, 1991, J GEN INTERN MED, V6, P133, DOI 10.1007/BF02598309; Morgan M, 1978, QRB Qual Rev Bull, V4, P33; NORTON PG, 1985, J FAM PRACTICE, V21, P289; Nowlen PM., 1988, NEW APPROACH CONTINU; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, IN PRESS CAN MED ASS; PALMER RH, 1985, MED CARE, V23, P751, DOI 10.1097/00005650-198506000-00001; PERERA DR, 1983, J FAM PRACTICE, V16, P785; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; PINKERTON RE, 1980, JAMA-J AM MED ASSOC, V244, P2183, DOI 10.1001/jama.244.19.2183; POLLACK MM, 1991, CRIT CARE MED, V19, P12, DOI 10.1097/00003246-199101000-00008; PORIES WJ, 1994, WORLD J SURG, V18, P745, DOI 10.1007/BF00298921; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PUGH JA, 1989, ARCH INTERN MED, V149, P426, DOI 10.1001/archinte.149.2.426; PUTNAM RW, 1989, CAN MED ASSOC J, V140, P806; PUTNAM RW, 1985, CAN MED ASSOC J, V132, P1025; RABIN DL, 1994, ANN INTERN MED, V121, P513, DOI 10.7326/0003-4819-121-7-199410010-00007; RAISCH DW, 1990, AM J HOSP PHARM, V47, P1766, DOI 10.1093/ajhp/47.8.1766; RESTUCCIA JD, 1982, MED CARE, V20, P46, DOI 10.1097/00005650-198201000-00004; Rogers EM., 1983, DIFFUSION INNOVATION; ROGERS JL, 1982, MED CARE, V20, P63, DOI 10.1097/00005650-198201000-00005; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; SANAZARO PJ, 1978, NEW ENGL J MED, V298, P1171, DOI 10.1056/NEJM197805252982104; SIBLEY JC, 1982, NEW ENGL J MED, V306, P511, DOI 10.1056/NEJM198203043060904; SOUMERAI SB, 1993, JAMA-J AM MED ASSOC, V270, P961, DOI 10.1001/jama.270.8.961; STEELE MA, 1989, DICP ANN PHARMAC, V23, P497, DOI 10.1177/106002808902300612; STROSS JK, 1980, ARTHRITIS RHEUM, V23, P846, DOI 10.1002/art.1780230711; STROSS JK, 1983, AM REV RESPIR DIS, V127, P739; STROSS JK, 1985, ARTHRITIS RHEUM, V28, P108, DOI 10.1002/art.1780280119; SULMASY DP, 1992, JAMA-J AM MED ASSOC, V267, P682; SZCZEPURA A, 1994, BRIT J GEN PRACT, V44, P19; TAPE TG, 1993, AM J MED, V94, P619, DOI 10.1016/0002-9343(93)90214-A; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; TURNER RC, 1990, ARCH INTERN MED, V150, P645, DOI 10.1001/archinte.150.3.645; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; WEINGARTEN MA, 1989, FAM PRACT, V6, P120, DOI 10.1093/fampra/6.2.120; WEXLER JR, 1975, AM J DIS CHILD, V129, P203, DOI 10.1001/archpedi.1975.02120390037008; WHITE CW, 1985, ANN INTERN MED, V102, P686, DOI 10.7326/0003-4819-102-5-686; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; WIGTON RS, 1981, JAMA-J AM MED ASSOC, V245, P1745; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; WINICKOFF RN, 1985, AM J PUBLIC HEALTH, V75, P43, DOI 10.2105/AJPH.75.1.43; WINICKOFF RN, 1984, MED CARE, V22, P527, DOI 10.1097/00005650-198406000-00003; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; 1994, ACAD MED, V69, P512; 1995, PHYSICIAL CHARACTERI; 1994, CME DIRECTORY; 1994, MEDLINE SEARCH STRAT, P29	122	1893	1920	4	164	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					700	705						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR835	7650822				2022-12-28	WOS:A1995RR83500015
J	JONASSON, O; KWAKWA, F; SHELDON, GF				JONASSON, O; KWAKWA, F; SHELDON, GF			CALCULATING THE WORKFORCE IN GENERAL-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE REFORM; PHYSICIAN; 21ST-CENTURY; NEED	Objective.-To provide a reasonable estimate of the patient care and resident physician workforce practicing general surgery in 1994. Design.-Data regarding general surgical residents and practicing general surgeons were obtained from four sources and compared with previously published numbers. Data Sources.-Information was derived from the American College of Surgeons' Longitudinal Study of Surgical Residents: 1992-1993; the American Medical Association's Physician Characteristics and Distribution in the United States, 1994 Edition; the American Board of Medical Specialties' database on general surgeons; and the American Board of Surgery recertification data from the files of diplomates since 1968. Each of these sources was analyzed separately to derive a count of graduates from general surgery residency programs and an estimate of fully trained general surgeons engaged in patient care activities. Results.-We found that approximately 600 graduates of general surgery residency programs enter the practice of general surgery each year, and we found a close correlation between maximum and minimum estimates of the number of fully trained general surgeons engaged in active patient care, certified general surgeons who are not retired, and currently certified general surgeons. This number (17 289 to 23 502) is approximately half that commonly used in calculations of the general surgery workforce (38 239). The larger number includes surgeons with subspecialty training beyond general surgery, surgical residents, and surgeons not engaged in patient care. Conclusions.-Estimations of the workforce in general surgery and predictions of future needs for general surgeons must be derived from the appropriate number of general surgery residents and practicing general surgeons.	AMER COLL SURGEONS, DEPT EDUC & SURG SERV, CHICAGO, IL 60611 USA; UNIV N CAROLINA, DEPT SURG, CHAPEL HILL, NC USA	American College of Surgeons; University of North Carolina; University of North Carolina Chapel Hill								BANE F, 1959, PHYSICIANS GROWING A; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; FEIL EC, 1993, JAMA-J AM MED ASSOC, V269, P2659, DOI 10.1001/jama.269.20.2659; Fein Rashi, 1967, DOCTOR SHORTAGE EC D; GINZBERG E, 1989, ACAD MED, V64, P495, DOI 10.1097/00001888-198909000-00001; GINZBERG E, 1986, PHYSICIAN SHORTAGE P; Harris J E, 1986, Health Aff (Millwood), V5, P73, DOI 10.1377/hlthaff.5.4.73; IGLEHART JK, 1994, NEW ENGL J MED, V330, P1167, DOI 10.1056/NEJM199404213301628; JACOBSEN SJ, 1987, HEALTH AFFAIR, V6, P48, DOI 10.1377/hlthaff.6.2.48; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V272, P37, DOI 10.1001/jama.272.1.37; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LEE RI, 1933, PUBLICATION COMMITTE, V22, P114; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; MULLAN F, 1994, MILBANK Q, V72, P385, DOI 10.2307/3350263; PERRY HB, 1984, SURGERY, V95, P243; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1083, DOI 10.1001/jama.270.9.1083; SHELDON GF, 1991, AM J SURG, V161, P294, DOI 10.1016/0002-9610(91)91147-B; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; 1990, AGING AM TRENDS PROJ; 1952, AM HLTH STATUS NEEDS, P114; 1995, APPROVED TRAINING PR; 1988, HRSPOD881 US DEP HLT; 1991, HSRA240890041 PUBL; 1992, 3RD US DEP HLTH HUM, P59; 1980, HRA81651 HLTH RES AD, V1; 1992, NATIONAL HLTH POLICY, V4, P9; 1994, LONGITUDINAL STUDY S; 1994, PHYSICIAN CHARACTERI; 1992, OTAH434 OFF TECHN AS, P43; 1967, REPORT NATIONAL ADVI, V1, P13; 1994, 4TH US DEP HLTH HUM, P21; 1988, 1ST US DEP HLTH HUM, P1	36	38	38	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					731	734						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650827				2022-12-28	WOS:A1995RR83500020
J	WOODS, KL				WOODS, KL			MEGA-TRIALS AND MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							RANDOMIZED TRIALS; INTRAVENOUS-MAGNESIUM; RAT-HEART; REPERFUSION; MORTALITY	Clinical management of acute myocardial infarction has been strongly influenced by large, simple trials (mega-trials) with unrestrictive protocols and limited data collection. The design has been adopted to increase statistical power to a maximum. Its validity rests on an effective randomisation procedure and intention-to-treat analysis of deaths. Experience has shown that mega-trials tend to generate effect-estimates nearer the null than those from conventional trials or meta-analyses. When a small or absent observed treatment effect (or subgroup effect) in a mega-trial contrasts with the results of conventionally designed trials, it is necessary to assess both null bias and failure to increase the true treatment effect to a maximum in the mega-trial. Null bias will arise when the contrast between treatment and no-treatment, or between subgroups, is blunted either by non-protocol therapy or by inaccuracy of data, including misclassification between subgroups. Each is more likely with an unrestrictive design. To increase the true treatment effect to a maximum, trial conditions must be specified with insight into mechanism, dose-dependence, and time-dependence. The mega-trial design is therefore unsuited to an exploratory role. These issues are illustrated by the examples of nitrates, angiotensin-converting-enzyme inhibitors, and magnesium in acute myocardial infarction but have general relevance to the validity and generalisability of simple trials.			WOODS, KL (corresponding author), UNIV LEICESTER, LEICESTER ROYAL INFIRM, DEPT MED & THERAPEUT, DIV CLIN PHARMACOL, LEICESTER LE2 7LX, LEICS, ENGLAND.							[Anonymous], 1994, Lancet, V344, P91; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ATAR D, 1994, J CARDIOVASC PHARM, V24, P603, DOI 10.1097/00005344-199410000-00011; BALL SG, 1993, LANCET, V342, P821; BARROS LFM, 1995, INT J CARDIOL, V48, P3, DOI 10.1016/0167-5273(94)02208-Z; BOLLI R, 1990, CIRCULATION, V82, P723, DOI 10.1161/01.CIR.82.3.723; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DUTOIT EF, 1992, CIRC RES, V70, P960, DOI 10.1161/01.RES.70.5.960; ERTL G, 1994, LANCET, V344, P1068, DOI 10.1016/S0140-6736(94)91717-5; HAMPTON J, 1993, LANCET, V342, P759; HARA A, 1990, N-S ARCH PHARMACOL, V342, P100; HERZOG WR, 1994, LANCET, V343, P1285; HUNT D, 1992, LANCET, V339, P753; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; JULIAN DG, 1994, LANCET, V344, P203, DOI 10.1016/S0140-6736(94)92811-8; OPIE LH, 1994, CARDIOVASC DRUG THER, V8, P533, DOI 10.1007/BF00877221; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1995, NEW ENGL J MED, V332, P118, DOI 10.1056/NEJM199501123320210; SIMOONS ML, 1994, LANCET, V344, P279, DOI 10.1016/S0140-6736(94)91333-1; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; WOODS KL, 1994, LANCET, V343, P816, DOI 10.1016/S0140-6736(94)92024-9; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; YUSUF S, 1988, LANCET, V1, P1088	28	56	57	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 2	1995	346	8975					611	614		10.1016/S0140-6736(95)91440-4	http://dx.doi.org/10.1016/S0140-6736(95)91440-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651008				2022-12-28	WOS:A1995RT18800013
J	HEMLEY, RJ				HEMLEY, RJ			SOUND AND FURY IN JUPITER	SCIENCE			English	Editorial Material							OSCILLATIONS; HYDROGEN		CARNEGIE INST WASHINGTON,CTR HIGH PRESSURE RES,WASHINGTON,DC 20005	Carnegie Institution for Science	HEMLEY, RJ (corresponding author), CARNEGIE INST WASHINGTON,GEOPHYS LAB,5251 BROAD BRANCH RD NW,WASHINGTON,DC 20005, USA.							ALAVI A, 1995, SCIENCE, V269, P1259; ASHCROFT NW, 1995, ELEMENTARY PROCESSES, P251; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; DUFFY TS, 1994, SCIENCE, V263, P1590, DOI 10.1126/science.263.5153.1590; HOHL D, 1993, PHYS REV LETT, V71, P541, DOI 10.1103/PhysRevLett.71.541; LEDERER SM, 1995, ICARUS, V114, P269, DOI 10.1006/icar.1995.1061; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; MOSSER B, 1993, ASTRON ASTROPHYS, V267, P604; MOSSER B, 1991, ASTRON ASTROPHYS, V251, P356; NATOLI V, 1995, PHYS REV LETT, V74, P1601, DOI 10.1103/PhysRevLett.74.1601; NELLIS WJ, 1995, SCIENCE, V269, P1249, DOI 10.1126/science.7652570; Zharkov V. N., 1992, HIGH PRESSURE RES AP, P393	12	1	1	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1233	1234		10.1126/science.7652568	http://dx.doi.org/10.1126/science.7652568			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652568				2022-12-28	WOS:A1995RR84200022
J	KHARBANDA, S; REN, RB; PANDEY, P; SHAFMAN, TD; FELLER, SM; WEICHSELBAUM, RR; KUFE, DW				KHARBANDA, S; REN, RB; PANDEY, P; SHAFMAN, TD; FELLER, SM; WEICHSELBAUM, RR; KUFE, DW			ACTIVATION OF THE C-ABL TYROSINE KINASE IN THE STRESS-RESPONSE TO DNA-DAMAGING AGENTS	NATURE			English	Article							CELL-CYCLE; PHOSPHORYLATION; BINDING	THE product of the c-abl gene is a non-receptor tyrosine kinase that is localized to the nucleus and cytoplasm. The precise function of c-Abl is unknown. Here we show that ionizing radiation activates c-Abl. Similar results were obtained with the alkylating agents cis-platinum and mitomycin C. We also demonstrate that cells deficient in c-Abl fail to activate Jun kinase (JNK/SAP kinase) after ionizing radiation or alkylating agent exposure and that reconstitution of c-Abl in these cells restores that response. In contrast, the stress response to tumour-necrosis factor is stimulated by a c-Abl-independent mechanism. These findings indicate that c-abl is involved in the stress response to DNA-damaging agents.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT BIOL,WALTHAM,MA 02254; UNIV WURZBURG,INST RADIOBIOL & CELL BIOL,MOLEC ONCOL LAB,D-97078 WURZBURG,GERMANY; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115	Brandeis University; University of Wurzburg; University of Chicago; Harvard University; Harvard Medical School	KHARBANDA, S (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CAN PHARMACOL,BOSTON,MA 02115, USA.							DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MATTIONI T, 1995, ONCOGENE, V10, P1325; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SALEEM A, 1995, J IMMUNOL, V154, P4150; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TOMASZ M, 1988, BIOCHEMISTRY-US, V27, P3182, DOI 10.1021/bi00409a009; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	19	454	470	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					785	788		10.1038/376785a0	http://dx.doi.org/10.1038/376785a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651539				2022-12-28	WOS:A1995RR83600043
J	VILLELLA, A; MAGGIONI, AP; VILLELLA, M; GIORDANO, A; TURAZZA, FM; SANTORO, E; FRANZOSI, MG				VILLELLA, A; MAGGIONI, AP; VILLELLA, M; GIORDANO, A; TURAZZA, FM; SANTORO, E; FRANZOSI, MG			PROGNOSTIC-SIGNIFICANCE OF MAXIMAL EXERCISE TESTING AFTER MYOCARDIAL-INFARCTION TREATED WITH THROMBOLYTIC AGENTS - THE GISSI-2 DATABASE	LANCET			English	Article							CORONARY-ARTERY DISEASE; ST-SEGMENT ELEVATION; CLINICAL-VARIABLES; MORTALITY; THERAPY; ISCHEMIA; SURGERY; PROGRESSION; PREDICTORS; STENOSES	Exercise testing helped in diagnosing postinfarction patients in the prethrombolytic era. Over the past decade acute myocardial infarction treatment has changed because of new thrombolytic therapies and consequently, the value of exercise testing is under debate. The GISSI-2 database allowed us to reevaluate the prognostic role of exercise testing in thrombolysed patients. The exercise test was performed in 6296 patients, on average 28 days after randomisation. The test was not performed in 3923 patients because of contraindications. The test was judged positive for residual ischaemia in 26% of the patients, negative in 38%, and non-diagnostic in 36%. Among the patients with a positive stress test result, 33% had symptoms, whereas 67% had silent myocardial ischaemia. The mortality rate was 7.1% among patients who did not have an exercise test and 7.1% for those with a positive test, 0.9% for those who had a negative test, and 1.3% for those who did not have a diagnostic test, In the adjusted analysis, symptomatic induced ischaemia, submaximal positive result, low work capacity, and abnormal systolic blood pressure were independent predictors of 6-month mortality (relative risks [RR] 2.54, 95% CI 1.27-5.08, 2.28, 1.17-4.45, 2.05, 1.23-3.42, and 1.86, 1.05-3.31, respectively). However, when these factors were tested simultaneously, only symptomatic induced ischaemia and low work capacity were confirmed as independent predictors of mortality (RR Cox 2.07, 95% CI 1.02-4.23 and 1.78, 1.06-2.99, respectively). Patients with a normal exercise response have an excellent medium-term prognosis and do not need further investigation. However, more evaluation should be devoted to the patients who cannot undergo exercise testing, because the potential to influence outcome appears to be much greater.	IRCCS, OSPED CASA SOLLIEVO SOFFERENZA, SAN GIOVANNI ROTONDO, ITALY; IST RIC FARMACOL MARIO NEGRI, MILAN, ITALY; ITALIAN WORKING GRP CARDIAC REHABIL, VERUNO, ITALY; OSPED FATEBENEFRATELLI OFTALMICO, MILAN, ITALY	IRCCS Casa Sollievo Della Sofferenza; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			santoro, eugenio/ABG-7901-2020; Maggioni, Aldo Pietro/AAL-5334-2020; Turazza, Fabio/AAB-8736-2020	santoro, eugenio/0000-0002-5719-9896; Maggioni, Aldo Pietro/0000-0003-2764-6779; Turazza, Fabio/0000-0002-2348-5309				[Anonymous], 1990, LANCET, V336, P65; BODENHEIMER MM, 1992, ANN INTERN MED, V116, P927, DOI 10.7326/0003-4819-116-11-927; BRUCE RA, 1988, CIRCULATION, V77, P897, DOI 10.1161/01.CIR.77.4.897; CARU B, 1983, G ITAL CARDIOL, V13, P276; CHAHINE RA, 1993, AM J CARDIOL, V72, P100, DOI 10.1016/0002-9149(93)90227-4; CHESEBRO JH, 1992, CIRCULATION, V86, P100; COX DR, 1972, J R STAT SOC B, V34, P187; DEBUSK RF, 1986, NEW ENGL J MED, V314, P161, DOI 10.1056/NEJM198601163140307; DEBUSK RF, 1989, ANN INTERN MED, V110, P470, DOI 10.7326/0003-4819-110-6-470; DWYER EM, 1984, J AM COLL CARDIOL, V4, P695, DOI 10.1016/S0735-1097(84)80395-2; FIORETTI P, 1985, AM J CARDIOL, V55, P1313, DOI 10.1016/0002-9149(85)90495-3; Fleiss JL, 1981, STAT METHODS RATES P, P218; FROELICHER VF, 1987, AM J MED, V83, P1045, DOI 10.1016/0002-9343(87)90940-5; GOTSMAN M, 1992, AM J CARDIOL, V70, P715, DOI 10.1016/0002-9149(92)90547-C; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HACKETT D, 1989, AM J CARDIOL, V63, P1517, DOI 10.1016/0002-9149(89)90018-0; JELINEK VM, 1982, BMJ-BRIT MED J, V284, P227, DOI 10.1136/bmj.284.6311.227; JENNINGS K, 1984, BRIT MED J, V288, P185, DOI 10.1136/bmj.288.6412.185; LAVIE CJ, 1991, AM J CARDIOL, V67, P116, DOI 10.1016/0002-9149(91)90431-J; LEROY F, 1993, EUR HEART J, V14, P1471, DOI 10.1093/eurheartj/14.11.1471; LICHTLEN PR, 1992, CIRCULATION, V86, P828, DOI 10.1161/01.CIR.86.3.828; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MARX BE, 1990, EUR HEART J, V11, P897, DOI 10.1093/oxfordjournals.eurheartj.a059611; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; MOISE A, 1984, AM J CARDIOL, V54, P1176, DOI 10.1016/S0002-9149(84)80063-6; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; RIVERS JT, 1990, J AM COLL CARDIOL, V16, P340, DOI 10.1016/0735-1097(90)90583-B; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; WATERS DD, 1985, J AM COLL CARDIOL, V5, P1, DOI 10.1016/S0735-1097(85)80077-2	32	92	95	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 26	1995	346	8974					523	529		10.1016/S0140-6736(95)91379-3	http://dx.doi.org/10.1016/S0140-6736(95)91379-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658777	Bronze			2022-12-28	WOS:A1995RQ98600007
J	RHYU, MS; KNOBLICH, JA				RHYU, MS; KNOBLICH, JA			SPINDLE ORIENTATION AND ASYMMETRIC CELL FATE	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; DROSOPHILA; PROSPERO; DIVISION		UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	RHYU, MS (corresponding author), NCI,BETHESDA,MD 20892, USA.		Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404				ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; CAVINESS VS, 1995, IN PRESS TRENDS NEUR; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; CHENG NN, 1995, GENETICS, V139, P549; CHENN A, 1995, CELL, V82; CONDRON BG, 1994, J NEUROSCI, V14, P5766; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KNOBLICH JA, 1995, IN PRESS NATURE; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SNYDER M, 1991, J CELL BIOL, V114, P515, DOI 10.1083/jcb.114.3.515; SPANA EP, 1995, IN PRESS DEVELOPMENT; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WADDLE JA, 1994, DEVELOPMENT, V120, P2317	21	67	67	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					523	526		10.1016/0092-8674(95)90022-5	http://dx.doi.org/10.1016/0092-8674(95)90022-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664329	Bronze			2022-12-28	WOS:A1995RR73400001
J	MEADE, TW; DYER, S; BROWNE, W; FRANK, AO				MEADE, TW; DYER, S; BROWNE, W; FRANK, AO			RANDOMIZED COMPARISON OF CHIROPRACTIC AND HOSPITAL OUTPATIENT MANAGEMENT FOR LOW-BACK-PAIN - RESULTS FROM EXTENDED FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the effectiveness over three years of chiropractic and hospital outpatient management for low back pain. Design-Randomised allocation of patients to chiropractic or hospital outpatient management. Setting-Chiropractic clinics and hospital outpatient departments within reasonable travelling distance of each other in 11 centres. Subjects-741 men and women aged 18-64 years with low back pain in whom manipulation was not contraindicated. Outcome measures-Change in total Oswestry questionnaire score and in score for pain and patient satisfaction with allocated treatment. Results-According to total Oswestry scores improvement in all patients at three years was about 29% more in those treated by chiropractors than in those treated by the hospitals. The beneficial effect of chiropractic on pain was particularly clear. Those treated by chiropractors had more further treatments for back pain after the completion of trial treatment. Among both those initially referred from chiropractors and from hospitals more rated chiropractic helpful at three years than hospital management. Conclusions-At three years the results confirm the findings of an earlier report that when chiropractic or hospital therapists treat patients with low back pain as they would in day to day practice those treated by chiropractic derive more benefit and long term satisfaction than those treated by hospitals.	NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London	MEADE, TW (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,WOLFSON INST PREVENT MED,MRC,LONDON EC1M 6BQ,ENGLAND.							Fairbank J C, 1980, Physiotherapy, V66, P271; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; SIMON R, 1975, BIOMETRICS, V31, P103	3	145	148	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					349	351		10.1136/bmj.311.7001.349	http://dx.doi.org/10.1136/bmj.311.7001.349			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640538	Green Published			2022-12-28	WOS:A1995RN46900011
J	REMUZZI, G; GOTTI, E				REMUZZI, G; GOTTI, E			THE GIRL WITH THE CURL	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							EPSTEIN-BARR-VIRUS; ORGAN-TRANSPLANTATION; DISORDERS; CHEMOTHERAPY		MARIO NEGRI INST PHARMACOL RES,I-24125 BERGAMO,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	REMUZZI, G (corresponding author), OSPED RIUNITI BERGAMO,VIA GAVAZZENI 11,I-24125 BERGAMO,ITALY.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				BERNSTEIN D, 1993, CIRCULATION, V88, P230; COHEN J, 1988, KIDNEY TRANSPLANTATI, P533; FRIZZERA G, 1992, NEOPLASTIC HEMATOPAT, P472; GARRETT TJ, 1993, CANCER, V72, P2782, DOI 10.1002/1097-0142(19931101)72:9<2782::AID-CNCR2820720941>3.0.CO;2-H; HANTO DW, 1985, TRANSPLANTATION, V39, P461, DOI 10.1097/00007890-198505000-00001; HORN M, 1990, CANCER, V66, P1468, DOI 10.1002/1097-0142(19901001)66:7<1468::AID-CNCR2820660705>3.0.CO;2-B; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; MELOSKY B, 1992, J AM SOC NEPHROL, V2, pS290; MORRISON VA, 1994, AM J MED, V97, P14, DOI 10.1016/0002-9343(94)90043-4; NALESNIK MA, 1988, AM J PATHOL, V133, P173; PENN I, 1990, NEW ENGL J MED, V323, P1767, DOI 10.1056/NEJM199012203232510; STARZL TE, 1984, LANCET, V11, P583; STRAUS SE, 1993, ANN INTERN MED, V118, P45, DOI 10.7326/0003-4819-118-1-199301010-00009; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; 1986, NEW ENGL J MED, V314, P801	16	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					928	931		10.1056/NEJM199510053331409	http://dx.doi.org/10.1056/NEJM199510053331409			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666881				2022-12-28	WOS:A1995RX19900009
J	BUCCA, C; ROLLA, G; BRUSSINO, L; DEROSE, V; BUGIANI, M				BUCCA, C; ROLLA, G; BRUSSINO, L; DEROSE, V; BUGIANI, M			ARE ASTHMA-LIKE SYMPTOMS DUE TO BRONCHIAL OR EXTRATHORACIC AIRWAY DYSFUNCTION	LANCET			English	Article							CHRONIC COUGH; METHACHOLINE CHALLENGE; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION; HYPERRESPONSIVENESS; REACTIVITY; STANDARDIZATION; OBSTRUCTION; HISTAMINE; CHILDREN	Patients with asthma-like symptoms may not have asthma but obstruction of the extrathoracic airway (EA). To evaluate if dysfunction of the EA causes asthma-like symptoms, we assessed bronchial and EA responsiveness to inhaled histamine in 441 patients who presented with at least one of three key symptoms-cough, wheeze, dyspnoea-but had neither documented asthma nor bronchial obstruction. The histamine concentrations causing a 20% fall in forced expiratory volume in 1 s (PC(20)FEV(1)) and a 25% fall in maximal mid-inspiratory flow (PC(25)MIF(50)) were used as respective thresholds of bronchial and EA responsiveness. Values 8 mg/mL or less indicated bronchial (B-HR) or EA hyper-responsiveness (EA-HR). The influence of concurrent upper respiratory tract diseases, such as post-nasal drip (PND), pharnygitis, laryngitis and sinusitis, was also assessed. We found four response patterns to the histamine challenge: EA-HR in 26.5% of the patients, B-HR in 11.1%, combined EA-HR and B-HR in 40.6%, and no-HR in 21.8%. Cough was reported by 79% of the patients, wheeze by 53%, and dyspnoea by 40%. Patients with cough as the sole presenting symptom (34.2%), as compared with those with wheeze and/or dyspnoea (20%), had significantly greater probability of having EA-HR (OR 5.35, 95% CI 3.25-8.82) and lower probability of having B-HR (OR 0.45, Cl 0.28-0.70); patients with cough plus wheeze and/or dyspnoea (45.8%) had significantly greater probability of having both EA-HR and B-HR than either those with cough alone (OR 2.48, Cl 1.49-4.13), or those with wheeze and/or dyspnoea but not cough (OR 1.74, Cl 1.36-2.22), EA-HR alone or combined with B-HR was strongly associated with EA diseases, particularly pharyngitis and PND. Cough was significantly associated with PND, either when it was the sole symptom (OR 2.16, Cl 1.14-4.09) or when it was combined with wheeze and/or dyspnoea (OR 3.53, Cl 1.97-6.33). Our results suggest that extrathoracic airway dysfunction may account for asthma-like symptoms, particularly chronic cough. This abnormality seems to be sustained by chronic diseases of the upper respiratory tract.	UNIV TURIN,DEPT CLIN & BIOL SCI,DIV RESP DIS,TURIN,ITALY; USL 7,PUBL HLTH SERV,TURIN,ITALY	University of Turin	BUCCA, C (corresponding author), UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,DIV INTERNAL MED,VIA GENOVA 3,I-10126 TURIN,ITALY.		brussino, luisa/J-2486-2012; Rolla, Giovanni/C-9901-2009; Bucca, Caterina/C-9886-2009	brussino, luisa/0000-0001-7249-7616; Rolla, Giovanni/0000-0001-5997-7172; Bucca, Caterina/0000-0002-9941-9236				ACRES JC, 1981, CHEST, V80, P207, DOI 10.1378/chest.80.2.207; AITKIN M, 1979, STATISTICAL MODELLIN, P110; BROWN IG, 1986, B EUR PHYSIOPATH RES, V22, P251; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BUCCA C, 1991, ALLERGY, V46, P147, DOI 10.1111/j.1398-9995.1991.tb00559.x; BUCCA C, 1990, CHEST, V98, P1133, DOI 10.1378/chest.98.5.1133; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAWLA SS, 1984, ANN ALLERGY, V53, P319; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1990, AM REV RESPIR DIS, V142, P497, DOI 10.1164/ajrccm/142.3.497; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GALVEZ RA, 1987, J ALLERGY CLIN IMMUN, V79, P331, DOI 10.1016/0091-6749(87)90150-3; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES, P122; HOPP RJ, 1986, J ALLERGY CLIN IMMUN, V74, P154; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; LEE DA, 1983, BRIT MED J, V286, P1257; MILLER RD, 1973, AM REV RESPIR DIS, V108, P475; MORTAGY AK, 1986, BRIT MED J, V293, P525, DOI 10.1136/bmj.293.6546.525; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SHIM C, 1972, AM REV RESPIR DIS, V106, P233, DOI 10.1164/arrd.1972.106.2.233	27	96	99	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					791	795		10.1016/S0140-6736(95)91617-2	http://dx.doi.org/10.1016/S0140-6736(95)91617-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674743	Bronze			2022-12-28	WOS:A1995RW25800008
J	BRAHE, C; SERVIDEI, S; ZAPPATA, S; RICCI, E; TONALI, P; NERI, G				BRAHE, C; SERVIDEI, S; ZAPPATA, S; RICCI, E; TONALI, P; NERI, G			GENETIC HOMOGENEITY BETWEEN CHILDHOOD-ONSET AND ADULT-ONSET AUTOSOMAL RECESSIVE SPINAL MUSCULAR-ATROPHY	LANCET			English	Note								Molecular diagnosis of childhood proximal spinal muscular atrophy has been enhanced by the discovery of the survival motor neuron (SMN) gene, which is absent or truncated in 98.6% of patients. To determine whether deletion analysis of the SMN gene may also be diagnostic for adult-onset disease, we studied six patients and found deletions in all. This finding will facilitate the diagnosis of adult-onset spinal muscular atrophy, and provides evidence for genetic homogeneity between the clinically diverse adult and childhood forms of the disease.	UNIV CATTOLICA SACRO CUORE, A GEMELLI SCH MED, NEUROL INST, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	BRAHE, C (corresponding author), UNIV CATTOLICA SACRO CUORE, A GEMELLI SCH MED, INST MED GENET, I-00168 ROME, ITALY.		Servidei, Serenella/ABC-4262-2021; Ricci, Enzo/AAC-4448-2020	SERVIDEI, Serenella/0000-0001-8478-2799; RICCI, Enzo/0000-0003-3092-3597	Telethon [517] Funding Source: Medline	Telethon(Fondazione Telethon)		KAUSCH K, 1991, HUM GENET, V86, P317; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; PEARN J, 1980, LANCET, V1, P919; PEARN JH, 1978, BRAIN, V101, P591, DOI 10.1093/brain/101.4.591; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1	5	88	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					741	742		10.1016/S0140-6736(95)91507-9	http://dx.doi.org/10.1016/S0140-6736(95)91507-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658877				2022-12-28	WOS:A1995RU81000013
J	COX, JT				COX, JT			HPV DNA TESTING - CLINICAL BOON OR BOONDOGGLE	LANCET			English	Editorial Material							CYTOLOGY; SMEARS				COX, JT (corresponding author), UNIV CALIF SANTA BARBARA, STUDENT HLTH SERV, SANTA BARBARA, CA 93106 USA.							[Anonymous], 1993, ACTA CYTOL, V37, P115; COX JT, 1992, OBSTET GYNECOL, V80, P389; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; HATCH KD, 1995, AM J OBSTET GYNECOL, V172, P1150, DOI 10.1016/0002-9378(95)91473-0; HUTCHINSON ML, 1992, ACTA CYTOL, V36, P499; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LUNGU O, 1995, OBSTET GYNECOL, V85, P337, DOI 10.1016/0029-7844(94)00399-X; Meijer C. J., 1992, EPIDEMIOLOGY CERVICA, P271; SCHIFFMAN MH, 1994, CANCER RES, V54, pS1944; SCHIFFMAN MH, 1993, J NATL CANCER I, V85, P1868, DOI 10.1093/jnci/85.22.1868-a; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L	15	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 16	1995	346	8977					717	719						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658868				2022-12-28	WOS:A1995RU81000004
J	JACKSON, LA; HILSDON, R; FARLEY, MM; HARRISON, LH; REINGOLD, AL; PLIKAYTIS, BD; WENGER, JD; SCHUCHAT, A				JACKSON, LA; HILSDON, R; FARLEY, MM; HARRISON, LH; REINGOLD, AL; PLIKAYTIS, BD; WENGER, JD; SCHUCHAT, A			RISK-FACTORS FOR GROUP-B STREPTOCOCCAL DISEASE IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						RISK FACTORS; CROSS INFECTION; COMMUNITY-ACQUIRED INFECTIONS; STREPTOCOCCAL INFECTION; STREPTOCOCCUS AGALACTIAE	TOXOID CONJUGATE VACCINE; NONPREGNANT ADULTS; III POLYSACCHARIDE; INFECTION; BACTEREMIA; ANTIBODY; INFANTS; WOMEN	Objective: To determine risk factors for community-acquired and nosocomial group B streptococcal disease in adults. Design: Case-control study. Setting: 3 metropolitan areas in the United States with an aggregate population of 6.6 million persons. Patients: 219 nonpregnant adults with invasive group B streptococcal infection identified by a population-based surveillance in 1991 and 1992 and 645 hospital-matched controls. Results: The following conditions were associated with a significantly increased risk for community-acquired group B streptococcal infection after controlling for age in multivariate analysis: cirrhosis (odds ratio, 9.7 [95% CI, 3.5 to 26.9]; P <0.001), diabetes (odds ratio, 3.0 [CI, 1.9 to 4.7]; P <0.001), stroke (odds ratio, 3.5 [CI, 1.9 to 6.4]; P <0.001), breast cancer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P =0.002), decubitus ulcer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P =0.002), and neurogenic bladder (odds ratio, 4.6 [CI, 1.4 to 15.1]; P =0.01). Sixty-three percent of community case-patients had at least one of these conditions. Nosocomial infection (48 cases [22%]) was independently associated with the placement of a central venous line (odds ratio, 30.9 [CI, 5.2 to 184.1]; P <0.001), diabetes, congestive heart failure, and seizure disorder. Conclusions: Several chronic conditions were independently associated with group B streptococcal disease, and most case-patients had at least one of these conditions. If group B streptococcal vaccines being developed for prevention of neonatal disease are protective in adults, a vaccination strategy targeting those at highest risk has the potential to substantially reduce the burden of invasive group B streptococcal infection in adults.	CTR DIS CONTROL & PREVENT, CHILDHOOD & RESP DIS BRANCH, ATLANTA, GA 30333 USA; EMORY UNIV, SCH MED, ATLANTA, GA USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA; UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA	Centers for Disease Control & Prevention - USA; Emory University; Johns Hopkins University; University of California System; University of California Berkeley								[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ANTHONY BF, 1983, J INFECT DIS, V147, P776, DOI 10.1093/infdis/147.4.776; BAKER CJ, 1981, PEDIATRICS, V68, P544; BAKER CJ, 1986, J INFECT DIS, V154, P47, DOI 10.1093/infdis/154.1.47; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; BERKOWITZ K, 1990, J CLIN MICROBIOL, V28, P5, DOI 10.1128/JCM.28.1.5-7.1990; BLUMBERG HM, 1994, CLIN RES, V42, pA298; Breslow NE, 1980, IARC SCI PUBL, V32, P248; CASEY JI, 1982, AM J EPIDEMIOL, V116, P704, DOI 10.1093/oxfordjournals.aje.a113453; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P64; DILLON HC, 1982, J INFECT DIS, V145, P794, DOI 10.1093/infdis/145.6.794; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; Edwards MS, 1995, PRINCIPLES PRACTICE, V4, P1835; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; FINNEGAN OC, 1981, POSTGRAD MED J, V57, P202, DOI 10.1136/pgmj.57.665.202; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; GALLAGHER PG, 1986, REV INFECT DIS, V8, P175; HARRISON LH, 1995, J INFECT DIS, V171, P513, DOI 10.1093/infdis/171.2.513; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LERNER PI, 1977, MEDICINE, V56, P457, DOI 10.1097/00005792-197711000-00001; MADOFF LC, 1994, J CLIN INVEST, V94, P286, DOI 10.1172/JCI117319; MATHEW P, 1993, NEW ENGL J MED, V329, P1658; MILLER JD, 1982, SOUTHERN MED J, V75, P76, DOI 10.1097/00007611-198201000-00021; MUNOZ P, 1992, CLIN INFECT DIS, V14, P492, DOI 10.1093/clinids/14.2.492; OPAL SM, 1988, ARCH INTERN MED, V148, P641, DOI 10.1001/archinte.148.3.641; PAOLETTI LC, 1994, INFECT IMMUN, V62, P3236, DOI 10.1128/IAI.62.8.3236-3243.1994; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; PAOLETTI LC, 1992, INFECT IMMUN, V60, P4009, DOI 10.1128/IAI.60.10.4009-4014.1992; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; SMALL CB, 1984, AM J MED, V76, P367, DOI 10.1016/0002-9343(84)90653-3; VERGHESE A, 1986, REV INFECT DIS, V8, P912; WESSELS MR, 1993, INFECT IMMUN, V61, P4760, DOI 10.1128/IAI.61.11.4760-4766.1993; WESSELS MR, 1995, J INFECT DIS, V171, P879, DOI 10.1093/infdis/171.4.879; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; 1992, SAS P229 SAS I TECHN	37	196	198	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					415	420		10.7326/0003-4819-123-6-199509150-00003	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639440				2022-12-28	WOS:A1995RU43700003
J	POTTS, M				POTTS, M			NONSURGICAL ABORTION - WHOS FOR METHOTREXATE	LANCET			English	Editorial Material											POTTS, M (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.							CREININ MD, 1993, CONTRACEPTION, V48, P339, DOI 10.1016/0010-7824(93)90079-M; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; CREININ MD, 1993, CONTRACEPTION, V48, P519, DOI 10.1016/0010-7824(93)90114-M; DONNENFELD AE, 1994, TERATOLOGY, V49, P79, DOI 10.1002/tera.1420490202; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; TANAKA T, 1982, FERTIL STERIL, V37, P851; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1398; WINIKOFF B, 1995, FAM PLANN PERSPECT, V27, P142, DOI 10.2307/2136257	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					655	656		10.1016/S0140-6736(95)92276-8	http://dx.doi.org/10.1016/S0140-6736(95)92276-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658816				2022-12-28	WOS:A1995RU04800005
J	DUAN, DR; PAUSE, A; BURGESS, WH; ASO, T; CHEN, DYT; GARRETT, KP; CONAWAY, RC; CONAWAY, JW; LINEHAN, WM; KLAUSNER, RD				DUAN, DR; PAUSE, A; BURGESS, WH; ASO, T; CHEN, DYT; GARRETT, KP; CONAWAY, RC; CONAWAY, JW; LINEHAN, WM; KLAUSNER, RD			INHIBITION OF TRANSCRIPTION ELONGATION BY THE VHL TUMOR-SUPPRESSOR PROTEIN	SCIENCE			English	Article							FACTOR-SIII; IDENTIFICATION	Germline mutations in the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of tumors, including renal carcinoma, hemangioblastoma of the central nervous system, and pheochromocytoma. Here, a cellular transcription factor, Elongin (SIII), is identified as a functional target of the VHL protein. Elongin (SIII) is a heterotrimer consisting of a transcriptionally active subunit (A) and two regulatory subunits (B and C) that activate transcription elongation by RNA polymerase II. The VHL protein was shown to bind tightly and specifically to the Elongin B and C subunits and to inhibit Elongin (SIII) transcriptional activity in vitro. These findings reveal a potentially important transcriptional regulatory network in which the VHL protein may play a key role.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; NCI, SURG BRANCH, UROL ONCOL SECT, BETHESDA, MD 20892 USA; AMER RED CROSS, JEROME H HOLLAND LAB, DEPT BIOL MOLEC, ROCKVILLE, MD 20855 USA; OKLAHOMA MED RES FDN, PROGRAM MOLEC BIOL, OKLAHOMA CITY, OK 73104 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross; Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, UNPUB; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Chen D.-Y., UNPUB; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GAO JZ, 1995, CANCER RES, V55, P743; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lis JT, 1994, TRANSCRIPTION MECH R, P459; SHUIN T, 1994, CANCER RES, V54, P2852; TAN SY, 1994, J BIOL CHEM, V269, P25684; TORY K, 1981, JNCI-J NATL CANCER I, V81, P1079; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	26	476	492	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1402	1406		10.1126/science.7660122	http://dx.doi.org/10.1126/science.7660122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660122	Green Submitted			2022-12-28	WOS:A1995RT80600038
J	HARI, KL; SANTERRE, A; SEKELSKY, JJ; MCKIM, KS; BOYD, JB; HAWLEY, RS				HARI, KL; SANTERRE, A; SEKELSKY, JJ; MCKIM, KS; BOYD, JB; HAWLEY, RS			THE MEI-41 GENE OF DROSOPHILA-MELANOGASTER IS A STRUCTURAL AND FUNCTIONAL HOMOLOG OF THE HUMAN ATAXIA-TELANGIECTASIA GENE	CELL			English	Article							CELL-CYCLE CHECKPOINT; X-LINKED MUTANTS; DROSOPHILA-MELANOGASTER; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; DNA DAMAGE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-ABERRATIONS; CHROMATID INTERCHANGES; SOMATIC-CELLS	The D. melanogaster mei-41 gene is required for DNA repair, mitotic chromosome stability, and normal levels of meiotic recombination in oocytes. Here we show that the predicted mei-41 protein is similar in sequence to the ATM (ataxia telangiectasia) protein from humans and to the yeast rad3 and Mec1p proteins. There is also extensive functional overlap between mei-41 and ATM. Like ATM-deficient cells, mei-41 cells are exquisitely sensitive to ionizing radiation and display high levels of mitotic chromosome instability. We also demonstrate that mei-41 cells, like ATM-deficient cells, fail to show an irradiation-induced delay in the entry into mitosis that is characteristic of normal cells. Thus, the mei-41 gene of Drosophila may be considered to be a functional homolog of the human ATM gene.			HARI, KL (corresponding author), UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616, USA.			Sekelsky, Jeff/0000-0002-4424-677X; Hawley, R. Scott/0000-0002-6478-0494				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARLETT CF, 1985, ATAXIA TELANGIECTASI, P1; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1976, P NATL ACAD SCI USA, V73, P4140, DOI 10.1073/pnas.73.11.4140; BAKER BS, 1978, GENETICS, V90, P531; BAKER BS, 1972, GENETICS, V71, P255; Baker BS, 1976, GENETICS BIOL DROS B, P351; BANGA SS, 1986, MUTAT RES, V163, P157, DOI 10.1016/0027-5107(86)90044-8; BANGA SS, 1995, MOL GEN GENET, V246, P148, DOI 10.1007/BF00294677; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BOYD JB, 1976, GENETICS, V84, P485; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALVI BR, 1994, EMBO J, V13, P1636, DOI 10.1002/j.1460-2075.1994.tb06427.x; CARPENTER AT, 1974, GENETICS, V76, P453; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIEDBERG EC, 1995, DNA REPAIR; GATTI M, 1980, P NATL ACAD SCI-BIOL, V77, P1575, DOI 10.1073/pnas.77.3.1575; GATTI M, 1974, GENETICS, V77, P701; GATTI M, 1979, P NATL ACAD SCI USA, V76, P1377, DOI 10.1073/pnas.76.3.1377; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAWLEY RS, 1989, ANNU REV GENET, V23, P87, DOI 10.1146/annurev.genet.23.1.87; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NGUYEN TD, 1979, MUTAT RES, V63, P67, DOI 10.1016/0027-5107(79)90104-0; PIMPINELLI S, 1976, MUTAT RES, V35, P101, DOI 10.1016/0027-5107(76)90172-X; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YAMAMOTO AH, 1990, MUTAT RES, V29, P17	47	248	259	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					815	821		10.1016/0092-8674(95)90478-6	http://dx.doi.org/10.1016/0092-8674(95)90478-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671309	Bronze			2022-12-28	WOS:A1995RU75500016
J	KIM, J; IRVINE, KD; CARROLL, SB				KIM, J; IRVINE, KD; CARROLL, SB			CELL RECOGNITION, SIGNAL INDUCTION, AND SYMMETRICAL GENE ACTIVATION AT THE DORSAL-VENTRAL BOUNDARY OF THE DEVELOPING DROSOPHILA WING	CELL			English	Article							IMAGINAL DISK; ENCODES; SERRATE	Appendage formation in insects and vertebrates depends upon signals from both the anterior-posterior and dorsal-ventral (DV) axes. In Drosophila, wing formation is organized symmetrically around the DV boundary of the growing wing imaginal disc and requires interactions between dorsal and ventral cells. Compartmentalization of the wing disc, dorsal cell behavior, and the expression of two dorsally expressed putative signaling molecules, fringe (fng) and Serrate (Ser), are regulated by the apterous selector gene. Here, we demonstrate that fng and Ser have distinct roles in a novel cell recognition and signal induction process. fng serves as a boundary-determining molecule such that Ser is induced wherever cells expressing fng and cells not expressing fng are juxtaposed. Ser in turn triggers the expression of genes involved in wing growth and patterning on both sides of the DV boundary.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	KIM, J (corresponding author), UNIV WISCONSIN, MOLEC BIOL LAB, HOWARD HUGHES MED INST, MADISON, WI 53706 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER; NICHD NIH HHS [5R01-HD22780] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1995, DEVELOPMENT, V121, P619; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; HIZN U, 1994, CELL, V76, P77; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; Meinhardt H., 1991, Seminars in Developmental Biology, V2, P129; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PADDOCK SW, 1993, BIOTECHNIQUES, V14, P42; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANICOLA M, 1995, GENETICS, V139, P745; SPREICHER S, 1994, DEVELOPMENT, V120, P535; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; TIONG SYK, 1995, DEVELOPMENT, V121, P1649; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	39	243	245	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					795	802		10.1016/0092-8674(95)90476-X	http://dx.doi.org/10.1016/0092-8674(95)90476-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671307	Bronze			2022-12-28	WOS:A1995RU75500014
J	GOLDBERG, J; HUANG, HB; KWON, YG; GREENGARD, P; NAIRN, AC; KURIYAN, J				GOLDBERG, J; HUANG, HB; KWON, YG; GREENGARD, P; NAIRN, AC; KURIYAN, J			3-DIMENSIONAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN SERINE/THREONINE PHOSPHATASE-1	NATURE			English	Article							MICROCYSTIN-LR; CALCINEURIN; IDENTIFICATION; MECHANISM; DOMAIN; HYDROLYSIS; REFINEMENT; ISOFORMS; ENZYME; ACID	The crystal structure of mammalian protein phosphatase-1, complexed with the toxin microcystin and determined at 2.1 Angstrom resolution, reveals that it is a metalloenzyme unrelated in architecture to the tyrosine phosphatases. Two metal ions are positioned by a central beta-alpha-beta-alpha-beta scaffold at the active site, from which emanate three surface grooves that are potential binding sites for substrates and inhibitors. The carboxy terminus is positioned at the end of one of the grooves such that regulatory sequences following the domain might modulate function. The fold of the catalytic domain is expected to be closely preserved in protein phosphatases 2A and 2B (calcineurin).	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University				Nairn, Angus/0000-0002-7075-0195				ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGY JR, 1995, NAT STRUCT BIOL, V2, P114, DOI 10.1038/nsb0295-114; BARFORD D, 1994, J MOL BIOL, V235, P763, DOI 10.1006/jmbi.1994.1027; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; COHEN P, 1989, REV BIOCH, V58, P453; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; FISCHER EH, 1982, TRENDS BIOCHEM SCI, V7, P3, DOI 10.1016/0968-0004(82)90051-2; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEMMINGS HCJ, 1995, MOL CELLUAR MECHANIS, P279; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JENNY TF, 1995, PROTEINS, V21, P1, DOI 10.1002/prot.340210102; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM YH, 1993, J BIOL CHEM, V268, P18513; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1984, J BIOL CHEM, V259, P8847; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KOONIN EV, 1994, PROTEIN SCI, V3, P356; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIWAKIMATSUSHIMA R, 1992, J CANCER RES CLIN, V118, P420, DOI 10.1007/BF01629424; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; STONE RL, 1994, J BIOL CHEM, V269, P31323; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; VINCENT JB, 1991, J BIOL CHEM, V266, P17737; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; ZHANG ZJ, 1993, MOL CELL BIOCHEM, V128, P113, DOI 10.1007/BF01076762; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	50	730	746	4	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					745	753		10.1038/376745a0	http://dx.doi.org/10.1038/376745a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651533				2022-12-28	WOS:A1995RR83600032
J	LOVE, JJ; LI, XA; CASE, DA; GIESE, K; GROSSCHEDL, R; WRIGHT, PE				LOVE, JJ; LI, XA; CASE, DA; GIESE, K; GROSSCHEDL, R; WRIGHT, PE			STRUCTURAL BASIS FOR DNA BENDING BY THE ARCHITECTURAL TRANSCRIPTION FACTOR LEF-1	NATURE			English	Article							ALPHA-ENHANCER; NUCLEOPROTEIN STRUCTURES; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; MINOR-GROOVE; HMG DOMAIN; PROTEINS; BINDING; COMPLEX; TCF-1	LYMPHOID enhancer-binding factor (LEF-1) and the closely related T-cell factor 1 (TCF-1) are sequence-specific and cell-type-specific DNA-binding proteins that play important regulatory roles in organogenesis and thymocyte differentiation(1-5). LEF-1 participates in regulation of the enhancer associated with the T cell receptor (TCR)-alpha gene by inducing a sharp bend in the DNA and facilitating interactions between Ets-1, PEBP2-alpha, and ATF/CREB transcription factors bound at sites flanking the LEF-1 site(1,2,6,7). It seems that LEF-1 plays an architectural role in the assembly and function of this regulatory nucleoprotein complex(7,8). LEF-1 recognizes a specific nucleotide sequence through a high-mobilty-group (HMG) domain(1,2). Proteins containing HMG domains bind DNA in the minor groove, bend the double helix(6,9,10), and recognize four-way junctions and other irregular DNA structures(9,11). Here we report the solution structure of a complex of the LEF-1 HMG domain and adjacent basic region with its cognate DNA. The structure reveals the HMG domain bound in the widened minor groove of a markedly distorted and bent double helix. The basic region binds across the narrowed major groove and contributes to DNA recognition.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, SAN DIEGO, CA 92037 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Wright, Peter/0000-0002-1368-0223				CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GLESE K, 1991, GENE DEV, V5, P2567; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETERS R, 1995, BIOCHEMISTRY-US, V34, P4569, DOI 10.1021/bi00014a009; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SEIP S, 1994, J MAGN RESON SER B, V104, P172, DOI 10.1006/jmrb.1994.1072; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	31	527	536	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					791	795		10.1038/376791a0	http://dx.doi.org/10.1038/376791a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651541				2022-12-28	WOS:A1995RR83600045
J	REEVE, MA; FULLER, CW				REEVE, MA; FULLER, CW			A NOVEL THERMOSTABLE POLYMERASE FOR DNA-SEQUENCING	NATURE			English	Article							DOUBLE-STRANDED DNA; TAQ POLYMERASE; EXONUCLEASE ACTIVITY; GENE; PCR		AMERSHAM LIFE SCI INC,CLEVELAND,OH 44128		REEVE, MA (corresponding author), AMERSHAM INT PLC,AMERSHAM RES LABS,WHITE LION RD,AMERSHAM HP7 9LL,BUCKS,ENGLAND.			Fuller, Carl/0000-0003-2277-2119; Reeve, Michael/0000-0002-0747-9902				AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P498; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; KLENOW H, 1971, EUR J BIOCHEM, V22, P371, DOI 10.1111/j.1432-1033.1971.tb01554.x; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LEVEDAKOU EN, 1989, BIOTECHNIQUES, V7, P438; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; SAMOLS SB, 1995, COMMENTS, V21, P57; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	13	59	90	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					796	797		10.1038/376796a0	http://dx.doi.org/10.1038/376796a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651542				2022-12-28	WOS:A1995RR83600046
J	EVANS, DJ; BERNEY, DM; POLLOCK, DJ				EVANS, DJ; BERNEY, DM; POLLOCK, DJ			SYMPTOMATIC VITAMIN-E-DEFICIENCY DIAGNOSED AFTER HISTOLOGICAL RECOGNITION OF MYOMETRIAL LIPOFUSCINOSIS	LANCET			English	Note							MUSCLE; MALABSORPTION	We report a 44-year-old woman in whom intestinal bypass for obesity at age 23 resulted in chronic malabsorption. After hysterectomy for menorrhagia due to atypical endometrial hyperplasia, the finding of myometrial lipofuscinosis led to a demonstration of vitamin E deficiency. Vitamin E supplementation led to an unexpected improvement in the unsteadiness of gait and slurring of speech of which she had also complained. We suggest that supplementation with vitamin E should be routine in all patients with persistent severe steatorrhoea.	ROYAL LONDON HOSP,DEPT MORBID ANAT,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital	EVANS, DJ (corresponding author), ST MARYS HOSP,SCH MED,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND.			Berney, Daniel/0000-0001-5474-8696				EVANS HM, 1927, MEM U CALIF, V28; FOSTER CS, 1979, HISTOPATHOLOGY, V3, P1, DOI 10.1111/j.1365-2559.1979.tb02977.x; FOX B, 1967, J CLIN PATHOL, V20, P806, DOI 10.1136/jcp.20.6.806; HARDING AE, 1982, ANN NEUROL, V12, P419, DOI 10.1002/ana.410120503; MULLER DPR, 1986, POSTGRAD MED J, V62, P107, DOI 10.1136/pgmj.62.724.107; NEVILLE HE, 1983, NEUROLOGY, V33, P483, DOI 10.1212/WNL.33.4.483; RAYNER RJ, 1993, ARCH DIS CHILD, V69, P602, DOI 10.1136/adc.69.5.602; SIBONI A, 1987, ARCH PATHOL LAB MED, V11, P771; STAMP GWH, 1987, J CLIN PATHOL, V40, P798, DOI 10.1136/jcp.40.7.798	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					545	546		10.1016/S0140-6736(95)91384-X	http://dx.doi.org/10.1016/S0140-6736(95)91384-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658782				2022-12-28	WOS:A1995RQ98600012
J	LANE, RJM; BURGESS, AP; FLINT, J; RICCIO, M; ARCHARD, LC				LANE, RJM; BURGESS, AP; FLINT, J; RICCIO, M; ARCHARD, LC			EXERCISE RESPONSES AND PSYCHIATRIC-DISORDER IN CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RF,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND	Imperial College London; Imperial College London	LANE, RJM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT NEUROSCI,LONDON W6 8RF,ENGLAND.			Burgess, Adrian P/0000-0002-0977-8105				DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; LANE RJM, 1994, J NEUROL NEUROSUR PS, V57, P662, DOI 10.1136/jnnp.57.5.662-a; NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Wing J. K. C., 1974, MEASUREMENT CLASSIFI	5	18	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					544	545		10.1136/bmj.311.7004.544	http://dx.doi.org/10.1136/bmj.311.7004.544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663210	Green Published			2022-12-28	WOS:A1995RR73700020
J	THORLACIUS, S; TRYGGVADOTTIR, L; OLAFSDOTTIR, GH; JONASSON, JG; OGMUNDSDOTTIR, HM; TULINIUS, H; EYFJORD, JE				THORLACIUS, S; TRYGGVADOTTIR, L; OLAFSDOTTIR, GH; JONASSON, JG; OGMUNDSDOTTIR, HM; TULINIUS, H; EYFJORD, JE			LINKAGE TO BRCA2 REGION IN HEREDITARY MALE BREAST-CANCER	LANCET			English	Note							ANDROGEN RECEPTOR GENE; FAMILIES; RISKS	Breast cancer is rare in men, and family history of the disease is a risk factor. The recently discovered BRCA2 gene on chromosome 13q is thought to account for some families with increased risk of breast cancer, including male breast cancer. We descibe a family with multiple cases of male breast cancer but, interestingly, no increase in female breast cancer. Linkage to the BRCA2 region is demonstrated and all the affected men share the same haplotype for the BCRA2 markers and loss of the other alleles in their tumours.	ICELAND CANC SOC, MOLED & CELL BIOL RES LAB, IS-125 REYKJAVIK, ICELAND; ICELAND CANC SOC, ICELAND CANC REGISTRY, IS-125 REYKJAVIK, ICELAND; UNIV HOSP REYKJAVIK, DEPT PATHOL, REYKJAVIK, ICELAND	Landspitali National University Hospital			Ögmundsdóttir, Helga M/L-6970-2015	Tryggvadottir, Laufey/0000-0001-8067-9030; Jonasson, Jon G./0000-0002-2635-5032				ANDERSON DE, 1992, J NATL CANCER I, V84, P1114, DOI 10.1093/jnci/84.14.1114; BORRESEN AL, 1992, CANCER RES, V52, P3234; COLLINS N, 1995, ONCOGENE, V10, P1673; EASTON DF, 1993, AM J HUM GENET, V52, P678; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; TULINIUS H, 1992, J MED GENET, V29, P158, DOI 10.1136/jmg.29.3.158; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	10	80	84	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 26	1995	346	8974					544	545		10.1016/S0140-6736(95)91383-1	http://dx.doi.org/10.1016/S0140-6736(95)91383-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658781				2022-12-28	WOS:A1995RQ98600011
J	HORDER, M				HORDER, M			THE HARD BOILED SAINT - SELWYN-CLARKE IN HONG-KONG	BRITISH MEDICAL JOURNAL			English	Item About an Individual																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					492	495		10.1136/bmj.311.7003.492	http://dx.doi.org/10.1136/bmj.311.7003.492			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647647	Green Published			2022-12-28	WOS:A1995RQ67000018
J	ROWLANDS, J; MORROW, T; LEE, N; MILLMAN, A				ROWLANDS, J; MORROW, T; LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - ONLINE SEARCHING	BRITISH MEDICAL JOURNAL			English	Article									UNIV BATH,BATH BA2 7AY,AVON,ENGLAND; WESTERN EYE HOSP,LONDON,ENGLAND; HILLINGDON HOSP,LONDON,ENGLAND; GLOUCESTER ROYAL HOSP,GLOUCESTER,ENGLAND	University of Bath; Brunel University; Imperial College London	ROWLANDS, J (corresponding author), BMA LIB,BMA HOUSE,LONDON,ENGLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					500	504		10.1136/bmj.311.7003.500	http://dx.doi.org/10.1136/bmj.311.7003.500			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647650	Green Published			2022-12-28	WOS:A1995RQ67000022
J	DUCHESNE, M; SCHWEIGHOFFER, F; PARKER, F; CLERC, F; FROBERT, Y; THANG, MN; TOCQUE, B				DUCHESNE, M; SCHWEIGHOFFER, F; PARKER, F; CLERC, F; FROBERT, Y; THANG, MN; TOCQUE, B			IDENTIFICATION OF THE SH3 DOMAIN OF GAP AS AN ESSENTIAL SEQUENCE FOR RAS-GAP MEDIATED SIGNALING	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; P21 GTPASE; BINDING; PHOSPHORYLATION; PURIFICATION; RECEPTORS; INDUCTION	Guanosine triphosphatase activating protein (GAP) is an essential component of Ras signaling pathways. GAP functions in different cell types as a deactivator and a transmitter of cellular Ras signals. A domain (amino acids 275 to 351) encompassing the Src homology region 3 (SH3) of GAP was found to be essential for GAP signaling. A monoclonal antibody was used to block germinal vesicle breakdown (GVBD) induced by the oncogenic protein Ha-ras Lys12 in Xenopus oocytes. The monoclonal antibody, which was found to recognize the peptide containing amino acids 275 to 351 within the amino-terminal domain of GAP, did not modify the stimulation of the Ha-Ras-GTPase by GAP. Injection of peptides corresponding to amino acids 275 to 351 and 317 to 326 blocked GVBD induced by insulin or by Ha-Ras Lys12 but not that induced by progesterone. These findings confirm that GAP is an effector for Ras in Xenopus oocytes and that the SH3 domain is essential for signal transduction.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE,BP 14,F-94403 VITRY,FRANCE; CEA,CTR ETUD SACLAY,DRIPP,SERV PHARMACOL & IMMUNOL,F-91191 GIF SUR YVETTE,FRANCE; HOP ST ANTOINE,INSERM,U245,F-75571 PARIS 11,FRANCE	Sanofi-Aventis; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HIRAI S, 1984, DEV BIOL, V100, P214; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	25	135	147	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					525	528		10.1126/science.7678707	http://dx.doi.org/10.1126/science.7678707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	7678707				2022-12-28	WOS:A1993KJ07900038
J	COOPER, HM; HERBIN, M; NEVO, E				COOPER, HM; HERBIN, M; NEVO, E			OCULAR REGRESSION CONCEALS ADAPTIVE PROGRESSION OF THE VISUAL-SYSTEM IN A BLIND SUBTERRANEAN MAMMAL	NATURE			English	Article							MOLE RAT; RETINAL PROJECTIONS; SPALAX-EHRENBERGI; ALBINO-RAT; NUCLEUS; MELATONIN; VASOPRESSIN; PATHWAY; HAMSTER; BRAIN	THE mole rat, Spalax ehrenberghi, is an extreme example of natural visual degeneration in mammals: visual pathways are regressed and incomplete1, and the absence of visual cortical potentials or an overt behavioural response to light have led to the conclusion that Spalax is completely blind2-4. But structural and molecular investigations of the atrophied, subcutaneous eye suggest a functional role for the retina in light perception5,6, and entrainment of circadian locomotor and thermoregulatory rhythms by ambient light demonstrates a capacity for photoperiodic detection2,7-9. We report here that severe regression of thalamic and tectal structures involved in form and motion perception is coupled to a selective hypertrophy of structures subserving photoperiodic functions. As an alternative to the prevalent view that ocular regression results from negative or nonselective evolutionary processes10-12, the differential reduction and expansion of visual structures in Spalax can be explained as an adaptive response to the underground environment.	MUSEUM NATL HIST NAT, ANAT COMPAREE LAB, F-75005 PARIS, FRANCE; UNIV HAIFA, INST EVOLUT, HAIFA, ISRAEL	Museum National d'Histoire Naturelle (MNHN); University of Haifa	COOPER, HM (corresponding author), INSERM, U371, F-69500 BRON, FRANCE.		COOPER, HOWARD/M-7304-2014					BALKEMA GW, 1990, VISUAL NEUROSCI, V4, P593; BELTRAMINO C, 1980, NEUROENDOCRINOLOGY, V30, P238, DOI 10.1159/000123007; BRACE CL, 1963, AM NAT, V97, P39, DOI 10.1086/282252; BRONCHTI G, 1991, DEV BRAIN RES, V58, P159, DOI 10.1016/0165-3806(91)90002-Z; Cassone VM, 1988, J BIOL RHYTHM, V3, P71, DOI 10.1177/074873048800300106; Cei G., 1946, MONITORE ZOOL ITALIANO, V55, P69; COLLIN JP, 1981, PINEAL GLAND, V1, P27; COOPER AM, 1990, NEUROSCIENCE, V35, P335, DOI 10.1016/0306-4522(90)90087-K; COOPER HM, 1989, BRAIN RES, V477, P350, DOI 10.1016/0006-8993(89)91426-1; COOPER HM, IN PRESS J COMP NEUR; COOPER KE, 1979, J PHYSIOL-LONDON, V295, P33, DOI 10.1113/jphysiol.1979.sp012953; DEJONG WW, 1990, PROG CLIN BIOL RES, V335, P383; HAIM A, 1983, J EXP BIOL, V107, P59; HEIL P, 1991, NEUROREPORT, V2, P735, DOI 10.1097/00001756-199112000-00001; HETH G, 1986, J EXP ZOOL, V238, P1, DOI 10.1002/jez.1402380102; KASTING NW, 1983, BRAIN RES, V258, P127, DOI 10.1016/0006-8993(83)91237-4; KUDO M, 1988, NEUROSCI LETT, V93, P176, DOI 10.1016/0304-3940(88)90077-8; LEVINE JD, 1991, J COMP NEUROL, V306, P344, DOI 10.1002/cne.903060210; LUND RD, 1965, EXP NEUROL, V13, P302, DOI 10.1016/0014-4886(65)90118-4; MAGNIN M, 1989, BRAIN RES, V488, P390, DOI 10.1016/0006-8993(89)90737-3; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; NECKER R, 1992, NEUROREPORT, V3, P505, DOI 10.1097/00001756-199206000-00012; NELSON DE, 1991, J PHYSIOL-LONDON, V439, P115, DOI 10.1113/jphysiol.1991.sp018660; NEVO E, 1991, EVOLUTIONARY BIOL, V1, P1; PEVET P, 1984, J EXP ZOOL, V232, P41, DOI 10.1002/jez.1402320106; PEVET P, 1987, FUNDAMENTALS CLIN PI, P221; PICKARD GE, 1982, J COMP NEUROL, V211, P65, DOI 10.1002/cne.902110107; RADO R, 1988, ISR J ZOOL, V35, P105; SANYAL S, 1990, INVEST OPHTH VIS SCI, V31, P1398; SUGITA S, 1983, EXP NEUROL, V82, P413, DOI 10.1016/0014-4886(83)90413-2; TOGA AW, 1981, J COMP NEUROL, V199, P443, DOI 10.1002/cne.901990402; WEAVER DR, 1989, J NEUROSCI, V9, P2581; WILKENS H, 1971, EVOLUTION, V25, P530, DOI 10.1111/j.1558-5646.1971.tb01913.x; WRIGHT S, 1964, AM NAT, V98, P65, DOI 10.1086/282301	34	166	169	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					156	159		10.1038/361156a0	http://dx.doi.org/10.1038/361156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	7678449				2022-12-28	WOS:A1993KG46600060
J	WALD, TG; SHULT, P; KRAUSE, P; MILLER, BA; DRINKA, P; GRAVENSTEIN, S				WALD, TG; SHULT, P; KRAUSE, P; MILLER, BA; DRINKA, P; GRAVENSTEIN, S			A RHINOVIRUS OUTBREAK AMONG RESIDENTS OF A LONG-TERM-CARE FACILITY	ANNALS OF INTERNAL MEDICINE			English	Article						RHINOVIRUS; NURSING HOMES; RESPIRATORY TRACT INFECTIONS; DISEASE OUTBREAKS; LUNG DISEASES, OBSTRUCTIVE	ILLNESS; INFECTIONS; PRECIPITANTS; VIRUSES; ASTHMA	Objective: To describe the epidemiology of and clinical findings associated with a rhinovirus outbreak that occurred among institutionalized elderly persons. Design: Retrospective review of medical records and nursing surveillance reports. Setting: A 685-bed, long-term care facility for veterans and their spouses. Patients: 33 persons from whom rhinovirus was cultured. Measurements: Throat and nasopharyngeal virus culture; review of medical records to determine under-lying diseases, signs and symptoms of respiratory illness, illness duration, and interventions during illness; and review of nursing surveillance reports to determine room locations of ill persons. Results: Between 14 August and 2 September 1993, the number of respiratory illnesses increased. Throat and nasopharyngeal virus cultures were taken from 67 ill residents; 33 cultures yielded rhinovirus, and no other respiratory virus was isolated. Geographic clustering of persons infected with rhinovirus was observed. Of those persons with rhinovirus infections, 100% had upper respiratory symptoms, 34% had gastrointestinal symptoms, 71% had systemic symptoms, 66% had lower respiratory symptoms (including productive cough), and 52% had new abnormalities on lung auscultation. The 17 persons with rhinovirus infection who had chronic obstructive pulmonary disease had more severe illnesses: Five (29%) required glucocorticoid or bronchodilator therapy for illness-associated bronchospasm; 2 required transfer out of the facility; 1 developed a radiographically documented infiltrate; and 1 died of respiratory failure. Conclusions: Rhinovirus may cause epidemic, clinically important respiratory illness in nursing home residents. A large proportion of residents may become ill, and infection may be severe in persons with underlying lung disease.	UNIV WISCONSIN, SCH MED, INST AGING, MADISON, WI 53706 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, MADISON, WI USA; UNIV WISCONSIN, WISCONSIN STATE LAB HYG, MADISON, WI 53706 USA; WISCONSIN VET HOME, KING, WI 54946 USA	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison			Gravenstein, Stefan/O-1809-2019; Gravenstein, Stefan/G-1681-2011	Gravenstein, Stefan/0000-0001-6000-6859; 	NIA NIH HHS [AG00213, AG09632, AG00548] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000548, R01AG009632] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; DICK EC, 1967, AM J EPIDEMIOL, V86, P386, DOI 10.1093/oxfordjournals.aje.a120749; DICK EC, 1992, TXB PEDIATRIC INFECT, P1507; DOUGLAS RG, 1966, AM REV RESPIR DIS, V94, P159; EADIE MB, 1966, BMJ-BRIT MED J, V2, P671, DOI 10.1136/bmj.2.5515.671; FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x; FOX JP, 1985, AM J EPIDEMIOL, V122, P830, DOI 10.1093/oxfordjournals.aje.a114166; HENDLEY JO, 1969, AM J EPIDEMIOL, V89, P184, DOI 10.1093/oxfordjournals.aje.a120928; MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P321, DOI 10.1097/00006454-199304000-00011; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; OSTERWEIL D, 1990, J AM GERIATR SOC, V38, P659, DOI 10.1111/j.1532-5415.1990.tb01425.x; STENHOUSE AC, 1967, BMJ-BRIT MED J, V3, P461, DOI 10.1136/bmj.3.5563.461; VALENTI WM, 1982, J PEDIATR-US, V100, P722, DOI 10.1016/S0022-3476(82)80571-4; 1993, MMWR-MORBID MORTAL W, V42, P689	18	75	76	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					588	593		10.7326/0003-4819-123-8-199510150-00004	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677299				2022-12-28	WOS:A1995RY82800004
J	GOLDSTEIN, AM; FRASER, MC; STRUEWING, JP; HUSSUSSIAN, CJ; RANADE, K; ZAMETKIN, DP; FONTAINE, LS; ORGANIC, SM; DRACOPOLI, NC; CLARK, WH; TUCKER, MA				GOLDSTEIN, AM; FRASER, MC; STRUEWING, JP; HUSSUSSIAN, CJ; RANADE, K; ZAMETKIN, DP; FONTAINE, LS; ORGANIC, SM; DRACOPOLI, NC; CLARK, WH; TUCKER, MA			INCREASED RISK OF PANCREATIC-CANCER IN MELANOMA-PRONE KINDREDS WITH P16(INK4) MUTATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANT-MELANOMA; FAMMM SYNDROME; FAMILIAL MELANOMA; DYSPLASTIC NEVUS; PROGRESSION; LINKAGE; LOCUS	Background. A gene on chromosome 9p, p16(INK4), has been implicated in the pathogenesis of cutaneous malignant melanoma in 19 melanoma-prone families. In 10 of these kindreds mutations that impaired the function of the p16(INK4) protein (p16M alleles) cosegregated with the disease. By contrast, in the other nine kindreds the mutation did not alter the function of p16(INK4) (p16W alleles). We looked for differences in clinical and genetic epidemiologic features in these two groups of families. Methods. We compared the median ages at diagnosis of melanoma, number of melanomas, thickness of the tumors, and number of nevi in the kindreds. We estimated prospectively the risks of melanoma or other cancers in families followed for 6 to 18 years and the risks of other cancers since 1925 (the entire period) by comparing the number of cancer cases observed with the number expected. Results. The risk of invasive melanoma was increased by a factor of 75 in kindreds with p16W alleles and a factor of 38 in kindreds with p16W alleles. Although this difference was not significant (P=0.14), there was a striking difference in the risk of other tumors. In kindreds with p16M alleles, the risk of pancreatic cancer was increased by a factor of 13 in the prospective period (2 cases observed, 0.15 expected; standardized incidence ratio, 13.1; 95 percent confidence interval, 1.5 to 47.4) and by a factor of 22 in the entire period (7 cases observed, 0.32 expected; standardized incidence ratio, 21.8; 95 percent confidence interval, 8.7 to 44.8). In contrast, we found no cases of pancreatic cancer in kindreds with p16W alleles. Conclusions. The development of pancreatic cancer in kindreds prone to melanoma may require a p16M mutation. Genetic factors, such as the kind of mutation found in p16(INK4), may explain the inconsistent occurrence of other cancers in these kindreds.	NIH, WARREN G MAGNUSON CLIN CTR, DEPT NURSING, BETHESDA, MD 20892 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA; WESTAT CORP, ROCKVILLE, MD USA; WASHINGTON UNIV, SCH MED, DEPT SURG, ST LOUIS, MO 63110 USA; BATTELLE SRA, ROCKVILLE, MD USA; SEQUANA THERAPEUT INC, LA JOLLA, CA USA; UNIV PENN, SCH MED, PIGMENTED LES STUDY GRP, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Westat; Washington University (WUSTL); University of Pennsylvania; University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	GOLDSTEIN, AM (corresponding author), NCI, GENET EPIDEMIL BRANCH,EXECUT PLAZA N,RM 439, 6130 EXECUT BLVD, MSC 7372, BETHESDA, MD 20892 USA.		Tucker, Margaret A/B-4297-2015; Struewing, Jeffery P/I-7502-2013; Struewing, Jeffery P/C-3221-2008	Struewing, Jeffery P/0000-0002-4848-3334; Dracopoli, Nicholas/0000-0003-3962-4059				BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BERGMAN W, 1990, BRIT J CANCER, V61, P932, DOI 10.1038/bjc.1990.209; BOICE JD, 1991, NIH913180 PUBL; CALDAS C, 1994, NAT GENET, V8, P410, DOI 10.1038/ng1294-410c; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIXON WJ, 1992, BMDP STATISTICAL SOF; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1993, MELANOMA RES, V3, P271; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P40; KOPF A W, 1986, Journal of the American Medical Association, V256, P1915, DOI 10.1001/jama.256.14.1915; LI FP, 1988, CANCER RES, V48, P5358; LYNCH HT, 1981, BRIT J CANCER, V44, P553, DOI 10.1038/bjc.1981.225; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MILLER BA, 1993, NIH932789 PUBL; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PETTY EM, 1993, AM J HUM GENET, V53, P96; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SWERDLOW AJ, 1995, INT J CANCER, V61, P773, DOI 10.1002/ijc.2910610606; TUCKER MA, 1993, J INVEST DERMATOL, V100, pS350, DOI 10.1111/1523-1747.ep12470264; Walker G. J., 1994, American Journal of Human Genetics, V55, pA73; YOUNG JL, 1981, NCI MONOGRAPH, V57	32	477	486	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					970	974		10.1056/NEJM199510123331504	http://dx.doi.org/10.1056/NEJM199510123331504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666916	Bronze			2022-12-28	WOS:A1995RY58600004
J	POSTMA, DS; BLEECKER, ER; AMELUNG, PJ; HOLROYD, KJ; XU, JF; PANHUYSEN, CIM; MEYERS, DA; LEVITT, RC				POSTMA, DS; BLEECKER, ER; AMELUNG, PJ; HOLROYD, KJ; XU, JF; PANHUYSEN, CIM; MEYERS, DA; LEVITT, RC			GENETIC SUSCEPTIBILITY TO ASTHMA - BRONCHIAL, HYPERRESPONSIVENESS COINHERITED WITH A MAJOR GENE FOR ATOPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIRWAY RESPONSIVENESS; PULMONARY-FUNCTION; POPULATION-SAMPLE; SERUM IGE; METHACHOLINE; EXPRESSION; LINKAGE; HYPERREACTIVITY; CHROMOSOME-11Q; INTERLEUKIN-5	Background. Bronchial hyperresponsiveness, a risk factor for asthma, consists of a heightened bronchoconstrictor response to a variety of stimuli. The condition has a heritable component and is closely related to serum IgE levels and airway inflammation. The basis for these relations is unknown, as is the mechanism of genetic susceptibility to bronchial hyperresponsiveness. We attempted to define the interrelation between atopy and bronchial hyperresponsiveness and to investigate the chromosomal location of this component of asthma. Methods. We studied 303 children and grandchildren of 84 probands with asthma selected from a homogeneous population in the Netherlands. Ventilatory function, bronchial responsiveness to histamine, and serum total IgE were measured. The association between the last two variables was evaluated. Using analyses involving pairs of siblings, we tested for linkage between bronchial hyperresponsiveness and genetic markers on chromosome 5q31-q33, previously shown to be linked to a genetic locus regulating serum total IgE levels. Results. Serum total IgE levels were strongly correlated (r=0.65, P<0.01) in pairs of siblings concordant for bronchial hyperresponsiveness (defined as a greater than or equal to 20 percent decrease in the forced expiratory volume in one second produced by histamine [threshold dose, less than or equal to 16 mg per milliliter]), suggesting that these traits are coinherited. However, bronchial hyperresponsiveness was not correlated with serum IgE levels (r=0.04, P>0.10). Analyses of pairs of siblings showed linkage of bronchial hyperresponsiveness with several genetic markers on chromosome 5q, including D5S436 (P<0.001 for a histamine threshold value of less than or equal to 16 mg per milliliter). Conclusions. This study demonstrates that a trait for an elevated level of serum total IgE is coinherited with a trait for bronchial hyperresponsiveness and that a gene governing bronchial hyperresponsiveness is located near a major locus that regulates serum IgE levels on chromosome 5q. These findings are consistent with the existence of one or more genes on chromosome 5q31-q33 causing susceptibility to asthma.	UNIV GRONINGEN HOSP,GRONINGEN,NETHERLANDS; UNIV MARYLAND,SCH MED,BALTIMORE,MD; ASTHMA CTR,HAREN,NETHERLANDS; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	University of Groningen; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University				Holroyd, Kenneth/0000-0001-6050-3935	NHLBI NIH HHS [HL-48341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; CAULFIELD M, 1994, NEW ENGL J MED, V300, P1629; CHANDRASEKHARAP.SC, 1990, GENOMICS, V6, P94; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COOKSON WOCM, 1989, LANCET, V1, P1292; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HOPP RJ, 1988, ANN ALLERGY, V61, P184; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; KATZ MF, 1993, ADV INTERNAL MED, V38, P189; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KELLEHER K, 1991, BLOOD, V77, P1436; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P280, DOI 10.1016/0091-6749(74)90014-1; LANDER ES, 1994, SCIENCE, V266, P1584; LEVITT RC, 1989, J APPL PHYSIOL, V67, P1125, DOI 10.1152/jappl.1989.67.3.1125; LEVITT RC, 1990, AM J PHYSIOL, V258, pL157, DOI 10.1152/ajplung.1990.258.4.L157; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LNADER ES, 1994, SCIENCE, V265, P2037; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; Orie NGM, 1961, BRONCHITIS INT S; Ott J., 1991, ANAL HUMAN GENETIC L; PAUWELS R, 1985, EUR J RESPIR DIS, V66, P98; POSTMA DS, 1989, AM REV RESPIR DIS, V140, pS100, DOI 10.1164/ajrccm/140.3_Pt_2.S100; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P277; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1992, SAGE STATISTICAL ANA	53	635	662	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					894	900		10.1056/NEJM199510053331402	http://dx.doi.org/10.1056/NEJM199510053331402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666875	Bronze			2022-12-28	WOS:A1995RX19900002
J	MENDELL, JR; KISSEL, JT; AMATO, AA; KING, W; SIGNORE, L; PRIOR, TW; SAHENK, Z; BESSON, S; MCANDREW, PE; RICE, R; NAGARAJA, H; STEPHENS, R; LANTRY, L; MORRIS, GE; BURGHES, AHM				MENDELL, JR; KISSEL, JT; AMATO, AA; KING, W; SIGNORE, L; PRIOR, TW; SAHENK, Z; BESSON, S; MCANDREW, PE; RICE, R; NAGARAJA, H; STEPHENS, R; LANTRY, L; MORRIS, GE; BURGHES, AHM			MYOBLAST TRANSFER IN THE TREATMENT OF DUCHENNES MUSCULAR-DYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOMATIC REVERSION; MUSCLE-FIBERS; TRANSPLANTATION; PREDNISONE; LOCUS; TRIAL	Background. Myoblast transfer has been proposed as a technique to replace dystrophin, the skeletal-muscle protein that is deficient in Duchenne's muscular dystrophy. Donor myoblasts injected into muscles of affected patients can fuse with host muscle fibers, thus contributing their nuclei, which are potentially capable of replacing deficient gene products. Previous controlled trials involving a single transfer of myoblasts have been unsuccessful. Methods. We injected donor muscle cells once a month for six months to the biceps brachii muscles of one arm of each of 12 boys with Duchenne's muscular dystrophy. The opposite arms served as sham-injected controls. In each procedure 110 million cells donated by fathers or brothers were transferred. The patients were randomly assigned to receive either cyclosporine or placebo. Strength was measured by quantitative isometric muscle testing. Six months after the final myoblast transfer, the presence of dystrophin was assessed with the use of peptide antibodies specific to the deleted exons of the dystrophin gene. Results. There was no significant difference in muscle strength between arms injected with myoblasts and sham-injected arms, In one patient, 10.3 percent of muscle fibers expressed donor-derived dystrophin after myoblast transfer, Three other patients also had a low level of donor dystrophin (<1 percent); eight had none, Conclusions. Myoblasts transferred once a month for six months failed to improve strength in patients with Duchenne's muscular dystrophy. The value of exon-specific peptide antibodies in the interpretation of myoblast transfer results was demonstrated in a patient with Duchenne's muscular dystrophy who had a high percentage of donor-derived dystrophin. Specific variables affecting the efficiency of myoblast transfer need to be identified in order to improve upon this technique.	OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT STAT, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA; NE WALES INST, DIV RES, DEESIDE CH5 4BR, CLWYD, WALES	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Glyndwr University	MENDELL, JR (corresponding author), OHIO STATE UNIV, DEPT NEUROL, RM 463, MEANS HALL, 1654 UPHAM DR, COLUMBUS, OH 43210 USA.		King, Wendy/E-3388-2011	Burghes, Arthur/0000-0001-9031-1555	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000034] Funding Source: NIH RePORTER; NCRR NIH HHS [MOL-RR-00034] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALDRICH CD, 1979, TISSUE CULT ASS MAN, V5, P1147; BEGGS AH, 1990, HUM GENET, V86, P45; BLAU HM, 1990, ADV EXP MED BIOL, V280, P97; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; Bodmer W. F., 1989, IMMUNOBIOLOGY HLA, V1, P72; BROOKE MH, 1987, ARCH NEUROL-CHICAGO, V44, P812, DOI 10.1001/archneur.1987.00520200016010; BROOKE MH, 1983, MUSCLE NERVE, V6, P204, DOI 10.1002/mus.880060307; BURROW KL, 1991, NEUROLOGY, V41, P661, DOI 10.1212/WNL.41.5.661; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; COUR I, 1979, TISSUE CULT ASS MAN, V5, P1157; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HARDIMAN O, 1992, NEUROLOGY, V42, P1085, DOI 10.1212/WNL.42.5.1085; HARDIMAN O, 1993, NEUROLOGY, V43, P423; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUARD J, 1991, CLIN SCI, V81, P287, DOI 10.1042/cs0810287; HUARD J, 1992, TRANSPLANT P, V24, P3049; HUARD J, 1992, MUSCLE NERVE, V15, P550, DOI 10.1002/mus.880150504; KARPATI G, 1992, Neurology, V42, P387; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; KARPATI G, 1989, AM J PATHOL, V135, P27; KINOSHITA I, 1994, MUSCLE NERVE, V17, P1407, DOI 10.1002/mus.880171210; KLEIN CJ, 1992, AM J HUM GENET, V50, P950; Law P K, 1992, Cell Transplant, V1, P235; LAW PK, 1988, MUSCLE NERVE, V11, P525, DOI 10.1002/mus.880110602; LETHIET T, IN PRESS AM J MED GE; MACY ML, 1979, TCA MANUAL, V5, P1151; MAN NT, 1993, AM J HUM GENET, V52, P1057; MENDELL JR, 1991, ARCH NEUROL-CHICAGO, V48, P1229, DOI 10.1001/archneur.1991.00530240033013; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SHARMA KR, 1993, NEUROLOGY, V43, P527, DOI 10.1212/WNL.43.3_Part_1.527; TREMBLAY JP, 1993, CELL TRANSPLANT, V2, P99, DOI 10.1177/096368979300200203; VANROOD JJ, 1976, TRANSPLANT P, V8, P429; WALSH FS, 1990, ADV EXP MED BIOL, V280, P41; WINNARD AV, 1995, AM J HUM GENET, V56, P158	37	397	407	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					832	838		10.1056/NEJM199509283331303	http://dx.doi.org/10.1056/NEJM199509283331303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651473				2022-12-28	WOS:A1995RW88300003
J	BOUHOLAIGAH, I; ROWE, PC; KAN, J; CALKINS, H				BOUHOLAIGAH, I; ROWE, PC; KAN, J; CALKINS, H			THE RELATIONSHIP BETWEEN NEURALLY-MEDIATED HYPOTENSION AND THE CHRONIC FATIGUE SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEAD-UP TILT; PLACEBO-CONTROLLED TRIAL; UNEXPLAINED SYNCOPE; ORTHOSTATIC INTOLERANCE; ISOPROTERENOL; REPRODUCIBILITY; METHODOLOGY; BRADYCARDIA; PREVALENCE; POPULATION	Objective.-To compare the clinical symptoms and response evoked by upright tilt-table testing in healthy individuals and in a sample of those satisfying strict criteria for chronic fatigue syndrome. Design.-Case-comparison study with mean (SD) follow-up of 24 (5) weeks. Setting.-Tertiary care hospital. Patients and Other Participants.-A sample of 23 patients with chronic fatigue syndrome (five men and 18 women; mean age, 34 years), each of whom fulfilled the strict diagnostic criteria of the Centers for Disease Control and Prevention, was recruited from regional chronic fatigue support groups and from the investigators' clinical practices. There were 14 healthy controls (four men and 10 women; mean age, 36 years). Interventions.-Each subject completed a symptom questionnaire and underwent a three-stage upright tilt-table test (stage 1, 45 minutes at 70 degrees tilt; stage 2, 15 minutes at 70 degrees tilt with 1 to 2 mu g/min of isoproterenol; and stage 3, 10 minutes at 70 degrees with 3 to 4 mu g/min of isoproterenol). Patients were offered therapy with fludrocortisone, beta-adrenergic blocking agents, and disopyramide, alone or in combination, directed at neurally mediated hypotension. Main Outcome Measures.-Response to upright tilt and scores on symptom questionnaires prior to and during follow-up. Results.-An abnormal response to upright tilt was observed in 22 of 23 patients with chronic fatigue syndrome vs four of 14 controls (P<.001). Seventy percent of chronic fatigue syndrome patients, but no controls, had an abnormal response during stage 1 (P<.001). Nine patients reported complete or nearly complete resolution of chronic fatigue syndrome symptoms after therapy directed at neurally mediated hypotension. Conclusions.-We conclude that chronic fatigue syndrome is associated with neurally mediated hypotension and that its symptoms may be improved in a subset of patients by therapy directed at this abnormal cardiovascular reflex.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University								ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; BATES DW, 1993, ARCH INTERN MED, V153, P2759, DOI 10.1001/archinte.153.24.2759; BENTALL RP, 1993, BRIT J CLIN PSYCHOL, V32, P375, DOI 10.1111/j.2044-8260.1993.tb01070.x; BEST JB, 1971, LANCET, V2, P13534; CALKINS H, 1995, AM J MED, V98, P365, DOI 10.1016/S0002-9343(99)80315-5; CALKINS H, 1993, AM J MED, V95, P473, DOI 10.1016/0002-9343(93)90329-N; CALKINS H, 1995, AM HEART J, V129, P1159, DOI 10.1016/0002-8703(95)90398-4; CAMFIELD PR, 1990, CAN J NEUROL SCI, V17, P306, DOI 10.1017/S0317167100030626; CHEN X C, 1992, American Journal of Cardiology, V69, P755, DOI 10.1016/0002-9149(92)90501-O; ENGEL GL, 1950, FAINTING PHYSL PSYCH; FITZPATRICK AP, 1991, J AM COLL CARDIOL, V17, P125, DOI 10.1016/0735-1097(91)90714-K; FOUAD FM, 1986, ANN INTERN MED, V104, P298, DOI 10.7326/0003-4819-104-3-298; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GRUBB BP, 1992, PACE, V15, P1477, DOI 10.1111/j.1540-8159.1992.tb02921.x; GRUBB BP, 1993, MED SCI SPORT EXER, V25, P24, DOI 10.1249/00005768-199301000-00005; GRUBB BP, 1993, PACE, V16, P458, DOI 10.1111/j.1540-8159.1993.tb01608.x; GUNN WJ, 1993, CIBA F SYMP, V173, P83; HARRISON MH, 1985, AVIAT SPACE ENVIR MD, V56, P1059; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KAPOOR WN, 1994, AM J MED, V97, P78, DOI 10.1016/0002-9343(94)90051-5; KENNY RA, 1986, LANCET, V1, P1352; KLEINKNECHT RA, 1990, BEHAV RES THER, V28, P289, DOI 10.1016/0005-7967(90)90080-3; KOMAROFF AL, 1993, CIBA F SYMP, V173, P43; KOSINSKI DJ, 1994, CURR OPIN CARDIOL, V9, P53, DOI 10.1097/00001573-199401000-00007; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANE RM, 1994, J SEROTONIN RES, V1, P47; LEWIS T, 1932, BRIT MED J, V1, P873, DOI DOI 10.1136/BMJ.1.3723.873; LLOYD A, 1990, AM J MED, V89, P561, DOI 10.1016/0002-9343(90)90173-B; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MCCANCE RA, 1935, P R SOC LONDON B, V119, P245; McEwen OR, 1935, LANCET, V1, P1015; MILSTEIN S, 1990, AM J CARDIOL, V65, P1339, DOI 10.1016/0002-9149(90)91324-Y; NEWMAN D, 1993, PACE, V16, P715, DOI 10.1111/j.1540-8159.1993.tb01650.x; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; PRICE RK, 1992, PUBLIC HEALTH REP, V107, P514; ROSEN SG, 1982, AM J MED, V72, P847, DOI 10.1016/0002-9343(82)90559-9; ROSS BA, 1991, AM HEART J, V122, P748, DOI 10.1016/0002-8703(91)90521-I; ROWE PC, 1995, LANCET, V345, P623, DOI 10.1016/S0140-6736(95)90525-1; SCHONDORF R, 1993, NEUROLOGY, V43, P132, DOI 10.1212/WNL.43.1_Part_1.132; SHELDON R, 1992, AM J CARDIOL, V69, P1300, DOI 10.1016/0002-9149(92)91225-S; SHELDON R, 1992, J AM COLL CARDIOL, V19, P773, DOI 10.1016/0735-1097(92)90517-Q; Sra Jasbir S., 1993, Cardiology Clinics, V11, P183; SRA JS, 1992, J AM COLL CARDIOL, V19, P402, DOI 10.1016/0735-1097(92)90498-C; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRAUS SE, 1988, NEW ENGL J MED, V319, P1692, DOI 10.1056/NEJM198812293192602; STREETEN DHP, 1992, ARCH INTERN MED, V152, P1066, DOI 10.1001/archinte.152.5.1066; THILENIUS OG, 1991, PEDIATRICS, V87, P334; VANLIESHOUT JJ, 1991, CLIN SCI, V81, P575, DOI 10.1042/cs0810575; WEISSLER MW, 1959, AM HEART J, V57, P786	49	282	287	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					961	967		10.1001/jama.274.12.961	http://dx.doi.org/10.1001/jama.274.12.961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674527				2022-12-28	WOS:A1995RV73400031
J	BRUNBUISSON, C; DOYON, F; CARLET, J; DELLAMONICA, P; GOUIN, F; LEPOUTRE, A; MERCIER, JC; OFFENSTADT, G; REGNIER, B				BRUNBUISSON, C; DOYON, F; CARLET, J; DELLAMONICA, P; GOUIN, F; LEPOUTRE, A; MERCIER, JC; OFFENSTADT, G; REGNIER, B			INCIDENCE, RISK-FACTORS, AND OUTCOME OF SEVERE SEPSIS AND SEPTIC SHOCK IN ADULTS - A MULTICENTER PROSPECTIVE-STUDY IN INTENSIVE-CARE UNITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIENDOTOXIN MONOCLONAL-ANTIBODIES; GRAM-NEGATIVE BACTEREMIA; POSITIVE BLOOD CULTURES; PROGNOSIS; SYSTEM; DEFINITIONS; ENDOTOXIN; FAILURE; TRIAL	Objective-To examine the incidence, risk factors, and outcome of severe sepsis in intensive care unit (ICU) patients. Design and Setting.-Inception cohort study from a 2-month prospective survey of 11828 consecutive admissions to 170 adult ICUs of public hospitals in France. Patients.-Patients meeting clinical criteria for severe sepsis were included and classified as having documented infection tie, documented severe sepsis, n=742), or a clinical diagnosis of infection without microbiological documentation (ie, culture-negative severe sepsis, n=310). Main Outcome Measures.-Hospital and 28-day mortality after severe sepsis. Results.-Clinically suspected sepsis and confirmed severe sepsis occurred in 9.0 (95% confidence interval [CI], 8.5 to 9.5) and 6.3 (95% CI, 5.8 to 6.7) of 100 ICU admissions, respectively. The 28-day mortality was 56% (95% CI, 52% to 60%) in patients with severe sepsis, and 60% (95% CI, 55% to 66%) in those with culture-negative severe sepsis, Major determinants of both early (<3 days) and secondary deaths in the whole cohort were the Simplified Acute Physiology Score (SAPS) II and the number of acute organ system failures, Other risk factors for early death included a low arterial blood pH (<7.33) (P<.001) and shock (P=.03), whereas secondary deaths were associated with the admission category (P<.001), a rapidly or ultimately fatal underlying disease (P<.001), a preexisting fiver (P=.01), or cardiovascular (P=.002) insufficiency, hypothermia (P=.02), thrombocytopenia (P=.01), and multiple sources of infection (P=.02). In patients with documented sepsis, bacteremia was associated with early mortality (P=.03). Conclusions.-Only three of four patients presenting with clinically suspected severe sepsis have documented infection. However, patients with clinically suspected sepsis but without microbiological documentation and patients with documented infection share common risk factors and are at similarly high risk of death, In addition to the severity of illness score, acute organ failures and the characteristics of underlying diseases should be accounted for in stratification of patients and outcome analyses.	HOP HENRI MONDOR, SERV REANIMAT MED, F-94010 CRETEIL, FRANCE; HOP ST JOSEPH, SERV REANIMAT MED, PARIS, FRANCE; HOP ROBERT DEBRE, SERV REANIMAT MED, PARIS, FRANCE; HOP ST ANTOINE, SERV REANIMAT MED, PARIS, FRANCE; HOP BICHAT CLAUDE BERNARD, SERV REANIMAT MED, PARIS, FRANCE; HOP ARCHET, SERV REANIMAT MED, NICE, FRANCE; HOP LA TIMONE, SERV REANIMAT MED, MARSEILLE, FRANCE; DIRECT GEN SANTE, BUR MALAD TRANSMISSIBLES, PARIS, FRANCE; INST GUSTAVE ROUSSY, DEPT BIOSTAT, INSERM, U351, VILLEJUIF, FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Nice; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy								BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BRESLOW NE, 1980, STATISTICAL METHODS; BRUNBUISSON C, 1994, ARCH INTERN MED, V154, P2484; COMETTA A, 1992, NEW ENGL J MED, V327, P234; COX DR, 1972, J R STAT SOC, V34, P248; DEAN AD, 1993, EPI INFO VERSION 5 1; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEGALL JR, 1995, JAMA-J AM MED ASSOC, V273, P644, DOI 10.1001/jama.273.8.644; LEMESHOW S, 1994, JAMA-J AM MED ASSOC, V272, P1049, DOI 10.1001/jama.272.13.1049; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; PEDUZZI P, 1992, ARCH INTERN MED, V152, P529, DOI 10.1001/archinte.152.3.529; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; ROBERTS FJ, 1991, REV INFECT DIS, V13, P34; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1993, EPIDEMIOLOGICAL GRAP; 1990, SAS STAT USERS GUIDE; 1992, CHEST, V101, P1658	31	782	828	1	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					968	974		10.1001/jama.274.12.968	http://dx.doi.org/10.1001/jama.274.12.968			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674528				2022-12-28	WOS:A1995RV73400032
J	GUPTA, JK; CAVE, M; LILFORD, RJ; FARRELL, TA; IRVING, HC; MASON, G; HAU, CM				GUPTA, JK; CAVE, M; LILFORD, RJ; FARRELL, TA; IRVING, HC; MASON, G; HAU, CM			CLINICAL-SIGNIFICANCE OF FETAL CHOROID-PLEXUS CYSTS	LANCET			English	Article							PRENATAL-DIAGNOSIS; LATERAL VENTRICLE; DOWNS-SYNDROME; AMNIOCENTESIS; FETUSES; TRISOMY-18; PREGNANCY; RISK	Choroid plexus (CP) cysts are commonly detected on routine mid-trimester ultrasound scan. When associated anomalies are detected, the risk is sufficient to justify an invasive diagnostic test such as amniocentesis. However, the risk when no associated anomalies are detected is much less well defined. This information is required to determine the appropriate management in cases of apparently isolated CP cysts. We thought the only way to resolve the difficulties in counselling prospective parents was to conduct a prospective study in a large unselected population. A registry of fetal CP cysts detected over 3 years in the Yorkshire Region was compiled and we identified 524 CP cysts. These cases were then amalgamated and analysed with 1361 cases from prospective studies reported in the world English literature and a further 71 unpublished cases identified from a 2 year prospective series from Ninewells Hospital, Dundee. The risk of chromosomal abnormalities was 1 in 150 (95% CI 1 in 85, 1 in 261) when no fetal anatomic abnormalities, apart from the CP cysts themselves, were detected antenatally. The risk increased to approximately 1 in 3 if any other associated ultrasound abnormalities were detected antenatally. The risk did not appear to be related to whether or not cyst size diminished as gestation progresses, whether they were unilateral or bilateral, and whether they were small or large in size (60-80% <10 mm). 76% of aneuploidic cases were trisomy 18 and 17% were trisomy 21. The risk of Down's syndrome in fetuses with CP cysts but no other anomalies detected antenatally is 1 in 880. The probability of a chromosomal abnormality is high when CP cysts are associated with any other antenatally detected anomaly, indicating a clear need to offering amniocentesis. The predictive value is much lower when no other anomalies are detected. In such cases, it is probably advisable to regard CP cysts as an indication for detailed ultrasound assessment, rather than invasive testing.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV LEEDS,INST EPIDEMIOL & HLTH SERV RES,LEEDS,W YORKSHIRE,ENGLAND; ST JAMES UNIV HOSP,DEPT DIAGNOST RADIOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; LEEDS GEN INFIRM,DEPT OBSTET & GYNAECOL,LEEDS,W YORKSHIRE,ENGLAND	University of Dundee; University of Leeds; Saint James's University Hospital; Leeds General Infirmary; University of Leeds	GUPTA, JK (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OBSTET & GYNAECOL,DUNDEE DD1 9SY,SCOTLAND.			Farrell, Thomas/0000-0001-7775-2866				ACHIRON R, 1991, OBSTET GYNECOL, V78, P815; ANDREUSSI L, 1979, SURG NEUROL, V12, P53; BARKAI G, 1993, PRENATAL DIAG, V13, P843, DOI 10.1002/pd.1970130908; BENACERRAF BR, 1988, AM J OBSTET GYNECOL, V158, P404, DOI 10.1016/0002-9378(88)90165-2; BENACERRAF BR, 1990, AM J OBSTET GYNECOL, V162, P1001, DOI 10.1016/0002-9378(90)91304-U; CAMURRI L, 1989, PRENATAL DIAG, V9, P742, DOI 10.1002/pd.1970091011; CHAN L, 1989, OBSTET GYNECOL, V73, P703; CHINN DH, 1991, J ULTRAS MED, V10, P255; CHITKARA U, 1988, OBSTET GYNECOL, V72, P185; CHITTY LS, 1993, BR MED ULTRASOUND SO, V1, P40; CHUDLEIGH P, 1984, PRENATAL DIAG, V4, P135, DOI 10.1002/pd.1970040207; CLARK SL, 1988, OBSTET GYNECOL, V72, P585; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; FAKHRY J, 1985, J ULTRAS MED, V4, P561, DOI 10.7863/jum.1985.4.10.561; FITZSIMMONS J, 1989, OBSTET GYNECOL, V73, P257; GABRIELLI S, 1989, AM J OBSTET GYNECOL, V160, P1207, DOI 10.1016/0002-9378(89)90192-0; Gupta J. K., 1995, P231; HOWARD RJ, 1992, PRENATAL DIAG, V12, P685, DOI 10.1002/pd.1970120809; LILFORD RJ, 1994, BRIT J OBSTET GYNAEC, V101, P291, DOI 10.1111/j.1471-0528.1994.tb13612.x; NADEL AS, 1992, RADIOLOGY, V185, P545, DOI 10.1148/radiology.185.2.1410370; NYBERG DA, 1993, J ULTRAS MED, V12, P103; OSTLERE SJ, 1990, RADIOLOGY, V175, P753, DOI 10.1148/radiology.175.3.2188298; OSTLERE SJ, 1989, PRENATAL DIAG, V9, P205, DOI 10.1002/pd.1970090310; OSTLERE SJ, 1987, LANCET, V1, P1491; PLATT LD, 1991, AM J OBSTET GYNECOL, V164, P1652, DOI 10.1016/0002-9378(91)91451-2; PORTO M, 1993, J CLIN ULTRASOUND, V21, P103, DOI 10.1002/jcu.1870210205; ROOT S, 1994, AM J MED GENET, V49, P170, DOI 10.1002/ajmg.1320490203; SHUANGSH.S, 1965, ARCH PATHOL, V80, P214; SHUANGSHOTI S, 1966, NEUROLOGY, V16, P887, DOI 10.1212/WNL.16.9.887; TWINING P, 1991, BRIT J RADIOL, V64, P98, DOI 10.1259/0007-1285-64-758-98; WALKINSHAW SA, 1994, PRENATAL DIAG, V14, P663, DOI 10.1002/pd.1970140804; ZERRES K, 1992, HUM GENET, V89, P301	32	63	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					724	729		10.1016/S0140-6736(95)91502-8	http://dx.doi.org/10.1016/S0140-6736(95)91502-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658872				2022-12-28	WOS:A1995RU81000008
J	CHEN, BM; GRINNELL, AD				CHEN, BM; GRINNELL, AD			INTEGRINS AND MODULATION OF TRANSMITTER RELEASE FROM MOTOR-NERVE TERMINALS BY STRETCH	SCIENCE			English	Article							CELL-ADHESION; EXTRACELLULAR-MATRIX; SYNAPTIC STRENGTH; CALCIUM; CHANNELS; FIBRONECTIN; GADOLINIUM; JUNCTIONS; RECEPTORS; BLOCK	The stretch of a frog muscle within the physiological range can more than double the spontaneous and evoked release of neurotransmitter from its motor nerve terminals. Here, stretch enhancement of release was suppressed by peptides containing the sequence arginine-glycine-aspartic acid (RGD), which blocks integrin binding. Integrin antibodies also inhibited the enhancement obtained by stretching. Stretch enhancement depended on intraterminal calcium derived both from external calcium and from internal stores. Muscle stretch thus might enhance the release of neurotransmitters either by elevating internal calcium concentrations or by increasing the sensitivity of transmitter release to calcium in the nerve terminal.	UNIV CALIF LOS ANGELES, SCH MED, JERRY LEWIS NEUROMUSCULAR RES CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, AHMANSON LAB NEUROBIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030673] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30673, NS06232] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; [Anonymous], UNPUB; Chen B.-M., 1994, Society for Neuroscience Abstracts, V20, P58; CHEN BM, 1994, ADV SEC MESS PHOSPH, V29, P383; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DIPOLO R, 1983, ANNU REV PHYSIOL, V45, P313, DOI 10.1146/annurev.ph.45.030183.001525; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GRINNELL AD, 1983, J PHYSIOL-LONDON, V338, P221, DOI 10.1113/jphysiol.1983.sp014670; GRINNELL AD, 1989, J PHYSIOL-LONDON, V418, P397, DOI 10.1113/jphysiol.1989.sp017848; GRINNELL AD, 1980, J PHYSIOL-LONDON, V307, P301, DOI 10.1113/jphysiol.1980.sp013436; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; HUTTER OF, 1956, J PHYSIOL-LONDON, V133, P610, DOI 10.1113/jphysiol.1956.sp005613; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KORNBERG L, 1992, TRENDS PHARMACOL SCI, V13, P93, DOI 10.1016/0165-6147(92)90034-4; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; SWERUP C, 1991, ACTA PHYSIOL SCAND, V143, P21, DOI 10.1111/j.1748-1716.1991.tb09197.x; TURKANIS SA, 1973, J PHYSIOL-LONDON, V230, P391, DOI 10.1113/jphysiol.1973.sp010194; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	31	106	108	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1578	1580		10.1126/science.7667637	http://dx.doi.org/10.1126/science.7667637			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667637				2022-12-28	WOS:A1995RU81300042
J	SKEHEL, PA; MARTIN, KC; KANDEL, ER; BARTSCH, D				SKEHEL, PA; MARTIN, KC; KANDEL, ER; BARTSCH, D			A VAMP-BINDING PROTEIN FROM APLYSIA REQUIRED FOR NEUROTRANSMITTER RELEASE	SCIENCE			English	Article							SYNAPTIC PLASTICITY; FUSION; VESICLES; DOCKING; FAMILY	Before the fusion of synaptic vesicles with the plasma membrane, a protein complex is thought to form between VAMP-an integral membrane protein of the vesicle-and two proteins associated with the plasma membrane, SNAP-25 and syntaxin. The yeast two-hybrid interaction cloning system has now been used to identify additional proteins from Aplysia that interact directly with VAMP. A 33-kilodalton membrane protein, termed VAP-33 (VAMP-associated protein of 33 kilodaltons), was identified whose corresponding messenger RNA was detected only in the central nervous system and the gill of Aplysia. Presynaptic injection of antibodies specific for VAP-33 inhibited synaptic transmission, which suggests that VAP-33 is required for the exocytosis of neurotransmitter.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	SKEHEL, PA (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH045923] Funding Source: NIH RePORTER; NIMH NIH HHS [R37 MH45923-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARTSCH D, UNPUB; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHIN GJ, 1989, J NEUROSCI, V9, P38; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1993, J CELL SCI, P75; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KLASS MR, 1984, MOL CELL BIOL, V4, P529, DOI 10.1128/MCB.4.3.529; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; MARTIN KH, UNPUB; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; RAYPORT SG, 1986, J NEUROSCI, V6, P759; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SKEHEL PA, UNPUB; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; YAMASAKI S, 1994, P NATL ACAD SCI USA, V91, P4688, DOI 10.1073/pnas.91.11.4688	24	142	148	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1580	1583		10.1126/science.7667638	http://dx.doi.org/10.1126/science.7667638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667638				2022-12-28	WOS:A1995RU81300043
J	KARNI, A; MEYER, G; JEZZARD, P; ADAMS, MM; TURNER, R; UNGERLEIDER, LG				KARNI, A; MEYER, G; JEZZARD, P; ADAMS, MM; TURNER, R; UNGERLEIDER, LG			FUNCTIONAL MRI EVIDENCE FOR ADULT MOTOR CORTEX PLASTICITY DURING MOTOR SKILL LEARNING	NATURE			English	Article							CEREBRAL BLOOD-FLOW; SENSORY STIMULATION; TIME-COURSE; REPRESENTATION; HABITUATION; TASK	PERFORMANCE of complex motor tasks, such as rapid sequences of finger movements, can be improved in terms of speed and accuracy over several weeks by daily practice sessions, This improvement does not generalize to a matched sequence of identical component movements, nor to the contralateral hand, Here we report a study of the neural changes underlying this learning using functional magnetic resonance imaging (MRI) of local blood oxygenation level-dependent (BOLD)(1-4) signals evoked in primary motor cortex (Mi). Before training, a comparable extent of M1 was activated by both sequences, However, two ordering effects were observed: repeating a sequence within a brief time window initially resulted in a smaller area of activation (habituation), but later in a larger area of activation (enhancement), suggesting a switch in M1 processing mode within the first session (fast learning), By week 4 of training, concurrent with asymptotic performance, the extent of cortex activated by the practised sequence enlarged compared with the unpractised sequence, irrespective of order (slow learning), These changes persisted for several months, The results suggest a slowly evolving, long-term, experience-dependent reorganization of the adult M1, which may underlie the acquisition and retention of the motor skill.	NHLBI,CARDIAC ENERGET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	KARNI, A (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 49,ROOM 1B80,BETHESDA,MD 20892, USA.		Turner, Robert/C-1820-2008; Li, Chong/F-4265-2015	Turner, Robert/0000-0001-5055-9644; Meyer, Gundela/0000-0002-5730-828X; Jezzard, Peter/0000-0001-7912-2251				ASANUMA H, 1991, NEUROREPORT, V2, P217, DOI 10.1097/00001756-199105000-00001; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; JENKINS IH, 1994, J NEUROSCI, V14, P3775; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KAWASHIMA R, 1994, J NEUROSCI, V14, P3462; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEBIHAN D, 1993, P SOC MAGN RESON MED, V1, P11; MILLER EK, 1991, VISUAL NEUROSCI, V7, P357, DOI 10.1017/S0952523800004843; Milliken G. W., 1992, Society for Neuroscience Abstracts, V18, P506; MISHKIN M, 1984, NEUROBIOLOGY LEARNIN, P64; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PASCUALLEONE A, 1993, NEUROLOGY, V43, pA157; RADEMACHER J, 1993, CEREB CORTEX, V3, P313, DOI 10.1093/cercor/3.4.313; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; SANES JN, 1992, CEREB CORTEX, V2, P141, DOI 10.1093/cercor/2.2.141; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; STERLING MK, 1991, SCIENCE, V254, P716; WARACH S, 1992, J CEREBR BLOOD F MET, V12, P546, DOI 10.1038/jcbfm.1992.78	25	1347	1366	4	124	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					155	158						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675082				2022-12-28	WOS:A1995RU75400050
J	NICOLL, RA; MALENKA, RC				NICOLL, RA; MALENKA, RC			CONTRASTING PROPERTIES OF 2 FORMS OF LONG-TERM POTENTIATION IN THE HIPPOCAMPUS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; MOSSY-FIBER SYNAPSES; METHYL-D-ASPARTATE; MINIATURE SYNAPTIC CURRENTS; NITRIC-OXIDE SYNTHASE; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; RAT HIPPOCAMPUS; CA1 REGION; EXPRESSION	Activity-dependent enhancement of synaptic transmission, referred to as long-term potentiation (LTP), is observed at many synapses in the central nervous system. In the hippocampus two distinct forms of LTP have been identified. One involves the activation of the NMDA (N-methyl-D-aspartate) subtype of glutamate receptor and a rise in postsynaptic Ca2+, whereas the other, which is found at messy fibre synapses, is independent of NMDA receptors but does require a rise in presynaptic Ca2+. Although it is now generally accepted that messy fibre LTP is expressed presynaptically, the locus of expression for NMDA-receptor-dependent LTP is controversial. Here the two forms of LTP are compared and it is argued that the balance of evidence favours a postsynaptic locus for PIM DA-receptor-dependent LTP.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	NICOLL, RA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOLEC PHARMACOL, SAN FRANCISCO, CA 94143 USA.							ALGER BE, 1976, BRAIN RES, V110, P463, DOI 10.1016/0006-8993(76)90858-1; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; ASZTELY F, 1991, BRAIN RES, V558, P153, DOI 10.1016/0006-8993(91)90734-D; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIGGS CA, 1988, J PHYSIOL-LONDON, V404, P129, DOI 10.1113/jphysiol.1988.sp017282; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CUMMINGS JA, 1994, NEUROSCI LETT, V176, P110, DOI 10.1016/0304-3940(94)90883-4; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HANSE E, 1994, J NEUROSCI, V14, P5028; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; HUBER KM, 1995, J NEUROPHYSIOL, V73, P270, DOI 10.1152/jn.1995.73.1.270; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KNAPP AG, 1990, P NATL ACAD SCI USA, V87, P767, DOI 10.1073/pnas.87.2.767; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LANGDON RB, 1995, J NEUROBIOL, V26, P370, DOI 10.1002/neu.480260309; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MAREN S, 1993, P NATL ACAD SCI USA, V90, P9654, DOI 10.1073/pnas.90.20.9654; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MINOTA S, 1991, J PHYSIOL-LONDON, V435, P421, DOI 10.1113/jphysiol.1991.sp018517; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1993, INT CONGR SER, V1036, P203; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WOJTOWICZ JM, 1988, J NEUROSCI, V8, P4667; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; YAMAMOTO C, 1992, NEUROSCI LETT, V138, P111, DOI 10.1016/0304-3940(92)90484-O; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	82	650	669	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					115	118		10.1038/377115a0	http://dx.doi.org/10.1038/377115a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675078				2022-12-28	WOS:A1995RU75400038
J	SUN, XJ; WANG, LM; ZHANG, YT; YENUSH, L; MYERS, MG; GLASHEEN, E; LANE, WS; PIERCE, JH; WHITE, MF				SUN, XJ; WANG, LM; ZHANG, YT; YENUSH, L; MYERS, MG; GLASHEEN, E; LANE, WS; PIERCE, JH; WHITE, MF			ROLE OF IRS-2 IN INSULIN AND CYTOKINE SIGNALING	NATURE			English	Article							HEMATOPOIETIC-CELLS; RECEPTOR; PROTEIN; PHOSPHORYLATION; TRANSMISSION; SEQUENCE	THE protein IRS-1 acts as an interface between signalling proteins with Src-homology-2 domains (SH2 proteins) and the receptors for insulin, IGF-1, growth hormone, several interleukins (IL-4, IL-9, IL-13) and other cytokines(1-7). It regulates gene expression acid stimulates mitogenesis, and appears to mediate insulin/IGF-1-stimulated glucose transport(8). Thus, survival of the IRS-1(-/-) mouse with only mild resistance to insulin was surprising(9,10). This dilemma is provisionally resolved with our discovery of a second IRS-signalling protein, We purified and cloned a likely candidate called 4PS from myeloid progenitor cells and, because of its resemblance to IRS-1, we designate it IRS-2. Alignment of the sequences of IRS-2 acid IRS-1 revealed a highly conserved amino terminus containing a pleckstrin-homology domain and a phosphotyrosine-binding domain, and a poorly conserved carboxy terminus containing several tyrosine phosphorylation motifs. IRS-2 is expressed in many cells, including tissues from IRS-1(-/-) mice(11), and may be essential for signalling by several receptor systems.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; NIH,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; Harvard University			Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU XJ, IN PRESS MOL CELL BI; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PATTI ME, 1995, DIABETES, V44, pA31; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITFIELD K, 1991, INT J FORECASTING, V7, P65, DOI 10.1016/0169-2070(91)90034-S; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	36	746	766	1	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					173	177		10.1038/377173a0	http://dx.doi.org/10.1038/377173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675087				2022-12-28	WOS:A1995RU75400055
J	HATADA, MH; LU, XD; LAIRD, ER; GREEN, J; MORGENSTERN, JP; LOU, MZ; MARR, CS; PHILLIPS, TB; RAM, MK; THERIAULT, K; ZOLLER, MJ; KARAS, JL				HATADA, MH; LU, XD; LAIRD, ER; GREEN, J; MORGENSTERN, JP; LOU, MZ; MARR, CS; PHILLIPS, TB; RAM, MK; THERIAULT, K; ZOLLER, MJ; KARAS, JL			MOLECULAR-BASIS FOR INTERACTION OF THE PROTEIN-TYROSINE KINASE ZAP-70 WITH THE T-CELL RECEPTOR	NATURE			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; CYCLOSPORINE-A; SH2 DOMAINS; ZETA-CHAIN; RECOGNITION; CALCINEURIN; COMPLEXES; SUBUNIT; TAIL	The crystal structure of the tandem SH2 domains of human ZAP-70 in complex with a peptide derived from the zeta-subunit of the T-cell receptor reveals an unanticipated interaction between the two domains. A coiled coil of a-helices connects the two SH2 domains, producing apr interface that constitutes one of the two critical phosphotyrosine binding sites. These and other unique features provide the molecular basis for highly selective association of ZAP-70 with the T-cell receptor.			HATADA, MH (corresponding author), ARIAD PHARMACEUT INC,26 LANDSDOWNE ST,CAMBRIDGE,MA 02139, USA.			Green, Jeremy/0000-0003-4544-6412				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CCP4, 1979, CCP4 SUITE PROGRAMS; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; TANIGUCHI T, 1991, J BIOL CHEM, V268, P15790; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	47	301	311	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					32	38		10.1038/377032a0	http://dx.doi.org/10.1038/377032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659156				2022-12-28	WOS:A1995RT72500047
J	HORTON, R				HORTON, R			SPINNING THE RISKS AND BENEFITS OF CALCIUM-ANTAGONISTS	LANCET			English	Editorial Material																		BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620	2	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					586	587		10.1016/S0140-6736(95)91429-3	http://dx.doi.org/10.1016/S0140-6736(95)91429-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7650997				2022-12-28	WOS:A1995RT18800002
J	SEPKOWITZ, KA; ARMSTRONG, D				SEPKOWITZ, KA; ARMSTRONG, D			TREATMENT OF OPPORTUNISTIC INFECTIONS IN AIDS	LANCET			English	Editorial Material									NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	SEPKOWITZ, KA (corresponding author), MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021, USA.							BROWN AE, 1985, INFECTIOUS COMPLICAT; GLATT AE, 1994, INFECT DIS CLIN N AM, P8; 1993, HIV AIDS SURVEILLANC	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					588	589		10.1016/S0140-6736(95)91432-3	http://dx.doi.org/10.1016/S0140-6736(95)91432-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651000				2022-12-28	WOS:A1995RT18800005
J	BOTTINI, G; PAULESU, E; STERZI, R; WARBURTON, E; WISE, RJS; VALLAR, G; FRACKOWLAK, RSJ; FRITH, CD				BOTTINI, G; PAULESU, E; STERZI, R; WARBURTON, E; WISE, RJS; VALLAR, G; FRACKOWLAK, RSJ; FRITH, CD			MODULATION OF CONSCIOUS EXPERIENCE BY PERIPHERAL SENSORY STIMULI	NATURE			English	Article							VESTIBULAR STIMULATION; RETRACTABLE SEPTA; PET IMAGES	LACK of awareness of touch associated with brain damage transiently recover after stimulation of the vestibular system We used positron emission tomographic regional cerebral blood flow measurements to study the neurophysiological effect of vestibular stimulation on touch imperception in a subject with a right brain lesion. We tested the hypothesis that the vestibular system aids conscious tactile perception by introducing a bias in the neural system subserving body representation. We show that in normal subjects touch and vestibular signals share projections to the putamen, insula, somatosensory area II, premotor cortex and supramarginal gyrus. In our patient a subset of these regions (right putamen and insula) was spared by the lesion and was maximally active when touch and vestibular stimulations were combined. These results support the suggestion that our phenomenological consciousness is associated with activation in circumscribed brain areas specific to the particular sensation of which we are aware.	HAMMERSMITH HOSP, NEUROL INST, WELLCOME DEPT COGNIT NEUROL, LONDON, ENGLAND; HAMMERSMITH HOSP, MRC, CTR CLIN SCI, LONDON, ENGLAND; UNIV MILAN, IST SCI H SAN RAFFAELE, CNR, INB, MILAN, ITALY; UNIV ROMA LA SAPIENZA, IRCCS, CLIN S LUCIA, DIPARTIMENTO PSICOL, ROME, ITALY; UCL, DEPT PSYCHOL, LONDON, ENGLAND	Imperial College London; University of London; University College London; Imperial College London; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Sapienza University Rome; University of London; University College London	BOTTINI, G (corresponding author), OSPED NIGUARDA CA GRANDA, DIV NEUROL, I-20138 MILAN, ITALY.		Frith, Chris D/A-2171-2009; Vallar, Giuseppe/K-8443-2012; Frackowiak, Richard/H-4383-2011; PAULESU, ERALDO/C-2737-2017	Frith, Chris D/0000-0002-8665-0690; Vallar, Giuseppe/0000-0001-7015-0117; Frackowiak, Richard/0000-0002-3151-822X; BOTTINI, GABRIELLA/0000-0003-4683-6420; PAULESU, ERALDO/0000-0002-9224-754X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BOTTINI G, 1994, EXP BRAIN RES, V99, P164; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; FOX PT, 1989, J NUCL MED, V30, P141; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; LIDVALL HF, 1962, ACTA OTO-LARYNGOL, V53, P33; Mesulam M-M., 1985, CEREB CORTEX, P179, DOI DOI 10.1007/978-1-4757-9619-3_5; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, P643; SILBERSWEIG DA, 1993, J CEREBR BLOOD F MET, V13, P617, DOI 10.1038/jcbfm.1993.80; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; Talairach I., 1988, COPLANAR STEREOTACTI; TOWNSEND DW, 1991, IEEE T MED IMAGING, V10, P505, DOI 10.1109/42.108584; VALLAR G, 1993, BRAIN, V116, P71, DOI 10.1093/brain/116.1.71; VALLAR G, 1990, CORTEX, V26, P123, DOI 10.1016/S0010-9452(13)80078-0	16	118	121	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					778	781		10.1038/376778a0	http://dx.doi.org/10.1038/376778a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651537				2022-12-28	WOS:A1995RR83600041
J	SABROE, I; BLOOM, S; HUGHES, JMB; SHAUNAK, S; ROBERTSON, I; LYNN, WA				SABROE, I; BLOOM, S; HUGHES, JMB; SHAUNAK, S; ROBERTSON, I; LYNN, WA			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - THROMBOEMBOLIC OCCLUSION OF A PULMONARY ARTERIOVENOUS MALFORMATION - A VERY UNUSUAL PULMONARY-EMBOLISM	BRITISH MEDICAL JOURNAL			English	Discussion											SABROE, I (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0NN,ENGLAND.		Sabroe, Ian/AAE-5858-2019; Sabroe, Ian/I-5981-2013	Sabroe, Ian/0000-0001-9750-8975				HUGHES JMB, 1994, J ROY COLL PHYS LOND, V28, P247; SAPRU RP, 1969, BRIT HEART J, V31, P559; UEK J, 1994, THORAX, V49, P327; WHITE RI, 1988, RADIOLOGY, V169, P663, DOI 10.1148/radiology.169.3.3186989; WHYTE MKB, 1992, THORAX, V47, P790, DOI 10.1136/thx.47.10.790	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					553	555		10.1136/bmj.311.7004.553	http://dx.doi.org/10.1136/bmj.311.7004.553			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663214	Green Published			2022-12-28	WOS:A1995RR73700026
J	SAUNDERS, P; HERXHEIMER, A				SAUNDERS, P; HERXHEIMER, A			WHO MODEL LIST OF ESSENTIAL DRUGS - A BEACON THROUGH 2 DECADES	LANCET			English	Editorial Material									UNITED KINGDOM COCHRANE CTR,OXFORD,ENGLAND	Cochrane Centre	SAUNDERS, P (corresponding author), ESSENTIAL DRUGS PROJECT,LONDON,ENGLAND.		Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380				[Anonymous], 1977, WHO TECH REP SER, V615; 1990, LANCET, V335, P1003; 1995, WHO TECH REP SER, V850; WHODAP901, P13	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					519	519		10.1016/S0140-6736(95)91375-0	http://dx.doi.org/10.1016/S0140-6736(95)91375-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658773				2022-12-28	WOS:A1995RQ98600003
J	SICINSKI, P; DONAHER, JL; PARKER, SB; LI, TS; GARDNER, H; HASLAM, SZ; BRONSON, RT; ELLEDGE, SJ; WEINBERG, RA				SICINSKI, P; DONAHER, JL; PARKER, SB; LI, TS; GARDNER, H; HASLAM, SZ; BRONSON, RT; ELLEDGE, SJ; WEINBERG, RA			CYCLIN D1 PROVIDES A LINK BETWEEN DEVELOPMENT AND ONCOGENESIS IN THE RETINA AND BREAST	CELL			English	Article							MOUSE MAMMARY-GLAND; GENOMIC ORGANIZATION; CELL-CYCLE; GENES; AMPLIFICATION; EXPRESSION; ONTOGENY; CANCER; PROTOONCOGENE; PIGMENTOSA	Mice lacking cyclin D1 have been generated by gene targeting in embryonic stem cells. Cyclin D1-deficient animals develop to term but show reduced body size, reduced viability, and symptoms of neurological impairment. Their retinas display a striking reduction in cell number due to proliferative failure during embryonic development. In situ hybridization studies of normal mouse embryos revealed an extremely high level of cyclin al in the retina, suggesting a special dependence of this tissue on cyclin D1. In adult mutant females, the breast epithelial compartment fails to undergo the massive proliferative changes associated with pregnancy despite normal levels of ovarian steroid hormones, thus, steroid-induced proliferation of mammary epithelium during pregnancy may be driven through cyclin D1.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOWARD HUGHES MED INST,HOUSTON,TX 77030; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114; MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Baylor College of Medicine; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Michigan State University; Tufts University; Tufts University	SICINSKI, P (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NCI NIH HHS [R35CA39826] Funding Source: Medline; NIA NIH HHS [AG11085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADNANE J, 1989, ONCOGENE, V4, P1389; BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; BARKLEY MS, 1979, BIOL REPROD, V20, P733, DOI 10.1095/biolreprod20.4.733; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRESCIANI FRANCESCO, 1968, CELL TISSUE KINET, V1, P51, DOI 10.1111/j.1365-2184.1968.tb00193.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HALL JE, 1992, J CLIN ENDOCR METAB, V74, P600, DOI 10.1210/jc.74.3.600; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; HASLAM SZ, 1992, J STEROID BIOCHEM, V42, P589, DOI 10.1016/0960-0760(92)90449-S; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HASLAM SZ, 1988, J STEROID BIOCHEM, V31, P9, DOI 10.1016/0022-4731(88)90199-9; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIESS M, 1995, ONCOGENE, V10, P159; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nandi S., 1958, J NATL CANCER I, V21, P1040; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCHUURING E, 1992, CANCER RES, V52, P5229; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINBERG RH, 1991, PROGR RETINAL RES, P121; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; SUTHERLAND RL, 1993, J STEROID BIOCHEM, V47, P99, DOI 10.1016/0960-0760(93)90062-2; TAMARU T, 1993, NEUROSCI LETT, V153, P169, DOI 10.1016/0304-3940(93)90314-B; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E	51	895	910	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					621	630		10.1016/0092-8674(95)90034-9	http://dx.doi.org/10.1016/0092-8674(95)90034-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664341	Bronze			2022-12-28	WOS:A1995RR73400013
J	WOLOSHIN, P; SONG, KN; DEGNIN, C; KILLARY, AM; GOLDHAMER, DJ; SASSOON, D; THAYER, MJ				WOLOSHIN, P; SONG, KN; DEGNIN, C; KILLARY, AM; GOLDHAMER, DJ; SASSOON, D; THAYER, MJ			MSX1 INHIBITS MYOD EXPRESSION IN FIBROBLAST X 10T1/2 CELL HYBRIDS	CELL			English	Article							REGULATORY ELEMENTS; MOUSE EMBRYOGENESIS; HUMAN-CHROMOSOMES; MYOGENIN GENE; HOMEOBOX GENE; NEURAL-TUBE; MUSCLE; DIFFERENTIATION; 5-AZACYTIDINE; MYOBLASTS	Transfer of human chromosome 11, which contains the myoD locus, from primary fibroblasts into 10T(1/2) cells results in activation of myoD. In contrast, hybrids that retain human chromosome 11 and additional human chromosomes fail to activate myoD. We show that human chromosome 4 inhibits myoD activation. myoD enhancer/promoter reporter constructs show that repression is at the transcriptional level. Chromosome fragment-containing hybrids localize the repressing activity to the region of 4p that contains the homeobox gene MSX1. MSX1 is expressed in primary human fibroblasts and in 10T(1/2) cells containing human chromosome 4, while parental 10T(1/2) cells do not express Msx1, Forced expression of Msx1 represses myoD enhancer activity. Msx1 protein binds to the myoD enhancer and likely represses myoD transcription directly, Antisense MSX1 relieves repression mediated by chromosome 4. We conclude that MSX1 inhibits transcription of myoD and that myoD is a target for homeobox gene regulation.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030; UNIV PENN,SCH MED,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	Boston University; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Icahn School of Medicine at Mount Sinai	WOLOSHIN, P (corresponding author), OREGON HLTH SCI UNIV,DEPT MED & MOLEC GENET,PORTLAND,OR 97201, USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X	NIAMS NIH HHS [AR42644] Funding Source: Medline; NICHD NIH HHS [HD27585] Funding Source: Medline; NIGMS NIH HHS [GM49334] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042644] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOBER E, 1994, DEVELOPMENT, V120, P603; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Favaloro J, 1980, Methods Enzymol, V65, P718; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEWITT JE, 1991, GENOMICS, V11, P670, DOI 10.1016/0888-7543(91)90074-O; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RONG PM, 1992, DEVELOPMENT, V115, P657; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785	43	127	129	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					611	620		10.1016/0092-8674(95)90033-0	http://dx.doi.org/10.1016/0092-8674(95)90033-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664340	Bronze			2022-12-28	WOS:A1995RR73400012
J	LIN, CT; ROBERTSON, DE; AHMAD, M; RAIBEKAS, AA; JORNS, MS; DUTTON, PL; CASHMORE, AR				LIN, CT; ROBERTSON, DE; AHMAD, M; RAIBEKAS, AA; JORNS, MS; DUTTON, PL; CASHMORE, AR			ASSOCIATION OF FLAVIN ADENINE-DINUCLEOTIDE WITH THE ARABIDOPSIS BLUE-LIGHT RECEPTOR CRY1	SCIENCE			English	Article							COLI DNA PHOTOLYASE; THALIANA; IDENTIFICATION; CHROMOPHORE; ENZYME	The Arabidopsis thaliana HY4 gene encodes CRY1, a 75-kilodalton flavoprotein mediating blue light-dependent regulation of seedling development. CRY1 is demonstrated here to noncovalently bind stoichiometric amounts of flavin adenine dinucleotide (FAD). The redox properties of FAD bound by CRY1 include an unexpected stability of the neutral radical flavosemiquinone (FADH .). The absorption properties of this flavosemiquinone provide a likely explanation for the additional sensitivity exhibited by CRY1-mediated responses in the green region of the visible spectrum, Despite the sequence homology to microbial DNA photolyases, CRY1 was found to have no detectable photolyase activity.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,JOHNSON FDN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; HAHNEMANN UNIV,SCH MED,DEPT BIOL CHEM,PHILADELPHIA,PA 19102	University of Pennsylvania; University of Pennsylvania; Drexel University				Ahmad, Margaret/0000-0003-4524-5813	NIGMS NIH HHS [GM31704, GM38409, GM51956] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038409, R01GM051956, R01GM031704] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Briggs W. R., 1976, Light and plant development. [Smith, H.]., P7; DARWIN C, 1881, POWER MOVEMENT PLANT, P462; Dutton P L, 1978, Methods Enzymol, V54, P411; EKER APM, 1990, J BIOL CHEM, V265, P8009; Galland Paul, 1991, P65; GALSTON AW, 1950, SCIENCE, V111, P619, DOI 10.1126/science.111.2893.619; GRESSEL J, 1979, PHOTOCHEM PHOTOBIOL, V30, P749, DOI 10.1111/j.1751-1097.1979.tb07209.x; HANGARTER R, COMMUNICATION; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; KONJEVIC R, 1989, P NATL ACAD SCI USA, V86, P9876, DOI 10.1073/pnas.86.24.9876; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LIN C, IN PRESS P NATL ACAD; Lin C. H., UNPUB; LIPSON ED, 1991, SENSORY RECEPTORS SI, P1; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; TAKAO M, 1989, J BACTERIOL, V171, P6323, DOI 10.1128/jb.171.11.6323-6329.1989; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	26	354	382	0	53	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					968	970		10.1126/science.7638620	http://dx.doi.org/10.1126/science.7638620			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638620				2022-12-28	WOS:A1995RP73800033
J	HORTON, RC; BONSER, RS				HORTON, RC; BONSER, RS			INTERACTION BETWEEN CYCLOSPORINE AND FLUOXETINE	BRITISH MEDICAL JOURNAL			English	Letter											HORTON, RC (corresponding author), QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							BROSEN K, 1991, BRIT J CLIN PHARMACO, V32, P136, DOI 10.1111/j.1365-2125.1991.tb05630.x; KEOWN PA, 1982, TRANSPLANT P, V14, P659; SCOTT JP, 1988, MED TOXICOL ADV DRUG, V3, P107, DOI 10.1007/BF03259936	3	18	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					422	422		10.1136/bmj.311.7002.422	http://dx.doi.org/10.1136/bmj.311.7002.422			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640589	Green Published			2022-12-28	WOS:A1995RP55400015
J	PRENTICE, AM; JEBB, SA				PRENTICE, AM; JEBB, SA			OBESITY IN BRITAIN - GLUTTONY OR SLOTH	BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT; ENERGY-INTAKE; WEIGHT; HUMANS	The prevalence of clinical obesity in Britain has doubled in the past decade. The Health of the Nation initiative has set ambitious targets for reversing the trend in recognition of the serious health burden which will accrue, but efforts to develop prevention and treatment strategies are handicapped by uncertainty as to the aetiology of the problem. It is generally assumed that ready access to highly palatable foods induces excess consumption and that obesity is caused by simple gluttony. There is evidence that a high fat diet does override normal satiety mechanisms, However, average recorded energy intake in Britain has declined substantially as obesity rates have escalated. The implication is that levels of physical activity, and hence energy needs, have declined even faster. Evidence suggests that modern inactive lifestyles are at least as important as diet in the aetiology of obesity and possibly represent the dominant factor.			PRENTICE, AM (corresponding author), MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 2DH,ENGLAND.		Prentice, Andrew/AAG-1961-2019	Jebb, Susan/0000-0001-9190-2920				Bennett N, 1995, HLTH SURVEY ENGLAND; Blundell John E., 1993, American Journal of Clinical Nutrition, V57, p772S, DOI 10.1093/ajcn/57.5.772S; BOLTONSMITH C, 1994, INT J OBESITY, V18, P820; Colditz G A, 1992, Am J Clin Nutr, V55, p503S, DOI 10.1093/ajcn/55.2.503s; DIETZ WH, 1985, PEDIATRICS, V75, P807; FLATT JP, 1987, ANN NY ACAD SCI, V499, P104, DOI 10.1111/j.1749-6632.1987.tb36202.x; GARROW JS, 1992, LANCET, V340, P409, DOI 10.1016/0140-6736(92)91481-M; GIBNEY M J, 1990, Journal of Human Nutrition and Dietetics, V3, P245, DOI 10.1111/j.1365-277X.1990.tb00064.x; Gregory F., 1990, DIETARY NUTR SURVEY; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HILL JO, IN PRESS AM J CLIN N; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; LISSNER L, 1987, AM J CLIN NUTR, V46, P886, DOI 10.1093/ajcn/46.6.886; PRENTICE A M, 1989, Journal of Human Nutrition and Dietetics, V2, P95, DOI 10.1111/j.1365-277X.1989.tb00014.x; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; ROLLS BJ, 1994, AM J CLIN NUTR, V60, P476, DOI 10.1093/ajcn/60.4.476; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; Stubbs R. J., 1993, Proceedings of the Nutrition Society, V52, p35A; White A, 1993, HLTH SURVEY ENGLAND; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]; 1992, REPORT ACTIVITY PATT; 1994, SOCIAL TRENDS, V24; 1940, HOUSEHOLD FOOD CONSU; 1992, HOUSEHOLD FOOD CONSU	29	818	832	2	88	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					437	439		10.1136/bmj.311.7002.437	http://dx.doi.org/10.1136/bmj.311.7002.437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640595	Green Published			2022-12-28	WOS:A1995RP55400023
J	SHAUNAK, S; BROWN, P; MORGANHUGHES, JA				SHAUNAK, S; BROWN, P; MORGANHUGHES, JA			EXACERBATION OF IDIOPATHIC PARKINSONS-DISEASE BY NAPROXEN	BRITISH MEDICAL JOURNAL			English	Letter											SHAUNAK, S (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Brown, Peter/J-4307-2016	Brown, Peter/0000-0002-5201-3044				ANDERSON CB, 1984, NEUROLOGY, V34, P400, DOI 10.1212/WNL.34.3.400; CREMONDBARBARO A, 1983, J ROY SOC MED, V76, P435, DOI 10.1177/014107688307600533; ENEVOLDSON TP, 1990, BRIT MED J, V300, P540, DOI 10.1136/bmj.300.6723.540-c; SANDYK R, 1985, ANN NEUROL, V17, P104, DOI 10.1002/ana.410170124; WOOD N, 1988, J NEUROL NEUROSUR PS, V51, P731, DOI 10.1136/jnnp.51.5.731	5	6	6	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					422	422		10.1136/bmj.311.7002.422b	http://dx.doi.org/10.1136/bmj.311.7002.422b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640588	Green Published			2022-12-28	WOS:A1995RP55400017
J	BAYER, R; WILKINSON, D				BAYER, R; WILKINSON, D			DIRECTLY OBSERVED THERAPY FOR TUBERCULOSIS - HISTORY OF AN IDEA	LANCET			English	Review							HEALTH		NEW YORK STATE PSYCHIAT INST & HOSP,HIV CTR CLIN & BEHAV STUDIES,NEW YORK,NY 10032	New York State Psychiatry Institute	BAYER, R (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,600 W 168TH ST,NEW YORK,NY 10032, USA.		Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846	FIC NIH HHS [5D43#TW00231] Funding Source: Medline; NIMH NIH HHS [P50-MH43520] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043520] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V262, P436; CURRY F, 1964, BR J DIS CHEST, V46, P524; FOX W, 1962, Bull Int Union Tuberc, V32, P307; FOX W, 1958, Tubercle, V39, P269, DOI 10.1016/S0041-3879(58)80088-4; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; HOTCHKISS RL, 1993, NEW ENGL J MED, V329, P135, DOI 10.1056/NEJM199307083290215; JONES C, 1995, NY TIMES        0314, pB1; MCDONALD RJ, 1982, ANN INTERN MED, V96, P297, DOI 10.7326/0003-4819-96-3-297; MOODIE AS, 1967, AM REV RESPIR DIS, V95, P384; MOULDING T, 1966, AM J PUBLIC HEALTH N, V56, P416, DOI 10.2105/AJPH.56.3.416; SBARBARO JA, 1968, AM REV RESPIR DIS, V97, P895; SBARBARO JA, 1980, CLIN CHEST MED, V1, P253; SBARBARO JA, 1988, AM REV RESPIR DIS, V138, P1075; SBARBARO JA, 1981, AM REV RESPIR DIS, V123, P247; SBARBARO JA, 1979, CHEST S, V6, P750; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STRADLING P, 1963, Tubercle, V44, P71, DOI 10.1016/S0041-3879(63)80060-4; STRADLING P, 1958, LANCET, V2, P1066; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1988, TUBERCULOSIS NEW YOR; 1987, TUBERCULOSIS NEW YOR; 1980, AM REV RESPIR DIS, V212, P611; 1993, MMWR-MORBID MORTAL W, V42, pRR7; 1985, CHEST, V87, P177; 1964, B WORLD HEALTH ORGAN, V31, P247; 1959, B WORLD HEALTH ORGAN, V21, P51; 1985, CHEST, V87, P125	28	160	167	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1545	1548		10.1016/S0140-6736(95)91090-5	http://dx.doi.org/10.1016/S0140-6736(95)91090-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7677849	hybrid			2022-12-28	WOS:A1995RD79000012
J	JICK, SS; DEAN, AD; JICK, H				JICK, SS; DEAN, AD; JICK, H			ANTIDEPRESSANTS AND SUICIDE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To estimate the rate and means of suicide among people taking 10 commonly prescribed antidepressant drugs: dothiepin, amitriptyline, clomipramine, imipramine, flupenthixol, lofepramine, mianserin, fluoxetine, doxepin, and trazodone. Design-Open cohort study with a nested case-control analysis. Setting-General practices in the United Kingdom that used VAMP computers to maintain their patient records from January 1988 to February 1993. Subjects-172 598 people who had at least one prescription for one of the 10 antidepresssants during the study period. Main outcome measure-Suicide confirmed by general practitioner or on death certificate, or both. Results-143 people committed suicide. The overall rate of suicide was estimated to be 8.5 per 10 000 person years (95% confidence interval 7.2 to 10.0). Rates of suicide were higher in men than women (relative risk 2.8 (95% confidence interval 1.9 to 4.0)), people with a history of feeling suicidal (19.2 (9.5 to 38.7)), and people who had taken several different antidepressants (2.8 (1.8 to 4.3)). People who received high doses of antidepressants and those who had had a prescription in the 30 days before they committed suicide were also at higher risk than those who had received low doses and had had their prescriptions 30 or more days previously (2.3 (1.4 to 3.7) and 2.3 (1.6 to 3.4)) respectively. Rates of suicide were higher in patients who received fluoxetine, but this may be explained by selection biases which were present for those drug users. Conclusion-Several factors correlate with the risk of suicide in people taking antidepressants. After controlling for these factors, the risk of suicide was similar among the 10 study antidepressants. Overdose with antidepressants accounted for only 14% of the suicides.			JICK, SS (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				CASSIDY S, 1982, BRIT MED J, V295, P1021; DERBY LE, 1992, J CLIN PSYCHOPHARM, V12, P235; Henry J A, 1992, Eur J Med, V1, P343; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1992, PHARMACOTHERAPY, V12, P451; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; LEONARD BE, 1986, LANCET, V1, P1105; MONTGOMERY SA, 1992, INT CLIN PSYCHOPHARM, V95, P22; PAYNE CD, 1986, GENERALISED LINEAR I; Perry J, 1978, OXMIS PROBLEM CODES; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; TEICHER MN, 1991, J CLIN PSYCHIAT, V52, P108; 1993, EPILOG PLUS VERSION	15	205	208	2	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					215	218		10.1136/bmj.310.6974.215	http://dx.doi.org/10.1136/bmj.310.6974.215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7677826	Green Published			2022-12-28	WOS:A1995QE49600018
J	VERMA, A; HIRSCH, DJ; GLATT, CE; RONNETT, GV; SNYDER, SH				VERMA, A; HIRSCH, DJ; GLATT, CE; RONNETT, GV; SNYDER, SH			CARBON-MONOXIDE - A PUTATIVE NEURAL MESSENGER	SCIENCE			English	Article							NITRIC-OXIDE SYNTHESIS; HEME OXYGENASE; RAT-BRAIN; GUANYLATE-CYCLASE; SMOOTH-MUSCLE; ACTIVATION; RELAXATION; MECHANISM; RNA; VASODILATION	Carbon monoxide, an activator of guanylyl cyclase, is formed by the action of the enzyme heme oxygenase. By in situ hybridization in brain slices, discrete neuronal localization of messenger RNA for the constitutive form of heme oxygenase throughout the brain has been demonstrated. This localization is essentially the same as that for soluble guanylyl cyclase messenger RNA, In primary cultures of olfactory neurons, zinc protoporphyrin-9, a potent selective inhibitor of heme oxygenase, depletes endogenous guanosine 3',5'-monophosphate (cGMP). Thus, carbon monoxide, like nitric oxide, may be a physiologic regulator of cGMP. These findings, together with the neuronal localizations of heme oxygenase, suggest that carbon monoxide may function as a neurotransmitter.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; WALTER REED ARMY MED CTR,DEPT NEUROL,WASHINGTON,DC 20307; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Verma, Ajay/0000-0001-7715-0443	NIDA NIH HHS [DA00266] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline; NINDS NIH HHS [NS02131] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADEAGBO ASO, 1990, J PHARMACOL EXP THER, V252, P875; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CHERNICK RJ, 1989, HEPATOLOGY, V10, P365, DOI 10.1002/hep.1840100320; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6388; DIFIGLIA M, 1990, HUMAN NERVOUS SYSTEM, P1115; DIGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GRASER T, 1990, BIOMED BIOCHIM ACTA, V49, P293; HOKFELT T, 1984, SCIENCE, V225, P1326, DOI 10.1126/science.6147896; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KASA P, 1986, PROG NEUROBIOL, V26, P211, DOI 10.1016/0301-0082(86)90016-X; KOLBRIDE P, 1979, J GEN PHYSIOL, V79, P415; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MCFAUL SJ, 1987, TOXICOL APPL PHARM, V87, P464, DOI 10.1016/0041-008X(87)90252-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1983, BRAIN RES, V273, P9, DOI 10.1016/0006-8993(83)91088-0; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; RAMOS KS, 1989, BIOCHEM PHARMACOL, V38, P1368, DOI 10.1016/0006-2952(89)90347-X; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SUN Y, 1990, J BIOL CHEM, V265, P8212; SUNDERMAN FW, 1958, CLIN CHEM NY, V28, P2026; UTZ J, 1991, BIOCHEM PHARMACOL, V41, P1195, DOI 10.1016/0006-2952(91)90658-R; VEDERNIKOV YP, 1989, BIOMED BIOCHIM ACTA, V48, P601; Verma A., UNPUB; WEING JF, 1992, J NEUROCHEM, V58, P1140; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7794	43	1359	1434	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					381	384		10.1126/science.7678352	http://dx.doi.org/10.1126/science.7678352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	7678352				2022-12-28	WOS:A1993KG62400038
J	DEBELDER, AJ; RADOMSKI, MW; WHY, HJF; RICHARDSON, PJ; BUCKNALL, CA; SALAS, E; MARTIN, JF; MONCADA, S				DEBELDER, AJ; RADOMSKI, MW; WHY, HJF; RICHARDSON, PJ; BUCKNALL, CA; SALAS, E; MARTIN, JF; MONCADA, S			NITRIC-OXIDE SYNTHASE ACTIVITIES IN HUMAN MYOCARDIUM	LANCET			English	Note								Myocardial constitutive and inducible nitric oxide (NO) synthase activities were measured in right ventricular tissue from 17 patients with dilated cardiomyopathy (DCM). A significant activity of inducible enzyme was accompanied by a low activity of the constitutive NO synthase. Thus, the myocardium has the capacity to express both NO synthases. NO may have a physiological as well as a pathological role in the human myocardium.	WELLCOME RES LABS,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT CARDIOL,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London			Salas, Eduardo/AAL-4836-2020	Salas, Eduardo/0000-0002-6837-2471; bucknall, clifford/0000-0003-0662-5856				MONCADA S, 1991, PHARMACOL REV, V43, P109; OLSEN EGJ, 1979, AM HEART J, V98, P385, DOI 10.1016/0002-8703(79)90052-8; PALMER RMJ, 1992, BRIT J PHARMACOL, V105, P11, DOI 10.1111/j.1476-5381.1992.tb14202.x; RICHARDSON PJ, 1990, CURR OPIN CARDIOL, V5, P306, DOI 10.1097/00001573-199006000-00009; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SMITH JA, 1991, J PHYSIOL-LONDON, V439, P1; SMITH JC, 1992, CIRC RES, V70, P856	8	325	325	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					84	85		10.1016/0140-6736(93)92559-C	http://dx.doi.org/10.1016/0140-6736(93)92559-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	7678120				2022-12-28	WOS:A1993KF87000006
J	HOWARD, PK; SEFTON, BM; FIRTEL, RA				HOWARD, PK; SEFTON, BM; FIRTEL, RA			TYROSINE PHOSPHORYLATION OF ACTIN IN DICTYOSTELIUM ASSOCIATED WITH CELL-SHAPE CHANGES	SCIENCE			English	Article							BINDING PROTEINS; GENE-EXPRESSION; DISCOIDEUM; CHEMOTAXIS; IDENTIFICATION; POLYMERIZATION; MECHANISMS; MOTILITY; MULTIPLE; GROWTH	When Dictyostelium cells that have initiated their developmental program upon starvation are returned to growth medium, there is a rapid and transient de novo tyrosine phosphorylation of a 43-kilodalton protein. This protein was found to be actin. Most of the phosphorylation occurred in a single, minor acidic isoform of actin. Developing cells that had been returned to growth medium lost their pseudopod extensions, became round, and had reduced adhesion to the substratum. These effects occurred with kinetics that matched the increase in tyrosine phosphorylation of actin. In mutant cell lines in which the gene for the phosphotyrosine phosphatase PTP1 had been disrupted, tyrosine phosphorylation of actin was rapid and more prolonged. These cells responded with proportionally accelerated kinetics of cell rounding. Cell lines overexpressing PTP1 had diminished amplitude and duration of actin tyrosine phosphorylation and exhibited diminished cell-shape change and an accelerated return to the extended cell-shape morphology seen in starved cells.	UNIV CALIF SAN DIEGO, DEPT BIOL, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; SALK INST BIOL SCI, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA	University of California System; University of California San Diego; Salk Institute								AMATO PA, 1983, J CELL BIOL, V96, P750, DOI 10.1083/jcb.96.3.750; AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BURRIDGE K, 1986, Cancer Reviews, V4, P18; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; FARMER SR, 1989, CELL SHAPE DETERMINA, P173; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FUTRELLE RP, 1982, J CELL BIOL, V92, P807, DOI 10.1083/jcb.92.3.807; GARRELS JI, 1976, CELL, V9, P793, DOI 10.1016/0092-8674(76)90142-2; GERISCH G, 1982, ANNU REV PHYSIOL, V44, P535, DOI 10.1146/annurev.ph.44.030182.002535; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HOWARD P, UNPUB; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; MACLEOD C, 1980, DEV BIOL, V76, P263, DOI 10.1016/0012-1606(80)90378-4; MARIN FT, 1976, DEV BIOL, V48, P110, DOI 10.1016/0012-1606(76)90050-6; MCKEOWN M, 1981, J MOL BIOL, V151, P593, DOI 10.1016/0022-2836(81)90425-3; MCKEOWN M, 1981, COLD SPRING HARB SYM, V46, P495; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MCROBBIE SJ, 1986, CRC CR REV MICROBIOL, V13, P335, DOI 10.3109/10408418609108742; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MELAMED I, 1991, BIOCHEM BIOPH RES CO, V176, P1424, DOI 10.1016/0006-291X(91)90445-D; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROMANS P, 1985, J MOL BIOL, V186, P337, DOI 10.1016/0022-2836(85)90109-3; SCHWEIGER A, 1992, J CELL SCI, V102, P601; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SIMPSON PA, 1984, J CELL BIOL, V99, P287, DOI 10.1083/jcb.99.1.287; SONOBE S, 1986, J BIOL CHEM, V261, P4837; WATTS RG, 1991, CELL MOTIL CYTOSKEL, V19, P159, DOI 10.1002/cm.970190304; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	35	108	109	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1993	259	5092					241	244		10.1126/science.7678470	http://dx.doi.org/10.1126/science.7678470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678470				2022-12-28	WOS:A1993KF71900035
J	KUPFERSCHMIDT, H; BONT, A; SCHNORF, H; LANDIS, T; WALTER, E; PETER, J; KRAHENBUHL, S; MEIER, PJ				KUPFERSCHMIDT, H; BONT, A; SCHNORF, H; LANDIS, T; WALTER, E; PETER, J; KRAHENBUHL, S; MEIER, PJ			TRANSIENT CORTICAL BLINDNESS AND BIOCCIPITAL BRAIN-LESIONS IN 2 PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA	ANNALS OF INTERNAL MEDICINE			English	Note							NITRIC-OXIDE		UNIV ZURICH HOSP, DEPT MED, DIV CLIN PHARMACOL & TOXICOL, CH-8091 ZURICH, SWITZERLAND; UNIV BASEL HOSP, CH-4031 BASEL, SWITZERLAND; UNIV HOSP GENEVA, GENEVA, SWITZERLAND	University of Zurich; University Zurich Hospital; University of Basel; University of Geneva			Krähenbühl, Stephan/Z-4744-2019					Anton G., 1898, WIEN KLIN WOCHENSCHR, V11, P227; Bonkowsky H L, 1982, Semin Liver Dis, V2, P108, DOI 10.1055/s-2008-1040701; GOLDSTEIN NP, 1957, MAYO CLIN P, V32, P82; HIERONS R, 1957, BRAIN, V80, P176, DOI 10.1093/brain/80.2.176; KING PH, 1991, NEUROLOGY, V41, P1300, DOI 10.1212/WNL.41.8.1300; KUHN MJ, 1990, COMPUT MED IMAG GRAP, V14, P149; LAI CW, 1977, ARCH NEUROL-CHICAGO, V34, P310, DOI 10.1001/archneur.1977.00500170064013; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Riddoch G, 1917, BRAIN, V40, P15, DOI 10.1093/brain/40.1.15; SATO M, 1992, FOLIA OPHTHALMOL JPN, V4, P1378; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOODS RP, 1994, NEW ENGL J MED, V331, P1689, DOI 10.1056/NEJM199412223312505	12	84	86	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					598	600		10.7326/0003-4819-123-8-199510150-00006	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677301				2022-12-28	WOS:A1995RY82800006
J	LEVY, JA				LEVY, JA			A NEW HUMAN HERPESVIRUS - KSHV OR HHV8	LANCET			English	Editorial Material							SARCOMA		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LEVY, JA (corresponding author), UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143, USA.							AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; LEVY JA, 1983, LANCET, V2, P78; MILLER G, 1990, VIROLOGY, P1921; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	12	58	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					786	786		10.1016/S0140-6736(95)91611-3	http://dx.doi.org/10.1016/S0140-6736(95)91611-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674737				2022-12-28	WOS:A1995RW25800002
J	BAUM, RA; RUTTER, CM; SUNSHINE, JH; BLEBEA, JS; BLEBEA, J; CARPENTER, JP; DICKEY, KW; QUINN, SF; GOMES, AS; GRIST, TM; MCNEIL, BJ				BAUM, RA; RUTTER, CM; SUNSHINE, JH; BLEBEA, JS; BLEBEA, J; CARPENTER, JP; DICKEY, KW; QUINN, SF; GOMES, AS; GRIST, TM; MCNEIL, BJ			MULTICENTER TRIAL TO EVALUATE VASCULAR MAGNETIC-RESONANCE ANGIOGRAPHY OF THE LOWER-EXTREMITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MR-ANGIOGRAPHY; OCCLUSIVE DISEASE; RUNOFF VESSELS; ARTERIOGRAPHY; COMPLICATIONS; BYPASS; LIMB	Objectives.-To assess the value of magnetic resonance angiography (MRA) in presurgical evaluation of patients with severe lower limb atherosclerotic occlusive disease and to assess the feasibility of rapidly conducting rigorous technology assessment. Design.-Blinded, prospective study of consecutive patients with signs or symptoms of severe infrainguinal peripheral vascular disease who were candidates for percutaneous or surgical intervention, Using both descriptive statistics and multivariate logistic analyses, MRA was compared with contrast arteriography (CA) (the current technique) for imaging 15 arterial segments of the leg and foot. Intraoperative contrast angiography was the ''gold'' standard. Also studied was the effect of adding MRA to the information used in planning treatment. Setting.-Six US hospitals, one a community hospital. Patients.-A total of 155; 84% with either rest pain or tissue loss. Results.-Sensitivity in distinguishing patent segments from completely occluded segments was 83% for CA and 85% for MRA; both had 81% specificity, For distinguishing near-normal segments (suitable as bypass graft termini), CA was less sensitive than MRA (77% vs 82%), but more specific (92% vs 84%). After adjusting for same-reader effects, odds of correctly distinguishing patent segments were 1.6 times as great for MRA as for CA (P<.01); for distinguishing near-normal segments, the odds for CA were 1.5 times as great as for MRA (P<.05). The addition of MRA changed the treatment plan in 13% of patients; in 86% of these cases, the surgery actually performed indicated that the MRA-inclusive plan was superior. Conclusions.-Individually, MRA and CA are approximately equivalent in diagnostic accuracy, The addition of MRA to treatment plans based only on CA and other diagnostic information clearly improves the plans. Completed in 15 months (as planned), our study demonstrates the feasibility of conducting rigorous technology assessment rapidly enough to be timely even in fields in which diagnostic and treatment techniques are rapidly changing.	UNIV PENN,MED CTR,DEPT SURG,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; AMER COLL RADIOL,RES DEPT,RESTON,VA; UNIV CINCINNATI HOSP,DEPT RADIOL,CINCINNATI,OH; UNIV CINCINNATI HOSP,DEPT SURG,CINCINNATI,OH; YALE NEW HAVEN MED CTR,DEPT RADIOL,NEW HAVEN,CT 06504; GOOD SAMARITAN HOSP,DEPT RADIOL,PORTLAND,OR 97210; UNIV CALIF LOS ANGELES,MED CTR,DEPT RADIOL,LOS ANGELES,CA 90024; UNIV WISCONSIN HOSP,DEPT RADIOL,MADISON,WI 53792	University of Pennsylvania; Harvard University; Harvard Medical School; American College of Radiology; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Yale University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Wisconsin System; University of Wisconsin Madison	BAUM, RA (corresponding author), UNIV PENN,MED CTR,DEPT RADIOL,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Blebea, John/AAH-6643-2020; Rutter, Carolyn/AAZ-3677-2021	Grist, Thomas/0000-0003-3279-6931				CAMBRIA RP, 1993, J VASC SURG, V17, P1050, DOI 10.1016/0741-5214(93)90675-C; CARPENTER JP, 1992, J VASC SURG, V16, P807; EDELMAN RR, 1990, AM J ROENTGENOL, V154, P937, DOI 10.2214/ajr.154.5.2108568; FEEDER BJ, 1995, NY TIMES        0408, pD5; FEEDER BJ, 1995, NY TIMES        0408, pD1; FLANIGAN DP, 1982, SURGERY, V92, P627; HESSEL SJ, 1981, RADIOLOGY, V138, P273, DOI 10.1148/radiology.138.2.7455105; LIPSITZ SR, 1990, COMPUT BIOMED RES, V23, P268, DOI 10.1016/0010-4809(90)90021-4; MATTLE HP, 1991, J VASC SURG, V13, P838; MCCAULEY TR, 1994, RADIOLOGY, V192, P351, DOI 10.1148/radiology.192.2.8029396; MONETA GL, 1992, J VASC SURG, V15, P275, DOI 10.1016/0741-5214(92)90249-8; OWEN RS, 1993, RADIOLOGY, V187, P627, DOI 10.1148/radiology.187.3.8497607; OWEN RS, 1992, NEW ENGL J MED, V326, P1577, DOI 10.1056/NEJM199206113262428; PATEL KR, 1988, J VASC SURG, V7, P531, DOI 10.1067/mva.1988.avs0070531; RICCO JB, 1983, ANN SURG, V198, P646, DOI 10.1097/00000658-198311000-00015; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; RUTKOW IM, 1986, J VASC SURG, V3, P74, DOI 10.1067/mva.1986.avs0030074; SCARPATO R, 1981, ARCH SURG-CHICAGO, V92, P627; SCHEIBLER ML, 1993, MAGN RESON QUART, V9, P152; SHEHADI WH, 1980, RADIOLOGY, V137, P299, DOI 10.1148/radiology.137.2.7433658; SMITH TP, 1992, AM J ROENTGENOL, V158, P431, DOI 10.2214/ajr.158.2.1729803; WAUGH JR, 1992, RADIOLOGY, V182, P243, DOI 10.1148/radiology.182.1.1727290; YIN D, 1995, RADIOLOGY, V194, P755; YUCEL EK, 1993, RADIOLOGY, V187, P637, DOI 10.1148/radiology.187.3.8497608; 1995, ANN REPORT C 1995, P124	25	164	167	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					875	880		10.1001/jama.274.11.875	http://dx.doi.org/10.1001/jama.274.11.875			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674500				2022-12-28	WOS:A1995RU60300025
J	HONG, CC; HASHIMOTO, C				HONG, CC; HASHIMOTO, C			AN UNUSUAL MOSAIC PROTEIN WITH A PROTEASE DOMAIN, ENCODED BY THE NUDEL GENE, IS INVOLVED IN DEFINING EMBRYONIC DORSOVENTRAL POLARITY IN DROSOPHILA	CELL			English	Article							DORSAL-VENTRAL PATTERN; SERINE PROTEASE; BLOOD-COAGULATION; MESSENGER-RNA; LDL-RECEPTOR; MELANOGASTER; SEQUENCE; LOCALIZATION; ACTIVATION; ZYMOGEN	Dorsoventral polarity of the Drosophila embryo is induced by a ventral extracellular signal, which is produced by a locally activated protease cascade within the extraembryonic perivitelline compartment. Local activation of the protease cascade depends on a positional cue that is laid down during oogenesis outside the oocyte. Here we present evidence that the nudel gene encodes an essential component of this cue. The nudel gene, which is expressed in follicle cells covering the oocyte, encodes an unusual mosaic protein resembling an extracellular matrix protein with a central serine protease domain. Our findings suggest that embryonic dorsoventral polarity is defined by a positional cue that requires the nudel protein to anchor and to trigger the protease cascade producing the polarity-inducing signal.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University	HONG, CC (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520, USA.		Hong, Charles/C-9989-2010		NICHD NIH HHS [HD-07149] Funding Source: Medline; NIGMS NIH HHS [GM-49370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049370] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; FARGNOLI J, 1982, DEV BIOL, V92, P306, DOI 10.1016/0012-1606(82)90177-4; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GEHRING WJ, 1984, EMBO J, V3, P2077, DOI 10.1002/j.1460-2075.1984.tb02094.x; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAWLEY RJ, 1988, GENE DEV, V2, P341, DOI 10.1101/gad.2.3.341; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; KAY MA, 1985, MOL CELL BIOL, V5, P3583, DOI 10.1128/MCB.5.12.3583; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Merle J., 1968, DROSOPHILA INFORMATI, V43, P122; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MORISATO D, 1995, IN PRESS ANN REV GEN, V29; NEBES VL, 1991, J BIOL CHEM, V266, P22851; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POPODI E, 1988, DEV BIOL, V127, P248, DOI 10.1016/0012-1606(88)90312-0; POWSNER J, 1935, PHYSIOL ZOOL, V8, P474; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J, 1989, MOL CLONING LABORATO; SCHERER LJ, 1988, DEV BIOL, V130, P786, DOI 10.1016/0012-1606(88)90367-3; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SMITH C, 1994, GENETICS, V136, P1355; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STJOHNSTON D, 1992, CELL, V68, P201; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wieschaus E., 1986, P199; WIGGINS RC, 1979, J EXP MED, V150, P1122, DOI 10.1084/jem.150.5.1122; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	57	92	96	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					785	794		10.1016/0092-8674(95)90475-1	http://dx.doi.org/10.1016/0092-8674(95)90475-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671306	hybrid			2022-12-28	WOS:A1995RU75500013
J	NEWMAN, LS; MCKEEVER, MO; OKANO, HJ; DARNELL, RB				NEWMAN, LS; MCKEEVER, MO; OKANO, HJ; DARNELL, RB			BETA-NAP, A CEREBELLAR DEGENERATION ANTIGEN, IS A NEURON-SPECIFIC VESICLE COAT PROTEIN	CELL			English	Article							STIFF-MAN SYNDROME; TRANSMITTER RELEASE; SYNAPTIC VESICLES; MEMBRANE-PROTEINS; BREAST-CANCER; CLATHRIN; SYNAPTOTAGMIN; COMPLEX; CELLS; PHOSPHORYLATION	We have identified a target antigen in autoimmune cerebellar degeneration, beta-NAP, that is closely related to the beta-adaptin and beta-COP coat proteins. beta-NAP is a non-clathrin-associated phosphoprotein expressed exclusively in neurons, from E12 through adulthood. beta-NAP is present in the neuronal soma and nerve terminal as soluble and membrane-bound pools and is associated with a discrete set of nerve-terminal vesicles. These results establish beta-NAP as a neuron-specific vesicle coat protein. We propose a model in which beta-NAP mediates vesicle transport between the soma and the axon terminus and suggest that beta-NAP may represent a general class of coat proteins that mediates apical transport in polarized cells.			NEWMAN, LS (corresponding author), ROCKEFELLER UNIV, NEUROONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Darnell, Robert B/B-9022-2008	Darnell, Robert B/0000-0002-5134-8088; Okano, Hirotaka James/0000-0003-4611-7098	NIGMS NIH HHS [5T32 GM07739] Funding Source: Medline; NINDS NIH HHS [K08 NS01461] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001461] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CAMIDGE DR, 1994, J CELL SCI, V107, P709; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; Curtis Rory, 1994, Trends in Cell Biology, V4, P383, DOI 10.1016/0962-8924(94)90045-0; DARNELL RB, 1993, NEUROLOGY, V43, P114, DOI 10.1212/WNL.43.1_Part_1.114; DARNELL RB, 1991, J NEUROSCI, V11, P1224, DOI 10.1523/jneurosci.11-05-01224.1991; DARNELL RB, 1994, CURRENT DIAGNOSIS NE, P137; DAVLETOV B, 1993, J BIOL CHEM, V268, P6816; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; GIBBS RB, 1994, J COMP NEUROL, V341, P324, DOI 10.1002/cne.903410304; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HOWARD FM, 1963, MAYO CLIN PROC, V38, P203; HURTLEY SM, 1993, TRENDS BIOCHEM SCI, V18, P453, DOI 10.1016/0968-0004(93)90001-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IKONEN E, 1993, CURR BIOL, V3, P635, DOI 10.1016/0960-9822(93)90061-R; JACOBSON M, 1991, DEV DEV NEUROBIOLOGY, P252; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIU JP, 1994, J BIOL CHEM, V269, P21043; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARTINMOUTOT N, 1993, J PHYSIOLOGY-PARIS, V87, P37, DOI 10.1016/0928-4257(93)90022-L; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEVSNER J, 1994, IN PRESS GENE; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; POSNER JB, 1990, RES P ARNMD, V68, P187; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1993, NATURE, V366, P15, DOI 10.1038/366015a0; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	63	133	134	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					773	783		10.1016/0092-8674(95)90474-3	http://dx.doi.org/10.1016/0092-8674(95)90474-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671305	Bronze			2022-12-28	WOS:A1995RU75500012
J	FRITH, C				FRITH, C			FUNCTIONAL IMAGING AND COGNITIVE ABNORMALITIES	LANCET			English	Article							CEREBRAL BLOOD-FLOW; CHRONIC-SCHIZOPHRENIA; PREFRONTAL CORTEX; DYSFUNCTION; TOMOGRAPHY; PSYCHOSIS; COMPONENT; TASK; PET	From its initial labelling as dementia praecox, the disorder we now call schizophrenia has always been associated with cognitive impairments. While there was a time when these deficits were believed to be secondary to treatment and institutionalisation, there is now overwhelming evidence that cognitive impairments are an essential feature of schizophrenia. Precise specification of the form of these impairments has important implications for the nature of the underlying brain malfunction.			FRITH, C (corresponding author), HAMMERSMITH HOSP, CTR CLIN SCI,CYCLOTRON UNIT,INST NEUROL, DEPT COGNIT NEUROL, 150 DU CANE RD, LONDON W12 0NN, ENGLAND.		Frith, Chris D/A-2171-2009	Frith, Chris D/0000-0002-8665-0690				ALLEN HA, 1993, BRIT J PSYCHIAT, V163, P769, DOI 10.1192/bjp.163.6.769; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; Baddeley A.D., 1986, WORKING MEMORY THOUG; Baddeley Alan, 1993, P11; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P476, DOI 10.1007/BF00249601; DAVID AS, 1994, BRAIN DAM B, P269; DOLAN RJ, 1993, J NEUROL NEUROSUR PS, V56, P1290, DOI 10.1136/jnnp.56.12.1290; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Frith C D, 1991, Br J Psychiatry Suppl, P26; FRITH CD, 1987, PSYCHOL MED, V17, P631, DOI 10.1017/S0033291700025873; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; FRITH CD, 1983, PSYCHOL MED, V13, P779, DOI 10.1017/S0033291700051485; GOLDBERG TE, 1988, SCHIZOPHRENIA BULL, V14, P179, DOI 10.1093/schbul/14.2.179; GOULD LN, 1949, J NERV MENT DIS, V109, P418, DOI 10.1097/00005053-194910950-00005; HYDE TM, 1992, ARCH NEUROL-CHICAGO, V49, P401, DOI 10.1001/archneur.1992.00530280095028; INGVAR DH, 1974, ACTA PSYCHIAT SCAND, V50, P425, DOI 10.1111/j.1600-0447.1974.tb09707.x; JOHNSTONE EC, 1991, BR J PSYCHIATRY S13, V159; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; LIDDLE PF, 1991, BRIT J PSYCHIAT, V158, P340, DOI 10.1192/bjp.158.3.340; LYON N, 1986, J PSYCHIAT RES, V20, P137, DOI 10.1016/0022-3956(86)90013-0; MCGUIRE PK, 1993, LANCET, V342, P703, DOI 10.1016/0140-6736(93)91707-S; MCKENNA PJ, 1990, PSYCHOL MED, V20, P967, DOI 10.1017/S0033291700036667; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MLAKAR J, 1994, PSYCHOL MED, V24, P557, DOI 10.1017/S0033291700027719; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; NELSON HE, 1990, PSYCHOL MED, V20, P357, DOI 10.1017/S0033291700017670; PASSINGHAM RE, 1987, CIBA F SYMP, V132, P151; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PLAYFORD ED, 1992, ANN NEUROL, V32, P151, DOI 10.1002/ana.410320206; ROBBINS TW, 1990, SCHIZOPHRENIA BULL, V16, P391, DOI 10.1093/schbul/16.3.391; ROBERTSON G, 1987, BRIT MED BULL, V43, P634, DOI 10.1093/oxfordjournals.bmb.a072206; SAYKIN AJ, 1994, ARCH GEN PSYCHIAT, V51, P124; SHALLICE T, 1991, PSYCHOL MED, V21, P661, DOI 10.1017/S0033291700022303; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373, DOI 10.1152/jn.1995.73.1.373; SULLIVAN EV, 1994, BIOL PSYCHIAT, V36, P641, DOI 10.1016/0006-3223(94)91173-8; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; Wernicke C., 1906, GRUNDRISSE PSYCHIATR; [No title captured]	39	115	118	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 2	1995	346	8975					615	620		10.1016/S0140-6736(95)91441-2	http://dx.doi.org/10.1016/S0140-6736(95)91441-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RT188	7651009				2022-12-28	WOS:A1995RT18800014
J	HOPKINS, DR; AZAM, M; RUIZTIBEN, E; KAPPUS, KD				HOPKINS, DR; AZAM, M; RUIZTIBEN, E; KAPPUS, KD			ERADICATION OF DRACUNCULIASIS FROM PAKISTAN	LANCET			English	Article								In 1986 the World Health Organization targeted dracunculiasis (Guinea-worm disease), which seriously impairs socioeconomic development in 16 African countries, India, Pakistan, and Yemen, to be eradicated globally The target date for eradication by the end of 1995 was established in 1991. Pakistan eradicated dracunculiasis from the country in October, 1993, after a national campaign which began in 1987 with a nationwide village-by-village search for cases. The infection, which is transmitted by drinking water from ponds containing infected water fleas, was eradicated by using health education, cloth fillers, and the cyclopsicide, temephos; and in the later stages, by case containment. Methods pioneered in Pakistan's National Guinea Worm Eradication Program are now being applied in remaining endemic countries.	NATL INST HLTH,GUINEA WORM ERADICAT PROGRAM,ISLAMABAD,PAKISTAN; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	HOPKINS, DR (corresponding author), EMORY UNIV,CARTER CTR INC,1 COPENHILL,ATLANTA,GA 30307, USA.							HOPKINS DR, 1981, SCIENCE, V212, P495, DOI 10.1126/science.6451929; HOPKINS DR, 1991, B WORLD HEALTH ORGAN, V69, P533; KAPPUS K D, 1991, World Health Forum, V12, P220; PAUL JE, 1988, WASH231 WAT SAN HLTH; 1993, WKLY EPIDEMIOL REC, V68, P49; 1992, WKLY EPIDEMIOL REC, V67, P137; 1988, WKLY EPIDEMIOL REC, V63, P177; 1991, MMWR-MORBID MORTAL W, V40, P5; 1995, WKLY EPIDEMIOL REC, V70, P125	9	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					621	624		10.1016/S0140-6736(95)91442-0	http://dx.doi.org/10.1016/S0140-6736(95)91442-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651010				2022-12-28	WOS:A1995RT18800015
J	UDOLPH, G; LUER, K; BOSSING, T; TECHNAU, GM				UDOLPH, G; LUER, K; BOSSING, T; TECHNAU, GM			COMMITMENT OF CNS PROGENITORS ALONG THE DORSOVENTRAL AXIS OF DROSOPHILA NEUROECTODERM	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSPLANTED INDIVIDUAL CELLS; LINEAGE ANALYSIS; MIDLINE CELLS; SPINAL-CORD; EMBRYOS; MELANOGASTER; NEUROGENESIS; NEUROBLASTS; GUIDANCE	In the Drosophila embryo, the central nervous system (CNS) develops from a population of neural stem cells (neuroblasts) and midline progenitor cells, Here, the fate and extent of determination of CNS progenitors along the dorsoventral axis was assayed. Dorsal neuroectodermal cells transplanted into the ventral neuroectoderm or into the midline produced CNS lineages consistent with their new position. However, ventral neuroectodermal cells and midline cells transplanted to dorsal sites of the neuroectoderm migrated ventrally and produced CNS lineages consistent with their origin, Thus, inductive signals at the ventral midline and adjacent neuroectoderm may confer ventral identities to CNS progenitors as well as the ability to assume and maintain characteristic positions in the developing CNS. Furthermore, ectopic transplantations of wild-type midline cells into single minded (sim) mutant embryos suggest that the ventral midline is required for correct positioning of the cells.	UNIV MAINZ, INST GENET, D-55122 MAINZ, GERMANY	Johannes Gutenberg University of Mainz				Bossing, Torsten/0000-0002-3277-9130				BATE CM, 1976, J EMBRYOL EXP MORPH, V35, P107; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BOSSING T, UNPUB; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Campos-Ortega J. A., 1993, DEV DROSOPHILA MELAN, VII, P1091; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DOE CQ, 1992, DEVELOPMENT, V116, P855; Goodman C. S., 1993, DEV DROSOPHILA MELAN, VII, P1131; HALTER DA, 1995, DEVELOPMENT, V121, P317; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; NAMBU JR, 1993, COMP BIOCHEM PHYS A, V104, P399, DOI 10.1016/0300-9629(93)90439-B; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PACZEK M, 1993, DEVELOPMENT, V117, P205; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PROKOP A, 1994, DEVELOPMENT, V120, P2567; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SINK H, 1991, DEVELOPMENT, V112, P307; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P389, DOI 10.1007/BF00402872; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P445, DOI 10.1007/BF00375748; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; UDOLPH G, 1993, DEVELOPMENT, V118, P765; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	27	43	43	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	1995	269	5228					1278	1281		10.1126/science.7652576	http://dx.doi.org/10.1126/science.7652576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652576				2022-12-28	WOS:A1995RR84200038
J	SUDLOW, CM; RODGERS, H; KENNY, RA; THOMSON, RG				SUDLOW, CM; RODGERS, H; KENNY, RA; THOMSON, RG			SERVICE PROVISION AND USE OF ANTICOAGULANTS IN ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MITRAL-STENOSIS; THROMBOEMBOLIC COMPLICATIONS; SYSTEMIC EMBOLIZATION; RANDOMIZED TRIAL; GENERAL-PRACTICE; STROKE; WARFARIN; PREVENTION; PREVALENCE	Several large trials have shown that the risk of stroke in patients with non-valvar atrial fibrillation is reduced by treatment with warfarin. Implementing this research evidence requires not only an understanding of the trials' results and of the changes that they imply for clinicians' treatment decisions but also an appreciation of the organisation, quantity, and quality of services required to support these changes. Understanding of these implications is crucial for developing services that allow changes in practice to produce reductions in stroke incidence while minimising the risks of treatment. This article considers the developments in service provision that will probably be required to support the changes in clinical practice suggested by the trials' results. These services will be provided largely by doctors, and their development has implications for doctors in both primary and secondary care.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	SUDLOW, CM (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Sudlow, Cathie/0000-0002-7725-7520; Kenny, Rose Anne/0000-0002-9336-8124				[Anonymous], 1994, ARCH INTERN MED, V154, P1449; [Anonymous], 1994, LANCET, V343, P687; ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; BARNABY J, 1993, BRIT MED J, V306, P207, DOI 10.1136/bmj.306.6871.207-b; BATH PMW, 1993, BRIT MED J, V307, P1045, DOI 10.1136/bmj.307.6911.1045; BLACKSHEAR JL, 1993, AM J CARDIOL, V72, P840, DOI 10.1016/0002-9149(93)91079-W; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CAMM AJ, 1980, AM HEART J, V99, P598, DOI 10.1016/0002-8703(80)90733-4; CAMPBELL A, 1974, BRIT HEART J, V36, P1005; CAPLAN LR, 1986, ANN NEUROL, V19, P158, DOI 10.1002/ana.410190208; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CHIMOWITZ MI, 1993, STROKE, V24, P1015, DOI 10.1161/01.STR.24.7.1015; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CORBALAN R, 1992, AM HEART J, V124, P149, DOI 10.1016/0002-8703(92)90933-M; DOBLE N, 1987, J ROY SOC MED, V80, P627, DOI 10.1177/014107688708001009; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FLEGEL KM, 1991, J CLIN EPIDEMIOL, V44, P551, DOI 10.1016/0895-4356(91)90219-Y; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; KENNEDY RD, 1972, GERONTOL CLIN, V14, P5, DOI 10.1159/000245366; KITCHIN AH, 1977, BRIT HEART J, V39, P889, DOI 10.1136/hrt.39.8.889; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDAHL S, 1984, EUR HEART J, V5, P326, DOI 10.1093/oxfordjournals.eurheartj.a061659; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; MCINNES GT, 1987, J ROY COLL PHYS LOND, V21, P42; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; NADEAU SE, 1993, STROKE, V24, P2128, DOI 10.1161/01.STR.24.12.2128; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; PELL JP, 1993, BRIT J GEN PRACT, V43, P152; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, LANCET, V1, P175; ROSE G, 1978, BRIT HEART J, V40, P636; RUOCCO NA, 1986, J AM COLL CARDIOL, V7, pA165; SHAKESPEARE J, 1994, BRIT MED J, V308, P415, DOI 10.1136/bmj.308.6925.415a; TAYLOR F, 1994, BRIT MED J, V307, P1493; TOHGI H, 1991, EUR NEUROL, V31, P126, DOI 10.1159/000116661; 1994, STROKE, V25, P1315; 1991, CIRCULATION, V84, P527; 1993, 1991 CENSUS; 1993, LANCET, V342, P1255; 1990, NEW ENGL J MED, V323, P1505; 1992, ANN INTERN MED, V116, P1	48	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					558	560		10.1136/bmj.311.7004.558	http://dx.doi.org/10.1136/bmj.311.7004.558			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663216	Green Published			2022-12-28	WOS:A1995RR73700029
J	HACHIYA, N; MIHARA, K; SUDA, K; HORST, M; SCHATZ, G; LITHGOW, T				HACHIYA, N; MIHARA, K; SUDA, K; HORST, M; SCHATZ, G; LITHGOW, T			RECONSTITUTION OF THE INITIAL STEPS OF MITOCHONDRIAL PROTEIN IMPORT	NATURE			English	Article							YEAST MITOCHONDRIA; RECEPTORS	WE have reconstituted the initial steps of mitochondrial protein import with a purified precursor protein, a purified, ATP-dependent, cytosolic chaperone selective for mitochondrial precursors (mitochondrial import stimulating factor; MSF), and either intact mitochondria or intact or solubilized mitochondrial outer membranes. We show that the precursor-MSF complex first binds to the Mas37p/Mas70p subunits of the mitochondrial import receptor. After ATP-dependent release of MSF, the precursor is transferred from Mas37p/Mas70p to the Mas20p/Mas22p subunits of the receptor, and finally delivered to the import channel in the outer membrane, Import in the absence of the MSF bypasses Mas37p/Mas70p. The ATP-mediated transfer of a precursor from MSF to specific subunits of the import receptor is similar to the GTP-mediated transfer of precursors from the signal recognition particle to its receptor on the endoplasmic reticulum.	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	University of Basel; Kyushu University			Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884				ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAID A, 1983, METHOD ENZYMOL, V96, P192; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HONLINGER A, IN PRESS MOL CELL BI; KIEBLER M, 1994, J MEMBRANE BIOL, V135, P191; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465	17	154	156	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					705	709		10.1038/376705a0	http://dx.doi.org/10.1038/376705a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651521				2022-12-28	WOS:A1995RQ67200065
J	WALTER, EA; GREENBERG, PD; GILBERT, MJ; FINCH, RJ; WATANABE, KS; THOMAS, ED; RIDDELL, SR				WALTER, EA; GREENBERG, PD; GILBERT, MJ; FINCH, RJ; WATANABE, KS; THOMAS, ED; RIDDELL, SR			RECONSTITUTION OF CELLULAR-IMMUNITY AGAINST CYTOMEGALOVIRUS IN RECIPIENTS OF ALLOGENEIC BONE-MARROW BY TRANSFER OF T-CELL CLONES FROM THE DONOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOCYTE-T; VIRUS INFECTION; TRANSPLANTATION; GANCICLOVIR; DISEASE; PREVENTION; PNEUMONIA; GLOBULIN; RECOVERY; TRIAL	Background. Cytomegalovirus (CMV) disease in immunocompromised patients correlates with a deficiency of CD8+ cytotoxic T lymphocytes specific for CMV. We evaluated the safety and immunologic effects of immunotherapy with clones of these lymphocytes in recipients of allogeneic bone marrow transplants. Methods. Clones of CD8+ cytotoxic T cells specific for CMV proteins were isolated from the blood of bone marrow donors. Fourteen patients each received four intravenous infusions of these clones from their donors beginning 30 to 40 days after marrow transplantation. The reconstitution of cellular immunity against CMV was monitored before and during the period of infusions and for up to 12 weeks after the final infusion. The rearranged genes encoding the T-cell receptor served as markers in evaluating the persistence of the transferred T cells. Results. No toxic effects related to the infusions were observed. Cytotoxic T cells specific for CMV were reconstituted in all patients. In vitro measurements showed that cytotoxic activity against CMV was significantly increased (P<0.001) after the infusions in 11 patients who were deficient in such activity before therapy. The level of activity achieved after the infusions was similar to that measured in the donors. Analysis of rearranged T-cell-receptor genes in T cells obtained from two recipients indicated that the transferred clones persisted for at least 12 weeks. Cytotoxic-T-cell activity declined in patients deficient in CD4+ T-helper cells specific for CMV, suggesting that helper-T-cell function is needed for the persistence of transferred CD8+ T cells. Neither CMV viremia nor CMV disease developed in any of the 14 patients. Conclusions. The transfer of CMV-specific clones of CD8+ T cells derived from the bone marrow donor is a safe and effective way to reconstitute cellular immunity against CMV after allogeneic marrow transplantation.	UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Wilson, Matthew H/K-3193-2013		NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFORD CA, 1980, NATURAL HIST PERINAT, P125; BOECKH M, 1994, 8TH INT S INF IMM HO; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BOWDEN RA, 1991, BLOOD, V78, P246; CASANOVA JL, 1991, J EXP MED, V174, P1371, DOI 10.1084/jem.174.6.1371; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; FARRUGIA E, 1992, MAYO CLIN PROC, V67, P879, DOI 10.1016/S0025-6196(12)60828-3; FORMAN SJ, 1994, BLOOD, V83, P2393; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; LAUBSCHER A, 1988, J IMMUNOL METHODS, V110, P69, DOI 10.1016/0022-1759(88)90084-1; LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MCLAUGHLINTAYLOR E, 1994, J MED VIROL, V43, P103, DOI 10.1002/jmv.1890430119; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MILLER WJ, 1991, BONE MARROW TRANSPL, V7, P227; PADOVAN E, 1993, SCIENCE, V55, P422; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; QUINNAN GV, 1982, NEW ENGL J MED, V307, P7, DOI 10.1056/NEJM198207013070102; REDDEHASE MJ, 1987, J EXP MED, V165, P650, DOI 10.1084/jem.165.3.650; REDDEHASE MJ, 1985, J VIROL, V55, P264, DOI 10.1128/JVI.55.2.264-273.1985; REDDEHASE MJ, 1987, J VIROL, V61, P3102, DOI 10.1128/JVI.61.10.3102-3108.1987; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1992, SCIENCE, V257, P238; RIDDELL SR, 1991, J IMMUNOL, V146, P2795; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SMITH MA, 1994, INFECT DIS CLIN N AM, V8, P427; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; WIENS M, 1993, TRANSPLANT P, V25, P1985; ZAIA JA, 1994, BONE MARROW TRANSPL, P376	38	1490	1584	5	48	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1038	1044		10.1056/NEJM199510193331603	http://dx.doi.org/10.1056/NEJM199510193331603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675046				2022-12-28	WOS:A1995RZ34000003
J	MONTANER, JSG; SCHECHTER, MT; RACHLIS, A; GILL, J; BEAULIEU, R; TSOUKAS, C; RABOUD, J; CAMERON, B; SALOMON, H; DUNKLE, L; SMALDONE, L; WAINBERG, MA; FANNING, M; LALONDE, R; BERGERON, M; SCHLECH, W; SALIT, I; PHILLIPS, P; SPIRA, B; CONWAY, B; CASSOL, S; OSHAUGNESSY, M; THORNE, A; SINGER, J; AUCLAIR, C				MONTANER, JSG; SCHECHTER, MT; RACHLIS, A; GILL, J; BEAULIEU, R; TSOUKAS, C; RABOUD, J; CAMERON, B; SALOMON, H; DUNKLE, L; SMALDONE, L; WAINBERG, MA; FANNING, M; LALONDE, R; BERGERON, M; SCHLECH, W; SALIT, I; PHILLIPS, P; SPIRA, B; CONWAY, B; CASSOL, S; OSHAUGNESSY, M; THORNE, A; SINGER, J; AUCLAIR, C			DIDANOSINE COMPARED WITH CONTINUED ZIDOVUDINE THERAPY FOR HIV-INFECTED PATIENTS WITH 200 TO 500 CD4 CELLS/MM(3) - A DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						DIDANOSINE; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY; VIRUS INFECTIONS; ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; CLINICAL-TRIALS; 2',3'-DIDEOXYINOSINE; RESISTANT; MODELS; AZT	Objective: To compare the safety and efficacy of didanosine with that of continued zidovudine therapy in persons with human immunodeficiency virus (HIV) infection who had received zidovudine for at least 6 months and had CD4 cell counts of 200 to 500 CD4 cells/mm(3). Design: Double-blind, randomized controlled trial. Setting: 10 Canadian university-affiliate specialty clinics. Patients: 246 patients were assigned to receive standard doses of either zidovudine or didanosine. Outcome Measures: The primary clinical end point was the occurrence of a new, previously undiagnosed acquired immunodeficiency syndrome (AIDS)-defining illness or death. Results: 245 of 246 patients were eligible (118 receiving didanosine and 127 receiving zidovudine). Sixty-six percent were asymptomatic, 30% had AIDS-related complex, and 4% had AIDS. The median baseline CD4 count was 320 cells/mm(3). The median previous duration of zidovudine therapy was 471 days. Nine new AIDS-defining illnesses developed during the study; all but one were in the zidovudine group (relative risk, 7.9 [95% CI, 1.0 to 63.3; P = 0.02]). A change to didanosine led to a statistically significant increase in CD4 counts by week 2 that persisted until the end of the study at week 48 (P less than or equal to 0.01). Viral sensitivity studies (done in 102 patients) showed that 28% of the zidovudine group and 21% of the didanosine group had high-level in vitro resistance to zidovudine (50% inhibitory concentration greater than 0.8 mu M) at baseline (P = 0.49). Only one patient in the didanosine group developed high-level resistance to zidovudine during the study. In the zidovudine group, the cumulative probability of developing high-level resistance to zidovudine was 59% at 1 year (P = 0.01). Abdominal pain, leukopenia, and neutropenia were more frequent in the zidovudine group, and hyperuricemia was more frequent in the didanosine group (P < 0.05). Conclusion: In clinically stable patients with 200 to 500 CD4 cells/mm(3) who had tolerated zidovudine for at least 6 months, a change to didanosine led to a decrease in the rate of disease progression, a sustained increase in CD4 counts, and a decrease in the chances of developing high-level resistance to zidovudine. Both drugs were generally well tolerated.	CANADIAN HIV TRIALS NETWORK, VANCOUVER, BC, CANADA; BRISTOL MYERS SQUIBB CO, RES & DEV, WALLINGFORD, CT 06492 USA; BRISTOL MYERS SQUIBB CO, MONTREAL, PQ, CANADA	Bristol-Myers Squibb; Bristol-Myers Squibb	MONTANER, JSG (corresponding author), UNIV BRITISH COLUMBIA, ST PAULS HOSP, CTR EXCELLINCE HIV AIDS, 667-1081 BURRARD ST, VANCOUVER, BC V6Z 1Y6, CANADA.		Dodsley, Maria/G-7083-2016; Gill, Michael John/G-7083-2016	Dodsley, Maria/0000-0001-7587-558X; Gill, Michael John/0000-0002-8546-8790; Cameron, Bill/0000-0002-0090-3539; Schechter, Martin/0000-0001-6063-2155				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1987, MMWR-MORBID MORTAL W, V36, p1S; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; COOLEY TP, 1990, REV INFECT DIS, V12, pS552; COX DR, 1972, J R STAT SOC B, V34, P187; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DOLIN R, 1993, 9TH INT C AIDS BERL, P1; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P55, DOI 10.1016/0197-2456(84)90150-8; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GELMON K, 1989, AIDS, V3, P555, DOI 10.1097/00002030-198909000-00001; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MANTEL N, 1959, J NATL CANCER I, V22, P719; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; MONTANER JSG, 1994, LANCET, V343, P1356; RABOUD JM, 1995, 2ND NAT C HUM RETR W; RICHMAN DD, 1990, AM J MED, V88, pS8, DOI 10.1016/0002-9343(90)90414-9; SALOMON H, 1994, J CLIN MICROBIOL, V32, P2000, DOI 10.1128/JCM.32.8.2000-2002.1994; SELIGMANN M, 1994, LANCET, V343, P871; SPRUANCE SL, 1994, ANN INTERN MED, V120, P360, DOI 10.7326/0003-4819-120-5-199403010-00002; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; YARCHOAN R, 1990, REV INFECT DIS, V12, pS522	36	45	45	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					561	571		10.7326/0003-4819-123-8-199510150-00001	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677296				2022-12-28	WOS:A1995RY82800001
J	PIERCE, MA; JOHNSON, MD; MACIUNAS, RJ; MURRAY, MJ; ALLEN, GS; HARBISON, MA; CREASY, JL; KESSLER, RM				PIERCE, MA; JOHNSON, MD; MACIUNAS, RJ; MURRAY, MJ; ALLEN, GS; HARBISON, MA; CREASY, JL; KESSLER, RM			EVALUATING CONTRAST-ENHANCING BRAIN-LESIONS IN PATIENTS WITH AIDS BY USING POSITRON EMISSION TOMOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; NERVOUS-SYSTEM LYMPHOMA; BIOPSY; NEUROPATHOLOGY; ENCEPHALITIS	Objective: To determine whether a noninvasive method for evaluating contrast-enhancing brain lesions in patients with the acquired immunodeficiency syndrome (AIDS) can accurately differentiate between lymphoma and nonlymphoma diagnoses. This method is based on Toxoplasma serologic testing and positron emission tomography. Design: Prospective, nonrandomized, criterion-standard clinical study. Setting: An academic center in the mid-southeastern United States. Patients: 20 patients with AIDS and contrast-enhancing brain lesions. Interventions: Positron emission tomographic scanning and Toxoplasma serologic testing. Main Outcome Measure: Diagnoses were confirmed by clinical response, autopsy, or brain biopsy. Results: Eight patients had a confirmed diagnosis of toxoplasmosis, six had lymphoma, four had other diagnoses, and two were not evaluable. Seven of eight patients with toxoplasmosis had positron emission tomographic scans; all of these scans showed hypometabolic lesions consistent with a nonlymphoma diagnosis. The six patients with lymphoma all had hypermetabolic lesions on positron emission tomographic scans. The difference between these two sets of results was statistically significant (P < 0.001, Fisher exact test, two-tailed). The anti-Toxoplasma titer was greater than or equal to 1:4 in all patients with confirmed toxoplasmosis who had serologic testing and in three of six patients with lymphoma. Conclusions: Evaluating contrast-enhancing brain lesions in patients with AIDS by using Toxoplasma serologic testing and positron emission tomography can accurately guide therapy and obviate the need for most brain biopsies in these patients. A larger, national, multicenter study is needed to confirm our findings and to determine the effect of earlier diagnosis and treatment on morbidity and mortality in patients with AIDS and primary central nervous system lymphoma.			PIERCE, MA (corresponding author), VANDERBILT UNIV, MED CTR,SCH MED,DIV INFECT DIS,1211 21ST AVE S, MED ARTS BLDG, SUITE 539, NASHVILLE, TN 37232 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR00095] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERS KH, 1986, AM J PATHOL, V124, P537; BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; CIMINO C, 1991, ARCH INTERN MED, V151, P1381, DOI 10.1001/archinte.151.7.1381; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DEGIROLAMI U, 1990, ARCH PATHOL LAB MED, V114, P643; GALETTO G, 1993, JAMA-J AM MED ASSOC, V269, P92, DOI 10.1001/jama.269.1.92; HOFFMAN JM, 1993, J NUCL MED, V34, P567; LEVY RM, 1992, NEUROSURGERY, V30, P186, DOI 10.1227/00006123-199202000-00006; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MOSKOWITZ LB, 1984, ARCH PATHOL LAB MED, V108, P368; ROSENBLUM ML, 1988, AIDS NERVOUS SYSTEM, P1; ROSENFELD SS, 1992, J NUCL MED, V33, P532; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; 1990, ARCH INTERN MED, V150, P735	16	71	73	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					594	598		10.7326/0003-4819-123-8-199510150-00005	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677300				2022-12-28	WOS:A1995RY82800005
J	BERTOLET, BD; MCMURTRIE, EB; HILL, JA; BELARDINELLI, L				BERTOLET, BD; MCMURTRIE, EB; HILL, JA; BELARDINELLI, L			THEOPHYLLINE FOR THE TREATMENT OF ATRIOVENTRICULAR-BLOCK AFTER MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Note							SICK SINUS SYNDROME; ENDOGENOUS ADENOSINE; ORAL THEOPHYLLINE; AMINOPHYLLINE; ANTAGONISM; ATROPINE	Objective: To show that second- or third-degree atrioventricular block occurring as an early complication of acute inferior myocardial infarction is mediated by adenosine. Setting: Cardiac care unit. Design: Uncontrolled, observational, hypothesis-driven study. Patients: Patients who developed clinically significant atrioventricular nodal blockade within 4 hours of admission for acute inferior myocardial infarction. Intervention: Theophylline, 100 mg/min intravenously to a maximum of 250 mg. Measurements: Continuous multilead electrocardiographic monitoring before and after administration of theophylline. Results: During a 6-month period, eight men who had had acute inferior myocardial infarction developed clinically significant atrioventricular block. Three had third-degree block, and five had high-grade second-degree block. In all patients, 1:1 atrioventricular nodal conduction was restored and normal sinus rhythm reappeared within 3 minutes of the administration of theophylline. All patients remained free of arrhythmia for at least 24 hours. Conclusions: Adenosine produced by the ischemic myocardium may induce atrioventricular nodal block. In our patients, atrioventricular nodal block was resistant to conventional therapy such as atropine, but it responded to the adenosine antagonist theophylline.	VET AFFAIRS MED CTR, GAINESVILLE, FL USA; UNIV FLORIDA, HLTH SCI CTR, GAINESVILLE, FL 32610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; University of Florida	BERTOLET, BD (corresponding author), UNIV FLORIDA, J HILLIS MILLER HLTH CTR, BOX 100-277, GAINESVILLE, FL 32610 USA.							ALBONI P, 1991, AM HEART J, V122, P1361, DOI 10.1016/0002-8703(91)90578-6; [Anonymous], 1992, JAMA, V268, P2171; BELARDINELLI L, 1982, CIRC RES, V51, P569, DOI 10.1161/01.RES.51.5.569; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BELARDINELLI L, 1987, TOPICS PERSPECTIVES, P346; BERTOLET BD, 1994, J AM COLL CARDIOL, pA329; DIMARCO JP, 1985, J AM COLL CARDIOL, V6, P417, DOI 10.1016/S0735-1097(85)80181-9; ELLENHOGEN KA, 1988, AM HEART J 1, V16, P202; FREDHOLM BB, 1980, TRENDS PHARMACOL SCI, V1, P129; HAUGHT WH, 1994, AM HEART J, V128, P1255; ROFMAN M, 1972, CIRCULATION, V45, P703; SAITO D, 1993, J AM COLL CARDIOL, V21, P1199, DOI 10.1016/0735-1097(93)90246-W; SCLAROVSKY S, 1984, AM HEART J, V108, P19, DOI 10.1016/0002-8703(84)90539-8; SHAH PK, 1987, AM HEART J, V113, P194, DOI 10.1016/0002-8703(87)90029-9; VISKIN S, 1993, ANN INTERN MED, V118, P279, DOI 10.7326/0003-4819-118-4-199302150-00006; WESLEY RC, 1989, CIRCULATION, V80, P128, DOI 10.1161/01.CIR.80.1.128; WESLEY RC, 1986, J AM COLL CARDIOL, V8, P1232, DOI 10.1016/S0735-1097(86)80406-5	17	43	43	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					509	511		10.7326/0003-4819-123-7-199510010-00006	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661495				2022-12-28	WOS:A1995RW49500006
J	BITTL, JA; STRONY, J; BRINKER, JA; AHMED, WH; MECKEL, CR; CHAITMAN, BR; MARAGANORE, J; DEUTSCH, E; ADELMAN, B				BITTL, JA; STRONY, J; BRINKER, JA; AHMED, WH; MECKEL, CR; CHAITMAN, BR; MARAGANORE, J; DEUTSCH, E; ADELMAN, B			TREATMENT WITH BIVALIRUDIN (HIRULOG) AS COMPARED WITH HEPARIN DURING CORONARY ANGIOPLASTY FOR UNSTABLE OR POSTINFARCTION ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACORONARY THROMBUS; ANGIOSCOPIC EVALUATION; ARTERY OCCLUSION; NATIONAL-HEART; ACUTE CLOSURE; MORPHOLOGY; PECTORIS; DEATH; ANTITHROMBIN; ANGIOGRAPHY	Background. Heparin is often administered during and after coronary angioplasty to prevent closure of the dilated vessel. However, ischemic or hemorrhagic complications occur in 5 to 10 percent of treated patients. We studied whether these complications could be prevented when the direct thrombin inhibitor bivalirudin (Hirulog) was used in place of heparin. Methods. We performed a double-blind, randomized trial in 4098 patients undergoing angioplasty for unstable or postinfarction angina. Patients were assigned to receive either heparin or bivalirudin immediately before angioplasty. The primary end point was death in the hospital, myocardial infarction, abrupt vessel closure, or rapid clinical deterioration of cardiac origin. Results. In the total study group, bivalirudin did not significantly reduce the incidence of the primary end point (11.4 percent, vs. 12.2 percent for heparin) but did result in a lower incidence of bleeding (3.8 percent vs. 9.8 percent, P<0.001), In the prospectively stratified subgroup of 704 patients with postinfarction angina, bivalirudin therapy resulted in a lower incidence of the primary end point (9.1 percent vs, 14.2 percent, P=0.04) and a lower incidence of bleeding (3.0 percent vs. 11.1 percent, P<0.001), but in a similar cumulative rate of death, myocardial infarction, and repeated revascularization in the six months after angioplasty (20.5 percent vs, 25.1 percent, P=0.17). Conclusions. Bivalirudin was at least as effective as high-dose heparin in preventing ischemic complications in patients who underwent angioplasty for unstable angina, and it carried a lower risk of bleeding, Bivalirudin, as compared with heparin, reduced the risk of immediate ischemic complications in patients with postinfarction angina, but this difference was no longer apparent after six months.	HARVARD UNIV,SCH MED,BOSTON,MA; CASE WESTERN RESERVE UNIV HOSP,DEPT MED,CLEVELAND,OH; JOHNS HOPKINS UNIV HOSP,DEPT MED,BALTIMORE,MD 21205; ST LOUIS UNIV,DEPT MED,ST LOUIS,MO 63103; BIOGEN INC,CAMBRIDGE,MA 02142; TEMPLE UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19122	Harvard University; Harvard Medical School; Case Western Reserve University; Case Western Reserve University Hospital; Johns Hopkins University; Johns Hopkins Medicine; Saint Louis University; Biogen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	BITTL, JA (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.			Bittl, John/0000-0003-3254-5198				AHMED WH, 1993, AM J CARDIOL, V72, P544, DOI 10.1016/0002-9149(93)90349-H; AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; [Anonymous], 1993, CIRCULATION, V87, P38; ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; BENTIVOGLIO LG, 1994, J AM COLL CARDIOL, V24, P1195, DOI 10.1016/0735-1097(94)90098-1; BITTL JA, IN PRESS AM HEART J; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; CANNON CP, 1994, J AM COLL CARDIOL, V23, P993, DOI 10.1016/0735-1097(94)90581-9; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEFEYTER PJ, 1992, AM HEART J, V123, P1633, DOI 10.1016/0002-8703(92)90818-G; DEFEYTER PJ, 1991, CIRCULATION, V83, P927, DOI 10.1161/01.CIR.83.3.927; DEFEYTER PJ, 1991, CIRCULATION, V84, P446; DEFEYTER PJ, 1994, TXB INTERVENTIONAL C, V1, P274; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; EITZMAN DT, 1994, CIRCULATION, V89, P1523, DOI 10.1161/01.CIR.89.4.1523; ELLIS SG, 1988, J AM COLL CARDIOL, V11, P211, DOI 10.1016/0735-1097(88)90082-4; ELLIS SG, 1988, CIRCULATION, V77, P372, DOI 10.1161/01.CIR.77.2.372; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FREEMAN MR, 1989, CIRCULATION, V80, P17, DOI 10.1161/01.CIR.80.1.17; GOTOH K, 1988, CIRCULATION, V77, P526, DOI 10.1161/01.CIR.77.3.526; HATTERSLEY PG, 1966, J AMER MED ASSOC, V196, P436, DOI 10.1001/jama.196.5.436; HOGG PJ, 1989, P NATL ACAD SCI USA, V16, P3619; LARRAZET FS, 1994, J AM COLL CARDIOL, V23, P1321, DOI 10.1016/0735-1097(94)90373-5; LINCOFE AM, 1992, J AM COLL CARDIOL, V19, P926, DOI 10.1016/0735-1097(92)90272-O; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; MYLER RK, 1992, J AM COLL CARDIOL, V19, P1641, DOI 10.1016/0735-1097(92)90631-V; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P455; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; SASSOWER MA, 1993, AM HEART J, V126, P444, DOI 10.1016/0002-8703(93)91065-M; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TOPOL EJ, 1993, CIRCULATION, V87, P1622, DOI 10.1161/01.CIR.87.5.1622; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; UEHATA A, 1993, CIRCULATION, V88, P1724, DOI 10.1161/01.CIR.88.4.1724; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WHITE CJ, 1995, J AM COLL CARDIOL, V25, P1681, DOI 10.1016/0735-1097(95)00112-H; WOLFE MW, 1995, CIRCULATION, V92, P311, DOI 10.1161/01.CIR.92.3.311; 1972, ANN INTERN MED, V77, P677; 1994, CIRCULATION, V89, P1545; 1984, BIOSTAT ANAL, P122; 1988, JAMA-J AM MED ASSOC, V260, P2849; 1994, NEW ENGL J MED, V330, P956	46	415	426	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					764	769		10.1056/NEJM199509213331204	http://dx.doi.org/10.1056/NEJM199509213331204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643883				2022-12-28	WOS:A1995RU80900004
J	CHAISSON, RE; KERULY, JC; MOORE, RD				CHAISSON, RE; KERULY, JC; MOORE, RD			RACE, SEX, DRUG-USE, AND PROGRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL; AIDS; INFECTION; ZIDOVUDINE	Background. The rates of progression of human immunodeficiency virus (HIV) infection and survival have been reported to differ among sociodemographic groups, It is unclear whether these differences reflect biologic differences or differences in access to medical care. Methods. We measured disease progression and survival in a cohort of 1372 patients seropositive for HIV who were treated at a single urban center (median follow-up, 1.6 years). We calculated the rates of survival for the entire cohort and the rates of progression to the acquired immunodeficiency syndrome (AIDS) or death among the 740 patients who presented without AIDS. We used Cox proportional-hazards analysis to examine factors associated with progression to AIDS and death. Results. Progression to AIDS or death was associated with a CD4 cell count of 201 to 350 per cubic millimeter (relative risk, 2.0; P<0.001), the presence of symptoms at base line (relative risk, 2.0; P<0.001), prior antiretroviral therapy (relative risk, 1.7, P=0.003), and older age (relative risk per year of age, 1.02; P=0.03). However, there was no relation between disease progression and sex, race, injection-drug use, income, level of education, or insurance status. In the entire cohort, a lower CD4 cell count, a diagnosis of AIDS, older age, and the receipt of antiretroviral therapy before enrollment were associated with an increased risk of death, whereas the use of prophylaxis against pneumocystis pneumonia, zidovudine use after enrollment, and having a job at base line were associated with lower risks of death, There was no significant difference in survival between men and women, blacks and whites, injection-drug users and those who did not use drugs, or patients whose median annual incomes were $5,000 or less and those whose incomes were more than $5,000. Conclusions. Among patients with HIV infection who received medical care from a single urban center, there were no differences in disease progression or survival associated with sex, race, injection-drug use, or socioeconomic status. Differences found in other studies may reflect differences in the use of medical care.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University					AHRQ HHS [R01-HS0780902] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CHAISSON RE, 1991, AIDS, V5, P177, DOI 10.1097/00002030-199102000-00007; CHAISSON RE, 1993, AIDS, V7, P857, DOI 10.1097/00002030-199306000-00015; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; COX DR, 1972, J R STAT SOC B, V34, P187; EHMANN WC, 1994, J ACQ IMMUN DEF SYND, V7, P1095; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HOGG RS, 1994, LANCET, V344, P1120, DOI 10.1016/S0140-6736(94)90631-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; Lee E.T., 1992, STATISTICAL METHODS; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MELNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915, DOI 10.1001/jama.272.24.1915; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1994, JAMA-J AM MED ASSOC, V272, P1001, DOI 10.1001/jama.1994.03520130035018; MOORE RD, 1994, 34TH INT C ANT AG CH, P61; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SELIK RM, 1993, JAMA-J AM MED ASSOC, V270, P710; STANTON DL, 1994, J ACQ IMMUN DEF SYND, V7, P1050; TURNER BJ, 1994, J ACQ IMMUN DEF SYND, V7, P1250; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1994, MMWR-MORBID MORTAL W, V43, P644; 1994, LANCET, V343, P871; 1995, MMWR MORB MORTL WKLY, V44, P81; 1992, MMWR-MORBID MORTAL W, V41, P1	34	264	276	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					751	756		10.1056/NEJM199509213331202	http://dx.doi.org/10.1056/NEJM199509213331202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643881				2022-12-28	WOS:A1995RU80900002
J	JENG, GT; SCOTT, JR; BURMEISTER, LF				JENG, GT; SCOTT, JR; BURMEISTER, LF			A COMPARISON OF METAANALYTIC RESULTS USING LITERATURE VS INDIVIDUAL PATIENT DATA - PATERNAL CELL IMMUNIZATION FOR RECURRENT MISCARRIAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CLINICAL-TRIALS; SPONTANEOUS-ABORTION; PUBLICATION BIAS; STOPPING RULES; METAANALYSIS; OVERVIEWS; IMMUNOTHERAPY; LIMITATIONS; THERAPY; DESIGN	Objective.-To compare the meta-analytic results from published literature vs t Data Sources.-Individual patient data from 15 completed or ongoing trials on paternal white blood cell immunization as treatment for recurrent miscarriage were obtained through the American Society for Reproductive Immunology. Study Selection.-Only randomized controlled trials were selected. Within these eight selected trials, 202 patients were from four published studies, 43 were added by the same investigators after publication, and 140 were from four unpublished trials. Data Extraction.-Individual patient data were collected using a standardized form and double data entry. Data Synthesis.-Using the fixed treatment effect model, we found that the effect of immunization, denoted as the relative live-birth ratio (RR), was greater by pooling summary data from published articles (RR, 1.29; 95% confidence interval [Cl], 1.03 to 1.60) than by pooling all individual patient data from the same investigators (RR, 1.17, 95% Cl, 0.97 to 1.37) or when individual patient data were pooled from four unpublished trials (RR, 1.01 95% Cl, 0.74 to 1.28). A similar diminishing treatment effect for the same comparisons was observed using the random treatment effect model (RR, 1.38; 95% Cl, 0.89 to 1.87 using published summary data; RR, 1.18; 95% Cl, 0.98 to 1.42 using individual patient data; RR, 1.01; 95% Cl, 0.74 to 1.28 using unpublished trials). Conclusions.-Meta-analytic results may differ depending on the use of various data sources: whether the source was from summary statistics in the literature, from individual patient data provided by trialists, or from unpublished trials.	UNIV UTAH, DEPT OBSTET & GYNECOL, SALT LAKE CITY, UT USA	Utah System of Higher Education; University of Utah	JENG, GT (corresponding author), UNIV IOWA, DEPT PREVENT MED, IOWA CITY, IA 52242 USA.							AOKI K, 1994, AM J REPROD IMMUNOL, V32, P55; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BRESLOW NE, 1987, STATISTICAL METHODS, V1, P142; CAUCHI MN, 1991, AM J REPROD IMMUNOL, V25, P16, DOI 10.1111/j.1600-0897.1991.tb01057.x; CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; CHALMERS I, 1993, MILBANK Q, V71, P411, DOI 10.2307/3350409; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHRISTIANSEN OB, 1993, ACTA OBSTET GYNECOL, V72, P1; CLARK DA, 1991, AM J REPROD IMMUNOL, V25, P18, DOI 10.1111/j.1600-0897.1991.tb01058.x; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; COULAM CB, 1992, AM J REPROD IMMUNOL, V27, P124, DOI 10.1111/j.1600-0897.1992.tb00738.x; COWCHOCK S, 1991, AM J REPROD IMMUNOL, V26, P156, DOI 10.1111/j.1600-0897.1991.tb00717.x; DEMETS DL, 1987, STAT MED, V6, P341, DOI 10.1002/sim.4780060325; DENTON FT, 1990, RISK ANAL, V10, P131, DOI 10.1111/j.1539-6924.1990.tb01027.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Droitcour J, 1993, Int J Technol Assess Health Care, V9, P440; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FELSON DT, 1992, J CLIN EPIDEMIOL, V45, P885, DOI 10.1016/0895-4356(92)90072-U; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FRASER EJ, 1993, OBSTET GYNECOL, V82, P854; FRIEDENREICH CM, 1993, EPIDEMIOLOGY, V4, P295, DOI 10.1097/00001648-199307000-00004; GATENBY PA, 1993, AM J REPROD IMMUNOL, V29, P88, DOI 10.1111/j.1600-0897.1993.tb00571.x; GRAUBARD BI, 1994, STAT MED, V13, P509, DOI 10.1002/sim.4780130514; GREEN SJ, 1987, STAT MED, V6, P361, DOI 10.1002/sim.4780060329; GREENLAND S, 1990, STAT MED, V9, P247, DOI 10.1002/sim.4780090307; HASSELBLAD V, 1995, MED CARE, V33, P202; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; HO HN, 1991, AM J REPROD IMMUNOL, V25, P10, DOI 10.1111/j.1600-0897.1991.tb01056.x; HOUWELINGER HCV, 1993, STAT MED, V12, P2273; HUGHES MD, 1992, BIOMETRICS, V48, P41, DOI 10.2307/2532737; HUNT D, 1992, LANCET, V339, P753; JONES MP, 1989, BIOMETRICS, V45, P171, DOI 10.2307/2532043; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MATTHEWS JNS, 1995, STAT MED, V14, P115, DOI 10.1002/sim.4780140204; MCGILCHRIST CA, 1990, BIOMETR J, V32, P335; MOWBRAY JF, 1985, LANCET, V1, P941; Oakes M, 1993, Stat Methods Med Res, V2, P147; OLKIN I, 1995, J CLIN EPIDEMIOL, V48, P133, DOI 10.1016/0895-4356(94)00136-E; OZMINKOWSKI RJ, 1988, STAT MED, V7, P1207, DOI 10.1002/sim.4780071202; Rockette H E, 1988, Recent Results Cancer Res, V111, P99; SANDERCOCK P, 1993, ANN NY ACAD SCI, V703, P149, DOI 10.1111/j.1749-6632.1993.tb26344.x; SCOTT JR, 1994, CLIN OBSTET GYNECOL, V37, P768, DOI 10.1097/00003081-199409000-00027; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; SMITH SJ, 1994, EPIDEMIOLOGY, V5, P381, DOI 10.1097/00001648-199405000-00024; SPECTOR TD, 1991, J EPIDEMIOL COMMUN H, V45, P89, DOI 10.1136/jech.45.2.89; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Temple R, 1990, Int J Technol Assess Health Care, V6, P211; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; WACHTER KW, 1988, SCIENCE, V241, P1407, DOI 10.1126/science.3420397; WITTES RE, 1987, STAT MED, V6, P269, DOI 10.1002/sim.4780060312; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	58	114	116	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					830	836		10.1001/jama.274.10.830	http://dx.doi.org/10.1001/jama.274.10.830			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650808				2022-12-28	WOS:A1995RU32400032
J	FLINT, J; CORLEY, R; DEFRIES, JC; FULKER, DW; GRAY, JA; MILLER, S; COLLINS, AC				FLINT, J; CORLEY, R; DEFRIES, JC; FULKER, DW; GRAY, JA; MILLER, S; COLLINS, AC			A SIMPLE GENETIC-BASIS FOR A COMPLEX PSYCHOLOGICAL TRAIT IN LABORATORY MICE	SCIENCE			English	Article							ELEVATED PLUS-MAZE; ANXIETY; RAT; BEHAVIOR; DISORDER; LINKAGE	Psychological traits are commonly inferred from covariation in sets of behavioral measures that otherwise appear to have little in common. Emotionality in mice is such a trait, defined here by covariation in activity and defecation in a novel environment and emergence into the open arms of an elevated plus maze. Behavioral and quantitative trait analyses were conducted on four measures obtained from 879 mice from an F-2 intercross. Three loci, on murine chromosomes 1, 12, and 15, were mapped that influence emotionality. This trait, inferred from studies of strain, sex, and individual differences in rodents, may be related to human susceptibility to anxiety or neuroticism.	UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of Colorado System; University of Colorado Boulder; University of London; King's College London	FLINT, J (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.			Flint, Jonathan/0000-0002-9427-4429	NIDA NIH HHS [DA-00197, DA-05131] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000197] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; BROADHURST PL, 1960, EXPT PERSONALITY, V1, P3; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; Castle W E, 1921, Science, V54, P223, DOI 10.1126/science.54.1393.223; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEFRIES JC, 1978, BEHAV GENET, V8, P3, DOI 10.1007/BF01067700; DeFries JC, 1970, CONTRIBUTIONS BEHAVI, P23; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FANSELOW MS, 1991, MIDBRAIN PERIACQUEDU; GOLDSTEIN RB, 1994, ARCH GEN PSYCHIAT, V51, P383; GRAEFF FG, 1993, REV NEUROSCIENCE, V4, P181; Gray J.A., 1987, PSYCHOL FEAR STRESS, V2nd, P422; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; GREEN S, 1990, BEHAVIOURAL MODELS P; Hall CS, 1936, J COMP PSYCHOL, V22, P345, DOI 10.1037/h0059253; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P952; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P716; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LeDoux J E, 1992, Curr Opin Neurobiol, V2, P191, DOI 10.1016/0959-4388(92)90011-9; LINCOLN S, 1992, MAPPING GENES CONTRO; LIPP HP, 1989, EXPERIENTIA, V45, P845, DOI 10.1007/BF01954059; MAIER W, 1994, ARCH GEN PSYCHIAT, V51, P871; McGuffin P., 1994, SEMINARS PSYCHIATRIC; Montgomery KM, 1958, J COMP PHYSIOL PSYCH, V48, P254; Ott J., 1991, ANAL HUMAN GENETIC L; PANKSEPP J, 1982, BEHAV BRAIN SCI, V5, P407, DOI 10.1017/S0140525X00012759; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PAULS DL, 1993, NAT GENET, V3, P4, DOI 10.1038/ng0193-4; PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Plomin R, 1991, J Psychopharmacol, V5, P1, DOI 10.1177/026988119100500102; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; REDMOND DE, 1985, ANXIETY ANXIETY DISO, P530; TAYLOR MA, 1992, AM J PSYCHIAT, V149, P22; Wright S., 1968, EVOLUTION GENETICS P, V1; 1982, NEROPSYCHOLOGY ANXIE	41	327	334	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1432	1435		10.1126/science.7660127	http://dx.doi.org/10.1126/science.7660127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RT806	7660127				2022-12-28	WOS:A1995RT80600048
J	KIBEL, A; ILIOPOULOS, O; DECAPRIO, JA; KAELIN, WG				KIBEL, A; ILIOPOULOS, O; DECAPRIO, JA; KAELIN, WG			BINDING OF THE VONHIPPEL-LINDAU TUMOR-SUPPRESSOR PROTEIN TO ELONGIN-B AND ELONGIN-C	SCIENCE			English	Article							GENE; IDENTIFICATION; SEQUENCE; PRODUCT	Germ-line mutations of the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of human tumors, and somatic mutations of this gene have been identified in sporadic renal cell carcinomas and cerebellar hemangioblastomas. Two transcriptional elongation factors, Elongin B and C, were shown to bind in vitro and in vivo to a short, colinear region of the VHL protein (pVHL) that is frequently mutated in human tumors. A peptide replica of this region inhibited binding of pVHL to Elongin B and C, whereas a point-mutant derivative, corresponding to a naturally occurring VHL missense mutation, had no effect. These results suggest that the tumor suppression function of pVHL may be linked to its ability to bind to Elongin B and C.	CHILDRENS HOSP, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute								ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOSS K, 1987, GENE, V59, P285, DOI 10.1016/0378-1119(87)90336-2; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GARRETT KP, 1994, GENE, V150, P413, DOI 10.1016/0378-1119(94)90467-7; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, UNPUB; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; McKusick V.A., 1992, MENDELIAN INHERITANC; SHUIN T, 1994, CANCER RES, V54, P2852; WHALEY JM, 1994, AM J HUM GENET, V55, P1092	25	547	568	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1444	1446		10.1126/science.7660130	http://dx.doi.org/10.1126/science.7660130			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660130				2022-12-28	WOS:A1995RT80600051
J	CALANDRA, T; BERNHAGEN, J; METZ, CN; SPIEGEL, LA; BACHER, M; DONNELLY, T; CERAMI, A; BUCALA, R				CALANDRA, T; BERNHAGEN, J; METZ, CN; SPIEGEL, LA; BACHER, M; DONNELLY, T; CERAMI, A; BUCALA, R			MIF AS A GLUCOCORTICOID-INDUCED MODULATOR OF CYTOKINE PRODUCTION	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL GROWTH-FACTOR; CACHECTIN; ENDOTOXIN; MICE; INTERLEUKIN-1; INHIBITION; PITUITARY; STRESS; SHOCK	GLUCOCORTICOID hormones are important for vital functions and act to modulate inflammatory and immune responses(1,2). Yet, in contrast to other hormonal systems, no endogenous mediators have been identified that can directly counter-regulate their potent anti-inflammatory and immunosuppressive properties. Recent investigations of the protein macrophage migration inhibitory factor (MIF), which was discovered originally to be a T-lymphocyte-derived factor(3,4), have established it to be a pro-inflammatory pituitary and macrophage cytokine and a critical mediator of septic shock(5-7), Here we report the unexpected finding that low concentrations of glucocorticoids induce rather than inhibit MIF production from macrophages. MIF then acts to override glucocorticoid-mediated inhibition of cytokine secretion by lipopolysaccharide (LPS)-stimulated monocytes acid to overcome glucocorticoid protection against lethal endotoxaemia. These observations identify a unique counter-regulatory system that functions to control inflammatory and immune responses.	PICOWER INST MED RES,MANHASSET,NY 11030	Northwell Health			Donnelly, Thomas M/C-2717-2009; Calandra, Thierry/D-9017-2015	Donnelly, Thomas M/0000-0002-4399-2287; Calandra, Thierry/0000-0003-3051-1285; Christine, Metz/0000-0002-1013-1691				ABERNATHY RS, 1957, J LAB CLIN MED, V49, P708; ARYA SK, 1984, J IMMUNOL, V133, P273; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BERRY LJ, 1964, J EXP MED, V120, P721, DOI 10.1084/jem.120.5.721; BERTINI R, 1988, J EXP MED, V167, P1708, DOI 10.1084/jem.167.5.1708; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; GARTNER K, 1980, LAB ANIM, V14, P267, DOI 10.1258/002367780780937454; GELLER P, 1954, P SOC EXP BIOL MED, V86, P716; GILLIS S, 1979, J IMMUNOL, V123, P1624; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GOLDSTEIN RA, 1992, INFLAMMATION BASIC P, P1061; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LEW W, 1988, J IMMUNOL, V140, P1895; MITCHELL R, 1995, J IMMUNOL, V154, P3863; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; SILVERSTEIN R, 1991, J EXP MED, V173, P357, DOI 10.1084/jem.173.2.357; SPINK WW, 1954, J CLIN INVEST, V33, P540, DOI 10.1172/JCI102924; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; WEXLER BC, 1957, ENDOCRINOLOGY, V61, P300, DOI 10.1210/endo-61-3-300	25	989	1041	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					68	71		10.1038/377068a0	http://dx.doi.org/10.1038/377068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659164				2022-12-28	WOS:A1995RT72500058
J	ADAMSON, SJ; ALESSANDRI, LM; BADAWI, N; BURTON, PR; PEMBERTON, PJ; STANLEY, F				ADAMSON, SJ; ALESSANDRI, LM; BADAWI, N; BURTON, PR; PEMBERTON, PJ; STANLEY, F			PREDICTORS OF NEONATAL ENCEPHALOPATHY IN FULL-TERM INFANTS	BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL-PALSY; BIRTH ASPHYXIA	Objective-Preliminary investigation of the contribution of adverse antepartum and intrapartum factors to neonatal encephalopathy in singleton neonates born full term. Design-Matched case-control study based on incidence density sampling of controls. Setting-Two major teaching hospitals (one paediatric and one obstetric) and three peripheral maternity hospitals in Perth, Western Australia (population 1.2 million). Subjects-89 cases, all the full term singleton neonates born during an eight month period in 1992 who fulfilled one or more of six criteria during the first week of life (seizures, abnormal conscious state, persistent hypertonia or hypotonia, and feeding or respiratory difficulties of central origin). One full term control infant without neonatal encephalopathy was matched to each case by sex, hospital of delivery, time of day and day of the week of birth, and maternal health insurance status. Main outcome measures-Odds ratio estimates of relative risk of neonatal encephalopathy associated with antepartum and intrapartum factors. Results-Estimated incidence of moderate or severe encephalopathy in first week of life was 3.75 per 1000 full term live births. Thirteen cases and no controls had evidence suggestive of important intrapartum hypoxia, and in only five of these cases was the neurological condition at birth attributed to events during the intrapartum period. Univariate conditional logistic regression analysis identified significant differences between cases and controls for maternal vaginal bleeding in pregnancy, maternal thyroxine treatment, congenital abnormalities, induction of labour, interval from membrane rupture to delivery, maternal pyrexia in labour, augmentation of labour, abnormal intrapartum cardiotocograms, and meconium in labour. Family history of convulsions also approached significance. Conclusions-Our preliminary results suggest that intrapartum hypoxia, according to currently used criteria, was not the cause of neonatal encephalopathy in most cases in this population. Our findings suggest that many aetiologies of neonatal encephalopathy originate in the antepartum period.	INST CHILD HLTH RES,PERTH,WA 6872,AUSTRALIA; PRINCESS MARGARET HOSP CHILDREN,DEPT NEONATOL,SUBIACO,WA 6008,AUSTRALIA	Telethon Kids Institute; University of Western Australia			Badawi, Nadia/A-3179-2014; Burton, Paul R/H-7527-2016					ARMITAGE P, 1987, STATISTICAL METHODS; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P302, DOI 10.1111/j.1365-3016.1993.tb00406.x; BLAIR E, 1993, DEV MED CHILD NEUROL, V35, P449; Breslow N, 1980, STATISTICAL METHODS, V32; BURTON PR, 1994, STAT MED, V13, P1699, DOI 10.1002/sim.4780131702; COORSSEN EA, 1991, DEV MED CHILD NEUROL, V33, P730; COPAS J, 1984, J ROYAL STATISTICA A, V147, P35; DEESCOBAR GM, 1993, AM J CLIN NUTR, V57, pS280; DEMOTT RK, 1990, AM J OBSTET GYNECOL, V162, P1593, DOI 10.1016/0002-9378(90)90925-W; DEVLIN MM, 1990, J MED PRACTICE, V5, P215; ERGANDER U, 1983, ACTA PAEDIATR SCAND, V72, P321, DOI 10.1111/j.1651-2227.1983.tb09722.x; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; GLUCKMAN PD, 1992, DEV MED CHILD NEUROL, V34, P1010; HAGBERG G, 1976, ACTA PAEDIATR SCAND, V65, P403, DOI 10.1111/j.1651-2227.1976.tb04906.x; HENDERSONSMART D, 1991, MED J AUSTRALIA, V154, P576, DOI 10.5694/j.1326-5377.1991.tb121215.x; Joreskog K. G., 1989, LISREL; LEVENE MI, 1986, LANCET, V2, P67; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; MEYER BA, 1992, AM J OBSTET GYNECOL, V166, P612, DOI 10.1016/0002-9378(92)91685-4; MILLER G, 1989, ARCH DIS CHILD, V64, P557, DOI 10.1136/adc.64.4.557; MULLIGAN JC, 1980, J PEDIATR-US, V96, P903, DOI 10.1016/S0022-3476(80)80575-0; NELSON KB, 1984, JAMA-J AM MED ASSOC, V251, P1843, DOI 10.1001/jama.251.14.1843; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; PHAROAH POD, 1984, CLIN ENDOCRINOL, V21, P265, DOI 10.1111/j.1365-2265.1984.tb03468.x; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P623, DOI 10.5694/j.1326-5377.1991.tb121226.x; STEER PJ, 1989, OBSTET GYNECOL, V64, P715; TUCKER JM, 1990, CLIN OBSTET GYNECOL, V33, P515, DOI 10.1097/00003081-199009000-00017; 1989, LANCET, V2, P1251	31	121	122	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					598	602		10.1136/bmj.311.7005.598	http://dx.doi.org/10.1136/bmj.311.7005.598			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663254	Green Published			2022-12-28	WOS:A1995RT72300017
J	YOON, CH; LEE, JH; JONGEWARD, GD; STERNBERG, PW				YOON, CH; LEE, JH; JONGEWARD, GD; STERNBERG, PW			SIMILARITY OF SLI-1, A REGULATOR OF VULVAR DEVELOPMENT IN C-ELEGANS, TO THE MAMMALIAN PROTOONCOGENE C-CBL	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; TYROSINE KINASE; SH3 DOMAINS; V-CBL; CELL FATES; GENE; INDUCTION; ENCODES; LET-60; TRUNCATION	Vulval induction during Caenorhabditis elegans development is mediated by LET-23, a homolog of the mammalian epidermal growth factor receptor tyrosine kinase. The sli-1 gene is a negative regulator of LET-23 and is shown here to encode a protein similar to c-Cbl, a mammalian proto-oncoprotein. SLI-1 and c-Cbl share approximately 55 percent amino acid identity over a stretch of 390 residues, which includes a C3HC4 zinc-binding motif known as the RING finger, and multiple consensus binding sites for Src homology 3 (SH3) domains. SLI-1 and c-Cbl may define a new class of proteins that modify receptor tyrosine kinase-mediated signal transduction.	CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL IMMUNOL & BIOCHEM, SAN FRANCISCO, CA 94143 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California San Francisco				Sternberg, Paul/0000-0002-7699-0173				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRENNER S, 1974, GENETICS, V77, P71; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; JONGEWARD GD, 1995, GENETICS, V139, P1553; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; VILLENEUVE AM, COMMUNICATION; WILLIAMS BD, 1992, GENETICS, V131, P609; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	277	288	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1102	1105		10.1126/science.7652556	http://dx.doi.org/10.1126/science.7652556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652556				2022-12-28	WOS:A1995RQ74800044
J	HAGEN, SJ; HOFRICHTER, J; EATON, WA				HAGEN, SJ; HOFRICHTER, J; EATON, WA			PROTEIN REACTION-KINETICS IN A ROOM-TEMPERATURE GLASS	SCIENCE			English	Article							GEMINATE RECOMBINATION; CONFORMATIONAL-CHANGES; NEUTRON-SCATTERING; HEME-PROTEINS; RELAXATION DYNAMICS; SOLVENT VISCOSITY; LIGAND-BINDING; CO BINDING; MYOGLOBIN; TRANSITION	Protein reaction kinetics in aqueous solution at room temperature are often simplified by the thermal averaging of conformational substates. These substates exhibit widely varying reaction rates that are usually exposed by trapping in a glass at low temperature. Here, it is shown that the solvent viscosity, rather than the low temperature, is primarily responsible for the trapping. this was demonstrated by placement of myoglobin in a glass at room temperature and subsequent observation of inhomogeneous reaction kinetics. The high solvent viscosity slowed the rate of crossing the energy barriers that separated the substates and also suppressed any change in the average protein conformation after ligand dissociation.			HAGEN, SJ (corresponding author), NIH,PHYS CHEM LAB,BLDG 5,BETHESDA,MD 20892, USA.		Hagen, Stephen J/E-9737-2015	Hagen, Stephen J/0000-0002-3373-5033				AGMON N, 1988, BIOCHEMISTRY-US, V27, P3507, DOI 10.1021/bi00409a057; AGMON N, 1990, J PHYS CHEM-US, V94, P2959, DOI 10.1021/j100370a041; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1992, J CHEM PHYS, V97, P7270, DOI 10.1063/1.463500; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; CAMPBELL BF, 1987, SCIENCE, V238, P373, DOI 10.1126/science.3659921; CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Doster W., 1993, PROTEIN SOLVENT INTE, P375; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1994, PHYS TODAY, V47, P58, DOI 10.1063/1.881414; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; GREEN JL, 1994, J PHYS CHEM-US, V98, P13780, DOI 10.1021/j100102a052; GREEN JL, 1989, J PHYS CHEM-US, V93, P2880, DOI 10.1021/j100345a006; HAGEN SJ, UNPUB; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1983, HEMOGLOBINS STRUCTUR, P193; HOFRICHTER J, 1994, METHOD ENZYMOL, V232, P387; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; JACKLE J, 1986, REP PROG PHYS, V49, P171, DOI 10.1088/0034-4885/49/2/002; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; MAYER E, 1994, BIOPHYS J, V67, P862, DOI 10.1016/S0006-3495(94)80547-8; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SMITH J, 1990, P NATL ACAD SCI USA, V87, P1601, DOI 10.1073/pnas.87.4.1601; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; WOMERSLEY C, 1981, COMP BIOCHEM PHYS B, V70, P669, DOI 10.1016/0305-0491(81)90001-8	42	208	208	1	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					959	962		10.1126/science.7638618	http://dx.doi.org/10.1126/science.7638618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638618				2022-12-28	WOS:A1995RP73800030
J	JOSHUATOR, L; XU, HE; JOHNSTON, SA; REES, DC				JOSHUATOR, L; XU, HE; JOHNSTON, SA; REES, DC			CRYSTAL-STRUCTURE OF A CONSERVED PROTEASE THAT BINDS DNA - THE BLEOMYCIN HYDROLASE, GAL6	SCIENCE			English	Article							CYSTEINE PROTEINASE; PAPAIN; RESOLUTION; YEAST; REFINEMENT; CLONING; AMINOPEPTIDASE; SPECIFICITY; COMPLEX; SUBUNIT	Bleomycin hydrolase is a cysteine protease that hydrolyzes the anticancer drug bleomycin. The homolog in yeast, Gal6, has recently been identified and found to bind DNA and to act as a repressor in the Gal4 regulatory system, The crystal structure of Gal6 at 2.2 Angstrom resolution reveals a hexameric structure with a prominent central channel, The papain-like active sites are situated within the central channel, in a manner resembling the organization of active sites in the proteasome. The Gal6 channel is lined with 60 lysine residues from the six subunits, suggesting a role in DNA binding, The carboxyl-terminal arm of Gal6 extends into the active site cleft and may serve a regulatory function. Rather than each residing in distinct, separable domains, the protease and DNA-binding activities appear structurally intertwined in the hexamer, implying a coupling of these two activities.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JOSHUATOR, L (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,147-75CH,PASADENA,CA 91125, USA.			Joshua-Tor, Leemor/0000-0001-8185-8049; Xu, H. Eric/0000-0002-6829-8144	NIGMS NIH HHS [GM45162, GM40700] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, R37GM045162, R01GM040700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAPOTCHARTIER MP, 1994, EUR J BIOCHEM, V224, P497, DOI 10.1111/j.1432-1033.1994.00497.x; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; FERNANDEZ L, 1994, APPL ENVIRON MICROB, V60, P333; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HEINEMANN U, 1982, J MOL BIOL, V161, P591, DOI 10.1016/0022-2836(82)90410-7; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE G, 1971, BIOCHEM J, V124, P107, DOI 10.1042/bj1240107; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MISTOU MY, 1994, J MOL BIOL, V237, P160, DOI 10.1006/jmbi.1994.1215; MONDRAGON A, 1994, NATURE, V367, P138; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; MYLIN LM, 1990, METHOD ENZYMOL, V185, P297; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PICKERSGILL RW, 1991, ACTA CRYSTALLOGR B, V47, P766, DOI 10.1107/S0108768191003191; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rossmann M. G., 1972, MOL REPLACEMENT METH; SCHRODER E, 1993, FEBS LETT, V315, P38, DOI 10.1016/0014-5793(93)81128-M; SEBTI SM, 1991, CANCER RES, V51, P227; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VESANTO E, 1994, EUR J BIOCHEM, V224, P991, DOI 10.1111/j.1432-1033.1994.00991.x; VRUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330; Wohlrab Y, 1993, INT DAIRY J, V3, P685, DOI 10.1016/0958-6946(93)90083-C; WU A, UNPUB; XU H, UNPUB; XU HE, 1994, J BIOL CHEM, V269, P21177; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zheng W., UNPUB	55	119	120	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					945	950		10.1126/science.7638617	http://dx.doi.org/10.1126/science.7638617			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638617				2022-12-28	WOS:A1995RP73800026
J	BAKER, R; FRASER, RC				BAKER, R; FRASER, RC			DEVELOPMENT OF REVIEW CRITERIA - LINKING GUIDELINES AND ASSESSMENT OF QUALITY	BRITISH MEDICAL JOURNAL			English	Article							AUDIT; FEEDBACK	Review criteria are designed to enable clinicians and others to assess care. However, there is no established method for developing criteria, and they are often confused with guidelines. Criteria should comprise measurable activities that are appropriate for the setting in which they are to be used. They should also be based on research evidence and prioritised according to the strength of that evidence and effect on outcome. Good criteria can be used to aid implementation of guidelines by providing a standard against which to monitor performance and enabling clinical audit.			BAKER, R (corresponding author), UNIV LEICESTER,ELI LILLY NATL CLIN AUDIT CTR,DEPT GEN PRACTICE,LEICESTER LE5 4PW,LEICS,ENGLAND.							ASHTON CM, 1994, MED CARE, V32, P755, DOI 10.1097/00005650-199408000-00001; BAKER R, 1991, BRIT MED J, V303, P32, DOI 10.1136/bmj.303.6793.32; BAKER R, 1993, MONITORING DIABETES; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DONABEDIAN A, 1978, SCIENCE, V200, P856, DOI 10.1126/science.417400; FIELD M, 1992, DEV USE; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HICKS NR, 1994, BRIT MED J, V309, P730, DOI 10.1136/bmj.309.6956.730; IRVINE D, 1990, MED AUDIT SERIES, V2; Jones R H, 1993, Qual Health Care, V2, P217, DOI 10.1136/qshc.2.4.217; KESSNER DM, 1973, NEW ENGL J MED, V288, P189, DOI 10.1056/NEJM197301252880406; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; 1993, EL93115 NHS MAN EX D; 1992, BRIT MED J, V304, P1480	24	42	45	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					370	373		10.1136/bmj.311.7001.370	http://dx.doi.org/10.1136/bmj.311.7001.370			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640546	Green Published			2022-12-28	WOS:A1995RN46900020
J	KOVACS, JA; BASELER, M; DEWAR, RJ; VOGEL, S; DAVEY, RT; FALLOON, J; POLIS, MA; WALKER, RE; STEVENS, R; SALZMAN, NP; METCALF, JA; MASUR, H; LANE, HC				KOVACS, JA; BASELER, M; DEWAR, RJ; VOGEL, S; DAVEY, RT; FALLOON, J; POLIS, MA; WALKER, RE; STEVENS, R; SALZMAN, NP; METCALF, JA; MASUR, H; LANE, HC			INCREASES IN CD4 T-LYMPHOCYTES WITH INTERMITTENT COURSES OF INTERLEUKIN-2 IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PRELIMINARY-STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; HIV-INFECTION; RECOMBINANT INTERLEUKIN-2; INTERFERON-GAMMA; PHASE-I; TYPE-1 INFECTION; KAPOSIS SARCOMA; NATURAL-KILLER; SYNDROME AIDS	Background. Interleukin-2 is an important regulatory cytokine of the immune system, with potent effects on T cells, B cells, and natural killer cells. In vitro, interleukin-2 can induce the proliferation and differentiation of peripheral-blood mononuclear cells from patients infected with the human immunodeficiency virus (HIV). Methods. We treated 25 HIV-infected patients with interleukin-2 administered as a continuous infusion at a dosage of 6 to 18 million IU per bay for 5 days every 8 weeks during a period of 7 to 25 months. All patients also received at least one approved antiviral agent. Immunologic and virologic variables were monitored monthly. Results. In 6 of 10 patients with base-line CD4 counts higher than 200 per cubic millimeter, interleukin-2 therapy was associated with at least a 50 percent increase in the number of CD4 cells. Changes ranged from -81 to +2211 cells per cubic millimeter. Interleukin-2 therapy resulted in a decline in the percentage of CD8 lymphocytes expressing HLA-DR and an increase in the percentage of CD4 lymphocytes that were positive for the p55 chain of the interleukin-2 receptor. Four patients had a transient but consistent increase in the plasma HIV RNA level at the end of each infusion. In the remaining 15 patients, who had CD4 counts of 200 or fewer cells per cubic millimeter, interleukin-2 therapy was associated with increased viral activation, few immunologic improvements, and substantial toxic effects. Conclusions. Intermittent courses of interleukin-2 can improve some of the immunologic abnormalities associated with HIV infection in patients with more than 200 CD4 cells per cubic millimeter.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NIAID,WARREN GRANT MAGNUSON CLIN CTR,DEPT CRIT CARE MED,BETHESDA,MD; PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Polis, Michael/0000-0002-9151-2268	NIAID NIH HHS [N01-AI-05058] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CALIGIURI MA, 1993, J CLIN INVEST, V91, P123, DOI 10.1172/JCI116161; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; DAVEY RT, 1993, P NATL ACAD SCI USA, V90, P5608, DOI 10.1073/pnas.90.12.5608; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; FAN J, 1993, J IMMUNOL, V151, P5031; FARACE F, 1993, INT J CANCER, V54, P741, DOI 10.1002/ijc.2910540506; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8; GROUX H, 1993, EUR J IMMUNOL, V23, P1623, DOI 10.1002/eji.1830230734; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; KIMOTO M, 1980, J EXP MED, V152, P759, DOI 10.1084/jem.152.4.759; LANDAY A, 1990, AIDS, V4, P479, DOI 10.1097/00002030-199006000-00001; LANE HC, 1984, J BIOL RESP MODIF, V3, P512; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANE HC, 1990, ANN INTERN MED, V112, P388, DOI 10.7326/0003-4819-112-5-388_2; LANE HC, 1988, LANCET, V2, P1218; LANE HC, 1989, ANN INTERN MED, V111, P41, DOI 10.7326/0003-4819-111-1-41; LANE HC, 1989, J CLIN IMMUNOL, V9, P351, DOI 10.1007/BF00918667; LANG JM, 1988, LANCET, V2, P702; LOTZE MT, 1986, CANCER, V58, P2764, DOI 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z; MAZZA P, 1992, EUR J HAEMATOL, V49, P1; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MURRAY HW, 1992, AM J MED, V93, P234, DOI 10.1016/0002-9343(92)90059-K; PACHL CA, 1992, 32ND INT C ANT AG CH, P318; PEDERSEN C, 1990, NEW ENGL J MED, V322, P1757, DOI 10.1056/NEJM199006213222501; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; ROOK AH, 1983, J CLIN INVEST, V72, P398, DOI 10.1172/JCI110981; SCHNITTMAN SM, 1994, J INFECT DIS, V169, P981, DOI 10.1093/infdis/169.5.981; SCHWARTZ DH, 1991, J ACQ IMMUN DEF SYND, V4, P11; SHEARER GM, 1992, CHEM IMMUNOL, V54, P21; SIEGEL JP, 1991, J CLIN ONCOL, V9, P694, DOI 10.1200/JCO.1991.9.4.694; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STITES DP, 1986, CLIN IMMUNOL IMMUNOP, V38, P161, DOI 10.1016/0090-1229(86)90135-2; TEPPLER H, 1993, J INFECT DIS, V167, P291, DOI 10.1093/infdis/167.2.291; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; URDEA MS, 1993, AIDS, V7, pS11, DOI 10.1097/00002030-199311002-00004; VASUDEVACHARI MB, 1993, J CLIN IMMUNOL, V13, P185, DOI 10.1007/BF00919971; VOLBERDING P, 1987, AIDS RES HUM RETROV, V3, P115, DOI 10.1089/aid.1987.3.115; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9	44	388	409	2	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					567	575		10.1056/NEJM199503023320904	http://dx.doi.org/10.1056/NEJM199503023320904			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7646637				2022-12-28	WOS:A1995QJ09000004
J	JOHNSON, RJ; GRETCH, DR; YAMABE, H; HART, J; BACCHI, CE; HARTWELL, P; COUSER, WG; COREY, L; WENER, MH; ALPERS, CE; WILLSON, R				JOHNSON, RJ; GRETCH, DR; YAMABE, H; HART, J; BACCHI, CE; HARTWELL, P; COUSER, WG; COREY, L; WENER, MH; ALPERS, CE; WILLSON, R			MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS-C VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESSENTIAL MIXED CRYOGLOBULINEMIA; RECOMBINANT INTERFERON-ALFA; B VIRUS; ALPHA-INTERFERON; CONTROLLED TRIAL; NON-A; ANTIBODIES; CLONE	Background and Methods. Hepatitis C virus (HCV) infection causes both acute and chronic liver disease and is also associated with mixed cryoglobulinemia. Whether HCV is also associated with renal disease, as is the hepatitis B virus, is not known. We describe the clinical, pathologic, virologic, and immunologic features of eight patients with HCV infection who were referred to nephrologists for glomerulonephritis. Four patients were treated with interferon alfa. Results. All eight patients had proteinuria, and seven had decreased renal function. Renal biopsy in all patients revealed membranoproliferative glomerulonephritis, characterized by the deposition of IgG, IgM, and C3 in glomeruli. Electron microscopy of the biopsy specimens showed cryoglobulin-like structures in three of four patients. All eight patients had HCV RNA detected in their serum, elevated serum aminotransferase concentrations, and hypocomplementemia, and the majority had cryoglobulins and circulating immune complexes in their serum. Cryoprecipitates from the three patients who were tested contained HCV RNA and IgG anti-HCV antibodies to the nucleocapsid core antigen (HCVc or c22-3). IgM rheumatoid factors, present in all patients, bound anti-HCV IgG in all six patients tested. Four patients received interferon alfa for 2 to 12 months; all had evidence of decreased HCV replication and improvement of their renal and liver disease. Conclusions. Chronic HCV infection is associated with cryoglobulinemia and membranoproliferative glomerulonephritis. The pathogenesis is unknown, but may relate to deposition within glomeruli of immune complexes containing HCV, anti-HCV IgG, and IgM rheumatoid factors.	UNIV WASHINGTON,MED CTR,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT PATHOL,SEATTLE,WA 98195; HIROSAKI UNIV,SCH MED,DEPT MED,DIV NEPHROL,HIROSAKI,AOMORI 036,JAPAN	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Hirosaki University	JOHNSON, RJ (corresponding author), UNIV WASHINGTON,MED CTR,DEPT MED,DIV NEPHROL,BB-1257 HLTH SCI,SEATTLE,WA 98195, USA.		Wener, Mark/ABE-4491-2021	Johnson, Richard/0000-0003-3312-8193	NIDDK NIH HHS [DK 43422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK043422, R01DK043422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; Berger J, 1977, Adv Nephrol Necker Hosp, V7, P3; BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; CACOUB P, 1992, ANN INTERN MED, V116, P605, DOI 10.7326/0003-4819-116-7-605_2; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAMMACCO F, 1992, CLIN EXP IMMUNOL, V87, P352, DOI 10.1111/j.1365-2249.1992.tb03001.x; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DEBANDT M, 1991, CLIN EXP RHEUMATOL, V9, P659; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DISDIER P, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92014-S; DRUET P, 1973, CLIN EXP IMMUNOL, V15, P483; DURAND JM, 1992, J INFECT DIS, V165, P778, DOI 10.1093/infdis/165.4.778; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P95; FIORINI G, 1986, CLIN EXP IMMUNOL, V64, P65; FLORINCH.A, 1974, CLIN EXP IMMUNOL, V16, P599; FRANKEL AH, 1992, Q J MED, V82, P101; GALLI M, 1992, LANCET, V339, P989, DOI 10.1016/0140-6736(92)91562-M; GRETCH D, 1992, J CLIN MICROBIOL, V30, P2145, DOI 10.1128/JCM.30.8.2145-2149.1992; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; JOHNSON RJ, 1990, KIDNEY INT, V37, P663, DOI 10.1038/ki.1990.32; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KNOX TA, 1991, AM J MED, V91, P554, DOI 10.1016/0002-9343(91)90196-5; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; Levo Y, 1977, Trans Assoc Am Physicians, V90, P167; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; NEGRO F, 1992, P NATL ACAD SCI USA, V89, P2247, DOI 10.1073/pnas.89.6.2247; NOBLEJAMIESON G, 1992, LANCET, V339, P706, DOI 10.1016/0140-6736(92)90600-8; OZAWA T, 1976, ARCH PATHOL LAB MED, V100, P484; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PETERS M, 1989, SEMIN LIVER DIS, V9, P235, DOI 10.1055/s-2008-1040516; POPP JW, 1980, ANN INTERN MED, V92, P379, DOI 10.7326/0003-4819-92-3-379; RODRIGUEZITURBE B, 1984, KIDNEY INT, V25, P129, DOI 10.1038/ki.1984.19; ROLLINO C, 1991, NEPHRON, V59, P319, DOI 10.1159/000186573; 1990, NEW ENGL J MED, V323, P1756	38	792	806	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					465	470		10.1056/NEJM199302183280703	http://dx.doi.org/10.1056/NEJM199302183280703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	7678440				2022-12-28	WOS:A1993KM41700003
J	PTACEK, LJ; JOHNSON, KJ; GRIGGS, RC				PTACEK, LJ; JOHNSON, KJ; GRIGGS, RC			MECHANISMS OF DISEASE - GENETICS AND PHYSIOLOGY OF THE MYOTONIC MUSCLE DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HYPERKALEMIC PERIODIC PARALYSIS; DEPENDENT PROTEIN-KINASE; CHANNEL ALPHA-SUBUNIT; SODIUM-CHANNEL; PARAMYOTONIA-CONGENITA; CHLORIDE CHANNEL; DYSTROPHY LOCUS; LINKAGE RELATIONSHIPS; MUSCULAR-DYSTROPHY; INSULIN-RECEPTOR		CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON,ENGLAND; UNIV ROCHESTER,SCH MED,DEPT NEUROL,ROCHESTER,NY 14627; UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132	Imperial College London; University of Rochester; Utah System of Higher Education; University of Utah	PTACEK, LJ (corresponding author), UNIV UTAH,MED CTR,SCH MED,DEPT NEUROL,50 N MED DR,SALT LAKE CITY,UT 84132, USA.			Griggs, Robert/0000-0001-7988-4854				ABDALLA JA, 1992, NEUROLOGY, V42, P1426; ANDERSEN ED, 1971, ACTA PAEDIATR SCAND, V60, P559, DOI 10.1111/j.1651-2227.1971.tb06990.x; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BASTRON JA, 1960, NEUROMUSCULAR DISORD, V35; BECKER PE, 1977, PATHOGENESIS HUMAN M, P699; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROOK JD, 1992, GENOMICS, V13, P243, DOI 10.1016/0888-7543(92)90238-N; BRUNNER HG, 1993, NEW ENGL J MED, V328, P476, DOI 10.1056/NEJM199302183280705; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CREWS J, 1976, J NEUROL SCI, V28, P449, DOI 10.1016/0022-510X(76)90116-7; DESILVA SM, 1990, MUSCLE NERVE, V13, P21, DOI 10.1002/mus.880130106; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; EIBERG H, 1983, CLIN GENET, V24, P159; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; FRIZZELL R A, 1992, Current Biology, V2, P285, DOI 10.1016/0960-9822(92)90862-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FURMAN RE, 1978, ANN NEUROL, V4, P357, DOI 10.1002/ana.410040411; GAMSTORP I, 1956, ACTA PAEDIATR STOC S, V108, P1; GRIGGS RC, 1975, AM J MED, V59, P37, DOI 10.1016/0002-9343(75)90319-8; GRIGGS RC, 1989, NEUROLOGY, V39, P219, DOI 10.1212/WNL.39.2.219; HALL JG, 1990, AM J HUM GENET, V46, P857; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1992, AM J HUM GENET, V51, P10; HARPER PS, 1989, MAJOR PROBLEMS NEURO, V21; HELWEG-LARSEN H F, 1955, Acta Genet Stat Med, V5, P263; JANSEN G, 1992, GENOMICS, V13, P509, DOI 10.1016/0888-7543(92)90118-C; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; JOHNSON K, 1989, GENOMICS, V5, P746, DOI 10.1016/0888-7543(89)90116-X; KAKEHI T, 1990, J LAB CLIN MED, V115, P688; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOCH MC, 1991, HUM GENET, V88, P71, DOI 10.1007/BF00204932; KOCH MC, 1991, J MED GENET, V28, P583, DOI 10.1136/jmg.28.9.583; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEBEAU MM, 1989, CYTOGENET CELL GENET, V51, P338, DOI 10.1159/000132798; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P633, DOI 10.1002/mus.880100709; LEYBURN P, 1959, BRAIN, V82, P81, DOI 10.1093/brain/82.1.81; Lipicky R.J., 1973, NEW DEV ELECTROMYOGR, P451; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; Mohr J, 1954, STUDY LINKAGE MAN; MOORMAN JR, 1990, SCIENCE, V250, P688; MOXLEY RT, 1984, ANN NEUROL, V15, P157, DOI 10.1002/ana.410150208; PRYSTOWSKY EN, 1979, CIRCULATION, V60, P1360, DOI 10.1161/01.CIR.60.6.1360; PTACEK LJ, 1992, NEUROLOGY, V42, P431, DOI 10.1212/WNL.42.2.431; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; PTACEK LJ, 1992, NEUROLOGY, V42, P1046, DOI 10.1212/WNL.42.5.1046; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; RICKER K, 1990, ARCH NEUROL-CHICAGO, V47, P268, DOI 10.1001/archneur.1990.00530030034012; RIGGS JE, 1979, CLIN NEUROPHARMACOL, V4, P123; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; ROSES AD, 1975, J MEMBRANE BIOL, V20, P51, DOI 10.1007/BF01870627; RUDEL R, 1989, MUSCLE NERVE, V12, P281; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; SCHWARTZ O, 1962, ARCH OPHTHALMOL-CHIC, V68, P52; SHAW DJ, 1986, HUM GENET, V74, P267; SHAW DJ, 1985, HUM GENET, V70, P271; SHELBOURNE JG, 1993, NEW ENGL J MED, V328, P471; STALLINGS RL, 1988, AM J HUM GENET, V43, P144; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STREIB EW, 1987, MUSCLE NERVE, V10, P155, DOI 10.1002/mus.880100209; STREIB EW, 1987, MUSCLE NERVE, V10, P603, DOI 10.1002/mus.880100704; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Thomsen, 1876, ARCH PSYCHIAT NERVEN, V6, P702, DOI DOI 10.1007/BF02164912; TRUDELL RG, 1987, NEUROLOGY, V37, P488, DOI 10.1212/WNL.37.3.488; TYLER FH, 1951, J CLIN INVEST, V30, P492, DOI 10.1172/JCI102465; VANDENBERGH P, 1991, NEUROLOGY S1, V41, P419; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WALSH FS, 1988, J NEUROL NEUROSUR PS, V51, P136, DOI 10.1136/jnnp.51.1.136; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021; YAMAGATA H, 1992, LANCET, V339, P692, DOI 10.1016/0140-6736(92)90862-W; YANG J, 1990, J NEUROCHEM, V54, P954, DOI 10.1111/j.1471-4159.1990.tb02343.x	81	120	126	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					482	489						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	7678441				2022-12-28	WOS:A1993KM41700007
J	POPOV, S; BROWN, A; POO, MM				POPOV, S; BROWN, A; POO, MM			FORWARD PLASMA-MEMBRANE FLOW IN GROWING NERVE PROCESSES	SCIENCE			English	Article							NEURONS; GROWTH; ELONGATION; MOVEMENTS; CULTURE	Nerve growth requires addition of new plasma membrane material, which is generally believed to occur at the growth cone. Local incorporation of a fluorescent lipid analog into the plasma membrane of fast-growing Xenopus neurites revealed an anterograde bulk membrane flow that correlated with neurite elongation. The rate of membrane flow depended on the position of the labeled membrane segment along the neurite, increasing with distance from the soma. This result suggests that new membrane in growing Xenopus neurites is added not at the growth cone but at the cell body and along the neurite.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University			brown, abraham/R-8823-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts B., 1989, MOL BIOL CELL; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BRAY D, 1973, J CELL BIOL, V56, P702, DOI 10.1083/jcb.56.3.702; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; POPOV S, 1992, J NEUROSCI, V12, P77; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; TABTI N, 1991, CULTURING NERVE CELL; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207	16	68	69	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					244	246		10.1126/science.7678471	http://dx.doi.org/10.1126/science.7678471			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678471				2022-12-28	WOS:A1993KF71900036
J	SAHAI, J; GARBER, G; GALLICANO, K; OLIVERAS, L; CAMERON, DW				SAHAI, J; GARBER, G; GALLICANO, K; OLIVERAS, L; CAMERON, DW			EFFECTS OF THE ANTACIDS IN DIDANOSINE TABLETS ON DAPSONE PHARMACOKINETICS	ANNALS OF INTERNAL MEDICINE			English	Article						DIDANOSINE; DAPSONE; PHARMACOKINETICS; HIV SEROPOSITIVITY; ANTACIDS	PROPHYLAXIS; BIOEQUIVALENCE; FAILURE	Objective: To investigate 1) the effects of the magnesium-aluminum antacids in didanosine tablets on dapsone absorption in healthy volunteers and 2) the effects of the antacid formulation of active didanosine tablets on dapsone pharmacokinetics in patients seropositive for human immunodeficiency virus (HIV). Design: Two separate, randomized, two-period, two-treatment, crossover studies with a 21-day washout period between treatments. Setting: Clinical investigation unit of a university hospital. Participants: Six healthy men and six HIV-positive men. Measurements: Serial dapsone plasma concentrations were measured when dapsone, 100 mg, was administered alone and with either the third of four doses of didanosine placebo tablets (group 1) or the 27th of 28 doses of active didanosine tablets (group 2). In each study, pharmacokinetic variables were determined using noncompartmental methods and compared by analysis of variance. Results: When dapsone was administered alone, pharmacokinetic variables did not significantly differ from those with dapsone given in either combination (P > 0.10 for all comparisons). Conclusions: Didanosine, antacids, and other excipients in the currently used didanosine chewable tablets did not significantly affect plasma concentrations of dapsone.			SAHAI, J (corresponding author), OTTAWA GEN HOSP, CLIN INVEST UNIT, 501 SMYTH RD, OTTAWA, ON K1H 8L6, CANADA.		Cameron, Bill/E-9180-2010	Cameron, Bill/0000-0002-0090-3539				BREEN GA, 1994, ANTIMICROB AGENTS CH, V38, P2227, DOI 10.1128/AAC.38.9.2227; COLEMAN MD, 1990, BRIT J CLIN PHARMACO, V30, P761, DOI 10.1111/j.1365-2125.1990.tb03847.x; DAVEY RT, 1990, ANTIMICROB AGENTS CH, V34, P499, DOI 10.1128/AAC.34.4.499; GALLICANO K, 1994, ANTIMICROB AGENTS CH, V38, P894, DOI 10.1128/AAC.38.4.894; Gibaldi M., 1982, PHARMACOKINETICS, V2, P409; HAUSCHKE D, 1990, INT J CLIN PHARM TH, V28, P72; HORAI Y, 1985, J CHROMATOGR, V345, P447, DOI 10.1016/0378-4347(85)80187-0; HOROWITZ HW, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90649-N; HUENGSBERG M, 1993, LANCET, V341, P48, DOI 10.1016/0140-6736(93)92519-Y; IRSHAID YM, 1993, INT J CLIN PHARM TH, V31, P18; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; METROKA CE, 1991, NEW ENGL J MED, V325, P737; MIDHA KK, 1993, J PHARM SCI, V82, P138, DOI 10.1002/jps.2600820205; MIROCHNICK M, 1993, PEDIATR AIDS HIV INF, V4, P13; SAHAI J, 1993, CLIN PHARMACOL THER, V53, P292, DOI 10.1038/clpt.1993.24; STEINIJANS VW, 1991, INT J CLIN PHARM TH, V29, P323; ZUIDEMA J, 1986, CLIN PHARMACOKINET, V11, P299, DOI 10.2165/00003088-198611040-00003; 1993, AM HOSPITAL FORMULAR, P383	18	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					584	587		10.7326/0003-4819-123-8-199510150-00003	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677298				2022-12-28	WOS:A1995RY82800003
J	BILLI, JE; WISE, CG; BILLS, EA; MITCHELL, RL				BILLI, JE; WISE, CG; BILLS, EA; MITCHELL, RL			POTENTIAL EFFECTS OF MANAGED CARE ON SPECIALTY PRACTICE AT A UNIVERSITY MEDICAL-CENTER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REFORM	Background, The growth of managed care presents a challenge to academic medical centers, because the demand for the services of specialists is likely to continue decreasing, We estimated the number of enrollees the University of Michigan Medical Center would need in its health maintenance organization (HMO) system in order to provide revenue equivalent to the total revenue it received for professional specialty care in 1992. Methods. Rates of utilization and payment were based on the medical center's experience with managed care in 1992 in its independent practice association HMO, in which 25,000 members had capitated coverage and received primary and all specialty care from university physicians, and 15,000 members received primary care and most specialty care from physicians outside the university, We assumed that persons not enrolled in Medicare were all enrolled in managed-care plans. Primary care activity was excluded from the calculations of expense, revenue, and numbers of faculty members. Results. If all specialty services were provided by the university to HMO members, all the 21 specialties examined except obstetrics and gynecology and emergency services would require an enrollment of more than 250,000 to support the 1992 level of professional revenue and maintain the number of faculty members, If university services were provided only for referrals from a loosely affiliated network of community physicians in the HMO system, all the 19 specialties examined except plastic surgery would require an HMO enrollment of more than 1 million. In a combined model in which all specialty services were provided to 100,000 HMO members and network referrals were provided to 500,000 members, substantial changes in faculty composition would be needed in all the departments studied. Conclusions. Because of the large number of HMO members required, unless other changes occur, it is unrealistic to expect that the University of Michigan Medical Center could create an HMO or network large enough to support the specialty practice of the current number of faculty members at the 1992 level of financing.	UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	BILLI, JE (corresponding author), UNIV MICHIGAN, SCH MED, OFF DEAN, M7300 MED SCI BLDG 1, ANN ARBOR, MI 48109 USA.							BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; HEMPY B, 1994, WARREN SURVEYS; KRAKOWER J, 1994, ACAD MED, V69, P72, DOI 10.1097/00001888-199401000-00021; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; Weinber JP, 1994, JAMA-J AM MED ASSOC, V272, P222; 1994, 1994 GROUP FACULTY P	6	53	53	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					979	983		10.1056/NEJM199510123331507	http://dx.doi.org/10.1056/NEJM199510123331507			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666919				2022-12-28	WOS:A1995RY58600007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CENTER FOR DRUGS INAUGURATES FAX-ON-DEMAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-28	WOS:A1995RV73400006
J	DECOSAS, J; KANE, F; ANARFI, JK; SODJI, KDR; WAGNER, HU				DECOSAS, J; KANE, F; ANARFI, JK; SODJI, KDR; WAGNER, HU			MIGRATION AND AIDS	LANCET			English	Editorial Material							INFECTION		CTR COOPERAT INT SANTE & DEV,ABIDJAN,COTE IVOIRE; UNIV GHANA,INST STAT SOCIAL & ECON RES,LEGON,GHANA; FORCES ACT MIEUX ETRE MERE & ENFANT,LOME,TOGO; GTZ,DIV HLTH POPULAT & NUTR,ESCHBORN,GERMANY	University of Ghana	DECOSAS, J (corresponding author), GTZ REG AIDS PROGRAMME W & CENT AFRICA,BOX 9698 KIA,ACCRA,GHANA.							ANARFI JK, 1982, THESIS REGIONAL I PO; ASHITEY GA, 1994, EPIDEMIOLOGY DISEASE; KALE K, 1994, ACTES S SIDA MIGRATI, P32; KANE F, 1993, AIDS, V7, P1261, DOI 10.1097/00002030-199309000-00017; LALOU R, 1994, MIGRATION SIDA AFRIQ; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; Odotei I., 1992, MARITIME ANTHR STUDI, V5, P88; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; RICH V, 1995, LANCET, V346, P432, DOI 10.1016/S0140-6736(95)92797-2; SUDARKASA N, 1977, SIGNS, V3, P178, DOI 10.1086/493450	10	177	178	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					826	828		10.1016/S0140-6736(95)91631-8	http://dx.doi.org/10.1016/S0140-6736(95)91631-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674750				2022-12-28	WOS:A1995RW25800022
J	MORRIS, JDH; EDDLESTON, ALWF; CROOK, T				MORRIS, JDH; EDDLESTON, ALWF; CROOK, T			VIRAL-INFECTION AND CANCER	LANCET			English	Review							T-CELL LEUKEMIA; HEPATOCELLULAR-CARCINOMA; VIRUS; LINES; DNA; P53	Infection with specific viruses has a role in the pathogenesis of some cancers in human beings. However, the incidence of such cancers is much lower than the frequency of virus infection, suggesting either that infection alone does not result in cancer and that cellular events in addition to the presence of the virus must occur, or that cancer occurs only if viral proteins are expressed in an inappropriate cell type or in an immunocompromised host. Molecular analysis of viruses found in association with cancer has revealed that they function, at least in part, by encoding proteins which can associate with and subvert the function of host cell-encoded tumour suppressor proteins which regulate pathways of growth arrest and apoptosis. Better understanding of the mechanisms underlying this association will have diagnostic, prognostic, and therapeutic implications in the near future.			MORRIS, JDH (corresponding author), UNIV LONDON KINGS COLL, SCH MED & DENT, RAYNE INST, 123 COLDHARBOUR LANE, LONDON SE5 9NU, ENGLAND.							ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BEASLEY RP, 1981, LANCET, V2, P1129; BROOKS LA, 1995, IN PRESS CURRENT DIA; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; JOHNSON PJ, 1978, GUT, V19, P1022, DOI 10.1136/gut.19.11.1022; MCGRATH MS, 1991, J ACQ IMMUN DEF SYND, V4, P408; MIDDLETON T, 1991, ADV VIRUS RES, V40, P19; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; POUSSIN K, 1995, LANCET, V345, P413; RICKINSON AB, 1955, VIRUSES CANCER, P81; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; TURANT T, 1995, J VIROL, V69, P1851; VOUSDEN KH, 1991, SEMIN VIROL, V2, P307; WELLER IVD, 1994, SYMP SOC GEN MICROBI, V51, P293; YOSHIDA M, 1987, LANCET, V1, P1085; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZURHAUSEN H, 1989, ADV VIRAL ONCOL, P21	25	68	71	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 16	1995	346	8977					754	758		10.1016/S0140-6736(95)91510-9	http://dx.doi.org/10.1016/S0140-6736(95)91510-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658880				2022-12-28	WOS:A1995RU81000016
J	GLIKSON, M; ESPINOSA, RE; HAYES, DL				GLIKSON, M; ESPINOSA, RE; HAYES, DL			EXPANDING INDICATIONS FOR PERMANENT PACEMAKERS	ANNALS OF INTERNAL MEDICINE			English	Review							ORTHOTOPIC HEART-TRANSPLANTATION; LONG QT SYNDROME; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; SHORT ATRIOVENTRICULAR DELAY; SINUS NODE DYSFUNCTION; CARDIAC TRANSPLANTATION; ATRIAL ARRHYTHMIAS; UNEXPLAINED SYNCOPE; VASOVAGAL SYNCOPE	Purpose: To review the current clinical experience with new and expanding indications for permanent cardiac pacing. Data Sources: A MEDLINE search was done of the English-language literature published from 1980 through 1994 about indications for permanent pacing. Five major areas were identified and searched: cardiomyopathies, atrial fibrillation, the long QT syndrome, cardiac transplantation, and vasovagal syncope. A manual search was then done for other contributions, including abstracts. Study Selection: Because published reports in these areas are scarce, all of the peer-reviewed articles and most of the relevant abstracts found were reviewed. Data Extraction: Data were manually extracted from the various sources, and the reports were classified and summarized according to specific indications. Results: Pacing is becoming an important option in the treatment of patients with symptomatic drug-resistant hypertrophic obstructive cardiomyopathy. Symptomatic and hemodynamic benefits have been shown in patients with pacing over various periods of follow-up. In patients with the long QT syndrome in whom medical therapy had failed, pacing at relatively fast rates markedly reduced symptoms and almost completely abolished fainting spells. Preliminary results suggest that pacing may be beneficial in dilated cardiomyopathy and in preventing episodes of paroxysmal atrial fibrillation. Further studies are needed to clarify the mechanisms of and to improve selection criteria for pacing in these conditions. Our ability to select cardiac transplant recipients for permanent pacing and our ability to optimize the timing of pacing in these patients have recently improved considerably. The role of pacing therapy in patients with neurally mediated (vasovagal) syncope remains incompletely understood. Better classification of these patients, made according to the sequence of hemodynamic events leading to syncope, is likely to clarify the potential benefit of pacing in these patients and improve the selection of patients for pacing. Conclusion: Few peer-reviewed clinical trial have been done, and further studies are needed to confirm the promising effects of pacing in patients with these newly recognized and expanding indications for pacing.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic								Andersen H. R., 1993, European Heart Journal, V14, P252; ATTUEL P, 1988, PACE, V11, P1647, DOI 10.1111/j.1540-8159.1988.tb06289.x; AURICCHIO A, 1993, PACE, V16, P2034, DOI 10.1111/j.1540-8159.1993.tb00997.x; Barold S. Serge, 1992, Cardiology Clinics, V10, P573; BELLOCCI F, 1991, PACE, V14, P622; BENDITT DG, 1995, ANN INTERN MED, V122, P204, DOI 10.7326/0003-4819-122-3-199502010-00008; BEXTON RS, 1984, J AM COLL CARDIOL, V3, P712, DOI 10.1016/S0735-1097(84)80247-8; BEXTON RS, 1983, BRIT HEART J, V50, P555; BLANCHE C, 1992, J HEART LUNG TRANSPL, V11, P446; BONOW RO, 1983, AM J CARDIOL, V51, P1386, DOI 10.1016/0002-9149(83)90317-X; BRECKER SJD, 1992, LANCET, V340, P1308, DOI 10.1016/0140-6736(92)92492-X; BRINKER JA, 1993, NEW PERSPECTIVES CAR, P519; CANNON RO, 1992, J AM COLL CARDIOL, V19, pA120; CHANG AC, 1994, PACE, V17, P65, DOI 10.1111/j.1540-8159.1994.tb01352.x; COOPER MM, 1992, J THORAC CARDIOV SUR, V104, P812; COUMEL P, 1983, PACE, V6, P552, DOI 10.1111/j.1540-8159.1983.tb05295.x; DAUBERT C, 1993, NEW PERSPECTIVES CAR, P259; DAUBERT C, 1991, CIRCULATION S, V84, P453; DAUBERT C, 1993, PACE, V16, P885; DELUNA AB, 1988, EUR HEART J, V9, P1112, DOI 10.1093/oxfordjournals.eurheartj.a062407; DIBIASE A, 1991, AM J CARDIOL, V67, P1385, DOI 10.1016/0002-9149(91)90469-2; DISEGNI E, 1980, ARCH INTERN MED, V140, P1036, DOI 10.1001/archinte.140.8.1036; ELDAR M, 1992, J AM COLL CARDIOL, V20, P830, DOI 10.1016/0735-1097(92)90180-U; ELDAR M, 1987, J AM COLL CARDIOL, V10, P600, DOI 10.1016/S0735-1097(87)80203-6; ELLENBOGEN KA, 1988, AM HEART J, V116, P202, DOI 10.1016/0002-8703(88)90274-8; FAERESTRAND S, 1993, NEW PERSPECTIVES CAR, V3, P113; FANANAPAZIR L, 1992, CIRCULATION, V85, P2149, DOI 10.1161/01.CIR.85.6.2149; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FELICIANO Z, 1993, CIRCULATION, V88, P19; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FITZPATRICK A, 1989, LANCET, V1, P658, DOI 10.1016/S0140-6736(89)92155-7; FITZPATRICK AP, 1990, PACE, V13, P619, DOI 10.1111/j.1540-8159.1990.tb02078.x; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; FREEDMAN RA, 1986, J AM COLL CARDIOL, V7, P595, DOI 10.1016/S0735-1097(86)80470-3; GARSON A, 1993, CIRCULATION, V87, P1866, DOI 10.1161/01.CIR.87.6.1866; Gilgenkrantz J M, 1968, Arch Mal Coeur Vaiss, V61, P439; GRAS D, 1994, J AM COLL CARDIOL, pA11; Gross Jay N., 1992, Cardiology Clinics, V10, P609; HARPER GR, 1991, PACE, V14, P1787, DOI 10.1111/j.1540-8159.1991.tb02767.x; HAYES DL, 1990, PACE, V13, P501; HEINZ G, 1990, CHEST, V97, P890, DOI 10.1378/chest.97.4.890; HEINZ G, 1993, J CARDIAC SURG, V8, P417, DOI 10.1111/j.1540-8191.1993.tb00386.x; HEINZ G, 1992, PACE, V15, P2061, DOI 10.1111/j.1540-8159.1992.tb03022.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; HOCHLEITNER M, 1993, LANCET, V341, P629, DOI 10.1016/0140-6736(93)90387-V; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; HOCHLEITNER M, 1992, AM J CARDIOL, V70, P1320, DOI 10.1016/0002-9149(92)90769-U; JACQUET L, 1990, J AM COLL CARDIOL, V16, P832, DOI 10.1016/S0735-1097(10)80330-4; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; KACET S, 1991, PACE, V14, P1444, DOI 10.1111/j.1540-8159.1991.tb04062.x; KATO R, 1988, CURR CLIN P, V51, P15; LORIA K, 1988, J HEART TRANSPLANT, V7, P380; MABO P, 1991, PACE, V14, P648; MACKINTOSH AF, 1982, BRIT HEART J, V48, P584; MARKEWITZ A, 1993, J CARDIAC SURG, V8, P411, DOI 10.1111/j.1540-8191.1993.tb00385.x; MARKEWITZ A, 1988, PACE, V11, P1402, DOI 10.1111/j.1540-8159.1988.tb04987.x; MARTI V, 1991, PACE, V14, P1205, DOI 10.1111/j.1540-8159.1991.tb02855.x; MATSUMOTO K, 1993, CIRCULATION, V88, P210; MCAREAVEY D, 1992, AM J CARDIOL, V70, P651, DOI 10.1016/0002-9149(92)90207-F; MIYAMOTO Y, 1990, CIRCULATION, V82, P313; MONTERO JA, 1992, J HEART LUNG TRANSPL, V11, P799; MORGAN JM, 1991, PACE, V14, P667; MOSS AJ, 1991, CIRCULATION, V84, P1524, DOI 10.1161/01.CIR.84.4.1524; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; PARRY G, 1992, BRIT HEART J, V68, P195; PAYNE ME, 1991, J HEART LUNG TRANSPL, V10, P738; RONASZEKI A, 1990, PACE, V13, P1728, DOI 10.1111/j.1540-8159.1990.tb06880.x; ROSENQVIST M, 1993, CIRCULATION, V88, P19; SCHMID C, 1993, THORAC CARDIOV SURG, V41, P101, DOI 10.1055/s-2007-1013830; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P589; SCOTT CD, 1991, PACE, V14, P1792, DOI 10.1111/j.1540-8159.1991.tb02768.x; SCOTT CD, 1993, J HEART LUNG TRANSPL, V12, P534; SCOTT CD, 1993, BRIT HEART J, V69, P399; SEIDELIN PH, 1992, LANCET, V340, P369, DOI 10.1016/0140-6736(92)91443-C; SLADE AKB, 1994, J AM COLL CARDIOL, pA10; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; SUTTON R, 1990, PACE, V13, P1823, DOI 10.1111/j.1540-8159.1990.tb06897.x; SUTTON R, 1994, CARDIAC PACING ELECT, P15; Sutton R, 1992, EUR J CARDIAC PACING, V2, P180; WYNNE J, 1992, HEART DISEASE TXB CA, P1394; 1993, EUR J CARDIAC PACING, V3, P169	82	10	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					443	451		10.7326/0003-4819-123-6-199509150-00009	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639445				2022-12-28	WOS:A1995RU43700008
J	GREENWELL, PW; KRONMAL, SL; PORTER, SE; GASSENHUBER, J; OBERMAIER, B; PETES, TD				GREENWELL, PW; KRONMAL, SL; PORTER, SE; GASSENHUBER, J; OBERMAIER, B; PETES, TD			TEL1, A GENE INVOLVED IN CONTROLLING TELOMERE LENGTH IN SACCHAROMYCES-CEREVISIAE, IS HOMOLOGOUS TO THE HUMAN ATAXIA-TELANGIECTASIA GENE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; SCHIZOSACCHAROMYCES-POMBE; SHUTTLE VECTORS; DNA-REPAIR; YEAST; RECOVERY; MUTANTS; VPS34	Yeast chromosomes terminate in tracts of simple repetitive DNA (poly[G(1-3)T]). Mutations in the gene TEL1 result in shortened telomeres. Sequence analysis of TEL1 indicates that it encodes a very large (322 kDa) protein with amio acid motifs found in phosphatidylinositol/protein kinases. The closest homolog to TEL1 is the human ataxia telangiectasia gene.	UNIV N CAROLINA, CURRICULUM GENET & CELL BIOL, CHAPEL HILL, NC 27599 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV MUNICH, INST BIOCHEM, D-81375 MUNICH, GERMANY	University of North Carolina; University of North Carolina Chapel Hill; University of Chicago; University of Munich	GREENWELL, PW (corresponding author), UNIV N CAROLINA, DEPT BIOL, CB 3280, CHAPEL HILL, NC 27599 USA.			Gassenhuber, johann/0000-0001-5338-8238	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024110] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24110, GM52319] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Guthrie C, 1991, GUIDE YEAST GENETICS; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; LUSTIG AJ, 1993, GENOME ANAL, V7, P79; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PANDITA RK, 1995, CYTOGENET CELL GENET, V71, P86; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; STACK JH, 1994, J BIOL CHEM, V269, P31552; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WALMSLEY RM, 1985, P NATL ACAD SCI USA, V82, P506, DOI 10.1073/pnas.82.2.506; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	46	352	362	1	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					823	829		10.1016/0092-8674(95)90479-4	http://dx.doi.org/10.1016/0092-8674(95)90479-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671310	Bronze			2022-12-28	WOS:A1995RU75500017
J	SCHNITZER, JE; MCINTOSH, DP; DVORAK, AM; LIU, J; OH, P				SCHNITZER, JE; MCINTOSH, DP; DVORAK, AM; LIU, J; OH, P			SEPARATION OF CAVEOLAE FROM ASSOCIATED MICRODOMAINS OF GPI-ANCHORED PROTEINS	SCIENCE			English	Article							SIGNAL-TRANSDUCING MOLECULE; TRANS-GOLGI-NETWORK; T-CELL ACTIVATION; PLASMA-MEMBRANE; MDCK CELLS; EPITHELIAL-CELLS; TYROSINE KINASES; LINKED PROTEINS; PHOSPHATIDYLINOSITOL; RECEPTOR	In situ coating of the surface of endothelial cells in rat lung with cationic colloidal silica particles was used to separate caveolae from detergent-insoluble membranes rich in glycosyl phosphatidylinositol (GPI)-anchored proteins but devoid of caveolin. Immunogold electron microscopy showed that ganglioside G(M1)-enriched caveolae associated with an annular plasmalemmal domain enriched in GPI-anchored proteins. The purified caveolae contained molecular components required for regulated transport, including various lipid-anchored signaling molecules. Such specialized distinct microdomains may exist separately or together in the plasma membrane to organize signaling molecules and to process surface-bound ligands differentially.			SCHNITZER, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL52766, HL43278] Funding Source: Medline; NIAID NIH HHS [AI33372] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052766, R29HL043278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033372] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANEY LK, 1983, J BIOL CHEM, V258, P62; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; DAVIS LS, 1988, J IMMUNOL, V141, P2246; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GARCIA M, 1993, J CELL SCI, V104, P1281; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; JACOBSON BS, 1992, EUR J CELL BIOL, V58, P296; KELLER EA, 1992, EMBO J, V3, P863; KORTY PE, 1991, J IMMUNOL, V146, P4092; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LETARTEMUIRHEAD M, 1974, BIOCHEM J, V143, P51, DOI 10.1042/bj1430051; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PATTON WF, 1990, ELECTROPHORESIS, V11, P79, DOI 10.1002/elps.1150110116; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; RYAN US, 1982, J APPL PHYSIOL, V53, P914, DOI 10.1152/jappl.1982.53.4.914; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1995, AM J PHYSIOL, V37, pH48; SCHNITZER JE, 1992, J BIOL CHEM, V264, P24544; SCHNITZER JE, UNPUB; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P21230; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SU B, 1991, J CELL BIOL, V112, P377, DOI 10.1083/jcb.112.3.377; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231; ZHANG F, 1991, J CELL BIOL, V115, P75, DOI 10.1083/jcb.115.1.75	61	439	449	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1435	1439		10.1126/science.7660128	http://dx.doi.org/10.1126/science.7660128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660128				2022-12-28	WOS:A1995RT80600049
J	BRUCE, AK; JACOBSEN, E; DOSSING, H; KONDRUP, J				BRUCE, AK; JACOBSEN, E; DOSSING, H; KONDRUP, J			HYPOGLYCEMIA IN SPINAL MUSCULAR-ATROPHY	LANCET			English	Note							DYSTROPHY	Repeated episodes of hypoglycaemia were observed in two girls with spinal muscular atrophy. During a 12 h fast blood glucose fell to 3.4 and 2.7 mmol/L, respectively. One girl developed hypoglycaemia and ketonuria. Reduced gluconeogenesis was probably the cause of hypoglycaemia in these patients who had a muscle mass of about 10% of bodyweight (normal 30-40%). Hypoglycaemia must be suspected and treated when patients with severe muscle wasting due to chronic neuromuscular disorders are admitted comatose. In our experience this condition is often regarded as respiratory insufficiency.	NATL UNIV HOSP, RIGSHOSP, DEPT MED A, CLIN NUTR UNIT, COPENHAGEN, DENMARK; NATL UNIV HOSP, RIGSHOSP, DEPT INFECT DIS, RESP UNIT, COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	BRUCE, AK (corresponding author), NATL UNIV HOSP, RIGSHOSP, DEPT ANAESTHESIOL, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.		Kondrup, Jens/C-6193-2008					[Anonymous], 1985, ENERGY PROTEIN REQUI; FELIG P, 1970, NEW ENGL J MED, V282, P166; HAYMOND MW, 1978, NEUROLOGY, V28, P1224, DOI 10.1212/WNL.28.12.1224; HEYMSFIELD SB, 1983, AM J CLIN NUTR, V37, P478, DOI 10.1093/ajcn/37.3.478; MATTHEWS DE, 1990, J PARENT ENT NUTR, V15, P3; MORIYAMA M, 1988, TOHOKU J EXP MED, V154, P381, DOI 10.1620/tjem.154.381; OKADA K, 1992, J NUTR SCI VITAMINOL, V38, P141, DOI 10.3177/jnsv.38.141; SHILS MME, 1988, MODERN NUTRITION HLT, P546; SHU SG, 1989, BRAIN DEV-JPN, V11, P62, DOI 10.1016/S0387-7604(89)80011-7	9	31	31	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 2	1995	346	8975					609	610						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651007				2022-12-28	WOS:A1995RT18800012
J	[Anonymous]				[Anonymous]			END OF THE LINE IN SIGHT FOR FDA	NATURE			English	Editorial Material																		1995, NATURE, V376, P539	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					713	714						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651523				2022-12-28	WOS:A1995RR83600001
J	BENTLEY, E; MACKIE, IC				BENTLEY, E; MACKIE, IC			TRENDS IN PRESCRIPTIONS OF PARACETAMOL FOR CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES		UNIV MANCHESTER,HOSP DENT,DEPT DENT MED & SURG,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester								BENTLEY EM, 1993, HEALTH EDUC RES, V8, P519, DOI 10.1093/her/8.4.519; MACKIE IC, 1993, BRIT DENT J, V175, P93, DOI 10.1038/sj.bdj.4808242; 1979, BRIT MED J, V1, P1231	3	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					362	362		10.1136/bmj.311.7001.362	http://dx.doi.org/10.1136/bmj.311.7001.362			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640543	Green Published			2022-12-28	WOS:A1995RN46900017
J	TOUQUET, R; DRISCOLL, P; NICHOLSON, D				TOUQUET, R; DRISCOLL, P; NICHOLSON, D			TEACHING IN ACCIDENT AND EMERGENCY-MEDICINE - 10-COMMANDMENTS OF ACCIDENT AND EMERGENCY RADIOLOGY	BRITISH MEDICAL JOURNAL			English	Article								One of the many attractions of accident and emergency medicine is the wide and varied opportunities it provides for education, This is because of the acute nature of the work, which necessitates prompt and accurate decision making, However, in many instances the decisions have to be made by inexperienced senior house officers. Departments therefore need a safe system of practice that can be remembered and adhered to under stress. The 10 commandments is one such system for analysing emergency radiographs of all the regions of the body. This system lays down guidelines to protect both staff and hospitals from the inevitable mistakes that inexperienced doctors will make.	HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND		TOUQUET, R (corresponding author), ST MARYS HOSP,LONDON W2 1NY,ENGLAND.							CRAIG JO, 1993, PITFALLS DIAGNOSTI 3; CRAIG JOMC, 1989, CLIN RADIOL, V40, P343, DOI 10.1016/S0009-9260(89)80115-1; DELUCA SA, 1982, AM J ROENTGENOL, V138, P91, DOI 10.2214/ajr.138.1.91; GRECH P, 1981, CASUALITY RADIOLOGY; Guly HR, 1992, DIAGNOSTIC ERRORS TR; HARRIS NH, 1994, MED NEGLIGENCE; HILL G, 1991, A E RISK MANAGEMENT; JELINEK GA, 1990, ARCH EMERG MED, V7, P241; KEATS TE, 1988, ATLAS NORMAL ROENTGE; KNOTTENBELT JD, 1994, INJURY, V25, P311; LANDON BA, 1994, ATLAS TRAUMA MANAGEM; LOGAN M, 1994, CLIN RADIOL, V49, P192, DOI 10.1016/S0009-9260(05)81775-1; MORRIS F, 1990, BRIT MED J, V300, P165, DOI 10.1136/bmj.300.6718.165; NICHOLSON D, 1995, ABC EMERGENCY RADIOL; PERRY NM, 1991, ABC MAJOR TRAUMA; REMEDIOS D, 1993, IMAGING, V5, P171; TACHAKRA SS, 1987, BRIT J ACCIDENT EMER, V2, P8; TOUQUET R, 1994, J ROY SOC MED, V87, P720; TOUQUET R, 1986, BRIT MED J, V293, P1168; TOUQUET R, 1994, MED NEGLIGENCE; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7; VINCENT CA, 1988, ARCH EMERG MED, V5, P101; WILLIAMS PH, 1992, INJURY, V23, P140, DOI 10.1016/0020-1383(92)90054-V; 1994, MED STAFFING ACCIDEN; 1993, MAKING BEST USE DEP	25	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					642	645		10.1136/bmj.310.6980.642	http://dx.doi.org/10.1136/bmj.310.6980.642			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7661941	Green Published			2022-12-28	WOS:A1995QL98400022
J	PICKAR, D; HSIAO, JK				PICKAR, D; HSIAO, JK			CLOZAPINE TREATMENT OF SCHIZOPHRENIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							POSITRON EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; DOPAMINE; CHLORPROMAZINE; ABNORMALITIES; NEUROLEPTICS; DRUGS				PICKAR, D (corresponding author), NIMH,EXPTL THERAPEUT BRANCH,BLDG 10,ROOM 4N-212,BETHESDA,MD 20892, USA.			Pickar, David/0000-0002-8596-3687; Hsiao, John/0000-0003-3471-7539				ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P966; CALDWELL CB, 1992, SUICIDE LIFE-THREAT, V22, P479; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71; HIRSCH SR, 1994, SCHIZOPHRENIA; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MELTZER HR, 1989, J PHARMACOL EXP THER, V251, P3238; MELTZER HY, 1993, AM J PSYCHIAT, V150, P1630; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; PICKAR D, 1984, SCIENCE, V225, P954, DOI 10.1126/science.6474162; PICKAR D, 1988, SCHIZOPHRENIA BULL, V14, P255, DOI 10.1093/schbul/14.2.255; PICKAR D, 1995, LANCET, V345, P557, DOI 10.1016/S0140-6736(95)90469-7; PICKAR D, 1994, ARCH GEN PSYCHIAT, V51, P159; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WEINBERGER DR, 1994, J NEUROPSYCH CLIN N, V6, P419; WIK G, 1989, PSYCHOPHARMACOLOGY, V97, P309, DOI 10.1007/BF00439443	25	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					981	983						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV734	7674530				2022-12-28	WOS:A1995RV73400034
J	KAYE, D				KAYE, D			DIPSTICKS FOR DIAGNOSIS OF URINARY-TRACT INFECTION IN THE NURSING-HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BACTERIURIA				KAYE, D (corresponding author), MED COLL PENN,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; BALDASSARRE JS, 1991, MED CLIN N AM, V75, P375, DOI 10.1016/S0025-7125(16)30460-6; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BOSCIA JA, 1989, ANN INTERN MED, V110, P404, DOI 10.7326/0003-4819-110-5-404; GLECKMAN R, 1982, SOUTHERN MED J, V75, P551, DOI 10.1097/00007611-198205000-00011; PAPPAS PG, 1991, MED CLIN N AM, V75, P313, DOI 10.1016/S0025-7125(16)30456-4	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					868	868		10.1001/jama.274.11.868	http://dx.doi.org/10.1001/jama.274.11.868			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674489				2022-12-28	WOS:A1995RU60300008
J	BLACKHALL, LJ; MURPHY, ST; FRANK, G; MICHEL, V; AZEN, S				BLACKHALL, LJ; MURPHY, ST; FRANK, G; MICHEL, V; AZEN, S			ETHNICITY AND ATTITUDES TOWARD PATIENT AUTONOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER-PATIENT; TRUTH; CARE; PHYSICIANS; DISCLOSURE; DIAGNOSIS; PROXY	Objective.-To study differences in the attitudes of elderly subjects from different ethnic groups toward disclosure of the diagnosis and prognosis of a terminal illness and toward end-of-life decision making. Design.-Survey. Setting.-Thirty-one senior citizen centers within Los Angeles County, California. Respondents.-A stratified quota sample of 200 subjects aged 65 years and older self-identified as being from each of four ethnic groups: European American, African American, Korean American, or Mexican American (N=800). Main Outcome Measures and Results.-Korean Americans (47%) and Mexican Americans (65%) were significantly less likely than European Americans (87%) and African Americans (88%) to believe that a patient should be told the diagnosis of metastatic cancer. Korean Americans (35%) and Mexican Americans (48%) were less likely than African Americans (63%) and European Americans (69%) to believe that a patient should be told of a terminal prognosis and less likely to believe that the patient should make decisions about the use of life-supporting technology (28% and 41% vs 60% and 65%). Instead, Korean Americans and Mexican Americans tended to believe that the family should make decisions about the use of life support. On stepwise multiple logistic regression, ethnicity was the primary factor related to attitudes toward truth telling and patient decision making. Conclusions.-Korean-American and Mexican-American subjects were more likely to hold a family-centered model of medical decision making rather than the patient autonomy model favored by most of the African-American and European-American subjects. This finding suggests that physicians should ask their patients if they wish to receive information and make decisions or if they prefer that their families handle such matters.	UNIV SO CALIF,ANNENBERG SCH COMMUN,PACIFIC CTR HLTH POLICY & ETH,DEPT MED,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT OCCUPAT THERAPY,LOS ANGELES,CA; UNIV SO CALIF,DEPT PREVENT MED,LOS ANGELES,CA 90089	University of Southern California; University of Southern California; University of Southern California				FRANK, GELYA/0000-0002-7601-4236	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007001] Funding Source: NIH RePORTER; AHRQ HHS [1 R01 HS07001 01A1] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 1991, ANN INTERN MED, V115, P478; BEAUCHAMP TL, 1986, HIST THEORY INFORMED, P88; BEYENE Y, 1992, WESTERN J MED, V157, P328; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; DALLAVORGIA P, 1992, J MED ETHICS, V18, P67, DOI 10.1136/jme.18.2.67; Emanuel E J, 1990, J Clin Ethics, V1, P9; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; ESTAPE J, 1992, ANN ONCOL, V3, P451, DOI 10.1093/oxfordjournals.annonc.a058233; FREEDMAN B, 1993, ARCH INTERN MED, V153, P572, DOI 10.1001/archinte.153.5.572; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HOLLAND JC, 1987, CANCER INVEST, V5, P151, DOI 10.3109/07357908709018468; JAMES SA, 1984, AM J PUBLIC HEALTH, V74, P468, DOI 10.2105/AJPH.74.5.468; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Levine R J, 1991, Law Med Health Care, V19, P207; MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005; MULLER JH, 1992, WESTERN J MED, V157, P323; NELSON JL, 1992, HASTINGS CENT REP, V22, P6; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; Oken Donald, 1961, JAMA-J AM MED ASSOC, V175, P86; ORONA CJ, 1994, CAMB Q HEALTHC ETHIC, V3, P338, DOI 10.1017/S0963180100005156; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V277, P59; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; 1982, ETHICAL LEGAL IMPLIC, V1, P74; 1991, JAMA-J AM MED ASSOC, V265, P1868	30	681	689	0	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					820	825		10.1001/jama.274.10.820	http://dx.doi.org/10.1001/jama.274.10.820			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU324	7650806				2022-12-28	WOS:A1995RU32400030
J	DODGE, JA				DODGE, JA			MALE-FERTILITY IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material											DODGE, JA (corresponding author), QUEENS UNIV BELFAST,NUFFIELD DEPT CHILD HLTH,BELFAST,ANTRIM,NORTH IRELAND.		Chotirmall, Sanjay Haresh/K-4127-2015	Chotirmall, Sanjay Haresh/0000-0003-0417-7607				ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; AUGARTEN A, 1994, LANCET, V344, P1473, DOI 10.1016/S0140-6736(94)90292-5; BARRETO C, 1991, J MED GENET, V28, P420, DOI 10.1136/jmg.28.6.420; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; DEAN M, 1994, HUM GENET, V93, P364; FOGDESTAM I, 1994, 19TH EUR CYST FIBR C; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; LIU J, 1994, JAMA-J AM MED ASSOC, V272, P1858, DOI 10.1001/jama.272.23.1858; OATES RD, 1992, J ASSIST REPROD GEN, V9, P36, DOI 10.1007/BF01204112; STERN RC, 1995, LANCET, V346, P274, DOI 10.1016/S0140-6736(95)92165-6; STERN RC, 1983, LANCET, V1, P1401; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993; 1995, 1995 UK CYST FIBR SU; 1994, HUMAN FERTILISTION E	16	16	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					587	588		10.1016/S0140-6736(95)91431-5	http://dx.doi.org/10.1016/S0140-6736(95)91431-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7650999				2022-12-28	WOS:A1995RT18800004
J	[Anonymous]				[Anonymous]			CARE IN THE COMMUNITY	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					714	714						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651524				2022-12-28	WOS:A1995RR83600002
J	LEE, N; MILLMAN, A; OSBORNE, M; COX, J				LEE, N; MILLMAN, A; OSBORNE, M; COX, J			STORING AND MANAGING DATA ON A COMPUTER	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,LONDON,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND; CHASE FARM HOSP,ENFIELD,MIDDX,ENGLAND; WELLCOME CTR MED SCI,LONDON,ENGLAND	Brunel University; Imperial College London; Gloucestershire Royal Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					562	565		10.1136/bmj.311.7004.562	http://dx.doi.org/10.1136/bmj.311.7004.562			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663218	Green Published			2022-12-28	WOS:A1995RR73700032
J	ZIMMERLY, S; GUO, HT; PERLMAN, PS; LAMBOWITZ, AM				ZIMMERLY, S; GUO, HT; PERLMAN, PS; LAMBOWITZ, AM			GROUP-II INTRON MOBILITY OCCURS BY TARGET DNA-PRIMED REVERSE TRANSCRIPTION	CELL			English	Article							EVOLUTIONARY RELATIONSHIPS; CYTOCHROME-OXIDASE; RNA; MATURASE; YEAST; GENE; RETROVIRUSES; PROTEINS	Mobile group II introns encode reverse transcriptases and insert site specifically into intronless alleles (homing). Here, in vitro experiments show that homing of the yeast mtDNA group II intron aI2 occurs by reverse transcription at a double-strand break in the recipient DNA. A site-specific endonuclease cleaves the antisense strand of recipient DNA at position +10 of exon 3 and the sense strand at the intron insertion site. Reverse transcription of aI2-containing pre-mRNA is primed by the antisense strand cleaved in exon 3 and results in cotransfer of the intron and flanking exon sequences. Remarkably, the DNA endonuclease that initiates homing requires both the aI2 reverse transcriptase protein and aI2 RNA. Parallels in their reverse transcription mechanisms raise the possibility that mobile group II introns were ancestors of nuclear non-long terminal repeat retrotransposons and telomerases.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZIMMERLY, S (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NIGMS NIH HHS [GM31480, GM37949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949, R01GM031480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; EICKBUSH TH, 1992, NEW BIOL, V4, P430; Eickbush Thomas H., 1994, P121; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MOHR G, 1993, NUCLEIC ACIDS RES, V21, P4991, DOI 10.1093/nar/21.22.4991; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; SAINSARDCHANET A, 1994, J MOL BIOL, V242, P630, DOI 10.1006/jmbi.1994.1613; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J, 1989, MOL CLONING LABORATO; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	31	225	248	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					545	554		10.1016/0092-8674(95)90027-6	http://dx.doi.org/10.1016/0092-8674(95)90027-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664334	Bronze			2022-12-28	WOS:A1995RR73400006
J	MELLANBY, AR; PHELPS, FA; CRICHTON, NJ; TRIPP, JH				MELLANBY, AR; PHELPS, FA; CRICHTON, NJ; TRIPP, JH			SCHOOL SEX-EDUCATION - AN EXPERIMENTAL PROGRAM WITH EDUCATIONAL AND MEDICAL BENEFIT	BRITISH MEDICAL JOURNAL			English	Article							RISK-TAKING; TEENAGERS	Objectives-To develop and teach a school sex education programme that will lead to a decrease in sexual activity. Design-A matched internal and external control experiment, comparing control populations which received their own sex education programmes with populations which received a novel sex education intervention that included medical and peer led teaching. Setting-Comprehensive secondary schools; control and intervention populations within Devon, and distant controls from rural, semiurban, and urban areas of England excluding major conurbations. Subjects-Schoolchildren were taught from age 12 to 16; three successive cohorts of students were evaluated in school year 11 (mean age 16.0). Main outcome measures-questionnaire ducted under ''examination conditions'' invigilated by the research team and other trained medical staff. Results-In the intervention population, progressive increase in knowledge related to contraception, sexually transmitted diseases, and prevalence of sexual activity (chi(2) (trend) P<0.001 for all three series); relative increase between intervention and control populations in knowledge, relative decrease in attitudes suggesting that sexual intercourse is of itself beneficial to teenagers and their relationships, relative decrease in sexual activity, and relative increase in approval of their ''sex education'' (relative risk >1.00 with 95% confidence limits not including 1.00 for all series and for comparisons with both control populations); odds ratio (control v programme) for sexual activity of 1.45, controlling for sociodemographic variables. Conclusion-School sex education that includes specific targeted methods with the direct use of medical staff and peers can produce behavioural changes that lead to health benefit.	UNIV EXETER,POST GRAD SCH MED,DEPT CHILD HLTH,EXETER EX2 5SQ,DEVON,ENGLAND; UNIV EXETER,DEPT MATH STAT & OPERAT RES,EXETER,DEVON,ENGLAND	University of Exeter; University of Exeter								ALLEN I, 1991, FAMILY PLANNING PREG; CHRISTOPHER FS, 1991, FAM RELAT, V39, P68; CURTIS HA, 1988, ARCH DIS CHILD, V63, P373, DOI 10.1136/adc.63.4.373; DONOVAN C, 1990, BRIT MED J, V300, P1026, DOI 10.1136/bmj.300.6731.1026; ELLIOTT PM, 1989, BRIT MED J, V298, P288, DOI 10.1136/bmj.298.6669.288; EWLES L, 1995, PROMOTING HLTH PRACT; FORD N, 1992, J ADOLESCENCE, V15, P393, DOI 10.1016/0140-1971(92)90071-C; GLYNN TJ, 1989, J SCHOOL HEALTH, V59, P181, DOI 10.1111/j.1746-1561.1989.tb04698.x; HOWARD M, 1990, FAM PLANN PERSPECT, V22, P21, DOI 10.2307/2135434; Johnson AM, 1994, SEXUAL ATTITUDES LIF; KIRBY D, 1991, FAM PLANN PERSPECT, V23, P253, DOI 10.2307/2135776; KIRBY D, 1994, PUBLIC HEALTH REP, V109, P339; KIRBY D, 1991, EVAL PROGRAM PLANN, V14, P35, DOI 10.1016/0149-7189(91)90038-I; MELLANBY A, 1992, J ADOLESCENCE, V15, P449, DOI 10.1016/0140-1971(92)90074-F; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; NUTBEAM D, 1993, BMJ-BRIT MED J, V306, P102, DOI 10.1136/bmj.306.6870.102; Phelps F., 1994, HEALTH EDUC J, V53, P127, DOI [10.1177/001789699405300202, DOI 10.1177/001789699405300202]; QUICKE J, 1985, PASTORAL CARE    JUN, P91; TRIPP JH, 1994, AIDS CARE, V6, P453, DOI 10.1080/09540129408258660; 1992, STATE PUBLIC HLTH AN, P30; 1991, WORKING PARTY UNPLAN	21	69	72	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					414	417		10.1136/bmj.311.7002.414	http://dx.doi.org/10.1136/bmj.311.7002.414			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RP554	7640585	Green Published			2022-12-28	WOS:A1995RP55400012
J	OESTERLING, JE; MARTIN, SK; BERGSTRALH, EJ; LOWE, FC				OESTERLING, JE; MARTIN, SK; BERGSTRALH, EJ; LOWE, FC			THE USE OF PROSTATE-SPECIFIC ANTIGEN IN STAGING PATIENTS WITH NEWLY DIAGNOSED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE; CARCINOMA; SCINTIGRAPHY; SCANS	Objective.-To assess the need for obtaining radionuclide bone scans in the staging evaluation of patients with newly diagnosed, untreated prostate cancer. This determination was made on the basis of presenting prostate-specific antigen (PSA) levels. Design.-Retrospective review. Participants.-The medical records of 2064 consecutive patients with prostate cancer who were evaluated at the Mayo Clinic in Rochester, Minn, from January 1989 through December 1990 were reviewed. Eight hundred fifty-two patients with newly diagnosed, untreated disease and a serum PSA concentration less than 20.0 mug/L at presentation comprised the study population. Main Outcome Measure.-The rate of false-negative results associated with using the serum PSA concentration to predict bone scan findings. Results.-Five hundred sixty-one patients had a serum PSA concentration of 10.0 mug/L or less; only three had an abnormal bone scan result, and one had an indeterminate scan result. Of the 467 men whose PSA value was 8.0 mug/L or less (two times the upper limit of the reference range), none had bone scan results that were either abnormal or indeterminate. The rate of false-negative results for an abnormal bone scan result was 0% with a serum PSA value of 8.0 mug/L or less and 0.5% with a cutoff level of 10.0 mug/L. The 95% upper confidence limit for the rate of false-negative results for all PSA cutoff levels less than 20.0 mug/L was less than 2%. Conclusions.-For patients with newly diagnosed, untreated prostate cancer, a serum PSA concentration of 10.0 mug/L or less, and no skeletal symptoms, a staging radionuclide bone scan does not appear to be necessary. This clinical situation applies to 39% of all patients presenting with newly diagnosed prostate cancer. Since more than 130 000 new cases are diagnosed each year, approximately 50 000 patients are affected annually. If the $600 staging bone scan were eliminated for these patients, a significant economic savings to the health care system in this country would be effected.	MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905; ST LUKES ROOSEVELT HOSP,DEPT UROL,NEW YORK,NY; COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,NEW YORK,NY 10032	Mayo Clinic; Mount Sinai St. Luke's; Mount Sinai West; Columbia University	OESTERLING, JE (corresponding author), MAYO CLIN & MAYO FDN,DEPT UROL,200 1ST ST SW,ROCHESTER,MN 55905, USA.							BERGER GL, 1981, J UROLOGY, V125, P637, DOI 10.1016/S0022-5347(17)55144-7; CATALONA WJ, 1984, PROSTATE CANCER; CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8; LINDNER A, 1982, J UROLOGY, V128, P1181, DOI 10.1016/S0022-5347(17)53412-6; MCGREGOR B, 1978, BRIT J UROL, V50, P178, DOI 10.1111/j.1464-410X.1978.tb02798.x; MERRICK MV, 1985, BRIT J UROL, V57, P715, DOI 10.1111/j.1464-410X.1985.tb07039.x; ODONOGHUE EPN, 1978, BRIT J UROL, V50, P172, DOI 10.1111/j.1464-410X.1978.tb02797.x; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PAULSON DF, 1988, DIAGNOSIS MANAGEMENT, P417; ROCK RC, 1987, CLIN CHEM, V33, P2257; ROSEN PR, 1984, J NUCL MED, V25, P289; SCHAFFER DL, 1976, RADIOLOGY, V121, P431, DOI 10.1148/121.2.431; UTZ DC, 1969, J AMER MED ASSOC, V209, P1701, DOI 10.1001/jama.209.11.1701; 1992, CANCER FACTS FIGURES	14	185	191	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					57	60						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	7677962				2022-12-28	WOS:A1993KF02600027
J	IGLEHART, JK				IGLEHART, JK			HEALTH-POLICY REPORT - ACADEMIC MEDICAL-CENTERS ENTER THE MARKET - THE CASE OF PHILADELPHIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ANDERS G, 1995, WALL STREET J   0420, pA3; BILLI JE, 1995, NEW ENGL J MED, V333, P979, DOI 10.1056/NEJM199510123331507; DIBONA GF, 1995, MAR ANN M SUBSCR; GEORGE J, 1995, PHILADELPHIA BU 0505, P1; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; IGLEHART JK, 1995, HEALTH AFFAIR, V14, P304, DOI 10.1377/hlthaff.14.1.304; JOHN G, 1995, PHILADELPHIA BU 0623, P1; KELLY WN, 1994, GATHERING MOMENTUM N; LIPSON DJ, 1995, HEALTH AFFAIR, V14, P280, DOI 10.1377/hlthaff.14.2.280; NEWS J, 1995, T JEFFERSON U MAIN L; SHEA J, 1995, PENN HLTH MAGAZINE, V1, P4; SHEA J, 1995, PENN HLTH, V1, P10; WERNECKE ML, 1994, HLTH CARE JOB BASE S; WINSLOW R, 1994, WALL STREET J   0906, pA1; 1995, MAN HLTH CAR IMPL PH; 1994, 1994 ANN REP; 1994, HLTH INS COV PENNS C	17	38	38	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					1019	1023		10.1056/NEJM199510123331525	http://dx.doi.org/10.1056/NEJM199510123331525			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666912				2022-12-28	WOS:A1995RY58600034
J	GIBSON, PG; WLODARCZYK, J; HENSLEY, MJ; MURREEALLEN, K; OLSON, LG; SALTOS, N				GIBSON, PG; WLODARCZYK, J; HENSLEY, MJ; MURREEALLEN, K; OLSON, LG; SALTOS, N			USING QUALITY-CONTROL ANALYSIS OF PEAK EXPIRATORY FLOW RECORDINGS TO GUIDE THERAPY FOR ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article						ASTHMA; PEAK EXPIRATORY FLOW RATE; QUALITY CONTROL; FALSE-POSITIVE REACTIONS; FALSE-NEGATIVE REACTIONS	MANAGEMENT PLAN	Objective: To compare the action points in published asthma management plans with those derived from quality-control analysis of peak expiratory flow recordings. Design: Longitudinal observational study. Setting: An ambulatory asthma education and management program in a tertiary care hospital. Patients: 35 adults with asthma and exacerbation of asthma. Measurements: Peak expiratory flow diaries and symptom recordings. Results: Asthma action points from published asthma management guidelines had poor operating characteristics. The success rate was 35% when the action point was a peak expiratory flow rate less than 60% of the patient's best peak flow. The success rate improved to 88% when the action point was a peak expiratory flow rate less than 80% of the patient's best peak flow. Published action points had a high failure rate. Peak flow decreased to below the published action points during a stable period of asthma in 7% to 51% of patients studied. Action points defined using quality-control analysis did significantly better. A peak flow value less than 3 standard deviations below the patient's mean peak flow detected 84% of exacerbations and had a low failure rate (19%). Other quality-control tests had sensitivities of 91% and 71%. Quality-control action points could detect exacerbations up to 4.5 days earlier than conventional methods. Conclusions: Individualized action points can be derived for patients with asthma by applying quality-control analysis to peak flow recordings. These action points are more sensitive in detecting exacerbations of asthma and have fewer false-positive results. Action plans developed in this manner should be more useful for the early detection of deteriorating asthma.	ROYAL NEWCASTLE HOSP, ENVIRONM TOXICOL UNIT, NEWCASTLE, NSW 2300, AUSTRALIA; JOHN HUNTER HOSP, DEPT MED, NEWCASTLE, NSW 2310, AUSTRALIA	John Hunter Hospital	GIBSON, PG (corresponding author), UNIV NEWCASTLE, JOHN HUNTER HOSP, RESP MED UNIT, LOCKED BAG 1, HUNTER MAIL EXCHANGE, NEWCASTLE, NSW 2310, AUSTRALIA.		gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X				BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BOULET LP, 1994, CHEST, V106, pS184, DOI 10.1378/chest.106.4_Supplement.184S; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CLARK NM, 1992, AM REV RESPIR DIS, V145, P722, DOI 10.1164/ajrccm/145.3.722; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; DRUMMOND N, 1994, BRIT MED J, V308, P564, DOI 10.1136/bmj.308.6928.564; FITZGERALD JM, 1990, ASTHMA INFLAMMATORY, P265; GAUTRIN D, 1994, CHEST, V106, P1419, DOI 10.1378/chest.106.5.1419; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; GIBSON PG, 1993, MED J AUSTRALIA, V158, P775, DOI 10.5694/j.1326-5377.1993.tb121962.x; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; WOOLCOCK A, 1989, MED J AUSTRALIA, V151, P650, DOI 10.5694/j.1326-5377.1989.tb139640.x; 1991, NIH913042 US DEP HLT	15	62	64	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					488	+		10.7326/0003-4819-123-7-199510010-00002	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661491				2022-12-28	WOS:A1995RW49500002
J	KERR, EA; MITTMAN, BS; HAYS, RD; SIU, AL; LEAKE, B; BROOK, RH				KERR, EA; MITTMAN, BS; HAYS, RD; SIU, AL; LEAKE, B; BROOK, RH			MANAGED CARE AND CAPITATION IN CALIFORNIA - HOW DO PHYSICIANS AT FINANCIAL RISK CONTROL THEIR OWN UTILIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						MANAGED CARE; CAPITATION FEE; CALIFORNIA; UTILIZATION REVIEW; HEALTH MAINTENANCE ORGANIZATIONS	HMOS; INCENTIVES	Objective: To describe the structure and range of utilization management methods initiated by physicians in response to capitation. Design: Cross-sectional questionnaire. Setting: A large network-model health maintenance organization (133 contracting physician groups) in California. Participants: 94 (71%) physician groups caring for 2.9 million capitated patients. Measurements: Self-reported use of five major utilization management methods. Results: All physician groups reported using gatekeeping and preauthorization for certain referrals or tests. Most also used profiling of utilization patterns (79%), guidelines (70%), and managed care education (69%). Most physician groups asked gatekeepers to submit preauthorization requests for specialty referrals and restricted patient self-referral. For example, 60% of groups required preauthorization for an internal medicine subspecialty referral, and 7% allowed patient self-referral. Most groups also asked gatekeepers to obtain preauthorization for many tests (for example, 95% for magnetic resonance imaging and 53% for pulmonary function tests). Preauthorization requests were denied infrequently (less than 10% of the time) by more than 75% of groups. Of the 54 groups reporting utilization profiles to their physicians, 61% never adjusted for case-mix among patients and more than 60% suggested practice changes to their physicians based on utilization. Fewer than 35% of the groups used written guidelines for expensive tests that required preauthorization (such as angiography). Conclusions: Physicians are responding to capitation by using utilization management techniques, some at early stages of development, that were previously used only by insurers. This physician-initiated management approach represents a fundamental transformation in the practice of medicine.	RAND CORP, SANTA MONICA, CA 90407 USA; VET AFFAIRS MED CTR, CTR STUDY HLTHCARE PROVIDER BEHAV, SEPULVEDA, CA 91343 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, LOS ANGELES, CA 90095 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); Icahn School of Medicine at Mount Sinai; University of California System; University of California Los Angeles	KERR, EA (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, B-252 LOUIS FACTOR BLDG, 10833 LE CONTE AVE, LOS ANGELES, CA 90095 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X				Berenson R A, 1986, Health Aff (Millwood), V5, P141, DOI 10.1377/hlthaff.5.1.141; EISENBERG JM, 1985, ANN INTERN MED, V102, P537, DOI 10.7326/0003-4819-102-4-537; Gray BH., 1989, CONTROLLING COSTS CH; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; WELCH WP, 1990, MILBANK Q, V68, P221, DOI 10.2307/3350097; WELCH WP, 1987, J HEALTH POLIT POLIC, V12, P723, DOI 10.1215/03616878-12-4-723; Wickizer T M, 1990, Med Care Rev, V47, P327, DOI 10.1177/107755879004700303; 1994, ANN INTERN MED, V120, P423	11	176	176	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					500	+		10.7326/0003-4819-123-7-199510010-00004	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RW495	7661493				2022-12-28	WOS:A1995RW49500004
J	DAOUD, EG; DIMITRIJEVIC, R; MORADY, F				DAOUD, EG; DIMITRIJEVIC, R; MORADY, F			SYNCOPE MEDIATED BY POSTURALLY INDUCED VENTRICULAR-TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Note									UNIV MICHIGAN HOSP, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan								COGGINS DL, 1994, J AM COLL CARDIOL, V23, P1333, DOI 10.1016/0735-1097(94)90375-1; NAKAGAWA H, 1993, CIRCULATION, V88, P2607, DOI 10.1161/01.CIR.88.6.2607; PETERS M, 1946, AM HEART J, V32, P645, DOI 10.1016/0002-8703(46)90672-2	3	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					431	432		10.7326/0003-4819-123-6-199509150-00007	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639443				2022-12-28	WOS:A1995RU43700006
J	DOBRESCU, D; URSEA, B; POPE, M; ASCH, AS; POSNETT, DN				DOBRESCU, D; URSEA, B; POPE, M; ASCH, AS; POSNETT, DN			ENHANCED HIV-1 REPLICATION IN V-BETA-12 T-CELLS DUE TO HUMAN CYTOMEGALOVIRUS IN MONOCYTES - EVIDENCE FOR A PUTATIVE HERPESVIRUS SUPERANTIGEN	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; ENDOGENOUS SUPERANTIGENS; MICROBIAL SUPERANTIGENS; DENDRITIC CELLS; INFECTION; EXPRESSION; AIDS; STIMULATION	HIV-1 replicates more efficiently in cultured IL-2-dependent CD4 T cells expressing V beta 12 T cell receptors (TCRs) rather than other TCRs (Laurence et al., 1992). A viral reservoir is frequently established in V beta 12 T cells in HIV-1-infected patients. Here we show that cytomegalovirus (CMV) is responsible for V beta 12-selective HIV-1 replication that is indistinguishable from the effect of known superantigens (SAGs). This effect is dependent on direct contact of T cells with CMV-infected monocytes. CMV infection, but not ie1 or ie2 transfection, reproduces this effect in a monocytoid cell line (U937). In HIV-infected patients, the presence of CMV antibodies correlates with an HIV-1 viral load preferentially skewed to the V beta 12 subset. Together, these data suggest that a CMV gene product is responsible for a SAG-driven V beta 12-selective HIV-1 reservoir in vivo.	CORNELL UNIV,GRAD SCH MED SCI,HUMAN MOLEC IMMUNOBIOL LAB,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,DIV HEMATOL & ONCOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT CELL BIOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; Rockefeller University					NIAID NIH HHS [AI33322] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033322] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1993, IMMUNOL REV, V131, P5, DOI 10.1111/j.1600-065X.1993.tb01527.x; BACCALA R, 1992, RES IMMUNOL, V143, P288, DOI 10.1016/S0923-2494(92)80122-2; BHARDWAJ N, 1992, J EXP MED, V175, P267, DOI 10.1084/jem.175.1.267; BHARDWAJ N, 1994, INFECT IMMUN, V62, P135, DOI 10.1128/IAI.62.1.135-144.1994; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CLOUSE KA, 1989, J IMMUNOL, V143, P470; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COFFIN JM, 1992, SCIENCE, V255, P411, DOI 10.1126/science.1310360; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DOBRESCU D, 1995, P NATL ACAD SCI USA, V92, P5563, DOI 10.1073/pnas.92.12.5563; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; HELD W, 1994, J EXP MED, V180, P2347, DOI 10.1084/jem.180.6.2347; HIRSCH MS, 1984, REV INFECT DIS, V6, P726; HO WZ, 1991, AIDS RES HUM RETROV, V7, P689, DOI 10.1089/aid.1991.7.689; HOBER D, 1992, CLIN IMMUNOL IMMUNOP, V62, P168, DOI 10.1016/0090-1229(92)90069-Z; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JENKINS DE, 1994, J GEN VIROL, V75, P2337, DOI 10.1099/0022-1317-75-9-2337; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; LABRECQUE N, 1993, J EXP MED, V177, P1735, DOI 10.1084/jem.177.6.1735; LAFON M, 1994, J EXP MED, V180, P1207, DOI 10.1084/jem.180.4.1207; LAFON M, 1992, NATURE, V358, P507, DOI 10.1038/358507a0; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; Mocarski Edward S. Jr., 1993, P173; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NUMAZAKI K, 1992, MED MICROBIOL IMMUN, V181, P323; OKSENHENDLER E, 1993, AIDS, V7, P1023, DOI 10.1097/00002030-199307000-00023; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POSNETT DN, 1993, AIDS, V7, P625, DOI 10.1097/00002030-199305000-00003; POSNETT DN, 1993, SUPERANTIGENS PATHOG, P163; POSNETT DN, 1995, IN PRESS ANN NY ACAD, V1017; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SKOLNIK PR, 1994, J INFECT DIS, V157, P508; SMITH LR, 1992, EUR J IMMUNOL, V22, P641, DOI 10.1002/eji.1830220305; SMITH PD, 1992, J CLIN INVEST, V90, P1642, DOI 10.1172/JCI116035; SMITH TJ, 1993, BLOOD, V81, P1521; SODERBERG C, 1993, TRANSPLANT P, V25, P1416; STINSKI MF, 1978, J VIROL, V26, P686, DOI 10.1128/JVI.26.3.686-701.1978; TAYLORWIEDEMAN J, 1994, J VIROL, V68, P1597, DOI 10.1128/JVI.68.3.1597-1604.1994; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; WEBSTER A, 1989, LANCET, V2, P63	51	81	83	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					753	763		10.1016/0092-8674(95)90472-7	http://dx.doi.org/10.1016/0092-8674(95)90472-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671303	Bronze			2022-12-28	WOS:A1995RU75500010
J	KINNEY, HC; FILIANO, JJ; SLEEPER, LA; MANDELL, F; VALDESDAPENA, M; WHITE, WF				KINNEY, HC; FILIANO, JJ; SLEEPER, LA; MANDELL, F; VALDESDAPENA, M; WHITE, WF			DECREASED MUSCARINIC RECEPTOR-BINDING IN THE ARCUATE NUCLEUS IN SUDDEN-INFANT-DEATH-SYNDROME	SCIENCE			English	Article							VENTRAL MEDULLARY SURFACE; CHOLINERGIC MECHANISMS; VENTROLATERAL MEDULLA; AUGMENTS VENTILATION; CHEMOSENSITIVITY; INVOLVEMENT; OBLONGATA; CAT	Muscarinic cholinergic activity in the human arcuate nucleus at the ventral medullary surface is postulated to be involved in cardiopulmonary control, A significant decrease in [H-3]quinuclidinyl benzilate binding to muscarinic receptors in the arcuate nucleus is now shown to occur in sudden infant death syndrome (SIDS) infants, compared to infants dying acutely of known causes. In infants with chronic oxygenation abnormalities, binding is low in other nuclei, as well as in the arcuate nucleus. The binding deficit in the arcuate nucleus of SIDS infants might contribute to a failure of responses to cardiopulmonary challenges during sleep.	CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NEW ENGLAND RES INST,WATERTOWN,MA 02172; CHILDRENS HOSP,DEPT PEDIAT,BOSTON,MA 02115; UNIV MIAMI,SCH MED,DEPT PATHOL,MIAMI,FL 33101; PFIZER INC,CENT RES,DEPT NEUROSCI,GROTON,CT 06340	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; HealthCore, Inc; Harvard University; Boston Children's Hospital; University of Miami; Pfizer	KINNEY, HC (corresponding author), CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655, R01HD020991] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD20991, P30-HD18655] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREATTAVANLEY.S, 1990, J PHYSIOL-LONDON, V421, P171; BRUCE EN, 1991, BRAIN RES, V538, P211, DOI 10.1016/0006-8993(91)90432-U; BURTON MD, 1989, J APPL PHYSIOL, V66, P2565, DOI 10.1152/jappl.1989.66.6.2565; CHERNIACK NS, 1979, J PHYSIOL-LONDON, V287, P191, DOI 10.1113/jphysiol.1979.sp012654; CHIODINI BA, 1993, J PEDIATR-US, V123, P686, DOI 10.1016/S0022-3476(05)80841-8; CHONAN T, 1991, RESP PHYSIOL, V83, P77, DOI 10.1016/0034-5687(91)90094-Y; DAVIDSON TL, 1993, J APPL PHYSIOL, V74, P280, DOI 10.1152/jappl.1993.74.1.280; DEV NB, 1979, PFLUG ARCH EUR J PHY, V379, P29, DOI 10.1007/BF00622901; DONG XW, 1993, AM J PHYSIOL, V265, P494; FELDMAN JL, 1988, ANNU REV PHYSIOL, V50, P593; FILIANO JJ, 1990, J COMP NEUROL, V293, P448, DOI 10.1002/cne.902930308; FILIANO JJ, 1992, J NEUROPATH EXP NEUR, V51, P394, DOI 10.1097/00005072-199207000-00002; FLEMING H, 1991, J APPL PHYSIOL, V71, P2299, DOI 10.1152/jappl.1991.71.6.2299; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FOKUDA Y, 1979, PFLUEG ARCH, V379, P125; FOLGERING H, 1979, B EUR PHYSIOPATH RES, V15, P659; GILLIS RA, 1988, J PHARMACOL EXP THER, V247, P765; GOZAL D, 1994, J APPL PHYSIOL, V76, P276; HARA H, 1991, BRAIN RES, V545, P87, DOI 10.1016/0006-8993(91)91273-4; HUNT CE, 1992, CLIN PERINATOLOGY AP, P757; ISSA FG, 1992, J APPL PHYSIOL, V72, P439, DOI 10.1152/jappl.1992.72.2.439; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KINNEY HC, 1995, VENTRAL BRAINSTEM ME, P589; KINNEY HC, IN PRESS J COMP NEUR; LOESCHCKE HH, 1970, RESP PHYSIOL, V10, P184, DOI 10.1016/0034-5687(70)90082-4; MCALLEN RM, 1986, NEUROSCIENCE, V18, P43, DOI 10.1016/0306-4522(86)90177-6; MILLHORN DE, 1986, J APPL PHYSIOL, V61, P1249, DOI 10.1152/jappl.1986.61.4.1249; Natti E, 1991, DEV NEUROBIOLOGY BRE, P341; NATTIE EE, 1989, J APPL PHYSIOL, V66, P1462, DOI 10.1152/jappl.1989.66.3.1462; NATTIE EE, 1990, J APPL PHYSIOL, V69, P33, DOI 10.1152/jappl.1990.69.1.33; Olszewski J., 1967, CYTOARCHITECTURE HUM; PONS, 1993, MKM, V329, P377; PRABHAKAR NR, 1989, J APPL PHYSIOL, V66, P598, DOI 10.1152/jappl.1989.66.2.598; SCHLAEFKE ME, 1979, PFLUG ARCH EUR J PHY, V378, P231, DOI 10.1007/BF00592741; SNEDECOR GW, 1989, STATISTICAL METHODS, P374; WAMSLEY JK, 1981, J NEUROSCI, V1, P176; WILLINGER M, 1991, Pediatric Pathology, V11, P677	37	240	242	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1446	1450		10.1126/science.7660131	http://dx.doi.org/10.1126/science.7660131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660131				2022-12-28	WOS:A1995RT80600052
J	WEISS, RA; TAILOR, CS				WEISS, RA; TAILOR, CS			RETROVIRUS RECEPTORS	CELL			English	Review							ECOTROPIC MURINE RETROVIRUSES; AMINO-ACID TRANSPORTER; CELL-SURFACE RECEPTOR; APE LEUKEMIA-VIRUS; BINDING DOMAIN				WEISS, RA (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND.							ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; BAN J, 1993, J VIROL, V67, P1050, DOI 10.1128/JVI.67.2.1050-1057.1993; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BATTINI JL, 1995, J VIROL, V69, P715; CHU TT, 1995, J VIROL, V69, P2569; COSSET FL, 1995, IN PRESS J VIROL; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; JOHANN SV, 1993, J VIROL, V67, P6733, DOI 10.1128/JVI.67.11.6733-6736.1993; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LIEBER MM, 1975, P NATL ACAD SCI USA, V72, P2315, DOI 10.1073/pnas.72.6.2315; LITTMAN D, 1995, CURR TOPICS MICROBIO, V205; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; OLAH Z, 1994, J BIOL CHEM, V269, P25426; SOMIA NV, 1995, IN PRESS P NATL ACAD; TAILOR CS, 1993, J VIROL, V67, P6737, DOI 10.1128/JVI.67.11.6737-6741.1993; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; TALBOT SJ, 1995, J VIROL, V69, P3399, DOI 10.1128/JVI.69.6.3399-3406.1995; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Weiss RA, 1993, RETROVIRIDAE, P1; WILDON CA, 1994, J VIROL, V68, P7697; WILSON CA, 1994, J GEN VIROL, V75, P1901, DOI 10.1099/0022-1317-75-8-1901; WIMMER E, 1994, CELLULAR RECEPTORS A; ZEIJL MV, 1994, P NATL ACAD SCI USA, V91, P1168; ZINGLER K, 1995, J VIROL, V69, P4261, DOI 10.1128/JVI.69.7.4261-4266.1995	30	117	123	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					531	533		10.1016/0092-8674(95)90024-1	http://dx.doi.org/10.1016/0092-8674(95)90024-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664331	Bronze			2022-12-28	WOS:A1995RR73400003
J	BENNETT, PB; YAZAWA, K; MAKITA, N; GEORGE, AL				BENNETT, PB; YAZAWA, K; MAKITA, N; GEORGE, AL			MOLECULAR MECHANISM FOR AN INHERITED CARDIAC-ARRHYTHMIA	NATURE			English	Article							LONG QT SYNDROME; NA+-CHANNEL INACTIVATION; FREE MEMBRANE PATCHES; SODIUM-CHANNELS; CURRENTS	IN the congenital long-QT syndrome, prolongation of the cardiac action potential occurs by an unknown mechanism(1,2) and predisposes individuals to syncope and sudden death as a result of ventricular arrhythmias(3), Genetic heterogeneity has been demonstrated for autosomal dominant long-QT syndrome by the identification of multiple distinct loci(4,5), associated mutations in two candidate genes have recently been reported(6,7). One form of hereditary long QT (LQT3) has been linked to a mutation(7) in the gene encoding the human heart voltage-gated sodium-channel alpha-subunit (SCN5A on chromosome 3p21)(8). Here we characterize this mutation using heterologous expression of recombinant human heart sodium channels, Mutant channels show a sustained inward current during membrane depolarization, Single-channel recordings indicate that mutant channels fluctuate between normal and non-inactivating gating modes. Persistent inward sodium current explains prolongation of cardiac action potentials, and provides a molecular mechanism for this form of congenital long-QT syndrome.	VANDERBILT UNIV, MED CTR, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University	BENNETT, PB (corresponding author), VANDERBILT UNIV, MED CTR, DEPT PHARMACOL, NASHVILLE, TN 37232 USA.							ALZHEIMER C, 1993, J NEUROSCI, V13, P660; ATTWELL D, 1988, LANCET, V1, P1136; CARMELIET E, 1993, EUR HEART J, V14, P3, DOI 10.1093/eurheartj/14.suppl_H.3; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1995, CYTOGENET CELL GENET, V68, P67; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Higuchi R., 1989, PCR TECHNOLOGY, P61; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; JU YK, 1994, P ROY SOC B-BIOL SCI, V256, P163, DOI 10.1098/rspb.1994.0065; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KIYOSUE T, 1989, CIRC RES, V64, P389, DOI 10.1161/01.RES.64.2.389; MAKITA N, 1994, J BIOL CHEM, V269, P7571; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; PATLAK J, 1991, PHYSIOL REV, V71, P1047, DOI 10.1152/physrev.1991.71.4.1047; PATLAK JB, 1986, J GEN PHYSIOL, V87, P305, DOI 10.1085/jgp.87.2.305; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHWARTZ PJ, 1992, ANN NY ACAD SCI, V644, P112, DOI 10.1111/j.1749-6632.1992.tb31007.x; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VALENZUELA C, 1994, BIOPHYS J, V67, P161, DOI 10.1016/S0006-3495(94)80465-5; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910	25	705	721	1	14	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					683	685		10.1038/376683a0	http://dx.doi.org/10.1038/376683a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651517				2022-12-28	WOS:A1995RQ67200059
J	FEIGENSPAN, A; WASSLE, H; BORMANN, J				FEIGENSPAN, A; WASSLE, H; BORMANN, J			PHARMACOLOGY OF GABA RECEPTOR CL- CHANNELS IN RAT RETINAL BIPOLAR CELLS	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; GLYCINE RECEPTOR; PATCH-CLAMP; FUNCTIONAL EXPRESSION; MEMBRANE PATCHES; XENOPUS OOCYTES; SUBUNIT; CURRENTS; BICUCULLINE; STRYCHNINE	Gamma-AMINOBUTYRIC acid (GABA), a major inhibitory neurotransmitter in the mammalian nervous system, is known to operate bicuculline-sensitive Cl- channels through GABA(A) receptors and bicuculline-insensitive cation channels through GABA(B) receptors1,2. Recent observations indicate that the retina may contain GABA receptors with unusual pharmacological properties3-5. Here we report that GABA gates bicuculline-insensitive Cl- channels in rod bipolar cells of the rat retina, which were not modulated by flunitrazepam, pentobarbital and alphaxalone and were only slightly blocked by picrotoxinin. Moreover, the GABA(B) receptor agonist baclofen, and the antagonist 2-hydroxysaclofen had no effect. The underlying single-channel conductance was 7 pS and the open time 150 ms. These values are clearly different from those obtained for GABA(A) receptor channels recorded in other neurons of the same preparation, and in other parts of the brain1,6-8. The bicuculline- and baclofen-insensitive GABA receptors were activated selectively by the GABA analogue cis-4-aminocrotonic acid (CACA)9. Hence they may be similar to those receptors termed GABA(C) receptors10.	MAX PLANCK INST HIRNFORSCH,DEUTSCHORDENSTR 46,W-6000 FRANKFURT 71,GERMANY	Max Planck Society			Bormann, Joachim/E-6214-2011					Becker C.-M., 1992, HDB EXPT PHARM, V102, P539; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DREW CA, 1984, NEUROSCI LETT, V52, P317, DOI 10.1016/0304-3940(84)90181-2; FEIGENSPAN A, IN PRESS VISUAL NEUR; GAHWILER BH, 1984, NEUROSCIENCE, V11, P751, DOI 10.1016/0306-4522(84)90192-1; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JOHNSTON GA, 1975, J NEUROCHEM, V24, P157, DOI 10.1111/j.1471-4159.1975.tb07642.x; KARSCHIN A, 1990, J NEUROPHYSIOL, V63, P860, DOI 10.1152/jn.1990.63.4.860; LIPTON SA, 1989, VISUAL NEUROSCI, V3, P275, DOI 10.1017/S0952523800010026; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; PRIBILLA I, IN PRESS EMBO J; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SHIRASAKI T, 1991, BRAIN RES, V561, P77, DOI 10.1016/0006-8993(91)90751-G; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; YEH HH, 1990, VISUAL NEUROSCI, V4, P349, DOI 10.1017/S0952523800004557	26	360	365	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					159	162		10.1038/361159a0	http://dx.doi.org/10.1038/361159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	7678450				2022-12-28	WOS:A1993KG46600061
J	BRISTOW, LR				BRISTOW, LR			POSTING THE SIGNS ON THE ROAD TO THE 21ST-CENTURY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BRISTOW, LR (corresponding author), AMER MED ASSOC,515 N STATE ST,CHICAGO,IL 60610, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					984	986						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674531				2022-12-28	WOS:A1995RV73400035
J	DAVIS, SF; BYERS, RH; LINDEGREN, ML; CALDWELL, MB; KARON, JM; GWINN, M				DAVIS, SF; BYERS, RH; LINDEGREN, ML; CALDWELL, MB; KARON, JM; GWINN, M			PREVALENCE AND INCIDENCE OF VERTICALLY ACQUIRED HIV-INFECTION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS	Objective.-To estimate human immunodeficiency virus (HIV) type I prevalence among childbearing women, HIV incidence in infants, and the number of children living with HIV infection and acquired immunodeficiency syndrome as a result of transmission from mother to infant (vertical transmission). Design.-The national HIV serosurvey of childbearing women was used to estimate the incidence of vertically acquired HIV infection in children born between 1988 and 1993. Data from the national acquired immunodeficiency syndrome case surveillance system and a multicenter pediatric HIV surveillance project were modeled to estimate incidence in children born between 1978 and 1987. Setting.-Surveillance conducted by the Centers for Disease Control and Prevention, Atlanta, Ga, in collaboration with state and local health departments. Results.-Approximately 14920 HIV-infected infants were born in the United States between 1978 and 1993. Of these, an estimated 12240 children were living at the beginning of 1994; 26% were younger than 2 years, 35% were aged 2 to 4 years, and 39% were aged 5 years or older. Approximately 6530 HIV-infected women gave birth in the United States in 1993, and, based on a 25% vertical transmission rate, an estimated 1630 of their infants were HIV infected. Conclusions-These results provide a basis for estimating medical and other resource needs for HIV-infected women and their children and for measuring the impact of interventions to reduce vertical transmission of HIV.			DAVIS, SF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,E46,ATLANTA,GA 30333, USA.							AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; CALDWELL MB, 1992, PEDIATRICS, V90, P603; CALDWELL MB, 1992, PEDIATRICS, V90, P482; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; KARON JM, 1992, HIVNCID1092028 US DE; LINDSAY MK, 1991, OBSTET GYNECOL, V77, P599; LYON L, 1993, 9TH INT C AIDS BERL; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; SCHABLE B, 1995, PEDIATRICS, V95, P511; WANG MC, 1992, J AM STAT ASSOC, V87, P397, DOI 10.2307/2290270; 1989, MMWR MORB MORTAL SS7, V38, P1; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, HIV AIDS SURVEILLANC, V6, P1; IN PRESS VITAL STATI, V1; 1990, VITAL STATISTICS US, V1; 1994, VITAL STATISTICS US, V1; 1993, ANN SUMMARY BIRTHS M; 1993, VITAL STATISTICS US, V1; 1993, MMWR-MORBID MORTAL W, V42, P869	25	107	107	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					952	955		10.1001/jama.274.12.952	http://dx.doi.org/10.1001/jama.274.12.952			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674525				2022-12-28	WOS:A1995RV73400029
J	KUHEL, WI; WARD, RF				KUHEL, WI; WARD, RF			THYROID-CANCER IN CHILDREN	LANCET			English	Editorial Material											KUHEL, WI (corresponding author), CORNELL UNIV,COLL MED,DEPT CLIN OTOLARYNGOL,NEW YORK,NY 10021, USA.							Baverstock K F, 1993, World Health Stat Q, V46, P204; DEGROOT LJ, 1975, THYROID ITS DISEASES, P666; DUFFY BJ, 1950, J CLIN ENDOCR METAB, V101, P1296; HARNESS JK, 1971, ARCH SURG-CHICAGO, V10, P278; MAZZAFERRI EL, AM J MED; Winship T, 1970, CLIN P CHILDRENS HOS, V26, P327; ZIMMERMAN D, 1988, SURGERY, V10, P1157; ZIMMERMAN D, 1992, TREATMENT THYROID CA	8	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					719	720		10.1016/S0140-6736(95)91499-4	http://dx.doi.org/10.1016/S0140-6736(95)91499-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658869				2022-12-28	WOS:A1995RU81000005
J	KATZ, EB; STENBIT, AE; HATTON, K; DEPINHO, R; CHARRON, MJ				KATZ, EB; STENBIT, AE; HATTON, K; DEPINHO, R; CHARRON, MJ			CARDIAC AND ADIPOSE-TISSUE ABNORMALITIES BUT NOT DIABETES IN MICE DEFICIENT IN GLUT4	NATURE			English	Article							FACILITATIVE GLUCOSE TRANSPORTERS; LOCALIZATION; MUSCLE; RATS	THE insulin-sensitive glucose transporter, GLUT4, is the most abundant facilitative glucose transporter in muscle and adipose tissue, the major sites for postprandial glucose disposal, To assess the role of GLUT4 in glucose homeostasis, we have disrupted the murine GLUT4 gene. Because GLUT4 has been shown to be dysregulated in pathological states such as diabetes and obesity, it was expected that genetic ablation of GLUT4 would result in abnormal glucose homeostasis, The mice deficient in GLUT4 (GLUT4-null) are growth-retarded and exhibit decreased longevity associated with cardiac hypertrophy and severely reduced adipose tissue deposits, Blood glucose levels in female GLUT4-null mice are not significantly elevated in either the fasting or fed state; in contrast, male GLUT4-null mice have moderately reduced glycaemias in the fasted state and increased glycaemias in the fed state, However, both female and male GLUT4-null mice exhibit postprandial hyperinsulinaemia, indicating possible insulin resistance. Increased expression of other glucose transporters is observed in the liver (GLUT2) and heart (GLUT1) but not skeletal muscle. Oral glucose tolerance tests show that both female and male GLUT4-null mice clear glucose as efficiently as controls, but insulin tolerance tests indicate that these mice are less sensitive to insulin action, The GLUT4-null mice demonstrate that functional GLUT4 protein is not required for maintaining nearly normal glycaemia but that GLUT4 is absolutely essential for sustained growth, normal cellular glucose and fat metabolism, and expected longevity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BRESSLER R, 1993, CARDIOSCIENCE, V4, P133; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; DEFRONZO RA, 1991, DIABETES CARE, V4, P173; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; GARVEY WT, 1993, AM J PHYSIOL, V264, pH837, DOI 10.1152/ajpheart.1993.264.3.H837; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KRAEGEN EW, 1993, BIOCHEM J, V295, P387; LITWAN SE, 1990, AM J PHYSIOL, V258, pH551; LO CW, 1986, J CELL SCI, V81, P143; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MODAN M, 1991, DIABETES CARE, V14, P470, DOI 10.2337/diacare.14.6.470; OLEFSKY JM, 1993, EXPL MED BIOL, V334, P129; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Sambrook J, 1989, MOL CLONING LABORATO; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SLIEKER LJ, 1992, DIABETES, V41, P187, DOI 10.2337/diabetes.41.2.187; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1990, DIABETES, V39, P712, DOI 10.2337/diabetes.39.6.712	23	342	352	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					151	155		10.1038/377151a0	http://dx.doi.org/10.1038/377151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675081				2022-12-28	WOS:A1995RU75400049
J	PARTON, RG; SIMONS, K				PARTON, RG; SIMONS, K			DIGGING INTO CAVEOLAE	SCIENCE			English	Editorial Material							PROTEIN-TYROSINE KINASES; GPI-ANCHORED PROTEINS; TRANS-GOLGI-NETWORK; MEMBRANE; CELLS; COMPONENT; VESICLES				PARTON, RG (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY.		Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; Simons, Kai/0000-0002-9231-9996				Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CINEK T, 1992, J IMMUNOL, V149, P2262; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRA AM, IN PRESS P NATL ACAD; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MEMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, IN PRESS P NATL ACAD; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHENOY SA, 1994, J CELL BIOL, V126, P353; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535	28	281	282	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1398	1399		10.1126/science.7660120	http://dx.doi.org/10.1126/science.7660120			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660120				2022-12-28	WOS:A1995RT80600036
J	RIVO, ML; MAYS, HL; KATZOFF, J; KINDIG, DA				RIVO, ML; MAYS, HL; KATZOFF, J; KINDIG, DA			MANAGED HEALTH-CARE - IMPLICATIONS FOR THE PHYSICIAN WORKFORCE AND MEDICAL-EDUCATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAINTENANCE ORGANIZATIONS		COUNCIL GRAD MED EDUC,ROCKVILLE,MD 20857									COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; CORRIGAN JM, 1991, ACAD MED, V66, P656, DOI 10.1097/00001888-199111000-00002; CORRIGAN JM, 1992, J FAM PRACTICE, V35, P543; FELT S, 1994, HMO PRIMARY CARE STA; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; MILLER RH, 1994, ANNU REV PUBL HEALTH, V15, P437; MOORE GT, 1990, ACAD MED, V65, P427, DOI 10.1097/00001888-199007000-00001; MOORE GT, 1993, IMPACT MANAGED CARE; MOORE GT, 1994, ACAD MED, V69, P595; OTIS B, 1994, TAKING CARE PROGRAM; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; ROGERS MC, 1994, NEW ENGL J MED, V331, P1374, DOI 10.1056/NEJM199411173312013; Schimpff S C, 1992, Md Med J, V41, P595; THOMPSON RS, 1995, JAMA-J AM MED ASSOC, V273, P1130, DOI 10.1001/jama.273.14.1130; VELOSKI JJ, 1994, J OUTCOMES MANAGEMEN, V1, P17; WARTMAN SA, 1994, ARCH INTERN MED, V154, P2539, DOI 10.1001/archinte.154.22.2539; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WEITEKAMP MR, 1995, ACAD MED, V70, pS47, DOI 10.1097/00001888-199501000-00025; 1994, NATIONAL COMMITTEE Q; 1992, 3RD US DEP HLTH HUM; 1994, HMO1994 GROUP HLTH A; 1995, STUDIES RELATING QUA; 1994, AM MED NEWS     1226, P3; 1994, INTERDISCIPLINARY HL; 1993, PRIMARY CARE PHYSICI; 1994, AM MED NEWS     0808, P1; 1994, EBRI ISSUE BRIEF, V154, P1; 1994, DEV PARTNERSHIPS ACA; 1995, 1995 COGME PLEN SESS; 1995, PUBLIC HLTH TRUST SI	34	64	64	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					712	715		10.1001/jama.274.9.712	http://dx.doi.org/10.1001/jama.274.9.712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650824				2022-12-28	WOS:A1995RR83500017
J	HARTWIG, JH; BOKOCH, GM; CARPENTER, CL; JANMEY, PA; TAYLOR, LA; TOKER, A; STOSSEL, TP				HARTWIG, JH; BOKOCH, GM; CARPENTER, CL; JANMEY, PA; TAYLOR, LA; TOKER, A; STOSSEL, TP			THROMBIN RECEPTOR LIGATION AND ACTIVATED RAC UNCAP ACTIN FILAMENT BARBED ENDS THROUGH PHOSPHOINOSITIDE SYNTHESIS IN PERMEABILIZED HUMAN PLATELETS	CELL			English	Article							BINDING PROTEIN-RHO; PHOSPHATIDYLINOSITOL BISPHOSPHATE; STIMULATED PLATELETS; ALPHA-THROMBIN; GROWTH-FACTOR; GELSOLIN; POLYPHOSPHOINOSITIDES; 3-KINASE; PEPTIDE; CELLS	Cells respond to diverse external stimuli by polymerizing cytoplasmic actin, and recent evidence indicates that GTPases can specify where this polymerization takes place, Actin assembly in stimulated blood platelets occurs where sequestered monomers add onto the fast-growing (barbed) ends of actin filaments (F-actin), which are capped in the resting cells, We report that D3 and D4 polyphosphoinositides, PI(4)P, PI(4,5)P-2, PI(3,4)P-2, and PI(3,4,5)P-3, uncap F-actin in resting permeabilized platelets, The thrombin receptor-activating peptide (TRAP), GTP, and GTP gamma S, but not GDP beta S, also uncap F-actin in permeabilized platelets. GDP beta S inhibits TRAP-induced F-actin uncapping, and PI(4,5)P-2 overcomes this inhibition, Constitutively active mutant Rac, but not Rho, activates uncapping of F-actin, PI(4,5)P-2-binding peptides derived from gelsolin inhibit F-actin uncapping by TRAP, Rac, and GTP gamma S. TRAP and Rac induce rapid PI(4,5)P-2 synthesis in permeabilized platelets. The findings establish a signaling pathway for actin assembly involving Rac in which the final message is phosphoinositide-mediated F-actin uncapping.	Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, LA JOLLA, CA 92037 USA; BETH ISRAEL HOSP, DEPT MED, DIV HEMATOL, SIGNAL TRANSDUCT LAB, BOSTON, MA 02115 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center	HARTWIG, JH (corresponding author), BRIGHAM & WOMENS HOSP, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.				NHLBI NIH HHS [HL19429] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NIGMS NIH HHS [GM4428] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; APGAR JR, 1995, MOL BIOL CELL, V6, P97, DOI 10.1091/mbc.6.1.97; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CARSON MR, 1992, AM J PHYSIOL, V263, pL664, DOI 10.1152/ajplung.1992.263.6.L664; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DAVIES TA, 1989, J BIOL CHEM, V264, P19600; FOX JEB, 1984, J CELL BIOL, V98, P1985, DOI 10.1083/jcb.98.6.1985; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; GAUDETTE DC, 1993, J BIOL CHEM, V268, P13773; GOU DM, 1994, J CHEM SOC CHEM COMM, P2125, DOI 10.1039/c39940002125; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HASLAM RJ, 1984, BIOCHEM J, V222, P351, DOI 10.1042/bj2220351; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; REDMOND T, 1994, J BIOL CHEM, V269, P21657; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SULTAN C, 1991, J BIOL CHEM, V266, P23554; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	46	589	602	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					643	653		10.1016/0092-8674(95)90036-5	http://dx.doi.org/10.1016/0092-8674(95)90036-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664343	Bronze			2022-12-28	WOS:A1995RR73400015
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE	BRITISH MEDICAL JOURNAL			English	Note									UNIV LONDON ST GEORGES HOSP,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							CHALMERS I, 1985, BRIT MED J, V290, P1002, DOI 10.1136/bmj.290.6473.1002; Freiman J.A., 1992, MED USES STAT, P357, DOI [10.1201/9780429187445, DOI 10.1201/9780429187445]; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905	4	1061	1076	0	65	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					485	485		10.1136/bmj.311.7003.485	http://dx.doi.org/10.1136/bmj.311.7003.485			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647644	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1995RQ67000015
J	STALEY, KJ; SOLDO, BL; PROCTOR, WR				STALEY, KJ; SOLDO, BL; PROCTOR, WR			IONIC MECHANISMS OF NEURONAL EXCITATION BY INHIBITORY GABA(A) RECEPTORS	SCIENCE			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; GAMMA-AMINOBUTYRIC ACID; GYRUS GRANULE CELLS; SYNAPTIC POTENTIALS; MEDIATED RESPONSES; RAT HIPPOCAMPUS; PH; CONDUCTANCE; CHANNELS; SLICES	Gamma-aminobutyric acid A (GABA(A)) receptors are the principal mediators of synaptic inhibition, and yet when intensely activated, dendritic GABA(A) receptors excite rather than inhibit neurons. The membrane depolarization mediated by GABA(A) receptors is a result of the differential, activity-dependent collapse of the opposing concentration gradients of chloride and bicarbonate, the anions that permeate the GABA(A) ionophore. Because this depolarization diminishes the voltage-dependent block of the N-methyl-D-aspartate (NMDA) receptor by magnesium, the activity-dependent depolarization mediated by GABA is sufficient to account for frequency modulation of synaptic NMDA receptor activation. Anionic gradient shifts may represent a mechanism whereby the rate and coherence of synaptic activity determine whether bendritic GABA(A) receptor activation is excitatory or inhibitory.	UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	STALEY, KJ (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT NEUROL,B182,4200 E 9TH AVE,DENVER,CO 80262, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003527] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA03527] Funding Source: Medline; NICHD NIH HHS [HD27827] Funding Source: Medline; NINDS NIH HHS [NS01573] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ALVAREZLEEFMANS FJ, 1988, J PHYSIOL-LONDON, V406, P225, DOI 10.1113/jphysiol.1988.sp017378; AVOLI M, 1987, BRAIN RES, V400, P191, DOI 10.1016/0006-8993(87)90671-8; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; CHEN JCT, 1992, J NEUROPHYSIOL, V67, P29, DOI 10.1152/jn.1992.67.1.29; DAVIES CH, 1993, J PHYSIOL-LONDON, V472, P245, DOI 10.1113/jphysiol.1993.sp019945; DAVIES CH, 1992, NATURE, V349, P609; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; GROVER LM, 1993, J NEUROPHYSIOL, V69, P1541, DOI 10.1152/jn.1993.69.5.1541; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HUGENARD JR, 1986, J NEUROPHYSIOL, V56, P1; JAROLIMEK W, 1989, BRAIN RES, V505, P225, DOI 10.1016/0006-8993(89)91447-9; KAILA K, 1987, NATURE, V330, P163, DOI 10.1038/330163a0; KAILA K, 1993, J PHYSIOL-LONDON, V464, P273, DOI 10.1113/jphysiol.1993.sp019634; KAILA K, 1992, NEUROREPORT, V3, P105, DOI 10.1097/00001756-199201000-00028; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; LAMBERT NA, 1991, J NEUROPHYSIOL, V66, P1538, DOI 10.1152/jn.1991.66.5.1538; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; MOTT DD, 1992, SCIENCE, V252, P1718; MULLER W, 1991, J NEUROPHYSIOL, V65, P141, DOI 10.1152/jn.1991.65.1.141; MULLER W, 1989, BRAIN RES, V484, P184, DOI 10.1016/0006-8993(89)90361-2; NACHSHEN DA, 1988, J GEN PHYSIOL, V91, P289, DOI 10.1085/jgp.91.2.289; NICOLL RA, 1978, J PHYSIOL-LONDON, V283, P121, DOI 10.1113/jphysiol.1978.sp012491; PASTERNACK M, 1993, ACTA PHYSIOL SCAND, V148, P229, DOI 10.1111/j.1748-1716.1993.tb09553.x; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Russell JM, 1990, CHLORIDE CHANNELS CA; SMITH RL, 1995, J NEUROSCI, V15, P4057; STALEY K, 1994, J NEUROPHYSIOL, V72, P273, DOI 10.1152/jn.1994.72.1.273; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; THALMANN RH, 1988, NEUROSCI LETT, V21, P319; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; TOLKOVSKY AM, 1987, NEUROSCIENCE, V22, P1093, DOI 10.1016/0306-4522(87)92984-8; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; Woodbury D. M., 1982, ANTIEPILEPTIC DRUGS, P771; XIE XM, 1993, J PHYSIOL-LONDON, V460, P503, DOI 10.1113/jphysiol.1993.sp019484; [No title captured]	47	655	672	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					977	981		10.1126/science.7638623	http://dx.doi.org/10.1126/science.7638623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638623				2022-12-28	WOS:A1995RP73800036
J	GARCIAMORENO, C; TURMEN, T				GARCIAMORENO, C; TURMEN, T			INTERNATIONAL PERSPECTIVES ON WOMENS REPRODUCTIVE HEALTH	SCIENCE			English	Editorial Material											GARCIAMORENO, C (corresponding author), WHO,DIV FAMILY HLTH,CH-1211 GENEVA 27,SWITZERLAND.							ALTHAUS A, 1991, INT FAM PLAN PERSPEC, V17, P145; BONGAARTS J, 1995, STUD FAMILY PLANN, V26, P57, DOI 10.2307/2137932; ELIAS C, 1991, 5 POP COUNC WORK PAP; FONN S, COMMUNICATION; HEISE L, 1994, 255 WORLD BANK DISC; KAY B, 1991, QUALITY CALIDAD QUAL, V3; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232; 1994, WHOGPADIR944 REP; 1995, WHOFHE956; 1994, WHOGPASEF944 GLOB PR; 1994, 1994 INT C POP DEV C	11	8	8	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					790	792		10.1126/science.7638592	http://dx.doi.org/10.1126/science.7638592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638592				2022-12-28	WOS:A1995RN65000030
J	PARES, JM; PEREZGONZALEZ, A				PARES, JM; PEREZGONZALEZ, A			PALEOMAGNETIC AGE FOR HOMINID FOSSILS AT ATAPUERCA ARCHAEOLOGICAL SITE, SPAIN	SCIENCE			English	Article								A paleomagnetic investigation at the Gran Dolina site excavation (Atapuerca, Spain) shows that the sediments containing the recently discovered human occupation were deposited more than 780,000 years ago, near the time of the Matuyama-Brunhes boundary. Forty-one oriented samples were obtained from 22 sites along an 18-meter section of the Gran Dolina karst filling. The lower 16 sites displayed reversed-polarity magnetizations whereas the upper six sites were normal. The reversal spans the hominid finds at stratigraphic level TD6 (the Aurora stratum), and these hominid fossils are therefore the oldest in southern Europe.	CSIC,INST CIENCIES TERRA JAUME ALMERA,E-08028 BARCELONA,SPAIN; CSIC,CTR CIENCIAS MEDIOAMBIENTALES,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Geociencias Barcelona (GEO3BCN); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Ciencias Medioambientales (CCMA)								AGUIRE E, 1987, HOMBRE FOSIL IBEAS P; ARSUAGA JL, 1993, NATURE, V362, P534, DOI 10.1038/362534a0; BISCHOFF J, PB93066C303; CANDE SC, 1992, J GEOPHYS RES-SOL EA, V97, P13917, DOI 10.1029/92JB01202; CARBONELL E, 1995, SCIENCE, V269, P826, DOI 10.1126/science.7638598; CARBONELL E, 1994, J HUM EVOL, V26, P291, DOI 10.1006/jhev.1994.1018; Carracedo J.C., 1987, HOMBRE FOSIL IBEAS P, P193; DECASTILLAYLEON J, PB910096; FISHER R, 1953, PROC R SOC LON SER-A, V217, P295, DOI 10.1098/rspa.1953.0064; Grun R., 1987, HOMBRE FOSIL IBEAS P, P201; JOHNSON NM, 1985, J GEOL, V93, P27, DOI 10.1086/628917; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; LOVLIE R, 1995, GEOPHYS J INT, V120, P499, DOI 10.1111/j.1365-246X.1995.tb01834.x; OMS O, 1994, PHYS EARTH PLANET IN, V85, P173, DOI 10.1016/0031-9201(94)90015-9; SCHMIDT VA, 1982, SCIENCE, V217, P827, DOI 10.1126/science.217.4562.827; SUK D, 1990, NATURE, V345, P611, DOI 10.1038/345611a0; VALET JP, 1993, NATURE, V366, P234, DOI 10.1038/366234a0; Zijderveld J. D. A., 1967, METHODS PALEOMAGNETI, P254, DOI DOI 10.1016/B978-1-4832-2894-5.50049-5	18	188	192	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					830	832		10.1126/science.7638599	http://dx.doi.org/10.1126/science.7638599			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638599				2022-12-28	WOS:A1995RN65000042
J	KOLLEF, MH; SCHUSTER, DP				KOLLEF, MH; SCHUSTER, DP			MEDICAL PROGRESS - THE ACUTE RESPIRATORY-DISTRESS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CRITICALLY ILL PATIENTS; INVERSE RATIO VENTILATION; END-EXPIRATORY PRESSURE; INTENSIVE-CARE UNIT; FREQUENCY JET VENTILATION; HIGH-DOSE CORTICOSTEROIDS; HUMAN MONOCLONAL-ANTIBODY; PROTECTED SPECIMEN BRUSH; ORGAN-SYSTEM FAILURE; INHALED NITRIC-OXIDE				KOLLEF, MH (corresponding author), WASHINGTON UNIV, SCH MED,DEPT INTERNAL MED,DIV PULM & CRIT CARE, BOX 8052, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.							ABERLE DR, 1990, CLIN CHEST MED, V11, P737; ABERLE DR, 1988, RADIOLOGY, V168, P73, DOI 10.1148/radiology.168.1.3380985; ALLEN JN, 1989, NEW ENGL J MED, V321, P569, DOI 10.1056/NEJM198908313210903; ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; ANZUETO A, 1994, AM J RESP CRIT CARE, V149, pA567; ASHBAUGH DG, 1967, LANCET, V2, P319; ASHBAUGH DG, 1985, ARCH SURG-CHICAGO, V120, P530; BARTLETT RH, 1986, CHEST, V89, P684, DOI 10.1378/chest.89.5.684; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P1095, DOI 10.1164/ajrccm/144.5.1095; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1989, CHEST, V96, P849, DOI 10.1378/chest.96.4.849; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; BONE RC, 1987, CHEST, V92, P1032, DOI 10.1378/chest.92.6.1032; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1993, JAMA-J AM MED ASSOC, V269, P2134, DOI 10.1001/jama.269.16.2134; BONE RC, 1988, CHEST, V94, P448, DOI 10.1016/S0012-3692(16)33495-X; BONE RC, 1978, CRIT CARE MED, V6, P136, DOI 10.1097/00003246-197805000-00002; BORELLI M, 1988, AM REV RESPIR DIS, V138, P1480, DOI 10.1164/ajrccm/138.6.1480; BRICHON PY, 1993, CHEST, V104, P609, DOI 10.1378/chest.104.2.609; BUTLER J, 1990, CHEST, V97, P453, DOI 10.1378/chest.97.2.453; CARLILE PV, 1986, J APPL PHYSIOL, V60, P22, DOI 10.1152/jappl.1986.60.1.22; CARLON GC, 1983, CHEST, V84, P551, DOI 10.1378/chest.84.5.551; DANTZKER D R, 1986, Critical Care Clinics, V2, P527; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; DOUGLASS JA, 1992, AM REV RESPIR DIS, V146, P517, DOI 10.1164/ajrccm/146.2.517; DOWNS JB, 1987, CRIT CARE MED, V15, P459; DRAKE RE, 1988, J APPL PHYSIOL, V64, P487, DOI 10.1152/jappl.1988.64.2.487; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DREYFUSS D, 1992, INTENS CARE MED, V18, P139, DOI 10.1007/BF01709236; DYER RA, 1985, CRIT CARE MED, V13, P12, DOI 10.1097/00003246-198501000-00004; EAST TD, 1992, CHEST, V101, P697, DOI 10.1378/chest.101.3.697; EBERHARD L, 1992, J APPL PHYSIOL, V73, P479, DOI 10.1152/jappl.1992.73.2.479; EISENBERG PR, 1987, AM REV RESPIR DIS, V136, P662, DOI 10.1164/ajrccm/136.3.662; ELLIOTT CG, 1987, AM REV RESPIR DIS, V135, P634; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FEIN A, 1979, AM J MED, V67, P32, DOI 10.1016/0002-9343(79)90066-4; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; Fletcher J R, 1980, Adv Shock Res, V4, P103; FORRESTER JM, 1990, AM REV RESPIR DIS, V142, P462, DOI 10.1164/ajrccm/142.2.462; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; FROSTELL CG, 1993, ANESTHESIOLOGY, V78, P427, DOI 10.1097/00000542-199303000-00005; GAMMON RB, 1992, CHEST, V102, P568, DOI 10.1378/chest.102.2.568; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Gattinoni L, 1986, J Thorac Imaging, V1, P25, DOI 10.1097/00005382-198607000-00005; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; GATTINONI L, 1991, ADULT RESPIRATORY DI, P199; GLAUSER FL, 1988, AM REV RESPIR DIS, V138, P458, DOI 10.1164/ajrccm/138.2.458; GOLDENHEIM PD, 1984, NEW ENGL J MED, V311, P776, DOI 10.1056/NEJM198409203111206; GOLDENHEIM PD, 1984, NEW ENGL J MED, V311, P717, DOI 10.1056/NEJM198409133111106; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GRIFFIN D, 1992, CHEST, V102, P510, DOI 10.1378/chest.102.2.510; GUREVITCH MJ, 1986, CHEST, V89, P211, DOI 10.1378/chest.89.2.211; HANSENFLASCHEN J, 1993, AM REV RESPIR DIS, V147, P234, DOI 10.1164/ajrccm/147.1.234; HAUPT MT, 1991, CRIT CARE MED, V19, P1339, DOI 10.1097/00003246-199111000-00006; HEFFNER JE, 1993, AM REV RESPIR DIS, V147, P768, DOI 10.1164/ajrccm/147.3.768; HERNANDEZ LA, 1989, J APPL PHYSIOL, V66, P2364, DOI 10.1152/jappl.1989.66.5.2364; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HOLCROFT JW, 1986, ANN SURG, V203, P371, DOI 10.1097/00000658-198604000-00006; HOLZAPFEL L, 1987, INTENS CARE MED, V13, P100; HOOPER RG, 1990, CHEST, V97, P138, DOI 10.1378/chest.97.1.138; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; Hyers T M, 1993, New Horiz, V1, P466; IDELL S, 1985, CLIN CHEST MED, V6, P459; JEPSEN S, 1992, CRIT CARE MED, V20, P918, DOI 10.1097/00003246-199207000-00004; JOHNSON TH, 1982, CLIN CHEST MED, V3, P89; KACMAREK R M, 1987, Respiratory Care, V32, P466; KAPLAN JD, 1991, AM REV RESPIR DIS, V143, P150, DOI 10.1164/ajrccm/143.1.150; KIISKI R, 1992, AM REV RESPIR DIS, V146, P1131, DOI 10.1164/ajrccm/146.5_Pt_1.1131; KISSNER DG, 1987, AM REV RESPIR DIS, V136, P1250, DOI 10.1164/ajrccm/136.5.1250; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KOLLEF M, IN PRESS CHEST; KOLLEF MH, 1994, CRIT CARE CLIN, V10, P1; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; KOLLEF MH, 1992, HEART LUNG, V21, P74; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kumar A, 1973, Crit Care Med, V1, P181, DOI 10.1097/00003246-197307000-00001; LAIN DC, 1989, CHEST, V95, P1081, DOI 10.1378/chest.95.5.1081; LANGER M, 1988, CHEST, V94, P103, DOI 10.1378/chest.94.1.103; LAUFE MD, 1986, AM J MED, V80, P1022, DOI 10.1016/0002-9343(86)90659-5; LEATHERMAN JW, 1991, CHEST, V99, P1227, DOI 10.1378/chest.99.5.1227; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; Leeper K V Jr, 1993, New Horiz, V1, P550; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LEWIS JF, 1993, AM REV RESPIR DIS, V147; LODATO RF, 1990, CRIT CARE CLIN, V6, P749; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; LUCE JM, 1993, CRIT CARE MED, V21, P1233, DOI 10.1097/00003246-199308000-00026; LUGER A, 1986, CRIT CARE MED, V14, P458, DOI 10.1097/00003246-198605000-00004; MACINTYRE NR, 1994, CHEST, V105, P648; MACINTYRE NR, 1993, CHEST, V104, P334, DOI 10.1378/chest.104.2.334; MARCY TW, 1991, CHEST, V100, P494, DOI 10.1378/chest.100.2.494; MARCY TW, 1993, CHEST, V104, P578, DOI 10.1378/chest.104.2.578; MARINI JJ, 1992, AM REV RESPIR DIS, V146, P2, DOI 10.1164/ajrccm/146.1.2; MARINI JJ, 1992, J CRIT CARE, V7, P137, DOI 10.1016/0883-9441(92)90009-V; MARINI JJ, 1990, CLIN CHEST MED, V11, P673; MARINI JJ, 1988, AM REV RESPIR DIS, V138, P1169, DOI 10.1164/ajrccm/138.5.1169; MARINI JJ, 1991, VENTILATORY FAILURE, P269; MARQUETTE CH, 1993, AM REV RESPIR DIS, V147, P211, DOI 10.1164/ajrccm/147.1.211; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; MAUNDER RJ, 1986, JAMA-J AM MED ASSOC, V255, P2463, DOI 10.1001/jama.255.18.2463; MAUNDER RJ, 1986, AM REV RESPIR DIS, V133, P313; MCDONALD JA, 1991, CHEST, V99, pS87, DOI 10.1378/chest.99.3_Supplement.87S; MECKLENBURGH JS, 1986, BRIT J ANAESTH, V58, P1048, DOI 10.1093/bja/58.9.1048; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; MELOT C, 1987, AM REV RESPIR DIS, V136, P1232, DOI 10.1164/ajrccm/136.5.1232; MEYER KC, 1993, NEW ENGL J MED, V329, P1231, DOI 10.1056/NEJM199310213291704; MEYRICK B, 1986, Critical Care Clinics, V2, P405; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MILNE ENC, 1985, AM J ROENTGENOL, V144, P879, DOI 10.2214/ajr.144.5.879; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MONTGOMERY AB, 1989, AM REV RESPIR DIS, V139, P1548, DOI 10.1164/ajrccm/139.6.1548; MONTRAVERS P, 1993, CHEST, V103, P1017, DOI 10.1378/chest.103.4.1017; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P838; MUNOZ C, 1991, EUR J IMMUNOL, V21, P2177, DOI 10.1002/eji.1830210928; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; PARKER JC, 1990, AM REV RESPIR DIS, V142, P321, DOI 10.1164/ajrccm/142.2.321; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PEPE P E, 1986, Critical Care Clinics, V2, P377; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PESENTI A, 1990, INTENS CARE MED, V16, P349, DOI 10.1007/BF01735171; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PETTY TL, 1990, CRIT CARE CLIN, V6, P489; PETTY TL, 1982, CLIN CHEST MED, V3, P3; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; PINSKY M, 1991, AM REV RESPIR DIS, V143, P25, DOI 10.1164/ajrccm/143.1.25; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; REYES A, 1988, AM REV RESPIR DIS, V137, P1062, DOI 10.1164/ajrccm/137.5.1062; RINALDO JE, 1990, CLIN CHEST MED, V11, P621; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; ROGERS PL, 1991, CHEST, V99, P492, DOI 10.1378/chest.99.2.492; RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; RUSSELL JA, 1990, AM REV RESPIR DIS, V141, P659, DOI 10.1164/ajrccm/141.3.659; RUSSELL JA, 1990, AM REV RESPRI DIS, V142, P260; SASSOON CSH, 1990, CRIT CARE CLIN, V6, P605; SCHULLER D, 1991, CHEST, V100, P1068, DOI 10.1378/chest.100.4.1068; SCHUMACKER PT, 1990, CLIN CHEST MED, V11, P715; SCHUSTER DP, 1982, CRIT CARE MED, V10, P625, DOI 10.1097/00003246-198210000-00001; SCHUSTER DP, 1990, AM J MED, V88, P268, DOI 10.1016/0002-9343(90)90153-5; SCHUSTER DP, 1994, AM J RESP CRIT CARE, V149, P245, DOI 10.1164/ajrccm.149.1.8111590; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SEIDENFELD JJ, 1986, AM REV RESPIR DIS, V134, P12; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SIBBALD WJ, 1983, CHEST, V84, P452, DOI 10.1378/chest.84.4.452; SIBBALD WJ, 1981, CHEST, V79, P133, DOI 10.1378/chest.79.2.133; SIBBALD WJ, 1986, J CRIT CARE, V1, P197; SIMMONS RS, 1987, AM REV RESPIR DIS, V135, P924, DOI 10.1164/arrd.1987.135.4.924; SIVAK E D, 1986, Critical Care Clinics, V2, P511; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; SLOTMAN GJ, 1988, J TRAUMA, V28, P648, DOI 10.1097/00005373-198805000-00015; SMITH RC, 1987, INVEST RADIOL, V22, P859, DOI 10.1097/00004424-198711000-00003; SNYDER JV, 1987, OXYGEN TRANSPORT CRI, P358; SPECMARN A, 1993, J CRIT CARE, V8, P43, DOI 10.1016/0883-9441(93)90032-G; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; SPRUNG CL, 1981, AM REV RESPIR DIS, V124, P718; STEINBERG KP, 1993, AM REV RESPIR DIS, V148, P556, DOI 10.1164/ajrccm/148.3.556; STEINBERG KP, 1993, AM REV RESPIR DIS, V147, pA347; STOLLER J K, 1988, Respiratory Care, V33, P454; STOLLER JK, 1990, CLIN CHEST MED, V11, P755; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; SUFFREDINI AF, 1985, CRIT CARE MED, V13, P237, DOI 10.1097/00003246-198504000-00006; SUTER PM, 1994, CHEST, V105, P190, DOI 10.1378/chest.105.1.190; TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552; THARRATT RS, 1988, CHEST, V94, P755, DOI 10.1378/chest.94.4.755; TOCINO IM, 1984, AM J ROENTGENOL, V143, P987, DOI 10.2214/ajr.143.5.987; TOMASHEFSKI JF, 1990, CLIN CHEST MED, V11, P593; TORRES A, 1994, AM J RESP CRIT CARE, V149, P324, DOI 10.1164/ajrccm.149.2.8306025; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; VILLAR J, 1990, CRIT CARE CLIN, V6, P579; WENZEL R, 1991, 31ST INT C ANT AG CH, P294; WIEDEMANN HP, 1984, CHEST, V85, P656, DOI 10.1378/chest.85.5.656; WIEDEMANN HP, 1990, CLIN CHEST MED, V11, P723; WIEDEMANN HP, 1984, CHEST, V85, P537, DOI 10.1378/chest.85.4.537; WOODRING JH, 1985, CRIT CARE MED, V13, P786, DOI 10.1097/00003246-198510000-00003; YU MH, 1993, CRIT CARE MED, V21, P1635, DOI 10.1097/00003246-199311000-00010; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	187	425	439	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					27	37		10.1056/NEJM199501053320106	http://dx.doi.org/10.1056/NEJM199501053320106			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7646623				2022-12-28	WOS:A1995PZ49700006
J	HAMMOND, SK; SORENSEN, G; YOUNGSTROM, R; OCKENE, JK				HAMMOND, SK; SORENSEN, G; YOUNGSTROM, R; OCKENE, JK			OCCUPATIONAL EXPOSURE TO ENVIRONMENTAL TOBACCO-SMOKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PASSIVE SMOKING; HEART-DISEASE; AIR-QUALITY; WORKPLACE; NICOTINE; MONITOR	Objectives.-To measure occupational exposures to environmental tobacco smoke in diverse settings, including offices and production areas, and to evaluate the effectiveness of policies that restrict or ban smoking in the workplace. Design.-Survey. The average weekly concentration of environmental tobacco smoke was measured with passive monitors that sample nicotine, Approximately 25 samplers were placed in each worksite for 1 week. Setting.-Twenty-five Massachusetts worksites, including fire stations, newspaper publishers, textile dyeing plants, and manufacturers of valves, fiberoptics, flight instruments, batteries, adhesives, semiconductor equipment, filters, and tools and dies. Samples were collected in offices and production areas. Main Outcome Measures.-The distribution of nicotine concentrations in various work settings as a function of company smoking policy. These data were interpreted with three approaches: comparing measured concentrations with a published risk assessment; comparing occupational exposures with home exposures; and evaluating the ''cigarette equivalents'' to which workers were exposed. Results.-Worksite smoking policy had a major effect on the nicotine concentrations, which fell from a median of 8.6 mu g/m(3) in the open offices at worksites that allowed smoking to 1.3 mu g/m(3) in sites that restricted smoking, and to 0.3 mu g/m(3) in worksites that banned smoking, The nonoffice workspaces were affected similarly, with median concentrations of 2.3, 0.7, and 0.2 mu g/m(3) at worksites that allowed, restricted, and banned smoking, respectively. Conclusion.-All three evaluation methods indicated that occupational exposure to environmental tobacco smoke presents a substantial risk to workers in the absence of a policy restricting or banning smoking.	UNIV MASSACHUSETTS,SCH MED,DEPT FAMILY & COMMUNITY MED,WORCESTER,MA; UNIV MASSACHUSETTS,SCH MED,DEPT BEHAV MED,WORCESTER,MA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [U01 CA5167, U01 CA51686, U01 CA51688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051688, U01CA051686] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1986, ENV TOBACCO SMOKE ME; COUGHLIN J, 1989, AM J EPIDEMIOL, V130, P696; COULTAS DB, 1990, AM J PUBLIC HEALTH, V80, P988, DOI 10.2105/AJPH.80.8.988; EMMONS KM, 1992, AM J PUBLIC HEALTH, V82, P24, DOI 10.2105/AJPH.82.1.24; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GUERIN MR, 1992, CHEM ENV TOBACCO SMO, P151; HAMMOND SK, 1993, J NATL CANCER I, V85, P474, DOI 10.1093/jnci/85.6.474; HAMMOND SK, 1987, ATMOS ENVIRON, V21, P457, DOI 10.1016/0004-6981(87)90027-8; HAMMOND SK, 1987, ENVIRON SCI TECHNOL, V21, P494, DOI 10.1021/es00159a012; HAMMOND SK, 1989, MEASUREMENT TOXIC RE, P590; HAMMOND SK, 1993, SAMPLING ANAL AIRBON, P317; MATTSON ME, 1989, JAMA-J AM MED ASSOC, V261, P867, DOI 10.1001/jama.261.6.867; MILLAR WJ, 1988, SMOKE WORKPLACE EVAL; MURAMATSU M, 1984, ENVIRON RES, V35, P218, DOI 10.1016/0013-9351(84)90130-0; OLDAKER GB, 1987, ENVIRON SCI TECHNOL, V21, P994, DOI 10.1021/es50001a013; REPACE JL, 1993, RISK ANAL, V13, P463, DOI 10.1111/j.1539-6924.1993.tb00747.x; SCHENKER MB, 1990, 33 HLTH EFF I RES RE; Sorensen G, 1992, Am J Health Promot, V7, P103; SORENSEN G, 1991, AM J PUBLIC HEALTH, V81, P202; SORENSON G, IN PRESS AM J HLTH P; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; TRAVIS CC, 1990, ENVIRON SCI TECHNOL, V21, P415; 1987, IARC MONOGRAPHS EVAL, P38; 1992, EPA600690006F PUBL; 1986, HLTH CONSEQUENCES IN; [No title captured]; 1989, DHHS CDC8984111 PUBL; 1991, CURRENT INTELLIGENCE, V54	29	150	154	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					956	960		10.1001/jama.274.12.956	http://dx.doi.org/10.1001/jama.274.12.956			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV734	7674526				2022-12-28	WOS:A1995RV73400030
J	SICKEL, JZ				SICKEL, JZ			CASTLEMANS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SICKEL, JZ (corresponding author), UNIV ROCHESTER,MED CTR,ROCHESTER,NY 14642, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					776	776		10.1056/NEJM199509213331206	http://dx.doi.org/10.1056/NEJM199509213331206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643885				2022-12-28	WOS:A1995RU80900006
J	ASCHERIO, A; BIELLIK, R; EPSTEIN, A; SNETRO, G; GLOYD, S; AYOTTE, B; EPSTEIN, PR				ASCHERIO, A; BIELLIK, R; EPSTEIN, A; SNETRO, G; GLOYD, S; AYOTTE, B; EPSTEIN, PR			DEATHS AND INJURIES CAUSED BY LAND MINES IN MOZAMBIQUE	LANCET			English	Article							EXPERIENCE; HEALTH	Land mines in Mozambique are still causing death and injuries years after the initial dispute. Since 1980, 3400 people have had an amputation because of land mine injuries, However, there are no direct estimates of the number of deaths or casualties which are not treated in hospitals. In March, 1994, a medical team assembled by Physicians for Human Rights (PHR) conducted household surveys in the province of Manica and in the sub-district of Metuchira, province of Sofala. The object was to assess the frequency and severity of injuries and mortality caused by land mines in the civilian population. We found ratios of 8.1 and 16.7 casualties per 1000 living people in Manica and Metuchira, respectively. The prevalence of amputees was 3.2 per 1000 in Manica, and 2.3 in Metuchira. These figures are several folds higher than suggested by hospital data. The case fatality rate was 48%. Most of the victims were civilians (68%) and were injured by antipersonnel mines (81%). 16% of victims were women, and 7% were under 15 years of age. Our results suggest that the impact of land mines is substantially higher than originally thought.	PHYSICIANS HUMAN RIGHTS,BOSTON,MA 02116; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; WHO,HARARE,ZIMBABWE; MASSACHUSETTS DEPT PUBL HLTH,BOSTON,MA 02116; SAVE THE CHILDREN,WESTPORT,CT; UNIV WASHINGTON,SCH PUBL HLTH,SEATTLE,WA 98195; HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; World Health Organization; Massachusetts Department of Public Health; University of Washington; University of Washington Seattle; Harvard University								Anderson K, 1993, LANDMINES DEADLY LEG; BLAGDEN P, 1993, APR INT COMM RED CRO; BLAGDEN P, 1993, DEFENSE WEEK    0913, P11; CLIFF J, 1993, SOC SCI MED, V36, P843, DOI 10.1016/0277-9536(93)90076-G; CLIFF J, 1988, SOC SCI MED, V27, P717, DOI 10.1016/0277-9536(87)90331-5; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P63; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; SHEEHAN E, 1993, LANDMINE CASUALTIES; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P331, DOI 10.1001/jama.272.5.331; VINES A, 1944, LANDMINES MOZAMBIQUE, P42; 1993, HIDDEN KILLERS GLOBA	12	53	55	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					721	724		10.1016/S0140-6736(95)91501-X	http://dx.doi.org/10.1016/S0140-6736(95)91501-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658871				2022-12-28	WOS:A1995RU81000007
J	GOULD, KL; BUJA, LM; CASSCELLS, W; GOFF, D				GOULD, KL; BUJA, LM; CASSCELLS, W; GOFF, D			NONINVASIVE MANAGEMENT OF CORONARY-ARTERY DISEASE - DISCUSSION	LANCET			English	Discussion							ACUTE MYOCARDIAL-INFARCTION; ADVANCED ATHEROSCLEROSIS; STENOSIS SEVERITY; HEART-DISEASE; FLOW RESERVE; FOLLOW-UP; REGRESSION; ARTERIOGRAPHY; VASODILATION; DEPRESSION		UNIV TEXAS, SCH MED, DEPT PATHOL, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, SCH PUBL HLTH, HOUSTON, TX 77030 USA	University of Texas System; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	GOULD, KL (corresponding author), UNIV TEXAS, SCH MED,DEPT INTERNAL MED,DIV CARDIOL, ROOM 4258 MSB, 6431 FANNIN ST, HOUSTON, TX 77030 USA.			Buja, Louis Maximilian/0000-0001-8386-7029				[Anonymous], 1994, CIRCULATION, V89, P1329; ARMSTRONG ML, 1983, J CLIN INVEST, V71, P104, DOI 10.1172/JCI110738; ATKINSON RL, 1993, JAMA-J AM MED ASSOC, V270, P967, DOI 10.1001/jama.1993.03510080071034; BENZULY KH, 1994, CIRCULATION, V89, P1810, DOI 10.1161/01.CIR.89.4.1810; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BURR ML, 1989, LANCET, V2, P757; DAOUD AS, 1976, ARCH PATHOL LAB MED, V100, P372; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DEMER LL, 1989, CIRCULATION, V79, P825, DOI 10.1161/01.CIR.79.4.825; DIAMOND GA, 1990, J AM COLL CARDIOL, V16, P1017, DOI 10.1016/S0735-1097(10)80356-0; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GOULD KL, 1986, J AM COLL CARDIOL, V7, P775, DOI 10.1016/S0735-1097(86)80336-9; GOULD KL, 1991, J NUCL MED, V32, P579; GOULD KL, 1992, AM J CARDIOL, V69, P845, DOI 10.1016/0002-9149(92)90781-S; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459, DOI 10.1016/S0735-1097(10)80078-6; GOULD KL, 1994, CIRCULATION, V90, P1558, DOI 10.1161/01.CIR.90.3.1558; GOULD KL, 1991, CIRCULATION, V84, pI22; GOULD KL, IN PRESS JAMA; GOULD KL, 1991, CORONARY ARTERY STEN, P7; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; IRIBARREN C, 1995, JAMA-J AM MED ASSOC, V273, P1926, DOI 10.1001/jama.273.24.1926; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KARPE F, 1994, ATHEROSCLEROSIS, V106, P83, DOI 10.1016/0021-9150(94)90085-X; KIRKEEIDE RL, 1986, J AM COLL CARDIOL, V7, P103, DOI 10.1016/S0735-1097(86)80266-2; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDUZZI P, 1992, CIRCULATION, V86, P121; SACKS FM, 1994, LANCET, V344, P1182, DOI 10.1016/S0140-6736(94)90506-1; SEILER C, 1992, CIRCULATION, V85, P1987, DOI 10.1161/01.CIR.85.6.1987; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; STEINBERG D, 1993, NEW ENGL J MED, V328, P1487, DOI 10.1056/NEJM199305203282012; STEWART BF, 1994, J AM COLL CARDIOL, V23, P899, DOI 10.1016/0735-1097(94)90635-1; SUPERKO HR, 1994, CIRCULATION, V90, P1056, DOI 10.1161/01.CIR.90.2.1056; VARTIAINEN E, 1994, BRIT MED J, V309, P445, DOI 10.1136/bmj.309.6952.445; VESSELINOVITCH D, 1976, ATHEROSCLEROSIS, V23, P155, DOI 10.1016/0021-9150(76)90092-7; WEIDNER G, 1992, ANN INTERN MED, V117, P820, DOI 10.7326/0003-4819-117-10-820; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302	51	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 16	1995	346	8977					750	753		10.1016/S0140-6736(95)91509-5	http://dx.doi.org/10.1016/S0140-6736(95)91509-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658879				2022-12-28	WOS:A1995RU81000015
J	SEDVALL, G; FARDE, L				SEDVALL, G; FARDE, L			CHEMICAL BRAIN ANATOMY IN SCHIZOPHRENIA	LANCET			English	Article							LIVING HUMAN-BRAIN; POSITRON EMISSION TOMOGRAPHY; DOPAMINE RECEPTOR-BINDING; RAT-BRAIN; CHOLECYSTOKININ; CLOZAPINE; OCCUPANCY; PET; NEUROLEPTICS; HIPPOCAMPUS				SEDVALL, G (corresponding author), KAROLINSKA HOSP,DEPT CLIN NEUROSCI,PSYCHIAT SECT,S-17176 STOCKHOLM,SWEDEN.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041205, R01MH044814, R37MH044814] Funding Source: NIH RePORTER; NIMH NIH HHS [MH41205, MH44814] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRENE S, 1995, NEUROSCIENCE, V67, P37, DOI 10.1016/0306-4522(95)00037-J; CALSSON A, 1957, PSYCHOTROPIC DRUGS; CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140; Carlsson Arvid, 1994, P161; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; COON H, 1993, AM J HUM GENET, V52, P327; COSTA DP, 1994, BRIT J PSYCHIAT, V164, P16; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; DELAY J, 1952, C AL NEUROL LANGEU F; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; FARDE L, 1986, SCIENCE, V231, P258, DOI 10.1126/science.2867601; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; FARMERY SM, 1985, LIFE SCI, V36, P473, DOI 10.1016/0024-3205(85)90260-7; FERRIER IN, 1983, LIFE SCI, V33, P475; GATTAZ WF, 1982, ARCH PSYCHIAT NERVEN, V231, P221, DOI 10.1007/BF00343292; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GOLDMANRAKIC P, 1994, NEUROPSYCHOPHARMACOL, V10, pS22; HALL H, 1995, NEUROPSYCHOPHARMACOL, V11, P245; HALLDIN C, 1995, J NUCL MED, V36, P1275; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; HESS EJ, 1987, LIFE SCI, V40, P1487, DOI 10.1016/0024-3205(87)90381-X; HOFMANN A, 1955, SANDOZ J MED SCI, V2, P117; HURD YL, 1995, NEUROSCIENCE, V65, P571; KARLSSON P, IN PRESS PSYCHOPHARM; KARLSSON P, 1994, DEC ACNP ANN M SAN J, P11; KEBABIAN JW, 1972, P NATL ACAD SCI USA, V69, P2145, DOI 10.1073/pnas.69.8.2145; Kendler K. S., 1987, PSYCHOPHARMACOLOGY 3, P705; KERWIN RW, 1988, LANCET, V1, P583; KLINE NATHAN S., 1954, ANN NEW YORK ACAD SCI, V59, P107, DOI 10.1111/j.1749-6632.1954.tb45922.x; KORNHUBER J, 1989, J NEURAL TRANSM, V75, P1, DOI 10.1007/BF01250639; LEE T, 1978, NATURE, V274, P797; LIDOW MS, 1994, P NATL ACAD SCI USA, V91, P4353, DOI 10.1073/pnas.91.10.4353; LINDEFORS N, 1993, PROG NEUROBIOL, V40, P671, DOI 10.1016/0301-0082(93)90010-P; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; MEADORWOODRUFF JH, 1994, NEUROPSYCHOPHARMACOL, V10, P239, DOI 10.1038/npp.1994.27; MONTGOMERY SA, 1988, PSYCHOL MED, V18, P593, DOI 10.1017/S0033291700008278; NORDSTROM AL, 1993, PSYCHOPHARMACOLOGY, V110, P365, DOI 10.1007/BF02251294; NORDSTROM AL, IN PRESS PSYCHIATR R; NYBACK H, 1968, J PHARMACOL EXP THER, V162, P294; NYBERG S, 1993, PSYCHOPHARMACOLOGY, V110, P265, DOI 10.1007/BF02251280; OWEN F, 1978, LANCET, V2, P223, DOI 10.1016/S0140-6736(78)91740-3; PAULI S, IN PRESS EUROP ARCH; PAULI S, 1994, NEUROPSYCHOPHARMACOL, V10; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; PLETSCHER A, 1955, SCIENCE, V122, P374, DOI 10.1126/science.122.3165.374; RANDRUP A, 1967, PSYCHOPHARMACOLOGIA, V11, P300, DOI 10.1007/BF00404607; RAPPAPORT MS, 1993, BRAIN RES, V616, P242, DOI 10.1016/0006-8993(93)90215-9; REYNOLDS GP, 1994, J NEUROCHEM, V63, P1576; REYNTJENS A, 1986, DRUG DEVELOP RES, V8, P205, DOI 10.1002/ddr.430080124; SCHALLING M, 1990, P NATL ACAD SCI USA, V87, P8427, DOI 10.1073/pnas.87.21.8427; Schwartz J-C, 1992, SEMIN NEUROSCI, V4, P99, DOI 10.1016/1044-5765(92)90008-P; SEDVALL G, 1986, ARCH GEN PSYCHIAT, V43, P995; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SHAIKH S, 1993, LANCET, V341, P116, DOI 10.1016/0140-6736(93)92594-J; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; VANROSSUM JM, 1966, ARCH INT PHARMACOD T, V160, P492; WAGNER HN, 1983, SCIENCE, V221, P1264, DOI 10.1126/science.6604315; WALAAS SI, 1984, J NEUROSCI, V4, P84; WIESEL FA, 1994, PSYCHOPHARMACOLOGY, V114, P31, DOI 10.1007/BF02245441; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495; WOOLLEY DW, 1954, P NATL ACAD SCI USA, V40, P228, DOI 10.1073/pnas.40.4.228; [No title captured]	64	100	101	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					743	749		10.1016/S0140-6736(95)91508-7	http://dx.doi.org/10.1016/S0140-6736(95)91508-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658878				2022-12-28	WOS:A1995RU81000014
J	KUHN, R; SCHWENK, F; AGUET, M; RAJEWSKY, K				KUHN, R; SCHWENK, F; AGUET, M; RAJEWSKY, K			INDUCIBLE GENE TARGETING IN MICE	SCIENCE			English	Article							INVIVO EXPRESSION; MX GENE; INTERFERON; RECOMBINATION; BACTERIOPHAGE-P1; CELLS; VIRUS	A method of gene targeting that allows the inducible inactivation of a target gene in mice is presented. The method uses an interferon-responsive promoter to control the expression of Cre recombinase, Here, Cre was used to delete a segment of the DNA polymerase beta gene flanked by loxP recombinase recognition sites. Deletion was complete in liver and nearly complete in lymphocytes within a few days, whereas partial deletion was obtained in other tissues. This method can be used for the inducible inactivation of any other gene in vivo.	UNIV ZURICH, INST MOLEC BIOL 1, CH-8093 ZURICH, SWITZERLAND	University of Zurich	KUHN, R (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Rajewsky, Klaus/0000-0002-6633-6370				ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHANG KC, 1990, ARCH VIROL, V110, P151, DOI 10.1007/BF01311285; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; de Clercq E, 1980, Antibiot Chemother (1971), V27, P251; DOUGHERTY TF, 1952, PHYSIOL REV, V32, P379, DOI 10.1152/physrev.1952.32.4.379; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; GRESSER I, 1977, CELL IMMUNOL, V34, P406, DOI 10.1016/0008-8749(77)90262-3; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KUHN R, UNPUB; LOHLER J, UNPUB; MELTON DW, 1994, BIOESSAYS, V16, P633, DOI 10.1002/bies.950160907; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STAEHELI P, 1986, MOL CELL BIOL, V6, P4770, DOI 10.1128/MCB.6.12.4770; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	21	1485	1552	1	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1427	1429		10.1126/science.7660125	http://dx.doi.org/10.1126/science.7660125			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660125				2022-12-28	WOS:A1995RT80600046
J	YOST, HJ				YOST, HJ			VERTEBRATE LEFT-RIGHT DEVELOPMENT	CELL			English	Review							LEFT-RIGHT ASYMMETRY; LATERALITY; MOUSE; GENE				YOST, HJ (corresponding author), UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA.							AFZELIUS B A, 1976, Science (Washington D C), V193, P317; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; BROWN NA, 1990, DEVELOPMENT, V109, P1; BURN J, 1991, CIBA F SYMP, V162, P282; CASEY B, 1993, NAT GENET, V5, P403, DOI 10.1038/ng1293-403; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; DANOS MC, 1995, DEVELOPMENT, V121, P1467; Davidson RJ, 1995, BRAIN ASYMMETRY; FUJINAGA M, 1994, DEV BIOL, V162, P558, DOI 10.1006/dbio.1994.1109; GERHART J, 1989, DEVELOPMENT, V107, P37; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; ITASAKI N, 1991, ANAT EMBRYOL, V183, P29; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; MCGRATH J, 1992, GENOMICS, V14, P643, DOI 10.1016/S0888-7543(05)80163-6; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; PRIESS JR, 1994, CURR OPIN GENET DEV, V4, P563, DOI 10.1016/0959-437X(94)90073-C; SEO JW, 1992, CIRCULATION, V86, P642, DOI 10.1161/01.CIR.86.2.642; STALSBER.H, 1969, DEV BIOL, V19, P109, DOI 10.1016/0012-1606(69)90051-7; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; Wilhelmi H, 1921, ARCH ENTWICKLUNG ORG, V48, P517, DOI 10.1007/BF02554577; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YOST HJ, 1991, CIBA F SYMP, V162, P165	26	62	62	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					689	692		10.1016/0092-8674(95)90464-6	http://dx.doi.org/10.1016/0092-8674(95)90464-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671297	Bronze			2022-12-28	WOS:A1995RU75500002
J	RHODES, J; CHEN, H; HALL, SR; BEESLEY, JE; JENKINS, DC; COLLINS, P; ZHENG, B				RHODES, J; CHEN, H; HALL, SR; BEESLEY, JE; JENKINS, DC; COLLINS, P; ZHENG, B			THERAPEUTIC POTENTIATION OF THE IMMUNE-SYSTEM BY COSTIMULATORY SCHIFF-BASE-FORMING DRUGS	NATURE			English	Article							T-CELL ACTIVATION; ANTIGEN; LYMPHOCYTES; EXPRESSION; RESPONSES; RECEPTOR; CLONING; ACID	IMMUNE responses are orchestrated by CD4 T lymphocytes, which receive a cognitive signal when clonally distributed receptors are occupied by major histocompatibility complex (MHC) class II-bound peptides on antigen-presenting cells (APCs)(1,2). The APCs provide costimulatory signals, through macromolecules such as CD80, that regulate outcomes in terms of T-cell activation or anergy(3-6). We have studied essential complementary chemical events in the form of Schiff base formation between carbonyls and amines that are constitutively expressed on presenting cell and T-cell surfaces(7-9) and provide a new target for manipulation of immune responses(10,11). Here we show that small Schiff base-forming molecules can substitute for the physiological donor of carbonyl groups and provide a costimulatory signal to CD4 Th-cells through a mechanism that activates clofilium-sensitive K+ and Na+ transport. One such molecule, tucaresol, enhances CD4 Th-cell responses, selectively favouring a Th1-type profile of cytokine production, in vivo tucaresol potently enhances CD4 Th-cell priming and CD8 cytotoxic T-cell priming to viral antigens, and has substantial therapeutic activity in murine models of disease.	WELLCOME RES LABS,CORE SUPPORT GRP,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,EXPTL BIOL GRP,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories	RHODES, J (corresponding author), WELLCOME RES LABS,MOLEC IMMUNOL GRP,BECKENHAM BR3 3BS,KENT,ENGLAND.							AMARAL MC, 1993, IMMUNOLOGY, V79, P24; ATTALI B, 1992, J BIOL CHEM, V267, P8650; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GAO XM, 1990, J IMMUNOL, V144, P2883; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; Hall T.A., 1986, PRINCIPLES ANAL ELEC, P219; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Hedrick Stephen M., 1993, P383; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MOSMANN TR, 1992, ANNU REV IMMUNOL, V7, P145; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; RHODES J, 1995, ANN NY ACAD SCI, V754, P169, DOI 10.1111/j.1749-6632.1995.tb44450.x; RHODES J, 1990, J IMMUNOL, V145, P463; RHODES J, 1989, J IMMUNOL, V143, P1482; ROLAN PE, 1993, BRIT J CLIN PHARMACO, V35, P419, DOI 10.1111/j.1365-2125.1993.tb04160.x; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELGRADE MK, 1984, J GEN VIROL, V65, P515, DOI 10.1099/0022-1317-65-3-515; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Weiss Arthur, 1993, P467; Wroblewski Joanna, 1993, P317, DOI 10.1017/CBO9780511600371.023; ZHENG B, 1992, SCIENCE, V256, P1560, DOI 10.1126/science.1598588	25	118	130	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					71	75		10.1038/377071a0	http://dx.doi.org/10.1038/377071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659167				2022-12-28	WOS:A1995RT72500059
J	SCHARSCHMIDT, BF				SCHARSCHMIDT, BF			HEPATITIS-E - A VIRUS IN WAITING	LANCET			English	Editorial Material							NON-B HEPATITIS; NON-A		UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SCHARSCHMIDT, BF (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.							BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KHUROO MS, 1995, LANCET, V315, P1025; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; LOK ASF, 1994, J HEPATOL, V20, P567, DOI 10.1016/S0168-8278(05)80341-1; NANDA SK, 1995, GASTROENTEROLOGY, V108, P225, DOI 10.1016/0016-5085(95)90028-4; PAUL DA, 1994, J INFECT DIS, V169, P801, DOI 10.1093/infdis/169.4.801; PURDY MA, 1994, GASTROENTEROL CLIN N, V23, P537; REYES GR, 1990, SCIENCE, V24, P1335; VASHWANATHAN R, 1957, INDIAN J MED RES S, V45, P1; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L	11	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					519	520		10.1016/S0140-6736(95)91376-9	http://dx.doi.org/10.1016/S0140-6736(95)91376-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658774				2022-12-28	WOS:A1995RQ98600004
J	SIMON, MN; DEVIRGILIO, C; SOUZA, B; PRINGLE, JR; ABO, A; REED, SI				SIMON, MN; DEVIRGILIO, C; SOUZA, B; PRINGLE, JR; ABO, A; REED, SI			ROLE FOR THE RHO-FAMILY GTPASE CDC42 IN YEAST MATING-PHEROMONE SIGNAL PATHWAY	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE GENE; CELL-DIVISION-CYCLE; MOLECULAR-CLONING; BINDING PROTEIN; HUMAN HOMOLOG; POLARITY; ENCODES; KINASE; G25K	IN the budding yeast Saccharomyces cerevisiae, the process of conjugation of haploid cells of genotype MAT alpha and MAT alpha to form MAT alpha/alpha diploids is triggered by pheromones produced by each mating type. These pheromones stimulate a cellular response by interaction with receptors linked to a heterotrimeric G protein. Although genetic analysis indicates that the pheromone signal is transmitted through the G beta gamma dimer, the initial target(s) of G protein activation remain to be determined. Temperature-sensitive cells with mutations of the CDC24 and CDC42 genes, which are incapable of budding and of generating cell polarity at the restrictive temperature(1-3), are also unable to mate(4). Cdc24 acts as a guanylyl-nucleotide-exchange factor for the Rho-type GTPase Cdc42(5), which has been shown to be a fundamental component of the molecular machinery controlling morphogenesis in eukaryotic cells(6-10). Therefore, the inability of cdc24 and cdc42 mutants to mate has been presumed to be due to a requirement for generation of cell polarity and related morphogenetic events during conjugation, But here we show that Cdc42 has a direct signalling role in the mating-pheromone response between the G protein and the downstream protein kinase cascade.	SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill			De Virgilio, Claudio/B-4707-2012	De Virgilio, Claudio/0000-0001-8826-4323				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1992, YEAST, V8, P315, DOI 10.1002/yea.320080409; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEN WN, 1993, J BIOL CHEM, V268, P13280; EIBLE R, 1989, BIOTECHNIQUES, V13, P18; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1973, GENETICS, V74, P267; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	30	189	190	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					702	705		10.1038/376702a0	http://dx.doi.org/10.1038/376702a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651520				2022-12-28	WOS:A1995RQ67200064
J	HAMILTON, SR; LIU, B; PARSONS, RE; PAPADOPOULOS, N; JEN, J; POWELL, SM; KRUSH, AJ; BERK, T; COHEN, Z; TETU, B; BURGER, PC; WOOD, PA; TAQI, F; BOOKER, SV; PETERSEN, GM; OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; VOGELSTEIN, B; KINZLER, KW				HAMILTON, SR; LIU, B; PARSONS, RE; PAPADOPOULOS, N; JEN, J; POWELL, SM; KRUSH, AJ; BERK, T; COHEN, Z; TETU, B; BURGER, PC; WOOD, PA; TAQI, F; BOOKER, SV; PETERSEN, GM; OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; VOGELSTEIN, B; KINZLER, KW			THE MOLECULAR-BASIS OF TURCOTS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; NONPOLYPOSIS COLORECTAL-CANCER; AUTOSOMAL DOMINANT; GARDNERS-SYNDROME; COLON-CANCER; BRAIN-TUMORS; MUTATIONS; GENE; LOCUS; IDENTIFICATION	Background. Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and multiple colorectal adenomas. We attempted to define the syndrome at the molecular level. Methods. Fourteen families with Turcot's syndrome identified in two registries and the family originally described by Turcot and colleagues were studied. Germ-line mutations in the adenomatous polyposis coli (APC) gene characteristic of familial adenomatous polyposis were evaluated, as well as DNA replication errors and germline mutations in nucleotide mismatch-repair genes characteristic of hereditary nonpolyposis colorectal cancer. In addition, a formal risk analysis for brain tumors in familial adenomatous polyposis was performed with a registry data base. Results. Genetic abnormalities were identified in 13 of the 14 registry families. Germ-line APC mutations were detected in 10. The predominant brain tumor in these 10 families was medulloblastoma (11 of 14 patients, or 79 percent), and the relative risk of cerebellar medulloblastoma in patients with familial adenomatous polyposis was 92 times that in the general population (95 percent confidence interval, 29 to 269; P<0.001). In contrast, the type of brain tumor in the other four families was glioblastoma multiforme. The glioblastomas and colorectal tumors in three of these families and in the original family studied by Turcot had replication errors characteristic of hereditary nonpolyposis colorectal cancer. In addition, germ-line mutations in the mismatch-repair gene hMLH1 or hPMS2 were found in two families. Conclusions. The association between brain tumors and multiple colorectal adenomas can result from two distinct types of germ-line defects: mutation of the APC gene or mutation of a mismatch-repair gene. Molecular diagnosis may contribute to the appropriate care of affected patients.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV MED GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,DIV NEUROPATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; MT SINAI HOSP,FAMILIAL GASTROINTESTINAL CANC REGISTRY,TORONTO,ON M5G 1X5,CANADA; HOTEL DIEU QUEBEC,ANAT PATHOL LAB,QUEBEC CITY,PQ,CANADA; STRATTON VET AFFAIRS MED CTR,DEPT MED,DIV MED ONCOL,ALBANY,NY; ALBANY MED COLL,ALBANY,NY	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Laval University; Albany Medical College	HAMILTON, SR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,DIV GASTROINTESTINAL & LIVER PATHOL,ROSS BLDG,RM 632,BALTIMORE,MD 21205, USA.		Papadopoulos, Nickolas/K-7272-2012	Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345, R01CA045831, R01CA047527] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, CA47527, CA45831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAUGHMAN FA, 1969, NEW ENGL J MED, V281, P1345, DOI 10.1056/NEJM196912112812407; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUSSEY HJR, 1975, FAMILIAL POLYPOSIS C, P23; BUSSEY HJR, 1975, FAMILIAL POLYPOSIS C, P10; COHEN SB, 1982, J MED GENET, V19, P193, DOI 10.1136/jmg.19.3.193; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COSTA OL, 1987, DIS COLON RECTUM, V30, P391, DOI 10.1007/BF02555461; CRAIL H W, 1949, U S Nav Med Bull, V49, P123; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, pA166; GIARDIELLO FM, 1991, J PEDIATR-US, V119, P766, DOI 10.1016/S0022-3476(05)80297-5; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; GIARDIELLO FM, 1993, GASTROENTEROLOGY, V105, P1550, DOI 10.1016/0016-5085(93)90164-8; GIARDIELLO FM, 1991, GUT, V32, P1170, DOI 10.1136/gut.32.10.1170; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GURBUZ AK, 1994, GUT, V35, P377, DOI 10.1136/gut.35.3.377; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; HAMILTON SR, 1979, GASTROENTEROLOGY, V77, P1252; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ITOH H, 1993, INT J COLORECTAL DIS, V8, P87, DOI 10.1007/BF00299334; JARVIS L, 1988, DIS COLON RECTUM, V31, P907, DOI 10.1007/BF02554859; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KIKUCHI T, 1993, CANCER RES, V53, P957; KIM HG, 1994, AM J PATHOL, V145, P148; KINGSTON JE, 1983, ARCH DIS CHILD, V58, P959, DOI 10.1136/adc.58.12.959; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KROPILAK M, 1989, DIS COLON RECTUM, V32, P778, DOI 10.1007/BF02562128; LASSER DM, 1994, NEUROLOGY, V44, P1083, DOI 10.1212/WNL.44.6.1083; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIS JH, 1983, CANCER, V51, P524, DOI 10.1002/1097-0142(19830201)51:3<524::AID-CNCR2820510326>3.0.CO;2-I; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MCKUSICK VA, 1962, JAMA-J AM MED ASSOC, V182, P271, DOI 10.1001/jama.1962.03050420047012; MINAMI T, 1990, JPN J MED, V29, P391; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NEWTON HB, 1991, CANCER, V68, P1633, DOI 10.1002/1097-0142(19911001)68:7<1633::AID-CNCR2820680728>3.0.CO;2-1; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARAF F, 1994, GASTROEN CLIN BIOL, V18, P297; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PIERCE E R, 1970, Clinical Genetics, V1, P65; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RADIN DR, 1984, AM J ROENTGENOL, V142, P475, DOI 10.2214/ajr.142.3.475; ROCHLITZ CF, 1993, BRIT J CANCER, V68, P519, DOI 10.1038/bjc.1993.379; ROSENFELD M, 1991, Neurology, V41, P304; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; RUTZ HP, 1991, J NEUROSURG, V74, P813, DOI 10.3171/jns.1991.74.5.0813; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TITHECOTT GA, 1989, J PEDIATR SURG, V24, P1189, DOI 10.1016/S0022-3468(89)80117-4; TOPS CMJ, 1992, AM J MED GENET, V43, P888, DOI 10.1002/ajmg.1320430528; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; TURCOT J, 1959, Dis Colon Rectum, V2, P465, DOI 10.1007/BF02616938; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#	72	781	821	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					839	847		10.1056/NEJM199503303321302	http://dx.doi.org/10.1056/NEJM199503303321302			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7661930				2022-12-28	WOS:A1995QP22800002
J	HOOTON, TM; WINTER, C; TIU, F; STAMM, WE				HOOTON, TM; WINTER, C; TIU, F; STAMM, WE			RANDOMIZED COMPARATIVE TRIAL AND COST-ANALYSIS OF 3-DAY ANTIMICROBIAL REGIMENS FOR TREATMENT OF ACUTE CYSTITIS IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE; DOUBLE-BLIND; COLONIZATION; AMOXYCILLIN; MANAGEMENT; THERAPY; ADULTS	Objective.-To determine the efficacy, safety, and costs associated with four different 3-day regimens for the treatment of acute uncomplicated cystitis in women. Design.-A prospective randomized trial with a cost analysis. Study Population.-Women with acute cystitis attending a student health center. Interventions.-Treatment with 3-day oral regimens of trimethoprim-sulfamethoxazole, 160 mg/800 mg twice daily, macrocrystalline nitrofurantoin, 100 mg four times daily, cefadroxil, 500 mg twice daily, or amoxicillin, 500 mg three times daily. Results.-Six weeks after treatment, 32 (82%) of 39 women treated with trimethoprim-sulfamethoxazole were cured compared with 22 (61%) of 36 treated with nitrofurantoin (P=.04 vs trimethoprim-sulfamethoxazole), 21 (66%) of 32 treated with cefadroxil (P=.11 vs trimethoprim-sulfamethoxazole), and 28 (67%) of 42 treated with amoxicillin (P=.11 vs trimethoprim-sulfamethoxazole). Persistence of significant bacteriuria was less common with trimethoprim-sulfamethoxazole (3%) and cefadroxil (0%) compared with nitrofurantoin (16%; P=.05 vs trimethoprim-sulfamethoxazole) and amoxicillin (14%; P=.11 vs trimethoprim-sulfamethoxazole). Persistence of bacteriuria was associated with amoxicillin-resistant strains in the amoxicillin group but nitrofurantoin-susceptible strains in the nitrofurantoin group, Trimethoprim-sulfamethoxazole was more successful in eradicating Escherichia coli from rectal cultures soon after therapy and from urethral and vaginal cultures at all follow-up visits compared with the other treatment regimens. Adverse effects were reported by 16 (35%) of 46 patients receiving trimethoprim-sulfamethoxazole, 18 (43%) of 42 receiving nitrofurantoin, 12 (30%) of 40 receiving cefadroxil, and 13 (25%) of 52 receiving amoxicillin. The mean costs per patient were less with trimethoprim-sulfamethoxazole ($114) and amoxicillin ($131) compared with nitrofurantoin ($155) and cefadroxil ($155). Conclusions.-A 3-day regimen of trimethoprim-sulfamethoxazole is more effective and less expensive than 3-day regimens of nitrofurantoin, cefadroxil, or amoxicillin for treatment of uncomplicated cystitis in women. The increased efficacy of trimethoprim-sulfamethoxazole is likely related to its antimicrobial effects against E coli in the rectum, urethra, and vagina.			HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED,MADISON CLIN,1001 BROADWAY,SUITE 206,SEATTLE,WA 98122, USA.							BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; Berg A O, 1991, J Am Board Fam Pract, V4, P327; CHARLTON CAC, 1976, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.6002.124; COUNTS GW, 1982, REV INFECT DIS, V4, P484; FAIR WR, 1980, J UROLOGY, V123, P717, DOI 10.1016/S0022-5347(17)56104-2; FIHN SD, 1988, ANN INTERN MED, V108, P350, DOI 10.7326/0003-4819-108-3-350; GOSSIUS G, 1984, SCAND J INFECT DIS, V16, P373, DOI 10.3109/00365548409073963; GREENBERG RN, 1986, J INFECT DIS, V153, P277, DOI 10.1093/infdis/153.2.277; HENNING C, 1982, J ANTIMICROB CHEMOTH, V10, P73, DOI 10.1093/jac/10.suppl_B.73; HOOTON TM, 1991, MED CLIN N AM, V75, P339, DOI 10.1016/S0025-7125(16)30458-8; HOOTON TM, 1991, ANTIMICROB AGENTS CH, V35, P1479, DOI 10.1128/AAC.35.7.1479; JOHNSON JR, 1989, ANN INTERN MED, V111, P906, DOI 10.7326/0003-4819-111-11-906; KALOWSKI S, 1974, NEW ENGL J MED, V290, P385, DOI 10.1056/NEJM197402142900708; KUNIN CM, 1994, CLIN INFECT DIS, V18, P1, DOI 10.1093/clinids/18.1.1; LOHR JA, 1981, J PEDIATR-US, V99, P980, DOI 10.1016/S0022-3476(81)80037-6; NORRBY SR, 1990, REV INFECT DIS, V12, P458; RAPOPORT J, 1981, BRIT MED J, V283, P1302, DOI 10.1136/bmj.283.6302.1302; RUBERTO U, 1984, J PEDIATR-US, V104, P483, DOI 10.1016/S0022-3476(84)81124-5; SANDBERG T, 1985, SCAND J INFECT DIS, V17, P83, DOI 10.3109/00365548509070425; SIGURDSSON JA, 1983, ACTA MED SCAND, V213, P55; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; TRIENEKENS TAM, 1989, BRIT MED J, V299, P1319, DOI 10.1136/bmj.299.6711.1319; WALKER RC, 1991, MAYO CLIN PROC, V66, P1249, DOI 10.1016/S0025-6196(12)62477-X; WINBERG J, 1993, PEDIATR NEPHROL, V7, P509, DOI 10.1007/BF00852528; WINBERG J, 1993, INFECTION, V21, P201, DOI 10.1007/BF01728887; 1993, 1993 REED BOOK	26	107	110	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					41	45						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ042	7654268				2022-12-28	WOS:A1995PZ04200026
J	HOEY, T; WEINZIERL, ROJ; GILL, G; CHEN, JL; DYNLACHT, BD; TJIAN, R				HOEY, T; WEINZIERL, ROJ; GILL, G; CHEN, JL; DYNLACHT, BD; TJIAN, R			MOLECULAR-CLONING AND FUNCTIONAL-ANALYSIS OF DROSOPHILA TAF110 REVEAL PROPERTIES EXPECTED OF COACTIVATORS	CELL			English	Article							TRANSCRIPTION FACTOR; SYNERGISTIC ACTIVATION; PREINITIATION COMPLEX; BINDING-PROTEIN; TFIID COMPLEX; GENE; SP1; INVITRO; EXPRESSION; MECHANISM	The general transcription factor TFIID is a multiprotein complex containing the TATA-binding protein and several associated factors (TAFs), some of which may function as coactivators that are essential for activated, but not basal, transcription. Here we describe the isolation and characterization of the first gene encoding a TAF protein. The deduced amino acid sequence of TAF110 revealed the presence of several glutamine- and serine/threonine-rich regions reminiscent of the protein-protein interaction domains of the regulatory transcription factor Spl that are involved in transcription activation and multimerization. In both Drosophila cells and yeast, TAF110 specifically interacts with the glutamine-rich activation domains of Sp1. Moreover, purified Spl selectively binds recombinant TAF110 in vitro. These findings taken together suggest that TAF110 may function as a coactivator by serving as a site of protein-protein contact between activators like Sp1 and the TFIID complex.			HOEY, T (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Weinzierl, Robert/0000-0003-4095-9921				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; DYNLACHT BD, 1991, GENE DEV, V66, P563; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SKELLY S, 1987, P NATL ACAD SCI USA, V84, P8365, DOI 10.1073/pnas.84.23.8365; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	53	551	563	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					247	260		10.1016/0092-8674(93)90664-C	http://dx.doi.org/10.1016/0092-8674(93)90664-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678780				2022-12-28	WOS:A1993KK03800009
J	NODWELL, JR; GREENBLATT, J				NODWELL, JR; GREENBLATT, J			RECOGNITION OF BOXA ANTITERMINATOR RNA BY THE ESCHERICHIA-COLI ANTITERMINATION FACTORS NUSB AND RIBOSOMAL-PROTEIN S10	CELL			English	Article							ESCHERICHIA-COLI; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; ANTI-TERMINATION; NUCLEOTIDE-SEQUENCE; GENE PROTEIN; TRANSCRIPTION; REGION; SITE; OPERON	The boxA sequences of the E. coli ribosomal RNA (rrn) operons are sufficient to cause RNA polymerase to read through Rho-dependent transcriptional terminators. We show that a complex of the transcription antitermination factors NusB and ribosomal protein S10 interacts specifically with box A RNA. Neither Nus B nor S10 binds boxA RNA on its own, and neither NusA nor NusG affects the interaction of the NusB-S10 complex with boxA RNA. Mutations in boxA that impair its anti-termination activity compromise its interaction with NusB and S10, suggesting that ribosomal protein S10 regulates the synthesis of ribosomal RNA in bacteria. RNA containing the closely related boxA sequence from the bacteriophage lambda nutR site is not stably bound by NusB and S10. This probably explains why antitermination in phage lambda depends on the phage lambda N protein and the boxB component of the nut site, in addition to boxA.			NODWELL, JR (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA.							ALBRECHTSEN B, 1990, J MOL BIOL, V213, P123, DOI 10.1016/S0022-2836(05)80125-1; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BREWSTER JM, 1981, J BACTERIOL, V148, P897, DOI 10.1128/JB.148.3.897-903.1981; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; FRIEDMAN DI, 1976, VIROLOGY, V73, P119, DOI 10.1016/0042-6822(76)90066-0; GEORGOPOULOS CP, 1980, MOL GEN GENET, V179, P55, DOI 10.1007/BF00268446; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1984, CAN J BIOCHEM CELL B, V62, P79, DOI 10.1139/o84-012; GREENBLATT J, 1987, RNA POLYM REGULATION, P357; HOLBEN WE, 1984, P NATL ACAD SCI-BIOL, V81, P6789, DOI 10.1073/pnas.81.21.6789; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LI J, 1992, J BIOL CHEM, V267, P6012; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; MASON S, 1992, IN PRESS J BIOL CHEM; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN EA, 1980, CELL, V21, P257, DOI 10.1016/0092-8674(80)90133-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLINS PO, 1981, CELL, V26, P205, DOI 10.1016/0092-8674(81)90303-2; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; OLSON ER, 1982, CELL, V31, P61, DOI 10.1016/0092-8674(82)90405-6; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHAUER AT, 1987, J MOL BIOL, V194, P679, DOI 10.1016/0022-2836(87)90245-2; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SHARROCK RA, 1984, J BACTERIOL, V163, P704; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; WHALEN W A, 1990, New Biologist, V2, P975; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4515	42	132	135	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					261	268		10.1016/0092-8674(93)90665-D	http://dx.doi.org/10.1016/0092-8674(93)90665-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678781				2022-12-28	WOS:A1993KK03800010
J	GILLICK, MR				GILLICK, MR			A BROADER ROLE FOR ADVANCE MEDICAL PLANNING	ANNALS OF INTERNAL MEDICINE			English	Article							DIRECTIVES; PATIENT; OLDER; TRIAL	Advance planning for future illness should be broadened from medical care in the event of incompetence to all medical care for the elderly. To plan effectively, patients need an assessment of their overall medical condition: whether they are robust, frail, demented, or dying. They need to understand the kinds of complications often engendered by aggressive treatment, given their underlying status. Given information about their circumstances and their capacity to withstand medical interventions, patients, together with their physicians, need to formulate broad goals for medical care. There are significant barriers to implementing this scheme, but pressure from patients, structural changes in the practice of medicine that create incentives for planning, and educational strategies, including videotaped interviews and role-playing exercises, can facilitate this form of preventive medicine.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	GILLICK, MR (corresponding author), BETH ISRAEL HOSP, HEBREW REHABIL CTR AGED, DEPT MED ADM, 1200 CTR ST, BOSTON, MA 02131 USA.							AINSLIE N, 1994, ARCH INTERN MED, V154, P2225, DOI 10.1001/archinte.154.19.2225; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; Brock D W, 1991, Kennedy Inst Ethics J, V1, P28; Bronowski J., 1973, ASCENT MAN; Callahan Daniel, 1993, TROUBLED DREAM LIFE; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; Gillick MR, 1994, CHOOSING MED CARE OL; HOSKING MP, 1989, JAMA-J AM MED ASSOC, V261, P1909; Katz J., 1984, SILENT WORLD DOCTOR; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MEISEL A, 1981, JAMA-J AM MED ASSOC, V246, P2473, DOI 10.1001/jama.246.21.2473; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAKING HLTH CARE DEC; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; WU WC, 1988, J GEN INTERN MED, V3, P9, DOI 10.1007/BF02595749	21	51	51	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					621	624		10.7326/0003-4819-123-8-199510150-00009	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677304				2022-12-28	WOS:A1995RY82800009
J	GROSS, PA; HERMOGENES, AW; SACKS, HS; LAU, J; LEVANDOWSKI, RA				GROSS, PA; HERMOGENES, AW; SACKS, HS; LAU, J; LEVANDOWSKI, RA			THE EFFICACY OF INFLUENZA VACCINE IN ELDERLY PERSONS - A METAANALYSIS AND REVIEW OF THE LITERATURE	ANNALS OF INTERNAL MEDICINE			English	Review							NURSING-HOME; UNITED-STATES; A H3N2; MORTALITY; OUTBREAK; EPIDEMICS; PNEUMONIA; POPULATION; REDUCTION; ILLNESS	Objective: To quantify the protective efficacy of influenza vaccine in elderly persons. Data Sources: A MEDLINE search was done using the index terms influenza vaccine, vaccine efficacy, elderly, mortality, hospitalized, and pneumonia. Appropriate references in the initially selected articles were also reviewed. Study Selection: Only cohort observational studies with mortality assessment were included in the metaanalysis. In addition, 3 recent case-control studies, 2 cost-effectiveness studies, and 1 randomized, double-blind, placebo-controlled trial were reviewed. Data Extraction: Vaccine and epidemic virus strains, age and sex of patients, severity of illness, patient status, and study design were recorded. Upper respiratory illness, hospitalization, pneumonia, and mortality were used as outcome measures. Data Synthesis: In a meta-analysis of 20 cohort studies, the pooled estimates of vaccine efficacy (1 odds ratio) were 56% (95% CI, 39% to 68%) for preventing respiratory illness, 53% (CI, 35% to 66%) for preventing pneumonia, 50% (CI, 28% to 65%) for preventing hospitalization, and 68% (CI, 56% to 76%) for preventing death. Vaccine efficacy in the case-control studies ranged from 32% to 45% for preventing hospitalization for pneumonia, from 31% to 65% for preventing hospital deaths from pneumonia and influenza, from 43% to 50% for preventing hospital deaths from all respiratory conditions, and from 27% to 30% for preventing deaths from all causes. The randomized, double-blind, placebo-controlled trial showed a 50% or greater reduction in influenza-related illness. Recent cost-effectiveness studies confirm the efficacy of influenza vaccine in reducing influenza-related morbidity and mortality and show that vaccine provides important cost savings per year per vaccinated person. Conclusion: Despite the paucity of randomized trials, many studies confirm that influenza vaccine reduces the risks for pneumonia, hospitalization, and death in elderly persons during an influenza epidemic if the vaccine strain is identical or similar to the epidemic strain. Influenza immunization is an indispensable part of the care of persons 65 years of age and older. Annual vaccine administration requires the attention of all physicians and public health organizations.	SHEEHAN MEM HOSP, BUFFALO, NY 14203 USA; MT SINAI MED CTR, CLIN TRIALS UNIT, NEW YORK, NY 10029 USA; TUFTS NEW ENGLAND MED CTR, DIV CLIN CARE RES, BOSTON, MA 02111 USA; CTR BIOL EVALUAT & RES, DIV VIRAL PROD, ROCKVILLE, MD 20892 USA; UNIV MED & DENT NEW JERSEY, NEWARK, DE USA; US FDA, BETHESDA, MD USA	Icahn School of Medicine at Mount Sinai; Tufts Medical Center; US Food & Drug Administration (FDA); Rutgers State University New Brunswick; Rutgers State University Medical Center; US Food & Drug Administration (FDA)	GROSS, PA (corresponding author), HACKENSACK MED CTR, DEPT INTERNAL MED, 30 PROSPECT AVE, HACKENSACK, NJ 07601 USA.				PHS HHS [223-90-1102] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; ARROYO JC, 1984, AM J INFECT CONTROL, V12, P329, DOI 10.1016/0196-6553(84)90005-1; Aymard M, 1979, Dev Biol Stand, V43, P231; BARKER W, 1993, OPTIONS CONTROL INFL, V2, P143; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BASELSKI VS, 1992, CHEST, V102, pS571, DOI 10.1378/chest.102.5_Supplement_1.571S; BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; CARTTER ML, 1990, INFECT CONT HOSP EP, V11, P473; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P601; CURRIER M, 1988, MMJ (Maryland Medical Journal), V37, P781; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOWDLE WR, 1973, POSTGRAD MED J, V49, P159, DOI 10.1136/pgmj.49.569.159; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEERY BJ, 1976, MED J AUSTRALIA, V1, P540, DOI 10.5694/j.1326-5377.1976.tb140824.x; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; FRANK AL, 1983, AM J EPIDEMIOL, V118, P313, DOI 10.1093/oxfordjournals.aje.a113638; FYSON RE, 1983, CANADIAN DIS WEEKLY, V9, P37; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GOODMAN RA, 1982, JAMA-J AM MED ASSOC, V247, P1451, DOI 10.1001/jama.247.10.1451; GOOGINS JA, 1977, 91 CTR DIS CONTR INF, P24; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; GROSS PA, 1988, ARCH INTERN MED, V148, P559, DOI 10.1001/archinte.148.3.559; HASSELBLAD V, 1995, MED CARE, V33, P202; HOSKINS TW, 1979, LANCET, V1, P33; HOWELLS CHL, 1975, LANCET, V1, P381; KILBOURNE ED, 1987, INFLUENZA, P265; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; MEIKLEJOHN G, 1987, J AM GERIATR SOC, V35, P742, DOI 10.1111/j.1532-5415.1987.tb06352.x; MEIKLEJOHN G, 1989, J AM GERIATR SOC, V37, P407, DOI 10.1111/j.1532-5415.1989.tb02635.x; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; PATRIARCA PA, 1994, JAMA-J AM MED ASSOC, V272, P1700, DOI 10.1001/jama.272.21.1700; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; Perez-Tirse J, 1992, Pharmacoeconomics, V2, P198, DOI 10.2165/00019053-199202030-00003; PHAIR J, 1978, J LAB CLIN MED, V92, P822; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; RUBEN FL, 1974, JAMA-J AM MED ASSOC, V230, P863; S I., 1981, PRZYJACIOLKA, P43; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; SCHMITZ R, 1994, INFLUENZA VACCINATIO; Serie C, 1977, Dev Biol Stand, V39, P317; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; STRIKAS R, 1993, OPTIONS CONTROL INFL, V2, P153; STUART WH, 1969, J AMER MED ASSOC, V209, P232, DOI 10.1001/jama.209.2.232; TAYLOR JL, 1992, INFECT CONT HOSP EP, V13, P93; WILLIAMS GO, 1980, GERIATRICS, V35, P55; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	52	836	884	1	57	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					518	527		10.7326/0003-4819-123-7-199510010-00008	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661497				2022-12-28	WOS:A1995RW49500008
J	NISHIZAKA, T; MIYATA, H; YOSHIKAWA, H; ISHIWATA, S; KINOSITA, K				NISHIZAKA, T; MIYATA, H; YOSHIKAWA, H; ISHIWATA, S; KINOSITA, K			UNBINDING FORCE OF A SINGLE MOTOR MOLECULE OF MUSCLE MEASURED USING OPTICAL TWEEZERS	NATURE			English	Article							ACTIN FILAMENT; DIRECTION; MYOSIN; INVITRO; RIGOR; SPEED	THE unbinding and rebinding of motor proteins and their substrate filaments are the main components of sliding movement(1). We have measured the unbinding force between an actin filament and a single motor molecule of muscle, myosin, in the absence of ATP, by pulling the filament with optical tweezers(2). The unbinding force could be measured repeatedly on the same molecule, and was independent of the number of measurements and the direction of the imposed loads within a range of +/-90 degrees. The average unbinding force was 9.2 +/- 4.4 pN, only a few times larger than the sliding force(3-5) but an order of magnitude smaller than other intermolecular forces(6,7). From its kinetics(8) we suggest that unbinding occurs sequentially at the molecular interface, which is an inherent property of motor molecules.	WASEDA UNIV,SCH SCI & ENGN,DEPT PHYS,SHINJUKU KU,TOKYO 169,JAPAN; WASEDA UNIV,ADV RES CTR SCI & ENGN,SHINJUKU KU,TOKYO 169,JAPAN	Waseda University; Waseda University								ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ISHIWATA S, 1993, PHASE TRANSIT, V45, P105, DOI 10.1080/01411599308223720; KINOSITA K, 1991, J CELL BIOL, V115, P67, DOI 10.1083/jcb.115.1.67; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; MARSTON SB, 1982, BIOCHEM J, V203, P453, DOI 10.1042/bj2030453; MIYATA H, 1995, BIOPHYS J, V68, pS286; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; NISHIZAKA T, 1993, NATURE, V361, P269, DOI 10.1038/361269a0; NISHIZAKA T, 1995, BIOPHYS J, V68, pS75; SCHOENBERG M, 1985, BIOPHYS J, V48, P863, DOI 10.1016/S0006-3495(85)83847-9; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; TAWADA K, 1986, J MUSCLE RES CELL M, V7, P339, DOI 10.1007/BF01753655; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203	22	202	204	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					251	254		10.1038/377251a0	http://dx.doi.org/10.1038/377251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675112				2022-12-28	WOS:A1995RV87200046
J	SHANER, A; ECKMAN, TA; ROBERTS, LJ; WILKINS, JN; TUCKER, DE; TSUANG, JW; MINTZ, J				SHANER, A; ECKMAN, TA; ROBERTS, LJ; WILKINS, JN; TUCKER, DE; TSUANG, JW; MINTZ, J			DISABILITY INCOME, COCAINE USE, AND REPEATED HOSPITALIZATION AMONG SCHIZOPHRENIC COCAINE ABUSERS - A GOVERNMENT-SPONSORED REVOLVING-DOOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADDICTION SEVERITY INDEX; SUBSTANCE-ABUSE; DRUG-ABUSE; PSYCHIATRIC-PATIENTS; URINE; CHROMATOGRAPHY; VALIDITY	Background. Many patients with serious mental illness are addicted to drugs and alcohol. This comorbidity creates additional problems for the patients and for the clinicians, health care systems, and social-service agencies that provide services to this population. One problem is that disability income, which many people with serious mental illness receive to pay for basic needs, may facilitate drug abuse. In this study, we assessed the temporal patterns of cocaine use, psychiatric symptoms, and psychiatric hospitalization in a sample of schizophrenic patients receiving disability income. Methods. We evaluated 105 male patients with schizophrenia and cocaine dependence at the time of their admission to the hospital. They had severe mental illness and a long-term dependence on cocaine, with repeated admissions to psychiatric hospitals; many were homeless. The severity of psychiatric symptoms and urinary concentrations of the cocaine metabolite benzoylecgonine were evaluated weekly for 15 weeks. Results. Cocaine use, psychiatric symptoms, and hospital admissions all peaked during the first week of the month, shortly after the arrival of the disability payment, on the first day. The average patient spent nearly half his total income on illegal drugs. Conclusions. Among cocaine-abusing schizophrenic persons, the cyclic pattern of drug use strongly suggests that it is influenced by the monthly receipt of disability payments. The consequences of this cycle include the depletion of funds needed for housing and food, exacerbation of psychiatric symptoms, more frequent psychiatric hospitalization, and a high rate of homelessness. The troubling irony is that income intended to compensate for the disabling effects of severe mental illness may have the opposite effect.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SHANER, A (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,116A,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA.		Mintz, Jim/N-7385-2014	Mintz, Jim/0000-0002-8299-5851	NIMH NIH HHS [R01 MH48081] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048081] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTERMAN AI, 1983, J PSYCHIAT TREAT EV, V5, P377; BRADY K, 1990, AM J PSYCHIAT, V147, P1164; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COHEN J, 1992, MENTALLY ILL CHEM AB; CONE EJ, 1989, J FORENSIC SCI, V34, P15; DIXON L, 1991, AM J PSYCHIAT, V148, P224; DRAKE RE, 1991, NEW DIR MENT HLTH SE, V50, P3; FARRELL M, 1992, MENT PHYS DISABIL LA, V16, P236; FERRARA SD, 1992, J ANAL TOXICOL, V16, P217, DOI 10.1093/jat/16.4.217; GALANTER M, 1988, AM J DRUG ALCOHOL AB, V14, P211, DOI 10.3109/00952999809001548; HARTZ D, 1994, HOSP COMMUNITY PSYCH, V45, P491; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; Lukoff D, 1986, SCHIZOPHRENIA B, V12, P594, DOI DOI 10.1093/SCHBUL/12.4.578; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MELTZER HY, 1976, SCHIZOPHRENIA BULL, V2, P19, DOI 10.1093/schbul/2.1.19; OVERALL JE, 1962, PSYCHOL REP, V10, P799; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RICHARD ML, 1985, J CLIN PSYCHIAT, V46, P79; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBERTS LJ, 1992, NEW DIR MENT HLTH SE, V53, P55; SAFER DJ, 1987, HOSP COMMUNITY PSYCH, V38, P511; SATEL S, 1994, NEW REPUBLIC    0530, P18; SEALE JP, 1993, PRIMARY CARE, V20, P167; SHANER A, 1993, AM J PSYCHIAT, V150, P758; SPITZER RL, 1990, USERS GUIDE STRUTURE; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; SVENSSON JO, 1986, J ANAL TOXICOL, V10, P122, DOI 10.1093/jat/10.3.122; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; WATTS VW, 1986, J ANAL TOXICOL, V10, P198, DOI 10.1093/jat/10.5.198; YESAVAGE JA, 1983, J CLIN PSYCHIAT, V44, P259; ZISOOK S, 1992, AM J PSYCHIAT, V149, P552; 1993, DHHS SSA65008 SOC SE, P353; 1987, DIAGNOSTIC STATISTIC; 1994, WALL STREET J   0208, pA18; 1993, WALL STREET J   0128, pA18	39	163	163	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					777	783		10.1056/NEJM199509213331207	http://dx.doi.org/10.1056/NEJM199509213331207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU809	7643886				2022-12-28	WOS:A1995RU80900007
J	HILLMAN, BJ; OLSON, GT; COLBERT, RW; BERNHARDT, LB				HILLMAN, BJ; OLSON, GT; COLBERT, RW; BERNHARDT, LB			RESPONSES TO A PAYMENT POLICY DENYING PROFESSIONAL CHARGES FOR DIAGNOSTIC-IMAGING BY NONRADIOLOGIST PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COSTS	Objective.-To assess the impact of a payment policy denying reimbursement for the imaging-related professional services of nonradiologist physicians by comparing the use of and expenditures for diagnostic imaging examinations before and after implementation of the policy. Design.-Retrospective economic evaluation of claims and expenditures for diagnostic imaging examinations filed by physicians practicing in the 20 US counties having the greatest number of United Mine Workers of America Health and Retirement Funds (hereafter referred to as Funds) beneficiaries. Setting.-Insurance claims database of Funds beneficiaries, most of whom are elderly and live in rural communities and small towns. Intervention.-The January 1, 1993, implementation of a reimbursement policy denying payment of professional claims for diagnostic imaging of nonradiologist physicians. Main Outcome Measures.-Numbers and types of eligible claims and Funds payments for diagnostic imaging examinations during the year before and after the intervention, normalized for changes in the number of beneficiaries. Results.-Despite the rejection of $811 466 in claims disallowed by the policy, the Funds paid 12% more for diagnostic imaging performed in the 20 counties we studied during 1993 than during 1992. The Funds reimbursed 41% more claims per beneficiary for diagnostic imaging in 1993 than in 1992 (t=-8.03, P<.0001). The absolute number of professional claims per beneficiary increased more than did technical or global claims. Conclusions.-Despite a payment policy designed, in part, to reduce the Funds' imaging-related expenditures, the physicians we studied filed more claims, leading to greater expenditures. An increased number of self-referred technical claims and greater referral to hospital radiology departments likely account for most of the observed increases in utilization and costs.	FIRST HLTH STRATEGIES INC,PITTSBURGH,PA; UNITED MINE WORKERS AMER HLTH & RETIREMENT FUNDS,WASHINGTON,DC		HILLMAN, BJ (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT RADIOL,BOX 170,CHARLOTTESVILLE,VA 22908, USA.							CHRISTENSEN S, 1992, HEALTH SERV RES, V27, P65; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P349, DOI 10.2105/AJPH.83.3.349; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HILLMAN BJ, 1992, JAMA-J AM MED ASSOC, V268, P2050, DOI 10.1001/jama.268.15.2050; HOLAHAN J, 1979, US DHEW HCFA03006 HL; LEVIN DC, 1992, RADIOLOGY, V185, P701, DOI 10.1148/radiology.185.3.1438748; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P2055, DOI 10.1001/jama.268.15.2055; MITCHELL JM, 1991, JOINT VENTURES HLTH, P1; SWEDLOW A, 1992, NEW ENGL J MED, V327, P1502, DOI 10.1056/NEJM199211193272107; 1994, GAOHEHS952 GEN ACC O; 1993, ANN REPORT C, P121	13	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					885	887		10.1001/jama.274.11.885	http://dx.doi.org/10.1001/jama.274.11.885			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU603	7674502				2022-12-28	WOS:A1995RU60300027
J	MILLER, RW				MILLER, RW			LOOKING FOR ADVERSE REPRODUCTIVE OUTCOMES IN ATOMIC VETERANS - ARE SUCH STUDIES FEASIBLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MILLER, RW (corresponding author), INST MED,COMM STUDY FEASIBIL & NEED EPIDEMIOL STUDIES ADVE,WASHINGTON,DC 20418, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					865	865						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674486				2022-12-28	WOS:A1995RU60300004
J	COOK, DN; BECK, MA; COFFMAN, TM; KIRBY, SL; SHERIDAN, JF; PRAGNELL, IB; SMITHIES, O				COOK, DN; BECK, MA; COFFMAN, TM; KIRBY, SL; SHERIDAN, JF; PRAGNELL, IB; SMITHIES, O			REQUIREMENT OF MIP-1-ALPHA FOR AN INFLAMMATORY RESPONSE TO VIRAL-INFECTION	SCIENCE			English	Article							STEM-CELL PROLIFERATION; LYMPHOCYTES; CHEMOKINES; MIP-1-BETA; EXPRESSION	Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is a chemokine that has pro-inflammatory and stem cell inhibitory activities in vitro. Its biologic role in vivo was examined in mice in which the gene encoding MIP-1 alpha had been disrupted. Homozygous MIP-1 alpha mutant (-/-) mice were resistant to Coxsackievirus-induced myocarditis seen in infected wildtype (+/+) mice. Influenza virus-infected -/- mice had reduced pneumonitis and delayed clearance of the virus compared with infected +/+ mice. The -/- mice had no overt hematopoietic abnormalities. These results demonstrate that MIP-1 alpha is an important mediator of virus-induced inflammation in vivo.	UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; VET AFFAIRS MED CTR,DEPT INTERNAL MED,DURHAM,NC 27710; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; OHIO STATE UNIV,HLTH SCI CTR,DEPT ORAL BIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,HLTH SCI CTR,DEPT MED MICROBIOL & IMMUNOL,COLUMBUS,OH 43210; CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Beatson Institute	COOK, DN (corresponding author), UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.		Cook, Donald/E-5079-2019	Cook, Donald/0000-0002-0052-3755; Sheridan, John/0000-0002-6927-0266	NHLBI NIH HHS [R29HL46195, HL37001] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046195, R01HL037001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK MA, 1994, J NUTR, V124, P345, DOI 10.1093/jn/124.3.345; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; GILL BM, 1995, DIABETES, V44, P614, DOI 10.2337/diabetes.44.6.614; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HERMANN G, 1995, J NEUROIMMUNOL, V56, P179, DOI 10.1016/0165-5728(94)00145-E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KARPUS W, 1994, J IMMUNOL, V8, P1148; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KIM HS, 1988, NUCLEIC ACIDS RES, V18, P8887; MALTMAN J, 1994, J EXP MED, V178, P925; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PRAGNELL IB, 1988, BLOOD, V72, P196; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; WOODRUFF JF, 1974, J IMMUNOL, V113, P1726; WOODRUFF JF, 1980, AM J PATHOL, V101, P425	17	529	548	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1583	1585		10.1126/science.7667639	http://dx.doi.org/10.1126/science.7667639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667639				2022-12-28	WOS:A1995RU81300044
J	POWERS, T; WALTER, P				POWERS, T; WALTER, P			RECIPROCAL STIMULATION OF GTP HYDROLYSIS BY 2 DIRECTLY INTERACTING GTPASES	SCIENCE			English	Article							SIGNAL RECOGNITION PARTICLE; ELONGATION FACTOR-TU; 4.5S RNA; RIBONUCLEOPROTEIN; SUBUNIT; MODEL	The Escherichia coli guanosine triphosphate (GTP)-binding proteins Ffh and FtsY have been proposed to catalyze the cotranslational targeting of proteins to the bacterial plasma membrane. A mutation was introduced into the GTP-binding domain of FtsY that altered its nucleotide specificity from GTP to xanthosine triphosphate (XTP). The mutant FtsY protein stimulated GTP hydrolysis by a ribonucleoprotein consisting of Ffh and 4.5S RNA in a reaction that required XTP, and it hydrolyzed XTP in a reaction that required both the Ffh-4.5S ribonucleoprotein and GTP. Thus, nucleotide triphosphate hydrolysis by Ffh and FtsY is likely to occur in reciprocally coupled reactions in which the two interacting guanosine triphosphatases act as regulatory proteins for each other.			POWERS, T (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; Evnin L B, 1988, Ann N Y Acad Sci, V542, P61, DOI 10.1111/j.1749-6632.1988.tb25808.x; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HWANG YW, 1987, J BIOL CHEM, V262, P13081; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P482; SEGEL IH, 1975, ENZYME; SEGEL IH, COMMUNICATION; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	21	181	182	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1422	1424		10.1126/science.7660124	http://dx.doi.org/10.1126/science.7660124			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660124				2022-12-28	WOS:A1995RT80600044
J	RAULET, DH; HELD, W				RAULET, DH; HELD, W			NATURAL-KILLER-CELL RECEPTORS - THE OFFS AND ONS OF NK CELL RECOGNITION	CELL			English	Review							SUSCEPTIBILITY; SPECIFICITY; MOLECULES; COMPLEX; LYSIS		UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley	RAULET, DH (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Raulet, David/0000-0002-1257-8649				Bennett M, 1995, Semin Immunol, V7, P121, DOI 10.1006/smim.1995.0016; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CHANG C, 1995, IN PRESS EUR J IMMUN; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DANDREA A, 1995, IN PRESS J IMMUNOL; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; DANIELS BF, 1994, J EXP MED, V180, P687, DOI 10.1084/jem.180.2.687; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; KANE KP, 1994, J EXP MED, V179, P1011, DOI 10.1084/jem.179.3.1011; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; MASON LH, 1995, J EXP MED, V182, P293, DOI 10.1084/jem.182.2.293; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1995, IN PRESS J EXP MED; RYAN JC, 1995, J EXP MED, V181, P1911, DOI 10.1084/jem.181.5.1911; STONEMAN ER, 1995, J EXP MED, V182, P305, DOI 10.1084/jem.182.2.305; STORKUS WJ, 1989, P NATL ACAD SCI USA, V86, P2361, DOI 10.1073/pnas.86.7.2361; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; YABE T, 1993, IMMUNOGENETICS, V37, P455; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201	27	168	171	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					697	700		10.1016/0092-8674(95)90466-2	http://dx.doi.org/10.1016/0092-8674(95)90466-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671299	Bronze			2022-12-28	WOS:A1995RU75500004
J	MCGUIRE, CH				MCGUIRE, CH			REFLECTIONS OF A MAVERICK MEASUREMENT MAVEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV ILLINOIS, COLL MED, DEPT MED EDUC, CHICAGO, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								ABRAHAMSON S, 1991, ACAD MED, V66, pS89, DOI 10.1097/00001888-199109000-00050; ABRAHAMSON S, 1960, J MED EDUC, V44, P515; ANDERSON MB, 1993, ACAD MED, V68, P438; ANDERSON MB, 1993, ACAD MED, V68, P454; BARROWS HS, 1964, J MED EDUC, V39, P802; GORDON MS, 1974, AM J CARDIOL, V34, P350, DOI 10.1016/0002-9149(74)90038-1; HARDEN RM, 1979, MED EDUC, V13, P41; HARLESS WG, 1971, J MED EDUC, V46, P443; Hubbard JP, 1961, MULTIPLE CHOICE EXAM; LEVINE HG, 1970, J EDUC MEAS, V7, P63, DOI 10.1111/j.1745-3984.1970.tb00697.x; LEVINE HG, 1970, J MED EDUC, V45, P700; MAATSCH JL, 1983, EMERG MED ANN, V1, P183; MCGUIRE C, 1963, J MED EDUC, V38, P556; MCGUIRE CH, 1967, J EDUC MEAS, V4, P1, DOI 10.1111/j.1745-3984.1967.tb00562.x; MCGUIRE CH, 1994, ESTABLISHING STANDAR, P3; MCGUIRE CH, 1989, FURTHER DEV ASSESSIN, P46; MCGUIRE CH, 1975, 1975 ANN INV C NAT B; MCGUIRE CH, 1976, CLIN SIMULATION SELE; MILLER GE, 1965, B AM ACAD ORTHOP SUR, V13, P8; Nedelsky L, 1954, EDUC PSYCHOL MEAS, V14, P3, DOI 10.1177/001316445401400101; PAGE G, 1995, ACAD MED, V70, P104, DOI 10.1097/00001888-199502000-00012; 1960, DEFINITIONS CLIN COM	22	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					735	740						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650828				2022-12-28	WOS:A1995RR83500021
J	AGOSTONI, C; RIVA, E; TROJAN, S; BELLU, R; GIOVANNINI, M				AGOSTONI, C; RIVA, E; TROJAN, S; BELLU, R; GIOVANNINI, M			DOCOSAHEXAENOIC ACID STATUS AND DEVELOPMENTAL QUOTIENT OF HEALTHY TERM INFANTS	LANCET			English	Letter											AGOSTONI, C (corresponding author), UNIV MILAN,SAN PAOLO BIOMED INST,DEPT PAEDIAT,I-20142 MILAN,ITALY.		Bellù, Roberto/D-5028-2017; Agostoni, Carlo/B-3470-2015; Agostoni, Carlo/A-9303-2012	Bellù, Roberto/0000-0002-8108-9873; Agostoni, Carlo/0000-0002-5006-0832; 				AGOSTONI C, 1994, J AM COLL NUTR, V13, P658; AGOSTONI C, 1995, PEDIATR RES, V38, P262, DOI 10.1203/00006450-199508000-00021; BRUNET O, 1966, DEV PSYCHOL 1 ENFANC; CLANDININ MT, 1994, J PEDIATR-US, V125, pS25, DOI 10.1016/S0022-3476(06)80733-X; MAKRIDES, 1995, LANCET, V345, P2463; MAKRIDES M, 1994, AM J CLIN NUTR, V60, P189, DOI 10.1093/ajcn/60.2.189	6	47	48	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					638	638		10.1016/S0140-6736(95)91469-2	http://dx.doi.org/10.1016/S0140-6736(95)91469-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651024				2022-12-28	WOS:A1995RT18800040
J	CANNON, J; CULLINAN, P; TAYLOR, AN				CANNON, J; CULLINAN, P; TAYLOR, AN			CONSEQUENCES OF OCCUPATIONAL ASTHMA	BRITISH MEDICAL JOURNAL			English	Article											CANNON, J (corresponding author), NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,DOVEHOUSE ST,LONDON SW3 6LR,ENGLAND.							[Anonymous], 1980, CLASSIFICATION OCCUP; GANNON PFG, 1993, BRIT J IND MED, V50, P491; MERIDITH S, 1993, J EPIDEMIOL COMMUNIT, V47, P459; VENABLES KM, 1989, RESP MED, V83, P437, DOI 10.1016/S0954-6111(89)80078-2	4	60	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					602	603		10.1136/bmj.311.7005.602	http://dx.doi.org/10.1136/bmj.311.7005.602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663255	Green Published			2022-12-28	WOS:A1995RT72300018
J	LEHMANN, ED; HOPKINS, KD; GOSLING, RG				LEHMANN, ED; HOPKINS, KD; GOSLING, RG			ATHEROSCLEROSIS IN THE ASCENDING AORTA AND RISK OF ISCHEMIC STROKE	LANCET			English	Editorial Material							MAGNETIC-RESONANCE; WAVE VELOCITY		WHITTINGTON HOSP, ACAD DEPT MED, LONDON N19 5NF, ENGLAND; UNIV S BANK, SCH APPL SCI, LONDON, ENGLAND	University of London; University College London; London South Bank University	LEHMANN, ED (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROL, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BOGREN HG, 1989, AM HEART J, V118, P234, DOI 10.1016/0002-8703(89)90181-6; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOPKINS KD, 1994, LANCET, V343, P1447, DOI 10.1016/S0140-6736(94)92577-1; KISTLER JP, 1994, NEW ENGL J MED, V331, P1517, DOI 10.1056/NEJM199412013312211; LANNE T, 1992, ULTRASOUND MED BIOL, V18, P451, DOI 10.1016/0301-5629(92)90084-N; LEHMANN ED, 1993, ULTRASOUND MED BIOL, V19, P683, DOI 10.1016/0301-5629(93)90087-5; LEHMANN ED, 1994, LANCET, V344, P1763, DOI 10.1016/S0140-6736(94)92901-7; LEHMANN ED, IN PRESS CLIN SCI; MOHIADDIN RH, 1993, J APPL PHYSIOL, V74, P492, DOI 10.1152/jappl.1993.74.1.492; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WADA T, 1994, ARTERIOSCLER THROMB, V14, P479, DOI 10.1161/01.ATV.14.3.479	15	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 2	1995	346	8975					589	590		10.1016/S0140-6736(95)91433-1	http://dx.doi.org/10.1016/S0140-6736(95)91433-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651001				2022-12-28	WOS:A1995RT18800006
J	PIPKIN, FB				PIPKIN, FB			FORTNIGHTLY REVIEW - THE HYPERTENSIVE DISORDERS OF PREGNANCY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGIOTENSIN-II BINDING; LIPID-PEROXIDATION; ENDOTHELIAL-CELL; PRE-ECLAMPSIA; PREECLAMPSIA; WOMEN				PIPKIN, FB (corresponding author), UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DEPT OBSTET & GYNAECOL, NOTTINGHAM NG7 2UH, ENGLAND.							ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; ASSALI NS, 1952, AM J OBSTET GYNECOL, V63, P978, DOI 10.1016/0002-9378(52)90537-1; BAKER PN, 1991, BRIT J OBSTET GYNAEC, V98, P436, DOI 10.1111/j.1471-0528.1991.tb10336.x; BAKER PN, 1992, AM J OBSTET GYNECOL, V167, P487, DOI 10.1016/S0002-9378(11)91434-3; BEROYZ G, 1994, LANCET, V343, P619; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Chesley L, 1978, HYPERTENSIVE DISORDE; DAVEY DA, 1986, CLIN EXP HYPERTENS B, V5, P97, DOI 10.3109/10641958609023478; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; DUVEKOT JJ, 1993, AM J OBSTET GYNECOL, V169, P1382, DOI 10.1016/0002-9378(93)90405-8; EASTERLING TR, 1991, AM J OBSTET GYNECOL, V165, P902, DOI 10.1016/0002-9378(91)90436-U; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; GALLERY EDM, 1987, BAILLIERE CLIN OB GY, V1, P835, DOI 10.1016/S0950-3552(87)80037-8; GLEESON R, 1990, LANCET, V335, P225, DOI 10.1016/0140-6736(90)90316-W; GRYGLEWSKI RJ, 1988, HYPERTENSION, V12, P530, DOI 10.1161/01.HYP.12.6.530; HAYWARD C, 1992, AM J HUM GENET, V50, P749; HUBEL CA, 1989, AM J OBSTET GYNECOL, V161, P1025, DOI 10.1016/0002-9378(89)90778-3; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KILBY MD, 1993, BRIT J OBSTET GYNAEC, V100, P375, DOI 10.1111/j.1471-0528.1993.tb12983.x; KITZMILL.JL, 1973, AM J OBSTET GYNECOL, V115, P248, DOI 10.1016/0002-9378(73)90293-7; MASSE J, 1993, AM J OBSTET GYNECOL, V169, P501, DOI 10.1016/0002-9378(93)90608-L; MORGAN L, 1995, BRIT J OBSTET GYNAEC, V102, P489, DOI 10.1111/j.1471-0528.1995.tb11324.x; PAGE EW, 1976, AM J OBSTET GYNECOL, V126, P821, DOI 10.1016/0002-9378(76)90671-2; PICKLES CJ, 1989, AM J OBSTET GYNECOL, V160, P678, DOI 10.1016/S0002-9378(89)80057-2; PIPKIN FB, 1994, BRIT MED BULL, V50, P381, DOI 10.1093/oxfordjournals.bmb.a072898; PIPKIN FB, 1989, LANCET, V2, P482; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROBILLARD PY, 1994, LANCET, V344, P973, DOI 10.1016/S0140-6736(94)91638-1; TAUFIELD PA, 1987, NEW ENGL J MED, V316, P715, DOI 10.1056/NEJM198703193161204; TODA N, 1984, BRIT J PHARMACOL, V81, P301, DOI 10.1111/j.1476-5381.1984.tb10079.x; UOTILA JT, 1993, BRIT J OBSTET GYNAEC, V100, P270, DOI 10.1111/j.1471-0528.1993.tb15242.x; VISSER W, 1991, HYPERTENSION, V17, P1072, DOI 10.1161/01.HYP.17.6.1072; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; YLIKORKALA O, 1992, BAILLIERE CLIN OB GY, V6, P809, DOI 10.1016/S0950-3552(05)80190-7	34	29	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	1995	311	7005					609	613		10.1136/bmj.311.7005.609	http://dx.doi.org/10.1136/bmj.311.7005.609			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663256	Green Published			2022-12-28	WOS:A1995RT72300021
J	BERGGREN, KK; BARD, A; WILBUR, JL; GILLASPY, JD; HELG, AG; MCCLELLAND, JJ; ROLSTON, SL; PHILLIPS, WD; PRENTISS, M; WHITESIDES, GM				BERGGREN, KK; BARD, A; WILBUR, JL; GILLASPY, JD; HELG, AG; MCCLELLAND, JJ; ROLSTON, SL; PHILLIPS, WD; PRENTISS, M; WHITESIDES, GM			MICROLITHOGRAPHY BY USING NEUTRAL METASTABLE ATOMS AND SELF-ASSEMBLED MONOLAYERS	SCIENCE			English	Article							BEAM; SURFACES	Lithography can be performed with beams of neutral atoms in metastable excited states to pattern self-assembled monolayers (SAMs) of alkanethiolates on gold. An estimated exposure of a SAM of dodecanethiolate (DDT) to 15 to 20 metastable argon atoms per DDT molecule damaged the SAM sufficiently to allow penetration of an aqueous solution of ferricyanide to the surface of the gold. This solution etched the gold and transformed the patterns in the SAMs into structures of gold; these structures had edge resolution of less than 100 nanometers. Regions of SAMs as large as 2 square centimeters were patterned by exposure to a beam of metastable argon atoms. these observations suggest that this system may be useful in new forms of micro- and nanolithography.	HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; NATL INST STAND & TECHNOL,DIV ATOM PHYS,GAITHERSBURG,MD 20899; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; NATL INST STAND & TECHNOL,ELECTRON PHYS GRP,GAITHERSBURG,MD 20899	Harvard University; National Institute of Standards & Technology (NIST) - USA; Harvard University; National Institute of Standards & Technology (NIST) - USA			rolston, steven l/L-5175-2013; McClelland, Jabez/A-2358-2015; Sano, Michael/E-1715-2011; Prentiss, Mara/AAU-2940-2021	rolston, steven l/0000-0003-1671-4190; McClelland, Jabez/0000-0001-5672-5965; 	NIGMS NIH HHS [1-F32 GM16511-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016511] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT NL, 1992, SCIENCE, V257, P1380, DOI 10.1126/science.257.5075.1380; ADAMS CS, 1994, PHYS REP, V240, P143, DOI 10.1016/0370-1573(94)90066-3; BEHRINGER RE, 1994, J OPT SOC AM B, V11, P1166; BOZCO F, 1983, J CHEM PHYS, V78, P4256; BRAIN CD, 1987, J AM CHEM SOC, V114, P7155; BRAND JA, 1992, REV SCI INSTRUM, V63, P163, DOI 10.1063/1.1143000; CALVERT JM, 1992, THIN SOLID FILMS, V211, P359; CONRAD H, 1979, PHYS REV LETT, V42, P1082, DOI 10.1103/PhysRevLett.42.1082; DULCEY CS, 1991, SCIENCE, V252, P551, DOI 10.1126/science.2020853; DUNNING FB, 1971, J PHYS PT B ATOM M P, V4, P1696, DOI 10.1088/0022-3700/4/12/018; FAHEY DW, 1980, J PHYS E SCI INSTRUM, V13, P381, DOI 10.1088/0022-3735/13/4/004; HUANG JY, 1994, LANGMUIR, V10, P626, DOI 10.1021/la00015a005; KIM E, 1995, J ELECTROCHEM SOC, V142, P628, DOI 10.1149/1.2044112; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038; MCCLELLAND JJ, 1993, SCIENCE, V262, P877, DOI 10.1126/science.262.5135.877; MCCLELLAND JJ, IN PRESS J OPT SOC B; NUZZO RG, 1987, J AM CHEM SOC, V114, P1990; TIBERIO RC, 1993, APPL PHYS LETT, V62, P476, DOI 10.1063/1.108938; TIMP G, 1992, PHYS REV LETT, V69, P1636, DOI 10.1103/PhysRevLett.69.1636; Webb HW, 1924, PHYS REV, V24, P113, DOI 10.1103/PhysRev.24.113; WHITESIDE GM, IN PRESS HDB SURFACE; WILBUR JL, UNPUB; WILBUR JL, 1994, ADV MATER, V7, P600; WILBUR JL, IN PRESS ADV MATER; XIA Y, UNPUB	26	203	212	1	42	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1255	1257		10.1126/science.7652572	http://dx.doi.org/10.1126/science.7652572			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652572				2022-12-28	WOS:A1995RR84200030
J	YU, HT; SCHREIBER, SL				YU, HT; SCHREIBER, SL			STRUCTURE OF GUANINE-NUCLEOTIDE-EXCTRANGE FACTOR HUMAN MSS4 AND IDENTIFICATION OF ITS RAB-INTERACTING SURFACE	NATURE			English	Article							BINDING DOMAIN; PROTEIN; P21	GUANINE-NUCLEOTIDE-EXCHANGE factors (GEFs) promote the exchange of GDP for GTP in Ras GTPases, and thereby positively regulate their functions(1,2). Members of the Sec4/Ypt1/Rab branch of the Ras superfamily are essential for vesicular transport(3-6). A GEF for a subset of Rab proteins, termed mammalian suppressor of Sec4 (Mss4), has been identified(7). Here we use multidimensional NMR to determine the structure of human Mss4 (hMss4), which is the first tertiary structure established for a protein with GEF activity. Mss4 contains a central beta-sheet sandwiched between two small sheets. It also binds a Zn ion through Cys 23, Cys 26, Cys 94 and Cys 97. The Rab-binding surface of hMss4 has subsequently been delineated using chemical-shift perturbation experiments and site-directed mutagenesis. The active site of hMss4 involves the Zn2+-binding region and a neighbouring loop.	HARVARD UNIV, DEPT CHEM, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute				Yu, Hongtao/0000-0002-8861-049X				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; LAL CC, 1993, MOL CELL BIOL, V13, P1345; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; MITSOU MY, 1992, EMBO J, V11, P2391; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WATENPAUGH KD, 1980, J MOL BIOL, V138, P615, DOI 10.1016/S0022-2836(80)80020-9; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU HT, 1995, BIOCHEMISTRY-US, V34, P9103, DOI 10.1021/bi00028a020	29	51	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					788	791		10.1038/376788a0	http://dx.doi.org/10.1038/376788a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651540				2022-12-28	WOS:A1995RR83600044
J	PHELAN, M; PARKMAN, S				PHELAN, M; PARKMAN, S			HOW TO DO IT - WORK WITH AN INTERPRETER	BRITISH MEDICAL JOURNAL			English	Article							SPEAKING	The Audit Commission recently highlighted the need for health services to plan language services to help the problems of poor communication facing non-English speaking patients. Doctors and other health workers need to know how to work effectively when interviewing patients with an interpreter. This article describes the different options for helping non-English speaking patients; explains how interviews should be conducted with a trained interpreter, including those using sign language; and outlines the extent of interpreting services currently available in the United Kingdom, complete with a list of addresses of organisations offering interpreting services.	INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London			G, G/A-3459-2012					DAVID A, 1995, JAMA-J AM MED ASSOC, V273, P227; DODD W, 1983, FAM PRACT, V1, P42; KLINE F, 1980, AM J PSYCHIAT, V137, P1530; LAUNER J, 1978, BRIT MED J, V2, P934, DOI 10.1136/bmj.2.6142.934; MARCOS LR, 1979, AM J PSYCHIAT, V136, P171; 1994, WHAT SEEMS TO BE MAT	6	97	97	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					555	557		10.1136/bmj.311.7004.555	http://dx.doi.org/10.1136/bmj.311.7004.555			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663215	Green Published			2022-12-28	WOS:A1995RR73700027
J	IWATA, S; OSTERMEIER, C; LUDWIG, B; MICHEL, H				IWATA, S; OSTERMEIER, C; LUDWIG, B; MICHEL, H			STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF CYTOCHROME-C-OXIDASE FROM PARACOCCUS-DENITRIFICANS	NATURE			English	Article							CRYSTAL-STRUCTURES; PROTEIN STRUCTURES; SUBUNIT; REFINEMENT; 2-SUBUNIT; FEATURES; ACCURACY; COMPLEX; ENERGY; ENZYME	The crystal structure at 2.8 Angstrom resolution of the four protein subunits containing cytochrome c oxidase from the soil bacterium Paracoccus denitrificans, complexed with an antibody F-v fragment, is described. Subunit I contains 12 membrane-spanning, primarily helical segments and binds haem a and the haem a(3)-copper B binuclear centre where molecular oxygen Is reduced to water. Two proton transfer pathways, one for protons consumed in water formation and one for 'proton pumping', could be identified. Mechanisms for proton pumping are discussed.	MAX PLANCK INST BIOPHYS,D-60528 FRANKFURT,GERMANY; UNIV FRANKFURT,BIOZENTRUM,INST BIOCHEM,D-60439 FRANKFURT,GERMANY	Max Planck Society; Goethe University Frankfurt								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; ESSEN LO, 1995, THESIS J WOLFGANG GO; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HALTIA T, 1990, BIOCHEMISTRY-US, V33, P9731; HALTIA T, 1991, EMBO J, V8, P2015; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, BIOENERG BIOMEMBR, V25, P136; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P896; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; MORGAN JE, 1994, BIOENERG BIOMEMBR, V26, P599; OTWINOWSKI Z, 1991, 1991 P CCP4 STUD WEE, P80; OTWINOWSKI Z, 1993, 1991 P CCP4 STUD WEE, P56; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; RAITIO M, 1990, FEBS LETT, V261, P431, DOI 10.1016/0014-5793(90)80609-M; RICH PR, 1994, AUST J PL PHYSL, V22, P479; RIEDER R, 1980, J BIOL CHEM, V255, P4732; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.0259f.x; VANDEROOST J, 1992, EMBO J, V11, P3209, DOI 10.1002/j.1460-2075.1992.tb05398.x; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM M, 1996, BIOCHIM BIOPHYS ACTA, V1187, P106	46	1953	1978	4	156	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					660	669		10.1038/376660a0	http://dx.doi.org/10.1038/376660a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651515				2022-12-28	WOS:A1995RQ67200053
J	JOYCE, KA; REES, JE				JOYCE, KA; REES, JE			TRANSVERSE MYELITIS AFTER MEASLES, MUMPS, AND RUBELLA VACCINE	BRITISH MEDICAL JOURNAL			English	Letter											JOYCE, KA (corresponding author), HURSTWOOD PK NEUROL CTR,HAYWARDS HEATH RH16 4EX,W SUSSEX,ENGLAND.							BEHAN PO, 1977, BRIT MED J, V2, P166; FENICHEL GM, 1982, ANN NEUROL, V12, P119, DOI 10.1002/ana.410120202; HOLT S, 1976, BRIT MED J, V2, P1037, DOI 10.1136/bmj.2.6043.1037	3	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					422	422		10.1136/bmj.311.7002.422a	http://dx.doi.org/10.1136/bmj.311.7002.422a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640590	Green Published			2022-12-28	WOS:A1995RP55400016
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - LINKING YOUR COMPUTER TO THE OUTSIDE WORLD	BRITISH MEDICAL JOURNAL			English	Article									GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER,ENGLAND; HILLINGDON HOSP,LONDON,ENGLAND	Gloucestershire Royal Hospital; Brunel University; Imperial College London	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					381	384		10.1136/bmj.311.7001.381	http://dx.doi.org/10.1136/bmj.311.7001.381			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640550	Green Published			2022-12-28	WOS:A1995RN46900027
J	PETERSEN, RC; SMITH, GE; IVNIK, RJ; TANGALOS, EG; SCHAID, DJ; THIBODEAU, SN; KOKMEN, E; WARING, SC; KURLAND, LT				PETERSEN, RC; SMITH, GE; IVNIK, RJ; TANGALOS, EG; SCHAID, DJ; THIBODEAU, SN; KOKMEN, E; WARING, SC; KURLAND, LT			APOLIPOPROTEIN-E STATUS AS A PREDICTOR OF THE DEVELOPMENT OF ALZHEIMERS-DISEASE IN MEMORY-IMPAIRED INDIVIDUALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYPE-4 ALLELE; MENTAL STATUS; DEMENTIA; DIAGNOSIS	Objective.-The outcome of patients with mild cognitive impairment is not known, yet these patients present a difficult dilemma for the clinician. This study was designed to characterize the outcome of a group of patients with mild cognitive impairment and to determine whether the presence of the epsilon 4 allele on the apolipoprotein E gene (APOE) is a predictor of that outcome. Design.-A prospective, longitudinal inception cohort. Setting.-General community clinic. Participants.-A consecutive sample of 66 patients who met criteria for a diagnosis of a mild cognitive impairment and who had at least one clinical reevaluation was identified from the Mayo Clinic Alzheimer's Disease Center/Alzheimer's Disease Patient Registry. Interventions.-We evaluated patients initially and at 12- to 18-month intervals up to 54 months using standard neurological and neuropsychological measures such as the Mini-Mental State Examination, the Dementia Rating Scale, the Wechsler Adult Intelligence Scale-Revised, the Wechsler Memory Scale-Revised, and the Free and Cued Selective Reminding Test. The APOE status of study patients was determined. Main Outcome Measure.-The development of dementia as determined by the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition and the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria. Results.-Sixty-six individuals had been reevaluated once (mean of 18 months), 36 individuals twice (mean of 36 months), and 22 individuals on three occasions (mean of 54 months), with conversion rates to dementia at these intervals of 24%, 44%, and 55%, respectively. A multivariate Cox regression model demonstrated that possession of an APOE epsilon 4 allele was the strongest predictor of clinical outcome. Conclusions.-These data suggest the following: (1) patients with mild cognitive impairment can be clinically defined, (2) many members of this group progress to Alzheimer's disease, and (3) APOE epsilon 4 allele status appears to be a strong predictor of clinical progression.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PSYCHIAT & PSYCHOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV COMMUNITY INTERNAL MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL & LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	PETERSEN, RC (corresponding author), MAYO CLIN & MAYO FDN, DEPT NEUROL, ROCHESTER, MN 55905 USA.		Waring, Stephen/AAR-6870-2021	Waring, Stephen/0000-0002-9674-0083; Smith, Glenn/0000-0003-1506-9484	NIA NIH HHS [AG06786, AG08031] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG006786, P30AG008031] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681; Benton AL., 1983, MULTILINGUAL APHASIA; BENTON AL, 1988, CONTRIBUTIONS NEUROP; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSCHKE H, 1984, J CLIN NEUROPSYCHOL, V6, P433, DOI 10.1080/01688638408401233; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; HIXSON JE, 1990, J LIPID RES, V31, P545; Ivnik R., 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; IVNIK RJ, 1990, PSYCHOL ASSESSMENT, V2, P804; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; Jastak S., 1984, WIDE RANGE ACHIEVEME; Kaplan E, 1978, BOSTON NAMING TEST; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karusu T.B., 1976, GERIATRIC PSYCHIAT, P77; KOKMEN E, 1987, MAYO CLIN PROC, V62, P281, DOI 10.1016/S0025-6196(12)61905-3; KOKMEN E, 1991, ARCH NEUROL-CHICAGO, V48, P725, DOI 10.1001/archneur.1991.00530190071018; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Petersen R C, 1990, Aging (Milano), V2, P408; PETERSEN RC, 1992, NEUROLOGY, V42, P396, DOI 10.1212/WNL.42.2.396; PETERSEN RC, 1994, NEUROLOGY, V44, P867, DOI 10.1212/WNL.44.5.867; PETERSEN RC, 1993, ANN NEUROL, V34, P292; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; Rey A, 1964, LEXAMEN CLINIQUE PSY; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; TSAI MS, 1994, AM J HUM GENET, V54, P643; Wechsler D., 1945, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Weintraub S, 1982, ALZHEIMERS DIS REPOR, P189; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555; 1987, DIAGNOSTIC STATISTIC	45	632	656	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1274	1278		10.1001/jama.273.16.1274	http://dx.doi.org/10.1001/jama.273.16.1274			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7646655				2022-12-28	WOS:A1995QU57100030
J	COLLINS, R; PETO, R; FLATHER, M; PARISH, S; SLEIGHT, P; CONWAY, M; PIPILIS, A; BAIGENT, C; BARNETT, D; BOISSEL, JP; BUDAJ, A; CAIRNS, J; CEREMUZYNSKI, L; COHEN, AF; DEBACKER, G; DIAZ, R; DIENSTL, F; DOVE, P; FRANZOSI, MG; GENONI, M; HALON, DA; HEIKKILA, J; HENNEKENS, C; HORGAN, J; HUNT, D; KALA, R; KARATZAS, N; KEECH, A; KELTAI, M; KJEKSHUS, J; KORNITZER, M; KOSTER, R; LANDLESS, P; LECHLEITNER, P; LEIZOROVICZ, A; LEWIS, BS; LUNDKVIST, L; MACMAHON, S; MAGGIONI, A; MALACRIDA, R; MEYER, T; MOCCETTI, T; OCALLAGHAN, D; PAOLASSO, E; PIEGAS, LS; REIKVAM, A; RIDKER, P; RYAN, T; SCHRODER, R; SEABRAGOMES, R; SOUSA, JEMR; TOGNONI, G; TURPIE, A; VALENTIN, V; VARIGOS, J; WHITE, H; WILHELMSEN, L; WOODS, K; YUSUF, S; PIOMBO, A; GUZMAN, LA; MONTENEGRO, DC; IRUSTA, G; SCHNEIDER, RA; CUNEO, C; CHAMORRO, BH; ESPINOSA, GE; MORENO, M; RIOS, MM; DOLL, R; FOX, K; JULIAN, D; MEIER, P; SANDOYA, E; PEREZ, JE				COLLINS, R; PETO, R; FLATHER, M; PARISH, S; SLEIGHT, P; CONWAY, M; PIPILIS, A; BAIGENT, C; BARNETT, D; BOISSEL, JP; BUDAJ, A; CAIRNS, J; CEREMUZYNSKI, L; COHEN, AF; DEBACKER, G; DIAZ, R; DIENSTL, F; DOVE, P; FRANZOSI, MG; GENONI, M; HALON, DA; HEIKKILA, J; HENNEKENS, C; HORGAN, J; HUNT, D; KALA, R; KARATZAS, N; KEECH, A; KELTAI, M; KJEKSHUS, J; KORNITZER, M; KOSTER, R; LANDLESS, P; LECHLEITNER, P; LEIZOROVICZ, A; LEWIS, BS; LUNDKVIST, L; MACMAHON, S; MAGGIONI, A; MALACRIDA, R; MEYER, T; MOCCETTI, T; OCALLAGHAN, D; PAOLASSO, E; PIEGAS, LS; REIKVAM, A; RIDKER, P; RYAN, T; SCHRODER, R; SEABRAGOMES, R; SOUSA, JEMR; TOGNONI, G; TURPIE, A; VALENTIN, V; VARIGOS, J; WHITE, H; WILHELMSEN, L; WOODS, K; YUSUF, S; PIOMBO, A; GUZMAN, LA; MONTENEGRO, DC; IRUSTA, G; SCHNEIDER, RA; CUNEO, C; CHAMORRO, BH; ESPINOSA, GE; MORENO, M; RIOS, MM; DOLL, R; FOX, K; JULIAN, D; MEIER, P; SANDOYA, E; PEREZ, JE			ISIS-4 - A RANDOMIZED FACTORIAL TRIAL ASSESSING EARLY ORAL CAPTOPRIL, ORAL MONONITRATE, AND INTRAVENOUS MAGNESIUM-SULFATE IN 58,050 PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							LEFT-VENTRICULAR DYSFUNCTION; ISOSORBIDE DINITRATE; ANGIOTENSIN-II; CLINICAL-TRIAL; RAT-HEART; MORTALITY; SURVIVAL; INTERVENTION; ENLARGEMENT; REPERFUSION	58 050 patients entering 1086 hospitals up to 24 h (median 8 h) after the onset of suspected acute myocardial infarction (MI) with no clear contraindications to the study treatments (in particular, no cardiogenic shock or persistent severe hypotension) were randomised in a ''2 x 2 x 2 factorial'' study. The treatment comparisons were: (i) 1 month of oral captopril (6.25 mg initial dose titrated up to 50 mg twice daily) versus matching placebo; (ii) 1 month of oral controlled-release mononitrate (30 mg initial dose titrated up to 60 mg once daily) versus matching placebo; acid (iii) 24 h of intravenous magnesium sulphate (8 mmol initial bolus followed by 72 mmol) versus open control. There were no significant ''interactions'' between the effects of these three treatments, and the results for each are based on the randomised comparison of about 29 000 active versus 29 000 control allocated patients. Captopril There was a significant 7% (SD 3) proportional reduction in 5-week mortality (2088 [7.19%] captopril-allocated deaths vs 2231 [7.69%] placebo; 2p=002), which corresponds to an absolute difference of 4.9 SD 2.2 fewer deaths per 1000 patients treated for 1 month. The absolute benefits appeared to be larger (perhaps about 10 fewer deaths per 1000) in certain higher-risk groups, such as those presenting with a history of previous MI or with heart failure. The survival advantage appeared to be maintained in the longer term (5.4 [SD 2.8] fewer deaths per 1000 at 12 months). Captopril was associated with an increase of 52 (SD 2) patients per 1000 in hypotension considered severe enough to require termination of study treatment, of 5 (SD 2) per 1000 in reported cardiogenic shock, and of 5 (SD 1) per 1000 in some degree of renal dysfunction. it produced no excess of deaths on days 0-1, even among patients with low blood pressure at entry. Mononitrate There was no significant reduction in 5-week mortality, either overall (2129 [7.34%] mononitrate-allocated deaths vs 2190 [7.54%] placebo) or in any subgroup examined (including those not receiving shortterm non-study intravenous or oral nitrates at entry). Further follow-up did not indicate any later survival advantage. The only significant side-effect of the mononitrate regimen studied was an increase of 15 (SD 2) per 1000 in hypotension. Those allocated active treatment had somewhat fewer deaths on days 0-1, which is reassuring about the safety of using nitrates early in acute MI. Magnesium There was no significant reduction in 5-week mortality, either overall (2216 [7.64%] magnesium-allocated deaths vs 2103 [7.24%] control) or in any subgroup examined (including those treated early or late after symptom onset or in the presence or absence of fibrinolytic or antiplatelet therapies, or those at high risk of death). Further follow-up did not indicate any later survival advantage. In contrast with some previous small trials, there was a significant excess with magnesium of 12 (SD 3) per 1000 in heart failure and of 5 (SD 2) per 1000 in reported cardiogenic shock during or just after the infusion period. Magnesium was also associated with an increase of 11 (SD 2) per 1000 in hypotension considered severe enough to require termination of study treatment, of 3 (SD 0.6) per 1000 in bradycardia, and of 3 (SD 0.4) per 1000 in a cutaneous flushing or burning sensation (but assessment of magnesium involved open control). There was no evidence of a net adverse effect on mortality on days 0-1. Because of its size, ISIS-4 provides reliable evidence about the effects of adding each of these three treatments to established treatments for acute MI. Intravenous magnesium was ineffective, and although oral nitrate therapy appeared safe it did not produce a clear reduction in 1-month mortality. Other trials have shown that starting long-term converting enzyme inhibitor (CEI) therapy in the weeks or months after MI in patients with impaired ventricular function avoids about 2 deaths per 1000 patients per month of treatment. ISIS-4, GISSI-3, and smaller studies now collectively demonstrate that, for a wide range of patients without clear contraindications, CEI therapy started early in acute MI prevents about 5 deaths per 1000 in the first month (2p=0.006), with somewhat greater benefits in higher-risk patients. This benefit from 1 month of early CEI treatment seems to persist for at least the first year.	ESTUDIOS CARDIOL LATINOAMER, ROSARIO, ARGENTINA; SANAR ALLENDE, CORDOBA, ARGENTINA; CLIN PERGAMINO, PERGAMINO, BUENOS AIRES, ARGENTINA; HOSP SAN BERNARDO, SALTO, BUENOS AIRES, ARGENTINA; ROYAL MELBOURNE HOSP, MELBOURNE, VIC, AUSTRALIA; UNIV ZH GENT, GHENT, BELGIUM; HOP ERASME, BRUSSELS, BELGIUM; INST DANTE PAZZANESTE CARDIOL, SAO PAULO, BRAZIL; HAMILTON GEN HOSP, HAMILTON, ON, CANADA; CLIN LAS CONDES, SANTIAGO, CHILE; UNIV HELSINKI, CENT HOSP, HELSINKI, FINLAND; HOP NEUROCARDIOL, LYON, FRANCE; KLINIKUM STEGLITZ, BERLIN, GERMANY; HYGEIA, ATHENS, GREECE; HUNGARIAN INST CARDIOL, BUDAPEST, HUNGARY; LADY DAVIES CARMEL HOSP, HAIFA, ISRAEL; MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY; INST NACL CARDIOL, MEXICO CITY, DF, MEXICO; CTR HUMAN DRUG RES, LEIDEN, NETHERLANDS; ACAD MED CTR, AMSTERDAM, NETHERLANDS; GREEN LANE HOSP, AUCKLAND 3, NEW ZEALAND; AUCKLAND HOSP, AUCKLAND, NEW ZEALAND; NATL HOSP NORWAY, OSLO, NORWAY; SENTRALSJUKEHUSET & SOGN FJORDANE, FORDE, NORWAY; HOSP SANTA CRUZ, INST CORACAO, LINDA A VELHA, PORTUGAL; JOHANNESBURG HOSP, JOHANNESBURG, SOUTH AFRICA; DR PESET ALEIXANDRE, VALENCIA, SPAIN; OSPED CIVICO, LUGANO, SWITZERLAND; OSPED SAN GIOVANNI BELLINZONA, BELLINZONA, SWITZERLAND; UNIV SPITAL ZURICH, ZURICH, SWITZERLAND; UNIV OXFORD, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND; JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND; LEICESTER ROYAL INFIRM, LEICESTER, LEICS, ENGLAND; ROYAL SUSSEX CTY HOSP, BRIGHTON, E SUSSEX, ENGLAND; NATL HEART HOSP, LONDON, ENGLAND; BRITISH HEART FDN, LONDON, ENGLAND; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV BOSTON HOSP, BOSTON, MA 02118 USA; COLUMBIA UNIV, NEW YORK, NY USA; SOC URUGUAYA CARDIOL, MONTEVIDEO, URUGUAY; DR DOMINGO LUCIANI, CARACAS, VENEZUELA	Royal Melbourne Hospital; Ghent University; Universite Libre de Bruxelles; Instituto Dante Pazzanese de Cardiologia; McMaster University; Clinica Las Condes; University of Helsinki; Helsinki University Central Hospital; CHU Lyon; Clalit Health Services; Carmel Medical Center; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; National Institute of Cardiology - Mexico; University of Amsterdam; Academic Medical Center Amsterdam; Auckland City Hospital; University of Oslo; National Hospital Norway; University of Witwatersrand; Regional Hospital of Bellinzona & Valleys, San Giovanni; University of Zurich; University Zurich Hospital; University of Oxford; University of Oxford; University of Leicester; University of Brighton; Imperial College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Harvard University; Brigham & Women's Hospital; Columbia University	COLLINS, R (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED,ISIS,BHF,MRC, ICRF CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.		Cairns, John/AAI-8744-2021; De Backer, Guy/AAI-4607-2021; Cohen, Adam/G-3756-2010; Arteta-Arteta, Donaldo S/D-3894-2014	Arteta-Arteta, Donaldo S/0000-0001-8909-563X; Sandoya, Edgardo/0000-0003-4125-3293				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ALTURA BT, 1987, BRIT J PHARMACOL, V91, P449, DOI 10.1111/j.1476-5381.1987.tb11235.x; AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1994, Lancet, V344, P91; ANTMAN EM, 1994, CIRCULATION, V90, P325; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BALL SG, 1993, LANCET, V342, P821; BERTSCHAT F, 1989, MAGNESIUM-B, V11, P155; CASSCELLS W, 1994, LANCET, V343, P807, DOI 10.1016/S0140-6736(94)92020-6; COHEN J, 1994, SCIENCE, V264, P1534, DOI 10.1126/science.8202707; COLLINS R, 1995, OXFORD TXB MED; CONWAY M, 1989, Q J MED, V70, P973; DEVITA C, 1994, LANCET, V343, P1115; DIPASQUALE P, 1994, INT J CARDIOL, V43, P43; ERLEBACHER JA, 1984, J AM COLL CARDIOL, V4, P201, DOI 10.1016/S0735-1097(84)80203-X; ERTL G, 1982, CIRCULATION, V65, P40, DOI 10.1161/01.CIR.65.1.40; FERRARI R, 1986, J MOL CELL CARDIOL, V18, P487, DOI 10.1016/S0022-2828(86)80914-2; FLATHER M, 1994, EUR HEART J, V15, P608, DOI 10.1093/oxfordjournals.eurheartj.a060556; FOY SG, 1994, AM J CARDIOL, V73, P1180, DOI 10.1016/0002-9149(94)90178-3; FREEDMAN LS, 1992, STAT MED, V11, P23, DOI 10.1002/sim.4780110105; GALCERATOMAS J, 1993, EUR HEART J, V14, P259, DOI 10.1093/eurheartj/14.2.259; HALL AS, 1994, LANCET, V343, P1632; HAVERKAMP W, 1988, EUR HEART J, V9, P228; HOCHMAN JS, 1994, CIRCULATION, V90, P19; HUNT D, 1992, LANCET, V339, P753; JAMES MA, 1990, CLIN SCI, V79, P499, DOI 10.1042/cs0790499; JUGDUTT B, 1990, CIRCULATION, V82, P442; JUGDUTT B I, 1990, Journal of the American College of Cardiology, V15, p214A; JUGDUTT BI, 1993, CAN J CARDIOL, V9, P103; KENDALL MJ, 1990, J CLIN PHARM THER, V15, P169, DOI 10.1111/j.1365-2710.1990.tb00373.x; KINGMA JH, 1994, EUR HEART J, V15, P898, DOI 10.1093/oxfordjournals.eurheartj.a060608; KLONER RA, 1993, CLIN CARDIOL, V16, P95, DOI 10.1002/clc.4960160204; LATINI R, 1994, CLIN PHARMACOL THER, V56, P680, DOI 10.1038/clpt.1994.194; LIU LS, 1995, LANCET, V345, P686; Magrini F, 1988, Am J Med, V84, P55, DOI 10.1016/0002-9343(88)90205-7; MCALPINE HM, 1988, BRIT HEART J, V60, P117; MICHOROWSKI B, 1983, EUR HEART J, V4, P259, DOI 10.1093/oxfordjournals.eurheartj.a061457; NABEL EG, 1991, J AM COLL CARDIOL, V17, P467, DOI 10.1016/S0735-1097(10)80117-2; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PARKER JO, 1987, NEW ENGL J MED, V316, P1440, DOI 10.1056/NEJM198706043162303; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; PETO R, 1978, BIOMEDICINE, V28, P24; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PFEFFER MA, 1995, NEW ENGL J MED, V332, P118, DOI 10.1056/NEJM199501123320210; RAY SG, 1993, BRIT HEART J, V69, P215; RIDKER PM, 1993, CIRCULATION, V87, P1969, DOI 10.1161/01.CIR.87.6.1969; ROFFE C, 1994, BRIT HEART J, V71, P141; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SCHUSTER EH, 1979, CIRCULATION, V60, P1532, DOI 10.1161/01.CIR.60.7.1532; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SHECHTER M, 1993, CIRCULATION, V88, P395; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; THADANI U, 1980, CIRCULATION, V61, P526, DOI 10.1161/01.CIR.61.3.526; VANGILST WH, 1986, J CARDIOVASC PHARM, V8, P722; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; WOODS KL, 1994, LANCET, V343, P816, DOI 10.1016/S0140-6736(94)92024-9; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x; YUSUF S, 1993, CIRCULATION, V87, P2043, DOI 10.1161/01.CIR.87.6.2043; YUSUF S, 1988, LANCET, V1, P1088; 1991, AM J CARDIOL, V68, pD87; 1992, J AM COLL CARDIOL, V19, pA206	70	1528	1586	0	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	1995	345	8951					669	685						17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7661937				2022-12-28	WOS:A1995QM73200006
J	WHITE, RE; LEE, AB; SHCHERBATKO, AD; LINCOLN, TM; SCHONBRUNN, A; ARMSTRONG, DL				WHITE, RE; LEE, AB; SHCHERBATKO, AD; LINCOLN, TM; SCHONBRUNN, A; ARMSTRONG, DL			POTASSIUM CHANNEL STIMULATION BY NATRIURETIC PEPTIDES THROUGH CGMP-DEPENDENT DEPHOSPHORYLATION	NATURE			English	Article							CA-2+-ACTIVATED K+ CHANNELS; ANTERIOR-PITUITARY-CELLS; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; CALCIUM CHANNELS; CYCLIC-GMP; MODULATION; PHOSPHATASES; RECEPTOR; CYCLASE	NATRIURETIC peptides inhibit the release and action of many hormones through cyclic guanosine monophosphate (cGMp)1,2, but the mechanism of cGMP action is unclear3. In frog ventricular muscle and guinea-pig hippocampal neurons, cGMP inhibits voltage-activated Ca2+ currents by stimulating phosphodiesterase activity and reducing intracellular cyclic AMP4,5; however, this mechanism is not involved in the action of cGMP on other channels6 or on Ca2+ channels in other cells7,8. Natriuretic peptide receptors in the rat pituitary also stimulate guanylyl cyclase activity but inhibit secretion by increasing membrane conductance to potassium9,10. In an electrophysiological study on rat pituitary tumour cells11, we identified the large-conductance, calcium- and voltage-activated potassium channels (BK) as the primary target of another inhibitory neuropeptide, somatostatin. Here we report that atrial natriuretic peptide also stimulates BK channel activity in GH4C1 cells through protein dephosphorylation. Unlike somatostatin, however, the effect of atrial natriuretic peptide on BK channel activity is preceded by a rapid and potent stimulation of cGMP production and requires cGMP-dependent protein kinase activity. Protein phosphatase activation by cGMP-dependent kinase could explain the inhibitory effects of natriuretic peptides on electrical excitability and the antagonism of cGMP and cAMP in many systems12.	NIEHS, CELLULAR & MOLEC PHARMACOL LAB, RES TRIANGLE PK, NC 27709 USA; UNIV ALABAMA, DEPT PATHOL, BIRMINGHAM, AL 35294 USA; UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Alabama System; University of Alabama Birmingham; University of Texas System								ANTONI FA, 1990, J ENDOCRINOL, V126, P183, DOI 10.1677/joe.0.1260183; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DAYANITHI G, 1990, J ENDOCRINOL, V125, P39, DOI 10.1677/joe.0.1250039; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; DORFINGER LJ, 1983, ENDOCRINOLOGY, V13, P1541; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; Goldberg N D, 1973, Adv Cyclic Nucleotide Res, V3, P155; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; OHYA Y, 1989, PFLUG ARCH EUR J PHY, V414, P257, DOI 10.1007/BF00584624; ONO K, 1992, J PHYSIOL-LONDON, V454, P673, DOI 10.1113/jphysiol.1992.sp019286; REINHART PH, 1991, J NEUROSCI, V11, P1627; SCHONBRUNN A, 1990, METABOLISM, V39, P96, DOI 10.1016/0026-0495(90)90221-W; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; STEINER AL, 1979, METHOD HORM RADIOIMM, P3; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; TOHSE N, 1991, CIRC RES, V69, P325, DOI 10.1161/01.RES.69.2.325; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WILLIAMS DL, 1988, P NATL ACAD SCI USA, V85, P9360, DOI 10.1073/pnas.85.23.9360	31	241	252	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					263	266		10.1038/361263a0	http://dx.doi.org/10.1038/361263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	7678699				2022-12-28	WOS:A1993KH61400061
J	ZAGHOUANI, H; STEINMAN, R; NONACS, R; SHAH, H; GERHARD, W; BONA, C				ZAGHOUANI, H; STEINMAN, R; NONACS, R; SHAH, H; GERHARD, W; BONA, C			PRESENTATION OF A VIRAL T-CELL EPITOPE EXPRESSED IN THE CDR3 REGION OF A SELF IMMUNOGLOBULIN MOLECULE	SCIENCE			English	Article							DENDRITIC CELLS; LYMPHOCYTES-T; GENE SEGMENTS; FC-RECEPTORS; ANTIGEN; CHAIN; RECOGNITION; SURFACE	Synthetic peptides corresponding to microbial epitopes stimulate T cell immunity but their immunogenicity is poor and their half-lives are short. A viral epitope inserted into the complementarity-determining region 3 (CDR3) loop of the heavy chain of a self immunoglobulin (Ig) molecule was generated from the Ig context and was presented by I-E(d) class II molecules to virus-specific, CD4+ T cells. Chimeric Ig-peptide was presented 100 to 1000 times more efficiently than free synthetic peptide and was able to prime virus-specific T cells in vivo. These features suggest that antigenized Ig can provide an improved and safe vaccine for the presentation of microbial and other peptides.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; WISTAR INST,PHILADELPHIA,PA 19104	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; The Wistar Institute			Steinman, Ralph/F-7729-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013013, R01AI018316, R01AI013013, P01AI024460] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24460, AI13013, AI18316] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEGAY M, 1992, J VIROL, V66, P1199, DOI 10.1128/JVI.66.2.1199-1201.1992; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; CHIMINI G, 1989, J EXP MED, V169, P297, DOI 10.1084/jem.169.1.297; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; FREIMUTH P, 1990, RES MICROBIOL, V141, P995, DOI 10.1016/0923-2508(90)90139-H; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; HABERMAN AM, 1990, J IMMUNOL, V145, P3087; HAN YS, 1991, J EXP MED, V174, P733; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; MOSMANN TJ, 1983, IMMUNOL METHODS, V66, P55; NUSSENZWEIG MC, 1980, J EXP MED, V151, P1196, DOI 10.1084/jem.151.5.1196; NUSSENZWEIG MC, 1981, J EXP MED, V154, P168, DOI 10.1084/jem.154.1.168; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; RATHBUN GA, 1988, J MOL BIOL, V202, P383, DOI 10.1016/0022-2836(88)90272-0; ROMANI N, 1989, J EXP MED, V169, P1153, DOI 10.1084/jem.169.3.1153; SANZ I, 1987, P NATL ACAD SCI USA, V84, P1085, DOI 10.1073/pnas.84.4.1085; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; UNKELESS JC, 1981, ADV IMMUNOL, V31, P247, DOI 10.1016/S0065-2776(08)60922-0; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; ZAGHOUANI H, 1992, J IMMUNOL, V148, P3604; ZAGHOUANI H, UNPUB	25	112	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					224	227		10.1126/science.7678469	http://dx.doi.org/10.1126/science.7678469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678469				2022-12-28	WOS:A1993KF71900030
J	OGDEN, CW; REDDY, P; JOHNSON, H; RAMSAY, JWA; CARTER, SS				OGDEN, CW; REDDY, P; JOHNSON, H; RAMSAY, JWA; CARTER, SS			SHAM VERSUS TRANSURETHRAL MICROWAVE THERMOTHERAPY IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC BLADDER OUTFLOW OBSTRUCTION	LANCET			English	Article							TRANS-URETHRAL RESECTION; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; HYPERTHERMIA; HYPERPLASIA	Transurethral microwave thermotherapy (TUMT) is a single-session, minimally invasive outpatient treatment for patients with symptoms of benign prostatic bladder outflow obstruction. We designed a prospective randomised trial to identify any placebo response. Patients with a Madsen symptom score over 8 for at least 6 months were eligible for study. Two measurements of urinary flow less than 15 mL/s and a residual urine of under 350 mL were also required for entry. Patients with renal dysfunction, upper urinary tract disease, co-existing bladder disease, and malignant prostatic change were excluded. 43 patients were studied: 21 were randomised to receive a sham treatment and 22 to thermotherapy. Sham treatments were done with the urethral applicator in situ. 40 patients were available for evaluation at 3 months. 2 patients had delayed follow-up and 1 patient randomised to TUMT has undergone transurethral resection. The thermotherapy group showed a 70% decrease (from 14.5 to 4.3) in the mean Madsen score, a 53% increase in flow-rate (8.5 to 13.0 mL/s), and 92% decrease in residual urine volume (147 to 12 mL). No significant change was seen in these mean indices in the sham group. There was no difference in the main complication of transient haematuria between the two groups. However, there was a 22% frequency of acute retention in the TUMT group. The results show little significant placebo component to the subjective and objective improvement that occurs in patients who have received TUMT.			OGDEN, CW (corresponding author), CHARING CROSS HOSP,DEPT UROL,PROSTATE UNIT,LONDON W6 8RP,ENGLAND.							BAERT L, 1990, J UROLOGY, V144, P1383, DOI 10.1016/S0022-5347(17)39748-3; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BRUSKEWITZ RC, 1986, J UROLOGY, V136, P613, DOI 10.1016/S0022-5347(17)44991-3; CARTER S S, 1991, Journal of Endourology, V5, P137, DOI 10.1089/end.1991.5.137; DEVONEC M, 1991, Journal of Endourology, V5, P129, DOI 10.1089/end.1991.5.129; EDWARDS LE, 1983, HIST NONSURGICAL TRE, P30; FABRICIUS P G, 1991, Journal of Urology, V145, p363A; GRAVERSEN PH, 1989, J UROLOGY, V141, P475, DOI 10.1016/S0022-5347(17)40864-0; LEPOR H, 1989, J UROLOGY, V141, P1283, DOI 10.1016/S0022-5347(17)41282-1; LEPOR H, 1992, J UROLOGY, V147, P639, DOI 10.1016/S0022-5347(17)37331-7; LEPOR H, 1990, J UROLOGY, V143, P533, DOI 10.1016/S0022-5347(17)40012-7; LIBMAN E, 1987, UROLOGY, V29, P467, DOI 10.1016/0090-4295(87)90031-8; LINDNER A, 1987, BRIT J UROL, V60, P567, DOI 10.1111/j.1464-410X.1987.tb05043.x; LUNDHUS E, 1987, SCAND J UROL NEPHROL, V21, P9, DOI 10.3109/00365598709180282; MADSEN PO, 1983, BENIGN PROSTATIC HYP, P763; MCLOUGHLIN J, 1990, BRIT J UROL, V65, P313, DOI 10.1111/j.1464-410X.1990.tb14746.x; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; MELCHIOR J, 1974, J UROLOGY, V112, P634, DOI 10.1016/S0022-5347(17)59817-1; MOLLERNIELSON C, 1987, UROL INT, V40, P3; PETTERSSON S, 1992, J UROLOGY, V147, pA371; SAPOZINK MD, 1990, J UROLOGY, V143, P944, DOI 10.1016/S0022-5347(17)40146-7; STIRRAT GM, 1992, ANN ROY COLL SURG, V74, P80; YERUSHALMI A, 1985, J UROLOGY, V133, P873, DOI 10.1016/S0022-5347(17)49270-6; ZERBIB M, 1992, J UROLOGY, V147, P1048, DOI 10.1016/S0022-5347(17)37464-5	24	114	114	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					14	17		10.1016/0140-6736(93)92482-9	http://dx.doi.org/10.1016/0140-6736(93)92482-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	7678047				2022-12-28	WOS:A1993KF02700005
J	WINN, WC; WESTENFELD, FW				WINN, WC; WESTENFELD, FW			INFLUENZA-A VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											WINN, WC (corresponding author), UNIV VERMONT,COLL MED,BURLINGTON,VT 05405, USA.								0	5	5	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					912	912		10.1056/NEJM199510053331405	http://dx.doi.org/10.1056/NEJM199510053331405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666877				2022-12-28	WOS:A1995RX19900005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW SAFETY STANDARD FOR MEDICAL DEVICE WIRES PROPOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-28	WOS:A1995RV73400005
J	STEWART, T; TSAI, SJ; GRAYSON, H; HENDERSON, R; OPELZ, G				STEWART, T; TSAI, SJ; GRAYSON, H; HENDERSON, R; OPELZ, G			INCIDENCE OF DE-NOVO BREAST-CANCER IN WOMEN CHRONICALLY IMMUNOSUPPRESSED AFTER ORGAN-TRANSPLANTATION	LANCET			English	Article							MAMMARY-TUMOR VIRUS; NATURAL-KILLER-CELL; SUBSET	In mice, retrovirus-associated breast cancers are promoted by immune mechanisms, and immunosuppression during the premalignant phase reduces the incidence of breast cancer and prolongs life. If some women likewise have immune of cancer, the incidence of breast in receiving therapeutic immunosuppression should be lower than that in a comparable cohort of non-immunosuppressed women. We examined the incidence of de-novo breast cancer arising in women receiving immunosuppressive therapy after kidney or heart transplantation, comparing the figures with published rates. In 25 914 immunosuppressed women followed for 1-11 years there were 86 cases of breast cancer compared with 113.8 expected (p=0.009). Incidence was particularly low in the first transplant year with relative risk 0.49, rising to 0.84 in subsequent years. For all other major cancers the incidence was higher in the immunosuppressed women. If, as in mice, the reduced incidence of breast cancer is a direct effect of immunosuppression, these observations raise the possibility of therapeutic manipulation of specific immune mechanisms that promote tumour growth.	ROCHE DIAGNOST SYST INC,BRANCHBURG,NJ; UNIV NEWCASTLE UPON TYNE,DEPT MATH & STAT,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; UNIV HEIDELBERG,DEPT TRANSPLANTAT IMMUNOL,HEIDELBERG,GERMANY	Newcastle University - UK; Ruprecht Karls University Heidelberg	STEWART, T (corresponding author), OTTAWA GEN HOSP,ROOM LM18,501 SMYTH RD,OTTAWA,ON K1H 8L6,CANADA.							AVIS F, 1974, J NATL CANCER I, V52, P1041, DOI 10.1093/jnci/52.4.1041; BLAIR PB, 1971, ISRAEL J MED SCI, V7, P161; Callahan R, 1989, Immunol Ser, V43, P623; CANNON GB, 1977, INT J CANCER, V19, P487, DOI 10.1002/ijc.2910190409; CANNON GB, 1978, J NATL CANCER I, V61, P1181, DOI 10.1093/jnci/61.5.1181; CANNON GB, 1982, J NATL CANCER I, V68, P935; DION AS, 1987, J NATL CANCER I, V79, P207; DION AS, 1987, BREAST CANCER RES TR, V9, P155, DOI 10.1007/BF01807369; EMMANOUEL DS, 1981, CHRONIC RENAL FAILUR, P46; EVANS I, 1994, LANCET, V343, P1085; GELBER C, 1992, CANCER RES, V52, P6507; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Holland J. F., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P218; KATANO M, 1994, CANCER IMMUNOL IMMUN, V39, P161, DOI 10.1007/BF01533381; LEVINE PH, 1984, INT J CANCER, V33, P305, DOI 10.1002/ijc.2910330305; MCCOY JL, 1984, J NATL CANCER I, V72, P569; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MOORE DH, 1974, CANCER RES, V34, P2322; PARKIN DM, 1992, CANCER INCIDENCE 5 C, V6; Pogo B. G. T., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P218; PRENT RT, 1994, CANCER RES, V54, P908; PROSS HF, 1984, INT J CANCER, V34, P303, DOI 10.1002/ijc.2910340303; RAMEY WG, 1979, BRIT J SURG, V66, P848, DOI 10.1002/bjs.1800661205; ROBINSON E, 1993, CANCER IMMUNOL IMMUN, V37, P209, DOI 10.1007/BF01525437; RODER JC, 1982, J CLIN IMMUNOL, V2, P249, DOI 10.1007/BF00915064; SANNER T, 1979, Cancer Research, V39, P654; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; STEWART THM, 1994, LANCET, V344, P351, DOI 10.1016/S0140-6736(94)91396-X; STEWART THM, 1994, LANCET, V343, P403; WANG RF, 1995, J IMMUNOL, V154, P1797; WEI WZ, 1989, CANCER RES, V49, P2709; WEI WZ, 1993, SEMIN CANCER BIOL, V4, P205; WEI WZ, 1979, J IMMUNOL, V122, P2059; YEFENOF E, 1992, P NATL ACAD SCI USA, V89, P728, DOI 10.1073/pnas.89.2.728	35	186	188	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					796	798		10.1016/S0140-6736(95)91618-0	http://dx.doi.org/10.1016/S0140-6736(95)91618-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674744	Bronze			2022-12-28	WOS:A1995RW25800009
J	WIJGERDE, M; GROSVELD, F; FRASER, P				WIJGERDE, M; GROSVELD, F; FRASER, P			TRANSCRIPTION COMPLEX STABILITY AND CHROMATIN DYNAMICS IN-VIVO	NATURE			English	Article							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; LOCUS-CONTROL REGION; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITE; ACTIVATION-REGION; ERYTHROID-CELLS; EXPRESSION; ENHANCER	Distant regulatory sequences affect transcription through long-range chromatin interactions. Visualization of transcriptional activity of genes that compete for distant elements, using the globin locus as a model, has revealed the dynamics of chromatin Interactions in vivo. Multiple genes appear to be transcribed alternately rather than at the same time to generate several messenger RNAs in one cell. The regulator may stably complex with one gene at a time and switch back and forth between genes in a flip-flop mechanism.	NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	WIJGERDE, M (corresponding author), ERASMUS UNIV ROTTERDAM,MGC DEPT CELL BIOL & GENET,3015 GE ROTTERDAM,NETHERLANDS.		Fraser, Peter/B-7549-2009	Fraser, Peter/0000-0002-0041-1227				ARNDTJOVIN D, 1985, J HISTOCHEM CYTOCHEM, V25, P585; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; CURTIS PJ, 1977, COLD SPRING HARB SYM, V42, P971; DEVILLIERS J, 1982, COLD SPRING HARB SYM, V47, P911; DILLON N, 1990, NATURE, V350, P252; DIRKS RW, 1993, J CELL SCI, V104, P1187; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FRASER P, 1987, GENE DEV, V1, P885; FURUKAWA T, 1994, BLOOD, V83, P1412; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; STROUBOULIS J, 1994, THESIS OPEN U UK; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TERASIMA T, 1963, EXP CELL RES, V30, P344, DOI 10.1016/0014-4827(63)90306-9; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WASYLYK B, 1983, CELL, V32, P503, DOI 10.1016/0092-8674(83)90470-1; ZHANG G, 1994, NATURE, V372, P22	36	420	429	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					209	213		10.1038/377209a0	http://dx.doi.org/10.1038/377209a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675106	Green Submitted			2022-12-28	WOS:A1995RV87200031
J	COHEN, BM; RENSHAW, PF; STOLL, AL; WURTMAN, RJ; YURGELUNTODD, D; BABB, SM				COHEN, BM; RENSHAW, PF; STOLL, AL; WURTMAN, RJ; YURGELUNTODD, D; BABB, SM			DECREASED BRAIN CHOLINE UPTAKE IN OLDER ADULTS - AN IN-VIVO PROTON MAGNETIC-RESONANCE SPECTROSCOPY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT-BRAIN; CEREBROSPINAL-FLUID; H-1-NMR SPECTROSCOPY; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; BARRIER TRANSPORT; CELL-MEMBRANES; METABOLISM; NEURONS; ACETYLCHOLINE	Objective.-To test the hypothesis that uptake of circulating choline into the brain decreases with age, because alterations in metabolism of choline may be a factor contributing to age-related degenerative changes in the brain. Design.-Cohort comparison in younger and older adults. Participants.-Subjects were chosen consecutively from lists of healthy volunteers screened by medical and psychiatric interviews and laboratory tests. Younger adults (n=12) were between the ages of 20 and 40 years (mean age, 32 years), and older adults (n=16) were between the ages of 60 and 85 years (mean age, 73 years). Interventions.-After fasting overnight, subjects received choline, as the bitartrate, to yield free choline equal to 50 mg/kg of body weight. Blood was drawn for determination of plasma choline concentration by high-performance liquid chromatography, and proton magnetic resonance spectroscopy (H-1-MRS) was performed to determine the relative concentration of cytosolic choline-containing compounds in the brain at baseline and after ingestion of choline. Main Outcome Measures.-Plasma choline and cytosolic choline-containing compounds in the brain, estimated as the ratio of the choline resonance to the creatine resonance on H-1-MRS scans of the basal ganglia, were compared following blinded analyses of data from subject cohorts studied at baseline and 3 hours after choline ingestion. Results.-Levels of plasma choline and cytosolic choline-containing compounds in brain were similar at baseline in younger and older subjects. Following ingestion of choline, plasma choline concentration increased by similar proportions (76% and 80%) in both younger and older subjects. Brain cytosolic choline-containing compounds increased substantially in younger subjects (mean increase, 60%; P<.001 vs baseline). Older subjects showed a much smaller increase in brain choline-containing compounds (mean, 16%, P<.001 vs the increase in younger subjects). Conclusion.-Uptake of circulating choline into the brain decreases with age. Given the key role of choline in neuronal structure and function, this change may be a contributing factor in onset in late life of neurodegenerative, particularly dementing, illnesses in which cholinergic neurons show particular susceptibility to loss.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; MIT,CLIN RES CTR,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,PSYCHOPHARMACOL UNIT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital	COHEN, BM (corresponding author), MCLEAN HOSP,CTR BRAIN IMAGING,115 MILL ST,BELMONT,MA 02178, USA.		Renshaw, Perry/O-1384-2018; Cohen, Bruce M./AAZ-4986-2020		NIMH NIH HHS [MH28783, MH31154, MH38313] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH028783, P01MH031154, R01MH028783] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ansell G B, 1977, Int Rev Neurobiol, V20, P1, DOI 10.1016/S0074-7742(08)60649-2; ARMSTRONG DM, 1993, NEUROBIOL AGING, V14, P457, DOI 10.1016/0197-4580(93)90104-J; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BARTUS RT, 1984, NUTRITION GERONTOLOG, P191; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BRINKMAN SD, 1982, J CLIN PSYCHOPHARM, V2, P281; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P799, DOI 10.1016/0730-725X(93)90197-L; COHEN BM, 1985, LIFE SCI, V37, P1403, DOI 10.1016/0024-3205(85)90079-7; COHEN BM, 1982, AM J PSYCHIAT, V139, P1162; CORNFORD EM, 1978, J NEUROCHEM, V30, P299, DOI 10.1111/j.1471-4159.1978.tb06530.x; FISCHER W, 1992, NEUROBIOL AGING, V13, P9, DOI 10.1016/0197-4580(92)90003-G; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; GRIFFEY RH, 1990, J MAGN RESON, V88, P161, DOI 10.1016/0022-2364(90)90120-X; GRINNA LS, 1977, GERONTOLOGY, V23, P452, DOI 10.1159/000212222; GROWDON JH, 1977, J NEUROCHEM, V28, P229, DOI 10.1111/j.1471-4159.1977.tb07732.x; GROWDON JH, 1977, ANN NEUROL, V1, P418, DOI 10.1002/ana.410010503; GROWDON JH, 1977, NEW ENGL J MED, V297, P524, DOI 10.1056/NEJM197709082971002; GUZE BH, 1991, PSYCHIAT RES-NEUROIM, V40, P195, DOI 10.1016/0165-1781(91)90158-L; HETHERINGTON HP, 1994, MAGNET RESON MED, V32, P565, DOI 10.1002/mrm.1910320504; HOLLISTER LE, 1978, LIFE SCI, V23, P17, DOI 10.1016/0024-3205(78)90319-3; ISHIMARU H, 1991, J PHARMACOBIO-DYNAM, V14, P321, DOI 10.1248/bpb1978.14.321; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P55, DOI 10.1016/0006-3223(91)90210-D; JERNIGAN TL, 1993, ARCH NEUROL-CHICAGO, V47, P27; JOPE RS, 1979, J NEUROSCI RES, V4, P69, DOI 10.1002/jnr.490040110; KANG YS, 1990, J PHARMACOBIO-DYNAM, V13, P353, DOI 10.1248/bpb1978.13.353; KAYE WH, 1982, BIOL PSYCHIAT, V17, P275; KIKINIS R, 1992, JMRI-J MAGN RESON IM, V2, P619, DOI 10.1002/jmri.1880020603; KLEIN J, 1990, J NEUROCHEM, V55, P1231, DOI 10.1111/j.1471-4159.1990.tb03129.x; KLEIN J, 1992, J NEUROCHEM, V58, P870, DOI 10.1111/j.1471-4159.1992.tb09337.x; KLEIN J, 1991, J NEUROCHEM, V57, P370, DOI 10.1111/j.1471-4159.1991.tb03762.x; KLEIN J, 1993, NEUROCHEM INT, V22, P293, DOI 10.1016/0197-0186(93)90058-D; LOFFELHOLZ K, 1993, PROG BRAIN RES, V98, P197; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; MILLER LG, 1990, BIOCHEM PHARMACOL, V40, P1179, DOI 10.1016/0006-2952(90)90381-T; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; MOHS RC, 1979, AM J PSYCHIAT, V136, P1275; MOORADIAN AD, 1988, BRAIN RES, V440, P328, DOI 10.1016/0006-8993(88)91002-5; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; PARDRIDGE WM, 1986, FASEB J, V45, P2047; PERRY EK, 1980, AGE AGEING, V9, P1, DOI 10.1093/ageing/9.1.1; PERRY EK, 1992, NEUROBIOL AGING, V13, P393, DOI 10.1016/0197-4580(92)90113-C; PETROFF OAC, 1988, COMP BIOCHEM PHYS B, V90, P249, DOI 10.1016/0305-0491(88)90069-7; PETROFF OAC, 1988, J NEUROCHEM, V51, P163, DOI 10.1111/j.1471-4159.1988.tb04850.x; PETROFF OAC, 1989, NEUROLOGY, V39, P1197, DOI 10.1212/WNL.39.9.1197; Rinn W E, 1988, J Geriatr Psychiatry Neurol, V1, P144, DOI 10.1177/089198878800100304; ROUSER G, 1968, LIPIDS, V3, P284, DOI 10.1007/BF02531202; SCHMIDT DE, 1981, NEUROPHARMACOLOGY, V20, P535, DOI 10.1016/0028-3908(81)90205-7; SCREMIN OU, 1993, PROG BRAIN RES, V98, P191; SHENTON ME, 1991, SCHIZOPHR RES, V5, P103, DOI 10.1016/0920-9964(91)90037-R; SPECTOR R, 1989, J NEUROCHEM, V53, P1667, DOI 10.1111/j.1471-4159.1989.tb09229.x; STOLL AL, 1995, BIOL PSYCHIAT, V37, P170, DOI 10.1016/0006-3223(94)00120-R; THAL LJ, 1983, ANN NEUROL, V13, P491, DOI 10.1002/ana.410130504; TROMMER BA, 1982, J NEUROCHEM, V39, P1704, DOI 10.1111/j.1471-4159.1982.tb08006.x; TUCEK S, 1984, PROG BIOPHYS MOL BIO, V44, P1, DOI 10.1016/0079-6107(84)90011-7; ULUS IH, 1976, SCIENCE, V194, P1060, DOI 10.1126/science.10629; WECKER L, 1978, SCIENCE, V199, P86, DOI 10.1126/science.199.4324.86; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; WURTMAN RJ, 1977, LANCET, V2, P68; WURTMAN RJ, 1985, NEUROCHEM INT, V7, P869; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1992, J AM COLL NUTR, V11, P473	62	116	121	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					902	907		10.1001/jama.274.11.902	http://dx.doi.org/10.1001/jama.274.11.902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674505				2022-12-28	WOS:A1995RU60300030
J	LILLIEN, L				LILLIEN, L			CHANGES IN RETINAL CELL FATE INDUCED BY OVEREXPRESSION OF EGF RECEPTOR	NATURE			English	Article							TGF-ALPHA; DIFFERENTIATION; GENE; PROLIFERATION; CULTURES; LINEAGE; INVITRO; PROTEIN; MOUSE; ENTRY	THE differentiation of multipotential progenitor cells in the vertebrate retina into photoreceptors, neurons and glial cells is regulated in part by cell-cell signalling(1-11). Transforming growth factor (TGF)-alpha is one of the extracellular signals implicated in the control of several aspects of retinal development, including proliferation and cell fate(5,6,11-13). The way cells interpret pleiotropic signals such as TGF-alpha is influenced by the level of expression of epidermal growth factor receptor (EGF-R) in some cell lines(14,15). To address the influence of receptor level on responses of retinal progenitor cells to TGF-alpha, additional copies of EGF-Rs were introduced in vitro and in vivo with a retrovirus. Normally irt vitro, low concentrations of TGF-alpha stimulated proliferation whereas high concentrations biased choice of cell fate, inhibiting differentiation into rod photoreceptors while promoting differentiation into Muller glial cells, We report here that introduction of extra EGF-Rs into progenitor cells in vitro reduced the concentration of TGF-alpha required for changes in rod and Muller cell differentiation but did not enhance proliferation, Introduction of extra EGF-Rs in vivo increased the proportion of clones that contained Muller glial cells, suggesting that receptor level is normally limiting, These findings demonstrate that responsiveness to extracellular signals during development can be modulated by the introduction of additional receptors, and suggest that the level of expression of receptors for these signals contributes to the regulation of cell fate.			LILLIEN, L (corresponding author), MED COLL PENN, DEPT ANAT & NEUROBIOL, 3200 HENRY AVE, PHILADELPHIA, PA 19072 USA.							ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; ALTSHULER D, 1992, DEVELOPMENT, V114, P947; ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; Ausubel FM, 1988, MOL REPROD DEV; BJORKLUND H, 1985, NEUROSCI LETT, V54, P363, DOI 10.1016/S0304-3940(85)80061-6; FERRI RT, 1995, DEVELOPMENT, V121, P1151; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HUNTER DD, 1992, NEURON, V8, P399, DOI 10.1016/0896-6273(92)90269-J; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; LEUTTEKE NC, 1993, CELL, V73, P263; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LINSER P, 1984, ANN NY ACAD SCI, V429, P430, DOI 10.1111/j.1749-6632.1984.tb12369.x; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; REH TA, 1992, J NEUROBIOL, V23, P1067, DOI 10.1002/neu.480230811; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SPARROW JR, 1990, DEV BRAIN RES, V51, P69, DOI 10.1016/0165-3806(90)90259-2; TAYLOR M, 1990, J NEUROBIOL, V21, P470, DOI 10.1002/neu.480210308; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WATANABE T, 1990, NEURON, V3, P461; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	30	222	226	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					158	162		10.1038/377158a0	http://dx.doi.org/10.1038/377158a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675083				2022-12-28	WOS:A1995RU75400051
J	SAINIO, V; KEMPPAINEN, E; PUOLAKKAINEN, P; TAAVITSAINEN, M; KIVISAARI, L; VALTONEN, V; HAAPIAINEN, R; SCHRODER, T; KIVILAAKSO, E				SAINIO, V; KEMPPAINEN, E; PUOLAKKAINEN, P; TAAVITSAINEN, M; KIVISAARI, L; VALTONEN, V; HAAPIAINEN, R; SCHRODER, T; KIVILAAKSO, E			EARLY ANTIBIOTIC-TREATMENT IN ACUTE NECROTIZING PANCREATITIS	LANCET			English	Article							ACUTE NECROTIZING PANCREATITIS; ENHANCED COMPUTED-TOMOGRAPHY; ACUTE FULMINANT PANCREATITIS; EARLY DIAGNOSIS; SEPTIC COMPLICATIONS; NECROSIS; INFECTION; PROGNOSIS; RESECTION; SURGERY	Despite improvements in surgical treatment and intensive care, mortality from severe acute pancreatitis remains high. We have carried out a randomised study of 60 consecutive patients with alcohol-induced necrotising pancreatitis to find out whether early antibiotic treatment can improve outcome. 30 patients were assigned cefuroxime (4.5 g/day intravenously) from admission. In the second group, no antibiotic treatment was given until clinical or microbiologically verified infection or after a secondary rise in C-reactive protein. The inclusion criteria were C-reactive protein concentration above 120 mg/L within 48 h of admission and low enhancement (<30 Hounsfield units) on contrast-enhanced computed tomography. There were more infectious complications in the non-antibiotic than in the antibiotic group (mean per patient 1.8 vs 1.0, p=0.01). The most common cause of sepsis was Staphylococcus epidermidis; positive cultures were obtained from pancreatic necrosis or the central venous line in 14 of 18 patients with suspected but blood-culture-negative sepsis, Mortality was higher in the non-antibiotic group (seven vs one in the antibiotic group; p=0.03). Four of the eight patients who died had cultures from pancreatic necrosis positive for Staph epidermidis. We conclude that cefuroxime given early in necrotising pancreatitis is beneficial and may reduce mortality, probably by decreasing the frequency of sepsis.	UNIV HELSINKI,CENT HOSP,RADIOL CLIN,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT MED 2,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	SAINIO, V (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT SURG 2,SF-00290 HELSINKI,FINLAND.							BEGER HG, 1989, SURG CLIN N AM, V69, P529; BEGER HG, 1986, GASTROENTEROLOGY, V91, P433, DOI 10.1016/0016-5085(86)90579-2; BITTNER R, 1987, DIGEST DIS SCI, V32, P1082, DOI 10.1007/BF01300192; BRADLEY EL, 1989, AM J SURG, V158, P472, DOI 10.1016/0002-9610(89)90290-0; BRADLEY EL, 1991, INT J PANCREATOL, V9, P67; BUCHLER M, 1993, HEPATO-GASTROENTEROL, V40, P563; CLAVIEN PA, 1988, AM J SURG, V155, P457, DOI 10.1016/S0002-9610(88)80113-2; CORFIELD AP, 1985, LANCET, V2, P403; DEGIDIO A, 1991, BRIT J SURG, V78, P133, DOI 10.1002/bjs.1800780204; FINCH WT, 1976, ANN SURG, V183, P667, DOI 10.1097/00000658-197606000-00008; FLEISCHER K, 1979, MED KLIN, V74, P1589; GERZOF SG, 1987, GASTROENTEROLOGY, V93, P1315, DOI 10.1016/0016-5085(87)90261-7; GUNTHER HJ, 1991, BAILLIERE CLIN GASTR, V5, P773, DOI 10.1016/0950-3528(91)90020-2; Horn J, 1981, Aktuelle Probl Chir Orthop, V19, P87; HURLEY JE, 1987, AM SURGEON, V53, P29; KARIMGANI I, 1992, GASTROENTEROLOGY, V103, P1902; KIVILAAKSO E, 1984, ANN SURG, V199, P426, DOI 10.1097/00000658-198404000-00009; KIVISAARI L, 1983, SCAND J GASTROENTERO, V18, P39, DOI 10.3109/00365528309181556; KIVISAARI L, 1984, GASTROINTEST RADIOL, V9, P27, DOI 10.1007/BF01887796; Kivisaari L, 1991, Acta Radiol Suppl, V377, P20; KIVISAARI L, 1979, ANN CLIN RES, V11, P90; LODE H, 1983, DEUT MED WOCHENSCHR, V108, P1908, DOI 10.1055/s-2008-1069849; MULLER F, 1989, MED KLIN, V84, P323; PATTI MG, 1990, SURG CLIN N AM, V70, P1277; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; RANSON JHC, 1977, SURGERY, V82, P99; RATTNER DW, 1992, AM J SURG, V163, P105, DOI 10.1016/0002-9610(92)90261-O; SCHRODER T, 1984, ANN CHIR GYNAECOL FE, V73, P268; SCHRODER T, 1985, EUR J RADIOL, V5, P273; SCHRODER T, 1991, ANN SURG, V214, P663, DOI 10.1097/00000658-199112000-00004	30	337	351	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					663	667		10.1016/S0140-6736(95)92280-6	http://dx.doi.org/10.1016/S0140-6736(95)92280-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658819				2022-12-28	WOS:A1995RU04800009
J	BRUNS, D; JAHN, R				BRUNS, D; JAHN, R			REAL-TIME MEASUREMENT OF TRANSMITTER RELEASE FROM SINGLE SYNAPTIC VESICLES	NATURE			English	Article							IDENTIFIED LEECH NEURONS; NEUROTRANSMITTER RELEASE; CHROMAFFIN CELLS; TRANSMISSION; CULTURE; FUSION; SYNAPTOBREVIN; ACETYLCHOLINE; TETANUS	NEUROTRANSMITTER release is mediated by Ca2+ dependent exocytosis of synaptic vesicles', Neither the amount of transmitter released from individual synaptic vesicles nor the kinetics of this process have yet been directly determined, Using carbon fibres as electrochemical detectors(2,3), we have measured release of the neurotransmitter serotonin from cultured neurons of the leech(4). This technique allowed us to monitor transmitter discharge from single synaptic vesicles as spike-like oxidation currents at high time resolution, providing new insight into the mechanism of neuronal exocytosis, Two types of signals were characterized, corresponding to exocytosis of small clear and large dense core vesicles present in these cells, A small vesicle discharges about 4,700 transmitter molecules with a time constant in the region of 260 mu s, whereas large vesicles release their content of approximately 80,000 molecules with a time constant of about 1.3 ms, Release from both vesicle types is initiated rapidly, with a rise time of less than 60 mu s, suggesting an abrupt opening of a preassembled fusion pore.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University	BRUNS, D (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.			Jahn, Reinhard/0000-0003-1542-3498				ADLER EM, 1991, J NEUROSCI, V11, P1496; ALMERS W, 1989, SECRETION ITS CONTRO, P269; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BARTFAI T, 1988, ANNU REV PHARMACOL, V28, P285, DOI 10.1146/annurev.pa.28.040188.001441; BEAUDET A, 1981, J PHYSIOLOGY PARIS, V77, P193; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FUCHS PA, 1982, J PHYSIOL-LONDON, V323, P195, DOI 10.1113/jphysiol.1982.sp014068; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HENDERSON L, 1983, J PHYSL, V399, P309; HENDERSON LP, 1983, J PHYSIOL-LONDON, V340, P347, DOI 10.1113/jphysiol.1983.sp014766; KUFFLER DP, 1987, J COMP NEUROL, V256, P516, DOI 10.1002/cne.902560404; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WRONA MZ, 1990, BIOORG CHEM, V18, P291, DOI 10.1016/0045-2068(90)90005-P	21	337	344	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					62	65		10.1038/377062a0	http://dx.doi.org/10.1038/377062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659162				2022-12-28	WOS:A1995RT72500056
J	EYPASCH, E; LEFERING, R; KUM, CK; TROIDL, H				EYPASCH, E; LEFERING, R; KUM, CK; TROIDL, H			PROBABILITY OF ADVERSE EVENTS THAT HAVE NOT YET OCCURRED - A STATISTICAL REMINDER	BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE RANDOMIZED TRIAL; LAPAROSCOPIC CHOLECYSTECTOMY; OPEN APPENDECTOMY; SAFETY	The probability of adverse and undesirable events during and after operations that have not yet occurred in a finite number of patients (n) can be estimated with Hanley's simple formula, which gives the upper limit of the 95% confidence interval of the probability of such an event: upper limit of 95% confidence interval=maximum risk=3/n (for n>30). Doctors and surgeons should keep this simple rule in mind when complication rates of zero are reported in the literature and when they have not (yet) experienced a disastrous complication in a procedure.			EYPASCH, E (corresponding author), UNIV COLOGNE,KLINIKEN STADT KOLN,DEPT SURG 2,OSTMERHEIMER STR 200,D-51109 COLOGNE,GERMANY.							ATTWOOD SEA, 1992, SURGERY, V112, P497; COLLET D, 1993, SURG ENDOSC-ULTRAS, V7, P334, DOI 10.1007/BF00725952; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; FRAZEE RC, 1994, ANN SURG, V219, P725, DOI 10.1097/00000658-199406000-00017; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V259, P1743; HEBEBRAND D, 1994, CHIRURG, V65, P112; KUM CK, 1993, BRIT J SURG, V80, P1599, DOI 10.1002/bjs.1800801236; LARSON GM, 1992, AM J SURG, V163, P221, DOI 10.1016/0002-9610(92)90105-Z; MCANENA OJ, 1991, LANCET, V338, P693, DOI 10.1016/0140-6736(91)91267-X; PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002; Pier A, 1991, Surg Laparosc Endosc, V1, P8; TATE JJT, 1993, LANCET, V342, P633, DOI 10.1016/0140-6736(93)91757-D; TROIDL H, 1992, ENDOSCOPY, V24, P252, DOI 10.1055/s-2007-1010477; TROIDL H, 1993, LANGENBECKS ARCH C S, P59; 1991, NEW ENGL J MED, V324, P1073	15	226	229	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					619	620		10.1136/bmj.311.7005.619	http://dx.doi.org/10.1136/bmj.311.7005.619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663258	Green Published			2022-12-28	WOS:A1995RT72300025
J	ZHOU, XJ; BENSON, KF; ASHAR, HR; CHADA, K				ZHOU, XJ; BENSON, KF; ASHAR, HR; CHADA, K			MUTATION RESPONSIBLE FOR THE MOUSE PYGMY PHENOTYPE IN THE DEVELOPMENTALLY-REGULATED FACTOR HMGI-C	NATURE			English	Article							GROUP PROTEIN HMG-I(Y); GENE; EXPRESSION; DOMAIN; LOCUS	GROWTH is one of the fundamental aspects in the development of an organism. Classical genetic studies have isolated four viable, spontaneous mouse mutants' disrupted in growth, leading to dwarfism. Pygmy is unique among these mutants because its phenotype cannot be explained by aberrations in the growth hormone-insulin-like growth factor endocrine pathway(2-5). Here we show that the pygmy phenotype arises from the inactivation of Hmgi-c (ref. 6), a member of the Hmgi family(7) which function as architectural factors in the nuclear scaffolds and are critical in the assembly of stereospecific transcriptional complexes(9). Hmgi-c and another Hmgi family member, Hmgi(y) (ref. 10), were found to be expressed predominantly during embryogenesis. The HMGI proteins are known to be regulated by cell cycle-dependent phosphorylation which alters their DNA binding affinity(11). These results demonstrate the important role of HMGI proteins in mammalian growth and development.			ZHOU, XJ (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; Green MC., 1989, GENETIC VARIANTS STR, P12; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KING J, 1955, GENETICS, V53, P487; LEHRACH H., 1990, GENOME ANAL, P39; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; NISSLEY SP, 1980, HORM METAB RES, V12, P158, DOI 10.1055/s-2007-996230; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SINHA YN, 1979, P SOC EXP BIOL MED, V162, P221, DOI 10.3181/00379727-162-40651; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; XIANG X, 1990, SCIENCE, V247, P967, DOI 10.1126/science.2305264	24	531	554	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					771	774		10.1038/376771a0	http://dx.doi.org/10.1038/376771a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651535				2022-12-28	WOS:A1995RR83600039
J	GROSSKURTH, H; MOSHA, F; TODD, J; MWIJARUBI, E; KLOKKE, A; SENKORO, K; MAYAUD, P; CHANGALUCHA, J; NICOLL, A; KAGINA, G; NEWELL, J; MUGEYE, K; MABEY, D; HAYES, R				GROSSKURTH, H; MOSHA, F; TODD, J; MWIJARUBI, E; KLOKKE, A; SENKORO, K; MAYAUD, P; CHANGALUCHA, J; NICOLL, A; KAGINA, G; NEWELL, J; MUGEYE, K; MABEY, D; HAYES, R			IMPACT OF IMPROVED TREATMENT OF SEXUALLY-TRANSMITTED DISEASES ON HIV-INFECTION IN RURAL TANZANIA - RANDOMIZED CONTROLLED TRIAL	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; TRANSMISSION; EPIDEMIOLOGY; FEMALE; TYPE-1; HEALTH; REGION	A randomised trial was done to evaluate the impact of improved sexually transmitted disease (STD) case management at primary health care level on the incidence of HIV infection in the rural Mwanza region of Tanzania. HIV incidence was compared in six intervention communities and six pair-matched comparison communities. A random cohort of about 1000 adults aged 15-54 years from each community was surveyed at baseline and at follow-up 2 years later. Intervention consisted of establishment of an STD reference clinic, staff training, regular supply of drugs, regular supervisory visits to health facilities, and health education about STDs. 12 537 individuals were recruited. Baseline HIV prevalences were 3.8% and 4.4% in the intervention and comparison communities, respectively. At follow-up, 8845 (71%) of the cohort were seen. Of those initially seronegative, the proportions seroconverting over 2 years were 48 of 4149 (1.2%) in the intervention communities and 82 of 4400 (1.9%) in the comparison communities. HIV incidence was consistently lower in the intervention communities in all six matched pairs. Allowing for the design and the effects community-randomised confounding factors, the estimated risk (95% CI 0.42-0.79, p=0.007). No change in reported sexual behaviour was observed in either group. We conclude that improved STD treatment reduced HIV incidence by about 40% in this rural population. This is the first randomised trial to demonstrate an impact of a preventive intervention on HIV incidence in a general population.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; AFRICAN MED & RES FDN,MWANZA,TANZANIA; NATL INST MED RES,MWANZA,TANZANIA; BUGANDO MED CTR,MWANZA,TANZANIA; REG MED OFF,MWANZA,TANZANIA; MUNICIPAL HLTH OFF,MWANZA,TANZANIA	University of London; London School of Hygiene & Tropical Medicine; African Medical & Research Foundation (AMREF); National Institute of Medical Research				Grosskurth, Heiner/0000-0001-9960-7280; Hayes, Richard/0000-0002-1729-9892; Todd, Jim/0000-0001-5918-4914; MAYAUD, Philippe/0000-0001-5730-947X				ARYA OP, 1973, B WORLD HEALTH ORGAN, V49, P587; BARONGO LR, 1992, AIDS, V6, P1521, DOI 10.1097/00002030-199212000-00016; CAMERON DW, 1989, LANCET, V2, P403; DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639; GROSSKURTH H, 1995, AIDS, V9, P927, DOI 10.1097/00002030-199508000-00015; GROSSKURTH H, 1993, 10TH M INT SOC STD R; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HAYES R, 1995, AIDS, V9, P919, DOI 10.1097/00002030-199508000-00014; HAYES RJ, 1995, J TROP MED HYG, V98, P1; KILLEWO JZJ, 1993, INT J EPIDEMIOL, V22, P528, DOI 10.1093/ije/22.3.528; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; NKOWANE B M, 1990, AIDS (London), V4, pS123; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; Over M, 1993, DIS CONTROL PRIORITI, P455; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WEST B, 1995, GENITOURIN MED, V71, P9; 1993, 1993 WORLD BANK WORL; 1991, WHO TECH REP SER, P810; 1991, WKLY EPIDEMIOL REC, V66, P353; 1990, WKLY EPIDEMIOL REC, V65, P281; 1995, WKLY EPIDEMIOL REC, V70, P7	25	1109	1124	0	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					530	536		10.1016/S0140-6736(95)91380-7	http://dx.doi.org/10.1016/S0140-6736(95)91380-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658778				2022-12-28	WOS:A1995RQ98600008
J	SWEENEY, KG; GRAY, DJP; STEELE, RJF; EVANS, PH				SWEENEY, KG; GRAY, DJP; STEELE, RJF; EVANS, PH			CAUTION NEEDED IN INTRODUCING WARFARIN TREATMENT - COMMENTARY	BRITISH MEDICAL JOURNAL			English	Note							ATRIAL-FIBRILLATION; RANDOMIZED TRIAL; PREVENTION				SWEENEY, KG (corresponding author), ST LEONARDS MED PRACTICE,EXETER EX1 1SF,DEVON,ENGLAND.			Evans, Philip/0000-0002-5277-3545; PEREIRA GRAY, DENIS/0000-0001-7917-3841				[Anonymous], 1994, ARCH INTERN MED, V154, P1449; [Anonymous], 1994, LANCET, V343, P687; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LOWE GDO, 1992, BRIT MED J, V305, P1445, DOI 10.1136/bmj.305.6867.1445; PETERSEN P, 1989, LANCET, V1, P175; 1991, CIRCULATION, V84, P527; 1993, LANCET, V342, P1255; 1990, NEW ENGL J MED, V323, P1505	11	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					560	561		10.1136/bmj.311.7004.560	http://dx.doi.org/10.1136/bmj.311.7004.560			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663217	Green Published			2022-12-28	WOS:A1995RR73700030
J	PARISH, S; COLLINS, R; PETO, R; YOUNGMAN, L; BARTON, J; JAYNE, K; CLARKE, R; APPLEBY, P; LYON, V; CEDERHOLMWILLIAMS, S; MARSHALL, J; SLEIGHT, P				PARISH, S; COLLINS, R; PETO, R; YOUNGMAN, L; BARTON, J; JAYNE, K; CLARKE, R; APPLEBY, P; LYON, V; CEDERHOLMWILLIAMS, S; MARSHALL, J; SLEIGHT, P			CIGARETTE-SMOKING, TAR YIELDS, AND NONFATAL MYOCARDIAL-INFARCTION - 14000 CASES AND 32000 CONTROLS IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH-HEART-HEALTH; FILTER CIGARETTE; LUNG-CANCER; NICOTINE; RISK; SMOKERS; COTININE	Objectives-To assess the effects of cigarette smoking on the incidence of non-fatal myocardial infarction, and to compare tar in different types of manufactured cigarettes. Methods-In the early 1990s responses to a postal questionnaire were obtained from 13 926 survivors of myocardial infarction (cases) recently discharged from hospitals in the United Kingdom and 32 389 of their relatives (controls). Blood had been obtained from cases soon after admission for the index myocardial infarction and was also sought from the controls. 4923 cases and 6880 controls were current smokers of manufactured cigarettes with known tar yields. Almost all tar yields were 7-9 or 12-15 mg/cigarette (mean 7.5 mg for low tar (<10 mg) and 13.3 for medium tar (greater than or equal to 10 mg)). The cited risk ratios were standardised for age and sex and compared myocardial infarction rates in current cigarette smokers with those in non-smokers who had not smoked cigarettes regularly in the past 10 years. Results-At ages 30-49 the rates of myocardial infarction in smokers were about five times those in non-smokers (as defined); at ages 50-59 they were three times those in non-smokers, and even at ages 60-79 they were twice as great as in non-smokers (risk ratio 6.3, 4.7, 3.1, 2.5, and 1.9 at 30-39, 40-49, 50-59, 60-69, 70-79 respectively; each 2P<0.00001). After standardisation for age, sex, and amount smoked, the rate of non-fatal myocardial infarction was 10.4% (SD 5.4) higher in medium tar than in low tar cigarette smokers (2P=0.06). This percentage was not significantly greater at ages 30-59 (16.6% (7.1)) than at 60-79 (1.0% (8.5)). In both age ranges the difference in risk between cigarette smokers and non-smokers was much larger than the difference between one type of cigarette and another (risk ratio 3.39 and 3.95 at ages 30-59 for smokers of similar numbers of low and of medium tar cigarettes, and risk ratio 2.35 and 2.37 at ages 60-79). Most possible confounding factors that could be tested for were similar in low and medium tar users, with no significant differences in blood lipid or albumin concentrations. Conclusion-The present study indicates that the imminent change of tar yields in the European Union to comply with an upper limit of 12 mg/cigarette will not increase (and may somewhat decrease) the incidence of myocardial infarction, unless they indirectly help perpetuate tobacco use. Even low tar cigarettes still greatly increase rates of myocardial infarction, however, especially among people in their 30s, 40s, and 50s, and far more risk is avoided by not smoking than by changing from one type of cigarette to another.	RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, EPIDEMIOL STUDIES UNIT, OXFORD OX2 6HE, ENGLAND; JOHN RADCLIFFE HOSP, DEPT CARDIAC, OXFORD OX3 9DU, ENGLAND; OXFORD BIORES LAB, OXFORD OX4 4GA, ENGLAND	Radcliffe Infirmary; University of Oxford; University of Oxford	PARISH, S (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; CASTELLI WP, 1981, LANCET, V2, P109, DOI 10.1016/S0140-6736(81)90297-X; COLLINS R, 1995, LANCET, V345, P669; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HAMMOND EC, 1976, ENVIRON RES, V12, P263, DOI 10.1016/0013-9351(76)90036-0; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HIGENBOTTAM T, 1982, J EPIDEMIOL COMMUN H, V36, P113, DOI 10.1136/jech.36.2.113; HUNT D, 1992, LANCET, V339, P753; KAUFMAN DW, 1983, NEW ENGL J MED, V308, P409, DOI 10.1056/NEJM198302243080801; KAUFMAN DW, 1989, AM J EPIDEMIOL, V129, P703, DOI 10.1093/oxfordjournals.aje.a115185; KNIGHT GJ, 1985, CLIN CHEM, V31, P118; LEE PN, 1981, J EPIDEMIOL COMMUN H, V35, P16, DOI 10.1136/jech.35.1.16; NEGRI E, 1993, BRIT MED J, V306, P1567, DOI 10.1136/bmj.306.6892.1567; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; Peto R, 1994, MORTALITY SMOKING DE; STELLMAN SD, 1989, PREV MED, V18, P518, DOI 10.1016/0091-7435(89)90010-8; VUTUC C, 1983, J NATL CANCER I, V71, P435; WALD N, 1991, UK SMOKING STATISTIC; Wald N, 1989, NICOTINE SMOKING LOW; WOODWARD M, 1993, ADDICTION, V88, P821, DOI 10.1111/j.1360-0443.1993.tb02096.x; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, BRIT J ADDICT, V87, P921; WYNDER EL, 1979, NEW ENGL J MED, V300, P894, DOI 10.1056/NEJM197904193001605; WYNDER EL, 1979, J NATL CANCER I, V62, P471, DOI 10.1093/jnci/62.3.471; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74; 1994, STATISTICAL B DEPT H, V14	29	159	162	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	1995	311	7003					471	477		10.1136/bmj.311.7003.471	http://dx.doi.org/10.1136/bmj.311.7003.471			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647641	Green Published			2022-12-28	WOS:A1995RQ67000012
J	HELLER, BA; HOLTEN, D; KIRMAIER, C				HELLER, BA; HOLTEN, D; KIRMAIER, C			CONTROL OF ELECTRON-TRANSFER BETWEEN THE L-SIDE AND M-SIDE OF PHOTOSYNTHETIC REACTION CENTERS	SCIENCE			English	Article							RHODOBACTER-SPHAEROIDES R-26; INITIAL CHARGE SEPARATION; BACTERIAL REACTION CENTERS; STARK-EFFECT SPECTROSCOPY; RHODOPSEUDOMONAS-VIRIDIS; PROTEIN INTERACTIONS; TRANSFER DYNAMICS; TRANSIENT STATES; BACTERIOPHEOPHYTIN; MECHANISM	An aspartic acid residue has been introduced near ring V of the L-side accessory bacteriochlorophyll (BChl(L)) of the photosynthetic reaction center in a Rhodobacter capsulatus mutant in which a His also replaces Leu 212 on the M-polypeptide. The initial stage of charge separation in the G(M201)D/L(M212)H double mutant yields similar to 70 percent electron transfer to the L-side cofactors, similar to 15 percent rapid deactivation to the ground state, and similar to 15 percent electron transfer to the so-called inactive M-side bacteriopheophytin (BPh(M)). It is suggested here that the Asp introduced at M201 modulates the reduction potential of BChl(L), thereby changing the energetics of charge separation. The results demonstrate that an individual amino acid residue can, through its influence on the free energies of the charge-separated states, effectively dictate the balance between the forward electron transfer reactions on the L-side of the RC, the charge-recombination processes, and electron transfer to the M-side chromophores.			HELLER, BA (corresponding author), WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130, USA.							ARLT T, 1993, P NATL ACAD SCI USA, V90, P11757, DOI 10.1073/pnas.90.24.11757; BIXON M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P301, DOI 10.1016/S0005-2728(05)80062-3; BIXON M, 1989, BIOCHIM BIOPHYS ACTA, V977, P273, DOI 10.1016/S0005-2728(89)80081-7; BIXON M, 1992, PHOTOSYNTHETIC BACTE, V2, P291; Breton J., 1990, STRUCTURE FUNCTION B; BYLINA EJ, 1988, NATURE, V336, P182, DOI 10.1038/336182a0; CHAN CK, 1991, P NATL ACAD SCI USA, V88, P11202, DOI 10.1073/pnas.88.24.11202; CHEKALIN SV, 1987, FEBS LETT, V216, P245, DOI 10.1016/0014-5793(87)80698-1; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Deisenhofer J., 1993, PHOTOSYNTHETIC REACT, V2; ECCLES J, 1983, P NATL ACAD SCI-BIOL, V80, P4959, DOI 10.1073/pnas.80.16.4959; ELKABBANI O, 1991, BIOCHEMISTRY-US, V30, P5361, DOI 10.1021/bi00236a006; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; FINKELE U, 1990, BIOCHEMISTRY-US, V29, P8517, DOI 10.1021/bi00489a002; FRIESNER RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P99, DOI 10.1016/S0005-2728(89)80062-3; GOLDSTEIN RA, 1988, BIOCHIM BIOPHYS ACTA, V934, P253, DOI 10.1016/0005-2728(88)90189-2; GOTTFRIED DS, 1991, BIOCHIM BIOPHYS ACTA, V1059, P76, DOI 10.1016/S0005-2728(05)80189-6; GRAY KA, 1992, EUR J BIOCHEM, V207, P723, DOI 10.1111/j.1432-1033.1992.tb17102.x; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HANSON LK, 1987, J AM CHEM SOC, V109, P4728, DOI 10.1021/ja00249a050; HELLER B, UNPUB; HELLER BA, 1995, BIOCHEMISTRY-US, V34, P5294, DOI 10.1021/bi00015a045; JIA YW, 1993, J PHYS CHEM-US, V97, P13180, DOI 10.1021/j100152a024; KELLOGG EC, 1989, PHOTOSYNTH RES, V22, P47, DOI 10.1007/BF00114766; KIRMAIER C, 1991, SCIENCE, V251, P922, DOI 10.1126/science.2000491; KIRMAIER C, 1985, BIOCHIM BIOPHYS ACTA, V810, P49, DOI 10.1016/0005-2728(85)90205-1; KIRMAIER C, 1995, J PHYS CHEM-US, V99, P8903, DOI 10.1021/j100021a067; KIRMAIER C, 1995, J PHYS CHEM-US, V99, P8910, DOI 10.1021/j100021a068; KIRMAIER C, 1991, BIOCHEMISTRY-US, V30, P609, DOI 10.1021/bi00217a003; KIRMAIER C, 1988, P NATL ACAD SCI USA, V85, P7562, DOI 10.1073/pnas.85.20.7562; KORNIYA H, 1988, P NATL ACAD SCI USA, V85, P9012; LAPORTE L, 1993, CHEM PHYS, V176, P615, DOI 10.1016/0301-0104(93)80265-B; LAPORTE L, IN PRESS CHEM PHYS; LOCKHART DJ, 1988, P NATL ACAD SCI USA, V85, P107, DOI 10.1073/pnas.85.1.107; LOSCHE M, 1987, P NATL ACAD SCI USA, V84, P7537, DOI 10.1073/pnas.84.21.7537; MAITI S, 1994, P NATL ACAD SCI USA, V91, P10360, DOI 10.1073/pnas.91.22.10360; MARCHI M, 1993, J AM CHEM SOC, V115, P4178, DOI 10.1021/ja00063a041; MCDOWELL LM, 1991, BIOCHEMISTRY-US, V30, P8315, DOI 10.1021/bi00098a006; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHELBEYERLE ME, 1988, BIOCHIM BIOPHYS ACTA, V932, P52, DOI 10.1016/0005-2728(88)90139-9; MURCHISON HA, 1993, BIOCHEMISTRY-US, V32, P3498, DOI 10.1021/bi00064a038; NAGARAJAN V, 1993, BIOCHEMISTRY-US, V32, P12324, DOI 10.1021/bi00097a008; OGRODNIK A, 1994, J PHYS CHEM-US, V98, P3432, DOI 10.1021/j100064a026; PALANIAPPAN V, 1995, J AM CHEM SOC, V117, P3647, DOI 10.1021/ja00117a048; PARSON WW, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251, DOI 10.1016/0005-2728(90)90192-7; ROBERT B, 1985, FEBS LETT, V183, P326, DOI 10.1016/0014-5793(85)80803-6; SCHENCK CC, 1981, BIOCHIM BIOPHYS ACTA, V635, P383, DOI 10.1016/0005-2728(81)90036-0; SCHERER POJ, 1989, CHEM PHYS, V131, P115, DOI 10.1016/0301-0104(89)87084-3; SCHMIDT S, 1994, CHEM PHYS LETT, V223, P116, DOI 10.1016/0009-2614(94)00429-3; SHKUROPATOV AY, 1993, FEBS LETT, V322, P168, DOI 10.1016/0014-5793(93)81561-D; STEPHAN MA, 1994, SCIENCE, V264, P810; TAGUCHI AKW, 1992, BIOCHEMISTRY-US, V31, P10345, DOI 10.1021/bi00157a024; THOMPSON MA, 1991, J AM CHEM SOC, V113, P8210, DOI 10.1021/ja00022a003; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; WILLIAMS JC, 1992, BIOCHEMISTRY-US, V31, P11209; WOODBURY NW, 1994, BIOCHEMISTRY-US, V33, P8101, DOI 10.1021/bi00192a015; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	58	192	200	1	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					940	945		10.1126/science.7638616	http://dx.doi.org/10.1126/science.7638616			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638616				2022-12-28	WOS:A1995RP73800025
J	LEVYLAHAD, E; WIJSMAN, EM; NEMENS, E; ANDERSON, L; GODDARD, KAB; WEBER, JL; BIRD, TD; SCHELLENBERG, GD				LEVYLAHAD, E; WIJSMAN, EM; NEMENS, E; ANDERSON, L; GODDARD, KAB; WEBER, JL; BIRD, TD; SCHELLENBERG, GD			A FAMILIAL ALZHEIMERS-DISEASE LOCUS ON CHROMOSOME-1	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E; LINKAGE ANALYSIS; TYPE-4 ALLELE; BETA-PROTEIN; GENE; HETEROGENEITY; MARKERS; CONSTRUCTION; MUTATION	The Volga German kindreds are a group of seven related families with autosomal dominant early-onset Alzheimer's disease (AD). Linkage to known AD-related loci on chromosomes 21 and 14 has been excluded. Significant evidence for linkage to AD in these families was obtained with D1S479 and there was also positive evidence for linkage with other markers in the region. A 112-base pair allele of D1S479 co-segregated with the disease in five of seven families, which is consistent with a common genetic founder. This study demonstrates the presence of an AD locus on chromosome 1q31-42.	VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; VET AFFAIRS MED CTR,DIV NEUROL,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921	NHGRI NIH HHS [HG00835] Funding Source: Medline; NIA NIH HHS [F32 AG05635, AG05136] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005635] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENJAMIN R, 1994, LANCET, V344, P473, DOI 10.1016/S0140-6736(94)91804-X; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BIRD TD, 1992, HETEROGENEITY ALZHEI, P118; BIRD TD, 1991, AM HIST SOC GERM RUS, V49; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BROUSSEAU T, 1994, NEUROLOGY, V342; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAVALLISFORZA LL, 1986, AM J HUM GENET, V38, P599; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HIXSON JE, 1990, J LIPID RES, V31, P545; HODGE SE, 1983, AM J HUM GENET, V35, P1139; KAMINO K, 1992, AM J HUM GENET, V51, P998; KONG A, 1993, GENET EPIDEMIOL, V10, P483, DOI 10.1002/gepi.1370100626; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LANNFELT L, 1993, NAT GENET, V4, P218, DOI 10.1038/ng0793-218; LEVYLAHAD E, IN PRESS ANN NEUROL; LIDDELL M, 1994, J MED GENET, V31, P197, DOI 10.1136/jmg.31.3.197; Lin S., 1994, American Journal of Human Genetics, V55, pA40; LIN SL, 1993, IMA J MATH APPL MED, V10, P1; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MORTON NE, 1955, AM J HUM GENET, V7, P277; OTT J, 1974, AM J HUM GENET, V26, P588; OTT J, 1992, AM J HUM GENET, V51, P283; Ott J., 1991, ANAL HUMAN GENETIC L; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; SHERRINGTON, 1995, NATURE, V375, P754; SMITH AD, 1994, LANCET, V344, P473; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TSAI MS, 1994, AM J HUM GENET, V54, P643; VANDUIJN CM, 1994, AM J HUM GENET, V55, P714; YU CE, 1994, AM J HUM GENET, V54, P631; 1993, LANCET, V342, P737	49	629	652	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					970	973		10.1126/science.7638621	http://dx.doi.org/10.1126/science.7638621			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638621				2022-12-28	WOS:A1995RP73800034
J	DALE, J; GREEN, J; REID, F; GLUCKSMAN, E; HIGGS, R				DALE, J; GREEN, J; REID, F; GLUCKSMAN, E; HIGGS, R			PRIMARY-CARE IN THE ACCIDENT AND EMERGENCY DEPARTMENT .2. COMPARISON OF GENERAL-PRACTITIONERS AND HOSPITAL DOCTORS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the process and outcome of ''primary care'' consultations undertaken by senior house officers, registrars, and general practitioners in an accident and emergency department. Design-Prospective, controlled intervention study. Setting-A busy, inner city accident and emergency department in south London. Subjects-Patients treated during a stratified random sample of 419 three hour sessions between June 1989 and May 1990 assessed at nurse triage as presenting with problems that could be treated in a primary care setting. 1702 of these patients were treated by sessionally employed local general practitioners, 2382 by senior house officers, and 557 by registrars. Main outcome measures-Process variables: laboratory and radiographic investigations, prescriptions, and referrals; outcome variables: results of investigations. Results-Primary care consultations made by accident and emergency medical staff resulted in greater utilisation of investigative, outpatient, and specialist services than those made by general practitioners. For example, the odds ratios for patients receiving radiography were 2.78 (95% confidence interval 2.32 to 3.34) for senior house officer v general practitioner consultations and 2.37 (1.84 to 3.06) for registrars v general practitioners. For referral to hospital specialist on call teams or outpatient departments v discharge to the community the odds ratios were 2.88 (2.39 to 3.47) for senior house officers v general practitioners and 2.57 (1.98 to 3.35) for registrars v general practitioners. Conclusion-Employing general practitioners in accident and emergency departments to manage patients with primary care needs seems to result in reduced rates of investigations, prescriptions, and referrals. This suggests important benefits in terms of resource utilisation, but the impact on patient outcome and satisfaction needs to be considered further.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT ACCID & EMERGENCY MED,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT PUBL HLTH,LONDON,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT ACCID & EMERGENCY MED,LONDON SE5 9RS,ENGLAND	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	DALE, J (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SE5 9PJ,ENGLAND.			Green, Judith/0000-0002-2315-5326; Dale, Jeremy/0000-0001-9256-3553				Bishop YM., 2007, DISCRETE MULTIVARIAT; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; NOREN J, 1980, NEW ENGL J MED, V302, P11, DOI 10.1056/NEJM198001033020103; 1994, LANCET, V343, P305; 1986, CLASSIFICATION ANAL	5	91	92	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					427	430		10.1136/bmj.311.7002.427	http://dx.doi.org/10.1136/bmj.311.7002.427			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640592	Green Published			2022-12-28	WOS:A1995RP55400019
J	CARBONELL, E; DECASTRO, JMB; ARSUAGA, JL; DIEZ, JC; ROSAS, A; CUENCABESCOS, G; SALA, R; MOSQUERA, M; RODRIGUEZ, XP				CARBONELL, E; DECASTRO, JMB; ARSUAGA, JL; DIEZ, JC; ROSAS, A; CUENCABESCOS, G; SALA, R; MOSQUERA, M; RODRIGUEZ, XP			LOWER PLEISTOCENE HOMINIDS AND ARTIFACTS FROM ATAPUERCA-TD6 (SPAIN)	SCIENCE			English	Article							DENTAL MORPHOLOGY; SITE	Human remains dating to more than 780,000 years ago are associated with a rich faunal and lithic assemblage in the Pleistocene cave site of Gran Dolina (TD), Sierra de Atapuerca, Burgos, Spain. The micromammal species represent the late Biharian (Mimomys savini zone), and the lithic objects represent pre-Acheulean technology (Mode 1) and comes from the TD6 level below the Matuyama-Brunhes boundary. The Gran Dolina hominid fossils cannot be comfortably accommodated in any of the defined Homo species. They could be considered a primitive form of Homo heidelbergensis, but a new species might be named in the future if the sample is enlarged. The new human fossil evidence demonstrates that Western Europe was settled at least since the late early Pleistocene.	CSIC, MUSEO NACL CIENCIAS NAT, E-28006 MADRID, SPAIN; UNIV COMPLUTENSE MADRID, FAC CC GEOL, DEPT PALAEONTOL, E-28040 MADRID, SPAIN; UNIV ZARAGOZA, FAC CIENCIAS, DEPT GEOL, E-50009 ZARAGOZA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); Complutense University of Madrid; University of Zaragoza	CARBONELL, E (corresponding author), UNIV ROVIRA & VIRGILI, ARQUEOL LAB, IMPERIAL TARRACO 1, E-43005 TARRAGONA, SPAIN.		Rosas, Antonio/D-9742-2016; d�ez, carlos/B-2126-2008; Gloria, Cuenca-Bescós/A-3616-2013; Mosquera, Marina/B-1140-2014; Rodriguez-Alvarez, Xose-Pedro/B-9057-2009; RODRIGUEZ, XOSE-PEDRO/A-1069-2008; Carbonell, Eudald/G-3003-2015; Sala Ramos, Robert/L-5674-2014	Rosas, Antonio/0000-0002-5829-9952; Gloria, Cuenca-Bescós/0000-0001-5125-9651; Mosquera, Marina/0000-0003-4823-6154; Rodriguez-Alvarez, Xose-Pedro/0000-0002-1852-2283; Sala Ramos, Robert/0000-0002-7168-824X; Bermudez de Castro, Jose Maria/0000-0003-1314-3273; diez, j.carlos/0000-0002-3856-1837; Arsuaga, Juan Luis/0000-0001-5361-2295				Aguirre E., 1990, Human Evolution, V5, P55, DOI 10.1007/BF02436474; AGUIRRE E, 1987, HOMBRE FOSIL IBEAS P, V1; AIELLO L, 1990, INTRO HUMAN EVOLUTIO, P127; ARSUAGA JL, 1993, NATURE, V362, P534, DOI 10.1038/362534a0; AUGUSTI J, 1992, COUR FORSCHUNGSINST, V153, P69; BELFERCOHEN A, 1994, WORLD ARCHAEOL, V26, P144, DOI 10.1080/00438243.1994.9980269; BOSINSKI G, 1992, PIU ANTICO POPOLAMEN, P51; CARBONELL E, 1994, J HUM EVOL, V26, P291, DOI 10.1006/jhev.1994.1018; CARBONELL E, 1992, CAHIER NOIR 6 NEW EL; COLTORTI M, 1982, NATURE, V300, P173, DOI 10.1038/300173a0; CUENCABESCOS G, IN PRESS REV ESPANOL; DECASTRO JMB, INPRESS HUMAN EVOLUT; Delitala M.C., 1983, ISERNIA PINETA ACCAM, P65; DELUMLEY H, 1988, ANTHROPOLOGIE, V92, P501; DEVOS J, 1994, SCIENCE, V266, P1726, DOI 10.1126/science.7992059; FEJFAR O, 1995, INT S EVOLUTION PHYL; FERNANDEZ-JALVO Y, 1992, J ARCHAEOL SCI, V19, P407, DOI 10.1016/0305-4403(92)90058-B; GABUNIA L, 1995, NATURE, V373, P509, DOI 10.1038/373509a0; Gagnepain J, 1992, PRIMI ABITANTI VALLE, P319; GAMBLE C, 1994, NATURE, V369, P275, DOI 10.1038/369275a0; Garcia-Anton M., 1989, THESIS U AUTONOMA MA; Gil E., 1991, CAHIERS QUATERNAIRE, V16, P337; Gladilin V.N., 1991, PREMIERS EUROPEENS, P217; Isaac G. L., 1981, IND MAS ANTIGUAS, p[101, 258]; Isaac G.L., 1984, ADV WORLD ARCHAEOLOG, P1; JOHANSON G, 1971, ODONTOL REV S, V22; MCPHERRON A, 1983, ISERNIA PINETA ACCAM, P67; PARES JM, 1995, SCIENCE, V269, P830, DOI 10.1126/science.7638599; Peretto C, 1991, ISERNIA PINETA NUOVI; RANOV VA, 1995, CURR ANTHROPOL, V36, P337, DOI 10.1086/204366; RANOV VA, 1991, PREMIERS EUROPEENS, P209; Rightmire G. P., 1990, EVOLUTION HOMO ERECT; ROSAS A, 1995, J HUM EVOL, V28, P533, DOI 10.1006/jhev.1995.1041; Schick K.D., 1993, EVOL ANTHR ISSUES NE, V2, P22, DOI DOI 10.1002/EVAN.1360020105; SMITH FH, 1980, AM J PHYS ANTHROPOL, V53, P589, DOI 10.1002/ajpa.1330530414; SWISHER CC, 1994, SCIENCE, V266, P1727, DOI 10.1126/science.266.5191.1727; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; THOUVENY N, 1984, NATURE, V308, P355, DOI 10.1038/308355a0; WOOD BA, 1987, J ANAT, V154, P121; WOOD BA, 1988, J ANAT, V156, P107; WOOD BA, 1992, NATURE, V355, P873; PB930066C03	42	338	346	0	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					826	830		10.1126/science.7638598	http://dx.doi.org/10.1126/science.7638598			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638598				2022-12-28	WOS:A1995RN65000041
J	DURING, MJ; NAEGELE, JR; OMALLEY, KL; GELLER, AI				DURING, MJ; NAEGELE, JR; OMALLEY, KL; GELLER, AI			LONG-TERM BEHAVIORAL RECOVERY IN PARKINSONIAN RATS BY AN HSV VECTOR EXPRESSING TYROSINE-HYDROXYLASE	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; AMINO-ACID DECARBOXYLASE; COLI BETA-GALACTOSIDASE; STRIATAL NEURONS; CEREBRAL-CORTEX; GENE-THERAPY; DOPAMINE; DISEASE; ORGANIZATION; INVIVO	One therapeutic approach to treating Parkinson's disease is to convert endogenous striatal cells into levo-3,4-dihydroxyphenylalanine (L-dopa)-producing cells. A defective herpes simplex virus type 1 vector expressing human tyrosine hydroxylase was delivered into the partially denervated striatum of 6-hydroxydopamine-lesioned rats, used as a model of Parkinson's disease. Efficient behavioral and biochemical recovery was maintained for 1 year after gene transfer. Biochemical recovery included increases in both striatal tyrosine hydroxylase enzyme activity and in extracellular dopamine concentrations. Persistence of human tyrosine hydroxylase was revealed by expression of RNA and immunoreactivity.	YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06510 USA; WESLEYAN UNIV, DEPT BIOL, MIDDLETOWN, CT 06457 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Yale University; Wesleyan University; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	DURING, MJ (corresponding author), YALE UNIV, SCH MED, DEPT SURG, NEW HAVEN, CT 06510 USA.		Geller, Alfred/C-6469-2012; During, Matthew/AAC-1388-2020	Naegele, Janice Rae/0000-0001-5151-0543	NEI NIH HHS [EY09749] Funding Source: Medline; NINDS NIH HHS [NS06208, NS28227] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY009749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006208, R29NS028227] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RL, 1984, J PATHOL, V143, P241, DOI 10.1002/path.1711430403; BAKAY RAE, 1987, ANN NY ACAD SCI, V495, P623, DOI 10.1111/j.1749-6632.1987.tb23705.x; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; CASS WA, 1993, J NEUROCHEM, V61, P2269, DOI 10.1111/j.1471-4159.1993.tb07469.x; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COKER GT, 1990, MOL BRAIN RES, V8, P93, DOI 10.1016/0169-328X(90)90052-F; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; DUBACH M, 1987, NEUROSCI LETT, V75, P205, DOI 10.1016/0304-3940(87)90298-9; DURING MJ, 1992, EXP NEUROL, V115, P193, DOI 10.1016/0014-4886(92)90053-S; EMSON PC, 1990, EXP BRAIN RES, V79, P427, DOI 10.1007/BF00608254; FEDEROFF HJ, 1992, P NATL ACAD SCI USA, V89, P1636, DOI 10.1073/pnas.89.5.1636; FREED R, 1992, NEW ENGL J MED, V327, P1640; FREED WJ, 1980, ANN NEUROL, V8, P510, DOI 10.1002/ana.410080508; FREESE A, 1991, NUCLEIC ACIDS RES, V19, P7219, DOI 10.1093/nar/19.25.7219; GAGE FH, 1991, TRENDS NEUROSCI, V14, P328, DOI 10.1016/0166-2236(91)90156-O; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P1149, DOI 10.1073/pnas.87.3.1149; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P8950, DOI 10.1073/pnas.87.22.8950; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GELLER AI, IN PRESS J NEUROCHEM; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HAYCOCK JW, COMMUNICATION; HEFTI F, 1980, PHARMACOL BIOCHEM BE, V12, P185, DOI 10.1016/0091-3057(80)90353-6; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; HORELLOU P, 1990, NEURON, V5, P393, DOI 10.1016/0896-6273(90)90078-T; JIAO SS, 1993, NATURE, V362, P450, DOI 10.1038/362450a0; KOSAKA T, 1987, EXP BRAIN RES, V68, P393; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LEWIS DA, 1993, NEUROSCIENCE, V54, P477, DOI 10.1016/0306-4522(93)90267-J; LI XM, 1992, J NEUROCHEM, V59, P1172, DOI 10.1111/j.1471-4159.1992.tb08363.x; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LOMBROSO PJ, 1993, J NEUROSCI, V13, P3064; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1727, DOI 10.1093/nar/14.4.1727; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; MCGEORGE AJ, 1987, BRAIN RES, V423, P318, DOI 10.1016/0006-8993(87)90855-9; MOSCA JD, 1985, J VIROL, V56, P867, DOI 10.1128/JVI.56.3.867-878.1985; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P6910, DOI 10.1021/bi00396a007; PERESE DA, 1989, BRAIN RES, V494, P285, DOI 10.1016/0006-8993(89)90597-0; REDMOND DE, 1986, LANCET, V1, P1125; ROBERT F, 1993, J NEUROCHEM, V60, P721, DOI 10.1111/j.1471-4159.1993.tb03207.x; ROHRER H, 1986, J NEUROSCI, V6, P2616; SCHNEIDER JS, 1994, BRAIN RES, V643, P86, DOI 10.1016/0006-8993(94)90012-4; SLADEK JR, 1988, PROG BRAIN RES, V78, P497; SMITH RE, UNPUB, P54011; Song S., UNPUB; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STAINES WA, 1981, BRAIN RES, V206, P446, DOI 10.1016/0006-8993(81)90545-X; STEVENS JG, 1987, SCIENCE, V235, P1056, DOI 10.1126/science.2434993; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TASHIRO Y, 1989, NEUROSCI LETT, V97, P6, DOI 10.1016/0304-3940(89)90130-4; TASHIRO Y, 1989, NEUROSCI LETT, V100, P29, DOI 10.1016/0304-3940(89)90655-1; VANHORNE C, 1992, J PHARMACOL EXP THER, V263, P1285; VECSEI L, 1992, NEUROLOGICAL DISORDE, P223; WANG J, 1994, J NEUROSURG, V80, P484, DOI 10.3171/jns.1994.80.3.0484; WATSON K, 1980, J GEN VIROL, V49, P149, DOI 10.1099/0022-1317-49-1-149; WESTERINK BHC, 1990, J NEUROCHEM, V54, P381, DOI 10.1111/j.1471-4159.1990.tb01884.x; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WILSON CJ, 1987, J COMP NEUROL, V263, P567, DOI 10.1002/cne.902630408; WOLFF JA, 1989, P NATL ACAD SCI USA, V86, P9011, DOI 10.1073/pnas.86.22.9011; YAHR MD, 1969, ARCH NEUROL-CHICAGO, V21, P343, DOI 10.1001/archneur.1969.00480160015001; YAHR MD, 1987, PARKINSONS DISEASE; YUREK DM, 1990, ANNU REV NEUROSCI, V13, P415, DOI 10.1146/annurev.neuro.13.1.415	62	314	336	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1399	1403		10.1126/science.266.5189.1399	http://dx.doi.org/10.1126/science.266.5189.1399			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7669103	Green Accepted			2022-12-28	WOS:A1994PT63200048
J	PERRINE, SP; GINDER, GD; FALLER, DV; DOVER, GH; IKUTA, T; WITKOWSKA, HE; CAI, SP; VICHINSKY, EP; OLIVIERI, NF				PERRINE, SP; GINDER, GD; FALLER, DV; DOVER, GH; IKUTA, T; WITKOWSKA, HE; CAI, SP; VICHINSKY, EP; OLIVIERI, NF			A SHORT-TERM TRIAL OF BUTYRATE TO STIMULATE FETAL-GLOBIN GENE-EXPRESSION IN THE BETA-GLOBIN DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICKLE-CELL-ANEMIA; ADULT ERYTHROID-CELLS; SODIUM-BUTYRATE; HEMOGLOBIN PRODUCTION; HYDROXYUREA; 5-AZACYTIDINE; DISEASE; THALASSEMIA; POLYMERIZATION; AUGMENTATION	Background. Fetal-globin (gamma-globin) chains inhibit the polymerization of hemoglobin S (sickle hemoglobin) and can functionally substitute for the beta-globin chains that are defective or absent in patients with the beta-thalassemias. Identifying safe mechanisms to stimulate fetal-hemoglobin production is therefore of great interest. Previous studies have shown that administering butyrate selectively stimulates the promoter of the human fetal-globin gene and leads to increases in gamma-globin-gene expression in the developing fetus, cultured cells, and animal models. Methods. To determine whether butyrate can stimulate fetal-globin production in humans, we treated three patients (3 to 13 years old) with sickle cell anemia and three patients (7 to 27 years old) with beta-thalassemia syndromes with a short course of intravenous infusions of arginine butyrate. The drug was infused continuously for either two or three weeks; the initial dose was 500 mg per kilogram of body weight per day. Globin-chain ratios, proportions of reticulocytes producing hemoglobin F (F reticulocytes), and levels of gamma-globin messenger RNA (mRNA) were determined before and during treatment. Results. In all six patients, fetal-globin synthesis increased by 6 to 45 percent above pretreatment levels (P<0.01). The proportion of F reticulocytes increased about twofold, and the level of gamma-globin mRNA increased twofold to sixfold. The increase in gamma-globin synthesis led to improvement in the globin-chain ratios in the patients with thalassemia. The treatment of one patient was extended for seven weeks, and her hemoglobin level increased from 4.7 to 10.2 g per deciliter (2.9 to 6.3 mmol per liter). Side effects were minimal; one patient had a transient increase in serum aminotransferase concentrations. Conclusions. In patients with beta-hemoglobinopathies butyrate, a natural fatty acid, can significantly and rapidly increase fetal-globin production to levels that can ameliorate beta-globin disorders. Further trials of this class of compounds are warranted to determine long-term tolerance and efficacy in patients with sickle cell anemia or beta-thalassemia.	HOSP SICK CHILDREN,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; BOSTON UNIV,SCH MED,BOSTON,MA 02118; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Minnesota System; University of Minnesota Twin Cities; Boston University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Johns Hopkins University	PERRINE, SP (corresponding author), CHILDRENS HOSP OAKLAND,RES INST,RM 115,747 52ND ST,OAKLAND,CA 94609, USA.		Olivieri, Nancy/AAI-2250-2020; Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579	NHLBI NIH HHS [HL-37118, HL-20895] Funding Source: Medline; NIDDK NIH HHS [DK-29902] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL037118, R01HL037118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029902, R01DK029902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALKHATTI A, 1987, NEW ENGL J MED, V317, P415, DOI 10.1056/NEJM198708133170704; BOYER SH, 1984, BLOOD, V64, P1053; BRITTENHAM G, 1977, AM J HEMATOL, V2, P25, DOI 10.1002/ajh.2830020104; BRITTENHAM GM, 1985, BLOOD, V65, P183; BURNS LJ, 1988, BLOOD, V72, P1536; CAI SP, 1990, J CLIN INVEST, V85, P550, DOI 10.1172/JCI114471; CHARACHE S, 1987, BLOOD, V69, P109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG JB, 1966, J MOL BIOL, V19, P91, DOI 10.1016/S0022-2836(66)80052-9; Conley CL, 1980, BLOOD PURE ELOQUENT, P319; CONSTANTOULAKIS P, 1989, BLOOD, V74, P1963; DANIEL P, 1989, CLIN CHIM ACTA, V181, P255, DOI 10.1016/0009-8981(89)90231-3; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; DESIMONE J, 1982, BLOOD, V60, P519; DOVER GJ, 1986, BLOOD, V67, P735; FALK RJ, 1992, NEW ENGL J MED, V326, P910, DOI 10.1056/NEJM199204023261402; FRIEDMAN AD, 1985, J CLIN INVEST, V75, P1359, DOI 10.1172/JCI111837; GALLO E, 1979, BRIT J HAEMATOL, V41, P211, DOI 10.1111/j.1365-2141.1979.tb05850.x; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; LEY TJ, 1983, BLOOD, V62, P370; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; MCARTHUR B, 1982, CLIN CHEM, V28, P1983; McDonagh K, 1991, BLOOD, V78, p255a; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PERRINE RP, 1972, LANCET, V2, P1163; PERRINE SP, 1989, BLOOD, V74, P454; PERRINE SP, 1988, P NATL ACAD SCI USA, V85, P8540, DOI 10.1073/pnas.85.22.8540; PERRINE SP, 1985, NEW ENGL J MED, V312, P334, DOI 10.1056/NEJM198502073120602; PERRINE SP, 1991, REGULATION HEMOGLOBI, P425; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; SHACKLETON CHL, 1991, J CHROMATOGR-BIOMED, V562, P175, DOI 10.1016/0378-4347(91)80576-X; VEITH R, 1985, NEW ENGL J MED, V313, P1571, DOI 10.1056/NEJM198512193132503; WOOD WG, 1983, BIOCHEM J, V215, P1; WOOD WG, 1980, BRIT J HAEMATOL, V45, P431, DOI 10.1111/j.1365-2141.1980.tb07163.x	44	423	446	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					81	86		10.1056/NEJM199301143280202	http://dx.doi.org/10.1056/NEJM199301143280202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	7677966				2022-12-28	WOS:A1993KG46700002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALPROSTADIL APPROVED AS IMPOTENCE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-28	WOS:A1995RV73400004
J	SERRUYS, PW; HERRMAN, JPR; SIMON, R; RUTSCH, W; BODE, C; LAARMAN, GJ; VANDIJK, R; VANDENBOS, AA; UMANS, VAWM; FOX, KAA; CLOSE, P; DECKERS, JW				SERRUYS, PW; HERRMAN, JPR; SIMON, R; RUTSCH, W; BODE, C; LAARMAN, GJ; VANDIJK, R; VANDENBOS, AA; UMANS, VAWM; FOX, KAA; CLOSE, P; DECKERS, JW			A COMPARISON OF HIRUDIN WITH HEPARIN IN THE PREVENTION OF RESTENOSIS AFTER CORONARY ANGIOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; THERAPY; INJURY; INHIBITION; THROMBOSIS; ARTERIES; DISEASE; PLACEBO; ANGINA; MODEL	Background. The likelihood of restenosis is a major limitation of coronary angioplasty. We studied whether hirudin, a highly selective inhibitor of thrombin with irreversible effects, would prevent restenosis after angioplasty. We compared two regimens of recombinant hirudin with heparin. Methods. We randomly assigned 1141 patients with unstable angina who were scheduled for angioplasty to receive one of three treatments: (1) a bolus dose of 10,000 IU of heparin followed by an intravenous infusion of heparin for 24 hours and subcutaneous placebo twice daily for three days (382 patients), (2) a bolus dose of 40 mg of hirudin followed by an intravenous infusion of hirudin for 24 hours and subcutaneous placebo twice daily for three days (381 patients), or (3) the same hirudin regimen except that 40 mg of hirudin was given subcutaneously instead of placebo twice daily for three days (378 patients). The primary end point was event-free survival at seven months. Other end points were early cardiac events (within 96 hours), bleeding and other complications of the study treatment, and angiographic measurements of coronary diameter at six months of follow-up. Results. At seven months, event-free survival was 67.3 percent in the group receiving heparin, 63.5 percent in the group receiving intravenous hirudin, and 68.0 percent in the group receiving both intravenous and subcutaneous hirudin (P=0.61). However, the administration of hirudin was associated with a significant reduction in early cardiac events, which occurred in 11.0, 7.9, and 5.6 percent of patients in the respective groups (combined relative risk with hirudin, 0.61; 95 percent confidence interval, 0.41 to 0.90; P=0.023). The mean minimal luminal diameters in the respective groups on follow-up angiography at six months were 1.54, 1.47, and 1.56 mm (P=0.08). Conclusions. Although significantly fewer early cardiac events occurred with hirudin than with heparin, hirudin had no apparent benefit with longer-term follow-up.	ACAD ZIEKENHUIS DIJKZIGT,ROTTERDAM,NETHERLANDS; CHRISTIAN ALBRECHTS UNIV KIEL,MED KLIN,D-24118 KIEL,GERMANY; FREE UNIV BERLIN,KLIN RUDOLF VIRCHOW,W-1000 BERLIN,GERMANY; MED KLIN 3,HEIDELBERG,GERMANY; ONZE LIEVE VROUW HOSP,AMSTERDAM,NETHERLANDS; ACAD ZIEKENHUIS GRONINGEN,GRONINGEN,NETHERLANDS; MED CTR KLOKKENBERG,BREDA,NETHERLANDS; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; CIBA GEIGY LTD,BASEL,SWITZERLAND; CARDIALYSIS BV,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; University of Kiel; Free University of Berlin; Onze Lieve Vrouwe Gasthuis Hospital; University of Groningen; Royal Infirmary of Edinburgh; Novartis; Cardialysis			Fox, keith A A/I-3742-2013	Fox, Keith/0000-0002-0140-2752				BERTRAND ME, 1990, CIRCULATION, V82, P190; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; CHESEBRO JH, 1991, J AM COLL CARDIOL, V17, pB96; CHESEBRO JH, 1992, CIRCULATION, V86, P100; Chesebro JH, 1989, CIRCULATION S2, V80, pII; CLOSE P, 1994, CORONARY ARTERY DIS, V5, P943; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; ERIKSSON BI, 1994, THROMB HAEMOSTASIS, V72, P227; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GROVES HM, 1986, ARTERIOSCLEROSIS, V6, P189, DOI 10.1161/01.ATV.6.2.189; GRUTTER MG, 1990, EMBO J, V8, P2361; HERAS M, 1990, CIRCULATION, V82, P1476, DOI 10.1161/01.CIR.82.4.1476; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; MCNAMARA CA, 1992, 4TH REST SUMM CLEV, P18; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SCHWARTZ RS, 1990, CIRCULATION, V82, P2190, DOI 10.1161/01.CIR.82.6.2190; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SERRUYS PW, 1994, QUANTITATVE CORONARY; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; STEIN B, 1989, J AM COLL CARDIOL, V14, P813, DOI 10.1016/0735-1097(89)90453-1; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; VANDENBOS AA, 1993, CIRCULATION, V88, P2058, DOI 10.1161/01.CIR.88.5.2058; VERSTRAETE M, 1993, J AM COLL CARDIOL, V22, P1080, DOI 10.1016/0735-1097(93)90419-2; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WILENTZ JR, 1987, CIRCULATION, V75, P636, DOI 10.1161/01.CIR.75.3.636; ZOLDHELYI P, 1994, CIRCULATION, V90, P2671, DOI 10.1161/01.CIR.90.6.2671; 1994, NEW ENGL J MED, V330, P956	30	368	372	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					757	763		10.1056/NEJM199509213331203	http://dx.doi.org/10.1056/NEJM199509213331203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643882	Green Published			2022-12-28	WOS:A1995RU80900003
J	ZHANG, MJ; HOELZER, D; HOROWITZ, MM; GALE, RP; MESSERER, D; KLEIN, JP; LOFFLER, H; SOBOCINSKI, KA; THIEL, E; WEISDORF, DJ				ZHANG, MJ; HOELZER, D; HOROWITZ, MM; GALE, RP; MESSERER, D; KLEIN, JP; LOFFLER, H; SOBOCINSKI, KA; THIEL, E; WEISDORF, DJ			LONG-TERM FOLLOW-UP OF ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN FIRST REMISSION TREATED WITH CHEMOTHERAPY OR BONE-MARROW TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Note							THERAPY	Objective: To determine whether the conclusions of a 1991 study, which showed that adults with acute lymphoblastic leukemia in first remission had similar leukemia-free survival rates when treated with chemotherapy or HLA-identical sibling bone marrow transplantation, remain valid after more than 4 years of additional follow-up. Design: Retrospective comparison of two cohorts of patients using left-truncated Cox regression to adjust for differences in baseline characteristics and time to treatment. Setting and Patients: Chemotherapy recipients were 484 consecutive patients with acute lymphoblastic leukemia in first remission treated in 44 hospitals in Germany that were participating in two consecutive trials of the German Acute Lymphoblastic Leukemia Therapy Trials Group. Transplant recipients were 234 consecutive recipients of HLA-identical sibling bone marrow transplants for acute lymphoblastic leukemia in first remission in 98 centers, worldwide, reporting data to the International Bone Marrow Transplant Registry. Interventions: Intensive combination chemotherapy or HLA-identical sibling bone marrow transplantation preceded by high-dose chemotherapy with or without total body irradiation. Measurements: Relapse, treatment-related mortality, and leukemia-free survival rate 9 years after first complete remission. Results: The conclusions of our previous analyses were confirmed. Actuarial relapse probabilities at 9 years were 60% (95% CI, 61% to 70%) for chemotherapy and 30% (CI, 22% to 37%) for transplantation (P < 0.0001). The leukemia-free survival rates at 9 years were 32% (CI, 27% to 37%) for chemotherapy and 34% (CI, 28% to 40%) for transplantation (P > 0.02). Conclusions: Fewer relapses but more treatment-related deaths were seen with transplantation than with chemotherapy. Thus, leukemia-free survival rates were similar in adults receiving transplantation and adults receiving chemotherapy for acute lymphoblastic leukemia in first remission.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, MILWAUKEE, WI 53226 USA; UNIV FRANKFURT, MED KLIN 3, D-60590 FRANKFURT, GERMANY; SALICK HLTH CARE INC, LOS ANGELES, CA 90048 USA; BIOMETR CTR THERAPEUT STUDIES, D-80663 MUNICH, GERMANY; CHRISTIAN ALBRECHTS UNIV KIEL, MED KLIN 2, D-24116 KIEL, GERMANY; FREE UNIV BERLIN, BERLIN, GERMANY; UNIV MINNESOTA, CTR HLTH, MINNEAPOLIS, MN 55455 USA	Medical College of Wisconsin; Goethe University Frankfurt; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Free University of Berlin; University of Minnesota System; University of Minnesota Twin Cities			horowitz, Mary/ABH-2173-2021		NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN PK, 1995, IN PRESS SCANDINAVIA; ANDERSON S, 1993, STATISTICAL METHODS; BARRETT AJ, 1989, BLOOD, V74, P862; CHAO NJ, 1990, ANN INTERN MED, V113, P340, DOI 10.7326/0003-4819-113-5-340; CHAO NJ, 1991, BLOOD, V78, P1923; GALE RP, 1987, BRIT J HAEMATOL, V65, P261, DOI 10.1111/j.1365-2141.1987.tb06851.x; HOELZER D, 1984, BLOOD, V64, P38; HOELZER D, 1988, BLOOD, V71, P123, DOI 10.1182/blood.V71.1.123.123; HOELZER DF, 1993, HEMATOL ONCOL CLIN N, V7, P139, DOI 10.1016/S0889-8588(18)30261-2; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; KLEIN JP, 1994, 3 MED COLL WISC DIV; SEBBAN C, 1994, J CLIN ONCOL, V12, P2580, DOI 10.1200/JCO.1994.12.12.2580	12	82	86	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					428	431		10.7326/0003-4819-123-6-199509150-00006	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639442				2022-12-28	WOS:A1995RU43700005
J	EKWALL, K; JAVERZAT, JP; LORENTZ, A; SCHMIDT, H; CRANSTON, G; ALLSHIRE, R				EKWALL, K; JAVERZAT, JP; LORENTZ, A; SCHMIDT, H; CRANSTON, G; ALLSHIRE, R			THE CHROMODOMAIN PROTEIN SWI6 - A KEY COMPONENT AT FISSION YEAST CENTROMERES	SCIENCE			English	Article							HETEROCHROMATIN-ASSOCIATED PROTEIN; POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; ANTIBODIES; DOMAIN	Centromeres attach chromosomes to the spindle during mitosis, thereby ensuring the equal distribution of chromosomes into daughter cells. Transcriptionally silent heterochromatin of unknown function is associated with centromeres in many organisms. In the fission yeast Schizosaccharomyces pombe, the silent mating-type loci, centromeres, and telomeres are assembled into silent heterochromatin-like domains. The Swi6 chromodomain protein affects this silencing, and now it is shown that Swi6p localizes with these three chromosomal regions. In cells lacking Swi6p, centromeres lag on the spindle during anaphase and chromosomes are lost at high rates. Thus, Swi6p is located at fission yeast centromeres and is required for their proper function.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST GENET,D-38106 BRAUNSCHWEIG,GERMANY	University of Edinburgh; Braunschweig University of Technology				Allshire, Robin/0000-0002-8005-3625; Ekwall, Karl/0000-0002-3029-4041	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; HAGAN IM, 1988, J CELL SCI, V89, P343; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KELLUM R, 1995, J CELL SCI, V108, P1407; KELLUM R, 1995, J CELL SCI, V108, P1419; KLAR AJS, 1992, TRENDS GENET, V8, P208, DOI 10.1016/0168-9525(92)90100-I; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1982, CURR OPIN CELL BIOL, V5, P999; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; WOODS A, 1989, J CELL SCI, V93, P491; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	22	254	255	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1429	1431		10.1126/science.7660126	http://dx.doi.org/10.1126/science.7660126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660126				2022-12-28	WOS:A1995RT80600047
J	WHITCOMB, ME				WHITCOMB, ME			A CROSS-NATIONAL COMPARISON OF GENERALIST PHYSICIAN WORKFORCE DATA - EVIDENCE FOR US SUPPLY ADEQUACY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE; UNITED-STATES	Objective.-To assess the adequacy of the US generalist physician workforce using population-based, cross-national physician workforce data. Design.-A comparative analysis of physician workforce data obtained from primary sources in Canada in 1991 and from England and Germany in 1993. Methods.-Generalist physician-to-population ratios were calculated for each country and the results compared in the context of how primary care services are delivered. The findings were used to create a framework for analyzing the adequacy of the generalist physician workforce of the United States. Main Outcome Measure.-The comparability of the number of primary care providers per 100 000 population in the US physician workforce with the number in Canada, England, and Germany. Results.-On a population basis, the size of the full-time US generalist physician workforce is larger than that of England, similar to that of Germany, and smaller than that of Canada. These size differences are largely reconciled when one takes into account differences in the way primary care services are delivered, the degree to which nurse practitioners are employed in each country, and the degree to which nongeneralist physicians provide primary care services. Conclusions.-The size of the US generalist physician workforce is currently adequate to meet the needs of the population. Policies designed to greatly expand the size of the US generalist physician workforce are ill-conceived.			WHITCOMB, ME (corresponding author), ASSOC AMER MED COLL,2450 N ST,WASHINGTON,DC 20037, USA.							COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; IGLEHART J, 1991, NEW ENGL J MED, V824, P503; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V271, P1505, DOI 10.1001/jama.271.19.1505; SANDIER S, 1989, HLTH CARE FINANCIN S, P33; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P2268, DOI 10.1001/jama.266.16.2268; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITCOMB ME, 1992, NEW ENGL J MED, V326, P1469, DOI 10.1056/NEJM199205283262205; 1994, PRIMARY CARE PHYSICI; 1993, ANN REPORT C; 1992, 3RD US DHHS COUNC GR; 1993, ANN REPORT C PHYSICI; 1993, 1993 GERMAN HLTH CAR; 1980, GRADUATE MED ED NATI	15	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					692	695						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650820				2022-12-28	WOS:A1995RR83500013
J	AHMED, AEH; NICHOLSON, KG; NGUYENVANTAM, JS				AHMED, AEH; NICHOLSON, KG; NGUYENVANTAM, JS			REDUCTION IN MORTALITY ASSOCIATED WITH INFLUENZA VACCINE DURING 1989-90 EPIDEMIC	LANCET			English	Article							VIRUS VACCINE; IMMUNIZATION; PREVENTION; INFECTION; EFFICACY; DISEASE; DEATHS	Influenza epidemics are associated with excess winter mortality Risk factors for influenza complications and death include chronic illness and living in residential care. In the UK uptake of influenza vaccine among high-risk groups is only 10-40%, partly because of scepticism about vaccine efficacy. We have assessed the efficacy of influenza vaccine in reducing mortality from certified influenza by a case-control study of subjects aged 16 years or older who died between Nov 4, 1989, and Feb 23, 1990, in 36 district health authorities in England. We reviewed general practitioners' records for 315 patients who died of influenza and 777 controls, matched for age, sex, and area of residence, who died a year after the epidemic. Information was collected on demography, the usual place of residence (institutional or noninstitutional), and the existence of chronic illness. Conditional logistic regression analysis for matched case-control studies showed that influenza vaccination reduced mortality by 41% (95% Cl 13-60) for all subjects. Further adjustments showed that among subjects who received the vaccine for the first time in 1989, Vaccination reduced mortality by 9% (0-59); however, among those who bad also been vaccinated previously, mortality was reduced by 75% (31-91). We detected no significant differences in the effect of vaccine between subjects who lived in institutions and in the community (p=0.16), or between subjects with high-risk medical conditions and those without (p=0.76). Influenza Vaccine is effective in reducing mortality from influenza, and efficacy seems to be greater after repeated annual vaccination than after first administration.	UNIV LEICESTER,SCH MED,DEPT MICROBIOL & IMMUNOL,LEICESTER LE1 9HN,LEICS,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT EPIDEMIOL & PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Leicester; University of Nottingham			Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655				ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; Ashley J., 1991, Population Trends, P16; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEERY BJ, 1979, J INFECT DIS, V139, P237, DOI 10.1093/infdis/139.2.237; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GOVAERT TME, 1994, VACCINE, V12, P1185, DOI 10.1016/0264-410X(94)90241-0; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GUNDELFINGER BF, 1958, NEW ENGL J MED, V259, P1005, DOI 10.1056/NEJM195811202592103; HALL CB, 1987, PEDIATRICS, V80, P275; HOSKINS TW, 1979, LANCET, V1, P33; KEITEL WA, 1988, AM J EPIDEMIOL, V127, P353, DOI 10.1093/oxfordjournals.aje.a114809; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; LENNOX IM, 1990, AGE AGEING, V19, P169, DOI 10.1093/ageing/19.3.169; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MORIO S, 1994, J EPIDEMIOL COMMUN H, V48, P46, DOI 10.1136/jech.48.1.46; NGUYENVANTAM JS, 1993, EPIDEMIOL INFECT, V111, P347, DOI 10.1017/S0950268800057058; NGUYENVANTAM JS, 1992, EPIDEMIOL INFECT, V108, P537, DOI 10.1017/S0950268800050032; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1987, VACCINE, V5, P302, DOI 10.1016/0264-410X(87)90156-3; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102; 1989, OPCS PP2892 MON; 1992, IMMUNISATION INFECTI	30	170	176	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					591	595		10.1016/S0140-6736(95)91434-X	http://dx.doi.org/10.1016/S0140-6736(95)91434-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651002				2022-12-28	WOS:A1995RT18800007
J	BROSENS, JJ; DESOUZA, NM; BARKER, FG				BROSENS, JJ; DESOUZA, NM; BARKER, FG			UTERINE JUNCTIONAL ZONE - FUNCTION AND DISEASE	LANCET			English	Note							MR; ADENOMYOSIS; MYOMETRIUM; UTERUS; CONTRACTIONS; EXPRESSION	The myometrium is usually thought of as a homogeneous mass of smooth muscle fibres. However, magnetic resonance studies of the uterus have revealed two distinct zones-the subendometrial myometrium or junctional zone and the outer myometrium. The junctional zone is not only structurally but also functionally different from the outer myometrium. For instance, myometrial contractions in a non-pregnant woman originate exclusively from the junctional zone, and their amplitude, frequency, and direction depend on the phase of the cycle. Irregular thickening of the junctional zone has been proposed as the magnetic resonance criterion for the diagnosis of diffuse adenomyosis. However, this magnetic resonance appearance relies on the disruption of the inner myometrial architecture secondary to smooth muscle hyperplasia but does not provide proof of mucosal invasion of the myometrium. We postulate that adenomyosis is a dichotomous disease characterised primarily by disruption of the inner myometrial architecture and function, with secondary infiltration of endometrial elements into the myometrium under certain circumstances. This hypothesis focuses on the inner myometrium and may explain the high incidence of superficial adenomyosis in dysfunctional uterine bleeding.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,ROBERT STEINER MAGNET RESONANCE UNIT,LONDON,ENGLAND; HAMMERSMITH HOSP,DEPT PATHOL,LONDON,ENGLAND	Imperial College London; Imperial College London	BROSENS, JJ (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON,ENGLAND.			Brosens, Jan/0000-0003-0116-9329				ANDREYKO JL, 1988, AM J OBSTET GYNECOL, V158, P903, DOI 10.1016/0002-9378(88)90092-0; BACON CR, 1995, J ENDOCRINOL, V144, P127, DOI 10.1677/joe.0.1440127; BARTON JW, 1993, RADIOLOGY, V186, P163, DOI 10.1148/radiology.186.1.7677973; BIRD CC, 1972, AM J OBSTET GYNECOL, V112, P583, DOI 10.1016/0002-9378(72)90781-8; BROSENS I, 1967, J PATHOL BACTERIOL, V93, P569, DOI 10.1002/path.1700930218; BROWN HK, 1991, RADIOLOGY, V179, P409, DOI 10.1148/radiology.179.2.1707545; BURROWS TD, 1993, HUM REPROD, V8, P475, DOI 10.1093/oxfordjournals.humrep.a138075; DARDENNE M, 1994, ENDOCRINOLOGY, V134, P2108, DOI 10.1210/en.134.5.2108; DEMAS BE, 1985, RADIOLOGY, V159, P123; DESOUZA NM, 1995, J RADIOL, V50, P75; DEVRIES K, 1990, AM J OBSTET GYNECOL, V162, P679, DOI 10.1016/0002-9378(90)90983-E; FRASER IS, 1994, BRIT J OBSTET GYNAEC, V101, P3, DOI 10.1111/j.1471-0528.1994.tb13688.x; GELLERSEN B, 1991, ENDOCRINOLOGY, V129, P158, DOI 10.1210/endo-129-1-158; HRICAK H, 1983, AM J ROENTGENOL, V141, P1119, DOI 10.2214/ajr.141.6.1119; LYONS EA, 1991, FERTIL STERIL, V55, P771; MCCARTHY S, 1989, RADIOLOGY, V171, P241, DOI 10.1148/radiology.171.1.2928531; MCCAUSLAND AM, 1991, AM J OBSTET GYNECOL, V166, P1619; MORI T, 1984, EXPERIENTIA, V40, P1385, DOI 10.1007/BF01951902; OSTRANDER PL, 1985, J NATL CANCER I, V74, P121; OTA H, 1992, AM J OBSTET GYNECOL, V167, P481, DOI 10.1016/S0002-9378(11)91433-1; SCOUTT LM, 1991, RADIOLOGY, V179, P403, DOI 10.1148/radiology.179.2.2014282; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; TURNBULL LW, 1995, BRIT J OBSTET GYNAEC, V102, P330, DOI 10.1111/j.1471-0528.1995.tb09141.x; 1985, HOSPITAL INPATIENT E	24	141	152	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					558	560		10.1016/S0140-6736(95)91387-4	http://dx.doi.org/10.1016/S0140-6736(95)91387-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658784	Bronze			2022-12-28	WOS:A1995RQ98600015
J	CROSLAND, A; JONES, R				CROSLAND, A; JONES, R			RECTAL BLEEDING - PREVALENCE AND CONSULTATION BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							IRRITABLE-BOWEL-SYNDROME; SYMPTOMS; DIAGNOSIS; DYSPEPSIA; DELAY	Objectives-To determine prevalence of rectal bleeding in the community and to examine factors that lead some patients to consult their general practitioner about rectal bleeding while others do not. Design-Questionnaire survey followed by semistructured interviews of sample of respondents with rectal bleeding. Setting-Two general practices on Tyneside. Subjects-2000 adult patients registered with the general practices were sent a validated questionnaire. Respondents with rectal bleeding were divided into consulters and non-consulters, and 30 patients from each group (matched for age, sex, and characteristics of bleeding) were interviewed. Main outcome measures-Prevalence of rectal bleeding, proportion of subjects with rectal bleeding who sought medical advice, and reasons for consulting or not consulting a doctor about rectal bleeding. Results-287 of the 1200 respondents to the questionnaire had noticed rectal bleeding at some time in their lives, and 231 had noticed it within previous 12 months. Only 118 (41%) of all respondents with rectal bleeding had ever sought medical advice for the problem. Those aged over 60 were most likely to have consulted, as were those who reported blood mixed with their stools. Main difference between those who had sought medical advice and those who had not was that consulters were more likely than non-consulters to perceive their symptoms as serious. Conclusions-Although rectal bleeding is common, only minority of patients seek medical advice for their bleeding. Perception of seriousness of symptoms seems to be most important factor in deciding whether to consult a doctor for rectal bleeding.	UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London	CROSLAND, A (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.							BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; BYLES JE, 1992, J EPIDEMIOL COMMUN H, V46, P241, DOI 10.1136/jech.46.3.241; DENT OF, 1990, DIS COLON RECTUM, V33, P851, DOI 10.1007/BF02051921; DENT OF, 1986, DIS COLON RECTUM, V29, P234; GOULSTON K, 1987, MED J AUSTRALIA, V146, P631, DOI 10.5694/j.1326-5377.1987.tb120441.x; GOULSTON KJ, 1986, LANCET, V2, P261; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; JONES RH, 1995, BRIT J CLIN PRACT, V49, P67; JONES RH, 1993, RECTAL BLEEDING GUID; KETTELL J, 1992, BRIT J GEN PRACT, V42, P459; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; MANT A, 1989, DIS COLON RECTUM, V32, P191, DOI 10.1007/BF02554525; RAFFERTY T, 1980, AM SURGEON, V46, P600; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; Strauss A., 1990, BASICS QUALITATIVE R; 1993, OPCS MONITOR     JUL	17	113	114	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					486	488		10.1136/bmj.311.7003.486	http://dx.doi.org/10.1136/bmj.311.7003.486			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647645	Green Published			2022-12-28	WOS:A1995RQ67000016
J	LEMPERT, T; GRESTY, MA; BRONSTEIN, AM				LEMPERT, T; GRESTY, MA; BRONSTEIN, AM			FORTNIGHTLY REVIEW - BENIGN POSITIONAL VERTIGO - RECOGNITION AND TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							SEMICIRCULAR CANAL OCCLUSION; EAR				LEMPERT, T (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, NEUROOTOL SECT, MRC, HUMAN MOVEMENT & BALANCE UNIT, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; BARBER HO, 1988, VESTIBULAR DISORDERS, P215; BLAKLEY BW, 1994, OTOLARYNG HEAD NECK, V110, P391, DOI 10.1177/019459989411000407; BRANDT T, 1980, ARCH OTOLARYNGOL, V106, P484; BRANDT T, 1990, J NEUROL SCI, V95, P3, DOI 10.1016/0022-510X(90)90113-2; Brandt T, 1993, J Vestib Res, V3, P373; DIX MR, 1952, ANN OTO RHINOL LARYN, V61, P987, DOI 10.1177/000348945206100403; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; FROEHLING DA, 1991, MAYO CLIN PROC, V66, P596, DOI 10.1016/S0025-6196(12)60518-7; GACEK RR, 1974, ANN OTO RHINOL LARYN, V83, P596, DOI 10.1177/000348947408300504; GACEK RR, 1991, LARYNGOSCOPE, V101, P855; HALL SF, 1979, J OTOLARYNGOL, V8, P151; HERDMAN SJ, 1993, ARCH OTOLARYNGOL, V119, P450; JOHNSSON LG, 1972, ANN OTO RHINOL LARYN, V81, P179, DOI 10.1177/000348947208100203; KATSARKAS A, 1978, J OTOLARYNGOL, V7, P320; Lindsay J R, 1956, ANN OTO RHINOL LARYN, V65, P692; MCCLURE JA, 1980, J OTOLARYNGOL, V9, P472; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; PARKER DE, 1968, ACTA OTOLARYNG STO S, V239, P1; PARNES LS, 1991, OTOLARYNG HEAD NECK, V104, P52, DOI 10.1177/019459989110400111; PARNES LS, 1993, ANN OTO RHINOL LARYN, V102, P325, DOI 10.1177/000348949310200501; PARNES LS, 1992, LARYNGOSCOPE, V102, P988; SCHUKNECHT HF, 1969, ARCH OTOLARYNGOL, V90, P765; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; YARDLEY L, 1994, BRIT MED J, V308, P1252, DOI 10.1136/bmj.308.6939.1252	25	42	44	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					489	491		10.1136/bmj.311.7003.489	http://dx.doi.org/10.1136/bmj.311.7003.489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647646	Green Published			2022-12-28	WOS:A1995RQ67000017
J	DALE, J; GREEN, J; REID, F; GLUCKSMAN, E				DALE, J; GREEN, J; REID, F; GLUCKSMAN, E			PRIMARY-CARE IN THE ACCIDENT AND EMERGENCY DEPARTMENT .1. PROSPECTIVE IDENTIFICATION OF PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; SERVICES	Objective-To compare patient characteristics and consultation activities for attenders at accident and emergency departments assessed by nurse triage as presenting with ''primary care'' or ''accident and emergency'' type problems. Design-One year prospective study. Setting-A busy, inner city accident and emergency department in south London. Subjects-Of the 5658 patients treated for new problems during a stratified random sample of 204 three hour sessions between 10 am and 9 pm during June 1989 to May 1990, all ''primary care'' (2065 patients) and a 10% random sample of ''accident and emergency'' (298 patients) were included in the analysis. Main outcome measures-Patient's age, sex, duration of presenting problem, diagnosis, laboratory and radiographic investigations, treatments, and referrals. Results-40.9% of attenders with new problems were classified by triage as presenting with ''primary care'' problems (95% confidence interval 39.6% to 42.2%). Primary care attenders were more likely than accident and emergency patients to be young adults, to have symptoms with a duration of longer than 24 hours, and to present problems not related to injury (all P<0.001). Accident and emergency patients were considerably more likely to be referred to on call teams and to be admitted. Even so, 9.7% of primary care patients were referred to on call teams and a further 8.9% were referred to the fracture clinic or advised to return to the accident and emergency department for follow up. Conclusion-Accident and emergency triage can be developed to identify patients with problems that are more Likely to be of a primary care type, and these patients are less likely to receive an investigation, minor surgical procedure, or referral. Many patients in this category, however, receive interventions likely to support their decision to attend accident and emergency rather than general practice. This may reflect limitations in the sensitivity of triage practice or a clinical approach of junior medical staff that includes a propensity to intervene.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT ACCID & EMERGENCY MED,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT PUBL HLTH,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT ACCID & EMERGENCY MED,LONDON SE5 9RS,ENGLAND	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	DALE, J (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SE5 9PJ,ENGLAND.			Dale, Jeremy/0000-0001-9256-3553; Green, Judith/0000-0002-2315-5326				ANDERSEN NA, 1984, FAM PRACT, V1, P79, DOI 10.1093/fampra/1.2.79; Bedford H E, 1992, Qual Health Care, V1, P29, DOI 10.1136/qshc.1.1.29; BLISS HA, 1982, NEW ENGL J MED, V306, P998; COHEN J, 1987, FAM PRACT, V4, P81, DOI 10.1093/fampra/4.2.81; DALE J, 1992, BRIT J GEN PRACT, V42, P90; DALE J, 1991, ARCH EMERG MED, V8, P210; DALE J, 1995, BRIT MED J, V311, P427, DOI 10.1136/bmj.311.7002.427; DERLET RW, 1990, ANN EMERG MED, V1, P262; Dolan B, 1994, Nurs Stand, V8, P34; DRISCOLL PA, 1987, ARCH EMERG MED, V4, P77; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GREEN J, 1992, SOC SCI MED, V35, P987, DOI 10.1016/0277-9536(92)90238-L; HANSAGI H, 1987, PUBLIC HEALTH, V101, P99, DOI 10.1016/S0033-3506(87)80046-X; Hansagi H, 1991, Qual Assur Health Care, V3, P51; Jeffery R, 1979, Sociol Health Illn, V1, P90, DOI 10.1111/1467-9566.ep11006793; KLJAKOVIC M, 1981, NZ MED J, V96, P49; MAGNUSSON G, 1980, SCAND J SOC MED, V8, P145; MORRISON WG, 1990, J ROY SOC MED, V83, P237, DOI 10.1177/014107689008300412; MYERS P, 1982, J ROY SOC MED, V75, P879; Reilly P M, 1981, J R Coll Gen Pract, V31, P223; SANDLER G, 1984, BRIT MED J, V289, P973, DOI 10.1136/bmj.289.6450.973; Wabschall J M, 1983, J Emerg Nurs, V9, P37; 1992, ACCIDENT EMERGENCY S; 1978, ROYAL COMMISSION NAT; 1992, REPORT COMPTROLLER A; 1986, CLASSIFICATION ANAL; 1992, REPORT INQUIRY LONDO	27	117	118	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					423	426		10.1136/bmj.311.7002.423	http://dx.doi.org/10.1136/bmj.311.7002.423			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640591	Green Published			2022-12-28	WOS:A1995RP55400018
J	HENG, MB; KEY, PJ				HENG, MB; KEY, PJ			CAMBODIAN HEALTH IN TRANSITION	BRITISH MEDICAL JOURNAL			English	Article								As conflict and suffering in Bosnia, Chechnya, Rwanda, and Zaire continue to be at the forefront of world attention, some countries seem to be largely forgotten. It is timely to take stock of conditions in the small country of Cambodia as it struggles to take its place after a long period of isolation. Countless Cambodians and ethnic Vietnamese have died there this year and during the past 25 years, victims of senseless killing or preventable disease.	OVERSEAS DEV INST,LONDON SW1E 5JL,ENGLAND; MINIST HLTH,PHNOM PENH,CAMBODIA										0	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					435	437		10.1136/bmj.311.7002.435	http://dx.doi.org/10.1136/bmj.311.7002.435			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640594	Green Published			2022-12-28	WOS:A1995RP55400022
J	FRIEDMANHILL, SR; ROBERTSON, LC; TREISMAN, A				FRIEDMANHILL, SR; ROBERTSON, LC; TREISMAN, A			PARIETAL CONTRIBUTIONS TO VISUAL FEATURE BINDING - EVIDENCE FROM A PATIENT WITH BILATERAL LESIONS	SCIENCE			English	Article							OSCILLATORY NEURONAL RESPONSES; ILLUSORY CONJUNCTIONS; CORTEX; CAT; SYNCHRONIZATION; PERCEPTION; ATTENTION	Neurophysiologists have documented the existence of multiple cortical areas responsive to different visual features. This modular organization has sparked theoretical interest in how the ''binding problem'' is solved. Recent data from a neurological patient (R.M.) with bilateral parietal-occipital lesions demonstrates that the binding problem is not just a hypothetical construct; it can be a practical problem, as rare as the selective inability to perceive motion or color. R.M. miscombines colors and shapes even under free viewing conditions and is unable to judge either relative or absolute visual locations. The evidence suggests that a single explanation-an inadequate spatial representation-can account for R.M.'s spatial judgment and feature-binding deficits.	UNIV CALIF DAVIS,VET ADM,DAVIS,CA 95616; PRINCETON UNIV,DEPT PSYCHOL,PRINCETON,NJ 08540	University of California System; University of California Davis; Princeton University	FRIEDMANHILL, SR (corresponding author), UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616, USA.							ANDERSEN RA, 1987, HDB PHYSL, V5, pCH12; ARGUIN M, 1994, BRAIN COGNITION, V24, P44, DOI 10.1006/brcg.1994.1003; CAVADA C, 1993, PROGR BRAIN RES, V95, pCH12; COHEN A, 1989, J EXP PSYCHOL HUMAN, V15, P650, DOI 10.1037/0096-1523.15.4.650; COHEN A, 1931, PSYCHOL SCI, V2, P106; CRICK F, 1984, P NATL ACAD SCI-BIOL, V81, P4586, DOI 10.1073/pnas.81.14.4586; Damasio AR, 1989, NEURAL COMPUT, V1, P123, DOI 10.1162/neco.1989.1.1.123; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; KEELE SW, 1988, J EXP PSYCHOL HUMAN, V14, P444; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; PRINZMETAL W, 1993, NOV PSYCH SOC M WASH; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; TREISMAN A, 1982, COGNITIVE PSYCHOL, V14, P107, DOI 10.1016/0010-0285(82)90006-8; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR, pCH18; VONDERMALSBURG C, 1985, BER BUNSEN PHYS CHEM, V89, P703, DOI 10.1002/bbpc.19850890625; VONDERMALSBURG C, 1981, INTERNAL REPORT M PL; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	25	366	376	0	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					853	855						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638604				2022-12-28	WOS:A1995RN65000049
J	MEINERT, CL				MEINERT, CL			THE INCLUSION OF WOMEN IN CLINICAL-TRIALS	SCIENCE			English	Editorial Material											MEINERT, CL (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P129; GILPIN AK, 1994, CONTROLLED CLIN TRIA, V15, pS64; HOLBROOK JT, 1994, CONTROLLED CLIN TRIA, V15, pS129; LEVINE C, 1994, CONTROLLED CLIN TRIA, V15, pS65; MERKATZ RB, 1993, NEW ENGL J MED, V329, P292, DOI 10.1056/NEJM199307223290429; Statistical design considerations in the multiple risk factor intervention trial (MRFIT), 1977, J CHRON DIS, V30, P261; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1994, FED REG         0328, V59; 1993, CONTROLLED CLIN TRIA, V14, P558; 1980, NIH INVENTORY CLIN T; 1993, CONTROLLED CLIN TRIA, V14, P559; 1977, DHEW FDA773040 PUBL; 1994, WOMEN HLTH RES ETHIC; 1988, CONTROLLED CLIN TRIA, V9, P97	14	15	15	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					795	796		10.1126/science.7638594	http://dx.doi.org/10.1126/science.7638594			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638594				2022-12-28	WOS:A1995RN65000032
J	KREISBERG, R				KREISBERG, R			WE BLEW IT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE; CHOLESTASIS; INFECTION; DISEASE		UNIV ALABAMA,SCH MED,BIRMINGHAM,AL	University of Alabama System; University of Alabama Birmingham	KREISBERG, R (corresponding author), BAPTIST HLTH SYST,BIRMINGHAM,AL 35211, USA.							BACH N, 1992, SEMIN LIVER DIS, V12, P205, DOI 10.1055/s-2007-1007392; BONACINI M, 1992, AM J MED, V92, P404, DOI 10.1016/0002-9343(92)90271-C; CARSON JL, 1993, ANN INTERN MED, V119, P576, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00005; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHAN TYK, 1993, LANCET, V342, P1532, DOI 10.1016/S0140-6736(05)80091-1; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; KOWDLEY KV, 1992, GASTROENTEROLOGY, V102, P2148, DOI 10.1016/0016-5085(92)90346-Z; MEDON PJ, 1984, J ETHNOPHARMACOL, V10, P235, DOI 10.1016/0378-8741(84)90005-9; MUNOZ SJ, 1990, HEPATOLOGY, V12, P342, DOI 10.1002/hep.1840120223; SCHWARZ ED, 1992, SEMIN LIVER DIS, V12, P142, DOI 10.1055/s-2007-1007386; Stein D. S., 1994, AIDS Clinical Care, V6, P17; STEIN DS, 1994, AIDS CLIN CARE, V6, P26; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001	17	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					945	949		10.1056/NEJM199504063321409	http://dx.doi.org/10.1056/NEJM199504063321409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7661934				2022-12-28	WOS:A1995QP89300009
J	SEUBERT, P; OLTERSDORF, T; LEE, MG; BARBOUR, R; BLOMQUIST, C; DAVIS, DL; BRYANT, K; FRITZ, LC; GALASKO, D; THAL, LJ; LIEBERBURG, I; SCHENK, DB				SEUBERT, P; OLTERSDORF, T; LEE, MG; BARBOUR, R; BLOMQUIST, C; DAVIS, DL; BRYANT, K; FRITZ, LC; GALASKO, D; THAL, LJ; LIEBERBURG, I; SCHENK, DB			SECRETION OF BETA-AMYLOID PRECURSOR PROTEIN CLEAVED AT THE AMINO TERMINUS OF THE BETA-AMYLOID PEPTIDE	NATURE			English	Article							ALZHEIMERS-DISEASE; DOMAIN; IDENTIFICATION; MUTATION; GENE	THE accumulation in brain of senile plaques containing beta-amyloid protein (Abeta) is a defining feature of Alzheimer's disease1-3. The amyloid precursor protein (APP)4 from which Abeta is derived is subject to several genetic mutations which segregate with rare familial forms of the disease, resulting in early onset of dementia and plaque formation5-9, suggesting that APP metabolism plays a causal role in the disease. Various cell types have been shown to release a soluble form of Abeta, thus allowing for the in vitro study of Abeta generation10-12. We report here evidence that a substantial portion of the APP secreted by human mixed brain cell cultures, as well as that present in cerebrospinal fluid, is of a novel form cleaved precisely at the amino terminus of Abeta, suggesting that a secretory pathway is involved in Abeta genesis.	UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SEUBERT, P (corresponding author), ATHENA NEUROSCI INC,800F GATEWAY BLVD,SAN FRANCISCO,CA 94080, USA.							ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kennedy Hilary, 1992, Neurodegeneration, V1, P59; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PULLIAM L, 1984, J VIROL METHODS, V9, P301, DOI 10.1016/0166-0934(84)90056-9; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729	26	511	547	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					260	263		10.1038/361260a0	http://dx.doi.org/10.1038/361260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	7678698				2022-12-28	WOS:A1993KH61400060
J	WHELAN, AJ; BARTSCH, D; GOODFELLOW, PJ				WHELAN, AJ; BARTSCH, D; GOODFELLOW, PJ			A FAMILIAL SYNDROME OF PANCREATIC-CANCER AND MELANOMA WITH A MUTATION IN THE CDKN2 TUMOR-SUPPRESSOR GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							IDENTIFICATION; ENDOCRINE		WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110; UNIV MARBURG,DEPT SURG,W-3550 MARBURG,GERMANY	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Philipps University Marburg								BARTSCH D, IN PRESS GENES CHROM; CALDAS C, 1994, NAT GENET, V8, P410, DOI 10.1038/ng1294-410c; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CUBILLA AL, 1979, MAYO CLIN PROC, V54, P449; EHRENTHAL D, 1987, CANCER, V59, P1661, DOI 10.1002/1097-0142(19870501)59:9<1661::AID-CNCR2820590923>3.0.CO;2-H; FRIEDMAN JM, 1976, CLIN GENET, V9, P463; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LYNCH HT, 1975, SURG GYNECOL OBSTET, V141, P517; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORI T, 1994, CANCER RES, V54, P3396; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REIMER RR, 1977, LANCET, V1, P911; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZHANG SY, 1994, CANCER RES, V54, P5050	23	231	238	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					975	977		10.1056/NEJM199510123331505	http://dx.doi.org/10.1056/NEJM199510123331505			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666917				2022-12-28	WOS:A1995RY58600005
J	SAINT, S; GO, AS; FRANCES, C; TIERNEY, LM				SAINT, S; GO, AS; FRANCES, C; TIERNEY, LM			RECORDS OF THE MASSACHUSETTS-GENERAL-HOSPITAL - A HOME-COURT ADVANTAGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco			Saint, Sanjay/AAF-5126-2019; Go, Alan S./AAE-7745-2019					BROWNER WS, 1988, DESIGNING CLIN RES E, P139; Engelberg Joseph, 1992, American Journal of Physiology, V263, pS45; GLANTZ SA, 1992, PRIMER BIOSTATISTICS, P110; MILLER RA, 1982, NEW ENGL J MED, V307, P468, DOI 10.1056/NEJM198208193070803; Sackett D, 1991, CLIN EPIDEMIOLOGY BA, P25; Scully R E, 1982, N Engl J Med, V307, P370, DOI 10.1056/NEJM198208053070610	6	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					883	884		10.1056/NEJM199509283331320	http://dx.doi.org/10.1056/NEJM199509283331320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651499				2022-12-28	WOS:A1995RW88300035
J	WALD, A; ZEH, J; SELKE, S; ASHLEY, RL; COREY, L				WALD, A; ZEH, J; SELKE, S; ASHLEY, RL; COREY, L			VIROLOGICAL CHARACTERISTICS OF SUBCLINICAL AND SYMPTOMATIC GENITAL HERPES INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-2; VIRAL-ISOLATION; RISK-FACTORS; WOMEN; ACQUISITION; TRANSMISSION; FREQUENCY; LESIONS	Background. The frequency, pattern, and anatomical sites of subclinical shedding of herpes simplex virus (HSV) in the genital tract, along with factors that predict such shedding, have not been well characterized. Methods. We studied prospectively the clinical and virologic course of genital herpes in 110 women. The women kept symptom diaries and provided daily samples from the vulva, cervix, and rectum for viral culture. Results. During a median follow-up of 105 days, subclinical shedding of Virus was identified in 36 of 65 women (55 percent) with HSV type 2 (HSV-2), in 16 of 31 women (52 percent) with HSV type 1 (HSV-1) and HSV-2, and in 4 of 14 women (29 percent) with only HSV-1. Among women with genital HSV-2 infection, subclinical shedding occurred on a mean of 2 percent of the days. The mean duration of viral shedding during subclinical episodes was 1.5 days, as compared with 1.8 days during symptomatic episodes. HSV was isolated from several sites in the genital tract and rectum in 17 percent of subclinical episodes and 22 percent of symptomatic episodes. Half the episodes of subclinical shedding of HSV occurred within seven days of a symptomatic recurrence. The risk of subclinical shedding increased with the frequency of symptomatic recurrences, Subclinical shedding was more frequent among women with more than 12 recurrences per year than among those with no symptomatic recurrences (odds ratio, 3.3; 95 percent confidence interval, 1.4 to 7.9); it was also more frequent among women who had recently acquired genital herpes (odds ratio for women with HSV acquired in the past year as compared with those who had had the infection for a year or more, 1.85; 95 percent confidence interval, 1.1 to 3.1). Conclusions. Among women with a history of genital herpes infection, subclinical shedding of HSV is common and accounts for nearly one third of the total days of reactivation of HSV infection in the genital tract. Women with frequent symptomatic recurrences also have frequent subclinical shedding and may be at high risk for transmitting HSV.	WASHINGTON UNIV,DEPT MED,DIV VIROL,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT STAT,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT LAB MED,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT MICROBIOL,SEATTLE,WA 98144				Wald, Anna/B-6272-2012; Corey, Lawrence/AAE-1796-2020	Wald, Anna/0000-0003-3486-6438; Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM E, 1979, OBSTET GYNECOL, V54, P171; ADAM E, 1980, AM J OBSTET GYNECOL, V137, P827, DOI 10.1016/0002-9378(80)90893-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1986, GENITOURIN MED, V62, P181; BARTON SE, 1987, GENITOURIN MED, V63, P102; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Bowman C A, 1990, Int J STD AIDS, V1, P174; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1985, AM J OBSTET GYNECOL, V153, P24, DOI 10.1016/0002-9378(85)90584-8; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON Y, 1993, J INFECT DIS, V167, P942, DOI 10.1093/infdis/167.4.942; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; JOHNSON RE, 1990, NEW ENGL J MED, V321, P7; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; MCCULLAGH P, 1983, GEN LINEAR MODELS, P73; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; RATTRAY MC, 1978, BRIT J VENER DIS, V54, P262; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107	24	413	421	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					770	775		10.1056/NEJM199509213331205	http://dx.doi.org/10.1056/NEJM199509213331205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643884	Bronze			2022-12-28	WOS:A1995RU80900005
J	PAK, CYC; SAKHAEE, K; ADAMSHUET, B; PIZIAK, V; PETERSON, RD; POINDEXTER, JR				PAK, CYC; SAKHAEE, K; ADAMSHUET, B; PIZIAK, V; PETERSON, RD; POINDEXTER, JR			TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH SLOW-RELEASE SODIUM-FLUORIDE	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS, POSTMENOPAUSAL; SODIUM FLUORIDE; FRACTURES; DELAYED-ACTION PREPARATIONS; CALCIUM COMPOUNDS	CALCIUM CITRATE; REFLECTION ULTRASOUND; BONE; FRACTURE; QUALITY	Objective: To test whether slow-release sodium fluoride inhibits spinal fractures and is safe to use. Design: Placebo-controlled randomized trial. Interventions: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it) compared with placebo. Calcium citrate, 400 mg calcium twice daily, continuously in both groups. Patients: 48 of 54 patients who received sodium fluoride and 51 of 56 patients who received placebo completed at least 1 year of the study. All patients had postmenopausal osteoporosis. Results: Compared with the placebo group, the fluoride group had a lower individual vertebral fracture rate (0.064 +/- 0.182 per patient-year compared with 0.205 +/- 0.297 per patient-year; P = 0.002), a higher unadjusted fracture-free rate (85.4% compared with 56.9%; P = 0.001), and a greater survival estimate (relative risk, 0.3 [95% CI, 0.12 to 0.76]) for new fractures; The recurrent spinal fracture rate did not differ between the two groups. The fluoride group had a substantial increase in L2-L4 bone mass of 4% to 5% per year for 4 years, a mean increase in femoral neck bone density of 2.38% +/- 3.33% pet year, and no change in radial shaft bone density. The frequency with which minor side effects and appendicular fractures occurred was similar in the two groups; no patients developed microfractures or gastric ulcers. Conclusion: Slow-release sodium fluoride and calcium citrate administered for 4 years inhibits new vertebral fractures (but not recurrent fractures), augments spinal and femoral neck bone mass, and is safe to use.	SCOTT & WHITE MEM HOSP & CLIN, TEMPLE, TX 76508 USA	Scott & White Medical Center	PAK, CYC (corresponding author), UNIV TEXAS, SW MED CTR DALLAS, CTR MINERAL METAB & CLIN RES, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016061] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00633] Funding Source: Medline; NIAMS NIH HHS [R01-AR-16061] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTICH PP, 1993, J BONE MINER RES, V8, P301; ANTICH PP, 1994, J BONE MINER RES, V9, pS327; DURESMITH BA, 1993, 4TH P INT S OST 1993, P146; FACCINI JM, 1974, CALC TISS RES, V16, P45, DOI 10.1007/BF02008212; FARLEY JR, 1983, SCIENCE, V222, P330; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; HARVEY JA, 1988, J BONE MINER RES, V3, P253; Lee E.T., 1992, STATISTICAL METHODS; PAK CYC, 1989, J BONE MINER RES, V4, P119; PAK CYC, 1989, J CLIN ENDOCR METAB, V68, P150, DOI 10.1210/jcem-68-1-150; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; PAK CYC, 1990, J BONE MINER RES, V5, P857; REED BY, 1993, J BONE MINER RES, V8, P19; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SAKBAEE K, 1991, BONE MINER, V14, P131; SMITHBINDMAN R, 1991, J BONE MINER RES, V6, P25; TAVES DR, 1970, FED PROC, V29, P1185; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; ZERWEKH JE, 1991, J BONE MINER RES, V6, P239; ZERWEKH JE, 1992, BONE MINER, V18, P65, DOI 10.1016/0169-6009(92)90800-S; ZERWEKH JE, 1994, BONE, V15, P691, DOI 10.1016/8756-3282(94)90319-0	21	195	201	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					401	408		10.7326/0003-4819-123-6-199509150-00001	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639438				2022-12-28	WOS:A1995RU43700001
J	DEREGE, PJF; WILLIAMS, SA; THERIEN, MJ				DEREGE, PJF; WILLIAMS, SA; THERIEN, MJ			DIRECT EVALUATION OF ELECTRONIC COUPLING MEDIATED BY HYDROGEN-BONDS - IMPLICATIONS FOR BIOLOGICAL ELECTRON-TRANSFER	SCIENCE			English	Article							PORPHYRIN-QUINONE COMPOUNDS; TUNNELING PATHWAYS; INTRAMOLECULAR ELECTRON; CYTOCHROME-C; DISTANCE DEPENDENCE; BENZENE-DERIVATIVES; CRYSTAL-STRUCTURE; FIXED-DISTANCE; ZINC PORPHYRIN; TRANSFER RATES	Three supramolecular bischromophoric systems featuring zinc(II) and iron(III) porphyrins have been synthesized to evaluate the relative magnitudes of electronic coupling provided by hydrogen, sigma, and pi bonds. Laser flash excitation generates the highly reducing singlet excited state of the (porphinato)zinc chromophore that can subsequently be electron transfer quenched by the (porphinato)iron(III) chloride moiety. Measurement of the photoinduced electron transfer rate constants enables a direct comparison of how well these three types of chemical interactions facilitate electron tunneling, In contrast to generally accepted theory, electronic coupling modulated by a hydrogen-bond interface is greater than that provided by an analogous interface composed entirely of carbon-carbon a bonds. These results bear considerably on the analysis of through-protein electron transfer rate data as well as on the power of theory to predict the path traversed by the tunneling electron in a biological matrix; moreover, they underscore the cardinal role played by hydrogen bonds in biological electron transfer processes.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	University of Pennsylvania			Williams, Scott/AAG-7029-2020					ALMARSSON O, 1993, J AM CHEM SOC, V115, P7093, DOI 10.1021/ja00069a005; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BERATAN DN, 1992, J PHYS CHEM-US, V96, P2852, DOI 10.1021/j100186a014; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BERATAN DN, 1986, J AM CHEM SOC, V108, P4321, DOI 10.1021/ja00275a014; BERATAN DN, 1991, ADV CHEM SER, V228, P71; BETTS JN, 1992, J AM CHEM SOC, V114, P4043, DOI 10.1021/ja00037a004; BOBROWSKI K, 1992, J PHYS CHEM-US, V96, P10036, DOI 10.1021/j100203a082; BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; CASIMIRO DR, 1993, J PHYS CHEM-US, V97, P13073, DOI 10.1021/j100152a007; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; COLAPIETRO M, 1982, ACTA CRYSTALLOGR B, V38, P1953, DOI 10.1107/S0567740882007651; COLAPIETRO M, 1978, ACTA CRYSTALLOGR B, V34, P3277, DOI 10.1107/S056774087801064X; DEREGE PJF, IN PRESS INORG CHIM; DIMAGNO SG, 1993, J ORG CHEM, V58, P5983, DOI 10.1021/jo00074a027; DIMAGNO SG, 1993, J AM CHEM SOC, V115, P2513, DOI 10.1021/ja00059a060; EATON SS, 1977, J AM CHEM SOC, V99, P6594, DOI 10.1021/ja00462a021; FARVER O, 1992, J AM CHEM SOC, V114, P5764, DOI 10.1021/ja00040a043; FRANZEN S, 1993, J PHYS CHEM-US, V97, P3040, DOI 10.1021/j100114a035; GAINES GL, 1991, J AM CHEM SOC, V113, P719, DOI 10.1021/ja00002a076; HARRIMAN A, 1992, J AM CHEM SOC, V114, P388, DOI 10.1021/ja00027a074; HELMS A, 1992, J AM CHEM SOC, V114, P6227, DOI 10.1021/ja00041a047; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; KHUNDKAR LR, 1994, J AM CHEM SOC, V116, P9700, DOI 10.1021/ja00100a040; KOBAYASHI H, 1975, ADV BIOPHYS, V8, P191; LHAYA Y, 1965, B CHEM SOC JPN, V38, P1144; LIN VSY, 1994, SCIENCE, V264, P1105, DOI 10.1126/science.8178169; LONGO FR, 1968, J HETEROCYCLIC CHEM, V6, P927; MARCUS RA, 1986, BIOCHIM BIOPHYS ACTA, V811, P265; MATAGA N, 1989, CHEM PHYS, V131, P473, DOI 10.1016/0301-0104(89)80192-2; MIKKELSEN KV, 1993, P NATL ACAD SCI USA, V90, P5443, DOI 10.1073/pnas.90.12.5443; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; OSUKA A, 1990, J AM CHEM SOC, V112, P4958, DOI 10.1021/ja00168a051; PAULSON BP, UNPUB; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PETERSONKENNEDY SE, 1986, J AM CHEM SOC, V108, P1739, DOI 10.1021/ja00268a004; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; RISSER SM, 1993, J AM CHEM SOC, V115, P2508, DOI 10.1021/ja00059a057; ROTHEMUND P, 1948, J AM CHEM SOC, V70, P1808, DOI 10.1021/ja01185a047; SAKATA Y, 1991, CHEM LETT, P1307, DOI 10.1246/cl.1991.1307; SAKATA Y, 1989, J AM CHEM SOC, V111, P8979, DOI 10.1021/ja00206a065; SCHAUER CK, 1985, INORG CHEM, V24, P4082, DOI 10.1021/ic00218a024; SESSLER JL, 1993, J AM CHEM SOC, V115, P10418, DOI 10.1021/ja00075a091; THERIEN MJ, 1991, ADV CHEM SER, V228, P191; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054; TURRO C, 1992, J AM CHEM SOC, V114, P4013, DOI 10.1021/ja00036a081; WASIELEWSKI MR, 1992, CHEM REV, V92, P435, DOI 10.1021/cr00011a005; WASIELEWSKI MR, 1985, J AM CHEM SOC, V107, P1080, DOI 10.1021/ja00290a066; WINKLER JR, 1992, CHEM REV, V92, P369, DOI 10.1021/cr00011a001; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	53	339	342	3	60	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1409	1413		10.1126/science.7660123	http://dx.doi.org/10.1126/science.7660123			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660123				2022-12-28	WOS:A1995RT80600040
J	VENTO, S; GUELLA, L; MIRANDOLA, F; CAINELLI, F; DIPERRI, G; SOLBIATI, M; FERRARO, T; CONCIA, E				VENTO, S; GUELLA, L; MIRANDOLA, F; CAINELLI, F; DIPERRI, G; SOLBIATI, M; FERRARO, T; CONCIA, E			EPSTEIN-BARR-VIRUS AS A TRIGGER FOR AUTOIMMUNE HEPATITIS IN SUSCEPTIBLE INDIVIDUALS	LANCET			English	Note							INFECTIOUS-MONONUCLEOSIS	During follow-up of healthy relatives of 13 patients with autoimmune hepatitis, seven cases of infectious mononucleosis due to Epstein-Barr virus (EBV) occurred. In two of these seven, before EBV infection, there was a defect in suppressor-inducer T lymphocytes specifically controlling immune responses to the asialoglycoprotein receptor, an antigen expressed on the hepatocyte surface. In these two, antibodies to this autoantigen persisted and increased after infectious mononucleosis, and autoimmune hepatitis developed within 4 months. In susceptible individuals, EBV is a trigger for autoimmune hepatitis.	A PUGLIESE HOSP,INFECT DIS UNIT,CATANZARO,ITALY		VENTO, S (corresponding author), UNIV VERONA,BORGO TRENTO HOSP,DEPT INFECT DIS,I-37124 VERONA,ITALY.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062; Cainelli, Francesca/0000-0003-1838-3946				COYLE PV, 1989, LANCET, V1, P899; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; MCFARLANE BM, 1985, J IMMUNOL METHODS, V77, P219, DOI 10.1016/0022-1759(85)90034-1; OBRIEN CJ, 1986, LANCET, V2, P350; SUTTON RNP, 1974, CLIN EXP IMMUNOL, V17, P427; VENTO S, 1987, LANCET, V1, P886; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; Vento S, 1990, Prog Liver Dis, V9, P335; VENTO S, 1984, LANCET, V1, P1200; WHITTINGHAM S, 1985, ANN INTERN MED, V102, P490, DOI 10.7326/0003-4819-102-4-490	10	139	144	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					608	609		10.1016/S0140-6736(95)91438-2	http://dx.doi.org/10.1016/S0140-6736(95)91438-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651006				2022-12-28	WOS:A1995RT18800011
J	DWEK, RA				DWEK, RA			GLYCOBIOLOGY - MORE FUNCTIONS FOR OLIGOSACCHARIDES	SCIENCE			English	Editorial Material							RESOLUTION				DWEK, RA (corresponding author), UNIV OXFORD,INST GLYCOBIOL,RODNEY PORTER BLDG,OXFORD OX1 3QU,ENGLAND.							BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; RUDD PM, 1995, THESIS OPEN U; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; WOODS RJ, 1994, NAT STRUCT BIOL, V1, P499, DOI 10.1038/nsb0894-499; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493	10	100	109	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1234	1235		10.1126/science.7652569	http://dx.doi.org/10.1126/science.7652569			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652569				2022-12-28	WOS:A1995RR84200023
J	CHENN, A; MCCONNELL, SK				CHENN, A; MCCONNELL, SK			CLEAVAGE ORIENTATION AND THE ASYMMETRIC INHERITANCE OF NOTCH1 IMMUNOREACTIVITY IN MAMMALIAN NEUROGENESIS	CELL			English	Article							CEREBRAL-CORTEX; CELL LINEAGE; RADIAL GLIA; PATTERNS; MOUSE; MIGRATION; NEURONS; FATE; GENE	Neurons in the mammalian central nervous system are generated from progenitor cells near the lumen of the neural tube. Time-lapse microscopy of dividing cells in slices of developing cerebral cortex reveals that cleavage orientation predicts the fates of daughter cells. Vertical cleavages produce behaviorally and morphologically identical daughters that resemble precursor cells; these symmetric divisions may serve to expand or maintain the progenitor pool. In contrast, horizontally dividing cells produce basal daughters that behave like young migratory neurons and apical daughters that remain within the proliferative zone. Notch1 immunoreactivity is distributed asymmetrically in mitotic cells, with Notch1 inherited selectively by the basal (neuronal) daughter of horizontal divisions. These results provide cellular and molecular evidence that cortical neurons are generated from asymmetric divisions.			CHENN, A (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051864] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365] Funding Source: Medline; NIMH NIH HHS [MH51864] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; BERRY M, 1965, J ANAT, V99, P691; CAVINESS VS, 1995, IN PRESS TRENDS NEUR; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DAILEY ME, 1994, J NEUROSCI, V14, P1060, DOI 10.1523/JNEUROSCI.14-03-01060.1994; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; GRAY GE, 1992, DEVELOPMENT, V114, P271; HICKS SP, 1968, ANAT REC, V160, P619, DOI 10.1002/ar.1091600311; HINDS JW, 1971, Z ZELLFORSCH MIK ANA, V115, P226, DOI 10.1007/BF00391127; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEVINE SM, 1988, J COMP NEUROL, V277, P441, DOI 10.1002/cne.902770309; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MARTIN AH, 1967, NATURE, V215, P1133; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MILLER MW, 1985, DEV BRAIN RES, V23, P187, DOI 10.1016/0165-3806(85)90040-9; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; NYE JS, 1994, DEVELOPMENT, V120, P2421; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; ROBERTS JS, 1993, DEV BIOL, V155, P396, DOI 10.1006/dbio.1993.1038; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SMART IHM, 1973, J ANAT, V116, P67; SPANA EP, 1995, IN PRESS DEVELOPMENT; STENSAAS LJ, 1968, Z ZELLFORSCH MIK ANA, V91, P341, DOI 10.1007/BF00440763; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Woods D F, 1993, J Cell Sci Suppl, V17, P171; ZAMENHOF S, 1986, DEV BRAIN RES, V31, P143	41	609	621	0	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					631	641		10.1016/0092-8674(95)90035-7	http://dx.doi.org/10.1016/0092-8674(95)90035-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664342	Bronze			2022-12-28	WOS:A1995RR73400014
J	IZAURRALDE, E; LEWIS, J; GAMBERI, C; JARMOLOWSKI, A; MCGUIGAN, C; MATTAJ, IW				IZAURRALDE, E; LEWIS, J; GAMBERI, C; JARMOLOWSKI, A; MCGUIGAN, C; MATTAJ, IW			A CAP-BINDING PROTEIN COMPLEX MEDIATING U SNRNA EXPORT	NATURE			English	Article							MESSENGER-RNA PRECURSORS; RECOGNITION; INVITRO; NUCLEUS	CAP structures are added cotranscriptionally to all RNA polymerase II transcripts(1,2). They affect several processes including RNA stability(3-5), pre-messenger RNA splicing(6-11), RNA export from the nucleus(12-14) and translation initiation(15-17). The effect of the cap on translation is mediated by the initiation factor eIF-4F (refs 15-19), whereas the effect on pre-mRNA splicing involves a nuclear complex (CBC) composed of two cap binding proteins, CBP80 and CBP20(11). A role for CBC in the nuclear export of capped RNAs has also been proposed(11,13), We report here the characterization of human and Xenopus CBP20s. Antibodies against recombinant CBP20 prevent interaction of CBC with capped RNAs in vitro. Following microinjection into Xenopus oocytes, the antibodies inhibit both pre-mRNA splicing and export of U small nuclear RNAs to the cytoplasm, These results demonstrate that CBC mediates the effect of the cap structure in U snRNA export, and provide direct evidence for the involvement of a cellular RNA-binding factor in the transport of RNA to the cytoplasm.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Izaurralde, Elisa/G-3239-2012; Gamberi, Chiara/L-5740-2013	Gamberi, Chiara/0000-0002-7122-6491; Izaurralde, Elisa/0000-0001-7365-2649; Mattaj, Iain/0000-0002-5537-8284				BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LANG V, 1994, J BIOL CHEM, V269, P6117; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; PATZELT E, 1987, NUCLEIC ACIDS RES, V15, P1387, DOI 10.1093/nar/15.4.1387; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SALDITTGEORGIEF.M, 1980, CELL, V19, P69; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0	30	286	295	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					709	712		10.1038/376709a0	http://dx.doi.org/10.1038/376709a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651522				2022-12-28	WOS:A1995RQ67200066
J	SCHWEITZER, R; HOWES, R; SMITH, R; SHILO, BZ; FREEMAN, M				SCHWEITZER, R; HOWES, R; SMITH, R; SHILO, BZ; FREEMAN, M			INHIBITION OF DROSOPHILA EGF RECEPTOR ACTIVATION BY THE SECRETED PROTEIN ARGOS	NATURE			English	Article							FAINT-LITTLE-BALL; TYROSINE KINASE; GENE ENCODES; HOMOLOG; EXPRESSION; ANTAGONIST; TORPEDO; MELANOGASTER	THE Drosophila homologue of the mammalian epidermal growth factor (EGF) receptor (DER)(1,2) is a receptor tyrosine kinase involved in many stages of fly development, including photoreceptor determination, and wing-vein formation(3-9). Its primary activating ligand is the Spitz protein(10,11), which is similar to mammalian TGF-alpha (ref. 12), Argos is a secreted protein that, like Spitz, contains a single EGF motif(13-15). It is a repressor of cell determination in the eye, and acts in other tissues, including the wing(16-18) Because Argos has the opposite effects to DER in the eye (the former blocks photoreceptor determination, the latter promotes it) we have tested whether it acts by blocking the DER pathway, We show that Argos does indeed repress this pathway in vivo and find that, in vitro, Argos protein can inhibit the activation of DER by Spitz, Thus the determination of cells by the DER pathway is regulated by a balance between extracellular activating and inhibiting signals. This is the first in vivo example of an extracellular inhibitor of a receptor tyrosine kinase.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	MRC Laboratory Molecular Biology; Weizmann Institute of Science			Schweitzer, Ronen/AAY-2127-2020	Schweitzer, Ronen/0000-0002-7425-5028; Shilo, Ben Zion/0000-0003-4903-8889; Freeman, Matthew/0000-0003-0410-5451				BRUNNER A, 1994, MECH DEVELOP, V48, P175, DOI 10.1016/0925-4773(94)90058-2; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; CLIFFORD RJ, 1989, GENETICS, V123, P771; COCHET C, 1984, J BIOL CHEM, V259, P2553; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; XU T, 1993, DEVELOPMENT, V117, P1223; ZAK NB, 1990, ONCOGENE, V5, P1589	30	219	222	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					699	702		10.1038/376699a0	http://dx.doi.org/10.1038/376699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651519				2022-12-28	WOS:A1995RQ67200063
J	LAMBERT, N; GROVER, L				LAMBERT, N; GROVER, L			THE MECHANISM OF BIPHASIC GABA RESPONSES	SCIENCE			English	Editorial Material							HIPPOCAMPAL PYRAMIDAL CELLS; RAT HIPPOCAMPUS; NEURONS; BICARBONATE; CONDUCTANCE; INHIBITION; CHLORIDE; ACID		MARSHALL UNIV,SCH MED,DEPT PHYSIOL,HUNTINGTON,WV 25755	Marshall University	LAMBERT, N (corresponding author), DUKE UNIV,MED CTR,VET ADM MED CTR,DEPT PHARMACOL,DURHAM,NC 27705, USA.							ALGER BE, 1979, NATURE, V281, P315, DOI 10.1038/281315a0; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; GROVER LM, 1993, J NEUROPHYSIOL, V69, P1541, DOI 10.1152/jn.1993.69.5.1541; HUGUENARD JR, 1986, J NEUROPHYSIOL, V56, P1; KAILA K, 1989, J PHYSIOL-LONDON, V416, P161, DOI 10.1113/jphysiol.1989.sp017755; KAILA K, 1993, J PHYSIOL-LONDON, V464, P273, DOI 10.1113/jphysiol.1993.sp019634; LAMBERT NA, 1991, J NEUROPHYSIOL, V66, P1538, DOI 10.1152/jn.1991.66.5.1538; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; TEYLER TJ, 1994, HIPPOCAMPUS, V4, P623, DOI 10.1002/hipo.450040602; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938	16	57	60	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					928	929		10.1126/science.7638614	http://dx.doi.org/10.1126/science.7638614			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638614				2022-12-28	WOS:A1995RP73800022
J	RYAN, MP; FRENCH, J; ALMAHDAWI, S; NIHOYANNOPOULOS, P; CLELAND, JGF; OAKLEY, CM				RYAN, MP; FRENCH, J; ALMAHDAWI, S; NIHOYANNOPOULOS, P; CLELAND, JGF; OAKLEY, CM			AN AN ETHICAL DEBATE - GENETIC TESTING FOR FAMILIAL HYPERTROPHIC CARDIOMYOPATHY IN NEWBORN-INFANTS - CLINICIAN PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article							HEAVY-CHAIN GENE; MUTATIONS; CHILDREN	Identification of genes for hypertrophic cardiomyopathy has made preclinical diagnoses possible in families with a mutation. As yet, however, no treatment prevents the development of myocardial hypertrophy, and medical intervention has not been shown to improve prognosis. A team from Hammersmith Hospital carrying out research into genetic causes of the disease report that they were asked by a couple to screen their daughter at birth. The couple also give their view of screening. We asked two medical geneticists, a cardiologist, and a paediatrician with an interest in ethics to comment on the implications.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN CARDIOL,LONDON W12 0NN,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND; UNIV WALES COLL CARDIFF,INST MED GENET,CARDIFF CF4 4XN,S GLAM,WALES	Imperial College London; Imperial College London; Cardiff University			Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016				ALMAHDAWI S, 1993, BRIT HEART J, V69, P136; ALMAHDAWI S, IN PRESS BR HEART J; CLARK AL, 1993, BMJ-BRIT MED J, V306, P409, DOI 10.1136/bmj.306.6875.409; CLARKE A, 1992, NEW ENGL J MED, V327, P1175; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MCKENNA WJ, 1988, J AM COLL CARDIOL, V11, P147, DOI 10.1016/0735-1097(88)90181-7; OESTMANSMITH I, 1991, BRIT HEART J, V66, P76; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703	11	16	16	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					856	857		10.1136/bmj.310.6983.856	http://dx.doi.org/10.1136/bmj.310.6983.856			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7677835	Green Published			2022-12-28	WOS:A1995QQ85700027
J	DOWELL, JS; SNADDEN, D; DUNBAR, JA				DOWELL, JS; SNADDEN, D; DUNBAR, JA			CHANGING TO GENERIC FORMULARY - HOW ONE FUNDHOLDING PRACTICE REDUCED PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To observe one general practice's attempt to reduce prescribing costs on becoming third wave fundholders through the introduction of a generic formulary applied to all new and repeat prescribing. To assess the impact on patients and prescribing patterns. Design-An observational study using interviews with patients and practitioners; questionnaires for patients and prescribing data. Setting-One urban general practice with five partners in Scotland. It became fundholding in April 1993. Subjects-71 searches of the register of repeat prescriptions identified 1274 potential changes in drugs. Questionnaires were sent to a stratified random sample of 280 patients four months after the changes were made; 33 interviews were conducted with 17 patients selected by local pharmacists to represent a wide range of opinion. Main outcome measures-Changes in prescribing and response and satisfaction of patients. Results-Of intended changes, 129 (70%) were in place after four months. Thirty three (20%) of the 167 patients who returned questionnaires were ''very unhappy,'' though interviews suggested that this was primarily with the communication they received rather than the change itself. Generic prescribing rose from one in three (37%) to over a half (58%). The volume of treatment dispensed (as treatment days) fell by 67 674 (10.7%), and the average cost per day's treatment fell by 3.1p from 32.3p per day in 1992 (9.4%), producing a total absolute saving of 24% (pound 137 712) over the first year. Conclusion-This practice has achieved a large reduction in prescribing costs rapidly. These were tolerated by patients, none of whom is thought to have left the practice for this reason. Great care must be taken to inform patients appropriately.	DOWNFIELD SURG,DUNDEE DD3 8NE,SCOTLAND		DOWELL, JS (corresponding author), WESTGATE HLTH CTR,TAYSIDE CTR GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND.		Dowell, Jonathan/M-6077-2019; Snadden, David/ABF-1586-2020; Dunbar, James A/G-3034-2012	Snadden, David/0000-0002-4818-1184; 				BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; Patton M. Q., 1990, QUALITATIVE EVALUATI, P280; 1994, PRESCRIPTION IMPROVE	7	71	71	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					505	508		10.1136/bmj.310.6978.505	http://dx.doi.org/10.1136/bmj.310.6978.505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7677830	Green Published			2022-12-28	WOS:A1995QJ59800028
J	MALMQVIST, M				MALMQVIST, M			BIOSPECIFIC INTERACTION ANALYSIS USING BIOSENSOR TECHNOLOGY	NATURE			English	Article							SURFACE-PLASMON RESONANCE; PROTEINS				MALMQVIST, M (corresponding author), PHARMACIA BIOSENSOR AB,S-75182 UPPSALA,SWEDEN.							ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; BORREBAECK CAK, 1992, BIO-TECHNOL, V10, P697, DOI 10.1038/nbt0692-697; BRIGHAMBURKE M, 1992, ANAL BIOCHEM, V205, P125, DOI 10.1016/0003-2697(92)90588-X; CEDERGREN L, 1991, AUG S STRUCT FUNCT M, P18; DUBS MC, 1992, J CHROMATOGR, V597, P391, DOI 10.1016/0021-9673(92)80136-I; DUBS MC, 1991, IMMUNOL LETT, V31, P59; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GRIFFITHS AD, IN PRESS EMBO J; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Jonsson U., 1992, ADV BIOSENSOR, P291; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KARLSSON R, 1992, STRUCTURE ANTIGENS, V1, P127; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LOFAS S, 1991, SENSOR ACTUAT B-CHEM, V5, P79, DOI 10.1016/0925-4005(91)80224-8; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MALMBORG AC, 1992, SCAND J IMMUNOL, V35, P643, DOI 10.1111/j.1365-3083.1992.tb02970.x; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; SJOLANDER S, 1991, ANAL CHEM, V63, P2338; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; VANCOTT TC, 1992, J IMMUNOL METHODS, V146, P163, DOI 10.1016/0022-1759(92)90225-I; ZEDERLUTZ G, 1993, MOL IMMUNOL, V30, P145, DOI 10.1016/0161-5890(93)90086-Q	24	518	583	4	119	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					186	187		10.1038/361186a0	http://dx.doi.org/10.1038/361186a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	7678451				2022-12-28	WOS:A1993KG46600070
J	HOES, AW; GROBBEE, DE; LUBSEN, J; TVELD, AJMI; VANDERDOES, E; HOFMAN, A				HOES, AW; GROBBEE, DE; LUBSEN, J; TVELD, AJMI; VANDERDOES, E; HOFMAN, A			DIURETICS, BETA-BLOCKERS, AND THE RISK FOR SUDDEN CARDIAC DEATH IN HYPERTENSIVE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						DEATH, SUDDEN, CARDIAC; HYPERTENSION; ADRENERGIC BETA-ANTAGONISTS; DIURETICS; POTASSIUM	CORONARY HEART-DISEASE; BLOOD-PRESSURE; ABNORMALITIES; ARRHYTHMIAS; MANAGEMENT; STROKE; MEN	Objective: To determine whether the use of non-potassium-sparing diuretics and beta-blockers is associated with an excess risk for sudden cardiac death in hypertensive patients. Design: Case-control study. Setting: Rotterdam, the Netherlands. Patients: 257 case-patients who had died suddenly while receiving drug therapy for hypertension and 257 living controls also receiving drug therapy for hypertension. Measurements: Detailed information on medication use and clinical characteristics of all case-patients and controls was collected from the files of general practitioners. Additional information on medication use was obtained from computerized pharmacy records. Results: Patients receiving non-potassium-sparing diuretics had an increased risk for sudden cardiac death (relative risk, 1.8 [95% CI, 1.0 to 3.1]) compared with a reference group treated primarily with potassium-sparing diuretics. The corresponding relative risk for beta-blocker use was 1.7 (CI, 1.1 to 2.6). The use of non-potassium-sparing diuretics without beta-blockers was associated with a higher risk for sudden death (relative risk, 2.2 [CI, 1.1 to 4.6]) than was concomitant use of non-potassium-sparing diuretics and beta-blockers (relative risk, 1.4 [CI, 0.6 to 3.0]). The risk for sudden cardiac death among recipients of non-potassium-sparing diuretics was more pronounced in those who had been receiving the diuretic for less than 1 year and in those aged 75 years or younger. Conclusions: The use of non-potassium-sparing diuretics and beta-blockers is associated with an increased risk for sudden cardiac death. This association may offset part of the mortality benefit of these drugs in the treatment of hypertension.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT GEN PRACTICE, 3000 DR ROTTERDAM, NETHERLANDS; SOC RECH CARDIOL SA, CH-1261 GIVRINS, SWITZERLAND; ERASMUS UNIV ROTTERDAM, SCH MED, ACAD HOSP DIJKZIGT, DEPT INTERNAL MED 1, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	HOES, AW (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1970, JAMA, V213, P1143; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; Breslow N, 1980, STATISTICAL METHODS, V32; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUPPLES LA, 1992, CIRCULATION S1, V85; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HOES AW, 1994, DRUGS, V47, P711, DOI 10.2165/00003495-199447050-00002; HOLME I, 1984, JAMA-J AM MED ASSOC, V251, P1298, DOI 10.1001/jama.251.10.1298; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KULLER LH, 1986, CIRCULATION, V73, P114, DOI 10.1161/01.CIR.73.1.114; LOWN B, 1986, HEART DISEASE TXB CA; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MIALL WE, 1987, NEPHRON S1, V47; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; MYERBURG RJ, 1992, CIRCULATION, V85, P2; OLSSON G, 1991, AM J HYPERTENS, V4, P151, DOI 10.1093/ajh/4.2.151; PAPADEMETRIOU V, 1986, AM HEART J, V111, P1217, DOI 10.1016/0002-8703(86)90041-4; PITT B, 1992, CIRCULATION, V85, P107; POOLEWILSON PA, 1987, J HYPERTENS, V5, pS51; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SINGH S, 1984, CIRCULATION, V70, P996; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603	27	124	125	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					481	+		10.7326/0003-4819-123-7-199510010-00001	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661490				2022-12-28	WOS:A1995RW49500001
J	HIRSCHTICK, RE; GLASSROTH, J; JORDAN, MC; WILCOSKY, TC; WALLACE, JM; KVALE, PA; MARKOWITZ, N; ROSEN, MJ; MANGURA, BT; HOPEWELL, PC; STANSELL, J; TURNER, J; OSMOND, D; MERRIFIELD, C; MOSSAR, M; HIRSCHTICK, R; MEISELMAN, L; MANGHISI, KJ; SCHNEIDER, RF; REICHMAN, LB; MANGURA, B; BARNES, S; RICHER, B; AU, J; COULSON, A; CLEMENTE, V; SARAVOLATZ, LD; JOHNSON, C; HUITSING, J; KRYSTOFORSKI, A; POOLE, WK; RAO, AV; CLAYTON, K; HANSON, N; JORDAN, M; THOMPSON, J; MYERS, D; LAVANGE, L; KATZIN, J; FULKERSON, W; WILCOSKY, T; LOU, Y; KALICA, AR; WITTES, J; FOLLMANN, D				HIRSCHTICK, RE; GLASSROTH, J; JORDAN, MC; WILCOSKY, TC; WALLACE, JM; KVALE, PA; MARKOWITZ, N; ROSEN, MJ; MANGURA, BT; HOPEWELL, PC; STANSELL, J; TURNER, J; OSMOND, D; MERRIFIELD, C; MOSSAR, M; HIRSCHTICK, R; MEISELMAN, L; MANGHISI, KJ; SCHNEIDER, RF; REICHMAN, LB; MANGURA, B; BARNES, S; RICHER, B; AU, J; COULSON, A; CLEMENTE, V; SARAVOLATZ, LD; JOHNSON, C; HUITSING, J; KRYSTOFORSKI, A; POOLE, WK; RAO, AV; CLAYTON, K; HANSON, N; JORDAN, M; THOMPSON, J; MYERS, D; LAVANGE, L; KATZIN, J; FULKERSON, W; WILCOSKY, T; LOU, Y; KALICA, AR; WITTES, J; FOLLMANN, D			BACTERIAL PNEUMONIA IN PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; INTRAVENOUS-DRUG-USERS; TRIMETHOPRIM-SULFAMETHOXAZOLE; PULMONARY COMPLICATIONS; AEROSOLIZED PENTAMIDINE; HOSPITALIZED-PATIENTS; CONTROLLED TRIAL; AIDS	Background. Patients with human immunodeficiency virus (HIV) infection are at increased risk for bacterial pneumonia in addition to opportunistic infection. However, the risk factors for bacterial pneumonia and its incidence in this population are not well defined. Methods. In a multicenter, prospective, observational study, we monitored 1130 HIV-positive and 167 HIV-negative participating adults for up to 64 months for pulmonary disease. The HIV-positive group comprised 814 homosexual or bisexual men, 261 injection-drug users, and 55 female partners of HIV-infected men, Results. There were 237 episodes of bacterial pneumonia among the HIV-positive participants (rate, 5.5 per 100 person-years), as compared with 6 episodes among the HIV-negative participants (rate, 0.9 per 100 person-years; P<0.001). The rate of bacterial pneumonia increased with decreasing CD4 lymphocyte counts (2.3, 6.8, and 10.8 episodes per 100 person-years in the strata with more than 500, 200 to 500, and fewer than 200 cells per cubic millimeter, respectively; P less than or equal to 0.022 for each comparison). injection-drug users had a higher rate of bacterial pneumonia than did homosexual or bisexual men or female partners, In the stratum with the fewest CD4 lymphocytes, cigarette smoking was associated with an increased rate of pneumonia. Mortality was almost four times higher among participants with an episode of pneumonia than among the others, Prophylaxis with trimethoprim-sulfamethoxazole was associated with a 67 percent reduction in confirmed episodes of bacterial pneumonia (P=0.007). Conclusions. Bacterial pneumonia is more frequent in HIV-positive persons than in seronegative controls, and the risk is highest among those with CD4 lymphocyte counts below 200 per cubic millimeter and among injection-drug users.	NORTHWESTERN UNIV,PULM MED SECT,CHICAGO,IL 60611; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; HENRY FORD HOSP,DETROIT,MI 48202; BETH ISRAEL MED CTR,NEW YORK,NY 10003; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY HOSP,NEW JERSEY MED SCH,NEWARK,NJ; RES TRIANGLE INST,CTR COORDINATING,RES TRIANGLE PK,NC 27709; NHLBI,BETHESDA,MD 20892	Northwestern University; University of California System; University of California Los Angeles; Henry Ford Health System; Henry Ford Hospital; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	HIRSCHTICK, RE (corresponding author), NORTHWESTERN UNIV,INFECT DIS SECT,303 E SUPERIOR,PASSAVANT 828,CHICAGO,IL 60611, USA.				DIVISION OF LUNG DISEASES [N01HR076030, N01HR076031, N01HR076029] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR7-6031, N01-HR7-6029, N01-HR7-6030] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; BATES JH, 1992, CHEST, V101, P1005, DOI 10.1378/chest.101.4.1005; BUSKIN SE, 1992, 8TH INT C AIDS 3RD S; CAIAFFA WT, 1993, AM J EPIDEMIOL, V138, P909, DOI 10.1093/oxfordjournals.aje.a116812; CAIAFFA WT, 1993, 9TH INT C AIDS 4TH S, P705; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Cohn D L, 1991, Infect Dis Clin North Am, V5, P485; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; GARCIALEONI ME, 1992, ARCH INTERN MED, V152, P1808, DOI 10.1001/archinte.152.9.1808; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P119; Kleinbaum D.G, 1982, EPIDEMIOLOGIC RES PR, P220; LEVY M, 1988, CHEST, V93, P43, DOI 10.1378/chest.93.1.43; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; MAGNENAT JL, 1991, AM REV RESPIR DIS, V144, P917, DOI 10.1164/ajrccm/144.4.917; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; MIENTJES GH, 1992, AIDS, V6, P207, DOI 10.1097/00002030-199202000-00012; MIENTJES GH, 1992, AIDS, V6, P526; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1356, DOI 10.1164/ajrccm/141.5_Pt_1.1356; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; NIEMAN R, 1992, pC312; NIEMAN RB, 1993, J ACQ IMMUN DEF SYND, V6, P1174; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; ODONNELL AE, 1988, CHEST, V94, P251, DOI 10.1378/chest.94.2.251; PERTEL P, 1992, J ACQ IMMUN DEF SYND, V5, P1069; PHAIR J, 1990, NEW ENGL J MED, V332, P161; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; RANKIN JA, 1988, CHEST, V94, P155, DOI 10.1378/chest.94.1.155; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; TOEWS GB, 1992, ANN INTERN MED, V117, P415; WALLACE JM, 1993, AM REV RESPIR DIS, V148, P1523, DOI 10.1164/ajrccm/148.6_Pt_1.1523; WALSH TJ, 1991, RESP DIS IMMUNOSUPPR, P640; WALSH TJ, 1992, ANN INTERN MED, V117, P415; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; WOODHEAD MA, 1987, LANCET, V1, P671; 1987, MMWR MORB MORTAL S1, V36, pS3; 1993, J CLIN EPIDEMIOL, V46, P497	42	485	491	2	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					845	851		10.1056/NEJM199509283331305	http://dx.doi.org/10.1056/NEJM199509283331305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651475				2022-12-28	WOS:A1995RW88300005
J	SAZAWAL, S; BLACK, RE; BHAN, MK; BHANDARI, N; SINHA, A; JALLA, S				SAZAWAL, S; BLACK, RE; BHAN, MK; BHANDARI, N; SINHA, A; JALLA, S			ZINC SUPPLEMENTATION IN YOUNG-CHILDREN WITH ACUTE DIARRHEA IN INDIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RURAL BANGLADESHI CHILDREN; MEDIATED IMMUNE-DEFICIENCY; PERSISTENT DIARRHEA; INTESTINAL PERMEABILITY; PERUVIAN CHILDREN; INFANTS; MALNUTRITION; PLASMA; CELL; POPULATIONS	Background. In developing countries the duration and severity of diarrheal illnesses are greatest among infants and young children with malnutrition and impaired immune status, both factors that may be associated with zinc deficiency. In children with severe zinc deficiency, diarrhea is common and responds quickly to zinc supplementation. Methods. To evaluate the effects of daily supplementation with 20 mg of elemental zinc on the duration and severity of acute diarrhea, we conducted a double-blind, randomized, controlled trial involving 937 children, 6 to 35 months of age, in New Delhi, India. All the children also received oral rehydration therapy and vitamin supplements. Results. Among the children who received zinc supplementation, there was a 23 percent reduction (95 percent confidence interval, 12 percent to 32 percent) in the risk of continued diarrhea. Estimates of the likelihood of recovery according to the day of zinc supplementation revealed a reduction of 7 percent (95 percent confidence interval, -9 percent to +22 percent) in the risk of continued diarrhea during days 1 through 3 and a reduction of 38 percent (95 percent confidence interval, 27 percent to 48 percent) after day 3. When zinc supplementation was initiated within three days of the onset of diarrhea, there was a 39 percent reduction (95 percent confidence interval, 7 percent to 61 percent) in the proportion of episodes lasting more than seven days. In the zinc-supplementation group there was a decrease of 39 percent (95 percent confidence interval, 6 percent to 70 percent) in the mean number of watery stools per day (P=0.02) and a decrease of 21 percent (95 percent confidence interval, 10 percent to 31 percent) in the number of days with watery diarrhea. The reductions in the duration and severity of diarrhea were greater in children with stunted growth than in those with normal growth. Conclusions. For infants and young children with acute diarrhea, zinc supplementation results in clinically important reductions in the duration and severity of diarrhea.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, BALTIMORE, MD USA; ALL INDIA INST MED SCI, INDIAN COUNCIL MED RES, ADV CTR DIARRHEAL DIS RES, DIV PEDIAT GASTROENTEROL, NEW DELHI, INDIA	Johns Hopkins University; All India Institute of Medical Sciences (AIIMS) New Delhi; Indian Council of Medical Research (ICMR)				Black, Robert/0000-0001-9926-7984				ALLEN LH, 1994, EUR J CLIN NUTR, V48, pS75; ARCASOY A, 1990, J PEDIATR GASTR NUTR, V11, P279, DOI 10.1097/00005176-199008000-00022; BAQUI AH, 1993, AM J EPIDEMIOL, V137, P355, DOI 10.1093/oxfordjournals.aje.a116682; BAQUI AH, 1993, AM J CLIN NUTR, V58, P543, DOI 10.1093/ajcn/58.4.543; BEISEL WR, 1982, AM J CLIN NUTR, V35, P417, DOI 10.1093/ajcn/35.2.417; BETTGER WJ, 1981, LIFE SCI, V28, P1425, DOI 10.1016/0024-3205(81)90374-X; BHAN MK, 1986, INDIAN J MED RES, V83, P9; BHANDARI N, 1994, BRIT MED J, V309, P1404, DOI 10.1136/bmj.309.6966.1404; BHANDARI N, 1992, ACTA PAEDIATR, V81, P3, DOI 10.1111/j.1651-2227.1992.tb12363.x; BLACK RE, 1984, AM J CLIN NUTR, V39, P87, DOI 10.1093/ajcn/39.1.87; BLACK RE, 1989, PEDIATR INFECT DIS J, V8, P210; BLACK RE, 1984, PEDIATRICS, V73, P799; BLACK RE, 1991, ACTA PAEDIATR SCAND, P133; BROWN KH, 1993, AM J CLIN NUTR, V58, P549, DOI 10.1093/ajcn/58.4.549; BROWN KH, 1994, J NUTR, V124, pS1455, DOI 10.1093/jn/124.suppl_8.1455S; CASTILLODURAN C, 1988, J PEDIATR-US, V113, P452, DOI 10.1016/S0022-3476(88)80627-9; CASTILLODURAN C, 1990, AM J CLIN NUTR, V51, P1088, DOI 10.1093/ajcn/51.6.1088; Cox D. R., 1984, ANAL SURVIVAL DATA; CUNNINGHAMRUNDLES C, 1979, FED PROC, V38, P1222; ELMES ME, 1980, J PATHOL, V130, P37, DOI 10.1002/path.1711300106; Evans P. H., 1993, Proceedings of the Nutrition Society, V52, p25A; FAUVEAU V, 1991, J TROP PEDIATRICS, V37, P31, DOI 10.1093/tropej/37.1.31; FENWICK PK, 1990, AM J CLIN NUTR, V52, P166, DOI 10.1093/ajcn/52.1.166; FORD RPK, 1985, J PEDIATR GASTR NUTR, V4, P568, DOI 10.1097/00005176-198508000-00012; FRIEDMAN LM, 1985, FUNDAMENTALS CLIN TR, P54; GEBHARD RL, 1983, J NUTR, V113, P855, DOI 10.1093/jn/113.4.855; GHISHAN FK, 1984, J PEDIATR GASTR NUTR, V3, P608, DOI 10.1097/00005176-198409000-00022; GOLDEN BE, 1985, TRACE ELEMENTS MAN A, V5, P228; GOLDEN BE, 1982, TRACE ELEMENT METABO, P73; GOLDEN MHN, 1985, NUTR RES S1, V5, pS700; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GUERRIERI A, 1986, EUR J PEDIATR, V145, P563, DOI 10.1007/BF02429067; HAMBIDGE KM, 1990, J TRACE ELEM ELECT H, V4, P229; HAMBIDGE KM, 1992, ACTA PAEDIATR, V81, P82, DOI 10.1111/j.1651-2227.1992.tb12377.x; JONES PE, 1981, GUT, V22, P194, DOI 10.1136/gut.22.3.194; KASCH P, 1979, FED PROC, V38, P605; KAY RG, 1975, LANCET, V2, P605; KOO SI, 1977, J NUTR, V107, P896, DOI 10.1093/jn/107.5.896; LISOWSKI J, 1970, Acta Biochimica Polonica, V17, P311; MATTHEWS DE, 1988, USING UNDERSTANDING, P164; MORAN JR, 1985, PEDIATR RES, V19, P968, DOI 10.1203/00006450-198509000-00020; MOYNAHAN EJ, 1974, LANCET, V2, P399; MURPHY SP, 1992, AM J CLIN NUTR, V56, P565, DOI 10.1093/ajcn/56.3.565; NAVEH Y, 1982, J PEDIATR-US, V101, P730, DOI 10.1016/S0022-3476(82)80303-X; PATRICK J, 1980, AM J CLIN NUTR, V33, P617, DOI 10.1093/ajcn/33.3.617; PATRICK J, 1978, CLIN SCI MOL MED, V54, P585, DOI 10.1042/cs0540585; PETERS TJ, 1976, CLIN SCI MOL MED, V51, P557, DOI 10.1042/cs0510557; PRASAD AS, 1991, AM J CLIN NUTR, V53, P403, DOI 10.1093/ajcn/53.2.403; PUFFER RR, 1973, PAHO SCI PUBLICATION; RODRIGUEZ A, 1985, ACTA PAEDIATR SCAND, V74, P770, DOI 10.1111/j.1651-2227.1985.tb10029.x; ROTHBAUM RJ, 1982, AM J CLIN NUTR, V35, P595; ROY S, 1986, P NUTR SOC, V45, pA39; ROY SK, 1992, J PEDIATR GASTR NUTR, V15, P289, DOI 10.1097/00005176-199210000-00010; RUZ M, 1987, FASEB J, V46, P748; SACHDEV HPS, 1988, J PEDIATR GASTR NUTR, V7, P877, DOI 10.1097/00005176-198811000-00015; SACHDEV HPS, 1990, ANN TROP PAEDIATR, V10, P63, DOI 10.1080/02724936.1990.11747411; SARKER SA, 1985, HUM NUTR-CLIN NUTR, V39C, P411; SAZAWAL S, 1991, INT J EPIDEMIOL, V20, P540, DOI 10.1093/ije/20.2.540; SCHLESINGER L, 1992, AM J CLIN NUTR, V56, P491, DOI 10.1093/ajcn/56.3.491; SUZUKI I, 1973, J BIOCHEM-TOKYO, V74, P627, DOI 10.1093/oxfordjournals.jbchem.a130285; TOMKINS A, 1993, P NUTR SOC, V52, P131, DOI 10.1079/PNS19930045; TRUDING R, 1974, J BIOL CHEM, V249, P3973; WARREN L, 1966, J CELL PHYSIOL, V68, P269, DOI 10.1002/jcp.1040680308; WAX Y, 1993, EPIDEMIOLOGY, V4, P120, DOI 10.1097/00001648-199303000-00007; WEAVER LT, 1985, ARCH DIS CHILD, V60, P326, DOI 10.1136/adc.60.4.326; WOLMAN SL, 1979, GASTROENTEROLOGY, V76, P458; 1992, SAS P229 SAS I TECHN, P435; 1977, VITAL HLTH STATIS 11, V165; 1990, NUTR REV, V48, P19	69	295	302	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					839	844		10.1056/NEJM199509283331304	http://dx.doi.org/10.1056/NEJM199509283331304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651474	Bronze			2022-12-28	WOS:A1995RW88300004
J	SAUNDERS, N; HAMMERSLEY, B				SAUNDERS, N; HAMMERSLEY, B			MAGNESIUM FOR ECLAMPSIA	LANCET			English	Editorial Material							PREECLAMPSIA-ECLAMPSIA; SULFATE				SAUNDERS, N (corresponding author), PRINCESS ANNE HOSP,SOUTHAMPTON,HANTS,ENGLAND.							BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; COTTON DB, 1992, AM J OBSTET GYNECOL, V166, P1127, DOI 10.1016/S0002-9378(11)90599-7; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; GOODWIN JS, 1984, JAMA-J AM MED ASSOC, V251, P2387, DOI 10.1001/jama.251.18.2387; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; SADEH M, 1989, STROKE, V20, P1273, DOI 10.1161/01.STR.20.9.1273; Sibai B M, 1992, Int J Obstet Anesth, V1, P167, DOI 10.1016/0959-289X(92)90024-X; SIBAI BM, 1984, AM J OBSTET GYNECOL, V150, P728, DOI 10.1016/0002-9378(84)90676-8; SIBAI BM, 1990, AM J OBSTET GYNECOL, V163, P1049, DOI 10.1016/0002-9378(90)91123-T; The Eclampsia Trial Collaborative Group, 1995, LANCET, V345, P1445	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					788	789		10.1016/S0140-6736(95)91614-8	http://dx.doi.org/10.1016/S0140-6736(95)91614-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674740				2022-12-28	WOS:A1995RW25800005
J	LU, ZL; SPERLING, G				LU, ZL; SPERLING, G			ATTENTION-GENERATED APPARENT MOTION	NATURE			English	Article							PERCEPTION; MECHANISMS; INFORMATION; MOVEMENT; VISION; SEARCH	MOTION perception mechanisms have recently been divided into three categories(1). First-order mechanisms(2-4) primarily extract motion from moving objects or features that differ from the background in luminance. Second-order mechanism(5,6) extract motion from moving properties, such as a moving area of flicker in which there is no difference in mean luminance between target and background. These first- and second-order motion mechanisms are primarily monocular. The existence of purely binocular, interocular and various other unusual kinds of apparent motion(7-13) has promoted conjectures of a third-order mechanism(1,14,15), but there has been no clear suggestion as to the actual computations that such a mechanism might perform. Here we demonstrate 'alternating feature' stimuli that produce apparent motion only when the observer selectively attends to one of the embedded features in the display. The latent motion in the alternating feature stimuli is invisible to first-or second-order motion mechanisms, and the direction of apparent motion depends on the particular feature attended. These findings suggest the mechanism of third-order motion: the locations of the most significant features are registered in a salience map, and motion is computed directly from this map.	UNIV CALIF IRVINE,INST MATH BEHAV SCI,IRVINE,CA 92717	University of California System; University of California Irvine	LU, ZL (corresponding author), UNIV CALIF IRVINE,DEPT COGNIT SCI,HUMAN INFORMAT PROC LAB,IRVINE,CA 92717, USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; Braddick OJ, 1978, VISUAL PSYCHOPHYSICS, P417; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; CAVANAGH P, 1989, VISION RES, V29, P1197, DOI 10.1016/0042-6989(89)90065-5; CAVE KR, 1990, COGNITIVE PSYCHOL, V22, P225, DOI 10.1016/0010-0285(90)90017-X; CHUBB C, 1989, P NATL ACAD SCI USA, V86, P2985, DOI 10.1073/pnas.86.8.2985; GEORGESON MA, 1989, VISION RES, V29, P1511, DOI 10.1016/0042-6989(89)90135-1; HALLETT PE, 1986, HDB PERCEPTION HUMAN, pCH10; Helmholtz H. v., 1925, HELMHOLTZS TREATISE; JULESZ B, 1968, VISION RES, V8, P433, DOI 10.1016/0042-6989(68)90111-9; KAHNEMAN D, 1992, COGNITIVE PSYCHOL, V24, P175, DOI 10.1016/0010-0285(92)90007-O; LU ZL, 1995, VISION RES, V35, P2697, DOI 10.1016/0042-6989(95)00025-U; PANTLE A, 1976, SCIENCE, V193, P500, DOI 10.1126/science.941023; PETERSIK JT, 1978, PERCEPTION, V7, P371, DOI 10.1068/p070371; REICHARDT W, 1957, Z NATURFORSCH 2B, V12, P447, DOI DOI 10.1515/ZNB-1957-0707; SHADLEN M, 1986, SCIENCE, V232, P95, DOI 10.1126/science.3952502; SHIH S, IN PRESS J EXP PSYCH; SHIPLEY WC, 1945, AM J PSYCHOL, V58, P545, DOI 10.2307/1417769; SOLOMON JA, 1994, VISION RES, V34, P2239, DOI 10.1016/0042-6989(94)90105-8; SPERLING G, 1995, PSYCHOL REV, V102, P502; SPERLING G, 1960, PSYCHOL MONOGRAPHS, V74; TREISMAN A, 1988, PSYCHOL REV, V95, P15, DOI 10.1037/0033-295X.95.1.15; VANSANTEN JPH, 1985, J OPT SOC AM A, V2, P300, DOI 10.1364/JOSAA.2.000300; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; VICTOR JD, 1990, VISION RES, V30, P289, DOI 10.1016/0042-6989(90)90044-L; WERKHOVEN P, 1993, VISION RES, V33, P463, DOI 10.1016/0042-6989(93)90253-S; ZANKER JM, 1993, VISION RES, V33, P553, DOI 10.1016/0042-6989(93)90258-X	28	154	154	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					237	239		10.1038/377237a0	http://dx.doi.org/10.1038/377237a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RV872	7675109				2022-12-28	WOS:A1995RV87200041
J	FISHER, M; PRICHARD, JW; WARACH, S				FISHER, M; PRICHARD, JW; WARACH, S			NEW MAGNETIC-RESONANCE TECHNIQUES FOR ACUTE ISCHEMIC STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOCAL CEREBRAL-ISCHEMIA; NMR-SPECTROSCOPY; HUMAN BRAIN; INFARCTION; LACTATE; METABOLITES; ADULT	Neuroimaging was revolutionized by the development of computed tomography (CT) and standard T-1- and T-2-weighted magnetic resonance imaging (MRI). Magnetic resonance imaging and CT can adequately distinguish hemorrhage from infarction and depict ischemic stroke 12 to 24 hours after onset. However, during the critical initial hours after the onset of ischemic stroke, these imaging technologies do not adequately demonstrate the location and extent of infarction. Diffusion-weighted MRI and perfusion imaging, as well as advances in magnetic resonance spectroscopy, will enhance our ability to evaluate ischemic stroke shortly after onset. Some of the uses of MRI techniques are as follows: (1) Diffusion-weighted imaging can depict the location and extent of the ischemic lesion as soon as a stroke patient is available for examination. (2) Perfusion imaging evaluates blood flow within the brain's microvasculature and can reveal regions of perfusion deficits corresponding to major vascular territories. (3) Magnetic resonance spectroscopy evaluates metabolic abnormalties associated with focal brain ischemia by specific biochemical measurements. These MRI techniques will rapidly provide important information to clinicians about ischemia, guiding diagnosis and helping in the development of acute stroke interventions to improve outcome.	UNIV MASSACHUSETTS,SCH MED,DEPT NEUROL,WORCESTER,MA 01605; YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	University of Massachusetts System; University of Massachusetts Worcester; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	FISHER, M (corresponding author), MED CTR CENT MASSACHUSETTS,DEPT NEUROL,119 BELMONT ST,WORCESTER,MA 01605, USA.		Warach, Steven/R-5074-2019					BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; BARKER PB, 1994, RADIOLOGY, V92, P723; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; BOTTOMLEY PA, 1986, RADIOLOGY, V160, P763, DOI 10.1148/radiology.160.3.3737915; BRUHN H, 1989, MAGNET RESON MED, V9, P126, DOI 10.1002/mrm.1910090115; EDELMAN RR, 1994, RADIOLOGY, V192, P600, DOI 10.1148/radiology.192.3.8058920; EDELMAN RR, 1994, RADIOLOGY, V192, P513, DOI 10.1148/radiology.192.2.8029425; FISHER M, 1992, ANN NEUROL, V32, P115, DOI 10.1002/ana.410320202; GIDEON P, 1993, P SOC MAGN RESON MED, V12, P1484; GRAHAM GD, 1993, STROKE, V24, P1891, DOI 10.1161/01.STR.24.12.1891; GRAHAM GD, 1992, STROKE, V23, P333, DOI 10.1161/01.STR.23.3.333; GRAHAM GD, 1995, STROKE, V26, P225, DOI 10.1161/01.STR.26.2.225; GROTTA J, 1994, CEREBROVASC DIS, V4, P115, DOI 10.1159/000108466; HASEGAWA Y, 1994, NEUROLOGY, V44, P1484, DOI 10.1212/WNL.44.8.1484; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HOEHNBERLAGE M, IN PRESS J CEREB BLO; HUGG JW, 1992, J CEREBR BLOOD F MET, V12, P734, DOI 10.1038/jcbfm.1992.104; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; LEVINE SR, 1992, RADIOLOGY, V185, P537, DOI 10.1148/radiology.185.2.1410369; MINEMATSU K, 1993, NEUROLOGY, V42, P397; MOHR JP, 1995, STROKE, V26, P807, DOI 10.1161/01.STR.26.5.807; MOSELEY ME, 1990, ACT NEUR S, V51, P207; PETROFF OAC, 1992, NEUROLOGY, V42, P1349, DOI 10.1212/WNL.42.7.1349; REITH W, 1995, NEUROLOGY, V45, P172, DOI 10.1212/WNL.45.1.172; ROBERTS DA, 1994, P NATL ACAD SCI USA, V91, P33, DOI 10.1073/pnas.91.1.33; SAKUMA H, 1991, RADIOLOGY, V180, P229, DOI 10.1148/radiology.180.1.2052700; SIEWERT B, 1994, NEUROLOGY S2, V4, pA182; VANDERSPRENKEL JWB, 1988, STROKE, V19, P1556, DOI 10.1161/01.STR.19.12.1556; WARACH S, 1992, RADIOLOGY, V182, P41, DOI 10.1148/radiology.182.1.1727307; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; WARACH S, 1995, NEUROLOGY, V45, pA287; WARACH S, 1993, P SOC MAGN RESON MED, V12, P249; WARACH S, IN PRESS J CEREB BLO	33	101	101	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					908	911						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674506				2022-12-28	WOS:A1995RU60300031
J	EBERS, GC; SADOVNICK, AD; RISCH, NJ; BULMAN, D; RICE, GPA; HASHIMOTO, SA; PATY, D; OGER, JJF; METZ, L; BELL, R; WARREN, S; HADER, W; AUTY, T; NATH, A; GRAY, T; OCONNOR, P; NELSON, R; FREEDMAN, M; BRUNET, D; PAULSETH, R; FRANCIS, G; DUQUETTE, P; MURRAY, TJ; BAHN, V; PRYSEPHILLIPS, W				EBERS, GC; SADOVNICK, AD; RISCH, NJ; BULMAN, D; RICE, GPA; HASHIMOTO, SA; PATY, D; OGER, JJF; METZ, L; BELL, R; WARREN, S; HADER, W; AUTY, T; NATH, A; GRAY, T; OCONNOR, P; NELSON, R; FREEDMAN, M; BRUNET, D; PAULSETH, R; FRANCIS, G; DUQUETTE, P; MURRAY, TJ; BAHN, V; PRYSEPHILLIPS, W			A GENETIC-BASIS FOR FAMILIAL AGGREGATION IN MULTIPLE-SCLEROSIS	NATURE			English	Article							TWINS; EPIDEMIOLOGY; CONCORDANCE	GENETIC-environmental interactions probably underlie spontaneous human autoimmune disorders, a category of complex traits thought to include multiple sclerosis (MS)(1). The geographical distribution and familiar aggregation of this disease have often been ascribed to the role of infectious agents(2), but there is no consensus, Increased family risks range from 300-fold(3,4) for monozygotic twins to 20-40-fold(5) for biological first-degree relatives over the general population prevalence of 0.1% (ref. 6). We screened a population-based sample of 15,000 individuals with MS by using standardized, personally administered questionnaires to identify adopted index cases and/or those who had adopted relatives, The frequency of MS among first-degree non-biological relatives living with the index case was no greater than expected from Canadian population prevalence data and significantly less than for biological relatives, These findings indicate that familial aggregation of MS is genetically determined: no effect of shared environment was detectable.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1W5,CANADA; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	University of British Columbia; Stanford University	EBERS, GC (corresponding author), UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON N6A 5A5,CANADA.			Sadovnick, Dessa/0000-0003-2987-2008; Ebers, George/0000-0003-4771-4177				BELLAMY N, 1992, ANN RHEUM DIS, V51, P588, DOI 10.1136/ard.51.5.588; DEAPEN D, 1992, ARTHRITIS RHEUM, V35, P311; EBERS G, 1987, NEW ENGL J MED, V315, P1638; EBERS GC, 1994, J NEUROIMMUNOL, V54, P117; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; KETY SS, 1976, BEHAV GENET, V6, P219, DOI 10.1007/BF01065721; KETY SS, 1994, ARCH GEN PSYCHIAT, V51, P442; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; LEITER EH, 1990, IMMUNOL TODAY, V11, P147, DOI 10.1016/0167-5699(90)90057-G; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309	14	478	485	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					150	151		10.1038/377150a0	http://dx.doi.org/10.1038/377150a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675080				2022-12-28	WOS:A1995RU75400048
J	LEIBOVICI, L; SAMRA, Z; KONIGSBERGER, H; DRUCKER, M; ASHKENAZI, S; PITLIK, SD				LEIBOVICI, L; SAMRA, Z; KONIGSBERGER, H; DRUCKER, M; ASHKENAZI, S; PITLIK, SD			LONG-TERM SURVIVAL FOLLOWING BACTEREMIA OR FUNGEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULTS	Objective.-To delineate long-term survival after an episode of bacteremia or fungemia and risk factors for mortality. Design.-Cohort study. Setting.-A 900-bed university hospital in Israel. Patients.-Study group comprising 1991 patients 18 years of age or older in whom bacteremia or fungemia were detected between March 1988 and October 1992, and a control group comprising 1991 inpatients without any infectious diseases, matched for age, sex, department, date of admission, and underlying disorders. Interventions.-None. Measurements.-Interval from the date of the first positive blood culture (study group) or from date of the identical hospital day (in the matched control patient) to the date of death as recorded in the Israeli National Population registry or, if alive, to June 1, 1994. Results.-The median age of patients was 72 years. in the study group, the mortality rate was 26% at 1 month, 43% at 6 months, 48% at 1 year, and 63% at 4 years, and the median survival was 16.2 months. In the control group, the mortality rate was 7% at 1 month, 27% at 1 year, and 42% at 4 years, and the median survival was greater than 75 months (P<.001). Factors significantly and independently associated with mortality in bacteremic patients were functional class (median survival, 0.5 month in bedridden patients), septic shock (median survival, 0.2 month), serum albumin (median survival, 1.1 months in the lowest quartile), serum creatinine (median survival, 2.9 months in the highest quartile), age (median survival, 2.9 months in the highest quartile [age >80 years]), inappropriate empirical antibiotic treatment (median survival, 4.9 months), nosocomial infection (median survival, 9.6 months), and malignancy (median survival, 2.4 months). Conclusions.-Bacteremia is associated with high short-term mortality, but also a sign of severely curtailed long-term prognosis, especially in patients with low functional capacity, low serum albumin, high serum creatinine, nosocomial infections, malignancy, inappropriate antimicrobial treatment, and septic shock and in elderly patients.	BEILINSON MED CTR,MICROBIOL LAB,IL-49100 PETAH TIQWA,ISRAEL; BEILINSON MED CTR,INFECT DIS UNIT,IL-49100 PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,RAMAT AVIV,ISRAEL	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	LEIBOVICI, L (corresponding author), BEILINSON MED CTR,DEPT MED B,IL-49100 PETAH TIQWA,ISRAEL.		Ashkenazi, Shai/V-7996-2019	Ashkenazi, Shai/0000-0001-7244-0679				AMIT M, 1994, SCAND J INFECT DIS, V26, P605, DOI 10.3109/00365549409011819; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; GEERDES HF, 1992, CLIN INFECT DIS, V15, P991, DOI 10.1093/clind/15.6.991; ISPAHANI P, 1987, Q J MED, V63, P427; LEIBOVICI L, 1991, ARCH INTERN MED, V151, P1801; LEIBOVICI L, 1992, CLIN INFECT DIS, V14, P436, DOI 10.1093/clinids/14.2.436; LEIBOVICI L, 1993, AGE AGEING, V22, P431, DOI 10.1093/ageing/22.6.431; MORIYAMA IM, 1989, AM J PUBLIC HEALTH, V79, P1349, DOI 10.2105/AJPH.79.10.1349; PHILLIPS A, 1989, LANCET, V2, P1434; WASUO Y, 1989, J CLIN EPIDEMIOL, V42, P577; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; 1994, STAT ABSTR ISRAEL 19, P151; 1985, SAS USERS GUIDE STAT, P155	14	140	141	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					807	812		10.1001/jama.274.10.807	http://dx.doi.org/10.1001/jama.274.10.807			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650804				2022-12-28	WOS:A1995RU32400028
J	OLSON, MF; ASHWORTH, A; HALL, A				OLSON, MF; ASHWORTH, A; HALL, A			AN ESSENTIAL ROLE FOR RHO, RAC, AND CDC42 GTPASES IN CELL-CYCLE PROGRESSION THROUGH G(1)	SCIENCE			English	Article							C-JUN ACTIVITY; PROTEIN-KINASE; ACTIVATION DOMAIN; ADP-RIBOSYLATION; GROWTH-FACTORS; PHOSPHORYLATION; SERINE-63; PRODUCT; GENE	Members of the Rho family of small guanosine triphosphatases (GTPases) regulate the organization of the actin cytoskeleton; Rho controls the assembly of actin stress fibers and focal adhesion complexes, Rac regulates actin filament accumulation at the plasma membrane to produce lamellipodia and membrane ruffles, and Cdc42 stimulates the formation of filopodia, When microinjected into quiescent fibroblasts, Rho, Rac, and Cdc42 stimulated cell cycle progression through G(1) and subsequent DNA synthesis. Furthermore, microinjection of dominant negative forms of Rac and Cdc42 or of the Rho inhibitor C3 transferase blocked serum-induced DNA synthesis. Unlike Ras, none of the Rho GTPases activated the mitogen-activated protein kinase (MAPK) cascade that contains the protein kinases c-Raf1, MEK (MAPK or ERK kinase), and ERK (extracellular signal-regulated kinase). Instead, Rac and Cdc42, but not Rho, stimulated a distinct MAP kinase, the c-Jun kinase JNK/SAPK (Jun NH2-terminal kinase or stress-activated protein kinase). Rho, Rac, and Cdc42 control signal transduction pathways that are essential for cell growth.	UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	OLSON, MF (corresponding author), UCL, CRC, SIGNAL TRANSDUCT & ONCOGENE GRP, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND.		Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; 				BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QLU RG, 1995, NATURE, V374, P457; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YAN MH, 1994, NATURE, V372, P798	28	1036	1058	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1270	1272		10.1126/science.7652575	http://dx.doi.org/10.1126/science.7652575			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652575				2022-12-28	WOS:A1995RR84200036
J	BLADT, F; RIETHMACHER, D; ISENMANN, S; AGUZZI, A; BIRCHMEIER, C				BLADT, F; RIETHMACHER, D; ISENMANN, S; AGUZZI, A; BIRCHMEIER, C			ESSENTIAL ROLE FOR THE C-MET RECEPTOR IN THE MIGRATION OF MYOGENIC PRECURSOR CELLS INTO THE LIMB BUD	NATURE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; EPITHELIAL INTERACTIONS; TYROSINE KINASE; EXPRESSION; IDENTIFICATION; PROTOONCOGENE; MUSCULATURE; PROTEIN; ORIGIN	LIMB muscles develop from cells that migrate from the somites(1,2). The signal that induces migration of myogenic precursor cells to the limb emanates from the mesenchyme of the limb bud(2,3). Here we report that the c-met-encoded receptor tyrosine kinase is essential for migration of myogenic precursor cells into the limb anlage and for migration into diaphragm and tip of tongue. In c-met homozygous mutant (-/-) mouse embryos, the limb bud and diaphragm are not colonized by myogenic precursor cells and, as a consequence, skeletal muscles of the limb and diaphragm do not form. In contrast, development of the axial skeletal muscles proceeds in the absence of c-met signalling. The specific ligand of the c-met protein, the motility and growth factor scatter factor/hepatocyte growth factor(4-9), is expressed in limb mesenchyme and can thus provide the signal for migration which is received by c-met. We have therefore identified a paracrine signalling system that regulates migration of myogenic precursor cells.	MAX DELBRUCK CENTRUM MOLEK MED, D-13122 BERLIN, GERMANY; UNIV ZURICH, INST NEUROPATHOL, CH-8091 ZURICH, SWITZERLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Zurich			Isenmann, Stefan/AAJ-3788-2020; Riethmacher, Dieter/AAB-8690-2022; Riethmacher, Dieter/A-6242-2010; Riethmacher, Dieter/AAP-2227-2021; Aguzzi, Adriano/A-3351-2008	Riethmacher, Dieter/0000-0002-4206-5529; Aguzzi, Adriano/0000-0002-0344-6708				BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOBER E, 1994, DEVELOPMENT, V120, P603; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GOULDING M, 1994, DEVELOPMENT, V120, P957; HAYASHI K, 1995, DEVELOPMENT, V121, P661; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; PAPAIOANNOU V, 1994, GENE TARGETING PRACT, P107; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZAMEGAR R, 1995, J CELL BIOL, V129, P1177	30	1042	1083	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					768	771		10.1038/376768a0	http://dx.doi.org/10.1038/376768a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651534				2022-12-28	WOS:A1995RR83600038
J	ERNST, E; RESCH, KL				ERNST, E; RESCH, KL			CONCEPT OF TRUE AND PERCEIVED PLACEBO-EFFECTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PAIN	We often and wrongly equate the response seen in the placebo arm of a clinical trial with the placebo effect. In order to obtain the true placebo effect, other non-specific effects can be identified by including an untreated control group in clinical trials. A review of the literature shows that most authors confuse the perceived placebo effect with the true placebo effect. The true placebo effect is highly variable, depending on several factors that are not fully understood. A distinction between the perceived and the true placebo effects would be helpful in understanding the complex phenomena involved in a placebo response.			ERNST, E (corresponding author), UNIV EXETER, POSTGRAD MED SCH, CTR COMPLEMENTARY HLTH STUDIES, EXETER EX2 4NT, DEVON, ENGLAND.							Andersen AN, 1990, ACTA OBSTET GYN SCAN, V69, P235, DOI 10.3109/00016349009028686; ERNST E, 1995, LANCET, V345, P65, DOI 10.1016/S0140-6736(95)91191-X; ERNST E, 1994, EUROPEAN J PHYSICAL, V4, P332; HASHISH I, 1986, BRIT J RHEUMATOL, V25, P77; HELMS JM, 1987, OBSTET GYNECOL, V69, P51; HO KH, 1988, J PSYCHOSOM RES, V32, P197, DOI 10.1016/0022-3999(88)90055-4; HOLROYD KA, 1990, PAIN, V42, P1, DOI 10.1016/0304-3959(90)91085-W; JOYCE CRB, 1994, LANCET, V344, P1279, DOI 10.1016/S0140-6736(94)90757-9; LEWITH GT, 1984, SOC SCI MED, V19, P1367, DOI 10.1016/0277-9536(84)90026-1; ODONNELL M, 1995, MONITOR WEEKLY  0301, P44; OH VMS, 1994, BRIT MED J, V309, P69, DOI 10.1136/bmj.309.6947.69; Richardson P. H., 1994, RAIN REV, V1, P15; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SARADETH T, 1994, PHLEBOLOGY, V9, P63, DOI 10.1177/026835559400900205; SINCLAIR R, 1988, ANESTHESIOLOGY, V68, P895, DOI 10.1097/00000542-198806000-00010; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609	16	270	276	1	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 26	1995	311	7004					551	553		10.1136/bmj.311.7004.551	http://dx.doi.org/10.1136/bmj.311.7004.551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663213	Green Published			2022-12-28	WOS:A1995RR73700025
J	DOUGLAS, RJ; KOCH, C; MAHOWALD, M; MARTIN, KAC; SUAREZ, HH				DOUGLAS, RJ; KOCH, C; MAHOWALD, M; MARTIN, KAC; SUAREZ, HH			RECURRENT EXCITATION IN NEOCORTICAL CIRCUITS	SCIENCE			English	Article							CAT VISUAL-CORTEX; INTRACORTICAL AXON COLLATERALS; LATERAL GENICULATE-NUCLEUS; RECEPTIVE-FIELD PROPERTIES; STRIATE CORTEX; SIMPLE CELLS; ORIENTATION SELECTIVITY; DIRECTIONAL SELECTIVITY; PYRAMIDAL CELLS; AREA 17	The majority of synapses in the mammalian cortex originate from cortical neurons. Indeed, the largest input to cortical cells comes from neighboring excitatory cells. However, most models of cortical development and processing do not reflect the anatomy and physiology of feedback excitation and are restricted to serial feedforward excitation. This report describes how populations of neurons in cat visual cortex can use excitatory feedback, characterized as an effective ''network conductance,'' to amplify their feedforward input signals and demonstrates how neuronal discharge can be kept proportional to stimulus strength despite strong, recurrent connections that threaten to cause runaway excitation. These principles are incorporated into models of cortical direction and orientation selectivity that emphasize the basic design principles of cortical architectures.	ETH ZURICH, CH-8006 ZURICH, SWITZERLAND; CALTECH, COMPUTAT & NEURAL SYST PROGRAM 13974, PASADENA, CA 91125 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, CTR BIOL & MED SYST, LONDON SW7 2BT, ENGLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Imperial College London	DOUGLAS, RJ (corresponding author), UNIV ZURICH, INST NEUROINFORMAT, CH-8006 ZURICH, SWITZERLAND.			Koch, Christof/0000-0001-6482-8067	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; AMIR Y, 1993, J COMP NEUROL, V334, P19, DOI 10.1002/cne.903340103; BERNANDER O, 1994, J NEUROPHYSIOL, V72, P2743, DOI 10.1152/jn.1994.72.6.2743; BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P625, DOI 10.1113/jphysiol.1971.sp009681; Braitenberg V, 1991, ANATOMY CORTEX; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; Davis J., 1994, LARGE SCALE NEURONAL; DOUGLAS R, 1994, IEEE INT C NEUR NETW, P1848; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P217, DOI 10.1113/jphysiol.1985.sp015821; FERSTER D, 1987, J NEUROSCI, V7, P1780; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; GANZ L, 1984, J NEUROPHYSIOL, V51, P294, DOI 10.1152/jn.1984.51.2.294; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRIEVE KL, 1991, EXP BRAIN RES, V87, P521; GROSSBERG S, 1988, NEURAL NETWORKS, V1, P17, DOI 10.1016/0893-6080(88)90021-4; GULYAS B, 1987, J NEUROPHYSIOL, V57, P1767, DOI 10.1152/jn.1987.57.6.1767; HEGGELUND P, 1981, EXP BRAIN RES, V42, P89; Hertz JA, 2018, INTRO THEORY NEURAL; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; KOCH C, 1990, J NEUROSCI, V10, P1728; LEVAY S, 1986, J NEUROSCI, V6, P3564; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAEX R, 1991, P NATL ACAD SCI USA, V88, P3549, DOI 10.1073/pnas.88.9.3549; MAEX R, 1995, THESIS LEUVEN U BELG; MARR D, 1970, PROC R SOC SER B-BIO, V176, P161, DOI 10.1098/rspb.1970.0040; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MASTRONARDE DN, 1987, J NEUROPHYSIOL, V57, P357, DOI 10.1152/jn.1987.57.2.357; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MCGUIRE BA, 1984, J NEUROSCI, V4, P3021; MCLEAN J, 1994, VISUAL NEUROSCI, V11, P271, DOI 10.1017/S0952523800001632; MEAD C, 1990, P IEEE, V78, P1629, DOI 10.1109/5.58356; MITCHISON G, 1992, TRENDS NEUROSCI, V15, P122, DOI 10.1016/0166-2236(92)90352-9; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; PETERS A, 1994, CEREB CORTEX, V4, P215, DOI 10.1093/cercor/4.3.215; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; SAUL AB, 1990, J NEUROPHYSIOL, V64, P206, DOI 10.1152/jn.1990.64.1.206; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SILLITO AM, 1977, J PHYSIOL-LONDON, V271, P699, DOI 10.1113/jphysiol.1977.sp012021; SOMERS D, 1995, P NATL ACAD SCI USA, V92, P3844; SUAREZ HH, IN PRESS J NEUROSCI; SUAREZ HH, 1995, THESIS CALTECH; Traub R.D., 1991, NEURONAL NETWORKS HI; VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531; White E.L., 1989, CORTICAL CIRCUITS SY; WILLSHAW DJ, 1969, NATURE, V222, P960, DOI 10.1038/222960a0; WORGOTTER F, 1991, J NEUROSCI, V11, P1959; XING P, 1991, NEUROREPORT, V2, P485	60	733	736	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	1995	269	5226					981	985		10.1126/science.7638624	http://dx.doi.org/10.1126/science.7638624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638624				2022-12-28	WOS:A1995RP73800037
J	MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R				MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R			ULTRASOUND-MEDIATED TRANSDERMAL PROTEIN DELIVERY	SCIENCE			English	Article							INTERFERON-GAMMA; ERYTHROPOIETIN; PHONOPHORESIS; SKIN	Transdermal drug delivery offers a potential method of drug administration. However, its application has been limited to a few low molecular weight compounds because of the extremely low permeability of human skin. Low-frequency ultrasound was shown to increase the permeability of human skin to many drugs, including high molecular weight proteins, by several orders of magnitude, thus making transdermal administration of these molecules potentially feasible. It was possible to deliver and control therapeutic doses of proteins such as insulin, interferon gamma, and erythropoeitin across human skin. Low-frequency ultrasound is thus a potential noninvasive substitute for traditional methods of drug delivery, such as injections.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM44884] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APFEL RE, 1986, IEEE T ULTRASON FERR, P139; BOMMER J, 1988, LANCET, V2, P406; Bronaugh RL, 1989, PERCUTANEOUS ABSORPT, P27; BURNETTE RR, 1989, TRANSDERMAL DRUG DEL, P247; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034; ELIAS JJ, 1989, PERCUTANEOUS ABSORPT, P1; FRIDEMAN RM, 1981, INTERFERONS PRIMER; GAERTNER W, 1954, J ACOUST SOC AM, V26, P977, DOI 10.1121/1.1907464; GRUPS JW, 1989, BRIT J UROL, V64, P218, DOI 10.1111/j.1464-410X.1989.tb06000.x; Kost J, 1993, TOPICAL DRUG BIOAVAI, P91; KRALL LP, 1988, WORLD BOOK DIABETES, P160; MITRAGOTRI S, 1995, J PHARM SCI, V84, P697, DOI 10.1002/jps.2600840607; MORIMOTO Y, 1992, J PHARM PHARMACOL, V44, P634, DOI 10.1111/j.2042-7158.1992.tb05484.x; NEWMAN JT, 1992, J AM PODIAT MED ASSN, V82, P432, DOI 10.7547/87507315-82-8-432; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PISHKO MV, 1991, ANAL CHEM, V63, P2268, DOI 10.1021/ac00020a014; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; Quillen WS, 1980, ATHL TRAIN, V15, P109; ROSSEL J, 1988, IEEE T BIOMED ENG, V35, P649; SKAUEN DM, 1984, INT J PHARMACEUT, V20, P235, DOI 10.1016/0378-5173(84)90171-6; STRINGFELLOW D, 1986, CLIN APPLICATIONS IN, P1; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; WALMSLEY AD, 1988, ULTRASOUND MED BIOL, V14; Walters KA., 1989, TRANSDERMAL DRUG DEL, P197; Wester R. C., 1993, TOPICAL DRUG BIOAVAI, P333	25	605	677	12	143	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					850	853		10.1126/science.7638603	http://dx.doi.org/10.1126/science.7638603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638603				2022-12-28	WOS:A1995RN65000048
J	QUINN, N				QUINN, N			FORTNIGHTLY REVIEW - PARKINSONISM - RECOGNITION AND DIFFERENTIAL-DIAGNOSIS	BRITISH MEDICAL JOURNAL			English	Article							PROGRESSIVE SUPRANUCLEAR PALSY; LEWY-BODY; CLINICAL-DIAGNOSIS; DISEASE; DEMENTIA; ACCURACY				QUINN, N (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, INST NEUROL, LONDON WC1N 3BG, ENGLAND.							BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949; BANNISTER R, 1972, BRAIN, V95, P457, DOI 10.1093/brain/95.3.457; BECK RO, 1994, J UROLOGY, V151, P1336, DOI 10.1016/S0022-5347(17)35246-1; BIGGINS CA, 1992, J NEUROL NEUROSUR PS, V55, P566, DOI 10.1136/jnnp.55.7.566; BYRNE EJ, 1989, J NEUROL NEUROSUR PS, V52, P709, DOI 10.1136/jnnp.52.6.709; Critchley M., 1981, RES PROGR PARKINSONS, P40; Dejerine J, 1900, NOUV ICONOG SALPETRI, V13, P330; DOONEIEF G, 1992, ARCH NEUROL-CHICAGO, V49, P305, DOI 10.1001/archneur.1992.00530270125028; FAHN S, 1983, NEUROLOGY, V2, P316; FINDLEY LJ, 1987, NEUROLOGY, V37, P1194, DOI 10.1212/WNL.37.7.1194; FORSTL H, 1993, BRIT J PSYCHIAT, V162, P385, DOI 10.1192/bjp.162.3.385; GEDDES JF, 1993, BRAIN, V116, P281, DOI 10.1093/brain/116.1.281; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; GRAHAM JG, 1969, J NEUROL NEUROSUR PS, V32, P28, DOI 10.1136/jnnp.32.1.28; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; LANTOS PL, 1994, J NEUROL NEUROSUR PS, V57, P129, DOI 10.1136/jnnp.57.2.129; LEES AJ, 1987, BUTTERWORTH INT MED, P272; MCKEITH IG, 1994, NEUROLOGY, V44, P872, DOI 10.1212/WNL.44.5.872; QUINN N, 1989, J NEUROL NEUROSUR PS, P78; QUINN N, 1994, BUTTERWORTH HEINEMAN, P262; QUINN NP, 1986, BRIT MED BULL, V42, P86, DOI 10.1093/oxfordjournals.bmb.a072104; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; RINNE JO, 1994, BRAIN, V117, P1183, DOI 10.1093/brain/117.5.1183; SHY GM, 1960, ARCH NEUROL-CHICAGO, V2, P511, DOI 10.1001/archneur.1960.03840110025004; STEELE JC, 1964, ARCH NEUROL-CHICAGO, V10, P333, DOI 10.1001/archneur.1964.00460160003001; STEPHEN PJ, 1984, LANCET, V2, P1082; TYRRELL PJ, 1989, LANCET, V2, P920; VANDEREECKEN H, 1960, J NEUROPATHOL EXP NE, V19, P591; WENNING GK, 1994, BRAIN, V117, P835, DOI 10.1093/brain/117.4.835	30	134	137	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					447	452		10.1136/bmj.310.6977.447	http://dx.doi.org/10.1136/bmj.310.6977.447			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7646647	Green Published			2022-12-28	WOS:A1995QJ24200025
J	CONIGLIONE, TC; BLOUGH, JA				CONIGLIONE, TC; BLOUGH, JA			THEN THERE WERE NONE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CONIGLIONE, TC (corresponding author), ST ANTHONY HOSP, 1000 N LEE ST, 3129, POB 205, OKLAHOMA CITY, OK 73101 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					630	632		10.7326/0003-4819-123-8-199510150-00013	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677307				2022-12-28	WOS:A1995RY82800013
J	FRAISE, AP				FRAISE, AP			DISINFECTION IN ENDOSCOPY	LANCET			English	Editorial Material							GLUTARALDEHYDE				FRAISE, AP (corresponding author), CITY HOSP,NHS TRUST,HOSP INFECT RES LAB,BIRMINGHAM,W MIDLANDS,ENGLAND.							BRADLEY CR, 1995, J HOSP INFECT, V29, P143, DOI 10.1016/0195-6701(95)90196-5; BROADLEY SJ, 1993, J HOSP INFECT, V23, P189, DOI 10.1016/0195-6701(93)90024-T; CALDER IM, 1992, LANCET, V339, P433, DOI 10.1016/0140-6736(92)90124-L; COATES D, 1992, J HOSP INFECT, V21, P241, DOI 10.1016/0195-6701(92)90135-9; COWAN RE, 1994, GUT, V35, P717, DOI 10.1136/gut.35.5.717-a; LYNAM PA, 1995, J HOSP INFECT, V30, P237, DOI 10.1016/S0195-6701(95)90322-4; LYNCH DA, 1994, ENDOSCOPY, V26, P351; TYLER R, 1990, J HOSP INFECT, V15, P339, DOI 10.1016/0195-6701(90)90090-B; VANKLINGEREN B, 1993, J HOSP INFECT, V25, P147, DOI 10.1016/0195-6701(93)90107-B	9	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					787	788		10.1016/S0140-6736(95)91613-X	http://dx.doi.org/10.1016/S0140-6736(95)91613-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674739				2022-12-28	WOS:A1995RW25800004
J	GAUTAM, M; NOAKES, PG; MUDD, J; NICHOL, M; CHU, GC; SANES, JR; MERLIE, JP				GAUTAM, M; NOAKES, PG; MUDD, J; NICHOL, M; CHU, GC; SANES, JR; MERLIE, JP			FAILURE OF POSTSYNAPTIC SPECIALIZATION TO DEVELOP AT NEUROMUSCULAR-JUNCTIONS OF RAPSYN-DEFICIENT MICE	NATURE			English	Article							DYSTROPHIN-RELATED PROTEIN; ADULT MUSCLE-FIBERS; ACETYLCHOLINE-RECEPTORS; 43K PROTEIN; CELLS; IDENTIFICATION; EXPRESSION; CLUSTERS	OF numerous synaptic components that have been identified, perhaps the best-studied are the nicotinic acetylcholine receptors (AChRs) of the vertebrate neuromuscular junction(1). AChRs are diffusely distributed on embryonic myotubes, but become highly concentrated (similar to 10,000 mu m(-2)) in the postsynaptic membrane as development proceeds. At least two distinct processes contribute to this accumulation. One is local synthesis: subsynaptic muscle nuclei transcribe AChR subunit genes at higher rates than extrasynaptic nuclei, so AChR messenger RNA is concentrated near synaptic sites(2,3). Second, once AChRs have been inserted in the membrane, they form high-density clusters by tethering to a subsynaptic cytoskeletal complex. A key component of this complex is rapsyn, a peripheral membrane protein of relative molecular mass 43K (refs 4, 5), which is precisely colocalized with AChRs at synaptic sites from the earliest stages of neuromuscular synaptogenesis(6). In heterologous systems, expression of recombinant rapsyn leads to clustering of diffusely distributed AChRs, suggesting that rapsyn may control formation of clusters(7,8). To assess the role of rapsyn in vivo, we generated and characterized mutant mice with a targeted disruption of the Rapsn gene. We report that rapsyn is essential for the formation of AChR clusters, but that synapse-specific transcription of AChR subunit genes can proceed in its absence.	UNIV WASHINGTON,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; UNIV WASHINGTON,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; Chu Gerald C., 1995, Seminars in Developmental Biology, V6, P175, DOI 10.1016/S1044-5781(06)80027-7; CROWDER CM, 1988, MOL CELL BIOL, V8, P5257, DOI 10.1128/MCB.8.12.5257; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAUTAM M, 1994, GENOMICS, V24, P366, DOI 10.1006/geno.1994.1629; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LAROCHELLE WJ, 1989, DEV BIOL, V132, P130, DOI 10.1016/0012-1606(89)90211-X; LUPA MT, 1989, J NEUROSCI, V9, P3937; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MERLIE JP, 1979, J BIOL CHEM, V254, P6320; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Sanes Joshua R., 1995, Seminars in Developmental Biology, V6, P163, DOI 10.1016/S1044-5781(06)80026-5; SANES JR, 1991, DEVELOPMENT, V113, P1181; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	30	456	464	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					232	236		10.1038/377232a0	http://dx.doi.org/10.1038/377232a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675108				2022-12-28	WOS:A1995RV87200040
J	LAYTON, M; PARISE, ME; CAMPBELL, CC; ADVANI, R; SEXTON, JD; BOSLER, EM; ZUCKER, JR				LAYTON, M; PARISE, ME; CAMPBELL, CC; ADVANI, R; SEXTON, JD; BOSLER, EM; ZUCKER, JR			MOSQUITO-TRANSMITTED MALARIA IN NEW-YORK-CITY, 1993	LANCET			English	Article								In August, 1993, 3 cases of Plasmodium falciparum malaria in people without recent travel histories or bloodborne exposure were reported in New York City. An epidemiological investigation confirmed the absence of risk factors for acquisition of malaria in two cases. The third case could not be definitively classified as locally acquired malaria because the patient had travelled to Thailand two years before malaria was diagnosed. The 3 individuals lived in separate houses in the same neighbourhood of Queens, New York and had onset of illness within a day of each other. The investigation consisted of patient interviews, active case finding, reviewing recent New York flight and shipping arrivals, and an entomological survey for anopheline mosquitoes and breeding sites. No other cases were identified. The 3 patients lived several miles from air and sea ports and prevailing winds would have carried any mosquitoes at those sites away from the patients' homes. By the time of the environmental investigation (September, 1993), the area was dry and neither adult nor larval anophelines were found. However, weather conditions at the probable time of infection (July, 1993) were very different. Malaria was probably transmitted to these 2 patients by local anopheline mosquitoes that had fed on infected human hosts. Mosquito-control measures were not implemented because there was no evidence of ongoing transmission. The occurrence of mosquito-transmitted malaria in New York City demonstrates the potential for reintroduction of malaria transmission into areas that are no longer endemic and emphasises the need for continued surveillance and prompt investigations, if cases without risk factors are reported.	NEW YORK CITY DEPT HLTH,ENVIRONM HLTH SERV,NEW YORK,NY 10013; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,STONY BROOK,NY; NEW YORK STATE DEPT HLTH,ARTHROPOD BORNE DIS PROGRAM,STONY BROOK,NY	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	LAYTON, M (corresponding author), NEW YORK CITY DEPT HLTH,BUR COMMUNICABLE DIS,125 WORTH ST,ROOM 300,BOX 22A,NEW YORK,NY 10013, USA.							BROOK JH, 1994, NEW ENGL J MED, V331, P22, DOI 10.1056/NEJM199407073310105; CHWATT LJB, 1985, ESSENTIAL MALARIOLOG, P148; ISAACSON M, 1989, B WORLD HEALTH ORGAN, V67, P737; MOLINEUX L, 1988, MALARIA PRINCIPLES P, P921; PRATT HD, 1960, DHEW728140; 1969, REPORT CERTIFICATION; 1992, NEWEST NEW YORKERS A; 1990, MMWR-MORBID MORTAL W, V40, P106; 1991, MMWR-MORBID MORTAL W, V40, P665; 1990, MMWR-MORBID MORTAL W, V39, P873	10	29	31	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					729	731		10.1016/S0140-6736(95)91503-6	http://dx.doi.org/10.1016/S0140-6736(95)91503-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658873				2022-12-28	WOS:A1995RU81000009
J	HUANG, P; WEBER, JT; SOSIN, DM; GRIFFIN, PM; LONG, EG; MURPHY, JJ; KOCKA, F; PETERS, C; KALLICK, C				HUANG, P; WEBER, JT; SOSIN, DM; GRIFFIN, PM; LONG, EG; MURPHY, JJ; KOCKA, F; PETERS, C; KALLICK, C			THE FIRST REPORTED OUTBREAK OF DIARRHEAL ILLNESS ASSOCIATED WITH CYCLOSPORA IN THE UNITED-STATES	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; CYANOBACTERIA; CYCLOSPORA; WATER SUPPLY; DISEASE OUTBREAKS	ORGANISM; PATHOGEN	Objective: To investigate and characterize the epidemiology of a diarrheal outbreak associated with a potentially new pathogen, Cyclospora species (previously referred to as Cyanobacteria [blue-green algae]-like bodies). Design: Three retrospective cohort studies supported by laboratory studies, environmental investigation, and community surveillance. Setting: A hospital in Chicago. Participants: Housestaff physicians and hospital administrative staff. Measurements: Identification of clinical features associated with illness and potential risks for acquisition of infection. Results: Illness was characterized by watery diarrhea, abdominal cramping, decreased appetite, and low-grade fever. Symptoms typically occurred in a distinctive cycle of remissions and exacerbations lasting up to several weeks. Stool cultures and examinations for known ova and parasites were negative. Microscopic examination of stool specimens from 11 ill persons showed many spherical bodies, 8 to 10 mu m in diameter, that were identified as Cyclospora organisms. The organisms disappeared by 9 weeks after onset of illness in the 7 patients from whom follow-up specimens were obtained. Epidemiologic studies implicated tap water from a physicians' dormitory as the most likely source of the outbreak. Environmental investigation suggested that stagnant water in a storage tank may have contaminated the water supply after a pump failure. Conclusions: This is the first reported outbreak of diarrhea associated with Cyclospora in the United States. Cyclospora may be a human enteric pathogen able to produce bouts of acute and relapsing diarrhea, and it should be considered in assessments of patients with unexplained, prolonged diarrheal illness.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA								BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; BERLIN OGW, 1994, CLIN INFECT DIS, V18, P606, DOI 10.1093/clinids/18.4.606; CHIODINI PL, 1994, T ROY SOC TROP MED H, V88, P369, DOI 10.1016/0035-9203(94)90385-9; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; DEAU AG, 1990, EPI INFO VERSION 5 W; GUSTAFSON TL, 1991, TRUE EPISTAT; HALE D, 1994, JAMA-J AM MED ASSOC, V271, P144, DOI 10.1001/jama.271.2.144; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; MADICO G, 1993, LANCET, V342, P122, DOI 10.1016/0140-6736(93)91330-O; ORTEGA YR, 1994, J PARASITOL, V80, P625, DOI 10.2307/3283201; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; RABOLD JG, 1994, LANCET, V344, P1360, DOI 10.1016/S0140-6736(94)90716-1; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; WURTZ R, 1994, CLIN INFECT DIS, V18, P620, DOI 10.1093/clinids/18.4.620; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; 1991, MMWR-MORBID MORTAL W, V40, P325	23	108	121	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					409	414		10.7326/0003-4819-123-6-199509150-00002	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639439				2022-12-28	WOS:A1995RU43700002
J	WANG, W; MEADOWS, LR; DENHAAN, JMM; SHERMAN, NE; CHEN, Y; BLOKLAND, E; SHABANOWITZ, J; AGULNIK, AI; HENDRICKSON, RC; BISHOP, CE; HUNT, DF; GOULMY, E; ENGELHARD, VH				WANG, W; MEADOWS, LR; DENHAAN, JMM; SHERMAN, NE; CHEN, Y; BLOKLAND, E; SHABANOWITZ, J; AGULNIK, AI; HENDRICKSON, RC; BISHOP, CE; HUNT, DF; GOULMY, E; ENGELHARD, VH			HUMAN H-Y - A MALE-SPECIFIC HISTOCOMPATIBILITY ANTIGEN DERIVED FROM THE SMCY PROTEIN	SCIENCE			English	Article							MASS-SPECTROMETRY; TRANSPLANTATION; HLA-A2.1; BINDING; GRAFT; HLA	H-Y is a transplantation antigen that can lead to rejection of male organ and bone marrow grafts by female recipients, even if the donor and recipient match at the major histocompatibility locus of humans, the HLA (human leukocyte antigen) locus, However, the origin and function of H-Y antigens has eluded researchers for 40 years. One human H-Y antigen presented by HLA-B7 was identified as an 11-residue peptide derived from SMCY, an evolutionarily conserved protein encoded on the Y chromosome, The protein from the homologous gene on the X chromosome, SMCX, differs by two amino acid residues in the same region. The identification of H-Y may aid in transplantation prognosis, prenatal diagnosis, and fertilization strategies.	LEIDEN UNIV HOSP, DEPT IMMUNOHAEMATOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, BLOOD BANK, 2333 AA LEIDEN, NETHERLANDS; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, BEIRNE CARTER CTR IMMUNOL RES, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA; PROMEGA CORP, MADISON, WI 53711 USA; BAYLOR COLL MED, DEPT OBSTET & GYNECOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT HUMAN MOLEC GENET, HOUSTON, TX 77030 USA; UNIV VIRGINIA, DEPT PATHOL, CHARLOTTESVILLE, VA 22903 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Virginia; University of Virginia; University of Virginia; Promega Corporation; Baylor College of Medicine; Baylor College of Medicine; University of Virginia			den Haan, Joke MM/A-4281-2010; Hunt, Donald F/I-6936-2012; Agoulnik, Alexander/AAK-3213-2020	den Haan, Joke MM/0000-0002-4421-6917; Hunt, Donald F/0000-0003-2815-6368; Agoulnik, Alexander/0000-0001-6587-6845; Sherman, Nicholas/0000-0003-3206-3113	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020963, R01AI020963, R01AI033993, R37AI033993] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33993, AI20963] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BILLINGHAM RE, 1960, J IMMUNOL, V85, P14; BORTIN MM, 1987, TRANSPLANT P, V19, P2655; CANTRELL MA, 1992, GENOMICS, V13, P1255, DOI 10.1016/0888-7543(92)90043-R; CHEN Y, 1994, J IMMUNOL, V152, P2874; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GOULMY E, 1976, LANCET, V2, P1206; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GOULMY E, 1979, J EXP MED, V149, P545, DOI 10.1084/jem.149.2.545; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HOROWITZ MM, 1989, BONE MARROW TRANSPL, V4, P221; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; MEADOWS LR, UNPUB; PARHAM P, 1977, J BIOL CHEM, V252, P7555; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0; SETTE A, 1994, J IMMUNOL, V153, P5586; SHAPIRO M, 1984, J IMMUNOGENET, V11, P209; TOKUDA S, 1977, NATURE, V267, P433, DOI 10.1038/267433a0; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; VANDERHARST D, 1994, BLOOD, V83, P1060; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153	35	307	321	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1588	1590		10.1126/science.7667640	http://dx.doi.org/10.1126/science.7667640			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667640	Green Submitted			2022-12-28	WOS:A1995RU81300046
J	CHISHOLM, AD; HORVITZ, HR				CHISHOLM, AD; HORVITZ, HR			PATTERNING OF THE CAENORHABDITIS-ELEGANS HEAD REGION BY THE PAX-6 FAMILY MEMBER VAB-3	NATURE			English	Article							PAIRED BOX; C-ELEGANS; GENE; NEMATODE; ANIRIDIA; MUTATIONS; BODY	THE Pax-6 genes are important for eye development in both vertebrates and Drosophila. Mutations in the human PAX6 gene are found in patients with a variety of eye disorders, including aniridia and Peters' anomaly(1-3), and mutations in the Drosophila Pax-6 homologue cause the eyeless phenotype(4). In the nematode Caenorhabditis elegans, vab-3 mutants display many defects in head-region development, including aberrant morphogenesis, transformation of hypodermal (epidermal-like) cell fates to those of posterior homologues, and abnormal specification of neurons, Here we show that vab-3 is a member of the Pax-6 gene family and is expressed in head-region cells, This C. elegans Pax-6 locus can also encode proteins lacking the paired domain(5). Our results suggest: that. a primordial role of the Pax-6 gene family could have been to pattern part of the head region, and that Pax-6 genes subsequently evolved to be more specifically involved in eye development.			CHISHOLM, AD (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, 68-425, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.			Chisholm, Andrew/0000-0001-5091-0537				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Burglin Thomas R., 1994, P25; BURR AH, 1985, PHOTOCHEM PHOTOBIOL, V41, P577, DOI 10.1111/j.1751-1097.1985.tb03529.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAMBERLIN HM, 1995, DEV BIOL, V170, P679, DOI 10.1006/dbio.1995.1246; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CLARK SG, 1994, GENETICS, V137, P987; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1993, HUM MOL GENET, V2, P915; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; MARTIN P, 1992, ONCOGENE, V7, P1721; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0; ZUKER CS, 1994, SCIENCE, V265, P742, DOI 10.1126/science.8047881	31	134	136	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					52	55		10.1038/377052a0	http://dx.doi.org/10.1038/377052a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659159				2022-12-28	WOS:A1995RT72500053
J	MACCHI, P; VILLA, A; GILIANI, S; SACCO, MG; FRATTINI, A; PORTA, F; UGAZIO, AG; JOHNSTON, JA; CANDOTTI, F; O'SHEA, JJ; VEZZONI, P; NOTARANGELO, LD				MACCHI, P; VILLA, A; GILIANI, S; SACCO, MG; FRATTINI, A; PORTA, F; UGAZIO, AG; JOHNSTON, JA; CANDOTTI, F; O'SHEA, JJ; VEZZONI, P; NOTARANGELO, LD			MUTATIONS OF JAK-3 GENE IN PATIENTS WITH AUTOSOMAL SEVERE COMBINED IMMUNE-DEFICIENCY (SCID)	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; X-CHROMOSOME INACTIVATION; CARRIERS; CELLS	SEVERE combined immune deficiency (SCID) represents a heterogenous group of hereditary diseases. Mutations in the common gamma-chain (gamma(c)), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID1,2, which is usually(!ly associated with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID), The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown, The Jak-3 protein kinase(3,4) has been found to associate,vith the gamma(c)-chain-containing cytokine receptors(4-9). Therefore Jak-3 or other STAT proteins with which it interacts(10,11) are candidate genes for autosomal recessive T- B+ SCID7. Here we investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3. One patient carries a mutation (Tyr100-->Cys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes. The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination. Both mutations resulted in markedly reduced levels of Jak-3, These findings show that abnormalities in the Jak/STAT signalling pathway can account for SCID in humans.	CNR, IST TECNOL BIOMED AVANZATE, I-20131 MILAN, ITALY; UNIV BRESCIA, DIPARTIMENTO MATERNO INFANTILE, BRESCIA, ITALY; NIH, NATL CTR HUMAN GENOME RES, CLIN GENE THERAPY BRANCH, BETHESDA, MD 20892 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Brescia; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Vezzoni, Paolo/K-3197-2018; Frattini, Annalisa/B-7684-2015; Vezzoni, Paolo/R-3416-2019; Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016; Ugazio, Alberto/AAA-6092-2020	Frattini, Annalisa/0000-0002-1166-3091; Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Vezzoni, Paolo/0000-0002-6382-3923; Candotti, Fabio/0000-0001-6399-6042; Villa, Anna/0000-0003-4428-9013				BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; DAMELL JE, 1994, SCIENCE, V264, P1415; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; GOUGEON ML, 1990, J IMMUNOL, V145, P2873; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHMALSTIEG FC, 1995, J CLIN INVEST, V95, P1169, DOI 10.1172/JCI117765; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WENGLER GS, 1993, J IMMUNOL, V150, P700; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	19	680	776	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					65	68		10.1038/377065a0	http://dx.doi.org/10.1038/377065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659163				2022-12-28	WOS:A1995RT72500057
J	BAIRD, PA; SADOVNICK, AD; YEE, IML; COLE, CW; COLE, L				BAIRD, PA; SADOVNICK, AD; YEE, IML; COLE, CW; COLE, L			SIBLING RISKS OF ABDOMINAL AORTIC-ANEURYSM	LANCET			English	Article							RELATIVES	There is evidence that the risk of abdominal aortic aneurysm (AAA) is greater in first-degree relatives of patients with the disorder than in the same age group of the general population. We conducted a 3-year study of siblings of AAA probands and siblings of a control group (cataract surgery patients) of the same age. Genetic information was obtained by interview from 126 probands and 100 controls; another family member was present at the interview. Medical records were obtained and further information verified before a sibling (over age 50) was assigned affected status. Of 427 siblings of probands, 19 (4.4%) had probable or definite AAA, compared with five (1.1%) of 451 siblings of controls. The lifetime cumulative risks of AAA at age 83 were 11.7% (SD 3.1) and 7.5% (4.1), respectively. The risk of AAA began at an earlier age and increased more rapidly for probands' siblings than for controls' siblings (p<0.01, log-rank test). A risk comparison, based on the results of ultrasound screening of 54 geographically accessible siblings of probands and the 100 controls showed a similar pattern. Ten (19%) siblings of probands and eight (8%) controls had AAA on ultrasound (lifetime cumulative risk 60.8% [18.9] vs 14.9% [5.1], p=0.01). These results show that familial factors influence the age of onset of AAA. We recommend routine ultrasound examination of siblings of patients with AAA.	UNIV OTTAWA,DIV VASC SURG,OTTAWA,ON,CANADA	University of Ottawa	BAIRD, PA (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED GENET,6174 UNIV BLVD,VANCOUVER,BC,CANADA.							ADAMS DCR, 1993, EUR J VASCULAR SURG, V7, P709, DOI 10.1016/S0950-821X(05)80721-2; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; CLIFTON MA, 1977, BRIT J SURG, V64, P765, DOI 10.1002/bjs.1800641102; COLE CW, 1989, CAN J SURG, V322, P117; COLLIN J, 1989, BRIT MED J, V299, P493, DOI 10.1136/bmj.299.6697.493; COLLIN J, 1988, LANCET, V2, P613; Collin J, 1988, Eur J Vasc Surg, V2, P83, DOI 10.1016/S0950-821X(88)80053-7; DARLING RC, 1989, J VASC SURG, V10, P39, DOI 10.1067/mva.1989.vs0100039; ESTES JE, 1950, CIRCULATION, V2, P258, DOI 10.1161/01.CIR.2.2.258; FITZGERALD P, 1995, BRIT J SURG, V82, P483, DOI 10.1002/bjs.1800820418; GLIEDMAN ML, 1957, ANN SURG, V146, P207, DOI 10.1097/00000658-195708000-00008; HANLEY WB, 1967, BRIT HEART J, V29, P852; Hattery R R, 1980, World J Surg, V4, P511; HERTZER NR, 1978, JAMA-J AM MED ASSOC, V240, P1966; JOHANSEN K, 1986, JAMA-J AM MED ASSOC, V256, P1934, DOI 10.1001/jama.256.14.1934; LEOPOLD GR, 1972, SURGERY, V72, P939; MAJUMDER PP, 1991, AM J HUM GENET, V48, P164; MALONEY JD, 1977, CIRCULATION, V56, P80; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; SABISTON DC, 1985, TXB SURGERY, P1830; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; TAYLOR LM, 1986, ANN VASC SURG, V1, P503; TILSON MD, 1984, AM J SURG, V147, P551, DOI 10.1016/0002-9610(84)90020-5; TILSON MD, 1984, SURG GYNECOL OBSTET, V158, P129; Victor D W Jr, 1985, J Ky Med Assoc, V83, P601; WEBSTER MW, 1991, J VASC SURG, V13, P9; WEBSTER MW, 1991, J VASC SURG, V13, P366, DOI 10.1067/mva.1991.26359; YAO JST, 1994, ANEURYSMS NEW FINDIN	28	61	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					601	604		10.1016/S0140-6736(95)91436-6	http://dx.doi.org/10.1016/S0140-6736(95)91436-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651004				2022-12-28	WOS:A1995RT18800009
J	STIELL, I; WELLS, G; LAUPACIS, A; BRISON, R; VERBEEK, R; VANDEMHEEN, K; NAYLOR, CD				STIELL, I; WELLS, G; LAUPACIS, A; BRISON, R; VERBEEK, R; VANDEMHEEN, K; NAYLOR, CD			MULTICENTER TRIAL TO INTRODUCE THE OTTAWA ANKLE RULES FOR USE OF RADIOGRAPHY IN ACUTE ANKLE INJURIES	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-ASSESSMENT; DECISION RULES; X-RAYS; GUIDELINES; FRACTURE; EMERGENCY; STANDARDS	Objective-To assess the feasibility and impact of introducing the Ottawa ankle rules to a large number of physicians in a wide variety of hospital and community settings over a prolonged period of time. Design-Multicentre before and after controlled clinical trial. Setting-Emergency departments of eight teaching and community hospitals in Canadian communities (population 10 000 to 3 000 000). Subjects-All 12 777 adults (6288 control, 6489 intervention) seen with acute ankle injuries during two 12 month periods before and after the intervention. Intervention-More than 200 physicians of varying experience were taught to order radiography according to the Ottawa ankle rules, Main outcome measures-Referral for ankle and foot radiography. Results-There were significant reductions in use of ankle radiography at all eight hospitals and within a priori subgroups: for all hospitals combined 82.8% control v 60.9% intervention (P < 0.001); for community hospitals 86.7% v 61.7%; (P < 0.001); for teaching hospitals 77.9% v 59.9%; (P < 0.001); for emergency physicians 82.1% v 61.6%; (P < 0.001); for family physicians 84.3% v 60.1%; (P < 0.001); and for housestaff 82.3% v 60.1%; (P < 0.001). Compared with patients without fracture who had radiography during the intervention period those who had no radiography spent less time in the emergency department (54.0 v 86.9 minutes; P < 0.001) and had lower medical charges ($70.20 v $161.60; P < 0.001), There was no difference in the rate of fractures diagnosed after discharge from the emergency department (0.5 v 0.4%). Conclusions-Introduction of the Ottawa ankle rules proved to be feasible in a large variety of hospital and community settings. Use of the rules over a prolonged period of time by many physicians of varying experience led to a decrease in ankle radiography, waiting times, and costs without an increased rate of missed fractures. The multiphase methodological approach used to develop and implement these rules may be applied to other clinical problems.	QUEENS UNIV,DIV EMERGENCY MED,KINGSTON,ON,CANADA; UNIV TORONTO,DIV EMERGENCY MED,TORONTO,ON,CANADA; INST CLIN EVALUAT SCI ONTARIO,TORONTO,ON,CANADA	Queens University - Canada; University of Toronto; University of Toronto	STIELL, I (corresponding author), LOEB MED RES INST,CLIN EPIDEMIOL UNIT,OTTAWA,ON K1Y 4E9,CANADA.							ANDERSON G, 1993, CAN MED ASSOC J, V148, P753; ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BASINSKI ASH, 1992, CAN MED ASSOC J, V146, P833; BRAND DA, 1982, NEW ENGL J MED, V306, P333, DOI 10.1056/NEJM198202113060604; BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; DIEHR P, 1988, MED DECIS MAKING, V8, P40, DOI 10.1177/0272989X8800800106; DUNLOP MG, 1986, BRIT MED J, V293, P603, DOI 10.1136/bmj.293.6547.603; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR, 1987, CLINIMETRICS; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HAYWARD RSA, 1993, CAN MED ASSOC J, V148, P507; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LLOYD S, 1986, CAN MED ASSOC J, V135, P973; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MATTHEWS MG, 1986, BRIT MED J, V293, P959; McCaig L F, 1994, Adv Data, P1; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; MONTAGUE AP, 1985, INJURY, V16, P545, DOI 10.1016/0020-1383(85)90082-8; RYD L, 1992, ACTA ORTHOP SCAND, V63, P443, DOI 10.3109/17453679209154764; STIELL IG, 1992, AM J EMERG MED, V10, P14, DOI 10.1016/0735-6757(92)90117-G; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STIELL IG, 1991, THESIS U OTTAWA OTTA; STOTHER IG, 1974, INJURY, V5, P213, DOI 10.1016/S0020-1383(74)80007-0; SUJITKUMAR P, 1986, ARCH EMERG MED, V3, P101; SVENSON J, 1988, LANCET, V1, P244; VARGISH T, 1983, INJURY, V14, P507, DOI 10.1016/0020-1383(83)90053-0; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1992, BRIT MED J, V304, P740; 1993, BRIT MED J, V306, P110; 1993, LANCET, V342, P877	35	195	197	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					594	597		10.1136/bmj.311.7005.594	http://dx.doi.org/10.1136/bmj.311.7005.594			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663253	Green Published			2022-12-28	WOS:A1995RT72300016
J	ALAVI, A; PARRINELLO, M; FRENKEL, D				ALAVI, A; PARRINELLO, M; FRENKEL, D			AB-INITIO CALCULATION OF THE SOUND-VELOCITY OF DENSE HYDROGEN - IMPLICATIONS FOR MODELS OF JUPITER	SCIENCE			English	Article							SOLID HYDROGEN; GROUND-STATE; OSCILLATIONS; EQUATION	First-priniciples molecular dynamics simulations were used to calculate the sound velocity of dense hydrogen, and the results were compared with extrapolations of experimental data that currently conflict with either astrophysical models or data obtained from recent global oscillation measurements of Jupiter. Excellent agreement with the extrapolated experimental data was obtained. These results strongly support the notion that the existing models for the jovian interior need to be revised.	MAX PLANCK INST FESTKORPERFORSCH,D-70569 STUTTGART,GERMANY; FOM,INST ATOM & MOLEC PHYS,1098 SJ AMSTERDAM,NETHERLANDS	Max Planck Society; AMOLF	ALAVI, A (corresponding author), UNIV CAMBRIDGE,DEPT CHEM,LENSFIELD RD,CAMBRIDGE CB2 1EW,ENGLAND.		Frenkel, Daan/G-2580-2014	Frenkel, Daan/0000-0002-6362-2021				ALVAI A, 1994, PHYS REV LETT, V73, P2599; ANSEN JP, 1986, THEORY SIMPLE LIQUID; BARBEE TW, 1989, PHYS REV LETT, V62, P1150, DOI 10.1103/PhysRevLett.62.1150; CEPERLEY DM, 1980, PHYS REV LETT, V45, P566, DOI 10.1103/PhysRevLett.45.566; CEPERLEY DM, 1987, PHYS REV B, V36, P2092, DOI 10.1103/PhysRevB.36.2092; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; DUFFY TS, 1994, SCIENCE, V263, P1590, DOI 10.1126/science.263.5153.1590; HEMLEY RJ, 1990, PHYS REV B, V42, P6458, DOI 10.1103/PhysRevB.42.6458; KOHANOFF J, 1995, PHYS REV LETT, V74, P626, DOI 10.1103/PhysRevLett.74.626; MERMIN ND, 1993, PHYS REV, V137, pA1441; MOSSER B, 1993, ASTRON ASTROPHYS, V267, P604; MOSSER B, 1991, ASTRON ASTROPHYS, V251, P356; NATOLI V, 1993, PHYS REV LETT, V70, P1952, DOI 10.1103/PhysRevLett.70.1952; ROSS M, 1983, J CHEM PHYS, V79, P1487, DOI 10.1063/1.445939; Stanley HE., 1971, PHASE TRANSITIONS CR; 1994, CRC HDB CHEM PHYSICS, P6	18	42	43	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1252	1254		10.1126/science.7652571	http://dx.doi.org/10.1126/science.7652571			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652571	Green Submitted			2022-12-28	WOS:A1995RR84200029
J	ROGAEV, EI; SHERRINGTON, R; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; LIANG, Y; CHI, H; LIN, C; HOLMAN, K; TSUDA, T; MAR, L; SORBI, S; NACMIAS, B; PIACENTINI, S; AMADUCCI, L; CHUMAKOV, I; COHEN, D; LANNFELT, L; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH				ROGAEV, EI; SHERRINGTON, R; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; LIANG, Y; CHI, H; LIN, C; HOLMAN, K; TSUDA, T; MAR, L; SORBI, S; NACMIAS, B; PIACENTINI, S; AMADUCCI, L; CHUMAKOV, I; COHEN, D; LANNFELT, L; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH			FAMILIAL ALZHEIMERS-DISEASE IN KINDREDS WITH MISSENSE MUTATIONS IN A GENE ON CHROMOSOME-1 RELATED TO THE ALZHEIMERS-DISEASE TYPE-3 GENE	NATURE			English	Article							LINKAGE	WE report the cloning of a novel gene (E5-1) encoded on chromosome 1 which has substantial nucleotide and amino-acid sequence similarity to the S182 gene on chromosome 14q24.3. Mutations, including three new missense mutations in the S182 gene, are associated with the AD3 subtype of early-onset familial Alzheimer's disease (AD)(1). Both the E5-1 and the S182 proteins are predicted to be integral membrane proteins with seven membrane-spanning domains, and a large exposed loop between the sixth and seventh transmembrane domains. Analysis of the nucleotide sequence of the open reading frame (ORF) of the E5-1 gene led to the discovery of two missense substitutions at conserved amino-acid residues in affected members of pedigrees with a form of familial AD that has a later age of onset than the AD3 subtype (50-70 years versus 30-60 years for AD3). These observations imply that the E5-1 gene on chromosome 1 and the S182 gene on chromosome 14q24.3 are members of a family of genes (presenilins) with related functions, and indicates that mutations in conserved residues of E5-1 could also play a role in the genesis of AD. Our results also indicate that still other AD susceptibility genes exist.	UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT MED NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT MED BIOPHYS,TORONTO,ON M5S 1A8,CANADA; TORONTO HOSP,DEPT MED,DIV NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA; UNIV FLORENCE,DEPT NEUROL & PSYCHIAT,FLORENCE,ITALY; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN NEUROSCI GERIATR MED,S-14186 HUDDINGE,SWEDEN	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Florence; Karolinska Institutet			Rogaev, Evgeny/AAN-7662-2020; Nacmias, Benedetta/J-5084-2018	Nacmias, Benedetta/0000-0001-9338-9040; PIACENTINI, SILVIA/0000-0002-2749-6785; sorbi, sandro/0000-0002-0380-6670	Canadian Institutes of Health Research [37920] Funding Source: Medline; NIA NIH HHS [U24 AG021886, P30 AG10133] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133, U24AG021886] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; HOLLMANN N, 1994, ANNU REV NEUROSCI, V17, P31; Katzman Robert, 1994, P105; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANNFELT L, 1993, NAT GENET, V4, P218, DOI 10.1038/ng0793-218; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0	9	1654	1735	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					775	778		10.1038/376775a0	http://dx.doi.org/10.1038/376775a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651536				2022-12-28	WOS:A1995RR83600040
J	ANDERSON, FH				ANDERSON, FH			THE RECTAL APPROACH TO TREATMENT IN DISTAL ULCERATIVE-COLITIS	LANCET			English	Editorial Material							COLONIC MUCOSA		HLTH SCI CTR,VANCOUVER,BC,CANADA	University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba	ANDERSON, FH (corresponding author), VANCOUVER HOSP,DIV GASTROENTEROL,VANCOUVER,BC,CANADA.							AZADKHAN AK, 1977, LANCET, V2, P892; BJORCK S, 1992, AGENTS ACTIONS, pC60; CEMPIERI M, 1995, GUT, V26, P400; CHAPMAN MAS, 1994, GUT, V35, P73, DOI 10.1136/gut.35.1.73; Fahey J, 1981, ADV INFLAMMAT RES, V2, P21; Grisham M, 1990, CAN J GASTROENTEROL, V4, P295, DOI 10.1155/1990/324287; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; NORDOY A, 1991, DRUGS, V42, P331, DOI 10.2165/00003495-199142030-00001; ROEDIGER WEW, 1980, LANCET, V2, P712; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; VERNIA P, 1995, DIGEST DIS SCI, V40, P305, DOI 10.1007/BF02065414	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					520	521		10.1016/S0140-6736(95)91377-7	http://dx.doi.org/10.1016/S0140-6736(95)91377-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658775				2022-12-28	WOS:A1995RQ98600005
J	GARFINKEL, D; LAUDON, M; NOF, D; ZISAPEL, N				GARFINKEL, D; LAUDON, M; NOF, D; ZISAPEL, N			IMPROVEMENT OF SLEEP QUALITY IN ELDERLY PEOPLE BY CONTROLLED-RELEASE MELATONIN	LANCET			English	Article							CIRCADIAN-RHYTHMS; RECEPTORS; HUMANS; CORTISOL; INSOMNIA; PLASMA; RAT	Melatonin, produced by the pineal gland at night, has a role in regulation of the sleep-wake cycle. Among elderly people, even those who are healthy, the frequency of sleep disorders is high and there is an association with impairment of melatonin production. We investigated the effect of a controlled-release formulation of melatonin on sleep quality in 12 elderly subjects (aged 76 [SD 8] years) who were receiving various medications for chronic illnesses and who complained of insomnia. In all 12 subjects the peak excretion of the main melatonin metabolite 6-sulphatoxymelatonin during the night was lower than normal and/or delayed in comparison with non-insomniac elderly people. In a randomised, double blind, crossover study the subjects were treated for 3 weeks with 2 mg per night of controlled-release melatonin and for 3 weeks with placebo, with a week's washout period. Sleep quality was objectively monitored by wrist actigraphy. Sleep efficiency was significantly greater after melatonin than after placebo (83 [SE 4] vs 75 [3]%, p<0.001) and wake time after sleep onset was significantly shorter (49 [14] vs 73 [13] min, p<0.001). Sleep latency decreased, but not significantly (19 [5] vs 33 [7] min, p=0.088). Total sleep time was not affected. The only adverse effects reported were two cases of pruritus, one during melatonin and one during placebo treatment; both resolved spontaneously. Melatonin deficiency may have an important role in the high frequency of insomnia among elderly people. Controlled-release melatonin replacement therapy effectively improves sleep quality in this population.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; MACCABI MED CARE & HLTH FUND,TEL AVIV,ISRAEL; NEURIM PHARMACEUT LTD,TEL AVIV,ISRAEL; MEONOT MACCABL,BAT YAM,ISRAEL; EDITH WOLFSON MED CTR,DAY CARE UNIT,HOLON,ISRAEL	Tel Aviv University								ARENDT J, 1988, CLIN ENDOCRINOL, V29, P205, DOI 10.1111/j.1365-2265.1988.tb00263.x; ARENDT J, 1985, J CLIN ENDOCR METAB, V60, P1166, DOI 10.1210/jcem-60-6-1166; BOJKOWSKI CJ, 1990, CLIN ENDOCRINOL, V33, P435, DOI 10.1111/j.1365-2265.1990.tb03882.x; BROOKS JO, 1993, SLEEP, V16, P151, DOI 10.1093/sleep/16.2.151; COLE RJ, 1992, SLEEP, V15, P461, DOI 10.1093/sleep/15.5.461; DAWSON D, 1993, J PINEAL RES, V15, P1, DOI 10.1111/j.1600-079X.1993.tb00503.x; GAUER F, 1993, NEUROENDOCRINOLOGY, V57, P120, DOI 10.1159/000126350; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; HAIMOV I, 1993, ANN M AM SLEEP DISOR; HAIMOV I, IN PRESS SLEEP; JAMES SP, 1990, NEUROPSYCHOPHARMACOL, V3, P19; KALES A, 1984, INSOMNIA, P63; LAUDON M, 1988, NEUROENDOCRINOLOGY, V48, P577, DOI 10.1159/000125066; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; MACFARLANE JG, 1991, BIOL PSYCHIAT, V30, P371, DOI 10.1016/0006-3223(91)90293-U; MCINTYRE IM, 1993, CHRONOBIOL INT, V10, P205, DOI 10.3109/07420529309073889; OAKNINBENDAHAN S, 1992, NEUROENDOCRINOLOGY, V11, P119; ROHERS T, 1983, J AM GERIATR SOC, V31, P364; SHARMA M, 1989, BIOL PSYCHIAT, V25, P305, DOI 10.1016/0006-3223(89)90178-9; VISWANATHAN M, 1992, NEUROENDOCRINOLOGY, V56, P864, DOI 10.1159/000126318; WALDHAUSER F, 1988, J CLIN ENDOCR METAB, V66, P648, DOI 10.1210/jcem-66-3-648	21	377	387	2	57	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					541	544		10.1016/S0140-6736(95)91382-3	http://dx.doi.org/10.1016/S0140-6736(95)91382-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658780				2022-12-28	WOS:A1995RQ98600010
J	WANNAMETHEE, G; SHAPER, AG; WHINCUP, PH; WALKER, M				WANNAMETHEE, G; SHAPER, AG; WHINCUP, PH; WALKER, M			LOW SERUM TOTAL CHOLESTEROL CONCENTRATIONS AND MORTALITY IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							FACTOR INTERVENTION TRIAL; CORONARY HEART-DISEASE; CANCER MORTALITY; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; BLOOD-LIPIDS; BODY-WEIGHT; EPIDEMIOLOGY; POPULATION	Objective-To examine the relation between low serum total cholesterol concentrations and causes of mortality. Design-Cohort study of men followed up for an average of 14.8 years (range 13.5-16.0 years). Setting-One general practice in each of 24 British towns. Subjects-7735 men aged 40-59 at screening selected at random from the 24 general practices. Main outcome measures-Deaths from all causes, cardiovascular causes, cancer, and non-cardiovascular, non-cancer causes. Results-During the mean follow up period of 14.8 years there were 1257 deaths from all causes, 640 cardiovascular deaths, 433 cancer deaths, and 184 deaths from other causes. Low serum cholesterol concentrations (<4.8 mmol/l), present in 5% (n=410) of the men, were associated with the highest mortality from all causes, largely due to a significant increase in cancer deaths (age adjusted relative risk 1.6 (95% confidence interval 1.1 to 2.3); <4.8 v 4.8-5.9 mmol/l) and in other non-cardiovascular deaths (age adjusted relative risk 1.9 (1.1 to 3.1)). Low serum cholesterol concentration was associated with an increased prevalence of several diseases and indicators of ill health and with lifestyle characteristics such as smoking and heavy drinking. After adjustment for these factors in the multivariate analysis the increased risk for cancer was attenuated (relative risk 1.4 (0.9 to 2.0)) and the inverse association with other non-cardiovascular, non-cancer causes was no longer significant (relative risk 1.5 (0.9 to 2.6); <4.8 v 4.8-5.9 mmol/l). The excess risks of cancer and of other non-cardiovascular deaths were most pronounced in the first five years and became attenuated and non-significant with longer follow up. By contrast, the positive association between serum total cholesterol concentration and cardiovascular mortality was seen even after more than 10 years of follow up. Conclusion-The association between comparatively low serum total cholesterol concentrations and excess mortality seemed to be due to preclinical cancer and other non-cardiovascular diseases. This suggests that public health programmes encouraging lower average concentrations of serum total cholesterol are unlikely to be associated with increased cancer or other non-cardiovascular mortality.			WANNAMETHEE, G (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107				ALVAREZ C, 1986, CLIN CHEM, V32, P142; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; COX DR, 1972, J R STAT SOC B, V34, P187; DAVEYSMITH G, 1992, JAMA-J AM MED ASSOC, V267, P70; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; HARRIS T, 1994, J CLIN EPIDEMIOL, V45, P595; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HULLEY SB, 1992, CIRCULATION, V87, P1026; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; JACOBS D, 1993, CIRCULATION, V86, P1046; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER MF, 1993, EUR HEART J, V14, P581, DOI 10.1093/eurheartj/14.5.581; PHILLIPS A, 1989, LANCET, V2, P1434; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SCHATZKIN A, 1987, LANCET, V2, P298; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WANNAMETHEE G, 1992, J EPIDEMIOL COMMUN H, V46, P197, DOI 10.1136/jech.46.3.197; WANNAMETHEE G, 1993, AM J EPIDEMIOL, V137, P735, DOI 10.1093/oxfordjournals.aje.a116734; 1982, JAMA-J AM MED ASSOC, V248, P2853	34	51	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					409	413		10.1136/bmj.311.7002.409	http://dx.doi.org/10.1136/bmj.311.7002.409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640584	Green Published			2022-12-28	WOS:A1995RP55400011
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			CHOOSING A COMPUTER-SYSTEM	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,HILLINGDON,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					46	49		10.1136/bmj.311.6996.46	http://dx.doi.org/10.1136/bmj.311.6996.46			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7646730	Green Published			2022-12-28	WOS:A1995RG97500031
J	WILLETT, WC; MANSON, JE; STAMPFER, MJ; COLDITZ, GA; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				WILLETT, WC; MANSON, JE; STAMPFER, MJ; COLDITZ, GA; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			WEIGHT, WEIGHT CHANGE, AND CORONARY HEART-DISEASE IN WOMEN - RISK WITHIN THE NORMAL-WEIGHT RANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAT DISTRIBUTION; FOLLOW-UP; BODY; MORTALITY; OBESITY	Objective.-To assess the validity of the 1990 US weight guidelines for women that support a substantial gain in weight at approximately 35 years of age and recommend a range of body mass index (BMI) (defined as weight in kilograms divided by the square of height in meters) from 21 to 27 kg/m(2), in terms of coronary heart disease (CHD) risk in women. Design.-Prospective cohort study. Setting.-Female registered nurses in the United States. Participants.-A total of 115 818 women aged 30 to 55 years in 1976 and without a history of previous CHD. Main Outcome Measure.-Incidence of CHD defined as nonfatal myocardial infarction or fatal CHD. Results.-During 14 years of follow-up, 1292 cases of CHD were ascertained. After controlling for age, smoking, menopausal status, postmenopausal hormone use, and parental history of CHD and using as a reference women with a BMI of less than 21 kg/m(2), relative risks (RRs) and 95% confidence intervals (Cls) for CHD were 1.19 (0.97 to 1.44) for a BMI of 21 to 22.9 kg/m(2), 1.46 (1.20 to 1.77) for a BMI of 23 to 24.9 kg/m(2), 2.06 (1.72 to 2.48) for a BMI of 25 to 28.9 kg/m(2), and 3.56 (2.96 to 4.29) for a BMI of 29 kg/m(2) or more. Women who gained weight from 18 years of age were compared with those with stable weight (+/-5 kg) in analyses that controlled for the same variables as well as BMI at 18 years of age. The RRs and Cls were 1.25 (1.01 to 1.55) for a 5- to 7.9-kg gain, 1.64 (1.33 to 2.04) for an 8- to 10.9-kg gain, 1.92 (1.61 to 2.29) for an 11- to 19-kg gain, and 2.65 (2.17 to 3.22) for a gain of 20 kg or more. Among women within the BMI range of 18 to 25 kg/m(2), weight gain after 18 years of age remained a strong predictor of CHD risk. Conclusions.-Higher levels of body weight within the ''normal'' range, as well as modest weight gains after 18 years of age, appear to increase risks of CHD in middle-aged women. These data provide evidence that current US weight guidelines may be falsely reassuring to the large proportion of women of der than 35 years who are within the current guidelines but have potentially avoidable risks of CHD.	BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	WILLETT, WC (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 24074, HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLDITZ GA, 1990, AM J CLIN NUTR, V51, P1100, DOI 10.1093/ajcn/51.6.1100; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; GARRISON RJ, 1993, INT J OBESITY, V17, P417; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1994, AM J EPIDEMIOL, V139, pS46; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; RIMM EB, 1993, AM J EPIDEMIOL, V138, P601; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P303, DOI 10.1093/oxfordjournals.aje.a117252; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; WOOD PD, 1993, CRIT REV FOOD SCI, V33, P369, DOI 10.1080/10408399309527635; 1960, BUILD BLOOD PRESSURE, V1; 1985, NUTRITION YOUR HLTH; 1990, NUTRITION YOUR HLTH; 1960, BUILD BLOOD PRESSURE, V2; 1994, J NUTR, V124, P2240	23	745	760	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					461	465		10.1001/jama.273.6.461	http://dx.doi.org/10.1001/jama.273.6.461			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7654270				2022-12-28	WOS:A1995QE49800028
J	TANAKA, Y; ADAMS, DH; HUBSCHER, S; HIRANO, H; SIEBENLIST, U; SHAW, S				TANAKA, Y; ADAMS, DH; HUBSCHER, S; HIRANO, H; SIEBENLIST, U; SHAW, S			T-CELL ADHESION INDUCED BY PROTEOGLYCAN-IMMOBILIZED CYTOKINE MIP-1-BETA	NATURE			English	Article							LYMPHOCYTES-T; CD44; PROTEIN; ACTIVATION; RECEPTOR; FAMILY; GLYCOSAMINOGLYCANS; HYALURONATE; MOLECULE-1; ADHERENCE	LYMPHOCYTE migration from blood into tissue depends on integrin-mediated adhesion to endothelium1-4. Adhesion requires not only integrin ligands on the endothelium, but also activation signals because T-cell integrins cannot bind well until they are activated. The physiological 'triggers' for T-cell adhesion are unknown, but cytokines may be good candidates as they are released during inflammation and trigger adhesion in neutrophils and monocytes2,5,6. We have identified a cytokine, macrophage inflammatory protein-1beta (MIP-1beta),that induces both chemotaxis and adhesion of T cells; MIP-1beta is most effective at augmenting adhesion of CD8+ T cells to the vascular cell adhesion molecule VCAM-1. We reasoned that, as cytokines in vivo will be rapidly washed away, MIP-1beta might be bound to endothelial surfaces and so induce adhesion in its immobilized form. Here we show that: (1) MIP-1beta is present on lymph node endothelium; (2) immobilized MIP-1beta induces binding of T cells to VCAM-1 in vitro. MIP-1beta was immobilized by binding to proteoglycan: a conjugate of heparin with bovine serum albumin and cellular proteoglycan CD44 were both effective. We propose that MIP-1beta and other cytokines with glycosaminoglycan-binding sites will bind to and be presented by endothelial proteoglycans to trigger adhesion selectively not only of lymphocyte subsets, but also of other cell types.	UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	TANAKA, Y (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.		Adams, David H/C-9092-2009	Adams, David H/0000-0001-6776-0336				ADAMS DH, 1991, J IMMUNOL, V147, P609; ADAMS DH, 1989, LANCET, V2, P1122; ARNAOUT MA, 1986, J CLIN INVEST, V78, P591; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HORGAN KJ, 1991, CURRENT PROTOCOLS IM; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALS ST, 1989, J IMMUNOL, V143, P851; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHAW LM, 1989, J EXP MED, V169, P303, DOI 10.1084/jem.169.1.303; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; TANAKA Y, IN PRESS IMMUN TODAY; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	40	801	814	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					79	82		10.1038/361079a0	http://dx.doi.org/10.1038/361079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7678446				2022-12-28	WOS:A1993KF71800053
J	CARRESE, JA; RHODES, LA				CARRESE, JA; RHODES, LA			WESTERN BIOETHICS ON THE NAVAJO RESERVATION - BENEFIT OR HARM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATTITUDES; PATIENT	Objective.-To understand the Navajo perspective regarding the discussion of negative information and to consider the limitations of dominant Western bioethical perspectives. Design.-Focused ethnography. Setting.-Navajo Indian reservation in northeast Arizona. Participants.-Thirty-four Navajo informants, including patients, biomedical health care providers, and traditional healers. Results.-Informants explained that patients and providers should think and speak in a positive way and avoid thinking or speaking in a negative way; 86% of those questioned considered advance care planning a dangerous violation of traditional Navajo values, These findings are consistent with hozho, the most important concept in traditional Navajo culture, which combines the concepts of beauty, goodness, order, harmony, and everything that is positive or ideal. Conclusions.-Discussing negative information conflicts with the Navajo concept hozho' and was viewed as potentially harmful by these Navajo informants, Policies complying with the Patient Self-determination Act, which are intended to expose all hospitalized Navajo patients to advance care planning, are ethically troublesome and warrant reevaluation.	UNIV WASHINGTON,DEPT ANTHROPOL,SEATTLE,WA 98195; UNIV WASHINGTON,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	CARRESE, JA (corresponding author), JOHNS HOPKINS UNIV,JOHNS HOPKINS BAYVIEW MED CTR,SCH MED,DEPT MED,DIV GEN INTERNAL MED,BALTIMORE,MD 21224, USA.							Agar Michael, 1986, SPEAKING ETHNOGRAPHY; BERNARD HR, 1988, RES METHODS CULTURAL, P97; BEYENE Y, 1992, WESTERN J MED, V157, P328; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CARRESE J, 1993, HASTINGS CENT REP, V23, P15, DOI 10.2307/3562585; GOODMAN JM, 1982, NAVAJO ATLAS; Guba E.G., 1985, NATURALISTIC INQUIRY, DOI DOI 10.1016/0147-1767(85)90062-8; JECKER NS, 1995, HASTINGS CENT REP, V25, P6, DOI 10.2307/3562484; JONSEN AR, 1992, CLIN ETHICS, P37; Katz J., 1984, SILENT WORLD DOCTOR; KLEINMAN A, 1988, ILLNESS NARRATIVES S, P230; Kluckhohn C., 1949, IDEOLOGICAL DIFFEREN; Locke R. F., 1976, BOOK NAVAJO; MELEIS AI, 1983, WESTERN J MED, V138, P889; MUECKE MA, 1993, CRITICAL ISSUES QUAL, P198; MUECKE MA, 1993, CRITICAL ISSUES QUAL, P203; PERKINS HS, 1993, J CLIN ETHIC, V4, P145; REICHARD GA, 1950, NAVAJO RELIG STUDY S; RHODES LA, 1990, MED ANTHR CONT THEOR, P159; Spradley J., 1979, ETHNOGRAPHIC INTERVI; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661; SWINBANKS D, 1989, NATURE, V339, P409, DOI 10.1038/339409a0; WITHERSPOON G, 1977, LANGUAGE ART NAVAJO, P24; Witherspoon Gary, 1977, LANGUAGE ART NAVAJO, P34; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334; Wyman LelandC., 1970, BLESSINGWAY; 1994, MONOGRAPH, P10; 1992, 922 IND HLTH SERV CI, P1	28	249	252	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					826	829		10.1001/jama.274.10.826	http://dx.doi.org/10.1001/jama.274.10.826			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650807				2022-12-28	WOS:A1995RU32400031
J	WHITCOMB, ME; MILLER, RS				WHITCOMB, ME; MILLER, RS			PARTICIPATION OF INTERNATIONAL MEDICAL GRADUATES IN GRADUATE MEDICAL-EDUCATION AND HOSPITAL-CARE FOR THE POOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the impact of limiting international medical graduate (IMG) participation in US graduate medical education (GME) on the delivery of hospital care to the poor. Methods.-To ascertain the pattern of IMG participation in GME and the degree to which the principal teaching hospitals with programs with large IMG enrollments provide care to the poor, we used data from the American Medical Association 1993 Annual Survey of Graduate Medical Education Programs and Teaching Institutions to analyze the pattern of IMG participation in GME in the six core specialties of internal medicine, family practice, obstetrics and gynecology, surgery, pediatrics, and psychiatry. Main Outcome Measures.-Programs were identified as IMG dependent if at least 50% of the resident physicians enrolled in the first year of the program were IMGs. All programs were linked to their principal teaching hospitals, and hospitals were assessed according to the number of programs based at each institution, the number of IMG-dependent programs at the institution, and whether no-pay patients and/or Medicaid/public assistance beneficiaries constituted more than 20% of the patients served. Results.-Of the 20 170 first-year resident physicians in the six core specialties, 31.8% were IMGs. The proportion of programs dependent on IMG enrollment was 27.7%, ranging from 5.2% in obstetrics and gynecology programs to 49.5% in psychiatry programs. About 72% of all first-year IMGs were in IMG-dependent programs. Of the 688 hospitals serving as principal teaching sites for programs in at least one of the six core specialties, 106 were categorized as dependent on IMG programs, but only 77 of those provided a disproportionate amount of care to the poor. Finally, 40% of IMG-dependent GME programs and 36% of first-year IMG residents were based in hospitals that did not provide a disproportionate amount of care to the poor. Conclusions.-Based on this analysis, 77 hospitals can arguably be considered dependent on IMG resident physicians to provide care to the poor. Moreover, a large number of IMG residents and IMG-dependent programs are in hospitals that do not provide a disproportionate amount of care to the poor. These findings show the scale of the problem policymakers must address if they choose to limit IMG access to GME while maintaining access of the poor to needed hospital care.	AMER MED ASSOC,DEPT RES & DATA ANAL,DIV GRAD MED EDUC,CHICAGO,IL 60610; ASSOC AMER MED COLL,DIV MED EDUC,WASHINGTON,DC	American Medical Association; Association of American Medical Colleges								IGLEHART JK, 1985, NEW ENGL J MED, V313, P831, DOI 10.1056/NEJM198509263131325; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; 1988, RESIDENCY REPLACEMEN; 1988, 1ST US DEP HLTH HUM, V2; 1994, 4TH US DEP HLTH HUM; 1988, ANALYSIS COST REPLAC; 1994, 1994 PHYS PAYM REV C; 1988, ANAL COSTS SERVICES; 1995, 7TH US DEP HLTH HUM	9	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					696	699		10.1001/jama.274.9.696	http://dx.doi.org/10.1001/jama.274.9.696			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650821				2022-12-28	WOS:A1995RR83500014
J	DU, ZJ; LANG, SM; SASSEVILLE, VG; LACKNER, AA; ILYINSKII, PO; DANIEL, MD; JUNG, JU; DESROSIERS, RC				DU, ZJ; LANG, SM; SASSEVILLE, VG; LACKNER, AA; ILYINSKII, PO; DANIEL, MD; JUNG, JU; DESROSIERS, RC			IDENTIFICATION OF A NEF ALLELE THAT CAUSES LYMPHOCYTE-ACTIVATION AND ACUTE DISEASE IN MACAQUE MONKEYS	CELL			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL ACTIVATION; MOLECULAR CLONE; RHESUS-MONKEYS; ANTIGEN; RETROVIRUS; AIDS; PHOSPHORYLATION; PATHOGENICITY; DETERMINANTS	Residues 17 and 18 in nef of SIVmac239 were changed from RQ to YE to create a translated sequence of SRPSGDLYERLLRARGETYGRLLGEVEDGYSQSP from residues 10-43. The YXXL motifs in this context match very well with consensus sequences for SH2 binding domains and are similar to ones present in nef of the acutely lethal pathogen SIVpbj14. The YE variant of SIVmac239, unlike SIVmac239 but like SIVpbj14, replicated well in resting peripheral blood mononuclear cell cultures, caused extensive T lymphocyte activation, and produced an acute disease in rhesus and pigtailed monkeys characterized by severe diarrhea, rash, and extensive lymphoid proliferation in the gastrointestinal tract. The YEnef gene transformed NIH 3T3 cells in culture. Both 239nef and YEnef were found to associate with src in cotransfected COS cells, and both 60 kDa src and 34 kDa nef were phosphorylated at tyrosine in these cells. The extent of tyrosine phosphorylation of 239nef was considerably less than that of YEnef in these assays. These findings identity an important determinant of the SIVpbj14 phenotype, and they provide evidence of a role for nef in signal transduction and cellular activation.			DU, ZJ (corresponding author), HARVARD UNIV, NEW ENGLAND REG PRIMATE RES CTR, SCH MED, SOUTHBOROUGH, MA 01772 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI25328] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; BARBARESCHI M, 1994, AM J CLIN PATHOL, V102, P171, DOI 10.1093/ajcp/102.2.171; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DITTMAR MT, 1995, P NATL ACAD SCI USA, V92, P1362, DOI 10.1073/pnas.92.5.1362; DOLLARD SC, 1994, J VIROL, V68, P7800, DOI 10.1128/JVI.68.12.7800-7809.1994; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; FULTZ PN, 1994, VIRUS RES, V32, P205, DOI 10.1016/0168-1702(94)90042-6; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; ISRAEL ZR, 1993, AIDS RES HUM RETROV, V9, P277, DOI 10.1089/aid.1993.9.277; JUNG JU, 1995, IN PRESS J BIOL CHEM; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LANDBERG G, 1990, EXP CELL RES, V187, P111, DOI 10.1016/0014-4827(90)90124-S; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	223	224	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	1995	82	4					665	674		10.1016/0092-8674(95)90038-1	http://dx.doi.org/10.1016/0092-8674(95)90038-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664345	Bronze			2022-12-28	WOS:A1995RR73400017
J	GENNIS, R; FERGUSONMILLER, S				GENNIS, R; FERGUSONMILLER, S			STRUCTURE OF CYTOCHROME-C-OXIDASE, ENERGY GENERATOR OF AEROBIC LIFE	SCIENCE			English	Editorial Material							X-RAY ABSORPTION; OXYGEN; ZINC; REDUCTION; SEQUENCE; COPPER; SITE; IRON		MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University	GENNIS, R (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; BUSE G, 1991, J BIOENERG BIOMEMBR, V23, P269, DOI 10.1007/BF00762222; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; DAY EP, 1993, BIOCHEMISTRY-US, V32, P7855, DOI 10.1021/bi00082a003; DEATHERAGE JF, 1982, J MOL BIOL, V158, P487, DOI 10.1016/0022-2836(82)90210-8; EINARSDOTTIR O, 1985, BIOCHEM BIOPH RES CO, V129, P840, DOI 10.1016/0006-291X(85)91968-0; ESPE MP, 1995, BIOCHEMISTRY-US, V34, P7593, DOI 10.1021/bi00023a005; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; HAN SH, 1990, J AM CHEM SOC, V112, P9445, DOI 10.1021/ja00182a001; HILL BC, 1993, J BIOENERG BIOMEMBR, V25, P115, DOI 10.1007/BF00762853; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; Keilin D, 1938, NATURE, V141, P870, DOI 10.1038/141870a0; KELLY M, 1993, J BIOL CHEM, V268, P16781; MARGOLIASH E, 1988, OXIDASES RELATED RED, P79; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NAQUI A, 1988, J BIOL CHEM, V263, P12342; NICHOLLS PN, CYTOCHROMES CELL RES; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; POWERS L, 1994, BBA-BIOENERGETICS, V1183, P504, DOI 10.1016/0005-2728(94)90078-7; RIZZUTO R, 1991, BIOCHIM BIOPHYS ACTA, V1129, P100, DOI 10.1016/0167-4781(91)90220-G; SCOTT RA, 1988, ANN NY ACAD SCI, V550, P53, DOI 10.1111/j.1749-6632.1988.tb35322.x; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; THOMAS JW, 1994, BIOCHEMISTRY-US, V33, P13013, DOI 10.1021/bi00248a010; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VALPUESTA JM, 1990, J MOL BIOL, V214, P237, DOI 10.1016/0022-2836(90)90158-I; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; WILMANNS M, UNPUB	33	54	61	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1063	1064		10.1126/science.7652553	http://dx.doi.org/10.1126/science.7652553			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652553				2022-12-28	WOS:A1995RQ74800032
J	VOJTEK, AB; COOPER, JA				VOJTEK, AB; COOPER, JA			RHO-FAMILY MEMBERS - ACTIVATORS OF MAP KINASE CASCADES	CELL			English	Review							BINDING				VOJTEK, AB (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3	23	259	264	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					527	529		10.1016/0092-8674(95)90023-3	http://dx.doi.org/10.1016/0092-8674(95)90023-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664330	Bronze			2022-12-28	WOS:A1995RR73400002
J	WANG, ND; FINEGOLD, MJ; BRADLEY, A; OU, CN; ABDELSAYED, SV; WILDE, MD; TAYLOR, LR; WILSON, DR; DARLINGTON, GJ				WANG, ND; FINEGOLD, MJ; BRADLEY, A; OU, CN; ABDELSAYED, SV; WILDE, MD; TAYLOR, LR; WILSON, DR; DARLINGTON, GJ			IMPAIRED ENERGY HOMEOSTASIS IN C/EBP-ALPHA KNOCKOUT MICE	SCIENCE			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; BROWN ADIPOSE-TISSUE; HEPATOMA-CELLS; GENE; LIVER; TRANSCRIPTION; EXPRESSION; METABOLISM; DISRUPTION	Mice homozygous for the targeted deletion of the c/ebp alpha gene, which expresses the CCAAT/enhancer-binding protein alpha (C/EBP alpha), did not store hepatic glycogen and died from hypoglycemia within 8 hours after birth. In these mutant mice, the amounts of glycogen synthase messenger RNA were 50 to 70 percent of normal and the transcriptional induction of the genes for two gluconeogenic enzymes, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, was delayed. The hepatocytes and adipocytes of the mutant mice failed to accumulate lipid and the expression of the gene for uncoupling protein, the defining marker of brown adipose tissue, was reduced. This study demonstrates that C/EBP alpha is critical for the establishment and maintenance of energy homeostasis in neonates.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045285] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYNSLEYGREEN A, 1977, ARCH DIS CHILD, V52, P573, DOI 10.1136/adc.52.7.573; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DEVOS P, 1974, BIOCHEM J, V140, P331, DOI 10.1042/bj1400331; ERICKSON RP, 1968, P NATL ACAD SCI USA, V59, P437, DOI 10.1073/pnas.59.2.437; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; HAWDON JM, 1993, ARCH DIS CHILD-FETAL, V68, P280, DOI 10.1136/adc.68.3_Spec_No.280; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KOCHAN Z, 1992, COMP BIOCHEM PHYS B, V101, P283, DOI 10.1016/0305-0491(92)90191-S; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEU J, 1990, EUR J PEDIATR, V150, P2, DOI 10.1007/BF01959470; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PHILIPPIDIS H, 1969, BIOCHEM J, V113, P651, DOI 10.1042/bj1130651; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang N., UNPUB; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	26	807	828	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1108	1112		10.1126/science.7652557	http://dx.doi.org/10.1126/science.7652557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652557				2022-12-28	WOS:A1995RQ74800046
J	RIKLIN, A; KATZ, E; WILLNER, I; STOCKER, A; BUCKMANN, AF				RIKLIN, A; KATZ, E; WILLNER, I; STOCKER, A; BUCKMANN, AF			IMPROVING ENZYME-ELECTRODE CONTACTS BY REDOX MODIFICATION OF COFACTORS	NATURE			English	Article							GLUCOSE-OXIDASE; POLYMERS; CENTERS	EFFICIENT electron transfer of redox proteins to and from their environment is essential for the use of such proteins in biotechnological applications such as amperometric biosensors and photosynthetic biocatalysts(1-3). But most redox enzymes lack pathways that can transport an electron from their embedded redox site to an electrode(4,5) or a diffusing photoexcited species(6). Electrical communication between redox proteins and electrode surfaces has been improved by aligning proteins on chemically modified electrodes(7-9), by attaching electron-transporting groups(10,11) and by immobilizing proteins in polymer matrices tethered by redox groups(12-14). Generally these methods involve contacting the enzymes at random with electron relay units, Here we report an approach that allows site-specific positioning of electron-mediating units in redox proteins, We strip glucose oxidase of its flavin adenine dinucleotide (FAD) cofactors, modify tbe latter with redox-active ferrocene-containing groups, and then reconstitute the apoprotein with these modified cofactors, In this way, electrical contact between an electrode and the resulting enzyme in solution is greatly enhanced in a controlled and reproducible way.	HEBREW UNIV JERUSALEM, INST CHEM, IL-91904 JERUSALEM, ISRAEL; GESELL BIOTECHNOL FORSCH MBH, DEPT ENZYMOL, D-38124 BRAUNSCHWEIG, GERMANY	Hebrew University of Jerusalem; Gesellschaft fur Biotechnologische Forschung mbH			Stocker, Achim/O-5217-2017	Stocker, Achim/0000-0001-6862-7887				ARMSTRONG FA, 1988, ACCOUNTS CHEM RES, V21, P407, DOI 10.1021/ar00155a004; BLUM L, 1991, BIOSENSORS PRINCIPLE; BUCK RP, 1990, BIOSENSOR TECHNOLOGY; Buckmann AF, 1994, FLAVINS AND FLAVOPROTEINS 1993, P597; DEGANI Y, 1989, J AM CHEM SOC, V111, P2357, DOI 10.1021/ja00188a091; DEGANI Y, 1988, J AM CHEM SOC, V110, P2615, DOI 10.1021/ja00216a040; FOULDS NC, 1988, ANAL CHEM, V60, P2473, DOI 10.1021/ac00173a008; GORTON L, 1992, ANALYST, V117, P1235, DOI 10.1039/an9921701235; HELLER A, 1990, ACCOUNTS CHEM RES, V23, P128, DOI 10.1021/ar00173a002; HELLER A, 1992, J PHYS CHEM-US, V96, P3579, DOI 10.1021/j100188a007; LIONDAGAN M, 1994, J CHEM SOC CHEM COMM, P2741, DOI 10.1039/c39940002741; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MORRIS DL, 1983, METHOD ENZYMOL, V92, P413; SCHUHMANN W, 1991, J AM CHEM SOC, V113, P1394, DOI 10.1021/ja00004a048; WILLNER I, 1992, BIOELECTROCH BIOENER, V29, P29, DOI 10.1016/0302-4598(92)80051-H; WILLNER I, 1993, ADV MATER, V5, P912, DOI 10.1002/adma.19930051206; WILLNER I, 1991, TOP CURR CHEM, V159, P153; WILLNER I, 1994, J AM CHEM SOC, V116, P1428, DOI 10.1021/ja00083a031	18	208	216	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					672	675		10.1038/376672a0	http://dx.doi.org/10.1038/376672a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	RQ672	7651516				2022-12-28	WOS:A1995RQ67200055
J	AABY, P; SAMB, B; SIMONDON, F; SECK, AMC; KNUDSEN, K; WHITTLE, H				AABY, P; SAMB, B; SIMONDON, F; SECK, AMC; KNUDSEN, K; WHITTLE, H			NONSPECIFIC BENEFICIAL EFFECT OF MEASLES IMMUNIZATION - ANALYSIS OF MORTALITY STUDIES FROM DEVELOPING-COUNTRIES	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD MORTALITY; GUINEA-BISSAU; RURAL BANGLADESH; VACCINATION; COMMUNITY; SURVIVAL; SENEGAL; TITER; AGE	Objective-To examine whether the reduction in mortality after standard titre measles immunisation in developing countries can be explained simply by the prevention of acute measles and its long term consequences. Design-An analysis of all studies comparing mortality of unimmunised children and children immunised with standard titre measles vaccine in developing countries. Studies-10 cohort and two case-control studies from Bangladesh, Benin, Burundi, Guinea-Bissau, Haiti, Senegal, and Zaire. Main outcome measures-Protective efficacy of standard titre measles immunisation against all cause mortality. Extent to which difference in mortality between immunised and unimmunised children could be explained by prevention of measles disease. Results-Protective efficacy against death after measles immunisation ranged from 30% to 86%. Efficacy was highest in the studies with short follow up and when children were immunised in infancy (range 44-100%). Vaccine efficacy against death was much greater than the proportion of deaths attributed to acute measles disease. In four studies from Guinea-Bissau, Senegal, and Burundi vaccine efficacy against death remained almost unchanged when cases of measles were excluded from the analysis. Diphtheria-tetanus-pertussis and polio vaccinations were not associated with reduction in mortality. Conclusion-These observations suggest that standard titre measles vaccine may confer a beneficial effect which is unrelated to the specific protection against measles disease.	ORSTOM,DAKAR,SENEGAL; UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL; MRC LABS,BANJUL,GAMBIA	Institut de Recherche pour le Developpement (IRD); University Cheikh Anta Diop Dakar; MRC Laboratory Molecular Biology	AABY, P (corresponding author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,ARTILLERIVEJ 5,DK-2300 COPENHAGEN,DENMARK.			Aaby, Peter/0000-0001-8331-1389; Simondon, Francois/0000-0003-0395-1314				AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1984, J TROP PEDIATRICS, V30, P164, DOI 10.1093/tropej/30.3.164; AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330, DOI 10.1093/oxfordjournals.aje.a115086; DULOU A, IN PRESS AM J EPIDEM; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; GARENNE M, 1986, ESTIMATION MORTALITE, P515; HARRIS MF, 1979, S AFR MED J, P38; HOLT EA, 1990, PEDIATRICS, V85, P188; HOLT EA, 1993, J INFECT DIS, V168, P1087, DOI 10.1093/infdis/168.5.1087; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; 1981, LANCET, V1, P764	20	255	257	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					481	485		10.1136/bmj.311.7003.481	http://dx.doi.org/10.1136/bmj.311.7003.481			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647643	Green Published			2022-12-28	WOS:A1995RQ67000014
J	GRANT, MR; GODIARD, L; STRAUBE, E; ASHFIELD, T; LEWALD, J; SATTLER, A; INNES, RW; DANGL, JL				GRANT, MR; GODIARD, L; STRAUBE, E; ASHFIELD, T; LEWALD, J; SATTLER, A; INNES, RW; DANGL, JL			STRUCTURE OF THE ARABIDOPSIS RPM1 GENE ENABLING DUAL-SPECIFICITY DISEASE RESISTANCE	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; SYRINGAE PV GLYCINEA; YAC CLONES; IDENTIFICATION; AVIRULENCE; LOCUS; DNA; EXPRESSION; PROTEIN; WALKING	Plants can recognize pathogens through the action of disease resistance (R) genes, which confer resistance to pathogens expressing unique corresponding avirulence (avr) genes. The molecular basis of this gene-for-gene specificity is unknown. The Arabidopsis thaliana RPM1 gene enables dual specificity to pathogens expressing either of two unrelated Pseudomonas syringae avr genes. Despite this function, RPM1 encodes a protein sharing molecular features with recently described single-specificity R genes. Surprisingly, RPM1 is lacking from naturally occurring, disease-susceptible Arabidopsis accessions.	MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill			Innes, Roger/A-5244-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046451] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29 GM 46451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AUSUBEL FM, 1907, CURRENT PROTOCOLS MO; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Crute I, 1994, ARABIDOPSIS, P705; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DANGL JL, 1993, INT REV CYTOL, V144, P53, DOI 10.1016/S0074-7696(08)61513-2; DANGL JL, 1992, PLANT CELL, V4, P1359, DOI 10.1105/tpc.4.11.1359; DANGL JL, 1992, PLANT J, V2, P3, DOI 10.1111/j.1365-313X.1992.00003.x; DANGL JL, 1994, BACTERIAL PATHOGENES, V192, P99; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ELLIS JG, 1995, P NATL ACAD SCI USA, V92, P4185, DOI 10.1073/pnas.92.10.4185; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; INNES RW, 1993, PLANT J, V4, P813, DOI 10.1046/j.1365-313X.1993.04050813.x; INNES RW, UNPUB; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; LEWALD J, UNPUB; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; Matallana E., 1992, Methods in Arabidopsis research., P144; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MOWERY P, UNPUB; PUTTERILL J, 1993, MOL GEN GENET, V239, P145, DOI 10.1007/BF00281613; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMIDT R, 1994, PLANT J, V5, P735, DOI 10.1111/j.1365-313X.1994.00735.x; SCHMIDT R, 1992, GENOME ANAL, V4, P71; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; TAMAKI S, 1988, J BACTERIOL, V170, P4846, DOI 10.1128/jb.170.10.4846-4854.1988; TRAUT TW, 1994, EUR J BIOCHEM, V229, P9; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	42	722	781	3	61	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					843	846		10.1126/science.7638602	http://dx.doi.org/10.1126/science.7638602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638602				2022-12-28	WOS:A1995RN65000046
J	FREY, PA; WHITT, SA; TOBIN, JB				FREY, PA; WHITT, SA; TOBIN, JB			A LOW-BARRIER HYDROGEN-BOND IN THE CATALYTIC TRIAD OF SERINE PROTEASES	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; ACTIVE-SITE; ALPHA-CHYMOTRYPSIN; HISTIDINE; PROTON; STABILIZATION; IMIDAZOLE; TRYPSIN; ENZYME; ACID	Spectroscopic properties of chymotrypsin and model compounds indicate that a low-barrier hydrogen bond participates in the mechanism of serine protease action. A low-barrier hydrogen bond between N delta 1 of His(57) and the beta-carboxyl group of Asp(102) in chymotrypsin can facilitate the formation of the tetrahedral adduct, and the nuclear magnetic resonance properties of this proton indicate that it is a low-barrier hydrogen bond. These conclusions are supported by the chemical shift of this proton, the deuterium isotope effect on the chemical shift, and the properties of hydrogen-bonded model compounds in organic solvents, including the hydrogen bond in cis-urocanic acid, in which the imidazole ring is internally hydrogen-bonded to the carboxyl group.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison	FREY, PA (corresponding author), UNIV WISCONSIN,GRAD SCH,INST ENZYME RES,MADISON,WI 53705, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028607, R01DK028607] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28607] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BREZINSKI B, 1981, ORG MAGN RESONANCE, V15, P78; CLARK JH, 1983, J CHEM SOC CHEM COMM, P136, DOI 10.1039/c39830000136; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DEGASZAFRAN Z, 1981, ORG MAGN RESONANCE, V16, P214, DOI 10.1002/mrc.1270160310; EDELBACHER S, 1943, HOPPESEYLERS Z PHYSL, V279, P63; EMSLEY J, 1980, CHEM SOC REV, V9, P91, DOI 10.1039/cs9800900091; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GERIT JA, 1993, J AM CHEM SOC, V115, P11552; GUNNARSSON G, 1976, CHEM PHYS LETT, V38, P96, DOI 10.1016/0009-2614(76)80264-3; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; HALKIDES CJ, 1993, J AM CHEM SOC, V115, P3332, DOI 10.1021/ja00061a043; HENDERSON R, 1971, BIOCHEM J, V124, P13, DOI 10.1042/bj1240013; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; Jencks W. P., 1970, HDB BIOCH, pJ187; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; KOSSIAKOFF AA, 1981, BIOCHEMISTRY-US, V20, P6462, DOI 10.1021/bi00525a027; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P4627, DOI 10.1021/bi00615a008; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P46; MORRISON H, 1980, J CHROMATOGR, V183, P83, DOI 10.1016/S0378-4347(00)81402-4; MURTHY ASN, 1970, J CHEM SOC A, P1251, DOI 10.1039/j19700001251; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROBILLAR.G, 1974, J MOL BIOL, V86, P541, DOI 10.1016/0022-2836(74)90179-X; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; ROGERS GA, 1974, J AM CHEM SOC, V96, P2473, DOI 10.1021/ja00815a028; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; ZEEGERSHUYSKENS T, 1990, J MOL LIQ, V46, P263, DOI 10.1016/0167-7322(90)80059-S; ZIMMERMAN SC, 1991, TETRAHEDRON, V47, P2649, DOI 10.1016/S0040-4020(01)81797-X	32	706	718	6	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1927	1930		10.1126/science.7661899	http://dx.doi.org/10.1126/science.7661899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7661899				2022-12-28	WOS:A1994NT84700044
J	GUMBER, SC; CHOPRA, S				GUMBER, SC; CHOPRA, S			HEPATITIS-C - A MULTIFACETED DISEASE - REVIEW OF EXTRAHEPATIC MANIFESTATIONS	ANNALS OF INTERNAL MEDICINE			English	Review							PORPHYRIA-CUTANEA-TARDA; VIRUS-INFECTION; MIXED CRYOGLOBULINEMIA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; LICHEN-PLANUS; MEMBRANOUS GLOMERULONEPHRITIS; SJOGRENS-SYNDROME; HIGH PREVALENCE; LIVER-DISEASE; ASSOCIATION	Purpose: To review the available data on the association between hepatitis C virus (HCV) infection and conditions reportedly related to infection with the virus and to assess the clinical implications of these associations. Data Sources: Pertinent articles were identified using the Paperchase database, which simultaneously searches the MEDLINE (1966 to present), Health (1975 to present), AIDSLINE (1980 to present), and Cancerlit databases. Study Selection: All studies for a given association were reviewed, but special attention was paid to randomized controlled trials where applicable. Results: According to the available data, HCV infection appears to be strongly associated with essential mixed cryoglobulinemia, membranoproliferative glomerulonephritis, and porphyria cutanea tarda. Evidence strongly suggests that HCV has a direct pathogenetic role in some patients with the first two conditions. The association with Mooren corneal ulcers and autoimmune thyroiditis is suggested, but more data are needed to confirm it. The data for the association between HCV infection and the Sjogren syndrome, lichen planus, and idiopathic pulmonary fibrosis remain weak. Although interferon therapy has been effective in patients with both essential mixed cryoglobulinemia and membranoproliferative glomerulonephritis, a high relapse rate has been noted in the latter condition. Conclusions: Patients with essential mixed cryoglobulinemia, membranoproliferative glomerulonephritis, and porphyria cutanea tarda should be tested for HCV infection. Conversely, signs and symptoms of these conditions should be sought in patients with chronic HCV infection. Interferon therapy is currently recommended only for patients with symptomatic essential mixed cryoglobulinemia.	BETH ISRAEL HOSP, DIV GASTROENTEROL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School								ACETI A, 1992, LANCET, V339, P1425, DOI 10.1016/0140-6736(92)91252-4; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; BONKOVSKY HL, 1989, HEPATOLOGY, V10, P354, DOI 10.1002/hep.1840100319; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; CAINELLI T, 1990, BRIT MED J, V300, P227; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN PR, 1990, GENETIC DISORDERS SK, P79; DAVDA R, 1993, AM J KIDNEY DIS, V22, P452, DOI 10.1016/S0272-6386(12)70152-X; de Verneuil H, 1978, Hum Genet, V44, P145; DECASTRO M, 1993, HEPATOLOGY, V17, P551, DOI 10.1002/hep.1840170405; Dienstag J L, 1981, Semin Liver Dis, V1, P45, DOI 10.1055/s-2008-1063929; DIVANO MC, 1992, DERMATOLOGY, V185, P132, DOI 10.1159/000247428; DOUTRE MS, 1992, DERMATOLOGY, V184, P229, DOI 10.1159/000247552; DOUTRELEPONT JM, 1993, LANCET, V341, P317, DOI 10.1016/0140-6736(93)92680-R; FARGION S, 1992, HEPATOLOGY, V16, P1322, DOI 10.1002/hep.1840160603; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1993, BLOOD, V81, P1132; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; HARLE JR, 1993, LANCET, V341, P904, DOI 10.1016/0140-6736(93)93119-L; HERRERO C, 1993, LANCET, V341, P788, DOI 10.1016/0140-6736(93)90562-U; HORIKOSHI S, 1993, NEPHRON, V64, P462, DOI 10.1159/000187372; IRVING WL, 1993, AM REV RESPIR DIS, V148, P1683, DOI 10.1164/ajrccm/148.6_Pt_1.1683; JOHNSON RJ, 1994, KIDNEY INT, V46, P1700, DOI 10.1038/ki.1994.471; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; JUBERT C, 1994, ARCH DERMATOL, V130, P73, DOI 10.1001/archderm.130.1.73; KING PD, 1994, AM J GASTROENTEROL, V89, P1047; LUNEL F, 1994, GASTROENTEROLOGY, V106, P1291, DOI 10.1016/0016-5085(94)90022-1; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MISIANI R, 1994, NEW ENGL J MED, V330, P751, DOI 10.1056/NEJM199403173301104; NAVAS S, 1995, HEPATOLOGY, V21, P279, DOI 10.1002/hep.1840210203; PAWLOTSKY JM, 1994, HEPATOLOGY, V19, P841, DOI 10.1016/0270-9139(94)90281-X; PAWLOTSKY JM, 1995, ANN INTERN MED, V122, P169, DOI 10.7326/0003-4819-122-3-199502010-00002; POET JL, 1994, J RHEUMATOL, V21, P1376; PROTZER U, 1993, GASTROENTEROLOGY, V104, P903, DOI 10.1016/0016-5085(93)91029-H; Rebora A., 1992, Journal of Dermatological Science, V4, P38, DOI 10.1016/0923-1811(92)90054-F; ROLLINO C, 1991, NEPHRON, V59, P319, DOI 10.1159/000186573; SANSONNO D, 1995, HEPATOLOGY, V21, P305; SHAPIRO CN, 1994, P AM ASS STUD LIV DI, P41; TRAN A, 1993, HEPATOLOGY, V18, P253, DOI 10.1002/hep.1840180205; UEDA T, 1992, AM REV RESPIR DIS, V146, P266, DOI 10.1164/ajrccm/146.1.266; WILSON SE, 1994, OPHTHALMOLOGY, V101, P736; YAMABE H, 1995, AM J KIDNEY DIS, V25, P67, DOI 10.1016/0272-6386(95)90628-2; Yamabe H., 1993, Journal of the American Society of Nephrology, V4, P291	44	431	440	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					615	620		10.7326/0003-4819-123-8-199510150-00008	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677303				2022-12-28	WOS:A1995RY82800008
J	FRANKS, S				FRANKS, S			MEDICAL PROGRESS - POLYCYSTIC-OVARY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FOLLICLE-STIMULATING-HORMONE; GONADOTROPIN-RELEASING-HORMONE; GROWTH FACTOR-I; LOW-DOSE GONADOTROPIN; INSULIN RESISTANCE; BINDING GLOBULIN; OBESE WOMEN; STEROID-SECRETION; HYPERANDROGENIC WOMEN; LUTEINIZING-HORMONE				FRANKS, S (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON W2 1PG,ENGLAND.							ADAMS J, 1985, LANCET, V2, P1375; ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; ANDERSON DC, 1974, CLIN ENDOCRINOL, V3, P69, DOI 10.1111/j.1365-2265.1974.tb03298.x; ARMAR NA, 1990, FERTIL STERIL, V53, P45; BARBIERI R L, 1984, Obstetrics and Gynecology, V64, p73S; BARDIN CW, 1967, J CLIN INVEST, V46, P891, DOI 10.1172/JCI105588; BARTH JH, 1988, DRUGS, V35, P83, DOI 10.2165/00003495-198835010-00005; BARTH JH, 1989, J CLIN ENDOCR METAB, V68, P966, DOI 10.1210/jcem-68-5-966; BERGH C, 1993, FERTIL STERIL, V59, P323; BOUCHARD C, 1993, ENDOCR REV, V14, P72, DOI 10.1210/er.14.1.72; BROWN JB, 1978, AUSTR NZ J OBSTETRIC, V18, P46; BUNKER CB, 1991, CLIN EXP DERMATOL, V16, P420, DOI 10.1111/j.1365-2230.1991.tb01226.x; BURGHEN GA, 1980, J CLIN ENDOCR METAB, V50, P113, DOI 10.1210/jcem-50-1-113; CAREY AH, 1993, CLIN ENDOCRINOL, V38, P653, DOI 10.1111/j.1365-2265.1993.tb02150.x; CAREY AH, 1994, HUM MOL GENET, V3, P1873, DOI 10.1093/hmg/3.10.1873; CARMINA E, 1992, AM J OBSTET GYNECOL, V167, P1807, DOI 10.1016/0002-9378(92)91779-A; CHANG RJ, 1985, CLIN OBSTET GYNAECOL, V12, P675; CHANG RJ, 1983, J CLIN ENDOCR METAB, V57, P356, DOI 10.1210/jcem-57-2-356; CHANG RJ, 1983, J CLIN ENDOCR METAB, V56, P897, DOI 10.1210/jcem-56-5-897; CIARALDI TP, 1992, J CLIN ENDOCR METAB, V75, P577, DOI 10.1210/jc.75.2.577; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; CONWAY GS, 1993, CLIN ENDOCRINOL, V38, P219, DOI 10.1111/j.1365-2265.1993.tb00996.x; CONWAY GS, 1990, CLIN ENDOCRINOL, V33, P593; CONWAY GS, 1992, CLIN ENDOCRINOL, V37, P119, DOI 10.1111/j.1365-2265.1992.tb02295.x; COOPER HE, 1968, AM J OBSTET GYNECOL, V100, P371, DOI 10.1016/S0002-9378(15)33704-2; COUZINET B, 1986, J CLIN ENDOCR METAB, V63, P1031, DOI 10.1210/jcem-63-4-1031; CUSAN L, 1990, J AM ACAD DERMATOL, V23, P462, DOI 10.1016/0190-9622(90)70241-9; CUSAN L, 1994, FERTIL STERIL, V61, P281; DAHLGREN E, 1992, ACTA OBSTET GYN SCAN, V71, P599, DOI 10.3109/00016349209006227; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DALE PO, 1992, ACTA ENDOCRINOL-COP, V126, P132, DOI 10.1530/acta.0.1260132; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; DUNAIF A, 1988, J CLIN ENDOCR METAB, V66, P131, DOI 10.1210/jcem-66-1-131; DUNAIF A, 1992, DIABETES, V41, P1257, DOI 10.2337/diabetes.41.10.1257; DUNAIF A, 1990, J CLIN ENDOCR METAB, V70, P699, DOI 10.1210/jcem-70-3-699; DUNAIF A, 1987, J CLIN ENDOCR METAB, V65, P499, DOI 10.1210/jcem-65-3-499; Dunaif Andrea, 1993, P301; EDEN JA, 1991, MED J AUSTRALIA, V155, P677, DOI 10.5694/j.1326-5377.1991.tb93959.x; EHRMANN DA, 1992, NEW ENGL J MED, V327, P157, DOI 10.1056/NEJM199207163270304; EVANS DJ, 1988, INT J OBESITY, V12, P157; FAUSER BCJM, 1992, CLIN ENDOCRINOL, V37, P445, DOI 10.1111/j.1365-2265.1992.tb02357.x; FAUSER BCJM, 1991, J CLIN ENDOCR METAB, V73, P811, DOI 10.1210/jcem-73-4-811; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; FERRIMAN D, 1979, CLIN ENDOCRINOL, V11, P291, DOI 10.1111/j.1365-2265.1979.tb03077.x; FLIER JS, 1985, DIABETES, V34, P101, DOI 10.2337/diabetes.34.2.101; FOX R, 1991, CLIN ENDOCRINOL, V34, P127, DOI 10.1111/j.1365-2265.1991.tb00282.x; FRANKS S, 1985, CLIN OBSTET GYNAECOL, V12, P605; FRANKS S, 1991, J ENDOCRINOL, V129, P317, DOI 10.1677/joe.0.1290317; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; FRANKS S, 1992, INFERTILITY, P237; FUTTERWEIT W, 1983, OBSTET GYNECOL S, V62, pS4; GADIR AA, 1990, CLIN ENDOCRINOL, V33, P585; GAMBRELL RD, 1973, OBSTET GYNECOL, V42, P429; GEFFNER ME, 1986, FERTIL STERIL, V45, P327; GILLINGSMITH C, 1994, J CLIN ENDOCR METAB, V79, P1158, DOI 10.1210/jc.79.4.1158; GIVENS JR, 1988, ENDOCRIN METAB CLIN, V17, P771, DOI 10.1016/S0889-8529(18)30409-2; GJONNAESS H, 1990, World Health Forum, V11, P214; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; GURGAN T, 1991, FERTIL STERIL, V56, P1176; HAGUE WM, 1988, CLIN ENDOCRINOL, V29, P593, DOI 10.1111/j.1365-2265.1988.tb03707.x; HAGUE WM, 1989, CLIN ENDOCRINOL, V30, P355, DOI 10.1111/j.1365-2265.1989.tb00433.x; HAMILTONFAIRLEY D, 1992, BRIT J OBSTET GYNAEC, V99, P128, DOI 10.1111/j.1471-0528.1992.tb14470.x; HAMILTONFAIRLEY D, 1990, BAILLIERE CLIN OB GY, V4, P609, DOI 10.1016/S0950-3552(05)80313-X; HAMILTONFAIRLEY D, 1991, HUM REPROD, V6, P1095, DOI 10.1093/oxfordjournals.humrep.a137491; HAMMERSTEIN J, 1983, J STEROID BIOCHEM, V19, P591, DOI 10.1016/0022-4731(83)90223-6; HARLASS FE, 1984, FERTIL STERIL, V42, P649; HOLTE J, 1994, CLIN ENDOCRINOL, V41, P473, DOI 10.1111/j.1365-2265.1994.tb02578.x; Hull M G, 1987, Gynecol Endocrinol, V1, P235, DOI 10.3109/09513598709023610; Jacobs H S, 1987, Gynecol Endocrinol, V1, P113, DOI 10.3109/09513598709082702; JACOBS HS, 1994, OVULATION INDUCTION, P267; JIALAL I, 1987, J CLIN ENDOCR METAB, V64, P1066, DOI 10.1210/jcem-64-5-1066; KAMRAVA MM, 1982, FERTIL STERIL, V37, P520; KAZER RR, 1990, J CLIN ENDOCR METAB, V71, P958, DOI 10.1210/jcem-71-4-958; KIDDY DS, 1992, CLIN ENDOCRINOL, V36, P105, DOI 10.1111/j.1365-2265.1992.tb02909.x; KIDDY DS, 1990, CLIN ENDOCRINOL, V32, P213, DOI 10.1111/j.1365-2265.1990.tb00857.x; KIDDY DS, 1989, CLIN ENDOCRINOL, V31, P757, DOI 10.1111/j.1365-2265.1989.tb01297.x; KIRSCHNER MA, 1972, METABOLISM, V21, P667, DOI 10.1016/0026-0495(72)90090-X; KIRSCHNER MA, 1983, J STEROID BIOCHEM, V19, P607, DOI 10.1016/0022-4731(83)90225-X; KOPELMAN PG, 1981, CLIN ENDOCRINOL, V15, P113, DOI 10.1111/j.1365-2265.1981.tb00644.x; LOBO RA, 1991, CLIN OBSTET GYNECOL, V34, P817, DOI 10.1097/00003081-199112000-00019; LUCIANO AA, 1984, FERTIL STERIL, V41, P719; LUNDE O, 1989, GYNECOL OBSTET INVES, V28, P23, DOI 10.1159/000293493; LUNENFELD B, 1978, DIAGNOSIS TREATMENT; Mak Hull, 1992, INFERTILITY, P33; MATTSSON LA, 1984, FERTIL STERIL, V42, P579; MCARTHUR JW, 1958, J CLIN ENDOCR METAB, V18, P1202, DOI 10.1210/jcem-18-11-1202; MENASHE Y, 1990, FERTIL STERIL, V53, P432; MILLER JA, 1986, CLIN ENDOCRINOL META, V15, P373, DOI 10.1016/S0300-595X(86)80031-7; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MURDOCH AP, 1986, CLIN ENDOCRINOL, V24, P165, DOI 10.1111/j.1365-2265.1986.tb00759.x; NESTLER JE, 1991, ENDOCRIN METAB CLIN, V20, P807, DOI 10.1016/S0889-8529(18)30245-7; NESTLER JE, 1989, AM J OBSTET GYNECOL, V161, P1095, DOI 10.1016/0002-9378(89)90640-6; NESTLER JE, 1992, POLYCYSTIC OVARY SYN, P265; NEW MI, 1992, POLYCYSTIC OVARY SYN, P145; ODRISCOLL JB, 1994, CLIN ENDOCRINOL, V41, P231, DOI 10.1111/j.1365-2265.1994.tb02535.x; PACHE TD, 1991, ULTRASOUND MED BIOL, V17, P589, DOI 10.1016/0301-5629(91)90029-V; PARISI L, 1984, J CLIN ULTRASOUND, V12, P21, DOI 10.1002/jcu.1870120106; PASQUALI R, 1989, J CLIN ENDOCR METAB, V68, P173, DOI 10.1210/jcem-68-1-173; PASQUALI R, 1991, J ENDOCRINOL INVEST, V14, P839, DOI 10.1007/BF03347939; PEIRIS AN, 1989, J CLIN ENDOCR METAB, V68, P715, DOI 10.1210/jcem-68-4-715; PLYMATE SR, 1988, J CLIN ENDOCR METAB, V67, P460, DOI 10.1210/jcem-67-3-460; POLSON DW, 1987, CLIN ENDOCRINOL, V26, P581, DOI 10.1111/j.1365-2265.1987.tb00813.x; POLSON DW, 1988, LANCET, V1, P870; POLSON DW, 1987, CLIN ENDOCRINOL, V26, P205, DOI 10.1111/j.1365-2265.1987.tb00778.x; PORETSKY L, 1987, ENDOCR REV, V8, P132, DOI 10.1210/edrv-8-2-132; PUGEAT M, 1991, J STEROID BIOCHEM, V40, P841, DOI 10.1016/0960-0760(91)90310-2; REED MJ, 1988, BAILLIERE CLIN OB GY, V2, P581, DOI 10.1016/S0950-3552(88)80045-2; ROBINSON S, 1992, CLIN ENDOCRINOL, V36, P537, DOI 10.1111/j.1365-2265.1992.tb02262.x; ROBINSON S, 1993, CLIN ENDOCRINOL, V39, P351, DOI 10.1111/j.1365-2265.1993.tb02376.x; ROSENBAUM D, 1993, AM J PHYSIOL, V264, pE197, DOI 10.1152/ajpendo.1993.264.2.E197; ROSENFIELD RL, 1990, FERTIL STERIL, V53, P785; ROSNER W, 1990, ENDOCR REV, V11, P80, DOI 10.1210/edrv-11-1-80; SAGLE MA, 1991, FERTIL STERIL, V55, P56; SCANLON MJ, 1988, CLIN ENDOCRINOL, V29, P529, DOI 10.1111/j.1365-2265.1988.tb03702.x; SHARP PS, 1991, CLIN ENDOCRINOL, V35, P253, DOI 10.1111/j.1365-2265.1991.tb03531.x; SHERMAN AI, 1979, AM J OBSTET GYNECOL, V135, P947, DOI 10.1016/0002-9378(79)90821-4; SHOHAM Z, 1991, FERTIL STERIL, V55, P1051; SHOUPE D, 1983, AM J OBSTET GYNECOL, V147, P588, DOI 10.1016/0002-9378(83)90023-6; SIMPSON J. L., 1992, POLYCYSTIC OVARY SYN, P59; SINGH A, 1990, J ENDOCRINOL, V124, pR1, DOI 10.1677/joe.0.124R001; SLOWINSKASRZEDN.J, 1992, J CLIN ENDOCR METAB, V74, P1432; STANHOPE R, 1987, FERTIL STERIL, V47, P872; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; STEINGOLD K, 1987, J CLIN ENDOCR METAB, V65, P773, DOI 10.1210/jcem-65-4-773; SWANSON M, 1981, J CLIN ULTRASOUND, V9, P219, DOI 10.1002/jcu.1870090504; TAKAHASHI K, 1992, INT J FERTIL, V37, P222; TEMPLE RC, 1990, CLIN ENDOCRINOL, V32, P689, DOI 10.1111/j.1365-2265.1990.tb00915.x; THOMPSON DL, 1990, CLIN ENDOCRINOL, V32, P283, DOI 10.1111/j.1365-2265.1990.tb00868.x; TOSCANO V, 1992, CLIN ENDOCRINOL, V36, P197, DOI 10.1111/j.1365-2265.1992.tb00958.x; VALDES CT, 1991, J CLIN ENDOCR METAB, V72, P642, DOI 10.1210/jcem-72-3-642; WALDSTREICHER J, 1988, J CLIN ENDOCR METAB, V66, P165, DOI 10.1210/jcem-66-1-165; WANG CF, 1980, FERTIL STERIL, V33, P479; WHITE D, 1995, CLIN ENDOCRINOL, V42, P475, DOI 10.1111/j.1365-2265.1995.tb02665.x; WILD RA, 1985, J CLIN ENDOCR METAB, V61, P946, DOI 10.1210/jcem-61-5-946; WILD RA, 1988, AM J OBSTET GYNECOL, V159, P423, DOI 10.1016/S0002-9378(88)80099-1; WILSHIRE GB, 1994, OVULATION INDUCTION, P245; YEH HC, 1987, RADIOLOGY, V163, P111, DOI 10.1148/radiology.163.1.3547491; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x; Zawadzki J, 1992, POLYCYSTIC OVARY SYN, P377	140	1507	1572	3	63	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					853	861		10.1056/NEJM199509283331307	http://dx.doi.org/10.1056/NEJM199509283331307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651477				2022-12-28	WOS:A1995RW88300007
J	JACKSON, R; BEAGLEHOLE, R				JACKSON, R; BEAGLEHOLE, R			ALCOHOL-CONSUMPTION GUIDELINES - RELATIVE SAFETY VS ABSOLUTE RISKS AND BENEFITS	LANCET			English	Editorial Material							MORTALITY; CANCER				JACKSON, R (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934				ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; BLACKWELDER WC, 1980, AM J MED, V68, P164, DOI 10.1016/0002-9343(80)90350-2; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GARFINKEL L, 1988, PREV MED, V17, P686, DOI 10.1016/0091-7435(88)90086-2; GAZIANO JM, 1995, BRIT MED J, V311, P3, DOI 10.1136/bmj.311.6996.3a; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; MEYER F, 1993, AM J EPIDEMIOL, V138, P225, DOI 10.1093/oxfordjournals.aje.a116851; USEHIMA H, 1986, STROKE, V17, P19; 1995, ALCOHOL HEART PERSPE	14	47	47	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					716	716		10.1016/S0140-6736(95)91496-X	http://dx.doi.org/10.1016/S0140-6736(95)91496-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658866				2022-12-28	WOS:A1995RU81000002
J	NIKOLOV, DB; CHEN, H; HALAY, ED; USHEVA, AA; HISATAKE, K; LEE, DK; ROEDER, RG; BURLEY, SK				NIKOLOV, DB; CHEN, H; HALAY, ED; USHEVA, AA; HISATAKE, K; LEE, DK; ROEDER, RG; BURLEY, SK			CRYSTAL-STRUCTURE OF A TFIIB-TBP-TATA-ELEMENT TERNARY COMPLEX	NATURE			English	Article							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; FUNCTIONAL DOMAINS; BINDING-PROTEIN; BOX COMPLEX; INITIATION; ACTIVATION	The crystal structure of the transcription factor IIB (TFIIB)/TATA box-binding protein (TBP)/TATA-element ternary complex is described at 2.7 Angstrom resolution, core TFIIB resembles cyclin A, and recognizes the preformed TBP-DNA complex through protein-protein and protein-DNA interactions. The amino-terminal domain of core TFIIB forms the downstream surface of the ternary complex, where it could fix the transcription start site. The remaining surfaces of TBP and the TFIIB can interact with TBP-associated factors, other class II initiation factors, and transcriptional activators and coactivators.	ROCKEFELLER UNIV,MOLEC BIOPHYS LABS,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Princeton University				Hisatake, Koji/0000-0002-5795-3115; Burley, Stephen K./0000-0002-2487-9713				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BRUNGER AT, 1992, XPLOR V 3 1 MANUAL; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRALAUKIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MOLDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PINTO I, 1994, J BIOL CHEM, V269, P30569; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P6077, DOI 10.1073/pnas.92.13.6077; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	478	487	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					119	128		10.1038/377119a0	http://dx.doi.org/10.1038/377119a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675079				2022-12-28	WOS:A1995RU75400039
J	CARPENTER, RHS; WILLIAMS, MLL				CARPENTER, RHS; WILLIAMS, MLL			NEURAL COMPUTATION OF LOG LIKELIHOOD IN CONTROL OF SACCADIC EYE-MOVEMENTS	NATURE			English	Article							SHORT REACTION-TIMES; EXPRESS SACCADES; LATENCIES; MONKEY; FIELD	THE latency between the appearance of a visual target and the start of the saccadic eye movement made to look at it varies from trial to trial to an extent that is inexplicable in terms of ordinary 'physiological' processes such as synaptic delays and conduction velocities. An alternative interpretation is that it represents the time needed to decide whether a target is in fact present: decision processes are necessarily stochastic, because they depend on extracting information from noisy sensory signals(1), In one such model(2), the presence of a target causes a signal in a decision unit to rise linearly at a rate r from its initial value s(0) until it reaches a fixed threshold theta, when a saccade is initiated, One can regard this decision signal as a neural estimate of the log likelihood of the hypothesis that the target is present, the threshold being the significance criterion or likelihood level at which the target is presumed to be present, Experiments manipulating the prior probability of the target's appearing confirm this notion: the latency distribution then changes in the way expected if s(0) simply reflects the prior log likelihood of the stimulus.			CARPENTER, RHS (corresponding author), UNIV CAMBRIDGE, PHYSIOL LAB, DOWNING ST, CAMBRIDGE CB2 3EG, ENGLAND.			Carpenter, Roger/0000-0003-2572-1448				BARLOW HB, 1980, PHILOS T ROY SOC B, V290, P71, DOI 10.1098/rstb.1980.0083; CARPENTER RHS, 1994, CONTEMPORARY OCULAR MOTOR AND VESTIBULAR RESEARCH: A TRIBUTE TO DAVID A. ROBINSON, P185; CARPENTER RHS, 1994, J PHYSIOL-LONDON, V488, pP4; Carpenter RHS, 1981, EYE MOVEMENTS COGNIT, P237; DALLOS PJ, 1963, IEEE T AUTOMAT CONTR, P218; EDWARDS AWF, 1972, LIKELIHOOD; FISCHER B, 1984, EXP BRAIN RES, V57, P191; FISCHER B, 1983, BRAIN RES, V260, P21, DOI 10.1016/0006-8993(83)90760-6; Fisher R. A., 1921, METRON             4, V1, P3, DOI DOI 10.1093/BIOMET/9.1-2.22; FUCHS AF, 1967, J PHYSIOL-LONDON, V191, P609, DOI 10.1113/jphysiol.1967.sp008271; GRICE GR, 1968, PSYCHOL REV, V75, P359, DOI 10.1037/h0026287; HANES DP, 1995, EXP BRAIN RES, V103, P85; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362, DOI 10.1152/jn.1977.40.2.362; NAZIR TA, 1991, PSYCHOL RES-PSYCH FO, V53, P281, DOI 10.1007/BF00920481; RATCLIFF R, 1978, PSYCHOL REV, V85, P59, DOI 10.1037//0033-295X.85.2.59; ROBINSON DA, 1973, KYBERNETIK, V14, P71, DOI 10.1007/BF00288906; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHILLER PH, 1987, J NEUROPHYSIOL, V57, P1033, DOI 10.1152/jn.1987.57.4.1033; WENBANSMITH MG, 1991, EXP BRAIN RES, V87, P218	19	639	641	2	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					59	62		10.1038/377059a0	http://dx.doi.org/10.1038/377059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659161				2022-12-28	WOS:A1995RT72500055
J	BARZANSKY, B; JONAS, HS; ETZEL, SI				BARZANSKY, B; JONAS, HS; ETZEL, SI			EDUCATIONAL-PROGRAMS IN US MEDICAL-SCHOOLS, 1994-1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,DEPT RES & DATA ANAL,CHICAGO,IL 60610	American Medical Association	BARZANSKY, B (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							GANEM JL, 1994, JAMA-J AM MED ASSOC, V272, P705; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; JOLLY P, 1995, ASS AM MED COLLEGES; LAZARUS GS, 1995, ACAD MED, V70, P87, DOI 10.1097/00001888-199502000-00007; 1994, 1994 NATIONAL DIRECT; 1984, J MED ED S, V59, P1	6	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					716	722		10.1001/jama.274.9.716	http://dx.doi.org/10.1001/jama.274.9.716			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650825				2022-12-28	WOS:A1995RR83500018
J	HESS, BM				HESS, BM			WELL REPLACE THE VALVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					680	680						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650812				2022-12-28	WOS:A1995RR83500001
J	NELLIS, WJ; ROSS, M; HOLMES, NC				NELLIS, WJ; ROSS, M; HOLMES, NC			TEMPERATURE-MEASUREMENTS OF SHOCK-COMPRESSED LIQUID-HYDROGEN - IMPLICATIONS FOR THE INTERIOR OF JUPITER	SCIENCE			English	Article							EQUATION-OF-STATE; MOLECULAR-HYDROGEN; FLUID NITROGEN; GIANT PLANETS; HIGH-DENSITY; DISSOCIATION; DEUTERIUM; KBAR	Shock temperatures of hydrogen up to 5200 kelvin were measured optically at pressures up to 83 gigapascals (830 kilobars). At highest pressures, the measured temperatures are substantially lower than predicted. These lower temperatures are caused by a continuous dissociative phase transition above 20 gigapascals. Because hydrogen is in thermal equilibrium in shock-compression experiments, the theory derived from the shock data can be applied to Jupiter. The planet's molecular envelope is cooler and has much less temperature variation than previously believed. The continuous dissociative phase transition suggests that there is no sharp boundary between Jupiter's molecular mantle and its metallic core. A possible convectively quiescent boundary layer might induce an additional layer in the molecular region, as has been predicted.	LAWRENCE LIVERMORE NATL LAB,DIV H,LIVERMORE,CA 94550	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	NELLIS, WJ (corresponding author), LAWRENCE LIVERMORE NATL LAB,INST GEOPHYS & PLANETARY PHYS,LIVERMORE,CA 94550, USA.							BARBEE TW, 1991, PHYS REV B, V44, P11563, DOI 10.1103/PhysRevB.44.11563; DICK RD, 1980, J CHEM PHYS, V73, P5264, DOI 10.1063/1.439955; DUFFY TS, 1994, SCIENCE, V263, P1590, DOI 10.1126/science.263.5153.1590; HOLMES N, UNPUB; HOLMES NC, 1995, REV SCI INSTRUM, V66, P2615, DOI 10.1063/1.1145597; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; HUBBARD WB, 1980, REV GEOPHYS, V18, P1, DOI 10.1029/RG018i001p00001; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; MITCHELL AC, 1981, REV SCI INSTRUM, V52, P347, DOI 10.1063/1.1136602; MOSSER B, 1991, ASTRON ASTROPHYS, V251, P356; NELLIS WJ, 1984, PHYS REV LETT, V53, P1248, DOI 10.1103/PhysRevLett.53.1248; NELLIS WJ, 1991, J CHEM PHYS, V94, P2244, DOI 10.1063/1.459895; NELLIS WJ, 1983, J CHEM PHYS, V79, P1480, DOI 10.1063/1.445938; NELLIS WJ, 1980, J CHEM PHYS, V73, P6137, DOI 10.1063/1.440105; RADOUSKY HB, 1986, PHYS REV LETT, V57, P2419, DOI 10.1103/PhysRevLett.57.2419; ROSS M, 1987, J CHEM PHYS, V86, P7110, DOI 10.1063/1.452360; ROSS M, 1983, J CHEM PHYS, V79, P1487, DOI 10.1063/1.445939; ROSS M, 1981, PHILOS T R SOC A, V303, P303, DOI 10.1098/rsta.1981.0204; SAUMON D, 1991, PHYS REV A, V44, P5122, DOI 10.1103/PhysRevA.44.5122; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; VANTHIEL M, 1973, PHYS REV LETT, V31, P979, DOI 10.1103/PhysRevLett.31.979; Zharkov V. N., 1992, HIGH PRESSURE RES AP, P393; ZHARKOV VN, 1976, JUPITER, P135	26	87	89	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1249	1252		10.1126/science.7652570	http://dx.doi.org/10.1126/science.7652570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652570				2022-12-28	WOS:A1995RR84200028
J	LAGA, M				LAGA, M			STD CONTROL FOR HIV PREVENTION - IT WORKS	LANCET			English	Editorial Material											LAGA, M (corresponding author), INST TROP MED,STD HIV RES & INTERVENT UNIT,B-2000 ANTWERP,BELGIUM.							BRABIN L, 1994, LANCET, V344, P300; BULTERYS M, 1994, AIDS, V8, P1585, DOI 10.1097/00002030-199411000-00010; BUVE A, 1993, 7TH INT C AIDS AFR; KARITA E, 1995, MAY P M EFF APPR AID; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; LAGA M, 1994, AIDS S1, V8, pS119; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; OVER M, 1993, DISEASE CONTROL PRIO, P456; RICHERT CA, 1993, AM J PUBLIC HEALTH, V83, P520, DOI 10.2105/AJPH.83.4.520	9	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					518	519		10.1016/S0140-6736(95)91374-2	http://dx.doi.org/10.1016/S0140-6736(95)91374-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658772				2022-12-28	WOS:A1995RQ98600002
J	DENG, CX; ZHANG, PM; HARPER, JW; ELLEDGE, SJ; LEDER, P				DENG, CX; ZHANG, PM; HARPER, JW; ELLEDGE, SJ; LEDER, P			MICE LACKING P21(C/P1/WAF1) UNDERGO NORMAL DEVELOPMENT, BUT ARE DEFECTIVE IN G1 CHECKPOINT CONTROL	CELL			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; GENE AMPLIFICATION; CDK2 ACTIVITY; APOPTOSIS; INHIBITOR; PROTEIN; IRRADIATION; EXPRESSION; DEFICIENT	p21(CIP1/WAF1) is a CDK inhibitor regulated by the tumor suppressor p53 and is hypothesized to mediate G1 arrest. p53 has been suggested to derive anti-oncogenic properties from this relationship. To test these notions, we created mice lacking p21(CIP1/WAF1). They develop normally and (unlike p53(-/-) mice) have not developed spontaneous malignancies during 7 months of observation. Nonetheless, p21(-/-) embryonic fibroblasts are significantly deficient in their ability to arrest in G1 in response to DNA damage and nucleotide pool perturbation. p21(-/-) cells also exhibit a significant growth alteration in vitro, achieving a saturation density as high as that observed In p53(-/-) cells. In contrast, other aspects of p53 function, such as thymocytic apoptosis and the mitotic spindle checkpoint, appear normal. These results establish the role of p21(CIP1/WAF1) in the G1 checkpoint, but suggest that the anti-apoptotic and the anti-oncogenic effects of p53 are more complex.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT HUMAN & MOLEC GENET,HOUSTON,TX 77030	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine			deng, chuxia/N-6713-2016	Harper, Jeffrey/0000-0002-6944-7236	NIA NIH HHS [AG11085] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1994, NAT GENET, V5, P225; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REOBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P71; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1993, ONCOGENE, V8, P1; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU F, 1995, P NATL ACAD SCI USA, V92, P1357; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	64	1918	1957	1	42	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					675	684		10.1016/0092-8674(95)90039-X	http://dx.doi.org/10.1016/0092-8674(95)90039-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664346	Bronze			2022-12-28	WOS:A1995RR73400018
J	RANTAKALLIO, P; LAARA, E; KOIRANEN, M				RANTAKALLIO, P; LAARA, E; KOIRANEN, M			A 28 YEAR FOLLOW-UP OF MORTALITY AMONG WOMEN WHO SMOKED DURING PREGNANCY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING	Objective-To investigate long term mortality among women who smoked during pregnancy and those who stopped smoking. Design-A follow up of a geographically defined cohort from 1966 through to 1993. Subjects-11 994 women in northern Finland expected to deliver in 1966, comprising 96% of all women giving birth in the area during that year. Smoking habits were recorded during pregnancy but not later. Main outcome measure-Mortality by cause (571 deaths). Results-The mortality ratio adjusted for age, place of residence, years of education and marital status was 2.3 (95% confidence interval 1.8 to 2.8) for the women who smoked during pregnancy and 1.6 (1.1 to 2.2) for those who stopped smoking before the second month of pregnancy, both compared with non-smokers. Among the smokers the relative mortality was higher for typical diseases related to tobacco intake, such as respiratory and oesophageal cancer and diseases of the cardiovascular and digestic organs and also for accidents and suicides. Conclusion-The risk of premature death seems to be higher in women who smoke during pregnancy than in other women who smoke. This may be explained either by the low proportion of those who stop later and the high proportion of heavy smokers or by other characteristics of these subjects that increase the risk.			RANTAKALLIO, P (corresponding author), UNIV OULU, DEPT PUBL HLTH SCI & GEN PRACTICE, AAPISTIE 1, SF-90220 OULU, FINLAND.							BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BUTLER NR, 1973, BRIT MED J, V4, P573, DOI 10.1136/bmj.4.5892.573; COLBY JP, 1994, SOC SCI MED, V38, P373, DOI 10.1016/0277-9536(94)90407-3; COX DR, 1972, J R STAT SOC B, V34, P187; Dixon W. J., 1990, BMDP STATISTICAL SOF; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; GRAHAM H, 1994, SOC SCI MED, V38, P691, DOI 10.1016/0277-9536(94)90459-6; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; PRITCHARD CW, 1994, J EPIDEMIOL COMMUN H, V48, P377, DOI 10.1136/jech.48.4.377; PUGH H, 1991, SOC SCI MED, V32, P1105, DOI 10.1016/0277-9536(91)90086-R; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; RANTAKALLIO P, 1969, ACTA PAEDIATR SC S, V0193; RANTAKALLIO P, 1983, ACTA PAEDIATR SCAND, V72, P747, DOI 10.1111/j.1651-2227.1983.tb09805.x; RANTAKALLIO P, 1983, PUBLIC HLTH REV, V11, P55; Rimpeld A., 1992, TOB CONTROL, V1, P285; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, LANCET, V340, P709; THORNTON A, 1994, J CLIN EPIDEMIOL, V47, P1143, DOI 10.1016/0895-4356(94)90101-5; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; [No title captured]	21	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	1995	311	7003					477	480		10.1136/bmj.311.7003.477	http://dx.doi.org/10.1136/bmj.311.7003.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647642	Green Published			2022-12-28	WOS:A1995RQ67000013
J	DALAKAS, MC				DALAKAS, MC			CALCIFICATIONS IN DERMATOMYOSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DALAKAS, MC (corresponding author), NINCDS,BLDG 36,RM 4D04,BETHESDA,MD 20892, USA.								0	4	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					978	978		10.1056/NEJM199510123331506	http://dx.doi.org/10.1056/NEJM199510123331506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666918				2022-12-28	WOS:A1995RY58600006
J	CHAULK, CP; MOORERICE, K; RIZZO, R; CHAISSON, RE				CHAULK, CP; MOORERICE, K; RIZZO, R; CHAISSON, RE			11 YEARS OF COMMUNITY-BASED DIRECTLY OBSERVED THERAPY FOR TUBERCULOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLICY; CARE	Objective.-To evaluate community-based directly observed therapy (DOT) for tuberculosis (TB) control. Design.-Ecological study. Methods.-Three comparisons were made in this descriptive study. (1) An 11-year retrospective comparison of TB case rates, sputum conversion rates (SCRs), rates of therapy completion, and confounding factors (acquired immunodeficiency syndrome [AIDS], immigration, unemployment, and poverty) in Baltimore, Md, with those of the five major US cities having the highest TB incidence in 1981 but which did not have comprehensive DOT programs. (2) An 11-year trend of TB in Baltimore and the 19 major US cities with the highest TB incidence in 1981. (3) A 7-year trend in TB in both city groups between 1985 and 1992. Setting.-Twenty US metropolitan cities with more than 250 000 residents. Results.-Since 1981, Baltimore experienced the greatest decline in TB incidence (35.6 cases per 100 000 population, 1981; 17.2 cases per 100 000 population, 1992 [-51.7%]), and city rank for TB (sixth in 1981, 28th in 1992). Conversely, the average incidence of TB increased 2.1% in the five-city cohort and increased 1.8% in the 19-city cohort. Since 1985, TB incidence increased 35.3% in the five-city cohort and 28.5% in the 19-city cohort, but declined 29.5% in Baltimore, From 1986 through 1992, Baltimore's DOT-managed cases had the highest annual SCRs at 3 months (mean, 90.7%), and the highest completion rates for standard anti-TB therapy (mean, 90.1%) when compared with the five cities, These trends could not be attributed to differentials in AIDS, immigration, poverty, or unemployment. Increasingly, more Baltimore cases were treated under DOT (86.5%, 1993) over time. Disease relapse rates remained low, even among HIV-infected patients, Within Baltimore, the documented SCR was significantly higher among DOT-managed cases compared with non-DOT-managed cases (P<.05); multidrug resistance remains rare (0.57%). Within Maryland, Baltimore accounted for 44.4% of all TB cases in 1981, compared with 28.7% in 1992 (P<.001). Conclusions.-In contrast to the national TB upswing during the 1980s, Baltimore experienced a substantial decline in TB following implementation of community-based DOT, despite highly prevalent medicosocial risk factors. Directly observed therapy facilitated high treatment completion rates and bacteriologic evidence of cure. Directly observed therapy could help reduce TB incidence in the United States, particularly in cities with high case rates.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; ANNIE E CASEY FDN,BALTIMORE,MD 21202; BALTIMORE CITY DEPT HLTH,DIV PREVENT MED & EPIDEMIOL,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								ADDINGTON WW, 1979, CHEST, V76, pS741; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; [Anonymous], 1981, Lancet, V1, P171; BARNHOORN F, 1992, SOC SCI MED, V34, P291, DOI 10.1016/0277-9536(92)90271-Q; BAYER R, 1993, AM J PUBLIC HEALTH, V83, P649, DOI 10.2105/AJPH.83.5.649; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; CHAULK CP, 1994, JAMA-J AM MED ASSOC, V271, P103, DOI 10.1001/jama.1994.03510260027017; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; DEAN AG, 1990, EPI INFO VERSION 5; Farmer P, 1991, Semin Respir Infect, V6, P254; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; GLASSER D, 1979, B INT UNION TUBERC, V54, P57; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HUDSON LD, 1973, JAMA-J AM MED ASSOC, V223, P139, DOI 10.1001/jama.223.2.139; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; ISEMAN MD, 1991, AM REV RESPIR DIS, V143, P697, DOI 10.1164/ajrccm/143.4_Pt_1.697; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MCDONALD RJ, 1982, ANN INTERN MED, V96, P297, DOI 10.7326/0003-4819-96-3-297; MOODIE AS, 1970, PUBLIC HEALTH REP, V85, P955, DOI 10.2307/4594014; MOODIE AS, 1967, AM REV RESPIR DIS, V96, P384; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; NAZARSTEWART V, 1992, AM REV RESPIR DIS, V146, P57, DOI 10.1164/ajrccm/146.1.57; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RUBEL AJ, 1992, PUBLIC HEALTH REP, V107, P626; SBARBARO JA, 1985, CLIN CHEST MED, V1, P253; SELIK RM, 1993, JAMA-J AM MED ASSOC, V263, P2991; SELWYN PA, 1989, ANN INTERN MED, V110, P761; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1991, ANN TUBERCULOSIS STA; 1992, AM REV RESPIR DIS, V146, P1623; 1980, 1980 CENSUS POPULATI, pCHD; 1984, AM REV RESPIR DIS, V129, P921; 1991, B INT UNION TUBERC L, V66, P61; 1993, AM J PUBLIC HEALTH, V83, P647; 1993, MMWR-MORBID MORTAL W, V42, P74; 1994, 1992 TUBERCULOSIS ST; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, 1990 CENSUS POPULATI; 1983, 1980 CENSUS POPULATI, pCHA; 1994, MMWR-MORBID MORTAL W, V43, P361; 1989, 1990 CENSUS POPULATI; 1989, MMWR-MORBID MORTAL W, V38, P1; 1993, TUBERCULOSIS PROGRAM; 1992, HIV AIDS SURVEILLANC; 1992, 1990 TUBERCULOSIS ST; 1992, MMWR-MORBID MORTAL W, V41, P507; 1992, MMWR-MORBID MORTAL W, V41, P1	54	202	205	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					945	951		10.1001/jama.274.12.945	http://dx.doi.org/10.1001/jama.274.12.945			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674524				2022-12-28	WOS:A1995RV73400028
J	FRIGOLETTO, FD; LIEBERIAN, E; LANG, JM; COHEN, A; BARSS, V; RINGER, S; DATTA, S				FRIGOLETTO, FD; LIEBERIAN, E; LANG, JM; COHEN, A; BARSS, V; RINGER, S; DATTA, S			A CLINICAL-TRIAL OF ACTIVE MANAGEMENT OF LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CESAREAN-SECTION; HOUSE; HORNE	Background. Active management of labor is a multifaceted program that, as implemented at the National Maternity Hospital in Dublin, is associated with a lower rate of cesarean delivery than the rate usually found in the United States. We conducted a randomized trial to evaluate the efficacy of this approach in lowering the rate of cesarean section among women delivering their first babies. Methods. We randomly assigned 1934 nulliparous women at low risk of complications of pregnancy, before 30 weeks' gestation, to active management of labor or to a usual-care group. The components of active management were customized childbirth classes; strict criteria for the diagnosis of labor; standardized management of labor, including early amniotomy and treatment with high-dose oxytocin; and one-to-one nursing. A low-risk subgroup was defined as including women with full-term, uncomplicated pregnancies who spontaneously went into labor (the protocol-eligible subgroup). Women meeting these criteria who had been randomly assigned to the active-management group were admitted to a separate unit where their labor was managed by trained, certified nurse-midwives. Results. There was no difference between groups in the rate of cesarean section either among all women (active management, 19.5 percent; usual care, 19.4 percent) or in the protocol-eligible subgroup (active management, 10.9 percent; usual care, 11.5 percent). In the protocol-eligible subgroup, the median duration of labor was shortened by 2.7 hours by active management (from 8.9 to 6.2 hours), and the rate of maternal fever was lower (7 percent vs. 11 percent, P = 0.007). The percentage of women in whom labor lasted longer than 12 hours was three times higher in the usual-care group than in the active-management group (26 percent vs, 9 percent, P<0.001). Conclusions. Active management of labor did not reduce the rate of cesarean section in nulliparous women but was associated with a somewhat shorter duration of labor and less maternal fever.	BRIGHAM & WOMENS HOSP,DEPT NEWBORN MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT OBSTET & GYNECOL,HARVARD COMMUNITY HLTH PLAN,BOSTON,MA 02115; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Boston University			Ringer, Steven/GQA-9604-2022		NICHD NIH HHS [R01-HD2681304] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026813] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKOURY HA, 1988, AM J OBSTET GYNECOL, V158, P255, DOI 10.1016/0002-9378(88)90133-0; FREEMAN RK, 1992, GUIDELINES PERINATAL; LEVENO KJ, 1989, AM J OBSTET GYNECOL, V160, P78, DOI 10.1016/0002-9378(89)90090-2; LEVENO KJ, 1985, AM J OBSTET GYNECOL, V153, P838, DOI 10.1016/0002-9378(85)90686-6; LOPEZZENO JA, 1992, NEW ENGL J MED, V326, P50; ODRISCOLL K, 1993, ACTIVE MANAGEMENT LA; ROETHLISBERGER FJ, 1939, MNAGEMENT WORKER ACC; TURNER MJ, 1988, OBSTET GYNECOL, V71, P150; 1995, TECHNICAL B AM COLLE, V207	9	182	183	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					745	750		10.1056/NEJM199509213331201	http://dx.doi.org/10.1056/NEJM199509213331201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643880	Bronze			2022-12-28	WOS:A1995RU80900001
J	KIOWSKI, W; SUTSCH, G; HUNZIKER, P; MULLER, P; KIM, J; OECHSLIN, E; SCHMITT, R; JONES, R; BERTEL, O				KIOWSKI, W; SUTSCH, G; HUNZIKER, P; MULLER, P; KIM, J; OECHSLIN, E; SCHMITT, R; JONES, R; BERTEL, O			EVIDENCE FOR ENDOTHELIN-1-MEDIATED VASOCONSTRICTION IN SEVERE CHRONIC HEART-FAILURE	LANCET			English	Article							PULMONARY-HYPERTENSION; ENDOTHELIN; VASODILATOR; REVERSAL; MUSCLE; PLASMA; BRAIN	Heart failure is commonly associated with high plasma concentrations of endothelin-1, a powerful vasoconstrictor produced by endothelium. The role of endogenously released endothelin-1 in the maintenance of vascular tone in chronic heart failure was administration of an endothelin bosentan. 24 patients with chronic heart failure received randomly and double blind two intravenous infusions of either placebo or bosentan (100 mg followed after 60 min by 200 mg). Systemic haemodynamics and plasma endothelin-1 and big-endothelin-1 concentrations were determined before and repeatedly during the 120 min observation period. Baseline endothelin-1 and big-endothelin-1 concentrations, which were above the normal range in all patients, correlated directly with the extent of pulmonary hypertension, with left and right heart filling pressures, and with pulmonary vascular resistance and inversely with cardiac index. Compared with placebo, bosentan reduced mean arterial pressure by 7.7% (95% Cl 7.1-9.7), pulmonary artery pressure by 13.7% (10.5-16.9), right atrial pressure by 18.2% (12.0-24.4), and pulmonary artery wedged pressure by 8.6% (5.3-12.0); it increased cardiac index by 13.6% (9.1-18.2), decreased systemic vascular resistance by 16.5% (13.2-19.8), and decreased pulmonary vascular resistance by 33.2% (22.4-44.0). Heart rate did not change. Plasma endothelin-1 concentrations rose more than twofold from baseline in bosentan recipients while big-endothelin-1 concentrations were unchanged. These findings indicate that, in patients with chronic heart failure who have high circulatory endothelin-1 concentrations, this peptide contributes to maintenance of vascular tone. The acute haemodynamic effects of bosentan suggest that chronic endothelin antagonism could be beneficial in such patients.	UNIV ZURICH HOSP,DEPT INTERNAL MED,DIV CARDIOL,ZURICH,SWITZERLAND; TRIEMLI HOSP,DEPT INTERNAL MED,DIV CARDIOL,ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,DIV CLIN PHARMACOL,CH-4002 BASEL,SWITZERLAND	University of Zurich; University Zurich Hospital; Triemli Hospital; Roche Holding			Oechslin, Erwin/AAU-3377-2020	Oechslin, Erwin/0000-0001-7084-8494				ADMIRAAL PJJ, 1990, HYPERTENSION, V15, P44, DOI 10.1161/01.HYP.15.1.44; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CODY RJ, 1992, CIRCULATION, V85, P504, DOI 10.1161/01.CIR.85.2.504; ELLENBOGEN KA, 1989, CIRCULATION, V79, P51, DOI 10.1161/01.CIR.79.1.51; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; HOLT P, 1986, EUR J CLIN PHARMACOL, V31, P9, DOI 10.1007/BF00870978; ITOH S, 1991, AM J PHYSIOL, V260, pH1106, DOI 10.1152/ajpheart.1991.260.4.H1106; KAPPELGAARD AM, 1976, CLIN CHIM ACTA, V67, P299; KIOWSKI W, 1987, AM J CARDIOL, V59, P1118, DOI 10.1016/0002-9149(87)90859-9; KIOWSKI W, 1994, CIRCULATION, V90, P27, DOI 10.1161/01.CIR.90.1.27; KIOWSKI W, 1991, CIRCULATION, V83, P469, DOI 10.1161/01.CIR.83.2.469; LERMAN A, 1991, CIRCULATION, V83, P1808, DOI 10.1161/01.CIR.83.5.1808; Loeffler B., 1994, ENDOTHELIUM, V1, P273, DOI [10.3109/10623329409100966, DOI 10.3109/10623329409100966]; MATSUMURA K, 1994, AM J PHYSIOL, V266, pR1403, DOI 10.1152/ajpregu.1994.266.4.R1403; MEFFORD IN, 1981, J NEUROSCI METH, V3, P207, DOI 10.1016/0165-0270(81)90056-X; OHLSTEIN EH, 1993, J CARDIOVASC PHARM, V22, P321; PATEL TR, 1994, EUR J PHARMACOL, V260, P65, DOI 10.1016/0014-2999(94)90010-8; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; SORENSEN SS, 1994, AM J PHYSIOL, V266, pF411, DOI 10.1152/ajprenal.1994.266.3.F411; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; TSUTAMOTO T, 1994, J AM COLL CARDIOL, V23, P1427, DOI 10.1016/0735-1097(94)90387-5; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANE JR, 1993, J LIPID MEDIATOR, V6, P395; WALSH WF, 1981, CIRCULATION, V64, P499, DOI 10.1161/01.CIR.64.3.499; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580; WEITZBERG E, 1993, CLIN PHYSIOL, V13, P653, DOI 10.1111/j.1475-097X.1993.tb00480.x; YANAGISAWA M, 1989, NATURE, V332, P411	30	499	506	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					732	736		10.1016/S0140-6736(95)91504-4	http://dx.doi.org/10.1016/S0140-6736(95)91504-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658874				2022-12-28	WOS:A1995RU81000010
J	GROVER, SA; COUPAL, L; HU, XF				GROVER, SA; COUPAL, L; HU, XF			IDENTIFYING ADULTS AT INCREASED RISK OF CORONARY-DISEASE - HOW WELL DO THE CURRENT CHOLESTEROL GUIDELINES WORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESEARCH CLINICS PREVALENCE; HEART-DISEASE; LIPOPROTEIN-CHOLESTEROL; SERUM-CHOLESTEROL; FRAMINGHAM; MORTALITY; PREDICTION; LIPIDS; COST; MEN	Objective. To assess the accuracy of lipid screening strategies to identify individuals at increased risk of coronary heart disease mortality. Patients.-The 15% random sample of adults recruited into the Lipid Research Clinic Prevalence and Follow-up Studies, which included 3678 men and women aged 35 to 74 years. Total plasma cholesterol levels, lipoprotein fractions, and other coronary risk factors at study entry were compared with subsequent coronary heart disease mortality (mean follow-up, 12.2 years). Outcome Measures.-The areas under receiver operating characteristic curves for blood lipids, lipid ratios, the screening guidelines proposed by the National Cholesterol Education Program, those of the Canadian Consensus Conference on Cholesterol, and a coronary risk model that used Framingham data. Main Results.-The current National Cholesterol Education Program guidelines (area under the curve, 0.74) were significantly (P=.03) more accurate than the old National Cholesterol Education Program guidelines (area, 0.72). The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level (area, 0.72) was as accurate as current National Cholesterol Education Program guidelines. The coronary risk model (area, 0.85) was superior (P<.003) to all other screening maneuvers, Compared with the current National Cholesterol Education Program guidelines, the risk model demonstrated superior test sensitivity (70% vs 45%) with only slightly reduced specificity (82% vs 86%). Conclusion.-The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level is as accurate as current American screening guidelines, Future guidelines should better incorporate high-density lipoprotein cholesterol levels and nonlipid risk factors to target high-risk individuals accurately.	MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DIV GEN INTERNAL MED,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOSTAT & EPIDEMIOL,MONTREAL,PQ,CANADA	McGill University; McGill University; McGill University; McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,1650 CEDAR AVE,MONTREAL,PQ H3G 1A4,CANADA.			Coupal, Louis/0000-0003-0828-9665				ABBOTT RD, 1982, PREV MED, V11, P131, DOI 10.1016/0091-7435(82)90013-5; ABBOTT RD, 1987, US DHEW NIH872284 PU; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BUSH TL, 1991, CIRCULATION, V83, P1287, DOI 10.1161/01.CIR.83.4.1287; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COOPER GR, 1992, JAMA-J AM MED ASSOC, V267, P1652, DOI 10.1001/jama.267.12.1652; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; HANLEY JA, 1988, RADIOLOGY, V148, P889; HEISS G, 1980, CIRCULATION, V61, P302, DOI 10.1161/01.CIR.61.2.302; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; MARTIN MJ, 1986, LANCET, V2, P933; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; METZ CE, 1984, INFORMATION PROCESSI, P432; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WILSON PWF, 1987, AM J CARDIOL, V59, pG91, DOI 10.1016/0002-9149(87)90165-2; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; 1974, REFERENCE MANUAL LIP, V1; 1981, HLTH CANADIANS REPOR; 1988, CAN MED ASSOC J, V139, P1; 1974, REFERENCE MANUAL LIP, V2; 1978, CORONARY RISK HDB ES; 1988, ARCH INTERN MED, V148, P36; 1993, JAMA-J AM MED ASSOC, V269, P8015; 1989, LIFE TABLES CANADA P; 1974, MANUAL LABORATORY OP, V1; 1984, JAMA-J AM MED ASSOC, V251, P351; 1979, CIRCULATION, V60, P427	35	185	187	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					801	806		10.1001/jama.274.10.801	http://dx.doi.org/10.1001/jama.274.10.801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650803				2022-12-28	WOS:A1995RU32400027
J	GOODWIN, S				GOODWIN, S			HELICOBACTERS SHED NEW LIGHT ON CHAPERONINS	LANCET			English	Editorial Material							PYLORI; PROTEIN				GOODWIN, S (corresponding author), UNITED ARAB EMIRATES UNIV,FAC MED,DEPT MED MICROBIOL,AL AIN,U ARAB EMIRATES.							AUSTIN JW, 1992, J BACTERIOL, V174, P7470, DOI 10.1128/jb.174.22.7470-7473.1992; COATES ARM, 1993, MOL MICROBIOL, V8, P787, DOI 10.1111/j.1365-2958.1993.tb01624.x; COATES ARM, IN PRESS CHAPERONINS; DOIDGE C, 1994, LANCET, V343, P919; DUNN BE, 1992, INFECT IMMUN, V60, P1946, DOI 10.1128/IAI.60.5.1946-1951.1992; ESCHWEILER B, 1993, ZBL BAKT-INT J MED M, V280, P73, DOI 10.1016/S0934-8840(11)80942-4; Ferrero R. L., 1995, Gut, V37, pA51; Ghiara P., 1995, Gut, V37, pA51; GOODWIN CS, 1990, EUR J CLIN MICROBIOL, V9, P1, DOI 10.1007/BF01969526; Kansau Imad, 1995, Gut, V37, pA65; Monath T. P., 1995, Gut, V37, pA52; Phadnis S. H., 1995, Gut, V37, pA19; SUERBAUM S, 1994, MOL MICROBIOL, V14, P959, DOI 10.1111/j.1365-2958.1994.tb01331.x; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	14	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					653	655		10.1016/S0140-6736(95)92275-X	http://dx.doi.org/10.1016/S0140-6736(95)92275-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658815				2022-12-28	WOS:A1995RU04800004
J	KRUMM, A; GROUDINE, M				KRUMM, A; GROUDINE, M			TUMOR SUPPRESSION AND TRANSCRIPTION ELONGATION - THE DIRE CONSEQUENCES OF CHANGING PARTNERS	SCIENCE			English	Editorial Material							RNA; ANTITERMINATION		UNIV WASHINGTON,SCH MED,DEPT RADIAT ONCOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KRUMM, A (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104, USA.							ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; DUAN RD, 1995, SCIENCE, V269, P1402; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KEPHART DD, 1992, MOL CELL BIOL, V12, P2078; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; NUDLER E, 1995, HARVEY LECT, V81, P353; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REINES D, 1994, TRANSCRIPTION MECHAN, P264; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	21	31	31	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1400	1401		10.1126/science.7660121	http://dx.doi.org/10.1126/science.7660121			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660121				2022-12-28	WOS:A1995RT80600037
J	KETCHUM, KA; JOINER, WJ; SELLERS, AJ; KACZMAREK, LK; GOLDSTEIN, SAN				KETCHUM, KA; JOINER, WJ; SELLERS, AJ; KACZMAREK, LK; GOLDSTEIN, SAN			A NEW FAMILY OF OUTWARDLY RECTIFYING POTASSIUM CHANNEL PROTEINS WITH 2 PORE DOMAINS IN TANDEM	NATURE			English	Article							EXPRESSION; K+	POTASSIUM channels catalyse the permeation of K+ ions across cellular membranes and are identified by a common structural moth, a highly conserved signature sequence of eight amino acids in the P domain of each channel's pore-forming alpha-subunit(1,2), Here we describe a novel K+ channel (TOK1) from Saccharomyces cerevisiae that contains two P domains within one continuous polypeptide, Xenopus laevis oocytes expressing the channel exhibit a unique, outwardly rectifying, K+-selective current. The channel is permeable to outward how of ions at membrane potentials above the K+ equilibrium potential; its conduction-voltage relationship is thus sensitive to extracellular K+ ion concentration. In excised membrane patches, external divalent cations block the channel in a voltage-dependent manner, and their removal in this configuration allows inward channel current, These attributes are similar to those described for inwardly rectifying K+ channels(3,4), but in the opposite direction, a previously uorecognized channel behaviour. Our results identify a new class of K+ channel which is distinctive in both its primary structure and functional properties. Structural homologues of the channel are present in the genome of Caenorhabditis elegans.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT GENET,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06536	Yale University; Yale University; Yale University	KETCHUM, KA (corresponding author), YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PEDIAT,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MIOSGA T, 1994, YEAST, V10, P965, DOI 10.1002/yea.320100712; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	24	344	359	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					690	695		10.1038/376690a0	http://dx.doi.org/10.1038/376690a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651518	Green Submitted			2022-12-28	WOS:A1995RQ67200061
J	ENGEL, A; HAYERHARTL, MK; GOLDIE, KN; PFEIFER, G; HEGERL, R; MULLER, S; DASILVA, ACR; BAUMEISTER, W; HARTL, FU				ENGEL, A; HAYERHARTL, MK; GOLDIE, KN; PFEIFER, G; HEGERL, R; MULLER, S; DASILVA, ACR; BAUMEISTER, W; HARTL, FU			FUNCTIONAL-SIGNIFICANCE OF SYMMETRICAL VERSUS ASYMMETRICAL GROEL-GROES CHAPERONIN COMPLEXES	SCIENCE			English	Article							ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; CENTRAL CAVITY; PROTEIN; HYDROLYSIS; SURFACE; BINDING	The Escherichia coli chaperonin GroEL and its regulator GroES are thought to mediate adenosine triphosphate-dependent protein folding as an asymmetrical complex, with substrate protein bound within the GroEL cylinder. In contrast, a symmetrical complex formed between one GroEL and two GroES oligomers, with substrate protein binding to the outer surface of GroEL, was recently proposed to be the functional chaperonin unit. Electron microscopic and biochemical analyses have now shown that unphysiologically high magnesium concentrations and increased pH are required to assemble symmetrical complexes, the formation of which precludes the association of unfolded polypeptide. Thus, the functional significance of GroEL:(GroES)(2) particles remains to be demonstrated.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; MAX PLANCK INST BIOCHEM, D-82150 MARTINSRIED, GERMANY	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Max Planck Society	ENGEL, A (corresponding author), UNIV BASEL, BIOZENTRUM, MAURICE E MULLER INST, CH-4056 BASEL, SWITZERLAND.		Hartl, F. Ulrich/Y-8206-2019; Hayer-Hartl, Manajit/V-8078-2017	Hayer-Hartl, Manajit/0000-0001-8213-6742	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRANK J, 1988, J MICROSC-OXFORD, V150, P99, DOI 10.1111/j.1365-2818.1988.tb04602.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5664	31	81	82	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					832	836		10.1126/science.7638600	http://dx.doi.org/10.1126/science.7638600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638600				2022-12-28	WOS:A1995RN65000043
J	WEISSMAN, MM; OLFSON, M				WEISSMAN, MM; OLFSON, M			DEPRESSION IN WOMEN - IMPLICATIONS FOR HEALTH-CARE RESEARCH	SCIENCE			English	Article							PSYCHIATRIC EPIDEMIOLOGY; PUERPERAL PSYCHOSES; MENTAL-DISORDERS; SOCIAL STRESS; PREGNANCY; POSTPARTUM; PREVALENCE; GENDER; PSYCHOTHERAPY; COMMUNITY	Epidemiologic data from around the world demonstrate that major depression is approximately twice as common in women than men and that its first onset peaks during the childbearing years. Progress has been made in understanding the epidemiology of depression and in developing effective treatments. Much remains to be learned about the basic pathogenesis of depression and the specific treatment needs of depressed women and their offspring, especially during the reproductive years.	NEW YORK STATE PSYCHIAT INST & HOSP, DIV CLIN & GENET EPIDEMIOL, NEW YORK, NY 10032 USA	New York State Psychiatry Institute	WEISSMAN, MM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA.		Olfson, Mark/AAA-8547-2021	Weissman, Myrna/0000-0003-3490-3075				[Anonymous], 1993, AM J PSYCHIAT, V150, P1; BALDWIN JA, 1989, ACTA PSYCHIAT SCAND, V80, P37, DOI 10.1111/j.1600-0447.1989.tb07167.x; BRESLAU N, IN PRESS PSYCHIATRY; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BROCKINGTON IF, 1990, BRIT J PSYCHIAT, V157, P331, DOI 10.1192/bjp.157.3.331; CANINO GJ, 1987, ARCH GEN PSYCHIAT, V44, P727; COHEN LS, 1992, CURR AFFECTIVE ILLNE, V11, P5; DAVIDSON J, 1985, ACTA PSYCHIAT SCAND, V71, P451, DOI 10.1111/j.1600-0447.1985.tb05057.x; DIMASCIO A, 1979, ARCH GEN PSYCHIAT, V36, P1450; DOWLATSHAHI D, 1990, PSYCHOL MED, V20, P655, DOI 10.1017/S0033291700017177; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FARAVELLI C, 1990, J AFFECT DISORDERS, V20, P135, DOI 10.1016/0165-0327(90)90127-T; FRANK E, 1988, AM J PSYCHIAT, V145, P41; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; GARVEY MJ, 1984, J REPROD MED, V29, P113; GLASSMAN AH, 1977, ARCH GEN PSYCHIAT, V34, P197; GOTLIB IH, 1989, J CONSULT CLIN PSYCH, V57, P269, DOI 10.1037/0022-006X.57.2.269; HOHMANN AA, 1989, MED CARE, V27, P478, DOI 10.1097/00005650-198905000-00004; KARAM E, 1991, OCT M INT TRAUM STRE; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KENDELL RE, 1985, J PSYCHOSOM RES, V29, P3, DOI 10.1016/0022-3999(85)90003-0; KERNS LL, 1986, J NERV MENT DIS, V174, P652, DOI 10.1097/00005053-198611000-00003; KESSLER RC, 1981, J HEALTH SOC BEHAV, V22, P49, DOI 10.2307/2136367; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KITAMURA T, 1993, PSYCHOL MED, V23, P967, DOI 10.1017/S003329170002643X; KLERMAN GL, 1974, AM J PSYCHIAT, V131, P186, DOI 10.1176/ajp.131.2.186; KUMAR R, 1993, PROG NEURO-PSYCHOPH, V17, P571, DOI 10.1016/0278-5846(93)90006-E; LEE CK, 1990, J NERV MENT DIS, V178, P242, DOI 10.1097/00005053-199004000-00004; LEPINE J P, 1989, Psychiatrie and Psychobiologie, V4, P267; MARTIN CJ, 1989, J AFFECT DISORDERS, V16, P283, DOI 10.1016/0165-0327(89)90083-9; Mastroianni AC, 1994, WOMEN HLTH RES ETHIC, VI; Miller L J, 1991, Psychiatr Med, V9, P275; Montgomery Stuart A., 1995, P1043; MORTOLA JF, 1989, PSYCHIAT CLIN N AM, V12, P69; OHARA MW, 1991, ARCH GEN PSYCHIAT, V48, P801; ORN H, 1988, ACTA PSYCHIAT SCAND, V77, P17, DOI 10.1111/j.1600-0447.1988.tb08543.x; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; ROBINS LN, 1991, PSYCHIATRIC DISORDER; ROHE GH, 1893, JAMA-J AM MED ASSOC, V21, P325; ROHE GH, 1993, JAMA-J AM MED ASSOC, V270, P1180; SARGEANT JK, 1990, ARCH GEN PSYCHIAT, V47, P519; SCHATZBERG AF, 1991, MANUAL CLIN PSYCHOPH, P315; SIMON G, 1995, AM J PSYCHIAT, V152, P352; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TUETH MJ, 1993, JAMA-J AM MED ASSOC, V270, P2177, DOI 10.1001/jama.1993.03510180047018; VIGGEDAL G, 1993, J CHILD PSYCHOL PSYC, V34, P295, DOI 10.1111/j.1469-7610.1993.tb00993.x; Weissman M.M., 1994, WORLD PSYCHIATR ASS, V2, P1; WEISSMAN MM, 1987, ARCH GEN PSYCHIAT, V44, P847; WEISSMAN MM, 1992, JAMA-J AM MED ASSOC, V268, P3098, DOI 10.1001/jama.1992.03490210080039; WELLS JE, 1989, AUST NZ J PSYCHIAT, V23, P315, DOI 10.3109/00048678909068289; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788; WISNER KL, 1993, AM J PSYCHIAT, V150, P1541; WITTCHEN HU, 1992, EUR ARCH PSY CLIN N, V241, P247, DOI 10.1007/BF02190261; WOLK SI, 1995, REV PSYCHIATRY, V14, pCH9; YONKERS KA, 1992, AM J PSYCHIAT, V149, P587; YONKERS KA, 1995, REV PSYCHIATRY, V2, P307; ZUCKERMAN B, 1990, J DEV BEHAV PEDIATR, V11, P190; 1993, 930551 US DEP HLTH H; 1980, DIAGNOSTIC STATISTIC	60	346	356	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					799	801		10.1126/science.7638596	http://dx.doi.org/10.1126/science.7638596			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638596	Green Submitted			2022-12-28	WOS:A1995RN65000034
J	FLETCHER, J; HICKS, NR; KAY, JDS; BOYD, PA				FLETCHER, J; HICKS, NR; KAY, JDS; BOYD, PA			USING DECISION-ANALYSIS TO COMPARE POLICIES FOR ANTENATAL SCREENING FOR DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							APPRAISAL; MARKERS; WOMEN	Objective-To compare different screening policies for Down's syndrome across a broad range of outcomes, using decision analysis, with particular reference to the role of maternal serum testing. Design-A decision tree was used to combine data from local sources and the medical literature to predict the likely frequency of several outcomes. Sensitivity analyses were used to test the robustness of the conclusions drawn. Setting-Oxfordshire Health Authority. Main outcome measures-live births with and without Down's syndrome; miscarriages with Down's syndrome; cases of Down's detected antenatally; amniocenteses (and associated miscarriages); direct NHS screening costs; number of women offered screening. Results-Screening policies for Down's syndrome that include serum testing can produce better population outcomes than programmes that do not. Each option for screening for Down's syndrome that we considered had significant drawbacks. In Oxfordshire, offering serum testing to women of all ages would prevent the birth of approximately one more baby with Down's syndrome per year than would a policy of screening for women aged 30 years or more. The cost of preventing this one extra Down's birth would be one or two normal babies lost after amniocentesis, 4500 blood tests for young women (with the associated anxiety and counselling), approximately 200 false positive serum test results and amniocenteses (with the associated anxiety and distress), and pound 90 000 for the extra tests, counselling, and amniocenteses. Opinions are divided as to which policy is the better option for the population. Conclusions-Decision analysis is a useful tool for determining the likely consequences of different policy options across a broad range of outcomes. This focuses debate and decision making on outcomes of care, which in turn makes it clear that the choice of screening programme for Down's syndrome depends on the relative importance ascribed to the different outcomes. If individuals' values vary widely it may be impossible to find one screening policy that meets the needs of all pregnant women.	OXFORDSHIRE HLTH AUTHOR,DEPT PUBL HLTH & HLTH POLICY,OXFORD OX3 7LG,ENGLAND; JOHN RADCLIFFE HOSP,DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT MATERN,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford				Hicks, Nicholas/0000-0002-7214-9678				AGER RP, 1987, LANCET, V2, P566; BHATTI N, 1992, BRIT MED J, V305, P770, DOI 10.1136/bmj.305.6856.770-a; CONNOR M, 1993, BRIT MED J, V306, P1705, DOI 10.1136/bmj.306.6894.1705; CUCKLE H, 1992, LANCET, V340, P799, DOI 10.1016/0140-6736(92)92349-K; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HICKS C, 1994, INDEPENDENT     0125, P20; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KEATINGE R, 1993, BRIT MED J, V307, P501, DOI 10.1136/bmj.307.6902.501-c; KEATINGE R, 1992, LANCET, V340, P1034, DOI 10.1016/0140-6736(92)93042-L; MACDONALD ML, 1991, OBSTET GYNECOL, V77, P963; MACRI VJ, 1992, BRIT MED J, V305, P768, DOI 10.1136/bmj.305.6856.768-b; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; MARTEAU TM, 1993, BMJ-BRIT MED J, V307, P146, DOI 10.1136/bmj.307.6897.146; OLIVER RWA, 1988, LANCET, V1, P709; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; REYNOLDS TM, 1993, OBSTET GYNECOL, V81, P447; SHACKLEY P, 1993, J PUBLIC HEALTH MED, V15, P175; SHACKLEY P, 1994, J PUBLIC HLTH MED, V16, P116; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; Stratham Helen, 1993, British Medical Journal, V307, P174; TABOR A, 1986, LANCET, V1, P1287; THORNTON JG, 1992, BRIT MED J, V298, P1099; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WISHART JG, 1991, BRIT MED J, V303, P468, DOI 10.1136/bmj.303.6800.468-c; 1993, BIOCH DETECTION DOWN	29	30	30	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					351	356		10.1136/bmj.311.7001.351	http://dx.doi.org/10.1136/bmj.311.7001.351			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640539	Green Published			2022-12-28	WOS:A1995RN46900012
J	LENSKI, RE; MITTLER, JE				LENSKI, RE; MITTLER, JE			THE DIRECTED MUTATION CONTROVERSY AND NEODARWINISM	SCIENCE			English	Article							MULTIPLE SPONTANEOUS MUTATIONS; ESCHERICHIA-COLI; ADAPTIVE EVOLUTION; MUTANTS; SELECTION; MUTAGENESIS; HYPOTHESIS; RESISTANCE; ORIGIN; OCCUR	According to neo-Darwinian theory, random mutation produces genetic differences among organisms whereas natural selection tends to increase the frequency of advantageous alleles. However, several recent papers claim that certain mutations in bacteria and yeast occur at much higher rates specifically when the mutant phenotypes are advantageous. Various molecular models have been proposed that might explain these directed mutations, but the models have not been confirmed. Critics contend that studies purporting to demonstrate directed mutation lack certain controls and fail to account adequately for population dynamics. Further experiments that address these criticisms do not support the existence of directed mutations.	EMORY UNIV, DEPT BIOL, ATLANTA, GA 30322 USA	Emory University	LENSKI, RE (corresponding author), MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA.			Lenski, Richard/0000-0002-1064-8375				ARMITAGE P, 1952, J ROY STAT SOC B, V14, P1; BENNETT JACK, 1960, HEREDITY, V15, P65, DOI 10.1038/hdy.1960.58; BENSON SA, 1988, NATURE, V336, P21, DOI 10.1038/336021c0; BENSON SA, 1991, GENETICS, V129, P647; BOE L, 1990, MOL MICROBIOL, V4, P597, DOI 10.1111/j.1365-2958.1990.tb00628.x; BOE L, 1991, MOL MICROBIOL, V5, P2541, DOI 10.1111/j.1365-2958.1991.tb02100.x; CAIRNS J, 1990, NATURE, V345, P213, DOI 10.1038/345213a0; CAIRNS J, 1988, NATURE, V336, P527, DOI 10.1038/336527c0; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CAMPBELL A, 1983, EVOLUTION GENES PROT, pCH13; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; CHARLESWORTH D, 1988, NATURE, V336, P525, DOI 10.1038/336525a0; Darwin C., 1877, ORIGIN SPECIES; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DEMEREC M, 1948, J BACTERIOL, V56, P63, DOI 10.1128/JB.56.1.63-74.1948; DEMEREC M, 1945, P NATL ACAD SCI USA, V34, P425; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1992, J BACTERIOL, V174, P1711, DOI 10.1128/jb.174.6.1711-1716.1992; FUTUYMA DJ, 1986, EVOLUTIONARY BIOL, P76; HALL BG, 1977, J BACTERIOL, V129, P540, DOI 10.1128/JB.129.1.540-543.1977; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1991, P NATL ACAD SCI USA, V88, P5882, DOI 10.1073/pnas.88.13.5882; HALL BG, 1991, GENETICA, V84, P73, DOI 10.1007/BF00116545; HALL BG, 1989, GENOME, V31, P265, DOI 10.1139/g89-044; HALL BG, 1991, NEW BIOL, V3, P729; HALL BG, 1990, GENETICS, V126, P5; HALL BG, 1992, P NATL ACAD SCI USA, V89, P4300, DOI 10.1073/pnas.89.10.4300; Jacobs Ferdinand, 1961, SEXUALITY GENETICS B, P3; JAYARAMAN R, 1992, J GENET, V71, P23, DOI 10.1007/BF02927873; KUSHNER SR, 1987, ESCHERICHIA COLI SAL, pCH61; Lamarck Jean--Baptiste, 1914, ZOOLOGICAL PHILOS; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LANDMAN OE, 1991, ANNU REV GENET, V25, P1, DOI 10.1146/annurev.ge.25.120191.000245; LEDERBERG J, 1989, GENETICS, V121, P395; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LEIGH EG, 1973, GENETICS, V73, P1; LENSKI RE, 1989, P NATL ACAD SCI USA, V86, P2775, DOI 10.1073/pnas.86.8.2775; LENSKI RE, 1984, GENETICS, V107, P1; LENSKI RE, 1989, TRENDS ECOL EVOL, V5, P148; LEVIN BR, 1983, COEVOLUTION, pCH5; Luria SE, 1943, GENETICS, V28, P491; LWOFF A, 1953, BACTERIOL REV, V17, P269, DOI 10.1128/MMBR.17.4.269-337.1953; MALAVASIC MJ, IN PRESS J MED VET M; Mayr E., 1982, GROWTH BIOL THOUGHT; MITTLER JE, 1990, NATURE, V345, P213, DOI 10.1038/345213b0; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; MITTLER JE, 1992, NATURE, V356, P446, DOI 10.1038/356446a0; NEWCOMBE HB, 1949, NATURE, V164, P50; NOVICK A, 1950, P NATL ACAD SCI USA, V36, P708, DOI 10.1073/pnas.36.12.708; PARTRIDGE L, 1988, NATURE, V336, P22, DOI 10.1038/336022a0; ROBERTSON BD, 1992, TRENDS GENET, V8, P422, DOI 10.1016/0168-9525(92)90325-X; RYAN FJ, 1952, J GEN MICROBIOL, V7, P69, DOI 10.1099/00221287-7-1-2-69; RYAN FJ, 1959, J GEN MICROBIOL, V21, P530, DOI 10.1099/00221287-21-3-530; RYAN FJ, 1955, GENETICS, V40, P726; RYAN FJ, 1952, NATURE, V169, P882, DOI 10.1038/169882b0; SARKAR S, 1991, BOST STUD PHILOS SCI, V129, P235; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEELE DF, 1992, GENETICS, V132, P9; STENT GS, 1971, MOL GENET, P144; STEWART FM, 1990, GENETICS, V124, P175; SYMONDS N, 1989, NATURE, V337, P119, DOI 10.1038/337119a0; TPASHNE M, 1986, GENETIC SWITCH GENE; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WITKIN EM, 1947, GENETICS, V32, P221; ZUGEL T, 1980, P NATL ACAD SCI USA, V77, P3529	68	147	149	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					188	194		10.1126/science.7678468	http://dx.doi.org/10.1126/science.7678468			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678468				2022-12-28	WOS:A1993KF71900020
J	ADAMS, SA; ROBSON, SC; GATHIRAM, V; JACKSON, TFHG; PILLAY, TS; KIRSCH, RE; MAKGOBA, MW				ADAMS, SA; ROBSON, SC; GATHIRAM, V; JACKSON, TFHG; PILLAY, TS; KIRSCH, RE; MAKGOBA, MW			IMMUNOLOGICAL SIMILARITY BETWEEN THE 170 KD AMEBIC ADHERENCE GLYCOPROTEIN AND HUMAN BETA-2 INTEGRINS	LANCET			English	Note							GALACTOSE-BINDING LECTIN; ENTAMOEBA-HISTOLYTICA; ANTIBODIES	Amoebiasis is an important cause of morbidity and mortality in developing countries. Virulence of Entamoeba histolytica depends on the trophozoite's being able to bind to colonic epithelium; binding is mediated by the 170 kD subunit of a 260 kD lectin. We found, by microcytofluorometry and western blotting studies, that this 170 kD subunit protein shares an epitope with human beta2 integrins-a subfamily of cell-surface glycoproteins expressed exclusively on leucocytes and involved in many adhesive and signalling interactions. The immunological similarity between these proteins may explain the trophozoite's ability to bind to and invade colonic epithelium.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,DIV MOLEC ENDOCRINOL,DU CANE RD,LONDON W12 0NN,ENGLAND; UNIV CAPE TOWN,SCH MED,MRC,LIVER RES CTR,CAPE TOWN,SOUTH AFRICA; UNIV NATAL,MRC,DURBAN,SOUTH AFRICA; UNIV NATAL,DEPT MED,DURBAN,SOUTH AFRICA	Imperial College London; University of Cape Town; University of Kwazulu Natal; University of Kwazulu Natal			Robson, Simon C./AAA-8537-2021	pillay, tahir/0000-0002-9982-9710	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHADEE K, 1987, J CLIN INVEST, V80, P1245, DOI 10.1172/JCI113199; JOYCE MP, 1988, AM J TROP MED HYG, V35, P159; MANN BJ, 1991, P NATL ACAD SCI USA, V88, P3248, DOI 10.1073/pnas.88.8.3248; PETRI WA, 1989, J BIOL CHEM, V264, P3007; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; PETRI WA, 1990, J IMMUNOL, V144, P4803; RAVDIN JI, 1990, J INFECT DIS, V162, P768, DOI 10.1093/infdis/162.3.768; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Walsh J.A., 1988, P93	10	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					17	19		10.1016/0140-6736(93)92483-A	http://dx.doi.org/10.1016/0140-6736(93)92483-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	7678048				2022-12-28	WOS:A1993KF02700006
J	IDJRADINATA, P; POLLITT, E				IDJRADINATA, P; POLLITT, E			REVERSAL OF DEVELOPMENTAL DELAYS IN IRON-DEFICIENT ANEMIC INFANTS TREATED WITH IRON	LANCET			English	Article							TEST-PERFORMANCE; THERAPY; SCORES; ANEMIA	Iron-deficient anaemic infants perform worse in tests of mental and motor development than do iron-sufficient infants of a comparable age. A randomised, double-blind trial was done to monitor the effects of iron supplementation on performance in the Bayley scales of mental and motor development among 12-18-month-old infants in Indonesia. Iron-deficient anaemic infants (n = 50) were assigned randomly to receive dietary ferrous sulphate or placebo for 4 months. Similar treatment randomisation was done among nonanaemic iron-deficient (n = 29) and iron-sufficient (n = 47) infants. Before intervention, the mean mental and motor scores of the iron-deficient anaemic infants were significantly (p < 0.01) lower than those of the nonanaemic iron-deficient and iron-sufficient classes. After intervention, developmental delays were reversed among iron-deficient anaemic infants who had received iron but they remained the same among placebo-treated iron-deficient anaemic infants. Neither ferrous sulphate nor placebo had significant effects on the scores of the other two iron-status classes. The poor performance of 12-18-month-old iron-deficient anaemic infants in the Bayley scales of mental and motor development can be improved to the level of performance of iron-sufficient infants by treatment with ferrous sulphate.	UNIV CALIF DAVIS,DEPT PEDIAT,DAVIS,CA 95616; PADJADJARAN STATE UNIV,FAC MED,DEPT CHILD HLTH,BANDUNG,INDONESIA; UNIV CALIF DAVIS,PROGRAM INT NUTR,DAVIS,CA 95616	University of California System; University of California Davis; Universitas Padjadjaran; University of California System; University of California Davis								AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; BAI DL, 1992, CHILD DEV, V63, P215, DOI 10.1111/j.1467-8624.1992.tb03608.x; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; Bertenthal B. I., 1984, CONTINUITIES DISCONT, P175, DOI DOI 10.1007/978-1-4613-2725-7_8; CALDWELL BM, 1975, INSTRUCTION MANUAL H; Cook T.C., 1979, QUASIEXPERIMENTATION; LOZOFF B, 1982, J PEDIATR-US, V101, P948, DOI 10.1016/S0022-3476(82)80016-4; LOZOFF B, 1987, PEDIATRICS, V79, P981; LOZOFF B, 1982, J PEDIATR-US, V100, P351, DOI 10.1016/S0022-3476(82)80428-9; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; OSKI FA, 1978, J PEDIATR-US, V92, P21, DOI 10.1016/S0022-3476(78)80063-8; Pocock SJ., 2013, CLIN TRIALS PRACTICA; POLLITT E, 1990, NUTR BRAIN, V8, P101; Pollitt E, 1990, ACTIVITY ENERGY EXPE, P279; POLLITT E, 1979, J PEDIATR, V92, P1977; WALTER T, 1983, J PEDIATR-US, V102, P519, DOI 10.1016/S0022-3476(83)80177-2; WALTER T, 1989, AM J CLIN NUTR, V50, P655, DOI 10.1093/ajcn/50.3.655; 1977, NCHS GROWTH CURVES C; 1968, JAMA-J AM MED ASSOC, V203, P407	19	305	318	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					1	4		10.1016/0140-6736(93)92477-B	http://dx.doi.org/10.1016/0140-6736(93)92477-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	7678046				2022-12-28	WOS:A1993KF02700001
J	GATTINONI, L; BRAZZI, L; PELOSI, P; LATINI, R; TOGNONI, G; PESENTI, A; FUMAGALLI, R				GATTINONI, L; BRAZZI, L; PELOSI, P; LATINI, R; TOGNONI, G; PESENTI, A; FUMAGALLI, R			A TRIAL OF GOAL-ORIENTED HEMODYNAMIC THERAPY IN CRITICALLY ILL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK SURGICAL PATIENTS; OXYGEN DELIVERY; SEPTIC SHOCK; POSTOPERATIVE-PATIENTS; CLINICAL-TRIAL; SUPRANORMAL VALUES; SURVIVORS; PATTERNS; MORTALITY; INCREASE	Background. Hemodynamic therapy to raise the cardiac index and oxygen delivery to supranormal levels may improve outcomes in critically ill patients. We studied whether increasing the cardiac index to a supranormal level (cardiac-index group) or increasing mixed venous oxygen saturation to a normal level (oxygen-saturation group) would decrease morbidity and mortality among critically ill patients, as compared with a control group in which the target was a normal cardiac index. Methods. A total of 10,726 patients in 56 intensive care units were screened, among whom 762 patients belonging to predefined diagnostic categories with acute physiology scores of 11 or higher were randomly assigned to the three groups (252 to the control group, 253 to the cardiac-index group, and 257 to the oxygen-saturation group). Results. The hemodynamic targets were reached by 94.3 percent of the control group, 44.9 percent of the cardiac-index group, and 66.7 percent of the oxygen-saturation group (P<0.001). Mortality was 48.4, 48.6, and 52.1 percent, respectively (P=0.638), up to the time of discharge from the intensive care unit and 62.3, 61.7, and 63.8 percent (P=0.875) at six months. Among patients who survived, the number of dysfunctional organs and the length of the stay in the intensive care unit were similiar in the three groups. No differences in mortality among the three groups were found for any diagnostic category. A subgroup analysis of the patients in whom hemodynamic targets were reached revealed similar mortality rates: 44.8, 40.4, and 39.0 percent. respectively (P=0.478). Conclusions. Hemodynamic therapy aimed at achieving supranormal values for the cardiac index or normal values for mixed venous oxygen saturation does not reduce morbidity or mortality among critically ill patients.	UNIV MILAN,IST ANESTESIA & RIANIMAZ,MILAN,ITALY; OSPED MAGGIORE,IST RICOVERO & CURA CARATTERE SCI,MILAN,ITALY; IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY; UNIV MILAN,OSPED SAN GERARDO,MONZA,ITALY	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; San Gerardo Hospital; University of Milan			Fumagalli, Roberto/AAB-9746-2019; Latini, Roberto/AAB-1410-2020; Brazzi, Luca/AAS-4978-2020; Pesenti, Antonio/H-7483-2012; Rocco, Patricia/I-7460-2012	Fumagalli, Roberto/0000-0003-0398-1329; Latini, Roberto/0000-0002-3729-4650; Brazzi, Luca/0000-0001-7059-0622; Pesenti, Antonio/0000-0003-2593-729X; Rocco, Patricia/0000-0003-1412-7136; Pelosi, Paolo/0000-0001-5055-3023; Gattinoni, Luciano/0000-0001-5380-2494				[Anonymous], 1995, Control Clin Trials, V16, P74; [Anonymous], 1990, Lancet, V336, P65; BAELE PL, 1982, ANESTH ANALG, V61, P513; BLAND RD, 1985, CRIT CARE MED, V13, P85, DOI 10.1097/00003246-198502000-00006; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOYD O, 1993, ANESTH ANALG, V76, P372; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; EDWARDS JD, 1989, CRIT CARE MED, V17, P1098, DOI 10.1097/00003246-198911000-00002; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MARTIN C, 1990, ACTA ANAESTH SCAND, V34, P413, DOI 10.1111/j.1399-6576.1990.tb03114.x; MILLER MJ, 1982, ANESTH ANALG, V61, P527; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, V3, P231; SHOEMAKER WC, 1983, AM J SURG, V146, P43, DOI 10.1016/0002-9610(83)90257-X; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1982, CRIT CARE MED, V10, P398, DOI 10.1097/00003246-198206000-00015; SHOEMAKER WC, 1967, ARCH SURG-CHICAGO, V95, P492; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009	22	975	1027	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1025	1032		10.1056/NEJM199510193331601	http://dx.doi.org/10.1056/NEJM199510193331601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675044				2022-12-28	WOS:A1995RZ34000001
J	JANATUINEN, EK; PIKKARAINEN, PH; KEMPPAINEN, TA; KOSMA, VM; JARVINEN, RMK; UUSITUPA, MIJ; JULKUNEN, RJK				JANATUINEN, EK; PIKKARAINEN, PH; KEMPPAINEN, TA; KOSMA, VM; JARVINEN, RMK; UUSITUPA, MIJ; JULKUNEN, RJK			A COMPARISON OF DIETS WITH AND WITHOUT OATS IN ADULTS WITH CELIAC-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUTEN; TOXICITY	Background. Wheat, rye, and barley damage the small-intestinal mucosa of patients with celiac disease; maize and rice are harmless. The effects of a diet containing oats are uncertain. Methods. In a randomized trial, we compared the effects of gluten-free diets without oats and with oats (with a goal of 50 to 70 g per day from three sources: two types of wheat-starch flour mixed with an equal amount of oats, muesli containing 60 percent oats, and rolled-oat breakfast cereal). Fifty-two adults with celiac disease in remission were followed for 6 months and 40 with newly diagnosed disease for 12 months. Endoscopy with duodenal biopsy was performed at the beginning and end of the study. Results. The mean (+/-SD) oat intake in the oat group was 49.9+/-14.7 g per day at 6 months for patients in remission and 46.6+/-13.3 g per day at 12 months for patients with newly diagnosed disease. The oat and control groups did not differ significantly in nutritional status, symptoms, or laboratory measures. Patients in remission, regardless of diet, did not have worsening architecture of the duodenal villi or increased mononuclear-cell infiltration. All the patients with new diagnoses were in remission at one year, except for one in the control group. Six patients in the oat group and five in the control group withdrew from the study. Conclusions. Moderate amounts of oats can be included in a gluten-free diet for most adult patients with celiac disease without adverse effects.	KUOPIO UNIV HOSP, DEPT CLIN NUTR, SF-70211 KUOPIO, FINLAND; TAMPERE UNIV HOSP, DEPT MED, DIV GASTROENTEROL, TAMPERE, FINLAND; UNIV KUOPIO, DEPT CLIN NUTR, SF-70211 KUOPIO, FINLAND; UNIV KUOPIO, DEPT PATHOL & FORENS MED, SF-70211 KUOPIO, FINLAND	Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital; University of Eastern Finland; University of Eastern Finland	JANATUINEN, EK (corresponding author), KUOPIO UNIV HOSP, DEPT MED, DIV GASTROENTEROL, POB 1777, SF-70211 KUOPIO, FINLAND.		Uusitupa, Matti Ilmari Julius/AAX-4929-2020					ALTMAN DG, 1989, STATISTICS CONFIDENC, P20; ANDERSON CM, 1972, ARCH DIS CHILD, V47, P292, DOI 10.1136/adc.47.252.292; BAKER PG, 1974, BRIT MED J, V4, P588; BAKER PG, 1976, POSTGRAD MED J, V52, P264, DOI 10.1136/pgmj.52.607.264; BANCROFT JD, 1982, THEORY PRACTICE HIST, P112; BELL L, 1981, J CAN DIET ASSOC, V42, P143; BROHULT S, 1954, PROTEINS           A, V2, P487; CAMPBELL JA, 1991, J CAN DIET ASSOC, V52, P161; CICLITIRA PJ, 1985, BRIT J NUTR, V53, P39, DOI 10.1079/BJN19850008; CORAZZA GR, 1985, J CLIN PATHOL, V38, P765, DOI 10.1136/jcp.38.7.765; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; DICKE W K, 1953, Acta Paediatr, V42, P34, DOI 10.1111/j.1651-2227.1953.tb05563.x; DICKE WK, 1950, THESIS UTRECHT U; DISSANAYAKE AS, 1974, BMJ-BRIT MED J, V4, P189, DOI 10.1136/bmj.4.5938.189; ELTON GAH, 1962, J SCI FOOD AGR, V13, P62, DOI 10.1002/jsfa.2740130112; EWART JAD, 1966, J SCI FOOD AGR, V17, P279, DOI 10.1002/jsfa.2740170613; GREFTE JMM, 1988, J CLIN PATHOL, V41, P886, DOI 10.1136/jcp.41.8.886; KENDALL MJ, 1972, LANCET, V2, P1065; KUMAR PJ, 1988, ARCH DIS CHILD, V63, P916, DOI 10.1136/adc.63.8.916; KUMAR PJ, 1979, GUT, V20, P743, DOI 10.1136/gut.20.9.743; MCNICHOLL B, 1979, GUT, V20, P126, DOI 10.1136/gut.20.2.126; MONTGOMERY AMP, 1988, GUT, V29, P1564, DOI 10.1136/gut.29.11.1564; MOULTON ALC, 1959, ARCH DIS CHILD, V34, P51, DOI 10.1136/adc.34.173.51; ROY-CHOUDHURY D, 1966, Scandinavian Journal of Gastroenterology, V1, P57; RUBIN CE, 1962, GASTROENTEROLOGY, V43, P621; Shewry P., 1992, COELIAC DIS, P305; VAN DE KAMER J H, 1953, Acta Paediatr, V42, P223, DOI 10.1111/j.1651-2227.1953.tb05586.x	27	252	254	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1033	1037		10.1056/NEJM199510193331602	http://dx.doi.org/10.1056/NEJM199510193331602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675045				2022-12-28	WOS:A1995RZ34000002
J	BRUCKERDAVIS, F; SKARULIS, MC; GRACE, MB; BENICHOU, J; HAUSER, P; WIGGS, E; WEINTRAUB, BD				BRUCKERDAVIS, F; SKARULIS, MC; GRACE, MB; BENICHOU, J; HAUSER, P; WIGGS, E; WEINTRAUB, BD			GENETIC AND CLINICAL-FEATURES OF 42 KINDREDS WITH RESISTANCE TO THYROID-HORMONE - THE NATIONAL-INSTITUTES-OF-HEALTH PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						THYROID HORMONES; THYROID HORMONE RESISTANCE SYNDROME; HEREDITARY DISEASES; PHENOTYPE; RECEPTORS, THYROID HORMONE	RECEPTOR-BETA GENE; GENERALIZED RESISTANCE; CONGENITAL HYPOTHYROIDISM; INAPPROPRIATE SECRETION; BINDING GLOBULIN; LIGAND-BINDING; TRIIODOTHYRONINE; HYPERTHYROIDISM; MUTATIONS; THYROXINE	Objective: To determine the genetic and clinical features of resistance to thyroid hormone in a study from a single institution. Design: Prospective, controlled study. Setting: National Institutes of Health. Patients: 104 patients with resistance to thyroid hormone from 42 kindreds and 114 unaffected relatives sharing the patients' environmental and genetic backgrounds. Measurements: Thyroid, cardiovascular, psychometric, hearing, speech, and growth testing; thyroid tests done at baseline and after TSH-releasing hormone stimulation; and DNA analysis for detection of mutations in the thyroid hormone receptor beta (TR beta) gene (exons 9 and 10). Assessment of tissue-specific compensation for resistance. Results: Inheritance was autosomal dominant in 22 families, sporadic in 14 families, and unknown in 6 families. We found mutations in 25 kindreds (64 patients); 16 mutations were in exon 9 and 9 were in exon 10 of the TR beta gene. In persons with resistance to thyroid hormone, we measured the increased incidence of goiter (65%), attention-deficit hyperactivity disorder (60%), IQ less than 85 (38%), speech impediment (35%), and short stature (18%). We also described new clinical features, such as frequent ear, nose, and throat infections (56%); low weight-for-height in children (32%); hearing loss (21%); and cardiac abnormalities (18%). Genotype, age, whether the mother had resistance to thyroid hormone, and sex influenced the phenotype. Tissue resistance varied from kindred to kindred and involved, in decreasing order, the pituitary gland, the brain, the bone, the liver, and the heart. Conclusions: This study underscores the incidence of classic features of resistance to thyroid hormone, describes new clinical characteristics of this condition for the first time, and stresses the heterogeneity of the phenotype.	NIDDK,MOLEC & CELLULAR ENDOCRINE BRANCH,BETHESDA,MD 20892; NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS M, 1994, J CLIN INVEST, V94, P506, DOI 10.1172/JCI117362; [Anonymous], 1982, JACKKNIFE BOOTSTRAP; BANTLE JP, 1982, ARCH INTERN MED, V142, P1867, DOI 10.1001/archinte.142.10.1867; BARTALENA L, 1990, ENDOCR REV, V11, P47, DOI 10.1210/edrv-11-1-47; BECKPECCOZ P, 1994, THYROID, V4, P225, DOI 10.1089/thy.1994.4.225; BECKPECCOZ P, 1994, J CLIN ENDOCR METAB, V78, P990; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BRENT GA, 1994, NEW ENGL J MED, V331, P847; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; CALVO R, 1990, J CLIN INVEST, V86, P889, DOI 10.1172/JCI114790; CHANNICK BJ, 1981, NEW ENGL J MED, V305, P497, DOI 10.1056/NEJM198108273050906; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; CHENG SY, 1994, BIOCHEMISTRY-US, V33, P4319, DOI 10.1021/bi00180a028; CHIOVATO L, 1992, ACTA MED AUST, V19, P91; CHOMCZYNSKI P, 1993, J CLIN ENDOCR METAB, V77, P281, DOI 10.1210/jc.77.1.281; COLE CH, 1984, H LANE HDB MANUAL PE, P57; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; COOPER DS, 1982, METABOLISM, V31, P504, DOI 10.1016/0026-0495(82)90242-6; DAVIES OL, 1980, STATISTICAL METHODS, V1; DAVIES SJ, 1993, J MED GENET, V30, P101, DOI 10.1136/jmg.30.2.101; DEFRIAS EC, 1993, CLIN PEDIATR, V32, P426, DOI 10.1177/000992289303200707; DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; DUSSAULT JH, 1992, THYROID TODAY, V15, P1; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FAGLIA G, 1987, HORM RES, V26, P79, DOI 10.1159/000180687; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; FLYNN TR, 1994, J BIOL CHEM, V269, P32713; FRANCOIS M, 1994, J PEDIATR-US, V124, P444, DOI 10.1016/S0022-3476(94)70373-6; GERSHENGORN MC, 1975, J CLIN INVEST, V56, P633, DOI 10.1172/JCI108133; GOTTSCHALK B, 1994, DEV MED CHILD NEUROL, V36, P216; GRACE MB, 1995, IN PRESS HUMAN MUTAT, V6; GRACE MB, 1994, THYROID S1, V4, P583; GRACE MB, 1994, THYROID S1, V4, P145; Greulich WW, 1959, RADIOGRAPHIC ATLAS S, P48; HALL P, 1991, BIOMETRICS, V47, P757, DOI 10.2307/2532163; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HAUSER P, 1993, NEW ENGL J MED, V328, P997, DOI 10.1056/NEJM199304083281403; HAYASHI Y, 1993, MOL ENDOCRINOL, V7, P1049, DOI 10.1210/me.7.8.1049; HAYASHI Y, 1994, THYROID S, V1, P73; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; KAPLAN MM, 1981, AM J MED, V70, P1115, DOI 10.1016/0002-9343(81)90885-8; KOPELMAN AE, 1983, AM J DIS CHILD, V137, P842, DOI 10.1001/archpedi.1983.02140350020006; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEMARCHANDBERAU.T, 1977, ACTA ENDOCRINOL-COP, V85, P44; LEVEY GS, 1990, AM J MED, V88, P642, DOI 10.1016/0002-9343(90)90533-J; LIEWENDAHL K, 1978, CLIN CHIM ACTA, V83, P41, DOI 10.1016/0009-8981(78)90204-8; LIU A, 1995, FEB REG M AM FED CLI; MAGNER JA, 1986, J ENDOCRINOL INVEST, V9, P459, DOI 10.1007/BF03346968; Mason RL, 1930, NEW ENGL J MED, V203, P1273, DOI 10.1056/NEJM193012252032601; MATOVINOVIC J, 1980, ENDEMIC GOITER ENDEM; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; MEYERHOFF WL, 1979, LARYNGOSCOPE 2 S19, V10, P1; MIELL JP, 1993, J CLIN ENDOCR METAB, V76, P950, DOI 10.1210/jc.76.4.950; MIXSON AJ, 1993, J CLIN INVEST, V91, P2296, DOI 10.1172/JCI116458; MIXSON AJ, 1992, J CLIN ENDOCR METAB, V75, P1039, DOI 10.1210/jc.75.4.1039; MOORADIAN AD, 1991, J ENDOCRINOL, V128, P79, DOI 10.1677/joe.0.1280079; NAGAYA T, 1993, J CLIN ENDOCR METAB, V77, P982, DOI 10.1210/jc.77.4.982; OBREGON MJ, 1984, ENDOCRINOLOGY, V114, P305, DOI 10.1210/endo-114-1-305; OPPENHEIMER JH, 1994, EUR J ENDOCRINOL, V130, P15, DOI 10.1530/eje.0.1300015; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; PERSANI L, 1994, J CLIN ENDOCR METAB, V78, P1034, DOI 10.1210/jc.78.5.1034; POITRINEAU P, 1993, ANN PEDIATR-PARIS, V40, P396; POLIKAR R, 1993, CIRCULATION, V87, P1435, DOI 10.1161/01.CIR.87.5.1435; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; REFETOFF S, 1994, ENDOCRINE REV MONOGR, V3, P336; SARNE DH, 1990, J CLIN ENDOCR METAB, V70, P1305, DOI 10.1210/jcem-70-5-1305; SARNE DH, 1988, J CLIN ENDOCR METAB, V66, P740, DOI 10.1210/jcem-66-4-740; SKARULIS M, 1993, THYROID S T, V7, P14; TAKAMATSU J, 1985, J CLIN ENDOCR METAB, V61, P672, DOI 10.1210/jcem-61-4-672; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; Vanderschueren-Lodeweyckx, 1983, ARCH DIS CHILD, V58, P419; WALTON KW, 1965, CLIN SCI, V29, P199; WEINTRAUB BD, 1981, ANN INTERN MED, V95, P339, DOI 10.7326/0003-4819-95-3-339; WEISS RE, 1993, J CLIN INVEST, V91, P2408, DOI 10.1172/JCI116474; WEISS RE, 1990, JAMA-J AM MED ASSOC, V264, P2245, DOI 10.1001/jama.264.17.2245; WEISS RE, 1994, J CLIN ENDOCR METAB, V78, P1525, DOI 10.1210/jc.78.6.1525; WEISS RE, 1993, J CLIN ENDOCR METAB, V76, P257, DOI 10.1210/jcem.76.1.8421095; WEISS RE, 1993, THYROID ST12, V3, P24; WESTGREN U, 1976, ACTA MED SCAND, V200, P493; WONG R, 1995, MOL MED, V1, P306, DOI 10.1007/BF03401555; WONG R, 1995, J INVEST MED S2, V42, pA223; WONG R, 1994, THYROID S1, V4, P149; WONG R, 1994, 76TH END SOC ANN M A, P523; YEN PM, 1992, J CLIN INVEST, V90, P1825, DOI 10.1172/JCI116058	90	183	190	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					572	583		10.7326/0003-4819-123-8-199510150-00002	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00002			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677297				2022-12-28	WOS:A1995RY82800002
J	ANNAS, GJ				ANNAS, GJ			THE HEALTH OF THE PRESIDENT AND PRESIDENTIAL-CANDIDATES - THE PUBLICS RIGHT-TO-KNOW	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Abrams Herbert L., 1992, PRESIDENT HAS BEEN S; ALTMAN LK, 1995, NY TIMES        0722, P9; ALTMAN LK, 1992, NY TIMES        0726, P1; ALTMAN LK, 1993, NY TIMES        0117, P26; ANNAS G, 1989, RIGHTS PATIENTS; ANNAS GJ, 1995, AM J PUBLIC HEALTH, V85, P1196, DOI 10.2105/AJPH.85.9.1196; ANNAS GJ, 1992, GENE MAPPING USING L; Berke RL, 1995, NY TIMES, P1; Bloom Mark, 1976, Med World News, V17, P34; BROWN WF, 1987, GEORGETOWN LAW J, V75, P1389; CHRISPELL KR, 1988, HIDDEN ILLNESS WHITE; Cramer R. B., 1992, WHAT IT TAKES WAY WH; CURRAN WJ, 1986, NEW ENGL J MED, V314, P300, DOI 10.1056/NEJM198601303140507; FERRELL RH, 1992, ILL ADIVSED PRESIDEN; GILBERT RE, 1992, MORTAL PRESIDENCY; GREENBERG DS, 1993, NATURE, V361, P125, DOI 10.1038/361125a0; HRUBAN RH, 1994, NEW ENGL J MED, V330, P1276, DOI 10.1056/NEJM199405053301805; Longaker Richard P., 1966, UCLA LAW REV, V13, P532; Post Jerrold M., 1993, ILLNESS STRIKES LEAD; Reagan Ronald, 1990, AM LIFE; TSONGAS P, 1992, NY TIMES        0506, pA29; 1995, NY TIMES        0811, pA10; 1992, WASHINGTON POST 1011, pA35	23	20	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					945	949		10.1056/NEJM199510053331420	http://dx.doi.org/10.1056/NEJM199510053331420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666895	Green Published			2022-12-28	WOS:A1995RX19900029
J	GREEN, MJ				GREEN, MJ			WHAT (IF ANYTHING) IS WRONG WITH RESIDENCY OVERWORK	ANNALS OF INTERNAL MEDICINE			English	Article							DOCTOR-PATIENT-RELATIONSHIP; GRADUATE MEDICAL-EDUCATION; HOUSE STAFF STRESS; SLEEP-DEPRIVATION; INTERNAL-MEDICINE; WORKING HOURS; PERFORMANCE; PHYSICIANS; CARE; IMPACT	Long work hours during residency are a time-honored tradition. Efforts have recently been made to shorten work hours. This paper examines the main arguments supporting reform: that sleep deprivation is harmful to patients and residents and that it is exploitative. Because the data on the harms and benefits are mixed and because exploitation is difficult to prove, a stronger argument for reducing work hours is an ethical one: that overwork interferes with the development of professional values and attitudes that are an essential part of the moral curriculum of residency. Providing a climate that promotes moral growth during training is an important curricular objective that may be better achieved by shortening work hours, providing better resident supervision, and using substitute workers for some of the noneducational tasks of residency.	UNIV WISCONSIN, SCH MED, PROGRAM MED ETH, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	GREEN, MJ (corresponding author), UNIV WISCONSIN, SCH MED, GEN INTERNAL MED SECT, J5-210 CLIN SCI CTR, 600 HIGHLAND AVE, MADISON, WI 53792 USA.		Green, Martin A/H-7567-2012	Green, Martin A/0000-0002-8860-396X; Green, Michael/0000-0002-4828-4749				ADLER R, 1980, PEDIATRICS, V66, P1000; ALPERT JS, 1988, ARCH INTERN MED, V148, P1507, DOI 10.1001/archinte.148.7.1507; ASCH DA, 1988, NEW ENGL J MED, V318, P771, DOI 10.1056/NEJM198803243181209; ASKEN MJ, 1983, J MED EDUC, V58, P382; BATES GW, 1987, J MED EDUC, V62, P443; BELL BM, 1991, B NEW YORK ACAD MED, V67, P385; BENSON JA, 1983, ANN INTERN MED, V99, P720, DOI 10.7326/0003-4819-99-5-720; BLOCH AL, 1989, JAMA-J AM MED ASSOC, V261, P3243, DOI 10.1001/jama.1989.03420220057018; BOICE JL, 1983, J MED EDUC, V58, P61; BOISAUBIN EV, 1988, J MED PHILOS, V13, P457, DOI 10.1093/jmp/13.4.457; BONANNI PP, 1989, NEW YORK STATE J MED, V89, P684; BUTTERFIELD PS, 1988, ARCH INTERN MED, V148, P1428, DOI 10.1001/archinte.148.6.1428; CAMERON JM, 1985, NEW ENGL J MED, V312, P1233, DOI 10.1056/NEJM198505093121906; COLFORD JM, 1989, JAMA-J AM MED ASSOC, V261, P889, DOI 10.1001/jama.261.6.889; CONIGLIARO J, 1993, J GEN INTERN MED, V8, P502, DOI 10.1007/BF02600112; COPPET D, 1992, UNDERSTANDING RITUAL, P120; COUSINS N, 1981, JAMA-J AM MED ASSOC, V245, P377; CUTLER NR, 1979, COMPR PSYCHIAT, V20, P61, DOI 10.1016/0010-440X(79)90060-9; DEACONSON TF, 1988, JAMA-J AM MED ASSOC, V260, P1721, DOI 10.1001/jama.260.12.1721; Denisco R A, 1987, J Clin Monit, V3, P22, DOI 10.1007/BF00770879; DEWEY J, 1916, DEMOCRACY ED, P51; DUNCAN DE, 1993, HARPERS, V286, P61; EVERETT GD, 1983, MED CARE, V21, P1187, DOI 10.1097/00005650-198312000-00005; Feldstein P. J., 1988, POLITICS HLTH LEGISL; FICKLIN FL, 1988, J MED EDUC, V63, P392; FOST NC, 1985, STRESS PEDIATRIC HOU, P60; FRIEDMAN FC, 1973, J MED EDUC, V48, P436; FRIEDMAN RC, 1971, NEW ENGL J MED, V285, P201, DOI 10.1056/NEJM197107222850405; GARBER AM, 1984, NEW ENGL J MED, V310, P1231, DOI 10.1056/NEJM198405103101906; GLICKMAN RM, 1988, NEW ENGL J MED, V318, P780, DOI 10.1056/NEJM198803243181212; GREEN MJ, 1995, IN PRESS ARCH INTERN; GROOPMAN LC, 1987, CULT MED PSYCHIAT, V11, P207, DOI 10.1007/BF00122564; GROUSE LD, 1981, JAMA-J AM MED ASSOC, V246, P2141; HART RP, 1987, J MED EDUC, V62, P940; HAWKINS MR, 1985, J MED EDUC, V60, P530; HOFFMAN J, 1995, NY TIMES        0207, pB1; JENSEN PS, 1981, ANN INTERN MED, V95, P769, DOI 10.7326/0003-4819-95-6-769; KASE N, 1991, B NEW YORK ACAD MED, V67, P378; KLEBANOFF MA, 1990, NEW ENGL J MED, V323, P1040, DOI 10.1056/NEJM199010113231506; KNICKMAN JR, 1992, ACAD MED, V67, P429, DOI 10.1097/00001888-199207000-00003; KNOWLES MS, 1980, MODERN PRACTICE ADUL, V84, P223; KOLLAR EJ, 1966, PSYCHOSOM MED, V28, P101, DOI 10.1097/00006842-196603000-00002; Konner M., 1987, BECOMING DOCTOR JOUR; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; LANDAU C, 1986, J MED EDUC, V61, P654; LEITZELL JD, 1981, JAMA-J AM MED ASSOC, V246, P2141; LEWIN ICF, 1990, STUDY EC IMPACT LEGI; LLOYD C, 1990, ED COMPETENT HUMANE, P94; MARION R, 1989, INTERN BLUES PRIVATE; MARTIN AR, 1986, J GEN INTERN MED, V1, P252, DOI 10.1007/BF02596195; MCCALL TB, 1989, JAMA-J AM MED ASSOC, V261, P909; MCCALL TB, 1988, NEW ENGL J MED, V318, P775, DOI 10.1056/NEJM198803243181210; MCMANUS IC, 1977, LANCET, V1, P413; MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; MILLER B, 1992, CHICAGO READER, V21, P14; MILLER B, 1992, CHICAGO READER, V21, P18; MIZRAHI T, 1986, GETTING RID PATIENTS, P33; NESBITT D, 1988, ANN INTERN MED, V109, P154, DOI 10.7326/0003-4819-109-2-154; NESSELL W, 1981, JAMA-J AM MED ASSOC, V246, P2142; PAGE L, 1995, NY TIMES        0116, pA5; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; Pellegrino E D, 1984, Theor Med, V5, P83, DOI 10.1007/BF00489248; PEREIRAOGAN G, 1994, J AM HEALTH POLICY, V4, P19; Perkoff G T, 1992, Fam Med, V24, P584; PULLEN RL, 1952, INTERNSHIP, P26; PURDUM TS, 1994, NY TIMES        0124, pA1; REYNOLDS PP, 1994, ANN INTERN MED, V120, P609, DOI 10.7326/0003-4819-120-7-199404010-00013; REYNOLDS PP, 1991, B NEW YORK ACAD MED, V67, P369; REZNICK RK, 1987, AM J SURG, V154, P520, DOI 10.1016/0002-9610(87)90269-8; RICH EC, 1990, JAMA-J AM MED ASSOC, V263, P953; ROBBINS J, 1990, WESTERN J MED, V152, P82; RUBIN R, 1991, J OCCUP ENVIRON MED, V33, P13, DOI 10.1097/00043764-199101000-00007; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; SCHWARTZ MA, 1985, PERSPECT BIOL MED, V28, P331; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; SHEEHAN TJ, 1980, EVAL HEALTH PROF, V3, P393; SMITH JW, 1986, JAMA-J AM MED ASSOC, V255, P1155, DOI 10.1001/jama.255.9.1155; SMITH LH, 1985, WESTERN J MED, V142, P814; SPARR LF, 1988, SOC SCI MED, V26, P1095, DOI 10.1016/0277-9536(88)90184-0; Starr P, 1982, SOCIAL TRANSFORMATIO; STOCKMAN JA, 1985, STRESS PEDIATRIC HOU, P52; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P53, DOI 10.1001/jama.272.1.53; TAYLOR AD, 1987, J MED EDUC, V62, P425; TURKEWITZ LJ, 1981, JAMA-J AM MED ASSOC, V246, P2141; Turner VW., 1969, RITUAL PROCESS STRUC, P213; ULIANA RL, 1984, J MED EDUC, V59, P118; VALKO RJ, 1975, DIS NERV SYST, V36, P26; WALERSTEIN SJ, 1989, NEW YORK STATE J MED, V89, P454; WEBB WB, 1974, PSYCHOPHYSIOLOGY, V11, P265, DOI 10.1111/j.1469-8986.1974.tb00543.x; WOLF MA, 1991, 103RD T AM CLIN CLIM, P225; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; ZINN W, 1993, ARCH INTERN MED, V153, P306, DOI 10.1001/archinte.153.3.306; 1994, PROFILE ACGME ACCRED; 1994, GRADUATE MED ED DIRE, P49	94	50	51	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					512	517		10.7326/0003-4819-123-7-199510010-00007	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RW495	7661496				2022-12-28	WOS:A1995RW49500007
J	SALAM, MA; SEAS, C; KHAN, WA; BENNISH, ML				SALAM, MA; SEAS, C; KHAN, WA; BENNISH, ML			TREATMENT OF SHIGELLOSIS .4. CEFIXIME IS INEFFECTIVE IN SHIGELLOSIS IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Note							TRIMETHOPRIM-SULFAMETHOXAZOLE; CHILDHOOD SHIGELLOSIS; COMPARATIVE EFFICACY; NALIDIXIC-ACID; AMPICILLIN; THERAPY; TRIAL; CIPROFLOXACIN; CEFTRIAXONE; CHILDREN	Objective: To compare the efficacy of cefixime with that of pivamdinocillin in the treatment of adults with acute dysentery caused by Shigella infection. Design: Randomized, double-blind clinical trial. Setting: A diarrhea treatment center in Dhaka, Bangladesh. Patients: 30 men with dysentery lasting 72 hours or less. Interventions: Patients were randomly assigned to receive either 400 mg of cefixime every 24 hours (n = 15) or 400 mg of pivamdinocillin every 6 hours (n = 15) for 5 days. All patients were hospitalized for 6 days. Patients in whom initial drug therapy failed received alternative antimicrobial therapy. Measurements: Physical examinations were done and symptoms were recorded daily, and body temperatures were measured every 6 hours. Stools were counted and examined for consistency and for the presence of blood and mucus. Therapy failed if symptoms of dysentery persisted for more than 72 hours or if, on study day 5, a patient had six stools, one watery or bloody-mucoid stool, or an oral temperature higher than 37.8 degrees C. Bacteriologic failure of therapy occurred if Shigella could be isolated from a stool sample on or after study day 3. Results: Therapy failed in seven (47%) patients given cefixime but in none of the patients given pivamdinocillin (P = 0.006). Patients given cefixime had longer duration of fever (median, 6 hours compared with 0 hours, P = 0.019), longer duration of the period with dysenteric stools (median, 4 days compared with 1 day, P = 0.001), and more stools during the 6 study days (median, 65 compared with 28, P = 0.002) than patients treated with pivamdinocillin. Bacteriologic failure of therapy occurred in 60% of patients (9 of 15) given cefixime and 13% of those (2 of 15) given pivamdinocillin (P = 0.009). Conclusion: Cefixime is ineffective in treating shigellosis in adults when used in the standard recommended dosage.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; INT CTR DIARRHOEAL DIS RES, DHAKA 1000, BANGLADESH; UNIV PERUANA CAYETANO HEREDIA, INST MED TROP ALEXANDER VONHUMBOLDT, LIMA 100, PERU	Tufts Medical Center; International Centre for Diarrhoeal Disease Research (ICDDR); Universidad Peruana Cayetano Heredia				Seas, Carlos/0000-0001-7067-9141				ARVIDSSON A, 1982, J ANTIMICROB CHEMOTH, V10, P207, DOI 10.1093/jac/10.3.207; ASHKENAZI S, 1993, J PEDIATR-US, V123, P817, DOI 10.1016/S0022-3476(05)80867-4; Bennish Michael L., 1995, P1499; BENNISH ML, 1990, J INFECT DIS, V162, P711, DOI 10.1093/infdis/162.3.711; BENNISH ML, 1992, J ANTIMICROB CHEMOTH, V30, P243, DOI 10.1093/jac/30.3.243; BENNISH ML, 1992, ANN INTERN MED, V117, P727, DOI 10.7326/0003-4819-117-9-727; BENNISH ML, 1992, CLIN INFECT DIS, V14, P1055, DOI 10.1093/clinids/14.5.1055; FAULKNER RD, 1987, PEDIATR INFECT DIS J, V6, P963, DOI 10.1097/00006454-198710000-00035; KABIR I, 1984, ANTIMICROB AGENTS CH, V25, P643, DOI 10.1128/AAC.25.5.643; NELSON JD, 1972, CHEMOTHERAPY, V17, P40, DOI 10.1159/000220837; NELSON JD, 1975, ANTIMICROB AGENTS CH, V7, P415, DOI 10.1128/AAC.7.4.415; ORENSTEIN WA, 1981, AM J MED SCI, V282, P27, DOI 10.1097/00000441-198107000-00004; POCOCK SJ, 1978, BRIT J CANCER, V38, P757, DOI 10.1038/bjc.1978.284; PRADO D, 1992, PEDIATR INFECT DIS J, V11, P644; QUINTILIANI R, 1994, INFECT DIS CLIN PRAC, V3, P1, DOI 10.1097/00019048-199401000-00001; RISSER WL, 1987, PEDIATR INFECT DIS J, V6, P1002, DOI 10.1097/00006454-198710000-00043; SALAM MA, 1988, J PEDIATR-US, V113, P901, DOI 10.1016/S0022-3476(88)80029-5; SALAM MA, 1991, REV INFECT DIS, V13, pS332; SHURIN P, 1987, PEDIATR INFECT DIS J, V6, P981; VARSANO I, 1991, J PEDIATR-US, V118, P627, DOI 10.1016/S0022-3476(05)83392-X	20	22	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					505	508		10.7326/0003-4819-123-7-199510010-00005	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661494				2022-12-28	WOS:A1995RW49500005
J	BEVERS, RFM; BAKKER, DJ; KURTH, KH				BEVERS, RFM; BAKKER, DJ; KURTH, KH			HYPERBARIC-OXYGEN TREATMENT FOR HEMORRHAGIC RADIATION CYSTITIS	LANCET			English	Article							THERAPY	Radiation-induced severe haemorrhagic cystitis is difficult to treat. Conventional treatments may decrease haematuria but do not affect the radiocystitis itself. Hyperbaric oxygen treatment has been reported to do both. We report the results of a prospective study of hyperbaric oxygen (20 sessions of 100% oxygen inhalation at 3 bar for 90 min in a multiplace hyperbaric chamber) to 40 patients with biopsy-proven radiation cystitis and severe haematuria. Haematuria disappeared completely or improved in 37 patients after treatment. Mean follow-up was 23.1 months (range 1-74); and the recurrence rate was 0.12/year. There were no adverse effects. Hyperbaric oxygen treatment should be considered for patients with severe radiation-induced haematuria.	UNIV AMSTERDAM,ACAD MED CTR,DEPT UROL,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam								Akiyama A, 1994, Nihon Hinyokika Gakkai Zasshi, V85, P1269; FELDMEIER JJ, 1994, UNDERSEA HYPERBAR M, V21, P467; GABB G, 1987, CHEST, V92, P1074, DOI 10.1378/chest.92.6.1074; GRIM PS, 1990, JAMA-J AM MED ASSOC, V263, P2216; KINDWALL EP, 1993, CLIN PLAST SURG, P589; LEE HC, 1994, UNDERSEA HYPERBAR M, V21, P321; MOSS WT, 1979, RAD ONCOLOGY RATIONA, P246; NAKADA T, 1992, EUR UROL, V22, P294; Noordzij JW., 1993, INT UROGYNECOL J, V4, P160; NORKOOL DM, 1993, J UROLOGY, V150, P332, DOI 10.1016/S0022-5347(17)35476-9; PARSONS CL, 1986, J UROLOGY, V136, P813, DOI 10.1016/S0022-5347(17)45087-7; RIJKMANS BG, 1989, EUR UROL, V16, P354; SCHOENROCK GJ, 1986, UROLOGY, V27, P271, DOI 10.1016/0090-4295(86)90289-X; WEISS JP, 1994, J UROLOGY, V151, P1514, DOI 10.1016/S0022-5347(17)35289-8	14	131	138	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					803	805		10.1016/S0140-6736(95)91620-2	http://dx.doi.org/10.1016/S0140-6736(95)91620-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674746				2022-12-28	WOS:A1995RW25800011
J	HARRISON, TW; TATTERSFIELD, AE				HARRISON, TW; TATTERSFIELD, AE			EXTRATHORACIC AIRWAY DYSFUNCTION	LANCET			English	Editorial Material							HYPERRESPONSIVENESS				HARRISON, TW (corresponding author), CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.							ANNESI I, 1992, EUR RESPIR J, V5, P1104; BRITTON J, 1986, EUR J RESPIR DIS, V68, P233; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BUCCA C, 1991, ALLERGY, V46, P147, DOI 10.1111/j.1398-9995.1991.tb00559.x; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; GOLDMAN J, 1991, THORAX, V46, P401, DOI 10.1136/thx.46.6.401; LISBOA C, 1989, AM REV RESPIR DIS, V122, P115; MILLER RD, 1969, MAYO CLIN PROC, V44, P145	8	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					786	787		10.1016/S0140-6736(95)91612-1	http://dx.doi.org/10.1016/S0140-6736(95)91612-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674738				2022-12-28	WOS:A1995RW25800003
J	HESLOP, HE; BENAIM, E; BRENNER, MK; KRANCE, RA; STRICKLIN, LM; ROCHESTER, RJ; BILLING, R				HESLOP, HE; BENAIM, E; BRENNER, MK; KRANCE, RA; STRICKLIN, LM; ROCHESTER, RJ; BILLING, R			RESPONSE OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE TO LYMPHOBLAST ANTIBODY CBL1	LANCET			English	Note								Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN USA; CV CANC CTR, SAN MARCOS, CA USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	HESLOP, HE (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38101 USA.		Brenner, Malcolm/Y-2509-2019; Heslop, Helen/AAC-9500-2020		NCI NIH HHS [CA 20180, CA 21745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANASETTI C, 1994, BLOOD, V84, P1320; ANTIN JH, 1994, BLOOD, V84, P1342, DOI 10.1182/blood.V84.4.1342.bloodjournal8441342; BILLING R, 1982, HYBRIDOMA, V1, P303, DOI 10.1089/hyb.1.1982.1.303; BLAISE D, 1995, LANCET, V345, P1144, DOI 10.1016/S0140-6736(95)90978-8; BYERS VS, 1990, BLOOD, V75, P1426; CHAO NJ, 1993, NEW ENGL J MED, V329, P1225, DOI 10.1056/NEJM199310213291703; HERVE P, 1992, BLOOD, V79, P3362; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; PRENTICE HG, 1984, LANCET, V1, P472; TAKAHASHI H, 1983, LANCET, V2, P1155	10	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 23	1995	346	8978					805	806		10.1016/S0140-6736(95)91621-0	http://dx.doi.org/10.1016/S0140-6736(95)91621-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674747				2022-12-28	WOS:A1995RW25800012
J	HORTON, R				HORTON, R			TOWARDS THE ELIMINATION OF TUBERCULOSIS	LANCET			English	Editorial Material																		ENARSON DA, 1995, LANCET, V346, P809, DOI 10.1016/S0140-6736(95)91623-7; RODEVAND O, 1995, LANCET, V346, P836, DOI 10.1016/S0140-6736(95)91646-6	2	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					790	790		10.1016/S0140-6736(95)91616-4	http://dx.doi.org/10.1016/S0140-6736(95)91616-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674742				2022-12-28	WOS:A1995RW25800007
J	GORLICH, D; VOGEL, F; MILLS, AD; HARTMANN, E; LASKEY, RA				GORLICH, D; VOGEL, F; MILLS, AD; HARTMANN, E; LASKEY, RA			DISTINCT FUNCTIONS FOR THE 2 IMPORTIN SUBUNITS IN NUCLEAR-PROTEIN IMPORT	NATURE			English	Article							GTP-BINDING PROTEIN; LOCATION; TRANSLOCATION; POLYPEPTIDE; MIGRATION; SEQUENCE; RAN/TC4; STEPS	THE import of nuclear proteins proceeds through the nuclear pore complex and requires nuclear localization signals (NLSs)(1,2), energy(3,4) and soluble factors(5), namely importin-alpha (M(r) 60K)(6-12,28), importin-beta (90K)(8-11,13) and Ran(14,15). Importin-alpha is primarily responsible for NLS recognition(6-12,29) and is a member of a protein family that includes the essential yeast nuclear pore protein SRP1p (ref. 16). As the first event, the complex of importin-alpha and importin-beta binds the import substrate in the cytosols(8,9). Here we show that this nuclear pore targeting complex initially docks as a single entity to the nuclear pore via importin-beta. Then the energy-dependent, Ran-mediated translocation through the pore results in the accumulation of import substrate and importin-alpha in the nucleus. In contrast, importin-beta accumulates at the nuclear envelope, but not in the nucleoplasm. Immunoelectron microscopy detects importin-beta on both sides of the nuclear pore. This suggests that the nuclear pore targeting complex might move as a single entity from its initial docking site through the central part of the nuclear pore before it disassembles on the nucleoplasmic side.	UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND; MAX DELBRUCK CENTRUM MOLEK MED, D-13122 BERLIN, GERMANY	University of Cambridge; Helmholtz Association; Max Delbruck Center for Molecular Medicine	GORLICH, D (corresponding author), WELLCOME CRC INST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		Görlich, Dirk/B-8296-2017; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P137; HARLOW E, 1988, ANTIBODIES LABORATOR; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	29	422	428	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 21	1995	377	6546					246	248		10.1038/377246a0	http://dx.doi.org/10.1038/377246a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675110				2022-12-28	WOS:A1995RV87200044
J	GOULD, KL; ORNISH, D; SCHERWITZ, L; BROWN, S; EDENS, RP; HESS, MJ; MULLANI, N; BOLOMEY, L; DOBBS, F; ARMSTRONG, WT; MERRITT, T; PORTS, T; SPARLER, S; BILLINGS, J				GOULD, KL; ORNISH, D; SCHERWITZ, L; BROWN, S; EDENS, RP; HESS, MJ; MULLANI, N; BOLOMEY, L; DOBBS, F; ARMSTRONG, WT; MERRITT, T; PORTS, T; SPARLER, S; BILLINGS, J			CHANGES IN MYOCARDIAL PERFUSION ABNORMALITIES BY POSITRON EMISSION TOMOGRAPHY AFTER LONG-TERM, INTENSE RISK FACTOR MODIFICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ENDOTHELIUM-DEPENDENT RELAXATION; LOW-FAT DIET; STENOSIS SEVERITY; FLOW RESERVE; ATHEROSCLEROSIS-REGRESSION; NONINVASIVE ASSESSMENT; PHYSICAL EXERCISE; COLESTIPOL-NIACIN; HEART-DISEASE	Objective.-To quantify changes in size and severity of myocardial perfusion abnormalities by positron emission tomography (PET) in patients with coronary artery disease after 5 years of risk factor modification. Design.-Randomized controlled trial. Setting.-Outpatient community setting. Intervention.-Randomization of patients to risk factor modification consisting of very low-fat vegetarian diet, mild to moderate exercise, stress management, and group support (experimental group, n=20) or to usual care by their own physicians, consisting principally of antianginal therapy (control group, n=15). Main Outcome Measures.-Quantitative coronary arteriography and PET at baseline and 5 years after randomization. Automated, objective measures of size and severity of perfusion abnormalities on rest-dipyridamole PET images and of stenosis severity on arteriograms were made by computer algorithms. Results.-Size and severity of perfusion abnormalities on dipyridamole PET images decreased (improved) after risk factor modification in the experimental group compared with an increase (worsening) of size and severity in controls. The percentage of left ventricle perfusion abnormalities outside 2.5 SDs of those of normal persons (based on 20 disease-free individuals) on the dipyridamole PET image of normalized counts worsened in controls (mean+/-SE, +10.3%+/-5.6%) and imp roved in the experimental group (mean+/-SE, -5.1%+/-4.8%) (P=.02); the percentage of left ventricle with activity less than 60% of the maximum activity on the dipyridamole PET image of normalized counts worsened in controls (+13.5%+/-3.8%) and improved in the experimental group (-4.2%+/-3.8%) (P=.002); and the myocardial quadrant on the PET image with the lowest average activity expressed as a percentage of maximum activity worsened in controls (-8.8%+/-2.3%) and improved in the experimental group (+4.9%+/-13.3%) (P=.001). The size and severity of perfusion abnormalities on resting PET images were also significantly improved in the experimental group as compared with controls. The relative magnitude of changes in size and severity of PET perfusion abnormalities was comparable to or greater than the magnitude of changes in percent diameter stenosis, absolute stenosis lumen area, or stenosis flow reserve documented by quantitative coronary arteriography, Conclusions.-Modest regression of coronary artery stenoses after risk factor modification is associated with decreased size and severity of perfusion abnormalities on rest-dipyridamole PET images. Progression or regression of coronary artery disease can be followed noninvasively by dipyridamole PET reflecting the integrated flow capacity of the entire coronary arterial circulation.	UNIV TEXAS, SCH MED, CTR POSITRON DIAGNOST & RES, HOUSTON, TX 77030 USA; PREVENT MED RES INST, SAUSALITO, CA USA; CALIF PACIFIC MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of Texas System; California Pacific Medical Center; University of California System; University of California San Francisco	GOULD, KL (corresponding author), UNIV TEXAS, SCH MED,DEPT MED,DIV CARDIOL,ROOM 4258MSB, 6431 FANNIN, HOUSTON, TX 77030 USA.				NHLBI NIH HHS [HL 26885, HL 42554, R01 HL 26882] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026885, R01HL042554] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; [Anonymous], 1994, CIRCULATION, V89, P1329; BENZULY KH, 1994, CIRCULATION, V89, P1810, DOI 10.1161/01.CIR.89.4.1810; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1991, CORONARY ARTERY DIS, V2, P875; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CHILIAN WM, 1990, AM J PHYSIOL, V258, pH529, DOI 10.1152/ajpheart.1990.258.2.H529; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DEMER L, 1988, PROG CARDIOVASC DIS, V30, P307, DOI 10.1016/0033-0620(88)90001-1; DEMER LL, 1989, CIRCULATION, V79, P825, DOI 10.1161/01.CIR.79.4.825; DEMER LL, 1990, J NUCL MED, V31, P259; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Glantz SA., 1987, PRIMER BIOSTATISTICS; GOLDSTEIN RA, 1983, J NUCL MED, V24, P907; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; GOULD KL, 1982, CIRCULATION, V66, P930, DOI 10.1161/01.CIR.66.5.930; GOULD KL, 1986, J AM COLL CARDIOL, V7, P775, DOI 10.1016/S0735-1097(86)80336-9; GOULD KL, 1991, J NUCL MED, V32, P579; GOULD KL, 1992, AM J CARDIOL, V69, P845, DOI 10.1016/0002-9149(92)90781-S; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459, DOI 10.1016/S0735-1097(10)80078-6; GOULD KL, 1994, CIRCULATION, V90, P1558, DOI 10.1161/01.CIR.90.3.1558; GOULD KL, 1991, CIRCULATION, V84, pI22; GOULD KL, 1988, CIRCULATION, V78, P237, DOI 10.1161/01.CIR.78.2.237; Gould KL, 1991, CORONARY ARTERY STEN; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HICKS K, 1989, J NUCL MED, V30, P1787; HODGSON JM, 1989, CIRCULATION, V79, P1043, DOI 10.1161/01.CIR.79.5.1043; HODGSON JM, 1993, J AM COLL CARDIOL, V21, P35, DOI 10.1016/0735-1097(93)90714-C; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KIRKEEIDE RL, 1986, J AM COLL CARDIOL, V7, P103, DOI 10.1016/S0735-1097(86)80266-2; KUO L, 1992, CIRC RES, V70, P465, DOI 10.1161/01.RES.70.3.465; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARCUS ML, 1988, J AM COLL CARDIOL, V11, P882, DOI 10.1016/0735-1097(88)90226-4; MARCUS ML, 1988, PROG CARDIOVASC DIS, V31, P39, DOI 10.1016/0033-0620(88)90010-2; MULLANI NA, 1983, J NUCL MED, V24, P898; OLIVER MF, 1994, LANCET, V344, P633; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1994, J AM COLL CARDIOL, pA131; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SCHULER G, 1992, J AM COLL CARDIOL, V19, P34, DOI 10.1016/0735-1097(92)90048-R; SEILER C, 1992, CIRCULATION, V85, P1987, DOI 10.1161/01.CIR.85.6.1987; SEILER C, 1993, J AM COLL CARDIOL, V21, P783, DOI 10.1016/0735-1097(93)90113-F; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SHIMOKAWA H, 1988, CIRCULATION, V78, P1421, DOI 10.1161/01.CIR.78.6.1421; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; Snedecor G. W, 1989, STAT METHODS, V8th; SPATZ C, 1984, BASIC STATISTICS; TAKAHASHI M, 1990, AM J PHYSIOL, V258, pH1, DOI 10.1152/ajpheart.1990.258.1.H1; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TOMITA T, 1990, CIRC RES, V66, P18, DOI 10.1161/01.RES.66.1.18; UREN NG, 1993, J AM COLL CARDIOL, V22, P650, DOI 10.1016/0735-1097(93)90172-W; VERBEUREN TJ, 1986, CIRC RES, V58, P552, DOI 10.1161/01.RES.58.4.552; WACKERS F J T, 1992, American Journal of Cardiac Imaging, V6, P42; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WHITE CW, 1984, NEW ENGL J MED, V310, P819, DOI 10.1056/NEJM198403293101304; XU EZ, 1991, J NUCL MED, V32, P161; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; ZHAO XQ, 1993, CIRCULATION, V88, P2744, DOI 10.1161/01.CIR.88.6.2744; 1992, STAT VIEW	72	224	227	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					894	901		10.1001/jama.274.11.894	http://dx.doi.org/10.1001/jama.274.11.894			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674504				2022-12-28	WOS:A1995RU60300029
J	HOUETO, P; HOFFMAN, JR; IMBERT, M; LEVILLAIN, P; BAUD, FJ				HOUETO, P; HOFFMAN, JR; IMBERT, M; LEVILLAIN, P; BAUD, FJ			RELATION OF BLOOD CYANIDE TO PLASMA CYANOCOBALAMIN CONCENTRATION AFTER A FIXED-DOSE OF HYDROXOCOBALAMIN IN CYANIDE POISONING	LANCET			English	Article								Hydroxocobalamin combines with cyanide to form cyanocobalamin. We hypothesised that the amount of cyanocobalamin formed after a fixed dose of hydroxocobalamin given for cyanide poisoning would correlate with initial blood cyanide concentration. We determined blood cyanide concentration in 12 patients exposed to residential fires, and compared this with markers of the amount of cyanocobalamin formed after treatment with 5 g intravenous hydroxocobalamin. All relationships were highly correlated (r(2) 0.79-0.95), for the whole group, and there appeared to be an almost linear relationship for the 9 patients with initial cyanide concentration below 40 mu mol/L. Above this concentration, no further cyanocobalamin was formed from a single 5 g dose of hydroxocobalamin. In one patient with initial blood cyanide concentration of 96 mu mol/L, however, plasma cyanocobalamin concentration approximately doubled after a second 5 g dose of hydroxocobalamin. 5 g of hydroxocobalamin appears capable of binding all available cyanide ions for blood cyanide concentrations up to about 40 mu mol/L. Beyond this, more hydroxocobalamin must be given for remaining cyanide ions to be bound. This information will allow clinicians to use rapidly measurable plasma cyanocobalamin concentrations to gauge severity of exposure and evaluate adequacy of treatment.	UNIV PARIS 07,HOP FERNAND WIDAL,TOXICOL LAB,PARIS,FRANCE; BRIGADE SAPEURS POMPIERS,SERV MED,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite								BARTELHEIMER EW, 1962, ARCH INT PHARMACOD T, V139, P99; BRIGHT JE, 1988, HUM TOXICOL, V7, P183, DOI 10.1177/096032718800700214; EVANS CL, 1964, BRIT J PHARM CHEMOTH, V23, P455, DOI 10.1111/j.1476-5381.1964.tb01603.x; Favier C, 1993, CLIN INT CARE, V4, P69; HOUETO P, 1994, J ANAL TOXICOL, V18, P154, DOI 10.1093/jat/18.3.154; HOUETO P, 1994, THERAPIE, V49, P68; LINELL JC, 1987, CLIN EXPT TOXICOLOGY, P427; MOUREU H, 1957, Arch Mal Prof, V18, P116; RIEDERS F, 1975, METHODOLOGY ANAL TOX, P113; RIOU B, 1990, J NEUROSURG ANESTH, V2, P296, DOI 10.1097/00008506-199012000-00008; SCHWARTZ D, 1963, METHODES STATISTIQUE	11	42	46	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					605	608		10.1016/S0140-6736(95)91437-4	http://dx.doi.org/10.1016/S0140-6736(95)91437-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651005				2022-12-28	WOS:A1995RT18800010
J	WANG, CR; CASTANO, AR; PETERSON, PA; SLAUGHTER, C; LINDAHL, KF; DEISENHOFER, J				WANG, CR; CASTANO, AR; PETERSON, PA; SLAUGHTER, C; LINDAHL, KF; DEISENHOFER, J			NONCLASSICAL BINDING OF FORMYLATED PEPTIDE IN CRYSTAL-STRUCTURE OF THE MHC CLASS-IB MOLECULE H2-M3	CELL			English	Article							DROSOPHILA-MELANOGASTER CELLS; COMPLEX CLASS-I; HISTOCOMPATIBILITY ANTIGEN; VIRAL PEPTIDES; PROTEIN; RECOGNITION; SPECIFICITY; RESOLUTION; HLA-A2; H-2M3	H2-M3 is a class Ib MHC molecule of the mouse with a 10(4)-fold preference for binding N-formylated peptides. To elucidate the basis of this unusual specificity, we expressed and crystallized a soluble form of M3 with a formylated nonamer peptide, fMYFINILTL, and determined the structure by X-ray crystallography. M3, refined at 2.1 Angstrom resolution, resembles class ia MHC molecules in its overall structure, but differs in the peptide-binding groove. The A pocket, which usually accommodates the free N-terminus of a bound peptide, is closed, and the peptide is shifted one residue, such that the P1 side chain is lodged in the a pocket, The formyl group is coordinated by His-9 and a bound water on the floor of the groove.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute	WANG, CR (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.		Castaño, A. Raul/A-5905-2012	Castaño, A. Raul/0000-0003-2107-8862				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; CHEN W, 1993, J EXP MED, V177, P869, DOI 10.1084/jem.177.3.869; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HERMEL E, 1992, THESIS U TEXAS DALLA; HOGQUIST KA, 1993, EUR J IMMUNOL, V23, P3028, DOI 10.1002/eji.1830231145; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE S, 1994, J EXP MED, V179, P579, DOI 10.1084/jem.179.2.579; KURLANDER RJ, 1992, SCIENCE, V257, P678, DOI 10.1126/science.1496381; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MILLER JEW, 1994, J CELL BIOCHEM, V18, P292; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROHREN EM, 1994, J IMMUNOL, V152, P5337; ROTZSCHKE O, 1993, NATURE, V361, P642, DOI 10.1038/361642a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; SMITH GP, 1994, INT IMMUNOL, V6, P1917, DOI 10.1093/intimm/6.12.1917; STROYNOWSKI I, 1994, CURR OPIN IMMUNOL, V6, P38, DOI 10.1016/0952-7915(94)90031-0; VYAS JM, 1995, J EXP MED, V181, P1817, DOI 10.1084/jem.181.5.1817; VYAS JM, 1992, J IMMUNOL, V149, P3605; WANG CR, 1993, P NATL ACAD SCI USA, V90, P2784, DOI 10.1073/pnas.90.7.2784; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WANG CR, 1995, IMMUNOGENETICS, V42, P63, DOI 10.1007/BF00164989; YUNG ACM, 1994, CELL, V76, P39; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	51	128	129	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					655	664		10.1016/0092-8674(95)90037-3	http://dx.doi.org/10.1016/0092-8674(95)90037-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664344	Bronze			2022-12-28	WOS:A1995RR73400016
J	XUE, D; HORVITZ, HR				XUE, D; HORVITZ, HR			INHIBITION OF THE CAENORHABDITIS-ELEGANS CELL-DEATH PROTEASE CED-3 BY A CED-3 CLEAVAGE SITE IN BACULOVIRUS P35 PROTEIN	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; C-ELEGANS; GENE CED-3; EXPRESSION; TRANSCRIPTION; PURIFICATION; APOPTOSIS; REQUIRES; ENCODES; HOMOLOG	THE baculovirus protein p35 inhibits programmed cell death in such diverse animals as insects, nematodes and mammals(1-5). Here we show that p35 protein is a substrate for and inhibitor of the Caenorhabditis elegans cell-death protease CED-3 (refs 6, 7) and a substrate for four CED-3-like vertebrate cysteine protease activities implicated in apoptosis in mammals(7-14). A p35 mutation that greatly reduced p35 activity in vitro as a CED-3 substrate and inhibitor abolished p35 activity in vivo in protecting against cell death in C. elegans. Introduction of the CED-3 cleavage site in p35 into the cowpox virus protein crmA, which inhibits mammalian apoptosis(14-19) but not programmed cell death in C. elegans, caused crmA to block CED3-mediated cell death. These observations suggest that p35 may prevent programmed cell death in C. elegans and other species by acting as a competitive inhibitor of cysteine proteases.			XUE, D (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			XUE, DING/0000-0002-8429-8136				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P75; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; FRIESEN PD, 1987, J VIROL, V61, P2264, DOI 10.1128/JVI.61.7.2264-2272.1987; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	435	449	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					248	251		10.1038/377248a0	http://dx.doi.org/10.1038/377248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675111				2022-12-28	WOS:A1995RV87200045
J	EVENS, RG				EVENS, RG			ROENTGEN RETROSPECTIVE - 100 YEARS OF A REVOLUTIONARY TECHNOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											EVENS, RG (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT INST RADIOL,510 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.							BELL L, 1896, ELEC WORLD ENG, V28, P729; BROWN P, 1936, AM MARTYRS SCI ROENT, P43; del Regato J A, 1973, Radiology, V107, P1; DONALDSON SW, 1954, ROENTGENOLOGIST COUR; EISENBERG RL, 1992, RADIOLOGY ILLUSTRATE, P22; ELSDALE H, 1896, 1894 REG SMITHS I AN, P679; EVENS RG, 1994, JAMA-J AM MED ASSOC, V271, P1714; GAGLIARDI RA, 1992, AJR AM J ROENTGENOL, V160, P1004; Glasser Otto, 1933, WC RONTGEN EARLY HIS; GOODMAN PC, 1994, XRAY ENTERS HOSPITAL, P6; JENKINSON EL, 1964, HIST AM BOARD RADIOL; JORDAN DS, 1896, APPLETONS POP SCI MO, V49, P597; KLICKSTEIN H, 1966, WC RONTGEN NEW KIND; Knight N., 1986, IMAGINING TOMORROW H, P10; NELSON PA, 1973, ARCH PHYS MED REHAB, V54, P608; RIGLER LG, 1945, RADIOLOGY, V45, P467, DOI 10.1148/45.5.467; RONTGEN WC, 1985, DEC P WURZB PHYS SOC; 1896, NY TIMES        0205, P9; 1896, NY TIMES        0116, P9; 1896, NY TIMES        0208, P9; 1903, 3RD T AM ROENTG RAY, P179; 1902, AM J MED SCI, P163; 1896, NY TIMES        0214, P9; 1900, JAMA-J AM MED ASSOC, V35, P688; 1896, SCI AM, V74, P103; 1898, JAMA-J AM MED ASSOC, V31, P1437; 1898, JAMA-J AM MED ASSOC, V31, P28; 1950, AM ROENTGEN RAY SOC; 1895, NY TIMES        0211, P16	29	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					912	916						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674507				2022-12-28	WOS:A1995RU60300032
J	LINDFORS, KK; ROSENQUIST, CJ				LINDFORS, KK; ROSENQUIST, CJ			THE COST-EFFECTIVENESS OF MAMMOGRAPHIC SCREENING STRATEGIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; FAMILY HISTORY; TRIAL; MORTALITY; AGE; INTERVAL; LESIONS; RISK	Objective.-To compare and analyze the cost-effectiveness of different mammographic screening strategies. Design.-A computer simulation model was developed to compare mammographic screening with observation without screening. Cost-effectiveness was expressed as marginal cost per year of life saved (MCYLS) and was calculated for the following mammographic screening strategies: (1) annual for ages 40 to 79 years; (2) annual for ages 50 to 79 years; (3) biennial for ages 50 to 79 years; (4) annual for ages 40 to 49 years with biennial for ages 50 to 79 years; (5) annual for ages 40 to 64 years with biennial for ages 65 to 79 years; (6) biennial for ages 40 to 49 years with annual for ages 50 to 79 years; and (7) annual for high-risk and biennial for normal-risk women aged 40 to 49 years with annual for ages 50 to 79 years. Data Sources.-The probability and cost of all outcomes were established from previously published data or community experience. Results.-The most cost-effective screening strategy is biennial mammography for women aged 50 to 79 years, with an MCYLS of $16 000. Adding annual mammography for women aged 40 to 49 years increases the MCYLS to $20 200, but is more cost-effective than other tested protocols that included women in their 40s; annual mammography for ages 40 to 49 years with biennial for ages 50 to 79 years is also more cost-effective than annual mammography for ages 50 to 79 years. Conclusion.-Screening programs that include women in their 40s can be as cost-effective as some that exclude such women. Choice of a screening strategy depends on financial resources and desired effectiveness.			LINDFORS, KK (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT RADIOL,2516 STOCKTON BLVD,TICON II 216,SACRAMENTO,CA 95817, USA.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BASSETT LW, 1991, AM J ROENTGENOL, V157, P21, DOI 10.2214/ajr.157.1.1646562; CARDENOSA G, 1995, AM J ROENTGENOL, V164, P1104, DOI 10.2214/ajr.164.5.7717213; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; CURPEN BN, 1995, AM J ROENTGENOL, V164, P1099, DOI 10.2214/ajr.164.5.7717212; DONEGAN WL, 1992, NEW ENGL J MED, V327, P937; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELLIS H, 1984, POSTGRAD MED J, V60, P653, DOI 10.1136/pgmj.60.708.653; FEIG SA, 1994, RADIOLOGY, V193, P311, DOI 10.1148/radiology.193.2.7972732; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; IKEDA DM, 1992, AM J ROENTGENOL, V159, P287, DOI 10.2214/ajr.159.2.1632342; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; LINDFORS KK, 1994, RADIOLOGY, V190, P217, DOI 10.1148/radiology.190.1.8259408; METTLIN C, 1994, CA-CANCER J CLIN, V44, P248, DOI 10.3322/canjclin.44.4.248; MOSKOWITZ M, 1986, RADIOLOGY, V161, P37, DOI 10.1148/radiology.161.1.3532183; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; PARKER SH, 1994, RADIOLOGY, V193, P359, DOI 10.1148/radiology.193.2.7972743; PARKER SH, 1990, RADIOLOGY, V176, P741, DOI 10.1148/radiology.176.3.2167501; RIES LAG, 1991, NIH912789 PUBL; ROBERTS MM, 1990, LANCET, V335, P241; ROSENQUIST CJ, 1994, RADIOLOGY, V191, P647, DOI 10.1148/radiology.191.3.8184041; Schmidt R, 1990, Adm Radiol, V9, P35; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SICKLES EA, 1991, RADIOLOGY, V179, P463, DOI 10.1148/radiology.179.2.2014293; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; SMART CR, 1994, CANCER, V74, P296, DOI 10.1002/cncr.2820741314; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; VOLKERS N, 1994, J NATL CANCER I, V86, P14, DOI 10.1093/jnci/86.1.14; 1991, STATISTICAL ABSTRACT, P84	34	106	108	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					881	884		10.1001/jama.274.11.881	http://dx.doi.org/10.1001/jama.274.11.881			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674501				2022-12-28	WOS:A1995RU60300026
J	VANHOUTTE, PM				VANHOUTTE, PM			THE MALE PARADOX	LANCET			English	Editorial Material							17-BETA-ESTRADIOL; RABBIT				VANHOUTTE, PM (corresponding author), INST RECH INT SERVIER,6 PL PLEIADES,F-92415 COURBEVOIE,FRANCE.		Vanhoutte, Paul M/B-4533-2009					FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; LAWRENCE WD, 1986, ENDOCRINOLOGY, V119, P2803, DOI 10.1210/endo-119-6-2803; Luscher T.F., 1990, ENDOTHELIUM MODULATO, V001-228; MILLER VM, 1990, AM J PHYSIOL, V258, pR1502, DOI 10.1152/ajpregu.1990.258.6.R1502; YUE P, 1995, CIRCULATION, V91, P1154, DOI 10.1161/01.CIR.91.4.1154	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					717	717		10.1016/S0140-6736(95)91497-8	http://dx.doi.org/10.1016/S0140-6736(95)91497-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658867				2022-12-28	WOS:A1995RU81000003
J	DEVRIES, A; VANOOSTROM, CTM; HOFHUIS, FMA; DORTANT, PM; BERG, RJW; DEGRUIJL, FR; WESTER, PW; VANKREIJL, CF; CAPEL, PJA; VANSTEEG, H; VERBEEK, SJ				DEVRIES, A; VANOOSTROM, CTM; HOFHUIS, FMA; DORTANT, PM; BERG, RJW; DEGRUIJL, FR; WESTER, PW; VANKREIJL, CF; CAPEL, PJA; VANSTEEG, H; VERBEEK, SJ			INCREASED SUSCEPTIBILITY TO ULTRAVIOLET-B AND CARCINOGENS OF MICE LACKING THE DNA EXCISION-REPAIR GENE XPA	NATURE			English	Article							A XERODERMA-PIGMENTOSUM; DAMAGED DNA; SEQUENCE; AFFINITY; CELLS	XERODERMA pigmentosum patients with a defect in the nucleotide-excision repair gene XPA are characterized by, for example, a >1,000-fold higher risk of developing sunlight-induced skin cancer(1-3). Nucleotide-excision repair (NER) is involved in the removal of a wide spectrum of DNA lesions, The XPA protein functions in a pre-incision step, the recognition of DNA damage(4-7). To permit the functional analysis of the XPA gene in vivo, we have generated XPA-deficient mice by gene targeting in embryonic stem cells, The YPA(-/-) mice appear normal, at least until the age of 13 months, XPA(-/-) mice are highly susceptible to ultraviolet (UV)-B-induced skin and eye tumours and to 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin tumours, We conclude that the XPA-deficient mice strongly mimic the phenotype of humans with xeroderma pigmentosum.	NATL INST PUBL HLTH & ENVIRONM PROTECT, CARCINOGENESIS & MUTAGENESIS LAB, 3720 BA BILTHOVEN, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, PATHOL LAB, 3720 BA BILTHOVEN, NETHERLANDS; UNIV UTRECHT, DEPT IMMUNOL, 3584 CX UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT DERMATOL, 3584 CX UTRECHT, NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University								ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DEGRUIJL FR, 1991, CANCER RES, V51, P979; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HOELJMAKERS JHJ, 1990, CANCER CELL, V2, P311; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; MAHER VM, 1984, PHARMACOL THERAPEUT, V25, P395, DOI 10.1016/0163-7258(84)90006-8; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SATOKATA I, 1992, HUM GENET, V88, P603, DOI 10.1007/BF02265282; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; VANOOSTROM CTM, 1994, NUCLEIC ACIDS RES, V22, P11, DOI 10.1093/nar/22.1.11; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x	17	345	350	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 14	1995	377	6545					169	173		10.1038/377169a0	http://dx.doi.org/10.1038/377169a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675086				2022-12-28	WOS:A1995RU75400054
J	SANDS, AT; ABUIN, A; SANCHEZ, A; CONTI, CJ; BRADLEY, A				SANDS, AT; ABUIN, A; SANCHEZ, A; CONTI, CJ; BRADLEY, A			HIGH SUSCEPTIBILITY TO ULTRAVIOLET-INDUCED CARCINOGENESIS IN MICE LACKING XPC	NATURE			English	Article							PIGMENTOSUM GROUP-C; CLONING; CELLS; GENE	COMPROMISE Of genetic information by mutation may result in the dysregulation of cellular growth control and subsequent tumour formation, Xeroderma pigmentosum (XP) is a rare autosomal disease characterized by hypersensitivity of the skin to sunlight and >1,000-fold increased risk of skin cancers in sun-exposed parts of the body, Cell fusion studies have revealed eight complementation groups In XP (A-G, and an XP-variant form); group C is one of the most common forms of the disease(1). We have isolated a mouse homologue of the human gene for XP group C and generated XPC-deficient mice by using embryonic stem cell technology. Mice homozygous for the XPC mutant allele (xpc(m1)/xpc(m1)) are viable and do not exhibit an increased susceptibility to spontaneous tumour generation at one year of age, However, xpc(m1)/xpc(m1) mice were found to be highly susceptible to ultraviolet-induced carcinogenesis compared with mice heterozygous for the mutant allele (xpc(m1)/+) and wild-type controls. Homozygous xpc(m1) mutant mice also display a spectrum of ultraviolet-exposure-related pathological skin and eye changes consistent with the human disease xeroderma pigmentosum group C.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV TEXAS MD ANDERSON,DEPT CARCINOGENESIS,SMITHVILLE,TX 78959	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center				Bradley, Allan/0000-0002-2349-8839				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1973, CANCER RES, V33, P362; GALIEGUEZOUITINA S, 1989, CARCINOGENESIS, V10, P1961, DOI 10.1093/carcin/10.10.1961; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HURT MA, 1993, PATHOLOGY INCIPIENT, P8; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEVER WF, 1990, HISTOPATHOLOGY SKIN, P523; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; STICH HF, 1973, MUTAT RES, V17, P127, DOI 10.1016/0027-5107(73)90261-3; TAKEBE H, 1972, MUTAT RES, V15, P98, DOI 10.1016/0027-5107(72)90099-1	16	215	223	2	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					162	165		10.1038/377162a0	http://dx.doi.org/10.1038/377162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675084				2022-12-28	WOS:A1995RU75400052
J	VANDEVEN, PJG; BEUTLER, JJ; KAATEE, R; BEEK, FJA; MALI, WPTM; GEYSKES, GG; KOOMANS, HA				VANDEVEN, PJG; BEUTLER, JJ; KAATEE, R; BEEK, FJA; MALI, WPTM; GEYSKES, GG; KOOMANS, HA			TRANSLUMINAL VASCULAR STENT FOR OSTIAL ATHEROSCLEROTIC RENAL-ARTERY STENOSIS	LANCET			English	Note							RENOVASCULAR HYPERTENSION; ANGIOPLASTY	We implanted transluminal stents in 24 hypertensive patients with a critical atherosclerotic ostial renal artery stenosis (28 arteries). Immediate revascularisation was successful in all. Follow-up angiography at 6 months, available in 18 patients, revealed restenosis twice. In another patient restenosis was suspected and confirmed by angiography at 2 months. Hence, the total restenosis rate was 3 of 19 patients (16%) and 3 of 23 arteries (13%). Two patients developed renal insufficiency due to cholesterol embolism. In the remaining 22 patients renal function improved (n=8) or stabilised (n=14). Although all had to resume antihypertensive treatment, blood pressure normalised in 15 patients, improved in one, remained unchanged in five and worsened in one.	UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT RADIOL,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center			Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				CANZANELLO VJ, 1989, HYPERTENSION, V13, P163, DOI 10.1161/01.HYP.13.2.163; DEAN RH, 1991, ANN SURG, V213, P446, DOI 10.1097/00000658-199105000-00010; Martin L G, 1992, J Vasc Interv Radiol, V3, P619, DOI 10.1016/S1051-0443(92)72907-8; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; PICOLI G, 1995, NEPHROL DIAL TRANSPL, V10, P444; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; REES CR, 1991, RADIOLOGY, V181, P505; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; STRANDNESS DE, 1994, AM J KIDNEY DIS, V24, P630, DOI 10.1016/S0272-6386(12)80224-1	10	141	144	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					672	674		10.1016/S0140-6736(95)92283-0	http://dx.doi.org/10.1016/S0140-6736(95)92283-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658821				2022-12-28	WOS:A1995RU04800012
J	WILSON, DS; GUENTHER, B; DESPLAN, C; KURIYAN, J				WILSON, DS; GUENTHER, B; DESPLAN, C; KURIYAN, J			HIGH-RESOLUTION CRYSTAL-STRUCTURE OF A PAIRED (PAX) CLASS COOPERATIVE HOMEODOMAIN DIMER ON DNA	CELL			English	Article							DROSOPHILA-MELANOGASTER; OPERATOR COMPLEX; PROTEIN; REFINEMENT; DOMAIN; GENE; SPECIFICITY; PARAMETERS; EXPRESSION; MODEL	The crystal structure of the paired homeodomain bound to DNA as a cooperative dimer has been determined to 2.0 Angstrom resolution. Direct contacts between each homeodomain and the DNA are similar to those described previously. In addition, an extensive network of water molecules mediates contacts between the recognition helix and the DNA major groove. Several symmetrical contacts between the two homeodomains underlie the cooperative interaction, and deformations in the DNA structure are necessary for the establishment of these contacts. Comparison with structures of homeodomains bound monomerically to DNA suggests that the binding of a single paired homeodomain can introduce these DNA distortions, thus preparing a template for the cooperative interaction with a second homeodomain. This study shows how the paired (Pax) class homeodomains have achieved cooperativity in DNA binding without the assistance of other domains, thereby enabling the recognition of target sequences that are long enough to ensure specificity.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University	WILSON, DS (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOPHYS LAB,NEW YORK,NY 10021, USA.			Desplan, Claude/0000-0002-6914-1413	NIGMS NIH HHS [GM-07982-12] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES SE, 1994, BIOCHEMISTRY-US, V33, P9187, DOI 10.1021/bi00197a022; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BURGLIN TR, 1995, IN PRESS P INT S BIO, V10; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MISMER D, 1989, GENETICS, V121, P77; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1993, J AM CHEM SOC, V115, P1189, DOI 10.1021/ja00056a077; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; WHITE R, 1994, CURR BIOL, V4, P48, DOI 10.1016/S0960-9822(00)00010-5; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	38	301	307	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					709	719		10.1016/0092-8674(95)90468-9	http://dx.doi.org/10.1016/0092-8674(95)90468-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671301	Bronze			2022-12-28	WOS:A1995RU75500006
J	HAYERHARTL, MK; MARTIN, J; HARTL, FU				HAYERHARTL, MK; MARTIN, J; HARTL, FU			ASYMMETRICAL INTERACTION OF GROEL AND GROES IN THE ATPASE CYCLE OF ASSISTED PROTEIN-FOLDING	SCIENCE			English	Article							SURFACE-PLASMON RESONANCE; HEAT-SHOCK PROTEINS; CHAPERONIN PROTEINS; CENTRAL CAVITY; HYDROLYSIS; BINDING; MITOCHONDRIA; HSP60	The chaperonins GroEL and GroES of Escherichia coli facilitate protein folding in an adenosine triphosphate (ATP)-dependent reaction cycle, The kinetic parameters for the formation and dissociation of GroEL-GroES complexes were analyzed by surface plasmon resonance. Association of GroES and subsequent ATP hydrolysis in the interacting GroEL toroid resulted in the formation of a stable GroEL:ADP:GroES complex. The complex dissociated as a result of ATP hydrolysis in the opposite GroEL toroid, without formation of a symmetrical GroEL:(GroES)(2) intermediate. Dissociation was accelerated by the addition of unfolded polypeptide. Thus, the functional chaperonin unit is an asymmetrical GroEL:GroES complex, and substrate protein plays an active role in modulating the chaperonin reaction cycle.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019; Hayer-Hartl, Manajit/V-8078-2017	Hayer-Hartl, Manajit/0000-0001-8213-6742	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HAYERHARTL MK, UNPUB; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5664; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567	42	134	137	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					836	841		10.1126/science.7638601	http://dx.doi.org/10.1126/science.7638601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638601				2022-12-28	WOS:A1995RN65000044
J	GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ				GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ			DOUBLE-BLIND TRIAL OF REPEATED TREATMENT WITH TRANSDERMAL NICOTINE FOR RELAPSED SMOKERS	BRITISH MEDICAL JOURNAL			English	Article							SMOKING CESSATION; PATCHES	Objective-To assess the efficacy and safety of a repeat course of treatment with transdermal nicotine for cessation of smoking in a brief intervention setting. Study design-Randomised, double blind, placebo controlled trial with follow up for 26 weeks. Subjects-629 smokers who had unsuccessfully attempted to stop smoking by using active transdermal nicotine and brief behavioural counselling. Smokers were motivated to quit smoking for a second time and smoked greater than or equal to 15 cigarettes a day. Interventions-Twelve weeks' treatment with active transdermal nicotine patches or placebo and brief counselling at monthly visits. Main outcome measure-Sustained smoking cessation for the 28 days before the visit at week 12 verified by expired carbon monoxide concentrations. Results-At 12 weeks 21/315 (6.7%) subjects allocated to active treatment had stopped smoking compared with 6/314 (1.9%) allocated to placebo (absolute difference 4.7%; 95% confidence interval 1.6% to 7.9%; P=0.003). At 26 weeks the rates were 20/315 (6.4%) and 8/314 (2.6%) (3.8%; 0.6% to 7.0%; P=0.021). Difficulty in sleeping was reported by 43/179 (24.0%) on active treatment and 19/143 (13.3%) on placebo (P=0.015). Severe reactions at the site of application were rare (6/322; 1.9%). Conclusions-Repeated treatment with transdermal nicotine together with brief counselling can improve the low success rates of smoking cessation in recently relapsed, moderate to heavy smokers. Questions remain about whether more intensive interventions or higher doses of nicotine could be more effective. The likelihood of severe reactions at the site of application with repeated treatment is low.	CIBA GEIGY NEW ZEALAND,AUCKLAND,NEW ZEALAND		GOURLAY, SG (corresponding author), MONASH UNIV,DEPT SOCIAL & PREVENT MED,MELBOURNE,VIC 3168,AUSTRALIA.		McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Forbes, Andrew/0000-0003-4269-914X				Abelin T, 1991, SMOKING CARDIOVASCUL, P35; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FOULDS J, 1992, PSYCHOPHARMACOLOGY, V106, P421, DOI 10.1007/BF02245429; GOURLAY SG, 1990, MED J AUSTRALIA, V153, P699, DOI 10.5694/j.1326-5377.1990.tb126327.x; GOURLAY SG, 1994, BRIT MED J, V309, P842, DOI 10.1136/bmj.309.6958.842; HAXBY D, 1994, J FAM PRACTICE, V38, P459; LEVIN ED, 1994, J CLIN PSYCHOPHARM, V14, P41; MATTICK RP, 1992, NCADA MONOGRAPH, V19, P15; MURRAY RP, 1993, AM J PUBLIC HEALTH, V83, P1251, DOI 10.2105/AJPH.83.9.1251; PIERCE JP, 1995, J NATL CANCER I, V87, P87, DOI 10.1093/jnci/87.2.87; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TONNESEN P, 1993, ADDICTION, V88, P533, DOI 10.1111/j.1360-0443.1993.tb02060.x; 1991, GOOD CLIN RES PRACTI	15	77	78	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					363	366		10.1136/bmj.311.7001.363	http://dx.doi.org/10.1136/bmj.311.7001.363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640544	Green Published			2022-12-28	WOS:A1995RN46900018
J	NWASOKWA, ON				NWASOKWA, ON			CORONARY-ARTERY BYPASS GRAFT DISEASE	ANNALS OF INTERNAL MEDICINE			English	Review							INTERNAL-MAMMARY-ARTERY; SAPHENOUS-VEIN GRAFTS; INFERIOR EPIGASTRIC ARTERY; HUMAN GASTROEPIPLOIC ARTERY; MUSCLE CELL-PROLIFERATION; VITAMIN-E CONSUMPTION; MYOCARDIAL REVASCULARIZATION; FOLLOW-UP; PROSTACYCLIN PRODUCTION; COLESTIPOL-NIACIN	Purpose: To review saphenous vein graft disease and its prevention and management. Data Sources: A MEDLINE search of articles published on saphenous vein and arterial bypass grafts. Study Selection: The reference sections of articles focused the selection of key studies. Data Extraction: Relevant data representing key findings were noted. Data Synthesis: The outcome of coronary artery bypass grafting with the saphenous vein graft is unsatisfactory because vein grafts are prone to occlusive disease. By 10 years after surgery, 50% have closed, mainly because of atherosclerosis. With vein graft disease and graft closure, symptoms return. The best way to prevent vein graft disease is to use the internal mammary artery graft. This has become the preferred graft because it is not affected by atherosclerosis. Consequently, it has a much higher patency rate: 90% after more than 10 years. This provides such clinical benefits as decreased occurrence of symptoms, better left ventricular performance, decreased need for reoperation, and prolongation of life. The limited supply of mammary arteries has stimulated interest in identifying alternative arterial grafts. Conclusions: To prevent vein graft disease, surgeons should bypass diseased coronary arteries with at least one arterial graft and take measures during the surgery to avoid endothelial injury to vein grafts. Treatment with antiplatelet agents decreases the vein graft occlusion rate. When graft atherosclerosis causes symptoms, reoperation will probably prolong life if an old graft to the left anterior descending coronary artery is diseased. Reoperation increases a patient's chance for survival if the surgeon uses at least one arterial graft.			NWASOKWA, ON (corresponding author), LONG ISL JEWISH MED CTR, HARRIS CHASANOFF HEART INST, DIV CARDIOL, NEW HYDE PK, NY 11042 USA.							AARNIO PTT, 1988, ANN THORAC SURG, V45, P390, DOI 10.1016/S0003-4975(98)90011-X; ACAR C, 1992, ANN THORAC SURG, V54, P652, DOI 10.1016/0003-4975(92)91007-V; ACCOLA KD, 1993, ANN THORAC SURG, V56, P872, DOI 10.1016/0003-4975(93)90347-K; ADCOCK OT, 1984, SURGERY, V96, P886; AKINS CW, 1994, ANN THORAC SURG, V58, P359, DOI 10.1016/0003-4975(94)92208-X; ANGELINI GD, 1989, ANN THORAC SURG, V48, P417, DOI 10.1016/S0003-4975(10)62869-X; ANGELINI GD, 1987, CARDIOVASC RES, V21, P28, DOI 10.1093/cvr/21.1.28; ANGELINI GD, 1987, J THORAC CARDIOV SUR, V94, P393; ARNETT EN, 1979, ANN INTERN MED, V91, P350, DOI 10.7326/0003-4819-91-3-350; ARNOLD M, 1972, J THORAC CARDIOV SUR, V64, P596; BAILLOT RG, 1985, ANN THORAC SURG, V40, P271, DOI 10.1016/S0003-4975(10)60040-9; BARNER HB, 1991, ANN THORAC SURG, V52, P429, DOI 10.1016/0003-4975(91)90902-3; BARNER HB, 1985, J THORAC CARDIOV SUR, V90, P668; BARNER HB, 1994, ANN THORAC SURG, V57, P8, DOI 10.1016/0003-4975(94)90356-5; BARNER HB, 1994, ANN THORAC SURG, V57, P1526, DOI 10.1016/0003-4975(94)90114-7; BASHOUR TT, 1986, AM HEART J, V111, P143, DOI 10.1016/0002-8703(86)90566-1; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BOYLAN MJ, 1994, J THORAC CARDIOV SUR, V107, P657; BRODY WR, 1972, AM J PATHOL, V66, P111; BROWN BG, 1985, CIRCULATION, V72, P138, DOI 10.1161/01.CIR.72.1.138; BUCHE M, 1992, J THORAC CARDIOV SUR, V103, P665; BULKLEY BH, 1978, AM HEART J, V95, P757, DOI 10.1016/0002-8703(78)90507-0; CALAFIORE AM, 1994, ANN THORAC SURG, V58, P185, DOI 10.1016/0003-4975(94)91097-9; CAMERON A, 1988, CIRCULATION, V77, P815, DOI 10.1161/01.CIR.77.4.815; CAMERON A, 1986, CIRCULATION, V74, P30; CAMERON AAC, 1995, J AM COLL CARDIOL, V25, P188, DOI 10.1016/0735-1097(94)00332-K; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; CAMPEAU L, 1983, CIRCULATION, V68, P1; CAMPEAU L, 1979, CIRCULATION, V60, pI1, DOI 10.1161/01.CIR.60.2.1; CAMPOS EE, 1993, J AM COLL CARDIOL, V21, P1175, DOI 10.1016/0735-1097(93)90242-S; CARACCIOLO EA, 1995, CIRCULATION, V91, P2335, DOI 10.1161/01.CIR.91.9.2335; CARACCIOLO EA, 1995, CIRCULATION, V91, P2325, DOI 10.1161/01.CIR.91.9.2325; CAREW TE, 1989, AM J CARDIOL, V64, pG18, DOI 10.1016/0002-9149(89)90951-X; CARRIER M, 1992, ANN THORAC SURG, V53, P115, DOI 10.1016/0003-4975(92)90768-Y; CARROZZA JP, 1992, J AM COLL CARDIOL, V20, P328, DOI 10.1016/0735-1097(92)90098-8; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CHAIKHOUNI A, 1986, J THORAC CARDIOV SUR, V92, P88; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; COLTHARP WH, 1991, ANN THORAC SURG, V52, P225, DOI 10.1016/0003-4975(91)91340-2; Conkle D M, 1973, Surg Forum, V24, P245; CONTI CR, 1993, CLIN CARDIOL, V16, P279, DOI 10.1002/clc.4960160401; COSGROVE DM, 1988, J THORAC CARDIOV SUR, V95, P850; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; DALY RC, 1988, J THORAC CARDIOV SUR, V96, P19; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; DEFEYTER PIMJ, 1993, J AM COLL CARDIOL, V21, P1539, DOI 10.1016/0735-1097(93)90366-9; Favaloro R G, 1968, Ann Thorac Surg, V5, P334; FIORE AC, 1990, ANN THORAC SURG, V49, P202, DOI 10.1016/0003-4975(90)90139-W; FITZGIBBON GM, 1991, J AM COLL CARDIOL, V17, P1075, DOI 10.1016/0735-1097(91)90834-V; FITZGIBBON GM, 1986, J THORAC CARDIOV SUR, V91, P773; FLEMMA RJ, 1975, ANN THORAC SURG, V20, P619, DOI 10.1016/S0003-4975(10)65753-0; FOSTER ED, 1989, CIRCULATION, V79, P34; FUCHS JCA, 1978, ANN SURG, V188, P1, DOI 10.1097/00000658-197807000-00001; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; FUSTER V, 1986, CIRCULATION, V73, P227, DOI 10.1161/01.CIR.73.2.227; FUSTER V, 1991, CARDIOLOGY FUNDAMENT, V2, P1172; GALBUT DL, 1993, J THORAC CARDIOV SUR, V106, P128, DOI 10.1016/S0022-5223(19)33749-3; GALBUT DL, 1990, ANN THORAC SURG, V49, P195, DOI 10.1016/0003-4975(90)90138-V; GARDNER TJ, 1990, ANN THORAC SURG, V49, P188, DOI 10.1016/0003-4975(90)90137-U; GEIRINGER E, 1951, J PATHOL BACTERIOL, V63, P201, DOI 10.1002/path.1700630204; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; GOLDMAN S, 1991, CIRCULATION, V84, P520, DOI 10.1161/01.CIR.84.2.520; GONZALEZSANTOS JM, 1984, THORAC CARDIOV SURG, V32, P346, DOI 10.1055/s-2007-1023421; GRANDJEAN JG, 1994, J THORAC CARDIOV SUR, V107, P1309, DOI 10.1016/S0022-5223(94)70052-4; GREEN GE, 1994, ANN THORAC SURG, V58, P74, DOI 10.1016/0003-4975(94)91074-X; GREEN GE, 1993, ANN THORAC SURG, V55, P967, DOI 10.1016/0003-4975(93)90127-4; Grondin C M, 1986, J Card Surg, V1, P313, DOI 10.1111/j.1540-8191.1986.tb00719.x; GRONDIN CM, 1984, CIRCULATION, V70, P208; GRONDIN CM, 1989, CIRCULATION, V79, P24; GROSSI EA, 1991, J THORAC CARDIOV SUR, V102, P342; GUNDRY SR, 1992, J THORAC CARDIOV SUR, V103, P896; HAMBY RI, 1977, AM HEART J, V93, P306, DOI 10.1016/S0002-8703(77)80249-4; HE GW, 1994, J THORAC CARDIOV SUR, V107, P196; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; HORNEFFER PJ, 1987, CIRCULATION, V76, P6; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; IVERT T, 1988, J THORAC CARDIOV SUR, V96, P1; JOYCE FS, 1994, ANN THORAC SURG, V58, P80, DOI 10.1016/0003-4975(94)91075-8; KAUFMANN UP, 1990, AM J CARDIOL, V65, P1430, DOI 10.1016/0002-9149(90)91349-B; KAY HR, 1976, ANN THORAC SURG, V21, P504, DOI 10.1016/S0003-4975(10)63917-3; KEON WJ, 1982, J THORAC CARDIOV SUR, V84, P849; KIESER TM, 1986, J THORAC CARDIOV SUR, V91, P767; KOUCHOUKOS NT, 1990, ANN THORAC SURG, V49, P210, DOI 10.1016/0003-4975(90)90140-2; KUNTZ RE, 1992, CIRCULATION, V86, P1827, DOI 10.1161/01.CIR.86.6.1827; LANDYMORE RW, 1987, ANN THORAC SURG, V44, P4, DOI 10.1016/S0003-4975(10)62342-9; LARSEN E, 1969, SCAND J GASTROENTERO, V4, P387, DOI 10.3109/00365526909180620; LIMET R, 1987, J THORAC CARDIOV SUR, V94, P773; LOGERFO FW, 1983, CIRCULATION, V68, P117; LOOP FD, 1990, ANN THORAC SURG, V49, P179, DOI 10.1016/0003-4975(90)90136-T; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LOOP FD, 1986, J THORAC CARDIOV SUR, V92, P827; LOOP FD, 1989, CIRCULATION, V79, P40; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; LYTLE BW, 1993, J THORAC CARDIOV SUR, V105, P605; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; LYTLE BW, 1987, J THORAC CARDIOV SUR, V93, P847; LYTLE BW, 1992, J THORAC CARDIOV SUR, V103, P831; LYTLE BW, 1989, J THORAC CARDIOV SUR, V97, P826; LYTLE BW, 1983, ANN THORAC SURG, V36, P540, DOI 10.1016/S0003-4975(10)60684-4; MALM T, 1992, J THORAC CARDIOV SUR, V104, P600; MARSHALL WG, 1986, ANN THORAC SURG, V42, P163, DOI 10.1016/S0003-4975(10)60511-5; MCENANY MT, 1982, J THORAC CARDIOV SUR, V83, P81; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MESTRES CA, 1986, THORAC CARDIOV SURG, V34, P356, DOI 10.1055/s-2007-1022172; MILLS NL, 1993, J THORAC CARDIOV SUR, V106, P579, DOI 10.1016/S0022-5223(19)33697-9; MORRIS JJ, 1990, CIRCULATION, V82, P214; NEITZEL GF, 1986, ARTERIOSCLEROSIS, V6, P594, DOI 10.1161/01.ATV.6.6.594; NGUYEN HC, 1994, ANN THORAC SURG, V58, P308, DOI 10.1016/0003-4975(94)92198-9; NWASOKWA ON, 1991, ANN INTERN MED, V114, P1035, DOI 10.7326/0003-4819-114-12-1035; OKIES JE, 1984, CIRCULATION, V70, P213; OKU T, 1990, ANN THORAC SURG, V49, P767, DOI 10.1016/0003-4975(90)90018-2; OLEARCHYK AS, 1988, J THORAC CARDIOV SUR, V96, P13; ONEIL GS, 1991, J THORAC CARDIOV SUR, V102, P561; PANTELY GA, 1979, NEW ENGL J MED, V301, P962, DOI 10.1056/NEJM197911013011803; PEDUZZI P, 1992, CIRCULATION, V86, P121; PIANA RN, 1994, J AM COLL CARDIOL, V23, P1296, DOI 10.1016/0735-1097(94)90370-0; POMERANTZ RM, 1992, AM J CARDIOL, V70, P161, DOI 10.1016/0002-9149(92)91269-A; PUIG LB, 1990, J THORAC CARDIOV SUR, V99, P251; PYM J, 1987, J THORAC CARDIOV SUR, V94, P256; RAJAH SM, 1985, J THORAC CARDIOV SUR, V90, P373; RATLIFF NB, 1989, ARCH PATHOL LAB MED, V113, P772; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSENGART TK, 1993, ANN THORAC SURG, V56, pS74, DOI 10.1016/0003-4975(93)91139-E; SAFIAN RD, 1994, CIRCULATION, V89, P302, DOI 10.1161/01.CIR.89.1.302; SALOMON NW, 1990, J THORAC CARDIOV SUR, V100, P250; SELMON M R, 1991, Journal of the American College of Cardiology, V17, p23A; SERGEANT P, 1991, EUR J CARDIO-THORAC, V5, P447, DOI 10.1016/1010-7940(91)90140-F; SIMS FH, 1987, ANN THORAC SURG, V44, P2, DOI 10.1016/S0003-4975(10)62341-7; SIMS FH, 1985, ARTERY, V13, P127; SIMS FH, 1983, AM HEART J, V105, P560, DOI 10.1016/0002-8703(83)90478-7; SINGH RN, 1986, ANN THORAC SURG, V41, P247, DOI 10.1016/S0003-4975(10)62763-4; SINGH RN, 1983, J THORAC CARDIOV SUR, V86, P359; SISTO T, 1989, ANN THORAC SURG, V47, P884, DOI 10.1016/0003-4975(89)90027-1; SOLYMOSS BC, 1988, CIRCULATION, V78, P140; SOYOMBO AA, 1993, CARDIOVASC RES, V27, P1961, DOI 10.1093/cvr/27.11.1961; SPENCER FC, 1986, NEW ENGL J MED, V314, P50, DOI 10.1056/NEJM198601023140109; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; SUMA H, 1989, ANN THORAC SURG, V47, P712, DOI 10.1016/0003-4975(89)90123-9; VANDERMEER J, 1994, J AM COLL CARDIOL, V24, P1181, DOI 10.1016/0735-1097(94)90096-5; VANSON JAM, 1990, J THORAC CARDIOV SUR, V99, P703; VERHEUL HA, 1991, AM J CARDIOL, V67, P24, DOI 10.1016/0002-9149(91)90093-Z; VINCENT JG, 1990, ANN THORAC SURG, V49, P323, DOI 10.1016/0003-4975(90)90164-2; WALTS AE, 1987, AM HEART J, V114, P718, DOI 10.1016/0002-8703(87)90780-0	147	110	124	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					528	545		10.7326/0003-4819-123-7-199510010-00009	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00009			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661498				2022-12-28	WOS:A1995RW49500009
J	SPENCE, JD; HUFF, MW; HEIDENHEIM, P; VISWANATHA, A; MUNOZ, C; LINDSAY, R; WOLFE, B; MILLS, D				SPENCE, JD; HUFF, MW; HEIDENHEIM, P; VISWANATHA, A; MUNOZ, C; LINDSAY, R; WOLFE, B; MILLS, D			COMBINATION THERAPY WITH COLESTIPOL AND PSYLLIUM MUCILLOID IN PATIENTS WITH HYPERLIPIDEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						COLESTIPOL; HYPERLIPIDEMIA; PSYLLIUM; HYPERCHOLESTEROLEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG	MODERATE HYPERCHOLESTEROLEMIA; PRUDENT DIET; CHOLESTEROL; LOVASTATIN; MILD; EFFICACY; DISEASE; ADJUNCT; FIBER; FAT	Objective: To test whether combining psyllium mucilloid with half the usual dose of colestipol reduces the adverse effects associated with colestipol and maintains or increases its efficacy in the treatment of hyperlipidemia. This strategy might make bile acid sequestrants, which are seldom used because they cause adverse effects such as bloating and constipation, more tolerable and less expensive. Design: A randomized, parallel-group, double-blind, controlled trial. Setting: An outpatient clinic in a tertiary care hospital. Patients: 121 patients who had moderate primary hypercholesterolemia (total cholesterol level >6 mmol/L and <8 mmol/L; triglyceride level <3 mmol/L) after following a low-fat diet for 1 year (National Cholesterol Education Program Step Two diet). Intervention: 5 g of cellulose placebo; 5 g of colestipol; 2.5 g of colestipol plus 2.5 g of psyllium; or 5 g of psyllium three times daily before meals for 10 weeks. Main Outcome Measures: At baseline and at weeks 4 and 10, fasting blood lipid levels and apoprotein concentrations were measured and a quality-of-life instrument was completed. Results: A combination of 2.5 g of psyllium and 2.5 g of colestipol was better tolerated than and as effective as either 5 g of colestipol alone or 5 g of psyllium alone. The combination therapy and colestipol alone did not differ significantly with respect to changes in individual lipid values. The ratio of total cholesterol to high-density lipoprotein cholesterol (HDL) was reduced by 18.2% (95% CI, 12.3% to 24%) with the combination therapy; by 10.6% (CI, 2.0% to 15.4%) with colestipol alone; by 6.1% (CI, 1.5% to 10.6%) with psyllium alone; and by 0.1% (CI, -4.8% to 7%) with placebo (P = 0.0002). Combination therapy reduced the ratio of total cholesterol to HDL significantly more than did colestipol alone or psyllium alone (P < 0.05). Conclusions: These findings suggest that adding psyllium to half the usual dose of bile acid sequestrant resins maintains the efficacy and improves the tolerability of these resins.	UNIV WESTERN ONTARIO, ROBARTS RES INST 416, LONDON, ON N6C 3Y8, CANADA; VICTORIA HOSP, SSC, LONDON, ON N6A 4G5, CANADA; VICTORIA HOSP, DIV NEPHROL, LONDON, ON N6A 4G5, CANADA	Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario)	SPENCE, JD (corresponding author), STROKE PREVENT & ATHEROSCLEROSIS RES CTR, ROBARTS & SIEBENS DRAKE RES INST, 1400 WESTERN RD, LONDON, ON N6G 2V2, CANADA.		Huff, Murray/G-3307-2011; Spence, J. David/K-6396-2013; Lindsay, Bob/G-3321-2011	Spence, J. David/0000-0001-7478-1098; 				ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; ANDERSON JW, 1988, ARCH INTERN MED, V148, P292, DOI 10.1001/archinte.148.2.292; ANDERSON JW, 1992, AM J CLIN NUTR, V56, P93, DOI 10.1093/ajcn/56.1.93; ARO A, 1981, DIABETOLOGIA, V21, P29, DOI 10.1007/BF03216219; BELL LP, 1989, JAMA-J AM MED ASSOC, V261, P3419, DOI 10.1001/jama.261.23.3419; Carmines E. G., 1979, RELIABILITY VALIDITY, DOI DOI 10.4135/9781412985642; CASTELLI WP, 1983, CIRCULATION, V67, P730, DOI 10.1161/01.CIR.67.4.730; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; GUYATT GH, 1986, CAN MED ASSOC J, V134, P889; HUFF MW, 1985, J LIPID RES, V26, P1175; HUFF MW, 1984, BIOCHIM BIOPHYS ACTA, V796, P251, DOI 10.1016/0005-2760(84)90125-5; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; JACKSON DN, 1976, BASIC PERSONALITY IN; JENKINS DJA, 1993, NEW ENGL J MED, V329, P21, DOI 10.1056/NEJM199307013290104; LEVIN EG, 1990, ARCH INTERN MED, V150, P1822, DOI 10.1001/archinte.150.9.1822; MARGETTS BM, 1987, CLIN SCI, V72, P343, DOI 10.1042/cs0720343; NORUSIS MJ, 1988, SPSSPC PLUS ADV STAT; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHROTT HG, 1995, AM J CARDIOL, V75, P34, DOI 10.1016/S0002-9149(99)80523-2; SPRECHER DL, 1993, ANN INTERN MED, V119, P545, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00001; SUHONEN R, 1983, ALLERGY, V38, P363, DOI 10.1111/j.1398-9995.1983.tb04132.x; SUPERKO HR, 1992, AM J CARDIOL, V70, P135, DOI 10.1016/0002-9149(92)91264-5; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WITZTUM JL, 1989, CIRCULATION, V79, P16, DOI 10.1161/01.CIR.79.1.16; YEO WW, 1992, CLIN HYPERTENSION, P709	25	33	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					493	+		10.7326/0003-4819-123-7-199510010-00003	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661492				2022-12-28	WOS:A1995RW49500003
J	BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B				BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B			USE OF GLYCOSAMINOGLYCANS TO INCREASE EFFICIENCY OF LONG-TERM CONTINUOUS PERITONEAL-DIALYSIS	LANCET			English	Note							CELL-PROLIFERATION; HEPARIN	Long-term continuous ambulatory peritoneal dialysis (CAPD) frequently induces progressive structural changes in the peritoneal membrane, leading to dialysis failure. Because heparin and glycosaminoglycans favourably remodel anatomical barriers exposed to injury, we studied the effect of intraperitoneal administration of glycosaminoglycans on peritoneal dialysis efficiency. 16 CAPD patients received glycosaminoglycans for 30 days followed by a 30-day wash-out. Glycosaminoglycans in urea and creatinine dialysate-to-plasma ratios significantly increased (means 0.86 and 0.78 at baseline, 0.92 and 0.82 at 30 days, respectively). Peritoneal protein loss was reduced, and serum albumin concentration increased. We now need to assess whether glycosaminoglycans can postpone dialysis failure in the long term.	UNIV PADUA,INST INTERNAL MED,PADUA,ITALY; UNIV PADUA,DIV NEPHROL,PADUA,ITALY; UMBERTO I GEN HOSP,DIV NEPHROL,MESTRE,ITALY	University of Padua; University of Padua; ULSS 3 Serenissima								BREBOROWICZ A, 1994, NEPHRON, V67, P346, DOI 10.1159/000187991; CAENAZZO C, 1995, NEPHROL DIAL TRANSPL, V10, P175; CHAIMOVITZ C, 1994, KIDNEY INT, V45, P1226, DOI 10.1038/ki.1994.163; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COFFEY AK, 1985, AM J PATHOL, V120, P248; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; GAMBARO G, 1994, J AM SOC NEPHROL, V5, P448; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369	10	48	49	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					740	741						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658876				2022-12-28	WOS:A1995RU81000012
J	DUPONT, RL; VOTH, EA				DUPONT, RL; VOTH, EA			DRUG LEGALIZATION, HARM REDUCTION, AND DRUG POLICY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MARIJUANA	The current U.S. policy options on drug use are reviewed in the context of the history of drug policy in the United States. A restrictive drug policy is a deterrent to drug use and helps reduce drug-related costs and societal problems. Although legalization or decriminalization of drugs might reduce some of the legal consequences of drug use, increased drug use would result in harmful consequences.	INST BEHAV & HLTH INC, WASHINGTON, DC USA; UNIV KANSAS, SCH MED, KANSAS CITY, KS USA	University of Kansas; University of Kansas Medical Center								BERMAN AL, 1990, AM J DIS CHILD, V144, P310, DOI 10.1001/archpedi.1990.02150270060026; BRECHER EM, 1972, LICIT ILLICIT DRUGS, P267; DELEON G, 1994, J ADDICT DIS, V13, P35, DOI 10.1300/J069v13n02_04; ERICKSON PG, 1993, PSYCHOACTIVE DRUGS H, P196; GOLD MS, 1991, GOOD NEWS DRUGS ALCO, P245; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P904, DOI 10.1001/jama.269.7.904; HORAN CM, 1990, SUBSTANCE ABUSE NATI; KLEBER HD, 1994, NEW ENGL J MED, V330, P361, DOI 10.1056/NEJM199402033300514; MAGUIRE K, 1992, SOURCEBOOK CRIMINAL, P491; MODEL KE, 1993, J AM STAT ASSOC, V88, P737, DOI 10.2307/2290758; MUSTO DF, 1987, AM DISEASE ORIGINS N; NADELMAN E, 1994, HARM REDUCTION APPRO; NAHAS G, 1992, MED J AUSTRALIA, V156, P495, DOI 10.5694/j.1326-5377.1992.tb126479.x; POLEN MR, 1993, WESTERN J MED, V158, P596; RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008; ROMER D, 1994, PEDIATRICS, V93, P1073; Rydell CP, 1994, CONTROLLING COCAINE; SCHWARTZ RH, 1987, PEDIATR CLIN N AM, V34, P305; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; VOTH EA, 1995, JAMA-J AM MED ASSOC, V273, P459, DOI 10.1001/jama.1995.03520300029027; 1994, PHS NIH943809 US DEP; 1993, GAOGGD9382 US GEN AC; 1991, DHHS ADM911704 US DE; 1992, DRUGS CRIME CRIMINAL, P126; 1993, DHHS SMA931980 NAT I; 1981, JAMA-J AM MED ASSOC, V246, P1823; 1987, AM J PSYCHIAT, V144, P698; 1991, JAMA-J AM MED ASSOC, V265, P2102	28	44	44	1	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					461	465		10.7326/0003-4819-123-6-199509150-00011	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639447				2022-12-28	WOS:A1995RU43700010
J	WHITEWAY, MS; WU, CL; LEEUW, T; CLARK, K; FOURESTLIEUVIN, A; THOMAS, DY; LEBERER, E				WHITEWAY, MS; WU, CL; LEEUW, T; CLARK, K; FOURESTLIEUVIN, A; THOMAS, DY; LEBERER, E			ASSOCIATION OF THE YEAST PHEROMONE RESPONSE G-PROTEIN BETA-GAMMA-SUBUNITS WITH THE MAP KINASE SCAFFOLD STE5P	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; GENE; PATHWAY; ENCODES; SEQUENCE; MUTANTS; RAS; TRANSCRIPTION	The mating response pathway of the yeast Saccharomyces cerevisiae includes a heterotrimeric guanine nucleotide-binding protein (G protein) that activates a mitogen-activated protein (MAP) kinase cascade by an unknown mechanism. An amino-terminal fragment of the MAP kinase scaffold protein Ste5p that interfered with pheromone-induced cell cycle arrest was identified. A haploid-specific interaction between the amino terminus of Ste5p and the G protein beta subunit Ste4p was also detected in a two-hybrid assay, and the product of a signaling-defective allele of STE4 was defective in this interaction. In cells with a constitutively activated pheromone response pathway, epitope-tagged Ste4p was coimmunoprecipitated with Ste5p, Thus, association of the G protein and the MAP kinase cassette via the scaffolding protein Ste5p may transmit the G protein signal.			WHITEWAY, MS (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,6100 ROYALMOUNT AVE,MONTREAL,PQ H4P 2R2,CANADA.		Fourest-Lieuvin, Anne/AGA-6504-2022; Thomas, David/M-7661-2017	Fourest-Lieuvin, Anne/0000-0003-1325-6788; Thomas, David/0000-0002-8854-762X				BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARLOW E, 1988, ANTIBODIES LABORATOR; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MUKAI Y, 1993, MOL CELL BIOL, V13, P2050, DOI 10.1128/MCB.13.4.2050; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NEER EJ, 1995, CELL, V80, P247; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; PERLMAN R, 1993, P NATL ACAD SCI USA, V90, P5474, DOI 10.1073/pnas.90.12.5474; PRINTEN JA, 1994, GENETICS, V138, P609; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WHITEWAY M, 1992, BIOCHEM CELL BIOL, V70, P1230, DOI 10.1139/o92-169; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	43	155	162	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1572	1575		10.1126/science.7667635	http://dx.doi.org/10.1126/science.7667635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667635				2022-12-28	WOS:A1995RU81300040
J	HORTON, R				HORTON, R			WILL DUESBERG NOW CONCEDE DEFEAT	LANCET			English	Editorial Material																		DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DUESBERG P, 1994, INT ARCH ALLERGY IMM, V103, P118, DOI 10.1159/000236617	2	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					656	656		10.1016/S0140-6736(95)92277-6	http://dx.doi.org/10.1016/S0140-6736(95)92277-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658817				2022-12-28	WOS:A1995RU04800006
J	MCGUFFIN, P; OWEN, MJ; FARMER, AE				MCGUFFIN, P; OWEN, MJ; FARMER, AE			GENETIC-BASIS OF SCHIZOPHRENIA	LANCET			English	Article							FAMILIAL ALZHEIMERS-DISEASE; DSM-III; ENVIRONMENTAL-FACTORS; TWIN CONCORDANCE; STRATEGIES; HETEROGENEITY; DISORDERS; RELATIVES; ETIOLOGY; ADOPTEES		UNIV WALES COLL MED, DEPT MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; UNIV WALES COLL MED, DEPT POSTGRAD MED EDUC, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University; Cardiff University	MCGUFFIN, P (corresponding author), UNIV WALES COLL MED, DEPT PSYCHOL MED, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.		McGuffin, Peter/A-1565-2012	McGuffin, Peter/0000-0002-9888-2907				ALEXANDER RC, 1990, PSYCHIAT RES, V31, P221, DOI 10.1016/0165-1781(90)90091-I; ASHERSON P, 1994, BRIT J PSYCHIAT, V164, P619, DOI 10.1192/bjp.164.5.619; ASHERSON P, 1994, AM J HUM GENET, V54, P386; BASSETT AS, 1994, AM J HUM GENET, V54, P864; Bleuler M., 1978, SCHIZOPHRENIC DISORD; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; Claridge G., 1988, SCHIZOPHRENIA MAJOR, P187; CLONINGER CR, 1985, ARCH GEN PSYCHIAT, V42, P15; CLONINGER CR, 1994, AM J MED GENET, V54, P83, DOI 10.1002/ajmg.1320540202; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CROCQ MA, 1992, J MED GENET, V29, P858, DOI 10.1136/jmg.29.12.858; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x; FARMER AE, 1983, PSYCHIAT RES, V8, P1, DOI 10.1016/0165-1781(83)90132-4; FARMER AE, 1987, ARCH GEN PSYCHIAT, V44, P634; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gottesman I.I., 1982, SCHIZOPHRENIA EPIGEN; GOTTESMAN II, 1989, ARCH GEN PSYCHIAT, V46, P867; GOTTESMAN II, 1967, P NATL ACAD SCI USA, V58, P199, DOI 10.1073/pnas.58.1.199; GOTTESMAN II, 1991, SCHIZOPHRENIA GENETI; HASEMAN JK, 1970, BEHAV GENET, V1, P11, DOI 10.1007/BF01067367; HESTON LL, 1966, BRIT J PSYCHIAT, V112, P819, DOI 10.1192/bjp.112.489.819; KELSOE JR, 1989, NATURE, V342, P238, DOI 10.1038/342238a0; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KENDLER KS, 1984, ARCH GEN PSYCHIAT, V41, P555; KENDLER KS, 1988, ARCH GEN PSYCHIAT, V45, P377; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KENDLER KS, 1994, ARCH GEN PSYCHIAT, V51, P456; KETY SS, 1983, AM J PSYCHIAT, V140, P720; KETY SS, IN PRESS ARCH GEN PS; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEBOYER M, 1991, BRIT J PSYCHIAT, V158, P605, DOI 10.1192/bjp.158.5.605; MCGUE M, 1985, Genetic Epidemiology, V2, P99, DOI 10.1002/gepi.1370020110; MCGUFFIN P, 1986, PSYCHOL MED, V16, P461, DOI 10.1017/S0033291700009302; MCGUFFIN P, 1994, BRIT J PSYCHIAT, V164, P593, DOI 10.1192/bjp.164.5.593; MCGUFFIN P, 1987, BRIT J PSYCHIAT, V150, P581, DOI 10.1192/bjp.150.5.581; MCGUFFIN P, 1990, AM J HUM GENET, V47, P524; Mott FW, 1910, BRIT MED J, V1910, P1013, DOI 10.1136/bmj.2.2597.1013; MURRAY RM, 1985, LANCET, V1, P1023; ONSTAD S, 1991, ACTA PSYCHIAT SCAND, V83, P395, DOI 10.1111/j.1600-0447.1991.tb05563.x; PENROSE LS, 1991, EUR ARCH PSY CLIN N, V240, P315, DOI 10.1007/BF02279760; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; RISCH N, 1990, AM J HUM GENET, V46, P242; ROSENTHAL D, 1968, TRANSMISSION SCHIZOP; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SHERRINGTON R, 1988, NATURE, V336, P164, DOI 10.1038/336164a0; Slater E, 1971, GENETICS MENTAL DISO; Slater E, 1947, MON PSYCHIATR NEUROL, V113, P50; SOBELL JL, 1992, GENOMICS, V12, P1, DOI 10.1016/0888-7543(92)90398-C; STROMGREN E, 1994, AM J MED GENET, V54, P405, DOI 10.1002/ajmg.1320540422; TIENARI P, 1991, SEARCH CAUSES SCHIZO, V2, P126; TSUANG MT, 1990, BRIT J PSYCHIAT, V156, P17, DOI 10.1192/bjp.156.1.17; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VOGLER GP, 1990, BEHAV GENET, V20, P461, DOI 10.1007/BF01067712; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WENDER PH, 1974, ARCH GEN PSYCHIAT, V30, P121; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC; 1994, NAT GENET, V8, P310	59	253	260	0	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 9	1995	346	8976					678	682		10.1016/S0140-6736(95)92285-7	http://dx.doi.org/10.1016/S0140-6736(95)92285-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU048	7658823				2022-12-28	WOS:A1995RU04800014
J	FENTON, JE; HONE, S; GORMLEY, P; ODWYER, TP; MCSHANE, DP; TIMON, CI				FENTON, JE; HONE, S; GORMLEY, P; ODWYER, TP; MCSHANE, DP; TIMON, CI			LESSON OF THE WEEK - HYPOPHARYNGEAL TUMORS MAY BE MISSED ON FLEXIBLE ESOPHAGOGASTROSCOPY	BRITISH MEDICAL JOURNAL			English	Article									ST JAMES HOSP,DEPT OTOLARYNGOL,DUBLIN 8,IRELAND; ST JAMES HOSP,DEPT HEAD & NECK SURG,DUBLIN 8,IRELAND; UNIV COLL HOSP GALWAY,GALWAY,IRELAND; MATER MISERICORDIAE HOSP,DUBLIN 7,IRELAND; MANCH HOSP,DUBLIN,IRELAND	Trinity College Dublin; Trinity College Dublin; Ollscoil na Gaillimhe-University of Galway; Mater Misericordiae University Hospital; University College Dublin								ADAMS GL, 1993, OTOLARYNGOLOGY HEAD, V3, P1955; BINGHAM BJ, 1986, ANN ROYAL COLLEGE SU, V68, P22; Logemann JA, 1983, EVALUATION TREATMENT; MARAN AGD, 1993, STELL MARANS HEAD NE, P161; PAIROLERO PC, 1989, PRINCIPLES SURG, P1103; THOMSON HG, 1989, J LARYNGOL OTOL, V103, P399, DOI 10.1017/S0022215100109053	6	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					623	624		10.1136/bmj.311.7005.623	http://dx.doi.org/10.1136/bmj.311.7005.623			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663260	Green Published			2022-12-28	WOS:A1995RT72300027
J	HEINSOHN, R; PACKER, C				HEINSOHN, R; PACKER, C			COMPLEX COOPERATIVE STRATEGIES IN GROUP-TERRITORIAL AFRICAN LIONS	SCIENCE			English	Article							PRISONERS-DILEMMA GAME; RECIPROCAL ALTRUISM; EVOLUTION; SCROUNGERS; PRODUCERS; FOOD	Female lions (Panthera leo) showed persistent individual differences in the extent to which they participated in group-territorial conflict. When intergroup encounters were simulated by playback of aggressive vocalizations, some individuals consistently led the approach to the recorded intruder, whereas others lagged behind and avoided the risks of fighting, The lead females recognized that certain companions were laggards but failed to punish them, which suggests that cooperation is not maintained by reciprocity. Modification of the ''odds'' in these encounters revealed that some females joined the group response when they were most needed, whereas other lagged even farther behind. The complexity of these responses emphasizes the great diversity of individual behavior in this species and the inadequacy of current theory to explain cooperation in large groups.	UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities	HEINSOHN, R (corresponding author), AUSTRALIAN NATL UNIV,DIV BOT & ZOOL,CANBERRA,ACT 0200,AUSTRALIA.							AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Barnard C. J., 1984, PRODUCERS SCROUNGERS; BARNARD CJ, 1981, ANIM BEHAV, V29, P543, DOI 10.1016/S0003-3472(81)80117-0; BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0; BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4; BOYD R, 1994, J THEOR BIOL, V168, P29; DUGATKIN LA, 1992, TRENDS ECOL EVOL, V7, P202, DOI 10.1016/0169-5347(92)90074-L; GRINNELL J, 1995, ANIM BEHAV, V49, P95, DOI 10.1016/0003-3472(95)80157-X; LIMA SL, 1989, AM NAT, V134, P828, DOI 10.1086/285015; MCCOMB K, 1993, P ROY SOC B-BIOL SCI, V252, P59, DOI 10.1098/rspb.1993.0046; MCCOMB K, 1994, ANIM BEHAV, V47, P379, DOI 10.1006/anbe.1994.1052; MESTERTONGIBBONS M, 1992, Q REV BIOL, V67, P267, DOI 10.1086/417658; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK M, 1993, P NATL ACAD SCI USA, V90, P5091, DOI 10.1073/pnas.90.11.5091; PACKER C, 1990, AM NAT, V136, P1, DOI 10.1086/285079; PACKER C, 1988, AM NAT, V132, P159, DOI 10.1086/284844; Packer C., 1985, P173; PACKER C, 1977, NATURE, V265, P441, DOI 10.1038/265441a0; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; PUSEY AE, 1987, BEHAVIOUR, V101, P275, DOI 10.1163/156853987X00026; PUSEY AE, 1994, BEHAV ECOL, V5, P362, DOI 10.1093/beheco/5.4.362; Schaller G. B., 1972, SERENGETI LION; SCHEEL D, 1991, ANIM BEHAV, V4, P697; STANDER PE, 1992, BEHAV ECOL SOCIOBIOL, V29, P445; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; VICKERY WL, 1991, AM NAT, V137, P847, DOI 10.1086/285197; WILKINSON GS, 1984, NATURE, V308, P181, DOI 10.1038/308181a0; WILSON DS, 1994, TRENDS ECOL EVOL, V9, P442, DOI 10.1016/0169-5347(94)90134-1	29	256	263	1	122	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1260	1262		10.1126/science.7652573	http://dx.doi.org/10.1126/science.7652573			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652573				2022-12-28	WOS:A1995RR84200032
J	QUINTERO, RA; JOHNSON, MP; ROMERO, R; SMITH, C; ARIAS, F; GUEVARAZULOAGA, F; COTTON, DB; EVANS, MI				QUINTERO, RA; JOHNSON, MP; ROMERO, R; SMITH, C; ARIAS, F; GUEVARAZULOAGA, F; COTTON, DB; EVANS, MI			IN-UTERO PERCUTANEOUS CYSTOSCOPY IN THE MANAGEMENT OF FETAL LOWER OBSTRUCTIVE UROPATHY	LANCET			English	Article							URINARY-TRACT OBSTRUCTION; CONGENITAL HYDRONEPHROSIS; RENAL-FUNCTION; INTERVENTION; INUTERO; BIOCHEMISTRY; DIAGNOSIS	In fetuses with lower obstructive uropathy, sonography cannot establish the cause of obstruction. We assessed whether percutaneous fetal cystoscopy could be useful in the evaluation and treatment of obstructive defects in utero. We inserted a fibreoptic endoscope through the lumen of the needle or trocar into the fetal bladder at the time of vesicocentesis or vesicoamniotic-shunt placement and looked at the the urethra, bladder neck, and ureteral orifices. Urethral vesicoamniotic shunting was considered in suitable cases; otherwise a percutaneous shunt was inserted. Fetal cystoscopy was possible in 11 of 13 patients referred. The bladder mucosa appeared haemorrhagic or oedematous in three, The ureteral orifices were seen in 9/11 fetuses, dilation was seen in five, but was only suspected in two by ultrasound. Ureteral webs were noted in two other fetuses. Two of seven fetuses underwent urethral vesicoamniotic shunting; urethral patency was achieved with urethral probing alone in one fetus. The remaining four fetuses were shunted with a standard technique. Fetal cystoscopy helps define the underlying conditions responsible for sonographic findings of lower obstructive uropathy, and allows the introduction of new treatments.	WAYNE STATE UNIV,HUTZEL HOSP,DEPT OBSTET & GYNECOL,DETROIT,MI; WAYNE STATE UNIV,HUTZEL HOSP,DEPT PEDIAT UROL,DETROIT,MI; ST JOHNS MERCY HOSP,DEPT OBSTET & GYNECOL,ST LOUIS,MO; CENT UNIV VENEZUELA,HOSP UNIV CARACAS,UNIDAD PERINATOL,CARACAS,VENEZUELA; NICHHD,PERINATOL RES BRANCH,BETHESDA,MD	Wayne State University; Wayne State University; Saint Johns Mercy Medical Center; University of Central Venezuela; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Romero, Roberto/A-5268-2019	Romero, Roberto/0000-0002-4448-5121				BECK AD, 1971, J UROLOGY, V105, P784, DOI 10.1016/S0022-5347(17)61629-X; BERKOWITZ RL, 1982, AM J OBSTET GYNECOL, V144, P367, DOI 10.1016/0002-9378(82)90239-3; BLACHAR A, 1994, PEDIATR NEPHROL, V8, P30, DOI 10.1007/BF00868254; CROMBLEHOLME TM, 1990, AM J OBSTET GYNECOL, V162, P1239, DOI 10.1016/0002-9378(90)90026-4; ELDER JS, 1987, LANCET, V2, P1007; EVANS MI, 1991, OBSTET GYNECOL, V77, P545; GOLBUS MS, 1982, AM J OBSTET GYNECOL, V142, P383, DOI 10.1016/S0002-9378(16)32377-8; GRANNUM PA, 1990, DIAGNOSTIC ULTRASOUN, P433; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P635, DOI 10.1001/jama.246.6.635; JOHNSON MP, 1994, AM J OBSTET GYNECOL, V170, P1770; KEATING M, 1993, PEDIATRIC SURGERY; KRAMER SA, 1983, J UROLOGY, V130, P641, DOI 10.1016/S0022-5347(17)51383-X; MANNING FA, 1983, AM J OBSTET GYNECOL, V145, P819, DOI 10.1016/0002-9378(83)90685-3; MCFADYEN IR, 1983, BRIT J OBSTET GYNAEC, V90, P342, DOI 10.1111/j.1471-0528.1983.tb08921.x; MULLER F, 1993, OBSTET GYNECOL, V82, P813; NAKAYAMA DK, 1986, J PEDIATR SURG, V21, P43, DOI 10.1016/S0022-3468(86)80651-0; NICOLINI U, 1991, PRENATAL DIAG, V11, P159, DOI 10.1002/pd.1970110305; NICOLINI U, 1987, LANCET, V2, P1338; NOIA G, 1989, Fetal Therapy, V4, P40; PADUANO L, 1991, J UROLOGY, V146, P1094, DOI 10.1016/S0022-5347(17)38009-6; QUINTERO RA, 1993, AM J OBSTET GYNECOL, V168, P1552, DOI 10.1016/S0002-9378(11)90797-2; QUINTERO RA, 1995, AM J OBSTET GYNECOL, V172, P206, DOI 10.1016/0002-9378(95)90115-9; REUSS A, 1988, LANCET, V2, P949; WILKINS IA, 1987, AM J OBSTET GYNECOL, V157, P694, DOI 10.1016/S0002-9378(87)80031-5	25	115	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					537	540		10.1016/S0140-6736(95)91381-5	http://dx.doi.org/10.1016/S0140-6736(95)91381-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658779				2022-12-28	WOS:A1995RQ98600009
J	RUSSELL, MB; OLESEN, J				RUSSELL, MB; OLESEN, J			INCREASED FAMILIAL RISK AND EVIDENCE OF GENETIC-FACTOR IN MIGRAINE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-POPULATION; PREVALENCE; AURA; HEADACHE	Objective-To investigate familial occurrence of migraine with and without aura. Design-Familial occurrence of migraine with and without aura among first degree relatives and spouses of probands with migraine with or without aura and those who had never had migraine. All interviews of first degree relatives and spouses were done blindly by a neurological resident. The operational diagnostic criteria of the International Headache Society were used. Setting-General population from Copenhagen County. Subjects-The 378 probands had 1109 first degree relatives and 229 spouses. Main outcome measures-Patterns of familial aggregation of migraine with and without aura as assessed by calculation of the population relative risk. Results-Compared with the general population the first degree relatives of probands with migraine without aura had 1.9 times the risk of migraine without aura and 1.4 times the risk of migraine with aura. The first degree relatives of probands with migraine with aura had nearly four times the risk of migraine with aura and no increased risk of migraine without aura. The first degree relatives of probands who had never had migraine had no increased risk of migraine either with or without aura. Spouses of probands with migraine without aura had 1.4 times the risk of migraine without aura whereas spouses of probands with migraine with aura had no increased risk of migraine with aura. Conclusion-The different familial patterns indicate that migraine without aura and migraine with aura have a different aetiology. Migraine without aura seems to be caused by a combination of genetic and environmental factors whereas migraine with aura is probably determined largely or exclusively by genetic factors.			RUSSELL, MB (corresponding author), UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT NEUROL,DK-2600 GLOSTRUP,DENMARK.			Olesen, Jes/0000-0002-6712-2702				ALLEN W, 1930, ARCH INTERN MED, V13, P590; BAIER WK, 1985, NEUROPEDIATRICS, V16, P84, DOI 10.1055/s-2008-1052549; BAROLIN GS, 1969, FORTSCHR NEUROL P I, V37, P521; CHRISTIANSEN V, 1925, REV NEUROL, V32, P854; DALSGAARDNIELSE.T, 1973, HEADACHE, V12, P168; DALSGAARDNIELSE.T, 1965, ACTA NEUROL SCAND, V41, P287; DAMICO D, 1991, ITAL J NEUROL SCI, V12, P581, DOI 10.1007/BF02336955; DEVOTO M, 1986, CEPHALALGIA, V6, P101, DOI 10.1046/j.1468-2982.1986.0602101.x; GOODELL H, 1954, ARCH NEUROLOGY PSYCH, V72, P375; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; LEONE M, 1994, CEPHALALGIA, V14, P280, DOI 10.1046/j.1468-2982.1994.1404280.x; MOCHI M, 1993, CEPHALALGIA, V13, P389, DOI 10.1046/j.1468-2982.1993.1306389.x; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1981, LANCET, V2, P438; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; RASMUSSEN BK, 1992, INT J EPIDEMIOL, V21, P1138, DOI 10.1093/ije/21.6.1138; RUSSELL MB, 1995, INT J EPIDEMIOL, V24, P612, DOI 10.1093/ije/24.3.612; RUSSELL MB, 1993, NEUROLOGY, V43, P1369, DOI 10.1212/WNL.43.7.1369; SELBY G, 1960, J NEUROL NEUROSUR PS, V23, P23, DOI 10.1136/jnnp.23.1.23; VILATELA EA, 1992, NEUROEPIDEMIOLOGY, V11, P46, DOI 10.1159/000110908; WATERS WE, 1971, BRIT MED J, V2, P77, DOI 10.1136/bmj.2.5753.77; WEISS KM, 1982, J CHRON DIS, V35, P539, DOI 10.1016/0021-9681(82)90073-X	25	272	276	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					541	544		10.1136/bmj.311.7004.541	http://dx.doi.org/10.1136/bmj.311.7004.541			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663209	Green Published			2022-12-28	WOS:A1995RR73700019
J	MURPHY, TD; KARPEN, GH				MURPHY, TD; KARPEN, GH			LOCALIZATION OF CENTROMERE FUNCTION IN A DROSOPHILA MINICHROMOSOME	CELL			English	Article							SATELLITE DNA; KINETOCHORE; CHROMOSOME; MELANOGASTER; YEAST; HETEROCHROMATIN; SEQUENCES; MITOSIS	The DNA elements responsible for centromere activity in a metazoan have been localized using the Drosophila minichromosome Dp1187. Deleted minichromosomes were generated by irradiation mutagenesis, and their molecular structures were determined by pulsed-field Southern blot analysis. Analyses of the transmission behavior of Dp1187 derivatives localized sequences necessary for chromosome inheritance within the centric heterochromatin. The essential core of the centromere is contained within a 220 kb region that includes significant amounts of complex DNA. Completely normal inheritance also requires similar to 200 kb on either side of the essential core. This flanking DNA predominantly contains highly repeated sequences, and the amount required for normal transmission differs among division types and between the sexes. We propose that the essential core is the site of kinetochore formation and that flanking DNA provides two functions: sister chromatid cohesion and indirect assistance in kinetochore formation or function.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	MURPHY, TD (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000747] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00747, R01 HG000747] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1987, CELL, V50, P391, DOI 10.1016/0092-8674(87)90493-4; ASHBURNER M, 1990, DROSOPHILA LABORATOR; AUIT JG, 1994, CURR OPIN CELL BIOL, V6, P41; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; Brinkley B R, 1992, Trends Cell Biol, V2, P15, DOI 10.1016/0962-8924(92)90139-E; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; COOK KR, 1994, P NATL ACAD SCI USA, V91, P5219, DOI 10.1073/pnas.91.12.5219; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; DVORKIN N, 1991, Journal of Cell Biology, V115, p92A; EARNSHAW W C, 1992, Current Opinion in Cell Biology, V4, P86, DOI 10.1016/0955-0674(92)90063-I; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; FULLER MT, 1995, CELL, V81, P5, DOI 10.1016/0092-8674(95)90364-X; Gilbert SF, 1991, DEV BIOL; GLASER RL, 1994, NUCLEIC ACIDS RES, V22, P5068, DOI 10.1093/nar/22.23.5068; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; HANNAH-ALAVA ALOHA, 1965, ADVANCE GENET, V13, P157, DOI 10.1016/S0065-2660(08)60049-8; HAWLEY RS, 1993, DEV GENET, V13, P440; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; John B, 1988, HETEROCHROMATIN MOL, P1; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1990, CELL, V63, P97; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; LE MH, 1995, IN PRESS GENETICS; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; LOHE AR, 1993, GENETICS, V134, P1149; MARSCHALL LG, 1995, J CELL BIOL, V128, P445, DOI 10.1083/jcb.128.4.445; MASON JM, 1984, P NATL ACAD SCI-BIOL, V81, P6090, DOI 10.1073/pnas.81.19.6090; Mather K, 1933, J GENET, V28, P1, DOI 10.1007/BF02981766; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MIDDLETON K, 1994, P NATL ACAD SCI USA, V91, P7212, DOI 10.1073/pnas.91.15.7212; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; TOMKIEL JE, 1993, CHROMOSOME SEGREGATI, P13; TOWER J, 1993, GENETICS, V133, P347; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	47	168	182	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					599	609		10.1016/0092-8674(95)90032-2	http://dx.doi.org/10.1016/0092-8674(95)90032-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664339	Green Accepted, Bronze			2022-12-28	WOS:A1995RR73400011
J	LIM, M; JACKSON, TA; ANFINRUD, PA				LIM, M; JACKSON, TA; ANFINRUD, PA			BINDING OF CO TO MYOGLOBIN FROM A HEME POCKET DOCKING SITE TO FORM NEARLY LINEAR FE-C-O	SCIENCE			English	Article							CARBON-MONOXIDE; INFRARED-SPECTROSCOPY; DIOXYGEN ADDUCT; RESOLUTION; PICOSECOND; CARBONMONOXYMYOGLOBIN; CARBOXYMYOGLOBIN; PHOTOSELECTION; OXYMYOGLOBIN; HEMOPROTEINS	The relative orientations of carbon monoxide (CO) bound to and photodissociated from myoglobin in solution have been determined with time-resolved infrared polarization spectroscopy. The bound CO is oriented less than or equal to 7 degrees from the heme normal, corresponding to nearly linear Fe-C-O. Upon dissociation from the Fe, CO becomes trapped in a docking site that orientationally constrains it to lie approximately in the plane of the heme. Because the bound and ''docked'' CO are oriented in nearly orthogonal directions, CO binding from the docking site is suppressed. These solution results help to establish how myoglobin discriminates against CO, a controversial issue dominated by the misconception that Fe-C-O is bent.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NIDDK NIH HHS [DK45306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045306, R29DK045306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANI J, 1986, CHEM PHYS LETT, V131, P147, DOI 10.1016/0009-2614(86)80533-4; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; ANFINRUD PA, 1994, P SOC PHOTO-OPT INS, V2138, P107, DOI 10.1117/12.181348; ANSARI A, 1993, BIOPHYS J, V64, P838, DOI 10.1016/S0006-3495(93)81445-0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; CAUGHEY WS, 1970, ANN NY ACAD SCI, V174, P148, DOI 10.1111/j.1749-6632.1970.tb49781.x; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; CHURG AK, 1978, J CHEM PHYS, V68, P1913, DOI 10.1063/1.435918; COLLMAN J P, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1326, DOI 10.1073/pnas.71.4.1326; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; Eaton W A, 1981, Methods Enzymol, V76, P175; HANSEN PA, 1989, CHEM PHYS, V131, P49, DOI 10.1016/0301-0104(89)87080-6; HENRY ER, 1993, BIOPHYS J, V64, P869, DOI 10.1016/S0006-3495(93)81447-4; HU SZ, 1994, J AM CHEM SOC, V116, P11187, DOI 10.1021/ja00103a056; IVANOV D, 1994, J AM CHEM SOC, V116, P4139, DOI 10.1021/ja00088a084; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; JAMESON GB, 1978, INORG CHEM, V17, P850, DOI 10.1021/ic50182a012; JEWSBURY P, 1994, BIOPHYS J, V67, P2236, DOI 10.1016/S0006-3495(94)80708-8; JEWSBURY P, 1994, J AM CHEM SOC, V116, P11586, DOI 10.1021/ja00104a056; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LANDAW SA, 1970, J CLIN INVEST, V49, P914, DOI 10.1172/JCI106311; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; LOCKE B, 1995, CHEM PHYS, V190, P155, DOI 10.1016/0301-0104(94)00360-M; MOFFAT K, COMMUNICATION; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PENG SM, 1976, J AM CHEM SOC, V98, P8032, DOI 10.1021/ja00441a025; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PISTORIUS CWFT, 1959, J CHEM PHYS, V31, P1439, DOI 10.1063/1.1730631; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROTHBERG LJ, 1991, P SPIE INT SOC OPT E, V1599, P309; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Stryer L., 1988, BIOCHEMISTRY-US; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TRAYLOR TG, 1981, ACCOUNTS CHEM RES, V14, P102, DOI 10.1021/ar00064a002	38	296	299	2	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					962	966		10.1126/science.7638619	http://dx.doi.org/10.1126/science.7638619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638619				2022-12-28	WOS:A1995RP73800031
J	OLSON, CR; GETTNER, SN				OLSON, CR; GETTNER, SN			OBJECT-CENTERED DIRECTION SELECTIVITY IN THE MACAQUE SUPPLEMENTARY EYE FIELD	SCIENCE			English	Article							UNILATERAL NEGLECT; VISUAL NEGLECT; RHESUS-MONKEYS; REPRESENTATION; RECOGNITION; MOVEMENTS; POSITION	Object-centered spatial awareness-awareness of the location, relative to an object, of its parts-plays an important role in many aspects of perception, imagination, and action. One possible basis for this capability is the existence in the brain of neurons with sensory receptive fields or motor action fields that are defined relative to an object-centered frame. In experiments described here, neuronal activity was monitored in the supplementary eye field of macaque monkeys making eye movements to the right or left end of a horizontal bar, Neurons were found to fire differentially as a function of the end of the bar to which an eye movement was made. This is direct evidence for the existence of neurons sensitive to the object-centered direction of movements.			OLSON, CR (corresponding author), UNIV MARYLAND,COLL DENT SURG,DEPT ORAL & CRANIOFACIAL BIOL SCI,BALTIMORE,MD 21201, USA.				NINDS NIH HHS [1 F32 NS09452, R01 NS27287] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009452, R01NS027287] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGUIN M, 1993, CORTEX, V29, P349, DOI 10.1016/S0010-9452(13)80188-8; BEHRMANN M, 1994, J COGNITIVE NEUROSCI, V6, P1, DOI 10.1162/jocn.1994.6.1.1; BEHRMANN M, 1994, ATTENTION PERFORMANC, V15, pCH14; BISIACH E, 1978, CORTEX, V14, P129, DOI 10.1016/S0010-9452(78)80016-1; BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; CARAMAZZA A, 1990, COGNITIVE NEUROPSYCH, V7, P391, DOI 10.1080/02643299008253450; CARAMAZZA A, 1990, NATURE, V346, P267, DOI 10.1038/346267a0; CHEN LL, 1995, J NEUROPHYSIOL, V73, P1104; Connor C. E., 1994, Society for Neuroscience Abstracts, V20, P1054; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; DERENZI E, 1989, CORTEX, V25, P231, DOI 10.1016/S0010-9452(89)80039-5; DRIVER J, 1991, COGNITIVE NEUROPSYCH, V8, P475, DOI 10.1080/02643299108253384; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; MCCLELLAND JL, 1986, PARALLEL DISTRIBUTED, V2, pCH16; MITZ AR, 1989, NEUROSCI LETT, V106, P157, DOI 10.1016/0304-3940(89)90219-X; NIKI H, 1974, BRAIN RES, V68, P197, DOI 10.1016/0006-8993(74)90389-8; OGDEN JA, 1985, NEUROPSYCHOLOGIA, V23, P273, DOI 10.1016/0028-3932(85)90112-5; OLSHAUSEN BA, 1993, J NEUROSCI, V13, P4700; REMMEL RS, 1984, IEEE T BIO-MED ENG, V31, P388, DOI 10.1109/TBME.1984.325352; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; RUSSO GS, 1993, J NEUROPHYSIOL, V69, P800, DOI 10.1152/jn.1993.69.3.800; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHLAG J, 1987, J NEUROPHYSIOL, V57, P179, DOI 10.1152/jn.1987.57.1.179; SCHLAG J, 1992, EXP BRAIN RES, V90, P302; TEHOVNIK EJ, 1993, EXP BRAIN RES, V96, P430; YOUNG AW, 1992, BRAIN, V115, P51, DOI 10.1093/brain/115.1.51	26	186	186	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					985	988		10.1126/science.7638625	http://dx.doi.org/10.1126/science.7638625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638625				2022-12-28	WOS:A1995RP73800038
J	JONES, J; HUNTER, D				JONES, J; HUNTER, D			CONSENSUS METHODS FOR MEDICAL AND HEALTH-SERVICES RESEARCH	BRITISH MEDICAL JOURNAL			English	Article							DEVELOPMENT PROGRAM; CLINICAL-TRIALS; DELPHI; CARE	Health providers face the problem of trying to make decisions in situations where there is insufficient information and also where there is an overload of (often contradictory) information. Statistical methods such as meta-analysis have been developed to summarise and to resolve inconsistencies in study findings-where information is available in an appropriate form. Consensus methods provide another means of synthesising information, but are liable to use a wider range of information than is common in statistical methods, and where published information is inadequate or non-existent these methods provide a means of harnessing the insights of appropriate experts to enable decisions to be made. Two consensus methods commonly adopted in medical, nursing, and health services research-the Delphi process and the nominal group technique (also known as the expert panel)-are described, together with the most appropriate situations for using them; an outline of the process involved in undertaking a study using each method is supplemented by illustrations of the authors' work. Key methodological issues in using the methods are discussed, along with the distinct contribution of consensus methods as aids to decision making, both in clinical practice and in health service development.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	JONES, J (corresponding author), UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,NUFFIELD COMMUNITY CARE STUDIES UNIT,LEICESTER LE1 7RH,LEICS,ENGLAND.							Attala J M, 1993, Issues Compr Pediatr Nurs, V16, P51, DOI 10.3109/01460869309078266; Battles J B, 1989, J Biocommun, V16, P2; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BELLAMY N, 1991, J RHEUMATOL, V18, P1908; BUCHAN MS, 1991, J CONTIN ED NURSE, V22, P109; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P1; COATES JF, 1975, TECHNOL FORECAST SOC, V7, P193, DOI 10.1016/0040-1625(75)90058-X; CROTTY M, 1993, J ADV NURS, V18, P150, DOI 10.1046/j.1365-2648.1993.18010150.x; Delbecq A, 1971, J APPL BEHAV SCI, V7, P467; Elder O C Jr, 1992, J Allied Health, V21, P105; FELSON DT, 1993, J RHEUMATOL, V20, P531; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Fraser CE, 1992, ACAD MED, V67, P696; GALLAGHER M, 1993, FAM PRACT, V10, P76, DOI 10.1093/fampra/10.1.76; GLASER EM, 1980, J APPL BEHAV SCI, V16, P79, DOI 10.1177/002188638001600107; Hayward R S, 1993, Ann Intern Med, V118, P731; HUNTER DJW, 1994, J EPIDEMIOL COMMUN H, V48, P58, DOI 10.1136/jech.48.1.58; JONES J, 1992, J ROY COLL PHYS LOND, V26, P36; Justice J, 1990, Am Pharm, VNS30, P43; KHAN JP, 1994, MED CARE, V32, P357; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; LIANG MH, 1991, J BONE JOINT SURG AM, V73A, P639, DOI 10.2106/00004623-199173050-00001; Linstone H.A., 1978, HDB FUTURES RES, P273; Manning D, 1989, J Am Coll Health, V38, P67; McGlynn E A, 1990, Int J Technol Assess Health Care, V6, P450; MCKEE M, 1992, MED EDUC, V26, P51, DOI 10.1111/j.1365-2923.1992.tb00123.x; McKee M, 1991, Qual Assur Health Care, V3, P89; MOBILY PR, 1993, INT J NURS STUD, V30, P537, DOI 10.1016/0020-7489(93)90025-P; MOSCOVICE I, 1988, J HLTH POLIT POLICY, V2, P388; NEIDLINGER SH, 1993, J NURS ADMIN, V23, P9, DOI 10.1097/00005110-199323050-00004; ORANGA HM, 1993, HEALTH POLICY PLANN, V8, P405, DOI 10.1093/heapol/8.4.405; PASSANNANTE MR, 1993, CHEST, V103, P825, DOI 10.1378/chest.103.3.825; PERRY S, 1987, NEW ENGL J MED, V317, P485, DOI 10.1056/NEJM198708203170806; PERRY S, 1980, NEW ENGL J MED, V303, P169, DOI 10.1056/NEJM198007173030334; PILL J, 1971, SOCIO ECON PLAN SCI, V5, P57, DOI 10.1016/0038-0121(71)90041-3; RAINHORN JD, 1994, B WORLD HEALTH ORGAN, V72, P257; Rizzolo M A, 1990, Comput Nurs, V8, P151; ROWE G, 1991, TECHNOL FORECAST SOC, V39, P235, DOI 10.1016/0040-1625(91)90039-I; Sackman H, 1975, DELPHI CRITIQUE; SCOTT EA, 1991, GUT, V9, P1066; SMITH DM, 1994, CANCER, V73, P1472, DOI 10.1002/1097-0142(19940301)73:5<1472::AID-CNCR2820730525>3.0.CO;2-M; STOCKING B, 1991, HIST IMPACT CONSENSU; ZIEMBA SE, 1991, AM J MED, V91, P576, DOI 10.1016/0002-9343(91)90209-G; 1991, CAN MED ASSOC J, V145, P114; 1991, CAN MED ASSOC J, V144, P1617; 1991, INT J TECHNOL ASSESS, V7, P236	46	2137	2175	1	90	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					376	380		10.1136/bmj.311.7001.376	http://dx.doi.org/10.1136/bmj.311.7001.376			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RN469	7640549	Green Published			2022-12-28	WOS:A1995RN46900025
J	WEILERRAVELL, D; SHUPAK, A; GOLDENBERG, I; HALPERN, P; SHOSHANI, O; HIRSCHHORN, G; MARGULIS, A				WEILERRAVELL, D; SHUPAK, A; GOLDENBERG, I; HALPERN, P; SHOSHANI, O; HIRSCHHORN, G; MARGULIS, A			PULMONARY-EDEMA AND HEMOPTYSIS INDUCED BY STRENUOUS SWIMMING	BRITISH MEDICAL JOURNAL			English	Article									IDF,MED CORPS,ISRAEL NAVAL MED INST,IL-31080 HAIFA,ISRAEL									NORSK P, 1986, EUR J APPL PHYSIOL O, V54, P608, DOI 10.1007/BF00943349; PASCOE JR, 1981, AM J VET RES, V42, P703; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U; WILMSHURST PT, 1989, LANCET, V1, P62	4	94	94	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					361	362		10.1136/bmj.311.7001.361	http://dx.doi.org/10.1136/bmj.311.7001.361			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640542	Green Published			2022-12-28	WOS:A1995RN46900016
J	HINDLER, C; NAZARETH, I; KING, M; COHEN, J; FARMER, R; GERADA, C				HINDLER, C; NAZARETH, I; KING, M; COHEN, J; FARMER, R; GERADA, C			DRUG-USERS VIEWS ON GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article									UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY CARE, LONDON N19 5NF, ENGLAND; ST GEORGE HOSP, SCH MED, LONDON SW17 0RE, ENGLAND; HURLEY CLIN, LONDON SE11 4HJ, ENGLAND	University of London; University College London; UCL Medical School; St Georges University London	HINDLER, C (corresponding author), ROYAL FREE HOSP, ACAD DEPT PSYCHIAT, LONDON NW3 2QG, ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Nazareth, Irwin/0000-0003-2146-9628				BENNETT T, 1986, BRIT J ADDICT, V81, P757; RICHARDS T, 1988, BRIT MED J, V296, P1082, DOI 10.1136/bmj.296.6629.1082; TELFER I, 1990, BRIT J ADDICT, V85, P137; 1993, REPORT AIDS DRUG MIS, P16	4	22	22	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					302	302		10.1136/bmj.310.6975.302	http://dx.doi.org/10.1136/bmj.310.6975.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7646645	Green Published			2022-12-28	WOS:A1995QF71700029
J	HSU, YT; MOLDAY, RS				HSU, YT; MOLDAY, RS			MODULATION OF THE CGMP-GATED CHANNEL OF ROD PHOTORECEPTOR CELLS BY CALMODULIN	NATURE			English	Article							FREE CALCIUM-CONCENTRATION; CYCLIC-GMP CASCADE; OUTER SEGMENTS; RETINAL RODS; GUANYLATE-CYCLASE; BINDING-PROTEINS; CONDUCTANCE; MEMBRANES; ADAPTATION; MECHANISM	PHOTOBLEACHING of rhodopsin in rod photoreceptors activates the visual cascade system leading to a decrease in cyclic GMP and the closure of cGMP-gated channels in the rod outer segment plasma membrane1-4. Calcium plays an important role in the recovery of the rod outer segment to its dark state by regulating the resynthesis of cGMP by guanylate cyclase5-7. Here we report that calmodulin, a Ca2+-binding protein present in the rod outer segment8,9, increases the apparent Michaelis constant of the channel for cGMP. This results in a decrease in the rate of cation influx into the rod outer segment by two- to sixfold at low cGMP concentrations and has the effect of increasing the sensitivity of the channel to small changes in cGMP levels during phototransduction. Biochemical studies indicate that calcium-calmodulin binds to a protein of M(r) 240K which is tightly associated with the channel10. On the basis of these studies, Ca2+ is suggested to play a central role in photorecovery and light adaptation, not only by regulating guanylate cyclase, possibly through recoverin6,7, but also by modulating the cGMP-gated channel through calmodulin interaction with the 240K protein.	UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia								CARETTA A, 1988, EUR J BIOCHEM, V177, P139, DOI 10.1111/j.1432-1033.1988.tb14354.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1986, J BIOL CHEM, V261, P2965; DLZHOOR AM, 1991, SCIENCE, V251, P915; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GLENNEY JR, 1982, P NATL ACAD SCI-BIOL, V79, P4002, DOI 10.1073/pnas.79.13.4002; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KAUPP UB, 1992, REV PHYSL, V54, P153; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2517; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; OGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P19, DOI 10.1093/oxfordjournals.jbchem.a134584; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; RATTO GM, 1988, J NEUROSCI, V8, P3240; SCHNETKAMP PPM, 1990, J GEN PHYSIOL, V96, P517, DOI 10.1085/jgp.96.3.517; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	30	327	330	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	1993	361	6407					76	79		10.1038/361076a0	http://dx.doi.org/10.1038/361076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7678445				2022-12-28	WOS:A1993KF71800052
J	HOTAMISLIGIL, GS; SHARGILL, NS; SPIEGELMAN, BM				HOTAMISLIGIL, GS; SHARGILL, NS; SPIEGELMAN, BM			ADIPOSE EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA - DIRECT ROLE IN OBESITY-LINKED INSULIN RESISTANCE	SCIENCE			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; LIPOPROTEIN-LIPASE ACTIVITY; SERINE PROTEASE HOMOLOG; SKELETAL-MUSCLE; MESSENGER-RNA; DECREASED EXPRESSION; 3T3-L1 ADIPOCYTES; DIABETES-MELLITUS; LIPID-METABOLISM; GENE-EXPRESSION	Tumor necrosis factor-alpha (TNF-alpha) has been shown to have certain catabolic effects on fat cells and whole animals. An induction of TNF-alpha messenger RNA expression was observed in adipose tissue from four different rodent models of obesity and diabetes. TNF-alpha protein was also elevated locally and systemically. Neutralization of TNF-alpha in obese fa/fa rats caused a significant increase in the peripheral uptake of glucose in response to insulin. These results indicate a role for TNF-alpha in obesity and particularly in the insulin resistance and diabetes that often accompany obesity.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEISEL WR, 1975, ANNU REV MED, V26, P9, DOI 10.1146/annurev.me.26.020175.000301; BELL GI, 1991, DIABETES, V40, P413, DOI 10.2337/diabetes.40.4.413; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; CAMERON DP, 1978, CLIN EXP PHARMACOL P, V5, P41, DOI 10.1111/j.1440-1681.1978.tb00650.x; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOY LN, 1992, J BIOL CHEM, V267, P12736; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; COLEMAN DL, 1982, DIABETES, V31, P1; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DINARELLO CA, 1987, IMMUNOL LETT, V16, P227, DOI 10.1016/0165-2478(87)90151-9; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; FEINGOLD KR, 1989, J CLIN INVEST, V83, P1116, DOI 10.1172/JCI113991; FEINGOLD KR, 1987, J CLIN INVEST, V80, P184, DOI 10.1172/JCI113046; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FRAKER DL, 1989, AM J PHYSIOL, V256, pE725, DOI 10.1152/ajpendo.1989.256.6.E725; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRUNFELD C, 1989, J LIPID RES, V30, P579; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; HOTAMISLIGIL GS, UNPUB; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1988, J LIPID RES, V29, P909; KETTELHUT IC, 1988, J CLIN INVEST, V81, P1384, DOI 10.1172/JCI113467; KOIVISTO VA, 1989, DIABETES, V38, P641, DOI 10.2337/diabetes.38.5.641; KUNKEL SL, 1989, CRIT REV IMMUNOL, V9, P93; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LARDY H, 1990, ANNU REV BIOCHEM, V59, P689, DOI 10.1146/annurev.biochem.59.1.689; LE JM, 1987, LAB INVEST, V56, P234; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LONNROTH P, 1991, J INTERN MED, V229, P23; Maniatis T, 1989, DECONTAMINATION DILU; MESZAROS K, 1987, BIOCHEM BIOPH RES CO, V149, P1, DOI 10.1016/0006-291X(87)91596-8; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MULLEN BJ, 1990, P SOC EXP BIOL MED, V193, P318; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PATTON JS, 1987, J CLIN INVEST, V80, P1587, DOI 10.1172/JCI113245; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PLATA-SALAMAN C R, 1989, Brain Behavior and Immunity, V3, P193, DOI 10.1016/0889-1591(89)90036-6; PRICE SR, 1986, ARCH BIOCHEM BIOPHYS, V251, P738, DOI 10.1016/0003-9861(86)90384-X; REAVEN GM, 1988, AM J MED, V85, P106, DOI 10.1016/0002-9343(88)90402-0; REY DA, 1987, AM J PHYSIOL, V253, pR794; RODBELL M, 1964, J BIOL CHEM, V239, P375; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SEMB H, 1987, J BIOL CHEM, V262, P8390; SHAFRIR E, 1990, DIABETES MELLITUS TH, P299; SHARGILL NS, UNPUB; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; Snick JV, 1990, ANNU REV IMMUNOL, V8, P253; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; STEPHENS JM, 1992, BIOCHEM BIOPH RES CO, V183, P417, DOI 10.1016/0006-291X(92)90497-9; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TENG MN, 1991, P NATL ACAD SCI USA, V88, P3535, DOI 10.1073/pnas.88.9.3535; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87	80	5659	5911	18	558	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					87	91		10.1126/science.7678183	http://dx.doi.org/10.1126/science.7678183			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	7678183				2022-12-28	WOS:A1993KE60100035
J	ABUELO, JG				ABUELO, JG			DIAGNOSING VASCULAR CAUSES OF RENAL-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Review							HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; PROGRESSIVE-SYSTEMIC-SCLEROSIS; CONVERTING ENZYME-INHIBITORS; CONGESTIVE-HEART-FAILURE; ESCHERICHIA-COLI O157-H7; ANTI-INFLAMMATORY DRUGS; ACUTE CORTICAL NECROSIS; CHOLESTEROL CRYSTAL EMBOLIZATION; TRANS-LUMINAL ANGIOPLASTY	The incidence of renal failure due to vascular diseases is increasing. Two reasons for this are the epidemic of atherosclerotic vascular disease in the aging population and the widespread use of vasoactive drugs that can adversely affect renal function. These vascular causes of renal failure include vasomotor disorders such as that associated with nonsteroidal anti-inflammatory drugs, small-vessel diseases such as cholesterol crystal embolization, and large-vessel diseases such as renal artery stenosis. These causes of azotemia are less familiar to physicians than more classic causes, such as acute tubular necrosis, and are less likely to be recognized in their early stages. This article describes the various vascular diseases that impair renal function and outlines the steps necessary to identify them. Although some of these conditions, such as renal artery stenosis, can gradually impair function, the vascular causes of acute renal failure are emphasized in this article. Because the vasculitides primarily cause renal failure through secondary glomerulonephritis, they are mentioned only briefly. Extensive testing is rarely necessary because the cause is usually suspected through syndrome recognition. The diagnosis can then be confirmed by the results of one or two additional tests or by improved renal function after treatment.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA	Brown University	ABUELO, JG (corresponding author), RHODE ISL HOSP, DIV RENAL DIS, 593 EDDY ST, PROVIDENCE, RI 02903 USA.							AGARWAL A, 1992, RENAL FAILURE, V14, P193, DOI 10.3109/08860229209039131; ALEXANDER RD, 1978, ARCH INTERN MED, V138, P381, DOI 10.1001/archinte.138.3.381; ALLAN A, 1989, DIS COLON RECTUM, V32, P426, DOI 10.1007/BF02563697; ALON U, 1984, AM J DIS CHILD, V138, P496, DOI 10.1001/archpedi.1984.02140430072019; AMARAL CFS, 1985, TOXICON, V23, P877, DOI 10.1016/0041-0101(85)90379-4; AMES PRJ, 1992, J RHEUMATOL, V19, P1802; AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; ANSARI Z, 1976, NEPHRON, V17, P28, DOI 10.1159/000180708; ARON NB, 1989, AM J KIDNEY DIS, V13, P189, DOI 10.1016/S0272-6386(89)80051-4; ASHERSON RA, 1993, J RHEUMATOL, V20, P874; ASHOURI OS, 1982, CLIN NEPHROL, V17, P212; AVVENTO L, 1988, AM J HEMATOL, V27, P221, DOI 10.1002/ajh.2830270314; BACIEWICZ FA, 1982, ANN THORAC SURG, V33, P631, DOI 10.1016/S0003-4975(10)60826-0; BADR KF, 1986, KIDNEY INT, V30, P474, DOI 10.1038/ki.1986.210; BALDUS WP, 1964, ANN INTERN MED, V60, P353, DOI 10.7326/0003-4819-60-3-353; BALE JF, 1980, AM J DIS CHILD, V134, P869, DOI 10.1001/archpedi.1980.02130210053014; BARDRAM L, 1985, ANN SURG, V201, P219; BARRETT BJ, 1994, J AM SOC NEPHROL, V5, P125; BAXTER BT, 1990, AM J SURG, V160, P197, DOI 10.1016/S0002-9610(05)80306-X; BEAUFILS H, 1990, CLIN NEPHROL, V34, P157; BENNETT WM, 1983, CIRC SHOCK, V11, P261; BENSON L, 1971, Journal of the Kansas Medical Society, V72, P138; BERG KJ, 1989, CLIN NEPHROL, V31, P232; BERNS AS, 1989, KIDNEY INT, V36, P730, DOI 10.1038/ki.1989.254; BERNS JS, 1992, AM J KIDNEY DIS, V19, P331, DOI 10.1016/S0272-6386(12)80449-5; BESARAB A, 1976, JAMA-J AM MED ASSOC, V235, P2838, DOI 10.1001/jama.235.26.2838; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BLACKSHEAR JL, 1983, ARCH INTERN MED, V143, P1130, DOI 10.1001/archinte.143.6.1130; BONSIB SM, 1985, AM J MED, V79, P520, DOI 10.1016/0002-9343(85)90043-9; BRANDT JR, 1994, J PEDIATR-US, V125, P519, DOI 10.1016/S0022-3476(94)70002-8; BRANDT P, 1981, NEPHRON, V27, P15, DOI 10.1159/000182013; BROWN JJ, 1965, BMJ-BRIT MED J, V2, P144, DOI 10.1136/bmj.2.5454.144; BUKOWSKI RM, 1982, PROG HEMOST THROMB, V6, P287; BUTKUS DE, 1992, TRANSPLANTATION, V54, P159; BYRD L, 1979, MEDICINE, V58, P270, DOI 10.1097/00005792-197905000-00006; Cade R, 1987, Am J Med, V82, P427, DOI 10.1016/0002-9343(87)90442-6; CANNON PJ, 1974, MEDICINE, V53, P1, DOI 10.1097/00005792-197401000-00001; CARMICHAEL DJS, 1986, LANCET, V1, P667; CARMICHAEL J, 1985, AM J MED, V78, P992, DOI 10.1016/0002-9343(85)90223-2; CARVALLO A, 1978, AM J MED, V65, P38, DOI 10.1016/0002-9343(78)90690-3; CHAPMAN AB, 1991, ANN INTERN MED, V115, P769, DOI 10.7326/0003-4819-115-10-769; CHUGH KS, 1983, AM J MED SCI, V286, P10, DOI 10.1097/00000441-198307000-00002; CLARKSON AR, 1970, Q J MED, V39, P227; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; COHEN EP, 1993, NEPHRON, V64, P626, DOI 10.1159/000187412; COHEN EP, 1990, AM J KIDNEY DIS, V15, P55, DOI 10.1016/S0272-6386(12)80592-0; COLIEN AH, 1985, AM J NEPHROL, V5, P305; COLT HG, 1988, MEDICINE, V67, P389, DOI 10.1097/00005792-198811000-00003; CONNOLLY JO, 1994, Q J MED, V87, P413; CONTE G, 1989, KIDNEY INT, V36, P1086, DOI 10.1038/ki.1989.304; COSBY RL, 1986, AM J MED, V81, P890, DOI 10.1016/0002-9343(86)90363-3; COSIO FG, 1985, LANCET, V2, P118; CROWLEY JP, 1983, ARCH INTERN MED, V143, P1011, DOI 10.1001/archinte.143.5.1011; DAHLBERG PJ, 1989, SURGERY, V105, P737; DARWISH R, 1984, AM J MED, V76, P1113, DOI 10.1016/0002-9343(84)90867-2; DATE A, 1986, NEPHRON, V42, P89, DOI 10.1159/000183642; DAVENPORT A, 1988, NEPHRON, V50, P55, DOI 10.1159/000185117; DAVIDMAN M, 1991, ARCH INTERN MED, V151, P1809, DOI 10.1001/archinte.151.9.1809; DAVIDSON EW, 1987, ANNU REV MED, V38, P361, DOI 10.1146/annurev.med.38.1.361; DEAN RH, 1977, SURGERY, V81, P53; Dejong PE, 1989, ANN INTERN MED, V110, P437, DOI 10.7326/0003-4819-110-6-437; DELAROCHA AG, 1981, CAN J SURG, V24, P218; DERAY G, 1987, CLIN NEPHROL, V27, P213; DERAY G, 1991, CLIN NEPHROL, V36, P93; DEUTSCH V, 1971, AM J MED, V50, P828, DOI 10.1016/0002-9343(71)90192-6; DIAMOND JR, 1993, AM J KIDNEY DIS, V21, P328, DOI 10.1016/S0272-6386(12)80756-6; DIPRETE DA, 1990, AM J KIDNEY DIS, V15, P357, DOI 10.1016/S0272-6386(12)80081-3; DISTLER A, 1991, CLIN NEPHROL, V36, P174; DOLISLAGER D, 1978, AM J DIS CHILD, V132, P55, DOI 10.1001/archpedi.1978.02120260057014; DONOHOE JF, 1992, KIDNEY INT, V41, P462, DOI 10.1038/ki.1992.65; EBERT TH, 1986, NEW ENGL J MED, V315, P308; EKNOYAN G, 1986, AM J NEPHROL, V6, P117, DOI 10.1159/000167066; ELLING H, 1980, SCAND J RHEUMATOL, V9, P206, DOI 10.3109/03009748009112348; ENDRENY RG, 1988, AM J KIDNEY DIS, V11, pA6; EPSTEIN M, 1994, J AM SOC NEPHROL, V4, P1735; EPSTEIN M, 1986, AM J MED, V80, P46, DOI 10.1016/0002-9343(86)90931-9; ERBSLOHMOLLER B, 1991, AM J MED, V90, P23, DOI 10.1016/0002-9343(91)90502-O; ESFORZADO N, 1991, AIDS, V5, P1041, DOI 10.1097/00002030-199108000-00026; EUGENE M, 1987, CLIN NEPHROL, V27, P46; EVANS TL, 1984, AM J HEMATOL, V17, P401, DOI 10.1002/ajh.2830170410; FANG LST, 1980, ARCH INTERN MED, V140, P531, DOI 10.1001/archinte.140.4.531; FARRUGIA E, 1993, MAYO CLIN PROC, V68, P157, DOI 10.1016/S0025-6196(12)60163-3; FERRI C, 1991, J RHEUMATOL, V18, P1826; FINE MJ, 1987, ANGIOLOGY, V38, P769, DOI 10.1177/000331978703801007; FISCHER RP, 1966, SURG GYNECOL OBSTETR, V123, P1019; FITZPATRICK MM, 1993, J PEDIATR-US, V122, P532; Fogel R I, 1987, R I Med J, V70, P501; FONG JSC, 1982, PEDIATR CLIN N AM, V29, P835; FRANKLIN SS, 1975, JAMA-J AM MED ASSOC, V231, P1148, DOI 10.1001/jama.231.11.1148; FRANKLIN WA, 1972, ARCH PATHOL, V94, P230; FREM GJ, 1994, J AM SOC NEPHROL, V4, P1643; GASPARINI M, 1992, J UROLOGY, V147, P567, DOI 10.1016/S0022-5347(17)37308-1; GAVRAS H, 1977, ARCH INTERN MED, V137, P1554, DOI 10.1001/archinte.137.11.1554; GAVRAS H, 1975, KIDNEY INT, V8, pS252; GENTILINI P, 1989, DIGESTION, V43, P1, DOI 10.1159/000199857; GERLOCK AJ, 1983, AM J ROENTGENOL, V140, P325, DOI 10.2214/ajr.140.2.325; GEWERTZ BL, 1977, ARCH SURG-CHICAGO, V112, P409; GIANANTONIO CA, 1968, J PEDIATR-US, V72, P757, DOI 10.1016/S0022-3476(68)80427-5; GILL TJ, 1958, AM J MED, V25, P780, DOI 10.1016/0002-9343(58)90016-0; GINES A, 1993, GASTROENTEROLOGY, V105, P229, DOI 10.1016/0016-5085(93)90031-7; GIROUX L, 1985, AM J KIDNEY DIS, V6, P28, DOI 10.1016/S0272-6386(85)80035-4; GOERGEN TG, 1981, AM J ROENTGENOL, V137, P176, DOI 10.2214/ajr.137.1.176; GOLDSTEIN MH, 1979, NEPHRON, V23, P263, DOI 10.1159/000181648; GOMES AS, 1989, RADIOLOGY, V170, P65, DOI 10.1148/radiology.170.1.2909121; GONZALO A, 1981, CLIN NEPHROL, V16, P193; GOUGE SF, 1989, AM J KIDNEY DIS, V14, P236, DOI 10.1016/S0272-6386(89)80079-4; GREENBERG A, 1983, CLIN RES, V31, pA429; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; GRIM CE, 1979, ANN INTERN MED, V91, P617, DOI 10.7326/0003-4819-91-4-617; GRUNFELD JP, 1980, KIDNEY INT, V18, P179, DOI 10.1038/ki.1980.127; GUELPA G, 1984, SCHWEIZ MED WSCHR, V114, P1870; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; HABIB R, 1974, PEDIATR NEPHROL, P291; HAGLEY MT, 1992, AM J NEPHROL, V12, P192, DOI 10.1159/000168444; HAKIM RM, 1985, AM J KIDNEY DIS, V5, P170, DOI 10.1016/S0272-6386(85)80046-9; HARRIS KP, 1988, TRANSPLANTATION, V46, P598, DOI 10.1097/00007890-198810000-00030; HASDAY JD, 1984, AM J MED, V76, P943, DOI 10.1016/0002-9343(84)91019-2; HAUGLUSTAINE D, 1981, CLIN NEPHROL, V15, P148; HAYSLETT JP, 1985, NEW ENGL J MED, V312, P1556, DOI 10.1056/NEJM198506133122407; HEANEY D, 1977, ARCH SURG-CHICAGO, V112, P641; HIBBARD BM, 1966, OBSTET GYNECOL, V27, P155; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; HOBARTH K, 1991, UROL INT, V47, P156; HODSON EM, 1978, J PEDIATR-US, V93, P756, DOI 10.1016/S0022-3476(78)81072-5; HOOVER LA, 1988, AM J KIDNEY DIS, V11, P66, DOI 10.1016/S0272-6386(88)80178-1; HRICIK DE, 1985, ANN INTERN MED, V103, P222, DOI 10.7326/0003-4819-103-2-222; HRICIK DE, 1990, J AM SOC NEPHROL, V1, P845; HULTMAN P, 1989, CLIN EXP IMMUNOL, V78, P470; ISLES CG, 1984, Q J MED, V53, P439; IVES HE, 1991, KIDNEY, P1497; JACOBSON HR, 1988, KIDNEY INT, V34, P729, DOI 10.1038/ki.1988.240; JOHANSEN K, 1981, ARCH SURG-CHICAGO, V116, P1232; JOLIVET J, 1983, CANCER TREAT REP, V67, P429; JONES AS, 1979, CLIN PEDIATR, V18, P286, DOI 10.1177/000992287901800506; JONES RE, 1987, J VASC SURG, V5, P479, DOI 10.1067/mva.1987.avs0050479; JORDAN J, 1990, J COMPUT ASSIST TOMO, V14, P155, DOI 10.1097/00004728-199001000-00034; KAGAN A, 1989, J RHEUMATOL, V16, P707; KAPLAN BS, 1976, PEDIATR CLIN N AM, V23, P761; KAPLAN BS, 1977, CLIN NEPHROL, V8, P495; KAPLAN BS, 1975, NEW ENGL J MED, V292, P1090, DOI 10.1056/NEJM197505222922102; KAUFMAN JJ, 1979, J UROLOGY, V121, P139, DOI 10.1016/S0022-5347(17)56699-9; KAUFMAN JL, 1987, SURGERY, V102, P63; KAYLOR WM, 1989, J UROLOGY, V141, P486, DOI 10.1016/S0022-5347(17)40867-6; KENNEDY SS, 1980, SEMIN THROMB HEMOST, V6, P341, DOI 10.1055/s-2007-1005107; KHANSUR T, 1991, AM J MED SCI, V301, P390, DOI 10.1097/00000441-199106000-00006; KING AJ, 1993, NEW ENGL J MED, V329, P948; KLEINKNECHT D, 1973, KIDNEY INT, V4, P390, DOI 10.1038/ki.1973.135; KLEINKNECHT D, 1973, DHEW NIH74608 PUB, P165; Kohler Susanne M., 1993, Journal of the American Society of Nephrology, V4, P535; KONE BC, 1986, ARCH INTERN MED, V146, P1405, DOI 10.1001/archinte.146.7.1405; KOVALCHIK MT, 1978, ANN INTERN MED, V89, P881, DOI 10.7326/0003-4819-89-6-881; KRANE NK, 1988, ARCH INTERN MED, V148, P2347, DOI 10.1001/archinte.148.11.2347; KROGSGAARD AR, 1986, ACTA MED SCAND, V220, P25; KUHLMANN U, 1985, AM J MED, V79, P692, DOI 10.1016/0002-9343(85)90519-4; KUTER DJ, 1991, NEW ENGL J MED, V325, P265; KWAAN HC, 1987, SEMIN HEMATOL, V24, P71; LACOMBE M, 1978, NOUV PRESSE MED, V7, P3333; LARAGH JH, 1960, J CLIN INVEST, V39, P1091, DOI 10.1172/JCI104124; LAUTIN EM, 1991, AM J ROENTGENOL, V157, P49, DOI 10.2214/ajr.157.1.2048539; LAWTON WJ, 1982, CLIN NEPHROL, V17, P277; Lazebnik N, 1985, Obstet Gynecol Surv, V40, P618, DOI 10.1097/00006254-198510000-00002; LENZ K, 1989, GUT, V30, P90, DOI 10.1136/gut.30.1.90; LEROY EC, 1978, AM J MED, V64, P974, DOI 10.1016/0002-9343(78)90452-7; LESESNE JB, 1989, J CLIN ONCOL, V7, P781, DOI 10.1200/JCO.1989.7.6.781; LESSMAN RK, 1978, ANN INTERN MED, V89, P477, DOI 10.7326/0003-4819-89-4-477; LEVENSON DJ, 1988, ACUTE RENAL FAILURE, P535; LIBERTINO JA, 1980, JAMA-J AM MED ASSOC, V244, P1340, DOI 10.1001/jama.244.12.1340; LJUNGMAN S, 1992, AM J CARDIOL, V70, P479, DOI 10.1016/0002-9149(92)91194-9; Loirat C, 1993, Adv Nephrol Necker Hosp, V22, P141; LUDMERER KM, 1981, AM J MED, V71, P468; MADIAS NE, 1981, AM J MED, V70, P1078, DOI 10.1016/0002-9343(81)90872-X; MADIAS NE, 1982, ARCH INTERN MED, V142, P693, DOI 10.1001/archinte.142.4.693; MAGUIRE RB, 1993, ANN INTERN MED, V119, P215, DOI 10.7326/0003-4819-119-3-199308010-00006; MAHLER F, 1986, NEPHRON, V44, P60, DOI 10.1159/000184049; MAHNENSMITH RL, 1992, AM J KIDNEY DIS, V19, P604, DOI 10.1016/S0272-6386(12)80843-2; MANN SJ, 1991, AM J MED, V90, P30, DOI 10.1016/0002-9343(91)90503-P; MANNESSE CK, 1991, CLIN NEPHROL, V36, P240; MARCOS OO, 1985, CLIN NEPHROL, V24, P265; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MARTIN LG, 1988, AM J ROENTGENOL, V150, P839, DOI 10.2214/ajr.150.4.839; MARTINPAREDERO V, 1983, ARCH SURG-CHICAGO, V118, P1417; MATLIN RA, 1974, AM J MED, V56, P110, DOI 10.1016/0002-9343(74)90756-6; MATTERN WD, 1972, AM J MED, V52, P187, DOI 10.1016/0002-9343(72)90068-X; MATTOO TK, 1989, J PEDIATR-US, V114, P814; MAY J, 1976, SURG GYNECOL OBSTET, V143, P411; MCCRAE KR, 1992, BLOOD, V80, P2697; MCGOWAN JA, 1986, AM J NEPHROL, V6, P135, DOI 10.1159/000167068; MCKAY DG, 1959, AM J OBSTET GYNECOL, V78, P546, DOI 10.1016/0002-9378(59)90526-5; MCNAIR A, 1986, ACTA MED SCAND, V220, P15; Mercier C, 1990, Ann Vasc Surg, V4, P166, DOI 10.1007/BF02001373; MESSINA LM, 1992, J VASC SURG, V15, P73, DOI 10.1016/0741-5214(92)70015-D; MESTRES CA, 1988, BRIT J SURG, V75, P578, DOI 10.1002/bjs.1800750626; MEYRIER A, 1988, AM J MED, V85, P139; MIGNON F, 1982, KIDNEY INT, V22, P327; MOORE RD, 1992, RADIOLOGY, V182, P649, DOI 10.1148/radiology.182.3.1535876; MOORTHY B, 1979, J PEDIATR-US, V95, P558, DOI 10.1016/S0022-3476(79)80765-9; MORALES JM, 1988, TRANSPLANTATION, V46, P163; MORRIS GC, 1962, JAMA-J AM MED ASSOC, V182, P609, DOI 10.1001/jama.1962.03050450009002; MROCZEK WJ, 1969, CIRCULATION, V40, P893, DOI 10.1161/01.CIR.40.6.893; MULLER FB, 1986, AM J MED, V80, P633, DOI 10.1016/0002-9343(86)90819-3; MURGO AJ, 1987, SEMIN HEMATOL, V24, P161; MURRAY BM, 1990, AM J KIDNEY DIS, V16, P66, DOI 10.1016/S0272-6386(12)80787-6; NEILD G, 1987, Q J MED, V63, P367; NEILL MA, 1985, ARCH INTERN MED, V145, P2215, DOI 10.1001/archinte.145.12.2215; NEWELL GC, 1987, AM J KIDNEY DIS, V9, P183, DOI 10.1016/S0272-6386(87)80053-7; NIAUDET P, 1985, KIDNEY INT, pS148; NICOLAU IB, 1982, NEPHRON, V32, P73; NOLAN CR, 1993, DISEASES KIDNEY, V2, P1555; NORA N, 1989, KIDNEY INT, V35, P414; NOVICK AC, 1983, J UROLOGY, V129, P907, DOI 10.1016/S0022-5347(17)52453-2; ODONOVAN RM, 1992, NEPHRON, V60, P187, DOI 10.1159/000186737; OFFNER G, 1986, EUR J PEDIATR, V144, P482, DOI 10.1007/BF00441743; OKEEFFE ST, 1992, ARCH INTERN MED, V152, P2197, DOI 10.1001/archinte.152.11.2197; OLIN JW, 1995, ANN INTERN MED, V122, P833, DOI 10.7326/0003-4819-122-11-199506010-00004; OSTER JR, 1992, ARCH INTERN MED, V152, P704, DOI 10.1001/archinte.152.4.704; OURIEL K, 1987, J VASC SURG, V5, P348, DOI 10.1067/mva.1987.avs0050348; OURSLER DP, 1993, AM J NEPHROL, V13, P167, DOI 10.1159/000168610; PACKER M, 1987, ANN INTERN MED, V106, P346, DOI 10.7326/0003-4819-106-3-346; PAPO J, 1985, ISRAEL J MED SCI, V21, P862; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PATEL R, 1990, AM J CARDIOL, V66, P868, DOI 10.1016/0002-9149(90)90370-G; PATTISON JM, 1992, Q J MED, V85, P883; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; PETITT RM, 1980, SEMIN THROMB HEMOST, V6, P350, DOI 10.1055/s-2007-1005108; PILMORE HL, 1995, AM J NEPHROL, V15, P90, DOI 10.1159/000168808; PIRSON Y, 1987, CLIN NEPHROL, V28, P250; PISCIOTTA AV, 1980, SEMIN THROMB HEMOST, V6, P330, DOI 10.1055/s-2007-1005106; PITCOCK JA, 1976, HUM PATHOL, V7, P333, DOI 10.1016/S0046-8177(76)80043-3; POCH E, 1990, AM J NEPHROL, V10, P514, DOI 10.1159/000168178; PONTICELLI C, 1980, ARCH INTERN MED, V140, P353, DOI 10.1001/archinte.140.3.353; POSTMA CT, 1993, J HYPERTENS, V11, pS204; POSTMA CT, 1991, ARCH INTERN MED, V151, P1531, DOI 10.1001/archinte.151.8.1531; RARICK MU, 1992, AM J HEMATOL, V40, P103, DOI 10.1002/ajh.2830400206; REAMS GP, 1986, HYPERTENSION, V8, P290, DOI 10.1161/01.HYP.8.4.290; REMUZZI G, 1989, AM J KIDNEY DIS, V13, P261, DOI 10.1016/S0272-6386(89)80032-0; RENGEL M, 1985, KIDNEY INT, V28, P299; RICCI MA, 1990, ARCH SURG-CHICAGO, V125, P1195; RICH MW, 1990, ARCH INTERN MED, V150, P1237, DOI 10.1001/archinte.150.6.1237; RIDKER PM, 1989, AM J MED, V87, P357; RIDOLFI RL, 1981, MEDICINE, V60, P413, DOI 10.1097/00005792-198111000-00003; RINGLARSEN H, 1981, GUT, V22, P585, DOI 10.1136/gut.22.7.585; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROWE JM, 1984, AM J MED, V77, P1111, DOI 10.1016/0002-9343(84)90198-0; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; RUBIN GD, 1994, RADIOLOGY, V190, P181, DOI 10.1148/radiology.190.1.8259402; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; SAKLAYEN MG, 1989, AM J NEPHROL, V9, P87, DOI 10.1159/000167942; SALYER WR, 1973, ANN INTERN MED, V78, P895, DOI 10.7326/0003-4819-78-6-895; SAWAYA B, 1988, AM J KIDNEY DIS, V12, P534, DOI 10.1016/S0272-6386(88)80107-0; SCHEFFT P, 1980, J UROLOGY, V124, P184, DOI 10.1016/S0022-5347(17)55365-3; SCHNEIDER PD, 1986, ANN INTERN MED, V105, P303, DOI 10.7326/0003-4819-105-2-303_3; SCHRIER RW, 1992, J AM SOC NEPHROL, V2, P1549; SCHWARTZ D, 1991, CHEST, V100, P1558, DOI 10.1378/chest.100.6.1558; SEGONDS A, 1979, CLIN NEPHROL, V12, P229; SEKKARIE M, 1994, AM J KIDNEY DIS, V23, P866, DOI 10.1016/S0272-6386(12)80142-9; SETARO JF, 1991, HYPERTENSION, V18, P289, DOI 10.1161/01.HYP.18.3.289; SEVITT LH, 1971, Q J MED, V40, P127; SHAFI T, 1978, ARCH INTERN MED, V138, P1218, DOI 10.1001/archinte.138.8.1218; SHAPIRO LS, 1989, NEW ENGL J MED, V321, P1270; SHEPS SG, 1972, AM J CARDIOL, V29, P55, DOI 10.1016/0002-9149(72)90125-7; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P501, DOI 10.1016/0002-9378(86)90266-8; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P777, DOI 10.1016/0002-9378(90)91009-2; SIEBELS M, 1995, AM J KIDNEY DIS, V25, P336, DOI 10.1016/0272-6386(95)90017-9; SIEGLER RL, 1994, J PEDIATR-US, V125, P511, DOI 10.1016/S0022-3476(94)70001-X; SIMON N, 1972, J AMER MED ASSOC, V220, P1209, DOI 10.1001/jama.220.9.1209; SKORECKI KL, 1992, KIDNEY INT, V42, P1, DOI 10.1038/ki.1992.253; SORRENTI LY, 1978, AM J DIS CHILD, V132, P59, DOI 10.1001/archpedi.1978.02120260061015; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; SOUQUIYYEH MZ, 1991, SAUDI KIDNEY DISEASE, V2, P90; STAPLETON FB, 1987, PEDIATR NEPHROL, V1, P314, DOI 10.1007/BF00849230; STEEN VD, 1984, AM J MED, V76, P779, DOI 10.1016/0002-9343(84)90986-0; STEENSMAVEGTER AJ, 1981, CLIN NEPHROL, V15, P102; STRATTA P, 1987, GYNECOL OBSTET INVES, V24, P225, DOI 10.1159/000298807; SVETKEY LP, 1991, HYPERTENSION, V17, P678, DOI 10.1161/01.HYP.17.5.678; SWANN RC, 1953, MEDICINE, V32, P215, DOI 10.1097/00005792-195305000-00002; TALIERCIO CP, 1986, ANN INTERN MED, V104, P501, DOI 10.7326/0003-4819-104-4-501; TALIERCIO CP, 1989, AM J CARDIOL, V64, P815, DOI 10.1016/0002-9149(89)90774-1; TAN EM, 1986, CLIN ASPECTS AUTOIMM, V1, P2; TEGTMEYER CJ, 1982, RADIOLOGY, V143, P631, DOI 10.1148/radiology.143.3.6210930; TEMPLETON PA, 1985, RADIOLOGY, V156, P308, DOI 10.1148/radiology.156.2.2861623; TERUEL JL, 1981, ARCH INTERN MED, V141, P1271, DOI 10.1001/archinte.141.10.1271; TEXTOR SC, 1985, ANN INTERN MED, V102, P308, DOI 10.7326/0003-4819-102-3-308; TEXTOR SC, 1982, AM SOC NEPHROL, P45; THIAGARAJAH S, 1984, AM J OBSTET GYNECOL, V150, P1; Torsello G, 1990, Eur J Vasc Surg, V4, P477, DOI 10.1016/S0950-821X(05)80787-X; TOTO RD, 1991, ANN INTERN MED, V115, P513, DOI 10.7326/0003-4819-115-7-513; TOTO RD, 1993, AKF NEPHROLOGY LETT, V10, P41; TRAUB YM, 1983, MEDICINE, V62, P335, DOI 10.1097/00005792-198311000-00001; TREVATHAN E, 1987, J PEDIATR-US, V111, P863, DOI 10.1016/S0022-3476(87)80207-X; TUMLIN JA, 1990, AM J MED SCI, V299, P366, DOI 10.1097/00000441-199006000-00002; VANDAMMELOMBAERTS R, 1988, J PEDIATR-US, V113, P913, DOI 10.1016/S0022-3476(88)80031-3; VANZEE BE, 1978, ANN INTERN MED, V89, P51, DOI 10.7326/0003-4819-89-1-51; VOGELZANG RL, 1988, RADIOLOGY, V169, P681, DOI 10.1148/radiology.169.3.3186991; WASSER WG, 1981, ARCH INTERN MED, V141, P1647, DOI 10.1001/archinte.141.12.1647; WEBB JG, 1990, ARCH INTERN MED, V150, P1535, DOI 10.1001/archinte.150.7.1535; WEISBERG LS, 1992, KIDNEY INT, V41, P1408, DOI 10.1038/ki.1992.206; WEISS RA, 1982, CLIN NEPHROL, V17, P104; WELLS JD, 1960, AM J MED, V29, P257, DOI 10.1016/0002-9343(60)90022-X; WHELAN JG, 1967, RADIOLOGY, V89, P682, DOI 10.1148/89.4.682; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; WHITE DJ, 1988, BRIT MED J, V296, P899, DOI 10.1136/bmj.296.6626.899; WILKINSON SP, 1978, J CLIN PATHOL, V31, P101, DOI 10.1136/jcp.31.2.101; YING CY, 1984, NEW ENGL J MED, V311, P1070, DOI 10.1056/NEJM198410253111702; YU SH, 1986, CLIN EXP HYPERTENS A, V8, P1211, DOI 10.3109/10641968609045483; ZARICH S, 1985, ARCH INTERN MED, V145, P108, DOI 10.1001/archinte.145.1.108; ZUCCHELLI P, 1982, ACUTE RENAL FAILURE, P152; ZWETTLER U, 1993, AM J KIDNEY DIS, V22, P53, DOI 10.1016/S0272-6386(12)70166-X; 1990, NEW ENGL J MED, V323, P1050; 1987, NEW ENGL J MED, V317, P819	309	42	42	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					601	614		10.7326/0003-4819-123-8-199510150-00007	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00007			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677302				2022-12-28	WOS:A1995RY82800007
J	NICHOL, KL; LIND, A; MARGOLIS, KL; MURDOCH, M; MCFADDEN, R; HAUGE, M; MAGNAN, S; DRAKE, M				NICHOL, KL; LIND, A; MARGOLIS, KL; MURDOCH, M; MCFADDEN, R; HAUGE, M; MAGNAN, S; DRAKE, M			THE EFFECTIVENESS OF VACCINATION AGAINST INFLUENZA IN HEALTHY, WORKING ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; IMPACT; MORTALITY; EPIDEMICS	Background. Although influenza causes substantial morbidity and mortality in all age groups, current recommendations emphasize annual immunization for people at high risk for complications of influenza. We conducted a double-blind, placebo-controlled trial of vaccination against influenza in healthy, working adults. Methods. In the fall of 1994, we recruited working adults from 18 to 64 years of age from in and around the Minneapolis-St Paul area and randomly assigned them to receive either influenza vaccine or placebo injections. The primary study outcomes included upper respiratory illnesses, absenteeism from work because of upper respiratory illnesses, and visits to physicians' office for upper respiratory illnesses. The economic benefits of vaccination were analyzed by estimating the direct and indirect costs associated with immunization and with upper respiratory illnesses. Results. We enrolled a total of 849 subjects. Baseline characteristics were similar in the two groups. During the follow-up period, consisting of the 1994-1995 influenza season (December 1, 1994, through March 31, 1995), those who received the vaccine reported 25 percent fewer episodes of upper respiratory illness than those who received the placebo (105 vs. 140 episodes per 100 subjects, P<0.001), 43 percent fewer days of sick leave from work due to upper respiratory illness (70 vs. 122 days per 100 subjects, P=0.001), and 44 percent fewer visits to physicians' offices for upper respiratory illnesses (31 vs. 55 visits per 100 subjects, P=0.004). The cost savings were estimated to be $46.85 per person vaccinated. Conclusions. Vaccination against influenza has substantial health-related and economic benefits for healthy, working adults.	HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN USA; BLUE PLUS, EAGAN, MN 55121 USA; AMER LUNG ASSOC MINNESOTA, ST PAUL, MN USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	NICHOL, KL (corresponding author), VET AFFAIRS MED CTR, GEN INTERNAL MED SECT 111O, 1 VET DR, MINNEAPOLIS, MN 55417 USA.			Margolis, Karen/0000-0003-1862-7402				EDMONDSON KW, 1970, MED J AUSTRALIA, V2, P6, DOI 10.5694/j.1326-5377.1970.tb84667.x; EDMONDSON WP, 1971, AM J EPIDEMIOL, V93, P480, DOI 10.1093/oxfordjournals.aje.a121282; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V271, P1578; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P186; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GONZALEZ ML, 1995, SOCIOECONOMIC CHARAC, P98; GOVAERT TME, 1993, BMJ-BRIT MED J, V307, P988, DOI 10.1136/bmj.307.6910.988; GREEN GP, 1995, EMPLOYMENT EARNING, V42, P207; KEITEL WA, 1988, AM J EPIDEMIOL, V127, P353, DOI 10.1093/oxfordjournals.aje.a114809; KOCHANEK KD, 1995, MONTHLY VITAL ST 6 S, V43; LAFORCE FM, 1994, AM J PREV MED, V10, P31, DOI 10.1016/S0749-3797(18)30513-0; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; REVICKI DA, 1994, MED CARE, V32, P401, DOI 10.1097/00005650-199404000-00008; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; SCHOENBAUM SC, 1987, AM J MED, V82, P26, DOI 10.1016/0002-9343(87)90557-2; SCHOENBAUM SC, 1976, NEW ENGL J MED, V295, P759, DOI 10.1056/NEJM197609302951405; SMITH JWG, 1979, J HYG-CAMBRIDGE, V83, P157, DOI 10.1017/S0022172400025936; SULLIVAN KM, 1993, AM J PUBLIC HEALTH, V83, P1712, DOI 10.2105/AJPH.83.12.1712; WEINGARTEN S, 1988, J GEN INTERN MED, V3, P32, DOI 10.1007/BF02595754; Yassi A, 1991, Can J Infect Dis, V2, P101; 1994, MMWR MORBMORTAL WKLY, V43, P1; 1995, ANN SUMMARY COMMUNIC, V23, P36; 1953, BRIT MED J, V2, P1173; 1993, MMWR-MORBID MORTAL W, V42, P601; 1995, VITAL STATISTICS U A, V2; 1964, BRIT MED J, V2, P267; 1994, PRACTICAL GUIDE PREV, P57; 1957, BRIT MED J, V2, P1	35	522	540	1	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					889	893		10.1056/NEJM199510053331401	http://dx.doi.org/10.1056/NEJM199510053331401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666874				2022-12-28	WOS:A1995RX19900001
J	BROCHARD, L; MANCEBO, J; WYSOCKI, M; LOFASO, F; CONTI, G; RAUSS, A; SIMONNEAU, G; BENITO, S; GASPARETTO, A; LEMAIRE, F; ISABEY, D; HARF, A				BROCHARD, L; MANCEBO, J; WYSOCKI, M; LOFASO, F; CONTI, G; RAUSS, A; SIMONNEAU, G; BENITO, S; GASPARETTO, A; LEMAIRE, F; ISABEY, D; HARF, A			NONINVASIVE VENTILATION FOR ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE RESPIRATORY-FAILURE; POSITIVE PRESSURE VENTILATION; MECHANICAL VENTILATION; FACE MASK; SUPPORT VENTILATION; AIRWAY PRESSURE; COLD PATIENTS; NASAL MASK; SURVIVAL; COPD	Background. In patients with acute exacerbations of chronic obstructive pulmonary disease, noninvasive ventilation may be used in an attempt to avoid endotracheal intubation and complications associated with mechanical ventilation. Methods. We conducted a prospective, randomized study comparing noninvasive pressure-support ventilation delivered through a face mask with standard treatment in patients admitted to five intensive care units over a 15-month period, Results. A total of 85 patients were recruited from a larger group of 275 patients with chronic obstructive pulmonary disease admitted to the intensive care units in the same period. A total of 42 were randomly assigned to standard therapy and 43 to noninvasive ventilation. The two groups had similar clinical characteristics on admission to the hospital. The use of noninvasive ventilation significantly reduced the need for endotracheal intubation (which was dictated by objective criteria): 11 of 43 patients (26 percent) in the noninvasive-ventilation group were intubated, as compared with 31 of 42 (74 percent) in the standard-treatment group (P<0.001). In addition, the frequency of complications was significantly lower in the noninvasive-ventilation group (16 percent vs. 48 percent, P=0.001), and the mean (+/-SD) hospital stay was significantly shorter for patients receiving noninvasive ventilation (23+/-17 days vs. 35+/-33 days, P=0.005), The in-hospital mortality rate was also significantly reduced with noninvasive ventilation (4 of 43 patients, or 9 percent, in the noninvasive-ventilation group died in the hospital, as compared with 12 of 42, or 29 percent, in the standard-treatment group; P=0.02). Conclusions. in selected patients with acute exacerbations of chronic obstructive pulmonary disease, noninvasive ventilation can reduce the need for endotracheal intubation, the length of the hospital stay, and the in-hospital mortality rate.	HOP HENRI MONDOR,INSERM,U296,F-94010 CRETEIL,FRANCE; UNIV PARIS,INT HOSP,INTENS CARE UNIT,PARIS,FRANCE; HOP ANTOINE BECLERE,RESP INTENS CARE UNIT,CLAMART,FRANCE; ST PAU HOSP,MED INTENS CARE UNIT,BARCELONA,SPAIN; UNIV ROME LA SAPIENZA HOSP,INTENS CARE UNIT,ROME,ITALY; HOP HENRI MONDOR,MED INTENS CARE UNIT,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Sapienza University Rome; University Hospital Sapienza Rome; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP			Lofaso, Frédéric/R-6100-2018; Conti, Giorgio/AAB-9546-2022; Simonneau, Gerald/ABE-6614-2020	Conti, Giorgio/0000-0002-8566-9365; 				ALTMAN DG, 1991, PRACTICAL STATISTICS, P270; ASMUNDSSON T, 1974, ANN INTERN MED, V80, P54, DOI 10.7326/0003-4819-80-1-54; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1989, AM REV RESPIR DIS, V139, P513, DOI 10.1164/ajrccm/139.2.513; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BURK RH, 1973, ARCH INTERN MED, V132, P865, DOI 10.1001/archinte.132.6.865; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; DERENNE JP, 1988, AM REV RESPIR DIS, V138, P1006, DOI 10.1164/ajrccm/138.4.1006; ELLIOTT M, 1994, PRINCIPLES PRACTICE, P427; ELLIOTT MW, 1990, BRIT MED J, V300, P358, DOI 10.1136/bmj.300.6721.358; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FERNANDEZ R, 1993, INTENS CARE MED, V19, P456, DOI 10.1007/BF01711087; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; ISABEY D, 1989, J APPL PHYSIOL, V67, P771, DOI 10.1152/jappl.1989.67.2.771; KAELIN RM, 1987, CHEST, V92, P971, DOI 10.1378/chest.92.6.971; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEGER P, 1988, American Review of Respiratory Disease, V137, P63; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; MENZIES R, 1989, CHEST, V95, P398, DOI 10.1378/chest.95.2.398; PETTY TL, 1985, LUNG BIOL HLTH DISEA, V28, P389; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; VITACCA M, 1993, INTENS CARE MED, V19, P450, DOI 10.1007/BF01711086; WARREN PM, 1980, LANCET, V1, P467; WYSOCKI M, 1993, CHEST, V103, P907, DOI 10.1378/chest.103.3.907	31	1238	1292	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					817	822		10.1056/NEJM199509283331301	http://dx.doi.org/10.1056/NEJM199509283331301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651472	Bronze			2022-12-28	WOS:A1995RW88300001
J	GALAKTIONOV, K; LEE, AK; ECKSTEIN, J; DRAETTA, G; MECKLER, J; LODA, M; BEACH, D				GALAKTIONOV, K; LEE, AK; ECKSTEIN, J; DRAETTA, G; MECKLER, J; LODA, M; BEACH, D			CDC25 PHOSPHATASES AS POTENTIAL HUMAN ONCOGENES	SCIENCE			English	Article							FISSION YEAST; BREAST-CARCINOMA; MITOTIC INDUCER; P34CDC2 KINASE; CDK2 ACTIVITY; CYCLIN; PHOSPHORYLATION; CELLS; ACTIVATION; INHIBITION	Cyclin-dependent kinases (CDKs) are activated by CDC25 phosphatases, which remove inhibitory phosphate from tyrosine and threonine residues. In human cells, CDC25 proteins are encoded by a multigene family, consisting of CDC25A, CDC25B, and CDC25C. In rodent cells, human CDC25A or CDC25B but not CDC25C phosphatases cooperate with either Ha-RAS(G12V) or loss of RB1 in oncogenic focus formation. Such transformants were highly aneuploid, grew in soft agar, and formed high-grade tumors in nude mice. Overexpression of CDC25B was detected in 32 percent of human primary breast cancers tested. The CDC25 phosphatases may contribute to the development of human cancer.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA; HARVARD UNIV, SCH MED, LAHEY CLIN MED CTR, BURLINGTON, MA 01805 USA; MITOTIX, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, DEACONESS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Harvard University; Lahey Hospital & Medical Center; Harvard University; Harvard Medical School								BOSARI S, 1992, VIRCHOWS ARCH A, V421, P291, DOI 10.1007/BF01660975; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, UNPUB; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE AKC, 1990, J CLIN ONCOL, V8, P1457, DOI 10.1200/JCO.1990.8.9.1457; LEE AKC, 1992, MODERN PATHOL, V5, P61; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MATSUDA M, 1991, JPN J GENET, V66, P701, DOI 10.1266/jjg.66.701; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; NAGATA A, 1991, NEW BIOL, V3, P959; NASSER IA, 1993, HUM PATHOL, V24, P950, DOI 10.1016/0046-8177(93)90108-S; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; POLYAK K, 1994, NATURE, V78, P59; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TOYOSHIMA H, 1994, NATURE, V78, P67; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	46	505	529	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1575	1577		10.1126/science.7667636	http://dx.doi.org/10.1126/science.7667636			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667636				2022-12-28	WOS:A1995RU81300041
J	SMITH, DM				SMITH, DM			PRESSURE ULCERS IN THE NURSING-HOME	ANNALS OF INTERNAL MEDICINE			English	Article							DECUBITUS ULCERS; SORE RISK; COST-EFFECTIVENESS; RANDOMIZED TRIAL; BRADEN SCALE; PREVENTION; THERAPY; RESIDENTS; DRESSINGS; SYSTEM	Objective: To review the literature on the causes, epidemiology, prevention, and treatment of pressure ulcers in nursing homes and to summarize this information for clinicians caring for nursing home residents. Data Sources: A MEDLINE search of English-language articles published between 1980 and October 1994 using the terms decubitus ulcer and elderly. References from identified articles were also examined. Study Selection: Articles were excluded if the title indicated that patients were not nursing home residents (unless data from nursing homes were limited or unavailable), that patients were not elderly, or that the ulcers were related to peripheral vascular disease or neuropathy. Data Extraction: Selected studies either contained original data or were meta-analyses. Prevalence studies were required to have an identifiable denominator risk factor and incidence studies were required to have an identifiable cohort and a specified duration of follow-up. Preference was given to risk factors identified through multivariate analyses. Studies of preventive and therapeutic interventions were required to have an identifiable control group; preference was given to randomized controlled trials. Data Synthesis: Seventeen percent to 35% of patients have pressure ulcers at the time of admission to a nursing home, and the prevalence of pressure ulcers among nursing home residents ranges from 7% to 23%. Among high-risk patients, the incidence of pressure ulcers is estimated to be 14/1000 patient-days. Residents at higher risk for developing ulcers are those who have limited ability to reposition themselves, cannot sense the need to reposition, have fecal incontinence, or cannot feed themselves. Occlusive dressings are as effective and less costly than traditional wet-to-dry saline dressings for treating earlier stages of pressure ulcers. There is no consensus on the use of specialized beds in the nursing home for promoting the healing of advanced-stage ulcers or for reducing the incidence of ulcers in high-risk patients. Specific interventions should not detract from careful, total assessment and management of the patient. Conclusions: Pressure ulcers in the nursing home are common problems associated with significant morbidity and mortality. Because resident characteristics can identify residents likely to develop ulcers, preventive measures can be implemented early. Therapy for advanced stages of pressure ulcers is expensive and prolonged. Involvement of the physician with the multidisciplinary nursing home team is essential for prevention and therapy.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA; REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	SMITH, DM (corresponding author), RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, 111GIM, 1481 W 10TH ST, INDIANAPOLIS, IN 46202 USA.							ABRUZZESE R, 1991, DECUBITUS, V4, P67; ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; Alterescu V, 1989, Decubitus, V2, P14; AMEIS A, 1980, POSTGRAD MED, V67, P177, DOI 10.1080/00325481.1980.11715373; [Anonymous], 1989, Decubitus, V2, P24; BENDY RH, 1964, ANTIMICROB AGENTS CH, V1, P147; BENNETT L, 1979, ARCH PHYS MED REHAB, V60, P309; BENNETT L, 1981, ARCH PHYS MED REHAB, V62, P392; BENNETT RG, 1989, J AM GERIATR SOC, V37, P235, DOI 10.1111/j.1532-5415.1989.tb06813.x; BERGSTROM N, 1987, NURS CLIN N AM, V22, P417; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERGSTROM N, 1987, NURS RES, V36, P205, DOI 10.1097/00006199-198707000-00002; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; BRESLOW RA, 1993, J AM GERIATR SOC, V41, P357, DOI 10.1111/j.1532-5415.1993.tb06940.x; BRYAN CS, 1983, ARCH INTERN MED, V143, P2093, DOI 10.1001/archinte.143.11.2093; COLWELL S, 1993, NEW STATESMAN SOC, V6, P28; DAROUICHE RO, 1994, ARCH INTERN MED, V154, P753, DOI 10.1001/archinte.154.7.753; DELATEUR BJ, 1976, ARCH PHYS MED REHAB, V57, P129; Dimant J, 1988, J Gerontol Nurs, V14, P18; DISA JJ, 1992, PLAST RECONSTR SURG, V89, P272, DOI 10.1097/00006534-199202000-00012; FERGUSONPELL MW, 1990, J REHABIL RES DEV S, V2, P49; FERRELL BA, 1993, JAMA-J AM MED ASSOC, V269, P494, DOI 10.1001/jama.269.4.494; Frantz R A, 1989, Decubitus, V2, P56; Frantz R A, 1991, Decubitus, V4, P37; FRAQNTZ RA, 1992, DECUBITUS, V5, P44; GARBER SL, 1978, AM J OCCUP THER, V32, P565; GLENCHUR H, 1981, MIL MED, V146, P432; GOMOLIN IH, 1983, J AM GERIATR SOC, V31, P710, DOI 10.1111/j.1532-5415.1983.tb04159.x; GOOSSENS RHM, 1994, CLIN PHYSIOL, V14, P111, DOI 10.1111/j.1475-097X.1994.tb00495.x; GORSE GJ, 1987, ARCH DERMATOL, V123, P766, DOI 10.1001/archderm.123.6.766; Graves E J, 1992, Vital Health Stat 13, P1; GRAVES EJ, 1994, VITAL HLTH STAT 13, V115, P1; GRAVES EJ, 1991, VITAL HLTH STAT 13, V108, P1; GRAVES RJ, 1991, VITAL HLTH STAT 13, V107, P1; Guin P, 1991, Decubitus, V4, P15; Hedrick-Thompson J, 1993, J ET Nurs, V20, P239; HOFMAN A, 1994, LANCET, V343, P568, DOI 10.1016/S0140-6736(94)91521-0; HOLZAPFEL SK, 1993, J ET NURS, V20, P2851; INMAN KJ, 1993, JAMA-J AM MED ASSOC, V269, P1139; KEMP MG, 1993, RES NURS HEALTH, V16, P89, DOI 10.1002/nur.4770160203; KEMP MG, 1990, RES NURS HEALTH, V13, P293, DOI 10.1002/nur.4770130505; Kertesz D, 1992, Clin Geriatr Med, V8, P835; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOSIAK M, 1959, Arch Phys Med Rehabil, V40, P62; KOSIAK M, 1958, Arch Phys Med Rehabil, V39, P623; Kraft M R, 1993, Decubitus, V6, P42; Krouskop T A, 1985, J Rehabil Res Dev, V22, P7, DOI 10.1682/JRRD.1985.07.0007; Landis EM, 1930, HEART-J STUD CIRC, V15, P209; Levine J M, 1992, Decubitus, V5, P23; LOFGREN RP, 1989, AM J PUBLIC HEALTH, V79, P735, DOI 10.2105/AJPH.79.6.735; Lyder C H, 1991, J ET Nurs, V18, P162; Maklebust J A, 1986, J Enterostomal Ther, V13, P85; Marchette L, 1991, Dimens Crit Care Nurs, V10, P321, DOI 10.1097/00003465-199111000-00006; MEIJER JH, 1994, ARCH PHYS MED REHAB, V75, P318, DOI 10.1016/0003-9993(94)90036-1; MICHOCKI RJ, 1976, J AM GERIATR SOC, V24, P323, DOI 10.1111/j.1532-5415.1976.tb06804.x; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MOSS RJ, 1991, J AM GERIATR SOC, V39, P905, DOI 10.1111/j.1532-5415.1991.tb04458.x; MUSTOE TA, 1994, ARCH SURG-CHICAGO, V129, P213; NORTON D, 1992, INVESTIGATION GERIAT, P193; Oleske D M, 1986, J Enterostomal Ther, V13, P90; PIEPER B, 1990, J ENTEROSTOMOL THER, V17, P1475; PINCHCOFSKYDEVIN GD, 1986, J AM GERIATR SOC, V34, P435, DOI 10.1111/j.1532-5415.1986.tb03411.x; Powell J W, 1989, Decubitus, V2, P56; REED JW, 1981, MARYLAND STATE MED J, V30, P45; ROBSON MC, 1992, ANN SURG, V216, P401, DOI 10.1097/00000658-199210000-00002; RUDENSKY B, 1992, SOUTHERN MED J, V85, P901, DOI 10.1097/00007611-199209000-00010; RUDMAN D, 1993, J AM GERIATR SOC, V41, P1317, DOI 10.1111/j.1532-5415.1993.tb06482.x; Salvadalena G D, 1992, J ET Nurs, V19, P160; SEILER WO, 1986, GERONTOLOGY, V32, P158, DOI 10.1159/000212783; SHEPARD MA, 1987, J AM GERIATR SOC, V35, P159, DOI 10.1111/j.1532-5415.1987.tb01346.x; SIEGLER EL, 1991, J GEN INTERN MED, V6, P507, DOI 10.1007/BF02598218; SMITH DM, 1991, J GEN INTERN MED, V6, P81, DOI 10.1007/BF02599399; SPECTOR WD, 1988, GERONTOLOGIST, V28, P830, DOI 10.1093/geront/28.6.830; Stewart T P, 1990, Decubitus, V3, P26; STRAUSS MJ, 1991, J FAM PRACTICE, V33, P52; SUGARMAN B, 1983, ARCH INTERN MED, V143, P683, DOI 10.1001/archinte.143.4.683; TAYLOR TV, 1974, LANCET, V2, P544; Thompson-Bishop J Y, 1992, Decubitus, V5, P42; VARMA AO, 1973, SURG GYNECOL OBSTET, V136, P281; WITKOWSKI JA, 1991, INT J DERMATOL, V30, P660, DOI 10.1111/j.1365-4362.1991.tb03498.x; WOOD JM, 1993, ARCH DERMATOL, V129, P999, DOI 10.1001/archderm.129.8.999; XAKELLIS GC, 1992, J AM GERIATR SOC, V40, P1250, DOI 10.1111/j.1532-5415.1992.tb03651.x; XAKELLIS GC, 1992, ARCH PHYS MED REHAB, V73, P463; YOUNG R, 1989, NEW STATESMAN SOC, V2, P52; 1992, NATIONAL SPECIALIZED	88	120	123	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					433	442		10.7326/0003-4819-123-6-199509150-00008	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU437	7639444				2022-12-28	WOS:A1995RU43700007
J	PASTERNACK, RF; COLLINGS, PJ				PASTERNACK, RF; COLLINGS, PJ			RESONANCE LIGHT-SCATTERING - A NEW TECHNIQUE FOR STUDYING CHROMOPHORE AGGREGATION	SCIENCE			English	Article							PORPHYRINS	Light scattering experiments are usually performed at wavelengths away from absorption bands, but for species that aggregate,enhancements in light scattering of several orders of magnitude can be observed at wavelengths characteristic of these species. Resonance light scattering is shown to be a sensitive and selective method for studying electronically coupled chromophore arrays. The approach is illustrated with several examples drawn from porphyrin and chlorin chemistry. The physical principles underlying resonance light scattering are discussed, and the advantages and limitations of the technique are reviewed.	SWARTHMORE COLL,DEPT PHYS & ASTRON,SWARTHMORE,PA 19081	Swarthmore College	PASTERNACK, RF (corresponding author), SWARTHMORE COLL,DEPT CHEM,500 COL AVE,SWARTHMORE,PA 19081, USA.							AKINS DL, 1994, J PHYS CHEM-US, V98, P3612, DOI 10.1021/j100065a012; ANGLISTER J, 1981, J CHEM PHYS, V74, P786, DOI 10.1063/1.441179; ANGLISTER J, 1979, CHEM PHYS LETT, V65, P50, DOI 10.1016/0009-2614(79)80123-2; ANGLISTER J, 1983, J CHEM PHYS, V78, P5358, DOI 10.1063/1.445489; ARENA G, 1995, INORG CHEM, V34, P2994, DOI 10.1021/ic00115a030; BAUER DR, 1975, J CHEM PHYS, V63, P588, DOI 10.1063/1.431091; BLANKENSHIP RE, 1988, LIGHT ENERGY TRANSDU, P32; Bohren C., 2008, ABSORPTION SCATTERIN; CHIARELLO R, 1988, J CHEM PHYS, V88, P1253, DOI 10.1063/1.454246; DEPAULA JC, 1995, BIOPHYS J, V68, P335, DOI 10.1016/S0006-3495(95)80192-X; DOUGHERTY TJ, 1992, ADV PHOTOCHEM, P275; FORD NC, 1985, DYNAMIC LIGHT SCATTE, P7; GIBBS EJ, 1988, BIOCHEM BIOPH RES CO, V157, P350, DOI 10.1016/S0006-291X(88)80054-8; MAGILL JV, 1985, J PHYS CHEM-US, V89, P734, DOI 10.1021/j100251a003; MILLER GA, 1978, J PHYS CHEM-US, V82, P616, DOI 10.1021/j100494a023; NELSON WH, 1982, INORG CHEM, V21, P1483, DOI 10.1021/ic00134a043; PASTEMACK RF, UNPUB; PASTERNA.RF, 1972, J AM CHEM SOC, V94, P4511, DOI 10.1021/ja00768a016; PASTERNACK RF, 1994, INORG CHEM, V33, P2062, DOI 10.1021/ic00087a053; PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P2406, DOI 10.1021/bi00279a016; PASTERNACK RF, 1993, J AM CHEM SOC, V15, P5393; PERKINS WR, 1992, BIOCHIM BIOPHYS ACTA, V1107, P271, DOI 10.1016/0005-2736(92)90414-H; RISEMAN J, 1950, J CHEM PHYS, V18, P512, DOI 10.1063/1.1747672; SCHUELER PA, 1993, ANAL CHEM, V65, P3177, DOI 10.1021/ac00070a003; STANTON SG, 1981, J CHEM PHYS, V75, P5615, DOI 10.1063/1.442000; STANTON SG, 1983, J CHEM PHYS, V78, P3365, DOI 10.1063/1.445212; ZERO K, 1985, DYNAMIC LIGHT SCATTE, P59	27	907	981	4	129	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					935	939		10.1126/science.7638615	http://dx.doi.org/10.1126/science.7638615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638615				2022-12-28	WOS:A1995RP73800024
J	WELLINGS, K; WADSWORTH, J; JOHNSON, AM; FIELD, J; WHITAKER, L; FIELD, B				WELLINGS, K; WADSWORTH, J; JOHNSON, AM; FIELD, J; WHITAKER, L; FIELD, B			PROVISION OF SEX-EDUCATION AND EARLY SEXUAL EXPERIENCE - THE RELATION EXAMINED	BRITISH MEDICAL JOURNAL			English	Article							LIFE-STYLES	Objective-To explore the relation between receipt of sex education and experience of first intercourse. Subjects and design-The national survey of sexual attitudes and lifestyles is based on a sample of 18 876 respondents aged 16-59, randomly selected from the Post Office's small-user postcode address file. Data were collected between May 1990 and November 1991 by personal interviews combining a self administered questionnaire with a face to face interview. Main outcome measures-Age at first intercourse, use of contraception at first intercourse, actual and preferred source of sex education (including school based lessons). Results-Median age at first intercourse fell by four years for women and three years for men over the past four decades, to 17 for both men and women aged 16-19 at the time of interview. Of those respondents for whom school was the main source of information about sexual matters, men were less likely, and women no more likely, to have had intercourse before the age of 16 than were those citing other main sources, such as friends and the media. Both men and women were more likely to have used some method of contraception. In multivariate analysis, these effects remained after controlling for the effect of current age, educational attainment, and religious affiliation. Conclusions-These data provide no evidence to support the concern that provision of school sex education might hasten the onset of sexual experience, These findings have important implications for the provision of sexual health education and highlight the need to carry out prospective and randomised studies of the impact of sex education,	ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1PG, ENGLAND; UCL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON WC1E 6AU, ENGLAND; SOCIAL & COMMUNITY PLANNING RES, LONDON EC1V 0AX, ENGLAND	Imperial College London; University of London; University College London; UCL Medical School	WELLINGS, K (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND.			Johnson, Anne/0000-0003-1330-7100	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; Johnson AM, 1994, SEXUAL ATTITUDES LIF; MELLANBY A, 1992, J ADOLESCENCE, V15, P449, DOI 10.1016/0140-1971(92)90074-F; WADSWORTH J, 1993, J ROY STAT SOC A STA, V156, P407, DOI 10.2307/2983066; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; WELLINGS K, 1994, SEXUAL BEHAVIOUR BRI; 1992, HLTH NATION STRATEGY; 1994, LANCET, V344, P899	8	68	71	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					417	420		10.1136/bmj.311.7002.417	http://dx.doi.org/10.1136/bmj.311.7002.417			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RP554	7640586	Green Published			2022-12-28	WOS:A1995RP55400013
J	SHERMAN, LA; TEMPLE, R; MERKATZ, RB				SHERMAN, LA; TEMPLE, R; MERKATZ, RB			WOMEN IN CLINICAL-TRIALS - AN FDA PERSPECTIVE	SCIENCE			English	Editorial Material									US FDA,OFF WOMENS HLTH,ROCKVILLE,MD 20857; US FDA,OFF COMMISSIONER,OPERAT OFF,ROCKVILLE,MD 20857; US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)								[Anonymous], 1989, GUIDELINE STUDY DRUG; BURKHARDT GH, COMMUNICATION; FROOM J, 1991, J CLIN EPIDEMIOL, V44, P1127, DOI 10.1016/0895-4356(91)90144-X; HALE V, UNPUB; JOHNSON LR, 1995, IN PRESS JAN P WORKS; MACHADO SF, UNPUB; MERKATZ RB, 1993, NEW ENGL J MED, V329, P292, DOI 10.1056/NEJM199307223290429; MURPHY D, 1993, FOOD DRUG LAW J, V48, P175; RAY BA, 1986, RES MONOGRAPH NAT I, V65; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; TEMPLE R, UNPUB; TOIGO TA, UNPUB; WENGER NK, 1992, JAMA-J AM MED ASSOC, V268, P1460, DOI 10.1001/jama.268.11.1460; YUSEF S, 1991, JAMA-J AM MED ASSOC, V266, P93; 1995, JAN P NAT TASK FORC; 1977, GENERAL CONSIDERATIO; 1993, GUIDELINE STUDY EVAL; 1995, PHYSICIANS DESK REFE, P1877; 1992, GAOHRD9317 PUBL; 1988, GUIDELINE FORMAT CON; 1989, GUIDE CLIN PREVENTIV, P258; 1995, NOV WORKSH GEND STUD; 1985, PHS8550206 DEP HLTH; 1992, AIDS PROJECT CITIZEN	24	27	27	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					793	795		10.1126/science.7638593	http://dx.doi.org/10.1126/science.7638593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638593				2022-12-28	WOS:A1995RN65000031
J	HEATH, I				HEATH, I			THE PERILS OF CHECKLIST MEDICINE - COMMENT	BRITISH MEDICAL JOURNAL			English	Article											HEATH, I (corresponding author), KENTISH TOWN HLTH CTR,CAVERSHAM GRP PRACTICE,LONDON NW5 2AJ,ENGLAND.							MCKEE M, 1995, BRIT MED J, V310, P101, DOI 10.1136/bmj.310.6972.101; TOON P, 1994, 65 ROYAL COLL GEN PR; Tudor Hart J, 1994, FEASIBLE SOCIALISM N; Willis J, 1995, PARADOX PROGR; 1995, 26 ROYAL COLL GEN PR	5	4	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					373	373		10.1136/bmj.311.7001.373	http://dx.doi.org/10.1136/bmj.311.7001.373			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640547	Green Published			2022-12-28	WOS:A1995RN46900021
J	DIGGORY, P; CASSELSBROWN, A; VAIL, A; ABBEY, LM; HILLMAN, JS				DIGGORY, P; CASSELSBROWN, A; VAIL, A; ABBEY, LM; HILLMAN, JS			AVOIDING UNSUSPECTED RESPIRATORY SIDE-EFFECTS OF TOPICAL TIMOLOL WITH CARDIOSELECTIVE OR SYMPATHOMIMETIC AGENTS	LANCET			English	Article							LUNG-FUNCTION TESTS; ELDERLY PATIENTS; GLAUCOMA; COMMUNITY; PRESSURE; DISEASE	Topical timolol given for the treatment or chronic simple glaucoma may cause unrecognised bronchospasm among elderly people. We recruited 80 patients aged over 60 years, who were without a history of airways disease and already used timolol, into a randomised crossover study comparing the effects on spirometry and exercise tolerance of changing to betaxolol or dipiverfrine therapy. Results showed an increase of 13% and 8% in mean peak flow rate and forced expiratory volume in 1 s (FEV(1)), respectively, when using betaxolol; and of 14% and 11% when using dipivefrine. There was also improved exercise tolerance with both agents. More than a quarter of the patients showed at least a 15% improvement in FEV, when changed from timolol. Analysis of enrolment symptoms and response to nebulised salbutamol failed to produce a method of identifying these patients. Timolol may impair respiratory function and exercise tolerance of elderly patients even if they have no history of reversible airways disease.	ST JAMESS UNIV HOSP, DEPT MED ELDERLY, LEEDS, W YORKSHIRE, ENGLAND; ST JAMESS UNIV HOSP, DEPT OPHTHALMOL, LEEDS, W YORKSHIRE, ENGLAND; UNIV LEEDS, INST EPIDEMIOL & HLTH SERV RES, DEPT PHARM, LEEDS, W YORKSHIRE, ENGLAND	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; University of Leeds				Vail, Andy/0000-0001-8274-2726				Avorn J, 1993, J Glaucoma, V2, P158; BANERJEE DK, 1987, BRIT J DIS CHEST, V81, P23, DOI 10.1016/0007-0971(87)90104-5; BERROSPI AR, 1982, ARCH OPHTHALMOL-CHIC, V100, P943, DOI 10.1001/archopht.1982.01030030951011; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; CAMPBELL SH, 1993, EYE, V7, P105, DOI 10.1038/eye.1993.22; CHOWIENCZYK PJ, 1982, BRIT MED J, V285, P15, DOI 10.1136/bmj.285.6334.15; CONNOLLY MJ, 1992, THORAX, V47, P410, DOI 10.1136/thx.47.6.410; DIGGORY P, 1993, EYE, V7, P661, DOI 10.1038/eye.1993.151; DIGGORY P, 1994, J ROY SOC MED, V87, P575; ENRIGHT PL, 1993, AM REV RESPIR DIS, V147, P125, DOI 10.1164/ajrccm/147.1.125; GAENSLER EA, 1966, ARCH ENVIRON HEALTH, V12, P146, DOI 10.1080/00039896.1966.10664355; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P205, DOI 10.1001/archopht.1991.01080020051041; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; JAY JL, 1988, BRIT J OPHTHALMOL, V72, P881, DOI 10.1136/bjo.72.12.881; KASS MA, 1979, ARCH OPHTHALMOL-CHIC, V97, P1865, DOI 10.1001/archopht.1979.01020020313004; MCMAHON CD, 1979, AM J OPHTHALMOL, V88, P736, DOI 10.1016/0002-9394(79)90674-3; MIGDAL C, 1994, OPHTHALMOLOGY, V101, P1651; PASSO MS, 1984, OPHTHALMOLOGY, V91, P1361; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; SCHOENE RB, 1981, JAMA-J AM MED ASSOC, V245, P1460, DOI 10.1001/jama.245.14.1460	21	76	77	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	1995	345	8965					1604	1606		10.1016/S0140-6736(95)90116-7	http://dx.doi.org/10.1016/S0140-6736(95)90116-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7646670				2022-12-28	WOS:A1995RE67000009
J	HAMDY, NAT; KANIS, JA; BENETON, MNC; BROWN, CB; JUTTMANN, JR; JORDANS, JGM; JOSSE, S; MEYRIER, A; LINS, RL; FAIREY, IT				HAMDY, NAT; KANIS, JA; BENETON, MNC; BROWN, CB; JUTTMANN, JR; JORDANS, JGM; JOSSE, S; MEYRIER, A; LINS, RL; FAIREY, IT			EFFECT OF ALFACALCIDOL ON NATURAL COURSE OF RENAL BONE-DISEASE IN MILD-TO-MODERATE RENAL-FAILURE	BRITISH MEDICAL JOURNAL			English	Article							BOVINE PARATHYROID CELLS; VITAMIN-D METABOLITES; TRADE-OFF HYPOTHESIS; SECONDARY HYPERPARATHYROIDISM; ILIAC BONE; HORMONE; INSUFFICIENCY; SERUM; OSTEODYSTROPHY; ALUMINUM	Objective-To determine whether alfacalcidol-used in management of overt renal bone disease-may safely prevent renal bone disease when used earlier in course of renal failure. Design-Double blind, prospective, randomised, placebo controlled study. Setting-17 nephrology centres from Belgium, France, the Netherlands, and the United Kingdom. Subjects-176 patients aged 18-81 with mild to moderate chronic renal failure (creatinine clearance 15-50 ml/min) and with no clinical, biochemical, or radiographic evidence of bone disease. Interventions-Alfacalcidol 0.25 mu g (titrated according to serum calcium concentration) or placebo given for two years. Main outcome measures-Quantitative histology of bone to assess efficacy of treatment and renal function to assess safety. Results-132 patients had histological evidence of bone disease at start of study. Biochemical, radiographic, and histological indices of bone metabolism were similar for the 89 patients given alfacalcidol and the 87 controls given placebo. After treatment, mean serum alkaline phosphatase activity and intact parathyroid hormone concentration had increased by 13% and 126% respectively in controls but had not changed in patients given alfacalcidol (P < 0.001). Hypercalcaemic episodes occurred in 10 patients given alfacalcidol (but responded to decreases in drug dose) and in three controls. Histological indices of bone turnover significantly improved in patients given alfacalcidol and significantly deteriorated in controls: among patients with abnormal bone histology before treatment, bone disease resolved in 23 (42%) of those given alfacalcidol compared with two (4%) of the controls (P < 0.001). There was no difference in rate of progression of renal failure between the two groups. Conclusion-Early administration of alfacalcidol can safely and beneficially alter the natural course of renal bone disease in patients with mild to moderate renal failure.	UNIV SHEFFIELD,SCH MED,DEPT HUMAN METAB & CLIN BIOCHEM,WHO,COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT RENAL MED & TRANSPLANTAT,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; ST ELIZABETH HOSP,DEPT INTERNAL MED,5002 TILBURG,NETHERLANDS; MED SPECTRUM TWENTE,DEPT INTERNAL MED NEPHROL,7511 ENSCHEDE,NETHERLANDS; HOP DU BOIS GUILLAUME,SERV NEPHROL,F-76233 BOIS GUILLAUME,FRANCE; HOP AVICENNE,SERV NEPHROL,F-93000 BOBIGNY,FRANCE; STUIVENBERG ALGEMEEN ZIEKENHUIS,B-2000 ANTWERP,BELGIUM; LEO LABS INC,AYLESBURY HP27 9RR,BUCKS,ENGLAND	University of Sheffield; World Health Organization; Northern General Hospital; Medical Spectrum Twente; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; ZNA Stuivenberg			Meyrier, Alain/GWQ-3527-2022					ADLER AJ, 1985, KIDNEY INT, V28, P932, DOI 10.1038/ki.1985.220; ALVAREZUDE F, 1978, KIDNEY INT, V14, P68, DOI 10.1038/ki.1978.90; BRICKER NS, 1972, NEW ENGL J MED, V286, P1093; BRICKMAN AS, 1974, ANN INTERN MED, V80, P161, DOI 10.7326/0003-4819-80-2-161; BROWN RC, 1987, J CLIN ENDOCR METAB, V65, P407, DOI 10.1210/jcem-65-3-407; CANTLEY LK, 1985, ENDOCRINOLOGY, V117, P2114, DOI 10.1210/endo-117-5-2114; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COBURN JW, 1977, VITAMIN D BIOCH CHEM, P657; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CUNDY T, 1985, BRIT MED J, V290, P271, DOI 10.1136/bmj.290.6464.271; Cundy T F, 1988, Contrib Nephrol, V64, P5; DELUCA HF, 1973, NEW ENGL J MED, V298, P359; ELLIS HA, 1973, J CLIN PATHOL, V26, P83, DOI 10.1136/jcp.26.2.83; FONSECA V, 1984, LANCET, V2, P1093; GARDINER PE, 1981, ANAL CHIM ACTA, V128, P57, DOI 10.1016/S0003-2670(01)84083-6; GOODMAN WG, 1992, ANNU REV MED, V43, P227; KANIS JA, 1977, NEW ENGL J MED, V296, P1073, DOI 10.1056/NEJM197705122961901; KANIS JA, 1988, BAILLIERE CLIN ENDOC, V2, P193, DOI 10.1016/S0950-351X(88)80013-2; KANIS JA, 1979, Q J MED, V48, P289; KANIS JA, 1977, CLIN ENDOCRINOL S, V7, P45; LLACH F, 1985, J CLIN ENDOCR METAB, V61, P601, DOI 10.1210/jcem-61-4-601; LOPEZHILKER S, 1986, J CLIN INVEST, V78, P1097, DOI 10.1172/JCI112666; MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187; MALLUCHE HH, 1992, KIDNEY INT, V42, pS62; MALLUCHE HH, 1976, KIDNEY INT, V9, P355, DOI 10.1038/ki.1976.42; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MASSRY SG, 1975, KIDNEY INT, V9, P467; MAWER EB, 1973, LANCET, V1, P626, DOI 10.1016/S0140-6736(73)92197-1; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PORTALE AA, 1984, J CLIN INVEST, V73, P1580, DOI 10.1172/JCI111365; SILVER J, 1985, P NATL ACAD SCI USA, V82, P4270, DOI 10.1073/pnas.82.12.4270; SOMERVILLE PJ, 1978, KIDNEY INT, V14, P245, DOI 10.1038/ki.1978.116; SZABO A, 1989, KIDNEY INT, V35, P1049, DOI 10.1038/ki.1989.89; TAUBE T, 1992, EUR J HAEMATOL, V49, P192; WOODS CG, 1968, J PATHOL BACTERIOL, V95, P411	35	269	274	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					358	363		10.1136/bmj.310.6976.358	http://dx.doi.org/10.1136/bmj.310.6976.358			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7677827	Green Published			2022-12-28	WOS:A1995QG72100017
J	GODFREY, J				GODFREY, J			THE POPE AND THE ONTOGENY OF PERSONS	NATURE			English	Editorial Material									UNIV EDINBURGH,CTR HUMAN ECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh								AQUINAS T, SOMME THEOLOGIQUE; JOHNPAUL II, CROSSING THRESHOLD H; 1994, NATURE, V371, P185	3	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					100	100		10.1038/373100a0	http://dx.doi.org/10.1038/373100a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7646629	Bronze			2022-12-28	WOS:A1995QB06300026
J	RODGERS, GP; DOVER, GJ; UYESAKA, N; NOGUCHI, CT; SCHECHTER, AN; NIENHUIS, AW				RODGERS, GP; DOVER, GJ; UYESAKA, N; NOGUCHI, CT; SCHECHTER, AN; NIENHUIS, AW			AUGMENTATION OF ERYTHROPOIETIN OF THE FETAL-HEMOGLOBIN RESPONSE TO HYDROXYUREA IN SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; NICKEL MESH; ANEMIA; POLYMERIZATION; STIMULATION; BABOONS	Background. Hydroxyurea increases the production of fetal hemoglobin in patients with sickle cell anemia, inhibiting the polymerization of hemoglobin S and potentially improving vaso-occlusive manifestations and hemolysis. Recombinant erythropoietin increases the number of reticulocytes containing fetal hemoglobin in laboratory animals and in humans. We studied whether hydroxyurea and erythropoietin might have a potentiating effect on the production of fetal hemoglobin in patients with sickle cell disease. Methods. We treated four patients who were receiving hydroxyurea for sickle cell disease (three who were homozygous for sickle cell anemia and one with sickle beta0-thalassemia) with escalating doses of intravenous erythropoietin for seven weeks, along with oral iron sulfate. Doses of hydroxyurea on four consecutive days were alternated with doses of erythropoietin on three consecutive days. Results. There was a 28 percent increase in the number of reticulocytes containing fetal hemoglobin and a 48 percent increase in the percentage of fetal hemoglobin, as compared with the maximal values obtained with hydroxyurea alone. The percentage of erythrocytes containing fetal hemoglobin (F cells) increased from 64 to 78 percent. As compared with hydroxyurea alone, treatment with hydroxyurea and erythropoietin decreased the mean (+/-SD) serum indirect bilirubin level from 0.8+/-0.2 to 0.5+/-0.1 mg per deciliter (13.3+/-2.9 to 8.9+/-2.2 mumol per liter) (P = 0.02), suggesting a further decrease in hemolysis. Red-cell filterability improved. Conclusions. Intravenous recombinant erythropoietin with iron supplementation alternating with hydroxyurea elevates fetal-hemoglobin and F-cell levels more than hydroxyurea alone. Such increases decrease intracellular polymerization of hemoglobin S and improve the overall rheologic characteristics of erythrocytes. A reduced dosage of hydroxyurea alternating with erythropoietin may prove less myelotoxic than hydroxyurea given daily or in pulsed-dose regimens. It may also increase levels of fetal hemoglobin in patients with sickle cell disease who have not been helped by hydroxyurea alone.	NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21205 USA; NIPPON MED COLL, DEPT PHYSIOL, TOKYO 113, JAPAN	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; Nippon Medical School	RODGERS, GP (corresponding author), NIDDKD, CHEM BIOL LAB, BLDG 10, RM 9N-307, BETHESDA, MD 20892 USA.			Schechter, Alan N/0000-0002-5235-9408				ADEKILE AD, 1985, AM J PEDIAT HEMATOL, V7, P295; al-Khatti A, 1988, Trans Assoc Am Physicians, V101, P54; ALKHATTI A, 1988, BLOOD, V72, P817; ALKHATTI A, 1987, NEW ENGL J MED, V317, P415, DOI 10.1056/NEJM198708133170704; Alter B P, 1989, Prog Clin Biol Res, V316B, P317; ARAI K, 1990, BIORHEOLOGY, V27, P47; BELILES RP, 1991, J AM COLL TOXICOL, V10, P269, DOI 10.3109/10915819109078636; BRITTENHAM GM, 1985, BLOOD, V65, P183; CAZZOLA M, 1987, J LAB CLIN MED, V110, P734; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; DOVER GJ, 1986, BLOOD, V67, P735; DOVER GJ, 1978, NEW ENGL J MED, V299, P1428, DOI 10.1056/NEJM197812282992603; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; GOLDBERG MA, 1990, NEW ENGL J MED, V323, P366, DOI 10.1056/NEJM199008093230602; HIRUMA H, 1991, CLIN HEMORHEOL, V11, P91; HUANG SZ, 1992, BLOOD, V80, pA343; KRANTZ SB, 1991, BLOOD, V77, P419; LEY TJ, 1983, BLOOD, V62, P370; McDonagh K T, 1989, Prog Clin Biol Res, V316B, P307; NOGUCHI CT, 1981, BLOOD, V58, P1057; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; RODGERS GP, 1991, JAMA-J AM MED ASSOC, V265, P2097, DOI 10.1001/jama.265.16.2097; RODGERS GP, 1985, J LAB CLIN MED, V106, P30; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; RODGERS GP, 1991, JH S CONT M, P377; Schechter A. N., 1987, MOL BASIS BLOOD DIS, P179; SHANNON KM, 1990, AM J PEDIAT HEMATOL, V12, P14; SHERWOOD JB, 1986, BLOOD, V67, P46; Stamatoyannopoulos G, 1989, Prog Clin Biol Res, V316B, P269; UMEMURA T, 1989, BLOOD, V74, P1571; VEITH R, 1985, NEW ENGL J MED, V313, P1571, DOI 10.1056/NEJM198512193132503; VICHINSKY E, 1991, JH S CONT M, P394; WRIGHT DG, 1991, CLIN RES, V39, pA171	36	212	219	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					73	80		10.1056/NEJM199301143280201	http://dx.doi.org/10.1056/NEJM199301143280201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	7677965	Bronze			2022-12-28	WOS:A1993KG46700001
J	BAGBY, S; KIM, SJ; MALDONADO, E; TONG, KI; REINBERG, D; IKURA, M				BAGBY, S; KIM, SJ; MALDONADO, E; TONG, KI; REINBERG, D; IKURA, M			SOLUTION STRUCTURE OF THE C-TERMINAL CORE DOMAIN OF HUMAN TFIIB - SIMILARITY TO CYCLIN-A AND INTERACTION WITH TATA-BINDING PROTEIN	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; NUCLEAR MAGNETIC-RESONANCE; FUNCTIONAL DOMAINS; INITIATION-FACTORS; DISTANCE GEOMETRY; CRYSTAL-STRUCTURE; ACTIVATION; SEQUENCE; ENCODES	TFIIB is an essential component of the machinery that transcribes protein-coding genes. The three-dimensional structure of the human TFIIB core domain (TFIIBc) has been determined using multidimensional heteronuclear magnetic resonance spectroscopy. The molecule consists of two direct repeats that adopt similar alpha-helical folds, conferring pseudo-twofold symmetry. An extensive, central basic surface including an amphipathic alpha helix is critical to the function of TFIIB as a bridge between the TBP-promoter complex and RNA polymerase II and associated general and regulatory transcription factors. Similarities between the TFIIBc and cyclin A folds indicate that elements of the eukaryotic cell cycle control apparatus evolved from more fundamental transcriptional control components, demonstrating a link between the transcription and cell cycle molecular machineries.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	University of Toronto; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	BAGBY, S (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,500 SHERBOURNE ST,TORONTO,ON M4X 1K9,CANADA.			Bagby, Stefan/0000-0003-2302-9511; Reinberg, Danny/0000-0003-4288-2016; Ikura, Mitsuhiko/0000-0002-9524-1303				ALEXANDROV NN, 1992, J MOL BIOL, V225, P5, DOI 10.1016/0022-2836(92)91021-G; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P2409, DOI 10.1021/bi00175a009; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brunger A. T., 1993, X PLOR MANUAL VERSIO; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; COLGAN J, 1995, MOL CELL BIOL, V15, P2311; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CRETI R, 1993, NUCLEIC ACIDS RES, V21, P2942, DOI 10.1093/nar/21.12.2942; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE S, 1995, IN PRESS NATURE; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V365, P520; NILGES M, 1991, COMPUTATIONAL ASPECT, P41; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SWINDELLS MB, 1995, NAT STRUCT BIOL, V2, P596, DOI 10.1038/nsb0795-596; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	60	117	122	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					857	867		10.1016/0092-8674(95)90483-2	http://dx.doi.org/10.1016/0092-8674(95)90483-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671313	Bronze			2022-12-28	WOS:A1995RU75500021
J	ZAKIAN, VA				ZAKIAN, VA			ATM-RELATED GENES - WHAT DO THEY TELL US ABOUT FUNCTIONS OF THE HUMAN GENE	CELL			English	Review							DNA-DAMAGE; HOMOLOG; KINASE; YEAST				ZAKIAN, VA (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.							ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRIEDBERG EC, 1995, DNA REPAIR; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; JACOBY DB, 1994, J BIOL CHEM, V269, P11484; JIMINEZ G, 1992, P NATL ACAD SCI USA, V89, P4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	28	271	282	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					685	687		10.1016/0092-8674(95)90463-8	http://dx.doi.org/10.1016/0092-8674(95)90463-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671296	Bronze			2022-12-28	WOS:A1995RU75500001
J	VANBIESEN, T; HAWES, BE; LUTTRELL, DK; KRUEGER, KM; TOUHARA, K; PORFIRI, E; SAKAUE, M; LUTTRELL, LM; LEFKOWITZ, RJ				VANBIESEN, T; HAWES, BE; LUTTRELL, DK; KRUEGER, KM; TOUHARA, K; PORFIRI, E; SAKAUE, M; LUTTRELL, LM; LEFKOWITZ, RJ			RECEPTOR-TYROSINE-KINASE-MEDIATED AND G-BETA-GAMMA-MEDIATED MAP KINASE ACTIVATION BY A COMMON SIGNALING PATHWAY	NATURE			English	Article							PROTEIN; P21(RAS); FIBROBLASTS; GRB2; RAS	MITOGEN-ACTIVATED protein (MAP) kinases mediate the phosphorylation and activation of nuclear transcription factors that regulate cell growth(1). MAP kinase activation may result from stimulation of either tyrosine-kinase (RTK) receptors, which possess intrinsic tyrosine kinase activity, or G-protein-coupled receptors (GPCR)(2-4). RTK-mediated mitogenic signalling involves a series of SH2- and SH3-dependent protein-protein interactions between tyrosine-phosphorylated receptor, Shc, Grb2 and Sos, resulting in Ras-dependent MAP kinase activation(5-7). The beta gamma subunits of heterotrimeric G proteins (G beta gamma) also mediate Ras-dependent MAP kinase activations(8-10) by an as-yet unknown mechanism. Here we demonstrate that activation of MAP kinase by G(i)-coupled receptors is preceded by the G beta gamma-mediated tyrosine phosphorylation of Shc, leading to an increased functional association between Shc, Grb2 and Sos. Moreover, disruption of the Shc-Grb2-Sos complex blocks G beta gamma-mediated MAP kinase activation, indicating that G beta gamma does not mediate MAP kinase activation by a direct interaction with Sos. These results indicate that G beta gamma-mediated MAP kinase activation is initiated by a tyrosine phosphorylation event and proceeds by a pathway common to both GPCRs and RTKs.	DUKE UNIV,MED CTR,DEPT MED CARDIOL,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,DURHAM,NC 27710; GLAXO WELLCOME INC,DEPT MOLEC CELL BIOL,RES TRIANGLE PK,NC 27709; ONYX PHARMACEUT,RICHMOND,CA 94806; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; GlaxoSmithKline; Kobe University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SPANDIDOS DA, 1984, NATURE, V322, P469; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196	27	401	404	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					781	784		10.1038/376781a0	http://dx.doi.org/10.1038/376781a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651538				2022-12-28	WOS:A1995RR83600042
J	LEESE, B; BOSANQUET, N				LEESE, B; BOSANQUET, N			CHANGE IN GENERAL-PRACTICE AND ITS EFFECTS ON SERVICE PROVISION IN AREAS WITH DIFFERENT SOCIOECONOMIC CHARACTERISTICS	BRITISH MEDICAL JOURNAL			English	Article							CONTRACT; PRACTITIONERS	Objective-To investigate the changes in the structure and service provision of general practice in areas with different socioeconomic characteristics. Design-Interview survey; postal questionnaire. Setting-260 group and 80 singlehanded general practices in six family health services authorities in England. Main outcome measures-Changes in computerisation, premises, staffing, incomes, and service provision since the introduction of the 1990 contract, including comparison with data from a study in 1987. Results-In 1993, 94% (245) of group practices were computerised compared with 38% in 1987, and 35% (90) of practices had used the cost rent scheme since 1987. Practice managers were employed in 88% (228) of group practices, and practice nurses in 96% (249) (61% and 60% respectively in 1987). Diabetes and asthma programmes were generally more common in the more affluent areas than elsewhere. A minority of practices (27% (9/33)) in the London inner city area achieved the higher target level for cervical smear testing, compared with 88% (230) overall. A similar trend was apparent for childhood immunisation. Perceived workload increased sharply between 1987 and 1993. Differences in the mean net incomes of general practitioners between areas were much lower than in 1987. Singlehanded practices generally had more problems than group practices in improving service provision. Conclusions-Practices in all areas have shown a strong response to the new incentives. The evidence suggests, however, that generally the urban and inner city practices still lag behind practices in rural and suburban areas in terms of practice structure and service provision.	UNIV LONDON,ST MARYS HOSP,SCH MED,HLTH POLICY UNIT,LONDON,ENGLAND	Imperial College London; University of London; London School of Hygiene & Tropical Medicine	LEESE, B (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							BAIN J, 1991, BRIT MED J, V302, P1183, DOI 10.1136/bmj.302.6786.1183; BAKER D, 1994, BRIT J GEN PRACT, V44, P68; BOSANQUET N, 1988, BRIT MED J, V296, P1576, DOI 10.1136/bmj.296.6636.1576; BOSANQUET N, 1989, FAMILY DOCTORS EC IN; BOSANQUET N, 1989, BRIT MED J, V293, P932; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LEESE B, 1992, SOC SCI MED, V35, P1303, DOI 10.1016/0277-9536(92)90183-Q; LEESE B, 1995, BRIT MED J, V310, P705, DOI 10.1136/bmj.310.6981.705; LOWY A, 1994, BRIT J GEN PRACT, V44, P364; MORRELL D, 1989, BRIT MED J, V298, P1005, DOI 10.1136/bmj.298.6679.1005; MYERSON S, 1992, MED SCI RES, V20, P461; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1989, PRACTICE BUDGETS GEN; 1989, GENERAL PRACTICE NHS; [No title captured]	17	41	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					546	550		10.1136/bmj.311.7004.546	http://dx.doi.org/10.1136/bmj.311.7004.546			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663212	Green Published			2022-12-28	WOS:A1995RR73700024
J	HEALEY, BG; FORAN, SE; WALT, DR				HEALEY, BG; FORAN, SE; WALT, DR			PHOTODEPOSITION OF MICROMETER-SCALE POLYMER PATTERNS ON OPTICAL IMAGING FIBERS	SCIENCE			English	Article							FABRICATION; ARRAYS	Microstructures were fabricated on optical imaging fibers with a photopolymerization technique. Monodisperse polymeric microarrays were produced containing spots of 2.5 micrometers in diameter spaced 4.5 micrometers apart. Polymer microarrays were also deposited on other substrates by using imaging fibers for light delivery. The technique allows micrometer-scale photopatterning with masks larger than the desired dimensions.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155	Tufts University					NIGMS NIH HHS [GM 48142] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNARD SM, 1991, NATURE, V353, P338, DOI 10.1038/353338a0; BEIN T, 1994, CHEM MATER, V6, P1109; BRONK KS, 1994, ANAL CHEM, V66, P3519, DOI 10.1021/ac00092a035; DABBOUSI BO, 1994, CHEM MATER, V6, P216, DOI 10.1021/cm00038a020; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GORMAN CB, 1995, CHEM MATER, V7, P252, DOI 10.1021/cm00050a003; GRANSTROM M, 1995, SCIENCE, V267, P1479, DOI 10.1126/science.267.5203.1479; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; HEALY BG, UNPUB; KLEIN JD, 1993, CHEM MATER, V5, P902, DOI 10.1021/cm00031a002; LANGER R, 1993, ACCOUNTS CHEM RES, V26, P537, DOI 10.1021/ar00034a004; LIU C, 1993, SCIENCE, V261, P597; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; MOGI M, 1989, P SPIE INT SOC OPT E, V1067, P172; NOBLE D, 1995, ANAL CHEM, V67, pA201; NOGLIK H, 1994, CHEM MATER, V6, P1593, DOI 10.1021/cm00046a003; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; PARTHASARATHY RV, 1994, CHEM MATER, V6, P1627, DOI 10.1021/cm00046a011; ROZSNYAI LF, 1992, ANGEW CHEM INT EDIT, V31, P759, DOI 10.1002/anie.199207591; SHIEH L, 1994, J CONTROL RELEASE, V29, P73, DOI 10.1016/0168-3659(94)90123-6; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; WALLENBERGER FT, 1995, SCIENCE, V267, P1274, DOI 10.1126/science.267.5202.1274; WHITNEY TM, 1993, SCIENCE, V261, P1316, DOI 10.1126/science.261.5126.1316; Y Chigusa, 1986, OPTOELECTRON DEVICES, V1, P203; YAN MD, 1993, J AM CHEM SOC, V115, P814, DOI 10.1021/ja00055a078; ZHOU HS, 1994, CHEM MATER, V6, P1534, DOI 10.1021/cm00045a010	26	54	74	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 25	1995	269	5227					1078	1080		10.1126/science.7652555	http://dx.doi.org/10.1126/science.7652555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652555				2022-12-28	WOS:A1995RQ74800036
J	TSUKIHARA, T; AOYAMA, H; YAMASHITA, E; TOMIZAKI, T; YAMAGUCHI, H; SHINZAWAITOH, K; NAKASHIMA, R; YAONO, R; YOSHIKAWA, S				TSUKIHARA, T; AOYAMA, H; YAMASHITA, E; TOMIZAKI, T; YAMAGUCHI, H; SHINZAWAITOH, K; NAKASHIMA, R; YAONO, R; YOSHIKAWA, S			STRUCTURES OF METAL SITES OF OXIDIZED BOVINE HEART CYTOCHROME-C-OXIDASE AT 2.8 ANGSTROM	SCIENCE			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; RESOLUTION; BINDING; COMPLEX; OXYGEN	The high resolution three-dimensional x-ray structure of the metal sites of bovine heart cytochrome c oxidase is reported. Cytochrome c oxidase is the largest membrane protein yet crystallized and analyzed at atomic resolution. Electron density distribution of the oxidized bovine cytochrome c oxidase at 2.8 Angstrom resolution indicates a dinuclear copper center with an unexpected structure similar to a [2Fe-2S]-type iron-sulfur center. Previously predicted zinc and magnesium sites have been located, the former bound by a nuclear encoded subunit on the matrix side of the membrane, and the latter situated between heme a(3) and Cu-A, at the interface of subunits I and II. The O-2 binding site contains heme a(3) iron and copper atoms (Cu-B) with an interatomic distance of 4.5 Angstrom; there is no detectable bridging ligand between iron and copper atoms in spite of a strong antiferromagnetic coupling between them. A hydrogen bond is present between a hydroxyl group of the hydroxyfarnesylethyl side chain of heme a(3) and an OH of a tyrosine. The tyrosine phenol plane is immediately adjacent and perpendicular to an imidazole group bonded to Cu-B, suggesting a possible role in intramolecular electron transfer or conformational control, the latter of which could induce the redox-coupled proton pumping. A phenyl group located halfway between a pyrrole plane of the heme a(3) and an imidazole plane liganded to the other home (heme a) could also influence electron transfer or conformational control.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University	TSUKIHARA, T (corresponding author), HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGOHRI AKOH,HYOGO 67812,JAPAN.		Yamashita, Eiki/V-6758-2019	Yamashita, Eiki/0000-0002-4278-0039; Aoyama, Hiroshi/0000-0001-7915-8975				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAKER GM, 1987, J BIOL CHEM, V262, P595; BERTAGNOLLI H, 1995, ANGEW CHEM INT EDIT, V34, P771, DOI 10.1002/anie.199507711; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, V32, P832; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1969, J BIOL CHEM, V250, P7602; EINERSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013; EINERSDOTTIR O, 1985, BIOCHEM BIOPH RES CO, V129, P840; ESPE MP, 1995, BIOCHEMISTRY-US, V34, P7593, DOI 10.1021/bi00023a005; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1983, TRENDS BIOCHEM SCI, V8, P398, DOI 10.1016/0968-0004(83)90302-X; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRONECK PMH, 1988, FEBS LETT, V247, P70; LEE SC, 1993, J AM CHEM SOC, V115, P5833, DOI 10.1021/ja00066a065; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MALMSTROM BG, 1993, FEBS LETT, V325, P49, DOI 10.1016/0014-5793(93)81411-R; NANTHAKUMAR A, 1993, J AM CHEM SOC, V115, P8513, DOI 10.1021/ja00071a097; OBLAD M, 1989, BIOCHIM BIOPHYS ACTA, V975, P267, DOI 10.1016/S0005-2728(89)80257-9; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; OTWINOWSKI Z, 1985, DENZO FILM PROCESSIN; PALMER G, 1976, P NATL ACAD SCI USA, V73, P2206, DOI 10.1073/pnas.73.7.2206; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; SEITER CHA, 1980, P NATL ACAD SCI-BIOL, V77, P1806, DOI 10.1073/pnas.77.4.1806; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Warburg O, 1929, BIOCHEM Z, V214, P64; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; YOSHIKAWA S, UNPUB	43	1281	1291	3	137	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 25	1995	269	5227					1069	1074		10.1126/science.7652554	http://dx.doi.org/10.1126/science.7652554			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652554				2022-12-28	WOS:A1995RQ74800034
J	HEYMANN, SJ				HEYMANN, SJ			PATIENTS IN RESEARCH - NOT JUST SUBJECTS, BUT PARTNERS	SCIENCE			English	Editorial Material							MEDICAL-CARE; FUNCTIONAL STATUS; CLINICAL-TRIALS; OUTCOMES; INVOLVEMENT; PARTICIPATION; PREFERENCES; SUBGROUPS; VALIDITY; QUALITY				HEYMANN, SJ (corresponding author), HARVARD UNIV,SCH MED,JOHN F KENNEDY SCH GOVT,BOSTON,MA 02115, USA.							ANGELL M, 1993, NEW ENGL J MED, V329, P271, DOI 10.1056/NEJM199307223290409; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BENNETT JC, 1993, NEW ENGL J MED, V329, P288, DOI 10.1056/NEJM199307223290428; BRODY DS, 1989, J GEN INTERN MED, V4, P506, DOI 10.1007/BF02599549; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; CAREY MA, 1992, EVAL HEALTH PROF, V15, P107, DOI 10.1177/016327879201500107; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; CLEARY PD, 1991, CONTROL CLIN TRIALS, V12, pS189, DOI 10.1016/S0197-2456(05)80023-6; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GREENFIELD S, 1989, PROVIDING QUALITY CA, P448; HEYMANN SJ, 1995, EQUAL PARTNERS; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; KAPLAN SH, 1989, MED CARE S, V3, pS110; KAPLAN SH, 1989, PROVIDING QUALITY CA, pS110; KAPLAN SH, 1989, PROVIDING QUALITY CA, P27; LEWIS CC, 1991, PEDIATRICS, V88, P351; McNeill P. M., 1993, ETHICS HUMAN EXPERIM; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	21	19	19	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					797	798		10.1126/science.7638595	http://dx.doi.org/10.1126/science.7638595			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638595				2022-12-28	WOS:A1995RN65000033
J	HARMER, M; DAVIES, KA; LUNN, JN				HARMER, M; DAVIES, KA; LUNN, JN			A SURVEY OF ACUTE PAIN SERVICES IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article											HARMER, M (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,DEPT ANAESTHET & INTENS CARE MED,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							CARTWRIGHT PD, 1991, ANAESTHESIA, V46, P188, DOI 10.1111/j.1365-2044.1991.tb09406.x; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; 1990, PAIN SURGERY; 1992, PAIN DISCOMFORT PALL	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					360	361		10.1136/bmj.311.7001.360	http://dx.doi.org/10.1136/bmj.311.7001.360			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640541	Green Published			2022-12-28	WOS:A1995RN46900015
J	GROVES, BM; ZUCKERMAN, B; MARANS, S; COHEN, DJ				GROVES, BM; ZUCKERMAN, B; MARANS, S; COHEN, DJ			SILENT VICTIMS - CHILDREN WHO WITNESS VIOLENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									YALE UNIV,YALE CHILD STUDY CTR,NEW HAVEN,CT 06520	Yale University	GROVES, BM (corresponding author), BOSTON UNIV,BOSTON CITY HOSP,SCH MED,DIV DEV & BEHAV PEDIAT,TALBOT 214,818 HARRISON AVE,BOSTON,MA 02118, USA.			Zuckerman, Barry/0000-0002-0044-2592	PHS HHS [MCJ009094] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cohen D J, 1987, Psychoanal Study Child, V42, P59; Davidson J.R.T., 1990, J TRAUMA STRESS, V3, P459, DOI [10.1002/jts.2490030314, DOI 10.1002/JTS.2490030314]; ETH S, 1985, HOSP COMMUNITY PSYCH, V36, P73; ETH S, 1985, EMERGING ISSUES CHIL, P285; Garbarino J., 1992, CHILDREN DANGER COPI; HUGHES HM, 1988, AM J ORTHOPSYCHIAT, V58, P77, DOI 10.1111/j.1939-0025.1988.tb01568.x; HURLEY DJ, 1990, CAN J PSYCHIAT, V35, P471, DOI 10.1177/070674379003500602; JAFFE P, 1986, AM J ORTHOPSYCHIAT, V56, P142, DOI 10.1111/j.1939-0025.1986.tb01551.x; Jaffe P., 1988, CANADIAN J COMMUNITY, V7, P157; Jaffe P., 1990, CHILDREN BATTERED WO, P20; LYONS JA, 1987, ANN PROGR CHILD PSYC, P451; MARANS S, IN PRESS MANY MEANIN; OSOFSKY J, CITED INDIRECTLY; PYNOOS RS, 1990, PSYCHIAT ANN, V20, P334, DOI 10.3928/0048-5713-19900601-11; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; PYNOOS RS, 1985, POSTTRAUMATIC STRESS, P19; SILVERN L, 1989, CHILD WELFARE, V68, P421; TAYLOR L, 1992, AM J DIS CHILD, V146, P487; TERR LC, 1983, AM J PSYCHIAT, V140, P1543; WIDOM CS, 1989, PSYCHOL BULL, V106, P3, DOI 10.1037/0033-2909.115.2.287; 1992, CAN THEY FEEL SAFE I	21	105	106	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					262	264		10.1001/jama.269.2.262	http://dx.doi.org/10.1001/jama.269.2.262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KF405	7678044				2022-12-28	WOS:A1993KF40500035
J	CARR, TW				CARR, TW			NATURAL-HISTORY OF PROSTATE-CANCER	LANCET			English	Editorial Material											CARR, TW (corresponding author), SOUTHEND HOSP,DEPT UROL,ESSEX,ENGLAND.							ANDREWS GS, 1949, J CLIN PATHOL, V2, P197, DOI 10.1136/jcp.2.3.197; CARR TW, 1988, LANCET, V1, P776; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; FAIR WR, 1992, PROSTATE S, V4, P79; FRANKS LM, 1956, LANCET, V2, P1037; GEORGE NJR, 1988, LANCET, V1, P494; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; HANKS GE, 1988, LANCET, V2, P217; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LERNER SP, 1991, J UROLOGY, V146, P1040, DOI 10.1016/S0022-5347(17)37997-1; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; WHITMORE WF, 1991, CANCER, V67, P1092	13	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					91	92		10.1016/0140-6736(93)92565-B	http://dx.doi.org/10.1016/0140-6736(93)92565-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	7678121				2022-12-28	WOS:A1993KF87000012
J	LIEBER, CS				LIEBER, CS			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - MEDICAL DISORDERS OF ALCOHOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC ETHANOL-CONSUMPTION; ALDEHYDE DEHYDROGENASE-ACTIVITIES; FAT-STORING CELLS; LIVER-DISEASE; H2-RECEPTOR ANTAGONISTS; GENETIC PREDISPOSITION; 1ST-PASS METABOLISM; ACETALDEHYDE; CIRRHOSIS; RAT		MT SINAI SCH MED,BRONX,NY	Icahn School of Medicine at Mount Sinai	LIEBER, CS (corresponding author), VET AFFAIRS MED CTR,CTR ALCOHOL RES & TREATMENT,130 W KINGSBRIDGE RD,BRONX,NY 10468, USA.				NIAAA NIH HHS [AA07275, AA03508, AA05934] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005934, P50AA003508] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABEL EL, 1991, ALCOHOL CLIN EXP RES, V15, P514, DOI 10.1111/j.1530-0277.1991.tb00553.x; ADAMS WL, 1993, JAMA-J AM MED ASSOC, V270, P1222, DOI 10.1001/jama.270.10.1222; ADAMS WL, 1993, JAMA-J AM MED ASSOC, V270, P2055; ANGELL M, 1994, NEW ENGL J MED, V331, P537, DOI 10.1056/NEJM199408253310810; ARAI M, 1984, BIOCHIM BIOPHYS ACTA, V797, P320, DOI 10.1016/0304-4165(84)90252-6; BARAONA E, 1991, LIFE SCI, V49, P1929, DOI 10.1016/0024-3205(91)90295-M; BARAONA E, 1993, LIFE SCI, V52, P2071; BASHIR R, 1992, J HEPATOL, V16, P316, DOI 10.1016/S0168-8278(05)80662-2; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CABALLERIA J, 1991, DIGEST DIS SCI, V36, P1673, DOI 10.1007/BF01296608; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CHEDID A, 1991, AM J GASTROENTEROL, V86, P210; DAY CP, 1991, HEPATOLOGY, V14, P798, DOI 10.1002/hep.1840140509; DAY CP, 1992, HEPATOLOGY, V15, P750; DIPADOVA C, 1992, JAMA-J AM MED ASSOC, V267, P83, DOI 10.1001/jama.267.1.83; DIPADOVA C, 1992, JAMA-J AM MED ASSOC, V268, P2652; ESPINA N, 1988, CARCINOGENESIS, V9, P761, DOI 10.1093/carcin/9.5.761; FRASER AG, 1992, ALIMENT PHARM THERAP, V6, P267; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FUKUNAGA T, 1993, ALCOHOL CLIN EXP RES, V17, P1198, DOI 10.1111/j.1530-0277.1993.tb05228.x; GARRO AJ, 1991, ALCOHOL CLIN EXP RES, V15, P395, DOI 10.1111/j.1530-0277.1991.tb00536.x; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GEJMAN PV, 1994, JAMA-J AM MED ASSOC, V271, P204, DOI 10.1001/jama.271.3.204; GOMBERG ESL, 1993, J NERV MENT DIS, V181, P211; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; GUIVERNAU M, 1987, J PHARMACOL EXP THER, V240, P59; GUPTA AM, 1995, ALCOHOL CLIN EXP RES, V19, P1083, DOI 10.1111/j.1530-0277.1995.tb00993.x; HASUMURA Y, 1985, PATHOBIOL HEPATIC FI, V7, P13; HERNANDEZMUNOZ R, 1990, ALCOHOL CLIN EXP RES, V14, P946, DOI 10.1111/j.1530-0277.1990.tb01843.x; HIGUCHI S, 1994, BIOCHEM BIOPH RES CO, V204, P1199, DOI 10.1006/bbrc.1994.2590; HIRANO T, 1992, HEPATOLOGY, V16, P1423; HOERNER M, 1986, RES COMMUN CHEM PATH, V54, P3; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; KENDLER KS, 1992, JAMA-J AM MED ASSOC, V268, P1877, DOI 10.1001/jama.268.14.1877; KERSHENOBICH D, 1988, NEW ENGL J MED, V318, P1709, DOI 10.1056/NEJM198806303182602; KUMAR S, 1990, HEPATOLOGY, V11, P159, DOI 10.1002/hep.1840110202; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; LEO MA, 1992, HEPATOLOGY, V15, P883, DOI 10.1002/hep.1840150522; LEO MA, 1988, HEPATOLOGY, V8, P412, DOI 10.1002/hep.1840080237; LEO MA, 1982, NEW ENGL J MED, V307, P597, DOI 10.1056/NEJM198209023071006; LEO MA, 1993, HEPATOLOGY, V17, P977; LEO MA, 1985, J BIOL CHEM, V260, P5228; LI JJ, 1992, HEPATOLOGY, V15, P373, DOI 10.1002/hep.1840150303; LI JJ, 1993, HEPATOLOGY, V17, P174; LI JJ, 1994, HEPATOLOGY, V19, P1418, DOI 10.1002/hep.1840190616; LIEBER CS, 1970, J BIOL CHEM, V245, P2505; LIEBER CS, 1991, AM J CLIN NUTR, V54, P976, DOI 10.1093/ajcn/54.6.976; LIEBER CS, 1994, GASTROENTEROLOGY, V106, P152, DOI 10.1016/S0016-5085(94)95023-7; LIEBER CS, 1989, J CLIN INVEST, V83, P1682, DOI 10.1172/JCI114068; LIEBER CS, 1990, DRUGS, V40, P1; LIEBER CS, 1992, MED NUTRITIONAL COMP; LINNOILA M, 1980, J STUD ALCOHOL, V41, P488, DOI 10.15288/jsa.1980.41.488; LOWENFELS AB, 1989, ALCOHOL CLIN EXP RES, V13, P109, DOI 10.1111/j.1530-0277.1989.tb00294.x; LUMENG L, 1994, GASTROENTEROLOGY, V107, P572, DOI 10.1016/0016-5085(94)90185-6; MAK KM, 1988, HEPATOLOGY, V8, P1027, DOI 10.1002/hep.1840080508; MALY IP, 1991, GASTROENTEROLOGY, V101, P1716, DOI 10.1016/0016-5085(91)90412-E; MANN K, 1992, ALCOHOL CLIN EXP RES, V16, P1052, DOI 10.1111/j.1530-0277.1992.tb00698.x; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; MENDENHALL CL, 1984, NEW ENGL J MED, V311, P1464, DOI 10.1056/NEJM198412063112302; MORGAN MY, 1977, BRIT MED J, V1, P939, DOI 10.1136/bmj.1.6066.939; MOSHAGE H, 1990, HEPATOLOGY, V12, P511, DOI 10.1002/hep.1840120311; NIEMELA O, 1987, HEPATOLOGY, V7, P1210, DOI 10.1002/hep.1840070607; ORREGO H, 1987, NEW ENGL J MED, V317, P1421, DOI 10.1056/NEJM198712033172301; PALMER RH, 1991, AM J GASTROENTEROL, V86, P1749; PARONETTO F, 1993, SEMIN LIVER DIS, V13, P183, DOI 10.1055/s-2007-1007348; PARRISH KM, 1993, J STUD ALCOHOL, V54, P450, DOI 10.15288/jsa.1993.54.450; Pequignot G, 1974, REV ALCOHOLISM, V20, p191 ; PERLOW W, 1977, GASTROENTEROLOGY, V72, P680; POTTER JF, 1987, GERONTOLOGY, V33, P380, DOI 10.1159/000212907; POUPON RE, 1992, HEPATOLOGY, V15, P1017, DOI 10.1002/hep.1840150608; RABINOVITZ M, 1989, ALCOHOL, V6, P465, DOI 10.1016/0741-8329(89)90053-0; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802; RANKIN JG, 1977, ALCOHOL LIVER, V3, P365; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; ROINE R, 1990, JAMA-J AM MED ASSOC, V264, P2406, DOI 10.1001/jama.264.18.2406; ROSMAN AS, 1993, ARCH INTERN MED, V153, P965, DOI 10.1001/archinte.153.8.965; SATO C, 1981, GASTROENTEROLOGY, V80, P140; SEITZ HK, 1993, GUT, V34, P1433, DOI 10.1136/gut.34.10.1433; SOHDA T, 1993, ALCOHOL ALCOHOL B S, V1, P69; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; TESCHKE R, 1982, J ENDOCRINOL INVEST, V5, P243, DOI 10.1007/BF03348330; TSUTSUMI M, 1989, HEPATOLOGY, V10, P437, DOI 10.1002/hep.1840100407; UPPAL R, 1991, ARCH INTERN MED, V151, P760, DOI 10.1001/archinte.151.4.760; WEINER FR, 1988, MOL ASPECTS MED, V10, P159, DOI 10.1016/0098-2997(88)90020-9; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WONDERGEM R, 1994, ALCOHOL CLIN EXP RES, V18, P1230, DOI 10.1111/j.1530-0277.1994.tb00110.x; WORNER TM, 1985, JAMA-J AM MED ASSOC, V254, P627, DOI 10.1001/jama.254.5.627; YAMADA S, 1985, GASTROENTEROLOGY, V88, P1799, DOI 10.1016/0016-5085(85)90003-4; 1990, 1990273930 DEP AGR P; 1986, SUMMARY VITAL STATIS; 1994, NEW ENGL J MED, V330, P1029	94	297	304	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1058	1065		10.1056/NEJM199510193331607	http://dx.doi.org/10.1056/NEJM199510193331607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675050				2022-12-28	WOS:A1995RZ34000007
J	STILLMAN, AE				STILLMAN, AE			MODERN TIMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1086	1087		10.1056/NEJM199510193331618	http://dx.doi.org/10.1056/NEJM199510193331618			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675072				2022-12-28	WOS:A1995RZ34000033
J	MULLER, B; ZULEWSKI, H; HUBER, P; RATCLIFFE, JG; STAUB, JJ				MULLER, B; ZULEWSKI, H; HUBER, P; RATCLIFFE, JG; STAUB, JJ			IMPAIRED ACTION OF THYROID-HORMONE ASSOCIATED WITH SMOKING IN WOMEN WITH HYPOTHYROIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; GOITER; THYROTROPIN; SMOKERS; DISEASE; TISSUES; CANCER; TSH	Background. The effect of smoking on thyroid function is controversial, and its effect on thyroid hormone action is unknown. We investigated the effects of cigarette smoking in women with various grades of hypothyroidism and in normal women. Methods. We studied 138 normal women and 135 women with primary hypothyroidism, of whom 84 had subclinical hypothyroidism and 51 overt hypothyroidism. Sixty of the women with hypothyroidism were reevaluated during thyroxine therapy. The women were categorized as smokers or nonsmokers according to their responses to a questionnaire. Thyroid function was evaluated by measurements of serum thyrotropin, free thyroxine, and triiodothyronine. Peripheral thyroid hormone action was assessed by a clinical score and measurements of ankle-reflex time and serum lipids and creatine kinase. Results. Among the women with subclinical hypothyroidism, the smokers had a higher mean (+/-SD) serum thyrotropin concentration (21.3+/-16.6 vs. 12.7+/-7.2 mU per liter, P=0.004) and a higher ratio of serum triiodothyronine to serum free thyroxine (by 30 percent, P=0.003) than the nonsmokers. Their serum concentrations of total cholesterol and low-density lipoprotein (LDL) cholesterol were higher (by 16 percent, P=0.013; and 28 percent, P=0.003, respectively). Among the women with overt hypothyroidism, the serum concentrations of thyrotropin, free thyroxine, and triiodothyronine were similar in the smokers and nonsmokers. As compared with the nonsmokers, the smokers had a clinical score indicating a greater degree of hypothyroidism (P<0.001), higher serum concentrations of total and LDL cholesterol (by 25 percent, P<0.001; and 24 percent, P=0.002, respectively), longer ankle-reflex time (by 25 percent, P<0.001), and higher serum concentrations of creatine kinase (by 236 percent, P<0.001). There were dose-response relations between smoking and serum concentrations of total and LDL cholesterol, serum creatine kinase concentrations, and ankle-reflex time in the women with overt hypothyroidism, and between smoking and serum concentrations of total and LDL cholesterol in the women with subclinical hypothyroidism. Conclusions. Smoking increases the metabolic effects of hypothyroidism in a dose-dependent way. This may be explained by alteration of both thyroid function and hormone action.	UNIV BASEL HOSP, DEPT CHEM PATHOL, HORMONE LAB, CH-4031 BASEL, SWITZERLAND; QUEEN ELIZABETH MED CTR, DEPT CLIN CHEM, WOLFSON RES LABS, BIRMINGHAM, W MIDLANDS, ENGLAND	University of Basel; Birmingham City University; University of Birmingham	MULLER, B (corresponding author), UNIV BASEL HOSP, DEPT MED, DIV ENDOCRINOL DIABET & METAB, PETERSGRABEN 4, CH-4031 BASEL, SWITZERLAND.		Mueller, Beat/G-2662-2012					ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; BERGHOUT A, 1987, CLIN ENDOCRINOL, V26, P273, DOI 10.1111/j.1365-2265.1987.tb00784.x; BILLEWICZ WZ, 1969, Q J MED, V38, P255; BRENT GA, 1994, NEW ENGL J MED, V331, P847; BROWMAN GP, 1993, NEW ENGL J MED, V328, P159, DOI 10.1056/NEJM199301213280302; CHRISTENSEN SB, 1984, J CLIN ENDOCR METAB, V58, P615, DOI 10.1210/jcem-58-4-615; CUZICK J, 1990, INT J CANCER, V45, P673, DOI 10.1002/ijc.2910450417; EDELMAN IS, 1974, NEW ENGL J MED, V290, P1303, DOI 10.1056/NEJM197406062902308; ERICSSON UB, 1991, J INTERN MED, V229, P67, DOI 10.1111/j.1365-2796.1991.tb00308.x; ERMANS AM, 1980, ROLE CASSAVA ETIOLOG, P93; HANDA K, 1990, ATHEROSCLEROSIS, V84, P189, DOI 10.1016/0021-9150(90)90090-6; HEGEDUS L, 1985, CLIN ENDOCRINOL, V22, P287, DOI 10.1111/j.1365-2265.1985.tb03242.x; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; LAVECCHIA C, 1988, PREV MED, V17, P712, DOI 10.1016/0091-7435(88)90090-4; LOEB JN, 1991, WERNER INGBARS THYRO, P1064; MELANDER A, 1981, ACTA MED SCAND, V209, P41; MUSCAT JE, 1991, AM HEART J, V121, P141, DOI 10.1016/0002-8703(91)90967-M; PETERSEN K, 1991, J INTERN MED, V229, P407, DOI 10.1111/j.1365-2796.1991.tb00367.x; ROSS DS, 1991, WERNER INGBARS THYRO, P1256; SACHS L, 1984, APPLIED STATISTICS H; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; Searle S.R., 1971, LINEAR MODELS; SEPKOVIC DW, 1984, ARCH INTERN MED, V144, P501, DOI 10.1001/archinte.144.3.501; STAUB JJ, 1985, CLIN ENDOCRINOL, V22, P567, DOI 10.1111/j.1365-2265.1985.tb00158.x; STAUB JJ, 1983, J CLIN ENDOCR METAB, V56, P449, DOI 10.1210/jcem-56-3-449; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; SUGAWARA M, 1982, P SOC EXP BIOL MED, V170, P431	27	115	119	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					964	969		10.1056/NEJM199510123331503	http://dx.doi.org/10.1056/NEJM199510123331503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666915	Bronze			2022-12-28	WOS:A1995RY58600003
J	GUTTMACHER, AE; MARCHUK, DA; WHITE, RI				GUTTMACHER, AE; MARCHUK, DA; WHITE, RI			CURRENT CONCEPTS - HEREDITARY HEMORRHAGIC TELANGIECTASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PULMONARY ARTERIOVENOUS-MALFORMATIONS; OSLER-WEBER DISEASE; VASCULAR MALFORMATIONS; MANIFESTATIONS; ESTROGEN; LESIONS; SYSTEM		UNIV VERMONT,COLL MED,DEPT PEDIAT,BURLINGTON,VT; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC; YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,NEW HAVEN,CT	University of Vermont; Duke University; Yale University				Marchuk, Douglas/0000-0002-3110-6671	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049171] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AASSAR OS, 1991, LARYNGOSCOPE, V101, P977; ADAMS HP, 1977, ARCH NEUROL-CHICAGO, V34, P101, DOI 10.1001/archneur.1977.00500140055011; BERNARD G, 1993, GASTROENTEROLOGY, V105, P482, DOI 10.1016/0016-5085(93)90723-P; BRANT AM, 1989, AM J OPHTHALMOL, V107, P642, DOI 10.1016/0002-9394(89)90261-4; BRAVERMAN IM, 1990, J INVEST DERMATOL, V95, P422, DOI 10.1111/1523-1747.ep12555569; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; DINES DE, 1974, MAYO CLIN PROC, V49, P460; ELDEN L, 1994, OTOLARYNG HEAD NECK, V111, P44, DOI 10.1177/019459989411100110; FERENCE BA, 1994, CHEST, V106, P1387, DOI 10.1378/chest.106.5.1387; FULBRIGHT RK, 1994, RADIOLOGY S211, V193; GOSTOUT CJ, 1988, MAYO CLIN PROC, V63, P993, DOI 10.1016/S0025-6196(12)64914-3; GUTTMACHER AE, 1994, AM J MED GENET, V52, P252, DOI 10.1002/ajmg.1320520232; HALPERN M, 1968, RADIOLOGY, V90, P1143, DOI 10.1148/90.6.1143; Hanes FA, 1909, B JOHNS HOPKINS HOSP, V20, P63; HARRISON DFN, 1982, LARYNGOSCOPE, V92, P314; HEUTINK P, 1994, J MED GENET, V31, P933, DOI 10.1136/jmg.31.12.933; HEWES RC, 1985, CARDIOVASC INTER RAD, V8, P151, DOI 10.1007/BF02552883; HUGHES JMB, 1990, CLIN RADIOL, V41, P297, DOI 10.1016/S0009-9260(05)81687-3; JESSURUN GAJ, 1993, CLIN NEUROL NEUROSUR, V95, P193, DOI 10.1016/0303-8467(93)90123-X; JOHSON DW, 1995, GENOME RES, V5, P21; MARTINI GA, 1978, GUT, V19, P531, DOI 10.1136/gut.19.6.531; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MCALLISTER KA, 1994, J MED GENET, V31, P927, DOI 10.1136/jmg.31.12.927; MCDONALD MT, 1994, NAT GENET, V6, P197, DOI 10.1038/ng0294-197; MORELLI JG, 1993, PEDIATRICS, V92, P603; Osler W, 1901, B JOHNS HOPKINS HOSP, V12, P333; OSLER W, 1957, STUDENT LIFE PHILOS, P46; PARKIN JL, 1981, OTOLARYNG HEAD NECK, V89, P204, DOI 10.1177/019459988108900212; PLAUCHU H, 1989, AM J MED GENET, V32, P291, DOI 10.1002/ajmg.1320320302; PLAUCHU H, 1984, POPULATION, V5, P765; PORTEOUS MEM, 1992, J MED GENET, V29, P527, DOI 10.1136/jmg.29.8.527; PORTEOUS MEM, 1994, J MED GENET, V31, P925, DOI 10.1136/jmg.31.12.925; PRESS OW, 1984, AM J MED, V77, P86, DOI 10.1016/0002-9343(84)90441-8; PUSKAS JD, 1993, ANN THORAC SURG, V56, P253, DOI 10.1016/0003-4975(93)91156-H; Rebeiz EE., 1991, OPER TECH OTOLARYNGO, V2, P177, DOI [DOI 10.1016/S1043-1810(10)80052-1, 10.1016/S1043-1810(10)80052-1]; REILLY PJ, 1984, AM J GASTROENTEROL, V79, P363; REMY J, 1994, RADIOLOGY, V191, P657, DOI 10.1148/radiology.191.3.8184042; REMY J, 1992, RADIOLOGY, V182, P809, DOI 10.1148/radiology.182.3.1535899; RENDU HJ, 1896, GAZ HOPITAUX, P1322; ROMAN G, 1978, ANN NEUROL, V4, P130, DOI 10.1002/ana.410040207; RUTGEERTS P, 1985, GUT, V26, P586, DOI 10.1136/gut.26.6.586; Saunders W H, 1973, Otolaryngol Clin North Am, V6, P745; SHOVLIN CL, 1994, NAT GENET, V6, P205, DOI 10.1038/ng0294-205; SUTTON HG, 1864, MED MIRROR, P769; VANCUTSEM E, 1990, LANCET, V335, P953, DOI 10.1016/0140-6736(90)91010-8; VASE P, 1986, GASTROENTEROLOGY, V91, P1079, DOI 10.1016/S0016-5085(86)80001-4; VASE P, 1981, ACTA MED SCAND, V209, P393; VINCENT P, 1995, HUM MOL GENET, V4, P945, DOI 10.1093/hmg/4.5.945; Weber FP, 1907, LANCET, V2, P160; WHITE RI, 1994, ANN THORAC SURG, V57, P519, DOI 10.1016/0003-4975(94)91047-2; WHITE RI, 1988, RADIOLOGY, V169, P663, DOI 10.1148/radiology.169.3.3186989; WILLINSKY RA, 1990, NEURORADIOLOGY, V32, P207, DOI 10.1007/BF00589113; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995	53	731	762	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					918	924		10.1056/NEJM199510053331407	http://dx.doi.org/10.1056/NEJM199510053331407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666879				2022-12-28	WOS:A1995RX19900007
J	TELZAK, EE; SEPKOWITZ, K; ALPERT, P; MANNHEIMER, S; MEDARD, F; ELSADR, W; BLUM, S; GAGLIARDI, A; SALOMON, N; TURETT, G				TELZAK, EE; SEPKOWITZ, K; ALPERT, P; MANNHEIMER, S; MEDARD, F; ELSADR, W; BLUM, S; GAGLIARDI, A; SALOMON, N; TURETT, G			MULTIDRUG-RESISTANT TUBERCULOSIS IN PATIENTS WITHOUT HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; PULMONARY TUBERCULOSIS; DRUG	Background. Investigations of outbreaks of multidrug-resistant tuberculosis have found low rates of treatment response and very high mortality, and they have mainly involved patients with advanced human immunodeficiency virus (HIV) infection. For patients without HIV infection, one study reported an overall rate of response to treatment of 56 percent, and the mortality from tuberculosis was 22 percent. We investigated treatment response and mortality rates in 26 HIV-negative patients in New York with multidrug-resistant tuberculosis. Methods. We obtained detailed data from seven teaching hospitals in New York City on patients with multidrug-resistant tuberculosis - defined as tuberculosis resistant at least to isoniazid and rifampin - who were HIV-negative on serologic testing. Lengths of times from diagnosis to the initiation of appropriate therapy and from the initiation of appropriate therapy to conversion to negative cultures were assessed. Therapeutic responses were evaluated by both microbiologic and clinical criteria. Results. Between March 1991 and September 1994, 26 HIV-negative patients were identified and treated. Of the 25 patients for whom adequate data were available for analysis, 24 (96 percent) had clinical responses; all 17 patients for whom data on microbiologic response were available had such a response. The median times from diagnosis to the initiation of appropriate therapy and from the initiation of therapy to culture conversion were 44 days (range, 0 to 181) and 69 days (range, 2 to 705), respectively. Side effects requiring the discontinuation of medication occurred in 4 of 23 patients (17 percent) who were treated with second-line antituberculosis medications. The median follow-up for the 23 patients who responded and who received appropriate therapy was 91 weeks (range, 41 to 225). Conclusions. In this report from New York City, HIV-negative patients with multidrug-resistant tuberculosis, contrary to previous reports, responded well to appropriate chemotherapy, both clinically and microbiologically.	ST CLARES HOSP & HLTH CTR,NEW YORK,NY 10019; NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY; HARLEM HOSP MED CTR,NEW YORK,NY; MONTEFIORE MED CTR,BRONX,NY; N CENT BRONX HOSP,BRONX,NY 10467; ST VINCENTS MED CTR,NEW YORK,NY 10011; BETH ISRAEL MED CTR,NEW YORK,NY	Cornell University; NewYork-Presbyterian Hospital; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Saint Vincents Hospital Manhattan; Harvard University; Beth Israel Deaconess Medical Center	TELZAK, EE (corresponding author), ALBERT EINSTEIN COLL MED,BRONX LEBANON HOSP CTR,DIV INFECT DIS,1650 GRAND CONCOURSE,BRONX,NY 10457, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EDLIN BR, 1993, 9TH INT C AIDS 4TH S; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Heifets Leonid B., 1994, P85; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; SEPKOWITZ KA, 1994, CLIN INFECT DIS, V18, P755, DOI 10.1093/clinids/18.5.755; SHAFER RW, 1995, J INFECT DIS, V171, P170, DOI 10.1093/infdis/171.1.170; SHARP V, 1994, 8TH INT S INF IMM HO; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; TELZAK EE, 1994, 8TH INT S INF IMM HO; VALLSPINOSA A, 1970, NEW ENGL J MED, V283, P616, DOI 10.1056/NEJM197009172831202; 1993, MMWR-MORBID MORTAL W, V42, P427; 1991, MMWR-MORBID MORTAL W, V40, P585	18	199	205	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					907	911		10.1056/NEJM199510053331404	http://dx.doi.org/10.1056/NEJM199510053331404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666876	Bronze, Green Published			2022-12-28	WOS:A1995RX19900004
J	WELLIVER, RC				WELLIVER, RC			RSV AND CHRONIC ASTHMA	LANCET			English	Editorial Material							VIRUS-SPECIFIC IGE; RESPIRATORY SYNCYTIAL VIRUS; INFECTION; PATHOGENESIS; SUBSEQUENT; CHILDHOOD; CHILDREN		CHILDRENS HOSP,BUFFALO,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	WELLIVER, RC (corresponding author), SUNY BUFFALO,DEPT PEDIAT,DIV INFECT DIS,BUFFALO,NY 14260, USA.							BUI RHD, 1987, J PEDIATR-US, V110, P87; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; HENDERSON FW, 1992, AM REV RESPIR DIS, V145, P283, DOI 10.1164/ajrccm/145.2_Pt_1.283; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; SIGURS N, 1995, PEDIATRICS, V95, P500; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEMPEL DA, 1981, MED CLIN N AM, V65, P1045, DOI 10.1016/S0025-7125(16)31488-2; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; WELLIVER RC, 1986, AM J DIS CHILD, V140, P34, DOI 10.1001/archpedi.1986.02140150036029	11	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					789	790		10.1016/S0140-6736(95)91615-6	http://dx.doi.org/10.1016/S0140-6736(95)91615-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674741				2022-12-28	WOS:A1995RW25800006
J	DOUGLAS, JDM; MCSHARRY, C; BLAIKIE, L; MORROW, T; MILES, S; FRANKLIN, D				DOUGLAS, JDM; MCSHARRY, C; BLAIKIE, L; MORROW, T; MILES, S; FRANKLIN, D			OCCUPATIONAL ASTHMA CAUSED BY AUTOMATED SALMON PROCESSING	LANCET			English	Article							LABORATORY-ANIMALS; FLOW; WORKERS; SMOKING; ALLERGY	Within 3 months of the opening of a salmon-processing plant in the UK, some workers complained of symptoms suggestive of occupational asthma. A survey of all 291 employees identified 24 (8.2%) with occupational asthma. The employees worked near machines which generated respirable aerosols containing salmon-serum proteins. The IgE response to these proteins was associated with occupational asthma (p<0.001), with increasing severity of symptoms (p<0.001), and with working distance from the aerosol source (p=0.037). The main factor which predisposed to IgE-antibody production and asthma was cigarette smoking (p<0.001), whereas atopy and a previous allergic history did not. The affected employees were reallocated to a low-exposure worksite and factory ventilation was improved. Eleven showed significant clinical and pulmonary function improvement, and continued in employment. Thirteen who still had symptoms were advised to leave, thereafter becoming symptom-free, and regaining normal respiratory function. Early recognition of symptoms and prompt action to reduce aerosol exposure avoided the long-term reduction in pulmonary functions often associated with occupational asthma.	WESTERN INFIRM & ASSOCIATED HOSP,DEPT IMMUNOL,GLASGOW,LANARK,SCOTLAND; UNILEVER RES & ENGN,SHARNBROOK,BEDS,ENGLAND; RAIGMORE HOSP,INVERNESS,SCOTLAND	Unilever	DOUGLAS, JDM (corresponding author), TWEEDDALE MED PRACTICE,HIGH ST,FT WILLIAM PH33 6EU,SCOTLAND.			McSharry, Charles/0000-0003-4758-9038				BURGE PS, 1993, OCCUP MED, V8, P279; BURGE PS, 1988, CHEST, V81, P105; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; DAVIES GE, 1983, BRIT J IND MED, V40, P442; EDWARDS RG, 1980, INT ARCH ALLER A IMM, V68, P352; GADDIE J, 1980, LANCET, V2, P1350; GANNON PF, 1993, J ALLERGY CLIN IMMUN, V91, P1121; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MALO JL, 1988, AM REV RESPIR DIS, V128, P807; MCSHARRY C, 1994, CLIN EXP IMMUNOL, V97, P499, DOI 10.1111/j.1365-2249.1994.tb06116.x; MEGURO T, 1990, IND HEALTH, V28, P133, DOI 10.2486/indhealth.28.133; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; NEWMANTAYLOR A, 1990, CHEST, V98, P209; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; SHERSON D, 1989, ALLERGY, V44, P336, DOI 10.1111/j.1398-9995.1989.tb00455.x; STENTON SC, 1995, BRIT MED J, V310, P1299, DOI 10.1136/bmj.310.6990.1299a; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; VENABLES KM, 1988, BRIT J IND MED, V45, P667; 1991, IND INJURIES DISABLE; 1990, HSE HSG61	24	78	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					737	740		10.1016/S0140-6736(95)91505-2	http://dx.doi.org/10.1016/S0140-6736(95)91505-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658875				2022-12-28	WOS:A1995RU81000011
J	HARRISON, LH; ALI, A; DWYER, DM; LIBONATI, JP; REEVES, MW; ELLIOTT, JA; BILLMANN, L; LASHKERWALA, T; JOHNSON, JA				HARRISON, LH; ALI, A; DWYER, DM; LIBONATI, JP; REEVES, MW; ELLIOTT, JA; BILLMANN, L; LASHKERWALA, T; JOHNSON, JA			RELAPSING INVASIVE GROUP-B STREPTOCOCCAL INFECTION IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; RECURRENCE; ENDOCARDITIS; OSTEOMYELITIS	MULTILOCUS ENZYME ELECTROPHORESIS; DISEASE; PENICILLIN; INFANT; COLONIZATION; ANTIBODY; FAILURE	Objective: To study recurrent group B streptococcal infection in adults. Design: Patients with more than one reported group B streptococcal infection were identified through active surveillance for this infection. Sterile-site group B streptococcal isolates were evaluated for serotype and molecular subtyping using restriction endonuclease analysis of chromosomal DNA (REAC). Setting: All acute-care hospitals in Maryland. Patients: Nonpregnant residents of Maryland 18 years of age or older. Results: 22 adults had at least two group B streptococcal episodes that were separated by 2 to 95 weeks (mean, 24 weeks). Of 395 patients with invasive group B streptococcal infection who survived the first episode and were followed for at least 1 year, 17 (4.3% [95% CI, 2.6% to 6.9%]) had more than one episode. Several patients were found to have endocarditis or osteomyelitis during the second episode. Group B streptococcal isolates from both episodes were obtained from 18 of 22 patients. Of the 18 isolate pairs, 13 (72% [CI, 46% to 90%]) had identical REAC patterns; the probability that at least 13 matches would be found by chance alone was less than 0.00001. Among patients with recurrent infection caused by the same strain, the interval between episodes was shorter (mean, 14 weeks) than that among patients with recurrent infection caused by another strain (mean, 43 weeks; P = 0.05). Conclusions: Recurrent group B streptococcal infection is common among adults and in most cases appears to be caused by relapse. The optimal management of adults with a first episode of group B streptococcal infection needs to be further defined to minimize the likelihood of recurrent disease.	UNIV MARYLAND, VET AFFAIRS MED CTR, SCH MED, BALTIMORE, MD 21201 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30333 USA; MARYLAND DEPT HLTH & MENTAL HYG, BALTIMORE, MD 21210 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Centers for Disease Control & Prevention - USA; Maryland Department of Health & Mental Hygiene	HARRISON, LH (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, ROOM 5515, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							BAKER CJ, 1974, JAMA-J AM MED ASSOC, V230, P1158, DOI 10.1001/jama.230.8.1158; BAKER CJ, 1981, PEDIATRICS, V68, P544; BARTON LL, 1982, CLIN PEDIATR, V21, P100, DOI 10.1177/000992288202100206; BINNICK AN, 1980, ARCH DERMATOL, V116, P798, DOI 10.1001/archderm.116.7.798; BLUMBERG HM, 1992, J INFECT DIS, V166, P574, DOI 10.1093/infdis/166.3.574; BRENNER DJ, 1988, J CLIN MICROBIOL, V26, P1524, DOI 10.1128/JCM.26.8.1524-1534.1988; BROUGHTON DD, 1976, J PEDIATR-US, V89, P183, DOI 10.1016/S0022-3476(76)80441-6; Campos A, 1992, Enferm Infecc Microbiol Clin, V10, P59; CHMEL H, 1984, OBSTET GYNECOL, V63, P862; DENNING DW, 1988, PEDIATR INFECT DIS J, V7, P729, DOI 10.1097/00006454-198810000-00013; DORAND RD, 1976, J PEDIATR-US, V89, P188, DOI 10.1016/S0022-3476(76)80444-1; ELLISON RT, 1987, JAMA-J AM MED ASSOC, V257, P3260, DOI 10.1001/jama.257.23.3260; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; Fleiss J. L., 1981, STATISTICAL METHODS, P1; GARDNER SE, 1979, AM J OBSTET GYNECOL, V135, P1062, DOI 10.1016/0002-9378(79)90737-3; HALL MA, 1992, INFECT IMMUN, V60, P5030, DOI 10.1128/IAI.60.12.5030-5035.1992; HAQUE KN, 1986, ANN TROP PAEDIATR, V6, P219, DOI 10.1080/02724936.1986.11748443; HARRISON LH, 1995, J INFECT DIS, V171, P513, DOI 10.1093/infdis/171.2.513; HARRISON LH, 1993, MOL EPIDEMIOLOGY PRI; HUNTER W, 1991, P ANN M AM SOC MICRO; KENNY JF, 1977, J PEDIATR-US, V91, P158, DOI 10.1016/S0022-3476(77)80473-3; Lancefield RC, 1934, J EXP MED, V59, P441, DOI 10.1084/jem.59.4.441; MCCRACKEN GH, 1976, J PEDIATR-US, V89, P313, DOI 10.1016/S0022-3476(76)80477-5; MILLARD DD, 1985, AM J DIS CHILD, V139, P964, DOI 10.1001/archpedi.1985.02140120010009; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; PAREDES A, 1976, J PEDIATR-US, V89, P191, DOI 10.1016/S0022-3476(76)80445-3; Passick J, 1989, J Arthroplasty, V4, P87, DOI 10.1016/S0883-5403(89)80057-9; PRUNIER L, 1988, ARCH MAL COEUR VAISS, V81, P925; REEVES MW, 1989, J CLIN MICROBIOL, V27, P313, DOI 10.1128/JCM.27.2.313-320.1989; RENCH MA, 1993, 33RD INT C ANT AG CH; RUIZGOMEZ D, 1979, SCAND J INFECT DIS, V11, P35, DOI 10.3109/inf.1979.11.issue-1.05; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SIEGEL JD, 1981, J PEDIATR-US, V99, P920, DOI 10.1016/S0022-3476(81)80022-4; TRUOG WE, 1976, J PEDIATR-US, V89, P185, DOI 10.1016/S0022-3476(76)80442-8; WALKER SH, 1976, J PEDIATR-US, V89, P187, DOI 10.1016/S0022-3476(76)80443-X; WALKER SH, 1977, J PEDIATR-US, V90, P333, DOI 10.1016/S0022-3476(77)80686-0; WESSELS MR, 1993, NEW ENGL J MED, V328, P1843, DOI 10.1056/NEJM199306243282510	38	53	56	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					421	427		10.7326/0003-4819-123-6-199509150-00004	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639441				2022-12-28	WOS:A1995RU43700004
J	FAUCI, AS				FAUCI, AS			NEW SCIENCE AIMED AT AN ANCIENT KILLER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											FAUCI, AS (corresponding author), NIAID,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							JACOBS WR, 1994, SCIENCE, V263, P227; 1995, P NATL ACAD SCI USA, V92, P1530; 1995, SCIENCE, V267, P1638	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					786	786		10.1001/jama.274.10.786	http://dx.doi.org/10.1001/jama.274.10.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650787				2022-12-28	WOS:A1995RU32400005
J	ASO, T; LANE, WS; CONAWAY, JW; CONAWAY, RC				ASO, T; LANE, WS; CONAWAY, JW; CONAWAY, RC			ELONGIN (SIII) - A MULTISUBUNIT REGULATOR OF ELONGATION BY RNA-POLYMERASE-II	SCIENCE			English	Article							TRANSCRIPTION FACTOR; PURIFICATION; IDENTIFICATION; SEQUENCE; PROTEIN	The Elongin (SIII) complex activates elongation by mammalian RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin is a heterotrimer composed of A, B, and C subunits of 110, 18, and 15 kilodaltons, respectively. Here, the mammalian Elongin A gene was isolated and expressed, and the Elongin (SIII) complex reconstituted with recombinant subunits. Elongin A is shown to function as the transcriptionally active component of Elongin (SIII) and Elongin B and C as regulatory subunits. Whereas Elongin C assembles with Elongin A to form an AC complex with increased specific activity, Elongin B, a member of the ubiquitin-homology gene family, appears to serve a chaperone-like function, facilitating assembly and enhancing stability of the Elongin (SIII) complex.	OKLAHOMA MED RES FDN, PROGRAM MOLEC & CELL BIOL, OKLAHOMA CITY, OK 73104 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Oklahoma Medical Research Foundation; Harvard University				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, UNPUB; ASO T, IN PRESS FASEB J; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GARRETT KP, 1994, GENE, V150, P413, DOI 10.1016/0378-1119(94)90467-7; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1994, TRANSCRIPTION MECHAN, P263; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, BIOTECHNIQUES, V16, P824; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	28	287	296	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1439	1443		10.1126/science.7660129	http://dx.doi.org/10.1126/science.7660129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660129				2022-12-28	WOS:A1995RT80600050
J	SEIFER, SD; VRANIZAN, K; GRUMBACH, K				SEIFER, SD; VRANIZAN, K; GRUMBACH, K			GRADUATE MEDICAL-EDUCATION AND PHYSICIAN PRACTICE LOCATION - IMPLICATIONS FOR PHYSICIAN WORKFORCE POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the relationship between graduate medical education and physician practice location. Design.-Cross-sectional analysis of physicians in active practice in 1993, classified by state of graduate medical education and stratified by specialty and professional activity. Logistic regression analysis was used to examine predictors of physicians remaining to practice in the same state in which they trained. Setting.-There were 82 871 allopathic physicians (national random sample) and 15 076 osteopathic physicians (universe) who completed graduate medical education between 1980 and 1992. Main Outcome Measure.-Practice location in the same state as graduate medical education. Results.-Overall, 51% of physicians are practicing in the state in which they obtained their graduate medical education (range among states, 6% to 71%). Generalist physicians are more likely than specialists to remain in their state of graduate medical education (odds ratio [OR], 1.36; 95% confidence interval [CI], 1.33 to 1.40) There is a weak negative association between the number of physicians in training per capita in a state and the likelihood of a physician remaining in the state to practice (OR, 0.90; 95% CI, 0.90 to 0.91, for an increment in resident supply of 10 per 100 000 population). New York and Massachusetts, the states with the highest numbers of residents per capita, retained 51% and 49%, respectively of their graduates, placing them near the median among states. Conclusions.-Most physician training and practice locations function as a national market, with physicians dispersing relatively widely after completing graduate medical education. States that produce high numbers of physicians per capita do not appear to play a unique role in training physicians to serve a national market. These findings pose challenges for states attempting to modify their physician supply and specialty mix.	UNIV CALIF SAN FRANCISCO,PRIMARY CARE RES CTR,CTR HLTH PROFESS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center			Grumbach, Kevin/L-9222-2016		AHRQ HHS [T32 HS00044] Funding Source: Medline; PHS HHS [2282-92-0048] Funding Source: Medline; AHRQ [2T32HS000044-18] Funding Source: Federal RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BURFIELD WB, 1986, J MED EDUC, V61, P545; EISENBERG JM, 1994, INQUIRY, V28, P241; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V272, P37, DOI 10.1001/jama.272.1.37; KING LN, 1994, NY TIMES        0823; KOSTERLITZ J, 1994, NATIONAL J      0820, P1970; MASON HR, 1975, JAMA-J AM MED ASSOC, V233, P49; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; Roback G, 1994, PHYSICIAN CHARACTERI; WEISKOTTEN HG, 1960, J MED EDUC, V35, P1071; Yett D E, 1974, Inquiry, V11, P125; 1993, HLTH CARE PROVIDER A; 1994, JAMA-J AM MED ASSOC, V272, P725; 1994, VITAL STATISTICS US	13	70	70	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	1995	274	9					685	691		10.1001/jama.274.9.685	http://dx.doi.org/10.1001/jama.274.9.685			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR835	7650819				2022-12-28	WOS:A1995RR83500012
J	GERASIMOVA, TI; GDULA, DA; GERASIMOV, DV; SIMONOVA, O; CORCES, VG				GERASIMOVA, TI; GDULA, DA; GERASIMOV, DV; SIMONOVA, O; CORCES, VG			A DROSOPHILA PROTEIN THAT IMPARTS DIRECTIONALITY ON A CHROMATIN INSULATOR IS AN ENHANCER OF POSITION-EFFECT VARIEGATION	CELL			English	Article							GYPSY TRANSPOSABLE ELEMENT; HAIRY-WING PROTEIN; ZINC FINGER PROTEIN; YELLOW LOCUS; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; MELANOGASTER; GENE; EXPRESSION; SUPPRESSOR	The suppressor of Hairy wing (su(Hw)) protein inhibits the function of transcriptional enhancers located distally from the promoter with respect to the location of su(Hw)-binding sites, This polarity is due to the ability of the su(Hw)-binding region to form a chromatin insulator. Mutations in modifier of mdg4 (mod(mdg4)) enhance the effect of su(Hw) by inhibiting the function of enhancers located on both sides of the su(Hw)-binding region. This inhibition results in a variegated expression pattern, and mutations in mod(mdg4) act as classical enhancers of position-effect variegation. The mod(mdg4) and su(Hw) proteins interact with each other. The mod(mdg4) protein controls the nature of the repressive effect of su(Hw): in the absence of mod(mdg4) protein, su(Hw) exerts a bidirectional silencing effect, whereas in the presence of mod(mdg4), the silencing effect is transformed into unidirectional repression.	RUSSIAN ACAD SCI,INST GENE BIOL,MOSCOW 117334,RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	GERASIMOVA, TI (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.		Simonova, Olga B/K-8890-2014	Corces, Victor/0000-0001-5140-4337; Simonova, Olga/0000-0001-9439-524X	NIGMS NIH HHS [GM35463] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035463] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CORCES VG, 1991, TRENDS GENET, V7, P86, DOI 10.1016/0168-9525(91)90062-U; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; GEORGIEV PG, 1989, MOL GEN GENET, V220, P121, DOI 10.1007/BF00260865; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P8593, DOI 10.1073/pnas.85.22.8593; GEYER PK, 1987, GENE DEV, V1, P996, DOI 10.1101/gad.1.9.996; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GINIGER E, 1994, DEVELOPMENT, V120, P1385; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; JACK J, 1991, DEVELOPMENT, V113, P735; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MARTIN M, 1989, MOL GEN GENET, V218, P118, DOI 10.1007/BF00330574; MAZO AM, 1989, EMBO J, V8, P903, DOI 10.1002/j.1460-2075.1989.tb03451.x; MOHLER J, 1982, CHROMOSOMA, V86, P457, DOI 10.1007/BF00330121; PARKHURST SM, 1988, GENE DEV, V2, P1205, DOI 10.1101/gad.2.10.1205; PARKHURST SM, 1986, MOL CELL BIOL, V6, P47, DOI 10.1128/MCB.6.1.47; PEIFER M, 1988, P NATL ACAD SCI USA, V85, P9650, DOI 10.1073/pnas.85.24.9650; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Sambrook J, 1989, MOL CLONING LABORATO; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PA, 1992, MOL GEN GENET, V233, P65, DOI 10.1007/BF00587562; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; SPRADLING AC, 1979, CELL, V16, P589, DOI 10.1016/0092-8674(79)90032-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLFFE AP, 1994, CURR BIOL, V4, P85, DOI 10.1016/S0960-9822(00)00022-1; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	42	248	255	1	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					587	597		10.1016/0092-8674(95)90031-4	http://dx.doi.org/10.1016/0092-8674(95)90031-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664338	hybrid			2022-12-28	WOS:A1995RR73400010
J	ROYCE, RG				ROYCE, RG			OBSERVATIONS ON THE NHS INTERNAL MARKET - WILL THE DODO GET THE LAST LAUGH	BRITISH MEDICAL JOURNAL			English	Article								Distinguishing between the theory and practice of the internal market has been obscured by the considerable controversy generated by the reforms themselves. In such an environment both the advocates and the opponents of a market based solution have tended to promote their respective claims by reference to underlying political philosophies and economic theories rather than practical experience. Royce gives his observations of the actual operation of the internal market with particular reference to the commissioning function in Wales. He highlights inadequacies and inequities in the current system and proposes some remedial actions. Central to these are the importance of ensuring equitable funding for all purchasers, acknowledging the necessity of rationing, and promoting efficient and effective health care, sometimes at the expense of patient choice and guaranteed local service provision.			ROYCE, RG (corresponding author), ST DAVIDS HOSP,DUFED HLTH COMMISSIONING AUTHOR,CARMARTHEN SA31 3HB,DYFED,WALES.							DYER C, 1955, BRIT MED J, V310, P687; Griffiths Roy, 1983, NHS MANAGEMENT INQUI; OWEN JW, 1994, LETT CHAIRMEN CHIEF; ROYCE R, 1994, BRIT J HEALTHC COMP, V11, P30; ROYCE R, 1993, BRIT J HEALTHC COMP, V10, P20; 1993, COSTING CONTRACTING; 1994, DGM94143  HLTH COMM; 1994, PATIENTS CHARTER CHA	8	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					431	433		10.1136/bmj.311.7002.431	http://dx.doi.org/10.1136/bmj.311.7002.431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640593	Green Published			2022-12-28	WOS:A1995RP55400020
J	NGUYEN, HQ; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				NGUYEN, HQ; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			THE ZINC FINGER TRANSCRIPTION FACTOR EGR-1 IS ESSENTIAL FOR AND RESTRICTS DIFFERENTIATION ALONG THE MACROPHAGE LINEAGE	CELL			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; IMMEDIATE EARLY RESPONSE; INDUCED TERMINAL DIFFERENTIATION; TETRADECANOYL PHORBOL ACETATE; COLONY-STIMULATING FACTORS; C-MYC; GENE-EXPRESSION; ONCOGENE EXPRESSION; INHIBITORY FACTOR; GROWTH-FACTORS	We have isolated cDNA clones of myeloid differentiation primary response (MyD) genes, activated in the absence of de novo protein synthesis following induction for differentiation along either the macrophage or granulocyte lineage in human myeloblastic leukemia HL-60 cells. One cDNA clone of a primary response gene, expressed upon macrophage differentiation, encoded for Egr-1, a zinc finger transcription factor. The Egr-1 gene was observed to be transcriptionally silent in HL-60 cells, but active in U-937 and M1 cells, the latter two being predetermined for macrophage differentiation. Egr-1 antisense oligomers in the culture media blocked macrophage differentiation in both myeloid leukemia cell lines and normal myeloblasts. HL-60 cells constitutively expressing an Egr-1 transgene (HL-60Egr-1) could be induced for macrophage, but not granulocyte, differentiation. These observations indicate that expression of Egr-1 is essential for and restricts differentiation of myeloblasts along the macrophage lineage.			NGUYEN, HQ (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.				NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACON TA, 1991, ONCOGENE RES, V6, P13; BERNSTEIN SH, 1991, CELL GROWTH DIFFER, V2, P273; BOISE LH, 1992, CELL GROWTH DIFFER, V3, P43; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DALTON WT, 1988, BLOOD, V71, P242; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GALLAGHER R, 1979, BLOOD, V54, P713; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HORAK H, 1982, EXP HEMATOL, V10, P123; JINGWEN L, 1991, J BIOL CHEM, V266, P5929; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KOEFFLER HP, 1983, BLOOD, V62, P709; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; METCALF D, 1985, CELL, V43, P5, DOI 10.1016/0092-8674(85)90004-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; NAGARAJAN L, 1990, BLOOD, V75, P82; NELSON DA, 1983, HEMATOLOGY, P1651; NEWBURGER PE, 1981, CANCER RES, V41, P1861; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SHABO Y, 1990, LEUKEMIA, V4, P797; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TORELLA C, 1982, CANCER RES, V42, P445; TOTORA G, 1990, P NATL ACAD SCI USA, V87, P705; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WINTROBE MM, 1981, CLIN HEMATOLOGY, P35; WU J, 1990, ONCOGENE, V5, P873	60	377	388	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					197	209		10.1016/0092-8674(93)90660-I	http://dx.doi.org/10.1016/0092-8674(93)90660-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678779	hybrid			2022-12-28	WOS:A1993KK03800005
J	TROLLFORS, B; TARANGER, J; LAGERGARD, T; LIND, L; SUNDH, V; ZACKRISSON, G; LOWE, CU; BLACKWELDER, W; ROBBINS, JB				TROLLFORS, B; TARANGER, J; LAGERGARD, T; LIND, L; SUNDH, V; ZACKRISSON, G; LOWE, CU; BLACKWELDER, W; ROBBINS, JB			A PLACEBO-CONTROLLED TRIAL OF A PERTUSSIS-TOXOID VACCINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BORDETELLA-PERTUSSIS; ANTIBODY-RESPONSE; FILAMENTOUS HEMAGGLUTININ	Background. Although many whole-cell vaccines have been effective in preventing pertussis, these vaccines are difficult to standardize and can produce side effects. In Sweden, pertussis became endemic during the 1970s despite vaccination. Because of its limited efficacy, the Swedish-made whole-cell vaccine was withdrawn in 1979. Methods. To evaluate the efficacy of an acellular vaccine consisting of pertussis toxin inactivated by hydrogen peroxide (pertussis toroid), we conducted a randomized, double-blind, placebo-controlled trial in Sweden. Infants were vaccinated with either diphtheria and tetanus toxoids atone (DT toxoids, 1726 infants) or diphtheria, tetanus, and pertussis toxoids (DTP toxoids, 1724 infants) at 3, 5, and 12 months of age. Results. There were no serious reactions. With the pertussis vaccine there were slightly more local reactions than with the DT toxoids alone, but the rates of postvaccination fever were the same. The main period of surveillance, which began 30 days after the third vaccination, continued for a median of 17.5 months. There were 312 cases of pertussis (72 in the DTP-toxoids group and 240 in the DT-toxoids group) that met the clinical criterion (paroxysmal cough lasting greater than or equal to 21 days) and laboratory criteria for pertussis as defined by the World Health Organization. The efficacy of this acellular vaccine was 71 percent (95 percent confidence interval, 63 to 78 percent). The recipients of DTP toxoids who had pertussis had cough of shorter duration than the recipients of DT toxoids, and fewer had whooping and vomiting. The vaccine efficacy after two doses was 55 percent (95 percent confidence interval, 12 to 78 percent), on the basis of 14 cases in the DTP-toxoids group and 31 in the DT-toxoids group that met the definition of the World Health Organization. Conclusions. A pharmacologically inert, acellular pertussis-toxoid vaccine that is easily standardized is safe and confers substantial protection against pertussis.	GOTHENBURG UNIV,DEPT PEDIAT,S-41124 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT MED MICROBIOL & IMMUNOL,GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CLIN BACTERIOL,GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT GERIATR MED,GOTHENBURG,SWEDEN; NICHHD,BETHESDA,MD 20892; NIAID,BETHESDA,MD 20892	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092905] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-9-2905] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1988, LANCET, Vi, P955; BAKER JD, 1992, J PEDIATR-US, V121, P523, DOI 10.1016/S0022-3476(05)81138-2; BARENKAMP SJ, 1992, INFECT IMMUN, V60, P1302, DOI 10.1128/IAI.60.4.1302-1313.1992; BLENNOW M, 1988, EUR J CLIN MICROBIOL, V7, P381, DOI 10.1007/BF01962341; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; CODY CL, 1981, PEDIATRICS, V68, P650; EDWARDS KM, 1991, PEDIATRICS, V88, P1019; FINE PEM, 1987, REV INFECT DIS, V9, P866; HOUARD S, 1989, RES MICROBIOL, V140, P477, DOI 10.1016/0923-2508(89)90069-7; ISACSON J, 1994, PEDIATR INFECT DIS J, V13, P22, DOI 10.1097/00006454-199401000-00006; KRANTZ I, 1989, INT J EPIDEMIOL, V18, P959, DOI 10.1093/ije/18.4.959; Pappenheimer AM., 1984, BACTERIAL VACCINES, P1; PITTMAN M, 1984, PEDIATR INFECT DIS J, V3, P467, DOI 10.1097/00006454-198409000-00019; REGAN J, 1977, J CLIN MICROBIOL, V6, P303; ROBBINS JB, 1993, PEDIATR INFECT DIS J, V12, P795, DOI 10.1097/00006454-199310000-00001; ROBINSON A, 1992, VACCINE, V10, P139, DOI 10.1016/0264-410X(92)90001-Z; SCHMITT HJ, 1993, EUR J PEDIATR, V152, P462, DOI 10.1007/BF01955049; SEKURA RD, 1988, J PEDIATR-US, V113, P806, DOI 10.1016/S0022-3476(88)80005-2; TARANGER J, 1994, LANCET, V344, P1703, DOI 10.1016/S0140-6736(94)90485-5; TROLLFORS B, 1988, J INFECT DIS, V158, P991, DOI 10.1093/infdis/158.5.991; VANDERZEE A, 1993, J BACTERIOL, V175, P141, DOI 10.1128/JB.175.1.141-147.1993; ZACKRISSON G, 1988, EUR J CLIN MICROBIOL, V7, P149, DOI 10.1007/BF01963068; ZACKRISSON G, 1988, EUR J CLIN MICROBIOL, V7, P764, DOI 10.1007/BF01975044; 1964, TOPLEY WILSONS PRINC, V2, P1668; 1951, BRIT MED J, V1, P1463; 1991, 1991 WHO M CAS DEF P; 1988, LANCET, V1, P1238	28	241	247	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1045	1050		10.1056/NEJM199510193331604	http://dx.doi.org/10.1056/NEJM199510193331604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675047				2022-12-28	WOS:A1995RZ34000004
J	ROSENTHAL, N				ROSENTHAL, N			MOLECULAR MEDICINE - RECOGNIZING DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING-SITE; SELECTION							Rosenthal, Nadia/0000-0002-7599-7365				BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; PAPAVASSILIOU AG, 1995, NEW ENGL J MED, V332, P45, DOI 10.1056/NEJM199501053320108; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P931, DOI 10.1056/NEJM199410063311408; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	4	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					925	927		10.1056/NEJM199510053331408	http://dx.doi.org/10.1056/NEJM199510053331408			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666880				2022-12-28	WOS:A1995RX19900008
J	PAI, RG; HEYWOOD, JT				PAI, RG; HEYWOOD, JT			ATHEROEMBOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PAI, RG (corresponding author), VET AFFAIRS MED CTR,LOMA LINDA,CA 92357, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					852	852		10.1056/NEJM199509283331306	http://dx.doi.org/10.1056/NEJM199509283331306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651476				2022-12-28	WOS:A1995RW88300006
J	WHITBY, D; HOWARD, MR; TENANTFLOWERS, M; BRINK, NS; COPAS, A; BOSHOFF, C; HATZIOANNOU, T; SUGGETT, FEA; ALDAM, DM; DENTON, AS; MILLER, RF; WELLER, IVD; WEISS, RA; TEDDER, RS; SCHULZ, TF				WHITBY, D; HOWARD, MR; TENANTFLOWERS, M; BRINK, NS; COPAS, A; BOSHOFF, C; HATZIOANNOU, T; SUGGETT, FEA; ALDAM, DM; DENTON, AS; MILLER, RF; WELLER, IVD; WEISS, RA; TEDDER, RS; SCHULZ, TF			DETECTION OF KAPOSI-SARCOMA ASSOCIATED HERPESVIRUS IN PERIPHERAL-BLOOD OF HIV-INFECTED INDIVIDUALS AND PROGRESSION TO KAPOSIS-SARCOMA	LANCET			English	Article							EPSTEIN-BARR-VIRUS; AIDS; CELLS	Kaposi sarcoma-associated herpesvirus (KSHV) is consistently found in biopsy samples from patients with AIDS-related and ''classical'' Kaposi's sarcoma.(KS). Although highly suggestive of a causal role of KSHV in the pathogenesis of KS, this observation does not exclude the possibility that KSHV, like other herpesviruses, is widely distributed and is a mere ''passenger'' in these lesions. Here we report that KSHV was detectable in peripheral blood mononuclear cells of 24/46 (52%) of KS patients, but in none of 134 blood donors or 26 HIV-uninfected hospital controls. KSHV detection increased with immunosuppression, as shown by a correlation with a reduced number of CD4-positive T-cells. Moreover, KSHV detection in peripheral blood cells of HIV-infected individuals without KS predicted the subsequent appearance of KS lesions. 143 patients who did not have KS at the time of their first (or only) blood sample were followed up for a median of 30 months. Of the 11 who had been KSHV positive 6 developed KS compared with only 12 out of 132 who were KSHV negative. These findings are compatible with a causative role of KSHV in KS. KSHV was rarely detected in sputum and throat swabs of HIV-infected patients, providing a potential explanation for the apparently limited spread of this virus.	INST CANC RES, VIROL LAB, LONDON SW3 6BJ, ENGLAND; UCL, SCH MED, DIV VIROL, LONDON, ENGLAND; UCL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School			Schulz, Thomas/AAA-1634-2019	Miller, Robert/0000-0003-2067-4291; Copas, Andrew/0000-0001-8968-5963				AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BAYLEY AC, 1985, LANCET, V1, P359; BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BERAL V, 1991, CANCER SURV, V10, P5; BOSHOFF C, 1995, LANCET, V345, P1043; BOYD MT, 1993, VIROLOGY, V196, P905, DOI 10.1006/viro.1993.1556; BROWNING PJ, 1994, BLOOD, V84, P2711, DOI 10.1182/blood.V84.8.2711.bloodjournal8482711; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COLLANDRE H, 1995, LANCET, V345, P1043, DOI 10.1016/S0140-6736(95)90779-3; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; GIRALDO G, 1972, J NATL CANCER I, V49, P1509, DOI 10.1093/jnci/49.6.1509; GOPAL MR, 1990, LANCET, V335, P1598, DOI 10.1016/0140-6736(90)91433-B; KAYE S, 1991, J VIROL METHODS, V35, P217, DOI 10.1016/0166-0934(91)90137-O; MITCHELL SM, 1994, J MED VIROL, V43, P336, DOI 10.1002/jmv.1890430404; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; QUINIBI W, 1988, AM J MED, V84, P225; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RABKIN CS, 1995, CLIN CANCER RES, V1, P257; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; RICKINSON AB, 1992, CANCER SURV, V13, P53; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SCHULZ TF, 1995, NATURE, V373, P17, DOI 10.1038/373017a0; ZIEGLER JL, 1985, AIDS ETIOLOGY DIAGNO, P223; 1987, MMWR-MORBID MORTAL W, V36, P1	28	764	782	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 23	1995	346	8978					799	802		10.1016/S0140-6736(95)91619-9	http://dx.doi.org/10.1016/S0140-6736(95)91619-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674745				2022-12-28	WOS:A1995RW25800010
J	SCALLY, G				SCALLY, G			DEALING WITH DUFFERS	LANCET			English	Editorial Material											SCALLY, G (corresponding author), S&W REG HLTH AUTHOR,BRISTOL,AVON,ENGLAND.							DONALDSON LJ, 1992, BRIT MED J, V304, P1257; ROSENTHAL M, 1995, INCOMPETENT DOCTOR; SHAW GB, 1945, DOCTORS DILEMMA; VIRCHOW R, 1985, COLLECTED ESSAYS PUB, V2; 1995, REV GUIDANCE DOCTORS	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					720	720		10.1016/S0140-6736(95)91500-1	http://dx.doi.org/10.1016/S0140-6736(95)91500-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658870				2022-12-28	WOS:A1995RU81000006
J	TOKGOZOGLU, LS; ASHIZAWA, T; PACIFICO, A; ARMSTRONG, RM; EPSTEIN, HF; ZOGHBI, WA				TOKGOZOGLU, LS; ASHIZAWA, T; PACIFICO, A; ARMSTRONG, RM; EPSTEIN, HF; ZOGHBI, WA			CARDIAC INVOLVEMENT IN A LARGE KINDRED WITH MYOTONIC-DYSTROPHY - QUANTITATIVE ASSESSMENT AND RELATION TO SIZE OF CTG REPEAT EXPANSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMISSION COMPUTED-TOMOGRAPHY; TRINUCLEOTIDE CAG REPEAT; MUSCULAR-DYSTROPHY; MESSENGER-RNA; ECHOCARDIOGRAPHIC EVALUATION; CONDUCTION SYSTEM; TRIPLET REPEAT; GCT REPEAT; DISEASE; PROTEIN	Objective.-To evaluate and quantitate cardiac involvement in myotonic dystrophy and assess whether the size of the trinucleotide (cytosine-thymine-guanine [CTG]) repeat expansion is a significant predictor of cardiac abnormalities. Design.-Case-control study of a large kindred with myotonic dystrophy. Patients.-Ninety-one bloodline members of the kindred underwent clinical and cardiac evaluation with electrocardiograms, echocardiography (with Doppler in the majority of cases), and genetic and neurologic evaluations. Affected individuals were age-matched to normal family members. Main Outcome Measures.-Electrocardiographic conduction abnormalities, wall motion abnormalities, mitral valve prolapse, and global parameters of systolic and diastolic function were determined by an observer blinded to all clinical data and genetic analysis. Results.-Compared with age-matched normals, patients with myotonic dystrophy (n=25) were more likely to have conduction abnormality (52% vs 9%), mitral valve prolapse (32% vs 9%), and wall motion abnormality (28% vs 0%) (all P<.05). Left ventricular ejection fraction and stroke volume were reduced compared with normals matched for age and heart rate (P<.05), whereas Doppler indexes of diastolic function were only marginally altered. Using multivariate analysis, the number of CTG repeats (range, 69 to 1367; normal, less than or equal to 37) was the strongest predictor of abnormalities in wall motion and electrocardiographic conduction (odds ratio of 16.5 and 5.07 per 500 repeats, respectively). The relation of mitral valve prolapse to the size of the CTG repeat was of borderline significance, Patients with more extensive neurologic findings (n=12) had a higher incidence of wall motion and/or electrocardiographic conduction abnormalities (83% vs 43%; P=.04). Conclusions.-Cardiac involvement in myotonic dystrophy affects predominantly the conduction system and myocardial function. Alterations in myocardial relaxation and diastolic properties, in contrast to skeletal muscle myotonia, are minor. In this kindred, the number of CTG repeats was a significant predictor of cardiac dysfunction in myotonic dystrophy.	METHODIST HOSP,ECHOCARDIOG LAB,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,CARDIOL SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; VET AFFAIRS MED CTR,HOUSTON,TX 77030	The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ANVRET M, 1993, HUM MOL GENET, V2, P1397, DOI 10.1093/hmg/2.9.1397; ASHIZAWA T, 1993, NEUROLOGY, V43, P2674, DOI 10.1212/WNL.43.12.2674; ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; ASHIZAWA T, 1992, NEUROLOGY, V42, P1877; ASHIZAWA T, 1992, AM J MED GENET, V42, P55, DOI 10.1002/ajmg.1320420113; BHARATI S, 1984, CHEST, V86, P444, DOI 10.1378/chest.86.3.444; BORGESNETO S, 1988, J AM COLL CARDIOL, V11, P962, DOI 10.1016/S0735-1097(98)90052-3; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CHURCH SC, 1967, ARCH INTERN MED, V119, P176, DOI 10.1001/archinte.119.2.176; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; FORSBERG H, 1988, CARDIOLOGY, V75, P241, DOI 10.1159/000174380; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GOTTDIENER JS, 1982, AM HEART J, V104, P77, DOI 10.1016/0002-8703(82)90644-5; GRIFFITH TW, 1911, QUART J MED, V5, P229; GRIGGS RC, 1975, AM J MED, V59, P37, DOI 10.1016/0002-9343(75)90319-8; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1992, AM J HUM GENET, V51, P10; HARPER PS, 1989, MYOTONIC DYSTROPHY, P13; HARTWIG GB, 1983, NEUROLOGY, V33, P657, DOI 10.1212/WNL.33.5.657; HIROMASA S, 1987, AM HEART J, V113, P1482, DOI 10.1016/0002-8703(87)90665-X; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; JANSEN G, 1994, AM J HUM GENET, V54, P575; KOVICK RB, 1975, CIRCULATION, V52, P447, DOI 10.1161/01.CIR.52.3.447; LAVEDAN C, 1993, AM J HUM GENET, V52, P875; LEWIS JF, 1984, CIRCULATION, V3, P425; MAHMARIAN JJ, 1990, J AM COLL CARDIOL, V15, P318, DOI 10.1016/S0735-1097(10)80055-5; MELACINI P, 1988, CLIN CARDIOL, V11, P231, DOI 10.1002/clc.4960110407; MOORMAN JR, 1985, MEDICINE, V64, P371, DOI 10.1097/00005792-198511000-00002; MOTTA J, 1979, AM J MED, V67, P467, DOI 10.1016/0002-9343(79)90795-2; MULVAGH S, 1992, J AM COLL CARDIOL, V20, P112, DOI 10.1016/0735-1097(92)90146-E; NGUYEN HH, 1988, J AM COLL CARDIOL, V11, P662, DOI 10.1016/0735-1097(88)91547-1; NOVELLI G, 1993, BIOCHEM MOL BIOL INT, V29, P291; NOVELLI G, 1993, BIOCHEM MED METAB B, V50, P85, DOI 10.1006/bmmb.1993.1049; OLOFSSON BO, 1988, BRIT HEART J, V59, P47; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PAYNE CA, 1963, AM HEART J, V65, P436, DOI 10.1016/0002-8703(63)90092-9; PERLOFF JK, 1984, AM J CARDIOL, V54, P1074, DOI 10.1016/S0002-9149(84)80147-2; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; REEVES WC, 1980, ARCH NEUROL-CHICAGO, V37, P273, DOI 10.1001/archneur.1980.00500540051004; RICKER K, 1994, NEUROLOGY, V44, P1448, DOI 10.1212/WNL.44.8.1448; ROKEY R, 1985, CIRCULATION, V71, P543, DOI 10.1161/01.CIR.71.3.543; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SCHILLER NB, 1989, J AM SOC ECHO, V5, P358; SMITH M D, 1991, Cardiology Clinics, V9, P193; STREIB EW, 1985, MUSCLE NERVE, V8, P650, DOI 10.1002/mus.880080804; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; VANREET RE, 1984, J AM COLL CARDIOL, V3, P243, DOI 10.1016/S0735-1097(84)80007-8; VENCO A, 1978, BRIT HEART J, V40, P1262; WEYMAN AE, 1994, PRINCIPLES PRACTICE, P391; WINTERS SJ, 1976, ANN INTERN MED, V85, P19, DOI 10.7326/0003-4819-85-1-19; WINTZEN AR, 1987, J NEUROL SCI, V80, P259, DOI 10.1016/0022-510X(87)90160-2; ZOGHBI WA, 1990, CIRCULATION, V82, P1316, DOI 10.1161/01.CIR.82.4.1316	59	64	65	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					813	819		10.1001/jama.274.10.813	http://dx.doi.org/10.1001/jama.274.10.813			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650805				2022-12-28	WOS:A1995RU32400029
J	HARTLEY, KO; GELL, D; SMITH, GCM; ZHANG, H; DIVECHA, N; CONNELLY, MA; ADMON, A; LEESMILLER, SP; ANDERSON, CW; JACKSON, SP				HARTLEY, KO; GELL, D; SMITH, GCM; ZHANG, H; DIVECHA, N; CONNELLY, MA; ADMON, A; LEESMILLER, SP; ANDERSON, CW; JACKSON, SP			DNA-DEPENDENT PROTEIN-KINASE CATALYTIC SUBUNIT - A RELATIVE OF PHOSPHATIDYLINOSITOL 3-KINASE AND THE ATAXIA-TELANGIECTASIA GENE-PRODUCT	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; KU-AUTOANTIGEN; PHOSPHORYLATION; ANTIGEN; REPAIR	DNA-dependent protein kinase (DNA-PK), which is involved in DNA double-stranded break repair and V(D)J recombination, comprises a DNA-targeting component called Ku and an similar to 460 kDa catalytic subunit, DNA-PKcs. Here, we describe the cloning of the DNA-PKcs cDNA and show that DNA-PKcs falls into the phosphatidylinositol (PI) 3-kinase family. Biochemical assays, however, indicate that DNA-PK phosphorylates proteins but has no detectable activity toward lipids, Strikingly, DNA-PKcs is most similar to PI kinase family members involved in cell cycle control, DNA repair, and DNA damage responses. These include the FKBP12-rapamycin-binding proteins Tor1p, Tor2p, and FRAP, S. pombe rad3, and the product of the ataxia telangiectasia gene, mutations in which lead to genomic instability and predisposition to cancer. The relationship of these proteins to DNA-PKcs provides important clues to their mechanisms of action.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; BABRAHAM INST,INOSITIDE LAB,CAMBRIDGE CB2 4AT,ENGLAND; TECHNION ISRAEL INST TECHNOL,IL-32000 HAIFA,ISRAEL	University of Cambridge; United States Department of Energy (DOE); Brookhaven National Laboratory; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Technion Israel Institute of Technology	HARTLEY, KO (corresponding author), UNIV CAMBRIDGE,WELCOME TRUST,CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Gell, David/0000-0003-0382-1181; Admon, Arie/0000-0003-0504-3950; divecha, nullin/0000-0001-9695-6039; Lees-Miller, Susan/0000-0001-5809-2516	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, IN PRESS TRENDS BIOC; JEGGO PA, 1995, IN PRESS BIOESSAYS; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	34	668	692	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					849	856		10.1016/0092-8674(95)90482-4	http://dx.doi.org/10.1016/0092-8674(95)90482-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671312	Bronze			2022-12-28	WOS:A1995RU75500020
J	MOL, CD; ARVAI, AS; SANDERSON, RJ; SLUPPHAUG, G; KAVLI, B; KROKAN, HE; MOSBAUGH, DW; TAINER, JA				MOL, CD; ARVAI, AS; SANDERSON, RJ; SLUPPHAUG, G; KAVLI, B; KROKAN, HE; MOSBAUGH, DW; TAINER, JA			CRYSTAL-STRUCTURE OF HUMAN URACIL-DNA GLYCOSYLASE IN COMPLEX WITH A PROTEIN INHIBITOR - PROTEIN MIMICRY OF DNA	CELL			English	Article							BACTERIOPHAGE-PBS2; DEAMINATION; GENE	Uracil-DNA glycosylase inhibitor (Ugi) is a B. subtilis bacteriophage protein that protects the uracil-containing phage DNA by irreversibly inhibiting the key DNA repair enzyme uracil-DNA glycosylase (UDG). The 1.9 Angstrom crystal structure of Ugi complexed to human UDG reveals that the Ugi structure, consisting of a twisted five-stranded antiparallel beta sheet and two alpha helices, binds by inserting a beta strand into the conserved DNA-binding groove of the enzyme without contacting the uracil specificity pocket, The resulting interface, which buries over 1200 Angstrom(2) on Ugi and involves the entire beta sheet and an alpha helix, is polar and contains 22 water molecules. Ugi binds the sequence-conserved DNA-binding groove of UDG via shape and electrostatic complementarity, specific charged hydrogen bonds, and hydrophobic packing enveloping Leu-272 from a protruding UDG loop. The apparent mimicry by Ugi of DNA interactions with UDG provides both a structural mechanism for UDG binding to DNA, including the enzyme-assisted expulsion of uracil from the DNA helix, and a crystallographic basis for the design of inhibitors with scientific and therapeutic applications.	OREGON STATE UNIV, DEPT AGR CHEM, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, CTR ENVIRONM HLTH SCI, CORVALLIS, OR 97331 USA; UNIV TRONDHEIM, UNIGEN CTR MOLEC BIOL, N-7005 TRONDHEIM, NORWAY	Oregon State University; Oregon State University; Oregon State University	MOL, CD (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES BLVD, LA JOLLA, CA 92037 USA.		Tainer, John/GWQ-4878-2022; Slupphaug, Geir/AAN-3794-2020	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500	NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823, GM46312] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312, R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICHARDSON JS, 1989, PREDICTION PROTEIN S, P2; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VERRI A, 1992, BIOCHEM J, V287, P1007, DOI 10.1042/bj2871007; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31	33	235	253	1	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					701	708		10.1016/0092-8674(95)90467-0	http://dx.doi.org/10.1016/0092-8674(95)90467-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671300	Bronze			2022-12-28	WOS:A1995RU75500005
J	MILLER, E; WAIGHT, PA; TEDDER, RS; SUTHERLAND, S; MORTIMER, PP; SHAFI, MS				MILLER, E; WAIGHT, PA; TEDDER, RS; SUTHERLAND, S; MORTIMER, PP; SHAFI, MS			INCIDENCE OF HIV-INFECTION IN HOMOSEXUAL MEN IN LONDON, 1988-94	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,LONDON W1P 6DB,ENGLAND; UNIV LONDON KINGS COLL,DULWICH HOSP,SCH MED & DENT,PUBL HLTH LAB,LONDON SE22 8QF,ENGLAND; CENT PUBL HLTH LAB,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND; CENT MIDDLESEX HOSP NHS TRUST,PUBL HLTH LAB,LONDON NW10 7NS,ENGLAND	University of London; University College London; University of London; King's College London; Public Health England	MILLER, E (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.			Shafi, Shuja/0000-0002-4659-8365; Tedder, Richard/0000-0002-9672-5721				HEYWARD WL, 1994, AIDS, V8, P1285, DOI 10.1097/00002030-199409000-00011; Waight P A, 1992, Commun Dis Rep CDR Rev, V2, pR85; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685	3	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					545	545		10.1136/bmj.311.7004.545	http://dx.doi.org/10.1136/bmj.311.7004.545			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663211	Green Published			2022-12-28	WOS:A1995RR73700021
J	VALE, JA; PROUDFOOT, AT				VALE, JA; PROUDFOOT, AT			PARACETAMOL (ACETAMINOPHEN) POISONING	LANCET			English	Article							FULMINANT HEPATIC-FAILURE; INTRAVENOUS N-ACETYLCYSTEINE; ACTIVATED-CHARCOAL; ADVERSE REACTIONS; OVERDOSE; EFFICACY; HEPATOTOXICITY; IPECAC; INDICATORS; PROGNOSIS		ROYAL INFIRM,EDINBURGH CTR,NATL POISONS INFORMAT SERV,EDINBURGH,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	VALE, JA (corresponding author), CITY HOSP,BIRMINGHAM CTR,NATL POISONS INFORMAT SERV,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.		Buckley, Nicholas A/D-4030-2012; Vale, Allister/AAA-9216-2019	Buckley, Nicholas A/0000-0002-6326-4711; 				AMITAI Y, 1987, PEDIATRICS, V80, P364; BATEMAN DN, 1984, HUM TOXICOL, V3, P393, DOI 10.1177/096032718400300504; BOND GR, 1993, ANN EMERG MED, V22, P1403, DOI 10.1016/S0196-0644(05)81986-9; BRAY GP, 1992, HUM EXP TOXICOL, V11, P265, DOI 10.1177/096032719201100405; BRAY GP, 1991, HUM EXP TOXICOL, V10, P435, DOI 10.1177/096032719101000612; CANALESE J, 1981, BRIT MED J, V282, P199, DOI 10.1136/bmj.282.6259.199; CARCENI P, 1995, LANCET, V345, P163; CHAN TYK, 1994, HUM EXP TOXICOL, V13, P542, DOI 10.1177/096032719401300806; CHEUNG L, 1994, NEW ENGL J MED, V330, P1907, DOI 10.1056/NEJM199406303302619; CRIPPIN JS, 1993, AM J GASTROENTEROL, V88, P590; DAVIDSON DG, 1966, BRIT MED J, V2, P497, DOI 10.1136/bmj.2.5512.497; DOUGLAS AP, 1976, LANCET, V1, P111; DOUIDAR SM, 1994, CLIN PEDIATR, V33, P42, DOI 10.1177/000992289403300107; ERIKSSON LS, 1992, J INTERN MED, V231, P567, DOI 10.1111/j.1365-2796.1992.tb00976.x; GAZZARD BG, 1977, POSTGRAD MED J, V53, P243, DOI 10.1136/pgmj.53.619.243; GRAY TA, 1987, Q J MED, V246, P811; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HARRISON PM, 1990, BMJ-BRIT MED J, V301, P964, DOI 10.1136/bmj.301.6758.964; JONES AF, 1989, LANCET, V2, P608; JONES AL, 1994, GUT, V35, P1290, DOI 10.1136/gut.35.9.1290; JONES AL, 1994, GUT, V35, pS5; KEAYS R, 1991, BRIT MED J, V303, P1026, DOI 10.1136/bmj.303.6809.1026; LAUTERBURG BH, 1988, GUT, V29, P1153, DOI 10.1136/gut.29.9.1153; LITOVITZ TL, 1994, AM J EMERG MED, V12, P546, DOI 10.1016/0735-6757(94)90276-3; MANT TGK, 1984, BRIT MED J, V289, P217, DOI 10.1136/bmj.289.6439.217; MCNAMARA RM, 1989, ANN EMERG MED, V18, P934, DOI 10.1016/S0196-0644(89)80456-1; MCNAMARA RM, 1988, ANN EMERG MED, V17, P243, DOI 10.1016/S0196-0644(88)80115-X; MINTON NA, 1988, HUM TOXICOL, V7, P33, DOI 10.1177/096032718800700106; MUTIMER DJ, 1994, GUT, V35, P809, DOI 10.1136/gut.35.6.809; NEUVONEN PJ, 1983, EUR J CLIN PHARMACOL, V24, P557, DOI 10.1007/BF00609903; OGRADY JG, 1991, BRIT MED J, V303, P221, DOI 10.1136/bmj.303.6796.221; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; PEREIRA LMMB, 1992, GUT, V33, P98, DOI 10.1136/gut.33.1.98; PRESCOTT LF, 1971, LANCET, V1, P519; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; PRESCOTT LF, 1980, BRIT MED J, V280, P46, DOI 10.1136/bmj.280.6206.46-b; PRESCOTT LF, 1989, EUR J CLIN PHARMACOL, V37, P501, DOI 10.1007/BF00558131; RUMACK BH, 1975, PEDIATRICS, V55, P871; RUMACK BH, 1978, PEDIATRICS, V62, P898; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SMILKSTEIN MJ, 1991, ANN EMERG MED, V20, P1058, DOI 10.1016/S0196-0644(05)81352-6; THOMSON JS, 1966, BRIT MED J, V2, P506, DOI 10.1136/bmj.2.5512.506; TIGHE TV, 1994, J TOXICOL-CLIN TOXIC, V32, P431, DOI 10.3109/15563659409011045; UNDERHILL TJ, 1990, ARCH EMERG MED, V7, P148; VALE JA, 1981, ARCH INTERN MED, V141, P394, DOI 10.1001/archinte.141.3.394; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845	47	146	149	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					547	552		10.1016/S0140-6736(95)91385-8	http://dx.doi.org/10.1016/S0140-6736(95)91385-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658783				2022-12-28	WOS:A1995RQ98600013
J	HANSEN, SK; TJIAN, R				HANSEN, SK; TJIAN, R			TAFS AND TFIIA MEDIATE DIFFERENTIAL UTILIZATION OF THE TANDEM ADH PROMOTERS	CELL			English	Article							ALCOHOL-DEHYDROGENASE GENE; DROSOPHILA TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; RNA-POLYMERASE; 2 PROMOTERS; CELL-LINES; FAT-BODY; MELANOGASTER; EXPRESSION; ENHANCER	The D. melanogaster alcohol dehydrogenase (Adh) gene is transcribed from two tandem promoters that are differentially utilized at various stages during development. To determine the mechanism of promoter selectivity, we have analyzed the activity of the Adh promoters both in vitro and in transfected cells. We found that selective promoter utilization is controlled by distinct initiator elements. Reconstitution of Adh transcription with purified components requires a specific TBP-TAF complex that, in concert with TFIIA, directs differential Adh promoter transcription. Fractionation of this TBP-TAF complex reveals that TAF(II)150 is required for discrimination between the proximal and distal promoters. We propose a mechanism for regulating differential promoter utilization during Drosophila development that involves the recognition of specific initiator elements by TAFs in the TFIID complex.			HANSEN, SK (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; ABEL T, 1993, DEVELOPMENT, V119, P623; AYER S, 1990, MOL CELL BIOL, V10, P3512, DOI 10.1128/MCB.10.7.3512; AYER S, 1992, MOL CELL BIOL, V12, P661, DOI 10.1128/MCB.12.2.661; BENYAJATI C, 1987, NUCLEIC ACIDS RES, V15, P7903, DOI 10.1093/nar/15.19.7903; BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; BENYAJATI C, 1992, NUCLEIC ACIDS RES, V20, P4481, DOI 10.1093/nar/20.17.4481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBIN V, 1989, GENE DEV, V3, P2191, DOI 10.1101/gad.3.12b.2191; CORBIN V, 1990, GENETICS, V124, P637; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; ENGLAND BP, 1990, J BIOL CHEM, V265, P5086; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FRANK DJ, 1995, J BIOL CHEM, V270, P6292, DOI 10.1074/jbc.270.11.6292; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MOSES K, 1990, MOL CELL BIOL, V10, P539, DOI 10.1128/MCB.10.2.539; PETERSON MG, 1991, NATURE, V354, P369; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SAVAKIS C, 1986, DEV BIOL, V114, P194, DOI 10.1016/0012-1606(86)90395-7; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SIMCOX AA, 1985, SOMAT CELL MOLEC GEN, V11, P63, DOI 10.1007/BF01534735; STJOHNSTON D, 1992, CELL, V68, P201; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEEKS JR, 1982, J BIOL CHEM, V257, P5884; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	43	101	102	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					565	575		10.1016/0092-8674(95)90029-2	http://dx.doi.org/10.1016/0092-8674(95)90029-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664336	Bronze			2022-12-28	WOS:A1995RR73400008
J	LEVYLAHAD, E; WASCO, W; POORKAJ, P; ROMANO, DM; OSHIMA, J; PETTINGELL, WH; YU, CE; JONDRO, PD; SCHMIDT, SD; WANG, K; CROWLEY, AC; FU, YH; GUENETTE, SY; GALAS, D; NEMENS, E; WIJSMAN, EM; BIRD, TD; SCHELLENBERG, GD; TANZI, RE				LEVYLAHAD, E; WASCO, W; POORKAJ, P; ROMANO, DM; OSHIMA, J; PETTINGELL, WH; YU, CE; JONDRO, PD; SCHMIDT, SD; WANG, K; CROWLEY, AC; FU, YH; GUENETTE, SY; GALAS, D; NEMENS, E; WIJSMAN, EM; BIRD, TD; SCHELLENBERG, GD; TANZI, RE			CANDIDATE GENE FOR THE CHROMOSOME-1 FAMILIAL ALZHEIMERS-DISEASE LOCUS	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; CATHEPSIN-E; LINKAGE; MUTATION; KINDREDS; MARKERS	A candidate gene for the chromosome 1 Alzheimer's disease (AD) locus was identified (STM2). The predicted amino acid sequence for STM2 is homologous to that of the recently cloned chromosome 14 AD gene (S182). A point mutation in STM2, resulting in the substitution of an isoleucine for an asparagine (N141I), was identified in affected people from Volga German AD kindreds. This N141I mutation occurs at an amino acid residue that is conserved in human S182 and in the mouse S182 homolog. The presence of missense mutations in AD subjects in two highly similar genes strongly supports the hypothesis that mutations in both are pathogenic.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108; MASSACHUSETTS GEN HOSP,GENET & AGING UNIT,BOSTON,MA 02129; DARWIN MOLEC,BOTHELL,WA 98021; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; VET AFFAIRS MED CTR,DIV NEUROL,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Massachusetts General Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Schmidt, Stephen/B-5398-2012; Tanzi, Rudolph/AAE-9622-2019; Schmidt, Stephen/AAC-6967-2019; Levy-Lahad, Ephrat/F-2186-2018	Tanzi, Rudolph/0000-0002-7032-1454; Levy-Lahad, Ephrat/0000-0002-2637-1921	NATIONAL INSTITUTE ON AGING [R01AG011762, R01AG011899] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG11762, AG0513C, R01-AG11899] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AZUMA T, 1992, J BIOL CHEM, V267, P1609; BERNSTEIN HG, 1994, BRAIN RES, V667, P287, DOI 10.1016/0006-8993(94)91509-1; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BIRD TD, 1991, J AM HISTO SOC GERM, V49, P1; BIRD TD, 1992, HETEROGENEITY ALZHEI, P118; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; KAMINO K, 1992, AM J HUM GENET, V51, P998; KOCH F, 1977, VOLGA GERMANS; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MULLAN M, 1992, NAT GENET, V2, P340, DOI 10.1038/ng1292-340; MUNROE DJ, 1995, P NATL ACAD SCI USA, V92, P2209, DOI 10.1073/pnas.92.6.2209; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAKANISHI H, 1993, EXP NEUROL, V121, P215, DOI 10.1006/exnr.1993.1088; Sambrook J, 1989, MOL CLONING LABORATO; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; Scheuerman R. D., 1985, VOLGA GERMANS PIONEE; SCHEUNER D, IN PRESS SOC NEUR AB; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SONG XH, IN PRESS SOC NEUR AB	30	2066	2151	1	77	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					973	977		10.1126/science.7638622	http://dx.doi.org/10.1126/science.7638622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638622				2022-12-28	WOS:A1995RP73800035
J	MONGELLA, G				MONGELLA, G			GLOBAL APPROACHES TO THE PROMOTION OF WOMENS HEALTH	SCIENCE			English	Editorial Material											MONGELLA, G (corresponding author), UN,WORLD CONFERENCE WOMEN 4,NEW YORK,NY 10017, USA.							COOK RJ, 1995, WOMENS HLTH HUMAN RI, P12; COOK RJ, 1994, WOMENS HLTH HUMAN RI, P7; DIXONMUELLER R, 1991, CULTURE SILENCE REPR, P1; Mitchell J. L., 1988, AIDS and Public Policy Journal, V3, P50; Mitchell Janet L, 1992, J Womens Health, V1, P35, DOI 10.1089/jwh.1992.1.35; 1994, WOMENS HLTH BETTER W, P12; 1995, 2ND REV NAIROBI FORW, P11; 1994, WOMENS HLTH, P18; 1995, 2ND REV IMPLEMENTATI, P11	9	10	12	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					789	790		10.1126/science.7638591	http://dx.doi.org/10.1126/science.7638591			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638591				2022-12-28	WOS:A1995RN65000029
J	CROFT, A				CROFT, A			MALARIA PROPHYLAXIS - TOXICITY OF MEFLOQUINE IS SIMILAR TO THAT OF OTHER CHEMOPROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Letter											CROFT, A (corresponding author), MINIST DEF,ARMY MED DIRECTORATE,ALDERSHOT GU12 5RR,HANTS,ENGLAND.							BRADLEY DJ, 1995, BRIT MED J, V310, P709, DOI 10.1136/bmj.310.6981.709; DESJARDINS RE, 1979, CLIN PHARMACOL THER, V26, P372; HANSFORD CH, 1995, LANCET, V345, P1049, DOI 10.1016/S0140-6736(95)90788-2; LUZZI GA, 1993, DRUG SAFETY, V8, P295, DOI 10.2165/00002018-199308040-00004; WHITE NJ, 1994, BRIT MED J, V308, P286, DOI 10.1136/bmj.308.6924.286	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					191	191		10.1136/bmj.311.6998.191b	http://dx.doi.org/10.1136/bmj.311.6998.191b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7677878	Green Published			2022-12-28	WOS:A1995RK15900054
J	BUTLER, C; PETERS, J; STOTT, N				BUTLER, C; PETERS, J; STOTT, N			GLYCATED HEMOGLOBIN AND METABOLIC CONTROL OF DIABETES-MELLITUS - EXTERNAL VERSUS LOCALLY ESTABLISHED CLINICAL TARGETS FOR PRIMARY-CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MICROVASCULAR COMPLICATIONS; TASK-PERFORMANCE; GENERAL-PRACTICE; HEMOGLOBIN	Objectives-To examine current targets for glycated haemoglobin as a marker for metabolic control in diabetes mellitus in relation to datasets from several areas, and to consider whether target setting could be improved. Design-Data collected from enhanced care records of general practices for a representative community based sample of people with diabetes. Setting and subjects-3022 people with diabetes on the lists of 37 general practices (total list size 222 550) in South Glamorgan in 1992; samples of glycated haemoglobin had been processed at two laboratories with different methodologies and reference ranges. Main outcome measures-Last glycated haemoglobin level measured in subjects for 1992 and published data from other studies considered in relation to existing goals and standards for the metabolic control of diabetes. Results-An ascertainment rate for people with diabetes of 1.36% was obtained. The rate of data capture for haemoglobin A1 was 75.7%, and the mean level for study samples was 10.5% at one laboratory and 10.0% at the other (similar values to those of comparable studies). These mean levels of haemoglobin A1 in representative populations of people with diabetes are poor or very. poor according to published standards, including those of the British Diabetic Association. These findings are set in the context of the psychology of goal setting and performance in complex clinical situations. Conclusion-Targets for clinical care that are set in the absence of normative data and local feasibility assessments should be treated with caution. Targets are more likely to enhance health care if target setters recognise the importance of psychological aspects of goal setting and motivation.	UNIV WALES HOSP, DEPT MED, CARDIFF CF4 4XW, S GLAM, WALES	Cardiff University	BUTLER, C (corresponding author), UNIV WALES COLL MED, LLANEDEYRN HLTH CTR, DEPT GEN PRACTICE, CARDIFF CF3 7PN, S GLAM, WALES.			Butler, Christopher/0000-0002-0102-3453				ALBERTI KGMM, 1994, DIABETIC MED, V11, P899, DOI 10.1111/j.1464-5491.1994.tb00376.x; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; [Anonymous], 1994, Diabetes Care, V17, P616; BANDURA A, 1991, NEBR SYM MOTIV, V38, P69; BOULTON AJM, 1993, DIABETIC MED, V10, P687, DOI 10.1111/j.1464-5491.1993.tb00148.x; DAY JL, 1992, DIABETIC MED, V9, P855, DOI 10.1111/j.1464-5491.1992.tb01905.x; DECI EL, 1971, J PERS SOC PSYCHOL, V18, P105, DOI 10.1037/h0030644; Deci EL, 1991, NEBR SYM MOTIV, P237; EARLEY PC, 1989, J APPL PSYCHOL, V74, P24, DOI 10.1037/0021-9010.74.1.24; FARMER A, 1991, BRIT J GEN PRACT, V41, P135; GROL R, 1993, BRIT J GEN PRACT, V43, P146; HAINES A, 1992, 58 ROYAL COLL GEN PR; HIGGS ER, 1992, DIABETIC MED, V9, P550, DOI 10.1111/j.1464-5491.1992.tb01837.x; HOWITT AJ, 1993, BRIT MED J, V307, P1046, DOI 10.1136/bmj.307.6911.1046; Krans HMJ, 1992, DIABETES CARE RES EU; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; LESTER E, 1989, ANN CLIN BIOCHEM, V26, P213, DOI 10.1177/000456328902600301; LOCKE EA, 1981, PSYCHOL BULL, V90, P125, DOI 10.1037/0033-2909.90.1.125; McWhinney I. R., 1981, TXB FAMILY MED; MORRIS LS, 1993, CLIN THER, V15, P593; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NEIL HAW, 1989, DIABETIC MED, V6, P608, DOI 10.1111/j.1464-5491.1989.tb01237.x; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PICKUP JC, 1993, DIABETIC MED, V10, P402, DOI 10.1111/j.1464-5491.1993.tb00090.x; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STOTT NCH, 1994, 1988 1933 U WAL COLL; TUCKET D, 1985, M EXPERTS; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Vroom V. H., 1964, WORK MOTIVATION; WILLIAMS G, 1994, LANCET, V343, P95, DOI 10.1016/S0140-6736(94)90822-2; WOOD RE, 1987, J APPL PSYCHOL, V72, P416, DOI 10.1037/0021-9010.72.3.416; 1993, BRIT MED J, V307, P1542; [No title captured]; 1993, RECOMMENDATIONS MANA	36	37	37	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	1995	310	6982					784	788		10.1136/bmj.310.6982.784	http://dx.doi.org/10.1136/bmj.310.6982.784			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP609	7677834	Green Published			2022-12-28	WOS:A1995QP60900024
